<SEC-DOCUMENT>0001047469-18-001209.txt : 20180301
<SEC-HEADER>0001047469-18-001209.hdr.sgml : 20180301
<ACCEPTANCE-DATETIME>20180301163212
ACCESSION NUMBER:		0001047469-18-001209
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180301
DATE AS OF CHANGE:		20180301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Corvus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001626971
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464670809
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37719
		FILM NUMBER:		18657886

	BUSINESS ADDRESS:	
		STREET 1:		863 MITTEN ROAD
		STREET 2:		SUITE 102
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		(650) 900-4520

	MAIL ADDRESS:	
		STREET 1:		863 MITTEN ROAD
		STREET 2:		SUITE 102
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>a2234682z10-k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg41901_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#du41901_index_to_consolidated_financial_statements">  INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>WASHINGTON, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM 10-K  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(Mark One)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> For the Fiscal Year Ended December&nbsp;31, 2017</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> OR</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR&nbsp;15(d) OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Corvus Pharmaceuticals,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=1>(Exact name of registrant as specified in its charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 001-37719</B></FONT><FONT SIZE=1><BR>
(Commission<BR>
File Number)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 46-4670809</B></FONT><FONT SIZE=1><BR>
(IRS Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>863 Mitten Road, Suite&nbsp;102, Burlingame, CA 94010</B></FONT><FONT SIZE=1><BR>
(Address of principal executive offices, including Zip Code) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Registrant's
telephone number, including area code: </FONT><FONT SIZE=1><B>(650)&nbsp;900-4520</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
registered pursuant to Section&nbsp;12(b) of the Act: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="42%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Title of each class </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Name of each exchange on which registered </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>Common Stock, $0.0001 par value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>The Nasdaq Global Market</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
registered pursuant to Section&nbsp;12(g) of the Act: </FONT><FONT SIZE=1><B>None</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities
Act.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
Act.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the issuer (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&sect;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant
was required to submit and post such files).&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K (&sect;&nbsp;229.405) is not contained
herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K or any
amendment to this Form&nbsp;10-K.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act.
(Check one): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="116pt" style="font-family:times;"></TD>
<TD WIDTH="9%" style="font-family:times;"></TD>
<TD WIDTH="91pt" style="font-family:times;"></TD>
<TD WIDTH="9%" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="9%" style="font-family:times;"></TD>
<TD WIDTH="136pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Small reporting company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging growth company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange
Act).&nbsp;Yes&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2017, the aggregate market value of the 8,497,239 shares of Common Stock held by non-affiliates of the registrant was approximately
$102.8&nbsp;million, computed by reference to the closing price as reported on The Nasdaq Stock Market. Shares of the registrant's common stock held by each officer and director and each person
known to the registrant to own 10% or more of the outstanding common stock of the registrant have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is
not a determination for other purposes. As of March&nbsp;1, 2018, 21,065,834 shares of the registrant's common stock were outstanding. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>DOCUMENTS INCORPORATED BY REFERENCE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Portions of the registrant's definitive proxy statement to be filed for its 2018 Annual Meeting of Stockholders are incorporated by reference into Part&nbsp;III
hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120&nbsp;days of the end of the fiscal year covered by this Annual Report on Form&nbsp;10-K. </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=642827,FOLIO='blank',FILE='DISK104:[18ZAA1.18ZAA41901]BA41901A.;11',USER='CHE107203',CD=';1-MAR-2018;13:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg41901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG41901A_main_toc"></A> </FONT></P>

<A NAME="bg41901_table_of_contents"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg41901_corvus_pharmaceuticals,_inc._a__cor02697"> </A>
<BR></FONT><FONT SIZE=2><B>  CORVUS PHARMACEUTICALS,&nbsp;INC.<BR>  ANNUAL REPORT ON FORM 10-K<BR>  TABLE OF CONTENTS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG41901_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da41901_part_i"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PART I</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da41901_item_1._business"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 1.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#da41901_item_1._business"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da41901_item_1._business"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg41901_item_1a._risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 1A.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dg41901_item_1a._risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg41901_item_1a._risk_factors"><FONT SIZE=2>35</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#do41901_item_1b._unresolved_staff_comments"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 1B.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#do41901_item_1b._unresolved_staff_comments"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unresolved Staff Comments</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#do41901_item_1b._unresolved_staff_comments"><FONT SIZE=2>77</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#do41901_item_2._properties"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 2.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#do41901_item_2._properties"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Properties</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#do41901_item_2._properties"><FONT SIZE=2>77</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#do41901_item_3._legal_proceedings"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 3.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#do41901_item_3._legal_proceedings"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Proceedings</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#do41901_item_3._legal_proceedings"><FONT SIZE=2>77</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#do41901_item_4._mine_safety_disclosures"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 4.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#do41901_item_4._mine_safety_disclosures"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mine Safety Disclosures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#do41901_item_4._mine_safety_disclosures"><FONT SIZE=2>77</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dq41901_part_ii"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PART II</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dq41901_item_5._market_for_registrant___ite04645"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 5.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dq41901_item_5._market_for_registrant___ite04645"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dq41901_item_5._market_for_registrant___ite04645"><FONT SIZE=2>78</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dq41901_item_6._selected_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 6.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#dq41901_item_6._selected_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dq41901_item_6._selected_financial_data"><FONT SIZE=2>80</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ds41901_item_7._management_s_discussio__ite03668"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 7.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ds41901_item_7._management_s_discussio__ite03668"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ds41901_item_7._management_s_discussio__ite03668"><FONT SIZE=2>81</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ds41901_item_7a._quantitative_and_qual__ite02669"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 7A.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ds41901_item_7a._quantitative_and_qual__ite02669"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ds41901_item_7a._quantitative_and_qual__ite02669"><FONT SIZE=2>92</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#du41901_item_8._financial_statements_and_supplementary_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 8.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#du41901_item_8._financial_statements_and_supplementary_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial Statements and Supplementary Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#du41901_item_8._financial_statements_and_supplementary_data"><FONT SIZE=2>93</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fq41901_item_9._changes_in_and_disagre__ite03576"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 9.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fq41901_item_9._changes_in_and_disagre__ite03576"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fq41901_item_9._changes_in_and_disagre__ite03576"><FONT SIZE=2>120</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fq41901_item_9a._controls_and_procedures"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 9A.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fq41901_item_9a._controls_and_procedures"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Controls and Procedures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fq41901_item_9a._controls_and_procedures"><FONT SIZE=2>120</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fq41901_item_9b._other_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 9B.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#fq41901_item_9b._other_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fq41901_item_9b._other_information"><FONT SIZE=2>121</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_part_iii"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PART III</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_item_10._directors,_executive___ite02336"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 10.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ja41901_item_10._directors,_executive___ite02336"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Directors, Executive Officers of the Registrant and Corporate Governance Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ja41901_item_10._directors,_executive___ite02336"><FONT SIZE=2>122</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_item_11._executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 11.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ja41901_item_11._executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ja41901_item_11._executive_compensation"><FONT SIZE=2>122</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_item_12._security_ownership_of__ite04004"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 12.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ja41901_item_12._security_ownership_of__ite04004"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ja41901_item_12._security_ownership_of__ite04004"><FONT SIZE=2>122</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_item_13._certain_relationships__ite03088"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 13.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ja41901_item_13._certain_relationships__ite03088"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Transactions, and Director Independence</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ja41901_item_13._certain_relationships__ite03088"><FONT SIZE=2>122</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_item_14._principal_accountant_fees_and_services"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 14.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ja41901_item_14._principal_accountant_fees_and_services"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Accounting Fees and Services</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ja41901_item_14._principal_accountant_fees_and_services"><FONT SIZE=2>122</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_part_iv"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PART IV</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_item_15._exhibits_and_financial_statement_schedules"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 15.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ja41901_item_15._exhibits_and_financial_statement_schedules"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exhibits and Financial Statement Schedules</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ja41901_item_15._exhibits_and_financial_statement_schedules"><FONT SIZE=2>122</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ja41901_item_16._form_10-k_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ITEM 16.</B></FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#ja41901_item_16._form_10-k_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Form&nbsp;10-K Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ja41901_item_16._form_10-k_summary"><FONT SIZE=2>126</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><A HREF="#sig"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Signatures</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#sig"><FONT SIZE=2>127</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=779052,FOLIO='i',FILE='DISK104:[18ZAA1.18ZAA41901]BG41901A.;6',USER='CHE105948',CD='28-FEB-2018;21:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi41901_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Forward-Looking Statements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Annual Report on Form&nbsp;10-K contains forward-looking statements that involve risks and uncertainties. All statements other than
statements of historical facts contained in this report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "could," "will,"
"would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential" or "continue" or the negative of these terms or other comparable
terminology. These forward-looking statements include, but are not limited to, statements about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations and beliefs regarding the potential benefits of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations regarding the clinical effectiveness of our product candidates and utility of our biomarker data; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the anticipated timing, costs and conduct of our planned clinical trials for CPI-444 and CPI-006, and planned preclinical studies and clinical
trials for other product candidates in our development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to develop, acquire and advance product candidates into, and successfully complete, clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of the completion of our ongoing clinical trial of CPI-444 and the timing and availability of clinical data from such clinical
trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> clinical and regulatory development plans with respect to CPI-444, CPI-006 and our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations regarding the potential market size and the size of the patient populations for CPI-444, CPI-006 and our additional product
candidates, if approved for commercial use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to commercialize CPI-444 and our additional product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our commercialization, marketing and manufacturing capabilities and strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the pricing and reimbursement of our product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the
projected terms of patent protection; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our or any existing or future collaborator's ability to obtain and maintain intellectual property protection for our technologies and product
candidates and our ability to operate our business without infringing the intellectual property rights of others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to establish and maintain collaborations and retain commercial rights for our product candidates in such collaborations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential benefits of strategic collaborations and our ability to enter into strategic arrangements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments and projections relating to our competitors and our industry, including competing therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding the effect of changes in the tax code as a result of recent federal tax legislation and uncertainty as to how some of
those changes may be applied; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our financial performance. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=746479,FOLIO='ii',FILE='DISK104:[18ZAA1.18ZAA41901]BI41901A.;6',USER='CHE108230',CD='28-FEB-2018;20:50' -->
<A NAME="page_bi41901_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
forward-looking statements in this Annual Report on Form&nbsp;10-K reflect our current views with respect to future events or to our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under
Part&nbsp;I, Item&nbsp;1A. Risk Factors and discussed elsewhere in this Annual Report on Form&nbsp;10-K. Given these uncertainties, you should not place undue reliance on these forward-looking
statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Annual Report on Form&nbsp;10-K also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data
regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar
methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly
stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications,
government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data
in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
where the context otherwise requires, in this Annual Report on Form&nbsp;10-K, "we," "us," "our" and the "Company" refer to Corvus Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Trademarks  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Annual Report on Form&nbsp;10-K includes trademarks, service marks and trade names owned by us or other companies. All trademarks,
service marks and trade names included in this Annual Report on Form&nbsp;10-K are the property of their respective owners. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>iii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=787850,FOLIO='iii',FILE='DISK104:[18ZAA1.18ZAA41901]BI41901A.;6',USER='CHE108230',CD='28-FEB-2018;20:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da41901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da41901_part_i"> </A>
<A NAME="toc_da41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Part&nbsp;I    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="da41901_item_1._business"> </A>
<A NAME="toc_da41901_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;Business    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that
precisely target crucial enzymes and proteins in the immune system to treat patients with cancer. Since we began operations in November 2014, we have built a pipeline of five immuno-oncology programs,
three of which focus on the adenosine-cancer axis to modulate an immune response. Our lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an
immune checkpoint. In January 2016, we began enrolling patients in a large expansion cohort trial for CPI-444. This Phase&nbsp;1/1b clinical trial is designed to examine safety, tolerability,
biomarkers and preliminary efficacy of CPI-444 in several solid tumor types, both as a single agent and in combination with Genentech,&nbsp;Inc.'s cancer immunotherapy, Tecentriq&reg;
(atezolizumab), a fully humanized monoclonal antibody targeting PD-L1. In November 2016, we completed enrollment of 48 patients in the first step of the Phase&nbsp;1/1b clinical trial, which was
designed to determine the optimal dose of CPI-444 as both a single agent therapy and in combination with Tecentriq for use in the cohort expansion stage of the trial. The expansion cohort portion of
the trial enrolled patients with non-small cell lung cancer ("NSCLC"), renal cell cancer ("RCC"), melanoma ("MEL"), triple negative breast cancer ("TNBC") and other cancers including
colorectal cancer, prostate cancer, head and neck cancer and bladder cancer at 35 leading medical centers in the U.S., Australia and Canada. We have enrolled over 235 patients in this clinical trial
to date. In 2017, both the single agent and combination arms of the NSCLC and RCC cohorts met the protocol-defined criteria for expansion from 14 to 26 patients, and both arms of the RCC&nbsp;cohort
further met the protocol-defined criteria for expansion to 48 patients. In December 2017, Genentech began enrolling patients in a Phase&nbsp;1b/2 trial that is evaluating CPI-444 in combination with
Tecentriq in patients with NSCLC under an umbrella protocol known as Morpheus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
other product and development candidates in our pipeline also continue to advance. In January 2018, we filed an IND for our second program, an anti-CD73 monoclonal antibody
("CPI-006") that inhibits the production of adenosine. We plan to initiate a Phase&nbsp;1/1b clinical trial in the first quarter of 2018. In addition, in 2017, we selected a lead development
candidate for our ITK program and are currently conducting IND-enabling studies. We plan to initiate a Phase&nbsp;1 clinical trial for this candidate in early 2019. We expect to select a development
candidate for our third adenosine program, a small molecule antagonist of the A2B receptor, in 2018. In 2017, we in-licensed a monoclonal antibody to a novel target in immuno-oncology. This antibody
is now undergoing optimization and we expect to initiate IND-enabling studies in 2018. We believe the breadth and status of our pipeline demonstrates our management team's expertise in understanding
and developing immuno-oncology assets as well as in identifying product candidates that can be in-licensed and further developed internally to treat many types of cancer. We hold worldwide rights to
all of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immuno-oncology
therapies that stimulate or enhance immune responses to tumors are a new and emerging approach with several potential benefits over existing therapies. First, the immune
system exhibits immunologic diversity and selectivity, which enables it to respond selectively to a large number of potential targets. Second, once triggered, the immune response can be amplified,
offering the potential to enhance the efficacy of treatment. Third, once activated, the immune system possesses immunologic memory, potentially providing for a durable and long-lasting response. Some
of the most successful types of immuno-oncology therapies are immune checkpoint inhibitors. Immune checkpoints are signaling molecules produced by or expressed on immune cells that act to shut down or
block an
immune response. In a healthy person, these checkpoints function to limit an immune response to ensure that the immune system does not overreact, which could lead to excessive inflammation and tissue
damage, as occurs in patients with autoimmune diseases or allergies. Tumor cells have evolved to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=102229,FOLIO='1',FILE='DISK104:[18ZAA1.18ZAA41901]DA41901A.;13',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_da41901_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>activate
these checkpoints to shield the tumor from immune response attacks, but studies have shown that immune checkpoint inhibitors can counter these tumor-protective measures and unleash the immune
system's cancer-destroying properties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA has approved agents that target specific immune checkpoints, including antibodies against the cytotoxic T-lymphocyte-associated antigen-4 ("CTLA-4"), programmed death 1 ("PD-1")
receptors, and programmed death receptor-ligand 1 ("PD-L1"). These antibodies represent the first immune checkpoint inhibitors to demonstrate effectiveness in the clinic, and preclinical data suggest
that there are many other immune checkpoints or targets that may be modulated to promote the activation of a patient's anti-tumor immune system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
we began operations in November 2014, we have built a pipeline of five immuno-oncology programs. Three of our programs are aimed at disabling cancer's ability to subvert immune
attack by inhibiting adenosine in the tumor microenvironment or by blocking its production by tumors. Adenosine activates an immune checkpoint, the adenosine A2A receptor, that is used by the body to
limit inflammation and immune responses. Adenosine accomplishes this by interacting with the A2A and A2B receptors expressed on several cells of the immune system; including T-cells, natural killer
("NK") cells, macrophages, dendritic cells and myeloid derived suppressor cells, as well as other cells. We are developing small molecules that selectively inhibit the binding of adenosine to either
A2A receptors or to A2B receptors. We also are developing injectable monoclonal antibodies that block the production of adenosine by tumors by inhibiting the cell surface enzyme CD73. Our fourth
program is aimed at developing product candidates that regulate T-cell activation and differentiation by inhibiting interleukin-2 inducible kinase ("ITK"). Several of our product candidates are orally
administered small molecules, which may provide for easier administration and facilitate their use in combination with other anti-cancer agents. Our oral product candidates are designed to be rapidly
eliminated from the body, which, in turn, could reduce the potential for excessive toxicity when used in combination with other antibody-based checkpoint inhibitors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
immuno-oncology product candidate pipeline includes the following: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CPI-444 Adenosine A2A Receptor Antagonist.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In February 2015, we in-licensed patent rights and know-how related to CPI-444 and
related molecules from
Vernalis (R&amp;D) Limited ("Vernalis"), where it was
under development for treatment of Parkinson's disease and other neurologic diseases. Vernalis and its corporate partner conducted two Phase&nbsp;1 clinical trials in healthy volunteers and one
Phase&nbsp;1b clinical trial in patients with attention deficit and hyperactivity disorder (ADHD), with an aggregate of approximately 75 healthy volunteers and patients dosed. These trials provided
early indications of a favorable safety profile and assessed pharmacokinetics, oral bioavailability and receptor occupancy for CPI-444. We conducted further testing in </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> models to evaluate CPI-444's immune-enhancing and anti-tumor properties. In these studies, orally administered
CPI-444 inhibited tumor growth in multiple mouse models of cancer as a single agent, in combination with anti-PD-1 agents and in combination with anti-PD-L1 agents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2015, we filed an investigational new drug ("IND") application for CPI-444 for treatment of several solid tumor types. In January 2016, we began enrolling patients in a large
expansion cohort clinical trial for CPI-444. This Phase&nbsp;1/1b clinical trial is designed to examine safety, tolerability, biomarkers and preliminary efficacy of CPI-444, both as a single agent
and in combination with Tecentriq, and includes patients with different types of solid tumors enrolled in disease-specific cohorts. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2016, we completed enrollment of the first step of the Phase&nbsp;1/1b clinical trial, which was designed to determine the optimal dose for use in the disease-specific
expansion cohort component of the trial. We also reported results of initial safety, tolerability, biomarkers and preliminary efficacy. In December 2016, we initiated the second step of the
Phase&nbsp;1/1b clinical trial with our optimal dose of CPI-444 as both a single agent therapy and in combination with Tecentriq. This portion of the trial enrolled patients in ten disease specific
cohorts; five of the cohorts receive CPI-444 as a single agent </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=764778,FOLIO='2',FILE='DISK104:[18ZAA1.18ZAA41901]DA41901A.;13',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_da41901_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>and
five receive CPI-444 in combination with Tecentriq. The cohorts include patients with NSCLC, MEL, RCC, TNBC and others (bladder cancer, prostate cancer and colorectal cancer with high mutation
rates). In 2017, both the single agent and combination arms of the NSCLC and RCC cohorts met the protocol-defined criteria for expansion from 14 to 26 patients, and both arms of the RCC&nbsp;cohort
further met the protocol-defined criteria for expansion to 48 patients. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issued U.S. patents that we in-licensed from Vernalis are directed to the composition of matter of CPI-444 and its method of use for treating disorders treatable by purine receptor
blocking. The composition of matter patent covering CPI-444 is expected to expire in the United States in July 2029, excluding any patent term extension that may be available. We hold an exclusive,
worldwide license under these patent rights and related know-how, including a limited right to grant sublicenses, for all fields of use, to develop, manufacture and commercialize products containing
certain adenosine receptor antagonists, including CPI-444. We have also filed patent applications covering the use of CPI-444 in combination with other checkpoint inhibitors, and the use of various
biomarkers to select and monitor patients receiving therapy. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-CD73 Adenosine Production Inhibitor.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In December 2014, we in-licensed from The Scripps Research Institute ("Scripps") a
mouse hybridoma clone
expressing an anti-human CD73 antibody, from which we have developed, CPI-006, a humanized anti-CD73 monoclonal antibody. We have further modified CPI-006 to improve binding to CD73 and maximize its
inhibition of catalytic activity. CD73 is an ectonucleotidase often found on lymphocytes, tumors and other tissues and is believed to play an important role in tumor immune suppression by catalyzing
the production of extracellular adenosine. In preclinical </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies, our humanized monoclonal anti-CD73 antibody has been shown to inhibit the
catalytic activity of CD73, resulting in the blocking of extracellular adenosine production by tumor cells, which we believe could stimulate or enhance immune response to tumors. In January 2018, we
filed an IND and, subject to FDA allowance, expect to initiate a Phase&nbsp;1/1b clinical trial in the first quarter of 2018. We hold a non-exclusive, world-wide license for all fields of use under
Scripps' rights in a hybridoma clone expressing an anti-CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma. In 2016, we
filed a patent application covering the composition of matter of CPI-006. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adenosine A2B Receptor Antagonist.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have in-licensed several selective and potent adenosine A2B receptor antagonists from
Vernalis. In addition, we
are synthesizing and have identified other A2B receptor antagonists from our internal research program. Adenosine A2B receptors have recently been found to play an important role in the immune
response to tumors. Similar to adenosine A2A receptors, adenosine binds to adenosine A2B receptors, which leads to immunosuppression. We intend to further develop our A2B agents to improve potency,
selectivity, pharmacokinetic behavior and immune enhancing properties. We expect to conduct preclinical studies similar to those we have conducted for CPI-444 in order to select a development
candidate in 2018. Upon selection, we intend to conduct further IND-enabling studies and potential Phase&nbsp;1 clinical trials. We hold an exclusive, worldwide license under certain Vernalis patent
rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing such compounds that have been developed using
the intellectual property rights that we in-license from Vernalis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ITK Inhibitor.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have developed selective, covalent inhibitors of ITK and are evaluating them in preclinical studies for
potency, safety and
efficacy. ITK, an enzyme that functions in T-cell signaling and differentiation, is expressed predominantly in T-cells, which are lymphocytes that play a vital role in immune responses. One of the key
survival mechanisms of tumors is believed to be the reprogramming of T-cells to create an inflammatory environment that inhibits anti-tumor immune response and favors tumor growth. We believe highly
selective inhibitors of this enzyme will facilitate induction of T-cell anti-tumor immunity and also may be useful in the treatment of T-cell lymphomas. We have selected a lead development candidate
for this program that was designed to bind selectively to T-cells. It is orally </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=274451,FOLIO='3',FILE='DISK104:[18ZAA1.18ZAA41901]DA41901A.;13',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_da41901_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>bioavailable
and has been shown to achieve cellular occupancy of the target in vivo in various animal models. We have initiated IND-enabling studies for our lead development candidate. Subject to the
completion of such studies and the submission and acceptance by the FDA of an IND, which we plan to file in 2018, we plan to advance the candidate into Phase&nbsp;1 clinical trials in cancer
patients in early 2019. We have filed patent applications covering composition of matter and uses of our ITK inhibitors and hold exclusive worldwide rights for all indications. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Company Origins and Team  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since we began operations in November 2014, our focus has been on improving and expanding upon the recent success achieved with immune
checkpoint inhibitors and on developing agents to new targets in the evolving immuno-oncology field. Our founders and management team consist of industry veterans who have played significant roles in
the discovery and development of successful oncology and immunology antibodies and drugs, including rituximab and ibrutinib. Our co-founders include our Chief Executive Officer, Richard A. Miller,
M.D., our Chief Financial Officer, Leiv Lea, and our Executive Vice President, Discovery Research, Joseph Buggy, Ph.D. Dr.&nbsp;Miller previously co-founded IDEC (which merged to form Biogen IDEC,
now Biogen), where he led research efforts on lymphoma, culminating in the development of rituximab. Dr.&nbsp;Miller, an oncologist, also co-founded and was the initial CEO of
Pharmacyclics,&nbsp;Inc. where he and colleagues in-licensed ibrutinib and, together with Dr.&nbsp;Buggy, led its development. Our Chief Financial Officer, Leiv Lea, has previously led finance
teams for emerging biotechnology companies, including Pharmacyclics. Mr.&nbsp;Lea has extensive commercial and operating experience in addition to having completed a number of financial and
strategic transactions. We have recruited industry veterans and experts to join our management team, and established collaborations with leading biotechnology companies, including Genentech, and
collaborative relationships with many leading academic research institutions. With our management team's expertise in developing both small molecule and antibody-based oncology treatments, we believe
we are well positioned to identify and develop novel therapeutic agents that have diverse but complementary mechanisms of action, allowing for their potential integration into immuno-oncology
treatment regimens for a broad variety of cancers. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to become a leader in the field of immuno-oncology treatments for multiple cancer indications. Specific elements of our strategy
are: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Leverage our expertise in immunology and oncology to identify, develop and commercialize new product
candidates.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have established development expertise and capabilities in synthetic chemistry, molecular biology, immunology and clinical
oncology, which we believe will help us advance product candidates in the immuno-oncology field. We plan to become a leader in the development and commercialization of product candidates targeting
adenosine in what is known as the adenosine-cancer axis, a key mechanism used by tumors to evade immune attack. Three of our product programs, are focused on the development of product candidates
targeting this axis, including an A2A receptor antagonist, an anti-CD73 antibody and an A2B receptor antagonist. We have also in-licensed a monoclonal antibody to a novel immuno-oncology target that
is independent of the adenosine axis. In addition to our internal research programs, we intend to seek opportunities to in-license other product candidates with a focus on the potential to address
unmet needs within our areas of expertise.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Utilize efficient clinical trial designs to enable us to identify the most promising clinical
indications.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Our Phase&nbsp;1/1b clinical trial is designed to evaluate multiple variables, such as single agent and combination therapy,
impact of prior therapy with immuno-oncology agents and the role of various biomarkers, which may allow us to determine tumor types that are most responsive to treatment with CPI-444 alone or in
combination. This approach has the potential to shorten development time by quickly identifying the most promising clinical indications, which would </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=873666,FOLIO='4',FILE='DISK104:[18ZAA1.18ZAA41901]DA41901A.;13',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_da41901_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>then
be evaluated in subsequent definitive pivotal trials. For instance, in 2017, both the single agent and combination arms of the NSCLC and RCC cohorts met the protocol-defined criteria for
expansion, and both arms of the RCC&nbsp;cohort further met the protocol-defined criteria for additional expansion. We believe the expansion design of our protocol has allowed us to select the most
promising development path to date and we intend to use similar clinical trial designs for our other product candidates in the future.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Advance product candidates for use alone or in combination with other oncology
treatments.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We intend to focus on product candidates with single agent activity, which are also designed to be combined synergistically with
other cancer therapies. We believe that many immuno-oncology therapeutic regimens will likely be built on a backbone of anti-PD-1/PD-L1 blockade, and our initial Phase&nbsp;1/1b clinical trial
includes the administration of CPI-444 in combination with Tecentriq. Our product candidates are designed to target the patient's immune system rather than a specific type of malignant cell, and, if
approved, could be suitable as a single agent as well as in combination with current and future immunotherapy agents as well as traditional cancer treatments, including chemotherapy, biologic therapy,
targeted therapy and radiation therapy.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Identify biomarkers to select patients and monitor treatment with our product
candidates.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Predicting optimal drug responses in patients requires the identification and validation of predictive biomarkers. We believe that
developing the ability to identify patient subsets most likely to respond to our product candidates will increase the clinical benefit to patients and improve the probability of success of our
clinical trials. Our Phase&nbsp;1/1b clinical trial of CPI-444 includes the examination of numerous biomarkers to identify those that may correlate with clinical efficacy and increase our likelihood
of success.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Pursue collaborative relationships, partnerships and in-licensing opportunities to help advance and expand
our product candidate portfolio</I></B></FONT><FONT SIZE=2>.&nbsp;&nbsp;In addition to developing product candidates through preclinical and clinical stages of development, we plan to
identify and pursue strategic collaborative relationships, partnerships and in-licensing opportunities, which could enhance the development of our programs and product candidates. As evidenced by our
collaboration with Genentech for CPI-444, we intend to build upon our relationships with leading biotechnology companies and research institutions to identify new opportunities to position us at the
forefront of immuno-oncology. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cancer Treatment and Immuno-oncology  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancer is the second leading cause of mortality in the United States, accounting for nearly one in every four deaths. Approximately 40% of
Americans will develop some form of cancer, and, according to the American Cancer Society, there were 1.7&nbsp;million new cases of cancer and 600,000 deaths due to cancer in the United States in
2017. Cancer treatment has traditionally included chemotherapy, biologic therapy, radiation, surgery or a combination of these approaches. Treatment with targeted agents is becoming more widely used.
These agents often react with specifically mutated proteins in cancer. Many different mutations are now known to occur in cancer and, in many cases, are responsible for driving tumor progression. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immuno-oncology
is a new and emerging approach to treating cancer that is based on stimulating or enhancing an immune response to the tumor. This approach is based on the findings that
the mutations occurring in cancer cells may be immunogenic and capable of eliciting an immune response against the tumor. Immuno-oncology therapies offer several potential advantages over existing
cancer therapies due to the intrinsic features of the immune system. For instance, the immune system exhibits immunologic diversity and selectivity, which enables it to respond to a large number of
potential targets. In addition, once triggered, the immune response can be amplified, offering the potential to enhance the efficacy of treatment. Furthermore, once activated, the immune system
possesses </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1044079,FOLIO='5',FILE='DISK104:[18ZAA1.18ZAA41901]DA41901A.;13',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_da41901_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>immunologic
memory, potentially providing for a durable and long-lasting response. Finally, because immunotherapy mechanisms are indifferent to tissue origin and are instead focused on immunogenic
mutations, which are often expressed across tumor types, immunotherapy may be widely applicable to many types of cancer and not limited to a particular tumor type. This allows for these agents to be
potentially active in a multitude of cancer histologies. However, while the modulation of the immune system to eradicate cancer has been a long-standing goal in cancer therapy, historically it has not
been possible to consistently produce clinically meaningful anti-tumor immune responses despite the immunogenicity of tumors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recently,
the reasons for the previous failures of immunologic approaches to cancer treatment have become better understood. Tumors evolve sophisticated survival mechanisms, allowing
them to avoid immune-mediated destruction as occurs with pathogens, such as bacteria or viruses. These mechanisms include the activation of immune checkpoints on cells of the immune system, which act
to block immune responses, and the reprogramming of T-cells to create an inflammatory environment that inhibits immune response and favors tumor growth. Immune checkpoints are signaling molecules
produced by or expressed on immune cells that shut down or block an immune response. In a healthy person, these checkpoints function to limit an immune response to ensure that the immune system does
not overreact, which could lead to excessive inflammation and tissue damage, as occurs in patients with autoimmune diseases or allergies. Tumors have evolved to activate these checkpoints to shield
them from immune response attacks. However, studies have shown that these mechanisms can be countered using immune checkpoint inhibitors, which can unleash the immune system's cancer-destroying
properties. The new found understanding of immune checkpoints has led to a revolution in cancer treatment and the growing field of immuno-oncology. Specific immune checkpoint inhibitors, including
antibodies against CTLA-4, PD-1 receptor or its ligand PD-L1 have produced impressive results in the clinic in a range of cancers, leading to FDA approvals for ipilimumab (anti-CTLA-4), nivolumab
(anti-PD-1), pembrolizumab (anti-PD-1), Tecentriq (anti-PD-L1), durvalumab (anti-PD-L1) and avelumab (anti-PD-L1). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite
their recent success, current checkpoint inhibitors suffer from several limitations. Only a subset of patients treated with checkpoint inhibitors exhibit robust anti-tumor
responses, and responses are often partial and temporary. Many patients initially respond, but then relapse due to the emergence of resistant pathways, which may occur due to tumor cell expression of
other checkpoints. Some patients
experience unusual toxicities related to an over-exuberant immune response against normal tissues leading to pneumonitis, hepatitis, colitis and other autoimmune related disorders. These limitations
have motivated a search for other immune checkpoint targets and the use of combinations of various checkpoint inhibitors in an attempt to improve efficacy, reduce resistance and limit or reduce
toxicity. To date, the use of combinations of immune checkpoint inhibitors has been limited by excessive and serious autoimmune toxicities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
recent success of checkpoint inhibitors has stimulated increased interest in utilizing various immunotherapy approaches to treating cancer, including vaccines, cellular therapies and
other immunomodulatory agents. These approaches include modulating the function of various immune cells. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Product Pipeline  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing novel checkpoint inhibitors and immuno-oncology therapies that we believe may overcome some of the limitations of current
immuno-oncology therapies. Three of our programs are aimed at disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment or by blocking its production by
tumors. Our fourth program is aimed at developing product candidates that regulate T-cell activation and differentiation by inhibiting ITK, an enzyme important in T cell differentiation and function.
We intend to commercialize any approved product candidates primarily in the United States and Europe for any oncology indications our product candidates are approved for. We expect cancer patients or
their healthcare providers to be our primary customers for any approved product candidates and expect that our commercial sales of such product </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=137950,FOLIO='6',FILE='DISK104:[18ZAA1.18ZAA41901]DA41901A.;13',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_da41901_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>candidates
will depend on the availability of adequate coverage and reimbursement from government health administration authorities, private health insurers and other third-party payors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following chart summarizes key information regarding our current product candidate pipeline and expected milestones: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g863102.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="370">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adenosine Inhibitors  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adenosine-Cancer Axis and Anti-tumor Immune Response  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adenosine activates an immune checkpoint, the adenosine A2A receptor, that is used by the body to limit inflammation and immune responses. It is
produced during acute, inflammatory processes in two steps. The first step is the catalytic conversion of adenosine triphosphate ("ATP") to adenosine monophosphate ("AMP") by the enzyme CD39. The
second and rate-limiting step is the conversion of AMP to adenosine by CD73, an enzyme expressed on the surface of several types of immune cells, tumor cells and cells of certain other tissues. Under
normal circumstances, the level of adenosine is increased to protect a person from over-injury in response to such stimuli as inflammation, infection or ischemia. However, as a self-protective
maneuver, many tumor types actively sustain increased levels of extracellular adenosine by production through CD73 or by direct secretion of adenosine. These increased levels of adenosine interact
with the A2A and A2B receptors expressed on several cells of the immune system, including T-cells, NK cells, macrophages, dendritic cells and myeloid derived suppressor cells, as well as other cells,
which has the effect of dampening the immune response to the tumor, a system known as the adenosine-cancer axis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=405459,FOLIO='7',FILE='DISK104:[18ZAA1.18ZAA41901]DA41901A.;13',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_da41901_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following figure provides an overview of adenosine production by tumors and its effects on the immune system: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da41901_adenosine-cancer_axis_immunosu__ade03872"> </A>
<A NAME="toc_da41901_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Adenosine-Cancer Axis<BR>  Immunosuppressive Effects of Adenosine Mediated through Multiple Pathways    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g843870.jpg" ALT="GRAPHIC" WIDTH="549" HEIGHT="309">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
immune system is composed of several cellular components that mediate a variety of functions in response to tumor cells and foreign pathogens. For instance, macrophages and dendritic
cells function primarily to process foreign antigens and tumor antigens. These cells then present such antigens to other cells, such as T-cells. The presentation of these antigens to T-cells
stimulates cytotoxic T-cells (also known as killer T-cells) to destroy the tumor cells or foreign pathogens. Other cells, such as NK cells, are capable of destroying tumor cells without the need for
antigen presentation from macrophages or dendritic cells. In addition, certain immune cells, such as myeloid derived suppressor cells and T regulatory cells, function to suppress or dampen immune
responses. The various cellular components of the immune system work in a coordinated manner to recognize and destroy pathogens and tumor cells, and then return the tissue to its normal state. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adenosine
hinders the immune response to tumors by both blocking the activation and effectiveness of immune cells capable of destroying tumor cells, and by increasing the number of
immune cells that act to suppress immune cells from responding to the tumor. For instance, adenosine reduces T-cell and NK cell production of cytokines, such as interleukin-2 ("IL-2") and gamma
interferon ("IFNg"), which results in the blockade or reduction in the ability of such cells to destroy tumor cells. Adenosine also leads to activation and proliferation of T regulatory cells, which
function to suppress or dampen immune responses. In addition, adenosine causes dendritic cells to both decrease the rate at which they present antigens to T-cells, thereby inhibiting the ability of
T-cells to destroy tumor cells, and decrease their production of co-stimulatory cytokines, which also has the effect of suppressing or dampening the immune response. Macrophages exposed to adenosine
will similarly decrease their function, which results in the suppression of immune activity. Finally, adenosine stimulates and increases the number of myeloid derived suppressor cells in the tumor
microenvironment, which suppresses immune responses to the tumor. As tumor cells evolve and form cancerous growths, they utilize these processes to evade immune attack and promote their survival. Many
of the effects of adenosine on the immune system are mediated through binding to A2A receptors present on several immune cells. Much less is known about A2B receptors, but they have recently been
found on certain immune cells, such as macrophages and myeloid derived suppressor cells, and adenosine binding to A2B receptors also appears to play a role in tumor induced immune suppression. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=12,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=371289,FOLIO='8',FILE='DISK104:[18ZAA1.18ZAA41901]DA41901A.;13',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc41901_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancer cells also appear to directly utilize adenosine to promote their own growth. Many solid tumors upregulate CD73 for increased adenosine production. In some
cases, it appears adenosine can stimulate growth in tumors by increasing a tumor's blood supply. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
significant body of data indicates that targeting the adenosine-cancer axis through the A2A&nbsp;receptor can promote anti-tumor immune responses leading to tumor regression.
Consistent with studies of the inhibition of the A2A receptor, A2A receptor gene knockout mice, which completely lack expression of the A2A receptor, exhibit improved anti-tumor immunity. In addition,
several preclinical tumor model studies have shown that treatment with A2A receptor inhibitors leads to tumor regression that is enhanced when administered in combination with various other checkpoint
inhibitors, such as anti-PD-1 therapies and anti-CTLA-4 therapies. Treatment with anti-CD73 antibodies has been shown to inhibit tumor growth in several pre-clinical animal tumor models. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lead Product Candidate: CPI-444, an A2A selective, orally administered antagonist of the adenosine
A2A&nbsp;receptor  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead product candidate, CPI-444, is a selective oral adenosine A2A receptor antagonist that we licensed from Vernalis in February 2015.
Since licensing CPI-444, we have conducted extensive laboratory studies </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> in animal
models to evaluate CPI-444's immune-enhancing and anti-tumor properties. In these studies, orally administered CPI-444 inhibited tumor growth in multiple mouse models of cancer as a single agent, in
combination with anti-PD-1, in combination with anti-PD-L1, in combination with other immune-oncology agents and in combination with certain chemotherapy drugs. We also have shown </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> that CPI-444
binds potently and selectively to human activated T-cells and blocks adenosine mediated immunosuppression by restoring T-cell
function. In addition, we have shown that there is anti-tumor activity in mice for a significant time following oral administration, which appears to be mediated through a long-lasting memory immune
response. Furthermore, we have shown in animal models that the treatment is well tolerated. Our IND in oncology was filed in October 2015, and we began enrolling patients in a Phase&nbsp;1/1b
clinical trial in January 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Human Safety and Pharmacokinetic Data for CPI-444  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to licensing CPI-444 from Vernalis, Vernalis and its corporate partner conducted two Phase&nbsp;1 clinical trials in healthy volunteers
and one Phase&nbsp;1b trial in patients with ADHD, with oral doses ranging from 30 mg/day to 300 mg/day. Two studies were completed in healthy human male volunteers, the first of which was a single
ascending dose or multiple dose study with 41 healthy volunteers. Of these 41 subjects, 21 were dosed in both the single ascending dose and multiple dose portions of the study. The second study was a
receptor occupancy study performed in six human subjects using PET imaging to determine receptor occupancy. The third study was a randomized, double blind, placebo controlled, cross-over
Phase&nbsp;1b trial in 28 patients with ADHD, which evaluated doses up to 200 mg/ day. The results of these studies were as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Safety and tolerability:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;In studies involving healthy volunteers, there was
no pattern in the incidence, severity, or relationship of adverse events to CPI-444 dose level. The main toxicity exhibited was gastro-intestinal disorders (abdominal pain, nausea) due to gastric
irritation; however, these findings were also observed in the placebo group. No differences in gastric endoscopy were seen between treatment and placebo groups. No dose limiting toxicities were
observed and no subject experienced a serious adverse event considered by the investigator to be related to CPI-444. There were no treatment-associated changes seen for any routine laboratory safety
tests. A minimal and transient increase in blood pressure that may have been dose-related was observed on day one, but was not detected by day 14 of continuous daily dosing. No </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=826793,FOLIO='9',FILE='DISK104:[18ZAA1.18ZAA41901]DC41901A.;11',USER='CHE106206',CD=';1-MAR-2018;13:35' -->
<A NAME="page_dc41901_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>clinically
significant cardiac abnormalities on telemetry or electrocardiogram recordings were observed. There were no clinically significant changes from baseline in physical examination findings and
there were no treatment-emergent clinically significant findings. Based on these studies, we believe that administration of CPI-444 was not associated with any clear evidence of toxicity. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Human pharmacokinetics:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;CPI-444 was absorbed promptly following oral
administration (lag time of less than 0.5&nbsp;hours) with maximum plasma concentrations ("Cmax") observed within four hours of dosing ("tmax"). The plasma half-life ("t1/2") of CPI-444 was
determined to be approximately 10&nbsp;hours after 14&nbsp;days of dosing. Preliminary data indicate that the effect of food on bioavailability of CPI-444 is negligible, indicating that the drug
can be given to fasting or fed patients. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc41901_human_pharmacokinetics_of_cpi-444"> </A>
<A NAME="toc_dc41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Human Pharmacokinetics of CPI-444    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>200 mg Once Daily Oral </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>100 mg Twice Daily Oral </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Day 1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Day 14 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Day 1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Day 14 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cmax (&micro;g/mL)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tmax (h)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cmin (&micro;g/mL)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Not applicable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Not applicable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>t1/2 (h)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Not calculated</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CPI-444 Clinical Development Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2016, we began enrolling patients in a Phase&nbsp;1/1b, open-label, expansion cohort design clinical trial for patients with
selected advanced, incurable cancers. The trial is examining oral CPI-444 administered as both a single agent and in combination with Tecentriq. Under our clinical trial collaboration agreement with
Genentech, we are responsible for the design, conduct and cost of the relevant studies, which are under the review of a joint development committee made up of our representatives and representatives
of Genentech. Genentech supplies Tecentriq. Pre-treatment and on-treatment tissue, blood and serum samples are collected and tested for a wide range of biomarkers including the characteristics of
immune cell infiltrates and expression of numerous genes in tumor tissue samples. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are currently conducting the trial in 35 sites in the United States, Australia and Canada. We have enrolled over 235 patients to date. Patients with NSCLC, MEL, RCC, TNBC, bladder
cancer, prostate cancer or colorectal cancer with high mutation rates are eligible for participation. Studies by others, utilizing anti-CTLA-4 therapies, anti-PD-1 therapies and anti-PD-L1 therapies
have shown that these tumors are more likely to possess immunogenic proteins that are capable of eliciting anti-tumor immune responses. As a result, we believe that selecting patients with these types
of tumors will enhance our chances of identifying patients responsive to CPI-444 therapy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary objectives of our clinical trial for CPI-444, as a single agent and in combination with Tecentriq, are to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluate the safety and tolerability of CPI-444 in cancer patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> determine optimum dosage based on safety, pharmacokinetic and pharmacodynamic data; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assess primary efficacy endpoints: overall response rate, duration of clinical benefit defined as complete response, partial response and
stable disease (stable disease defined as no disease progression for at least 3&nbsp;months). </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assess secondary efficacy endpoints: include progression free survival, duration of response, and overall survival; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=540412,FOLIO='10',FILE='DISK104:[18ZAA1.18ZAA41901]DC41901A.;11',USER='CHE106206',CD=';1-MAR-2018;13:35' -->
<A NAME="page_dc41901_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assess the potential role of various biomarkers to predict or monitor response to therapy. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are conducting the clinical trial of CPI-444 in two steps: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Step 1&#151;Dose Selection:&nbsp;&nbsp;We initiated the first step of the
clinical trial in January 2016. During this step, we determined the appropriate dosing based on safety, pharmacokinetic and biomarker studies. We randomized patients into one of four cohorts, with up
to twelve patients per cohort. In three of the cohorts, we tested single agent CPI-444 at three different doses and schedules as follows: 100 mg twice per day for 14&nbsp;days, 200 mg once per day
for 14&nbsp;days and 100 mg twice per day for 28&nbsp;days. Treatment cycles are 28&nbsp;days and patients continue on therapy until disease progression and/or toxicity. In the fourth cohort, we
evaluated 100 mg twice per day for 14&nbsp;days and then for 28&nbsp;days in combination with a fixed dose of Tecentriq. In each case, patients continued the therapy until there was evidence of
disease progression and/or toxicity. We completed the first step of the clinical trial in November 2016, after enrolling 48 patients, 47 of whom received study treatment and one of whom withdrew from
the study prior to receiving any therapy. The optimum dose of CPI-444 selected for step 2 was based on safety and pharmacodynamics.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Step 2&#151;Dose Expansion:&nbsp;&nbsp;We initiated this portion of the
clinical trial in November 2016. During this step, we have evaluated and plan to further evaluate the selected dose and schedule of CPI-444 as a single agent and in combination with Tecentriq in
disease-specific expansion cohorts. This phase of the study has ten cohorts, with five cohorts receiving single agent CPI-444 at a dose of 100mg twice per day for 28&nbsp;days and five cohorts
receiving the combination of CPI-444 at a dose of 100 mg twice per day for 28&nbsp;days and Tecentriq. Patients are placed into disease-specific cohorts based on type of cancer and prior exposure to
an anti-PD-1 or anti-PD-L1 antibody. Each cohort enrolled up to 14 patients, with cohorts expanded if evidence of anti-tumor activity was shown. If a response (defined as partial or complete tumor
response or disease stabilization for three months or more) in one or more patients out of 14 patients in a cohort was observed, then we expanded that cohort by twelve additional patients to a total
of 26 patients. If a response in five or more patients out of 26 patients in the expanded cohort was observed, then expanded that cohort again by an additional 22 patients, for a total of
48&nbsp;patients. To date, both the single agent and combination arms of the NSCLC and RCC cohorts met the protocol-defined criteria for expansion from 14 to 26 patients, and both arms of the RCC
cohort further met the protocol-defined criteria for expansion to 48 patients. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluation
of responses will be made according to the Response Evaluation Criteria in Solid Tumors ("RECIST") criteria. RECIST is a set of published rules that define when tumors in
cancer patients improve (respond), stay the same (stabilize), or worsen (progress) during treatments. The criteria were published in February 2000 by an international collaboration including the
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, and the National Cancer Institute of Canada Clinical Trials Group. The efficacy endpoints of
the study were response rate and disease control rate (defined as complete response, partial response or stable disease). Partial response ("PR") is defined as tumor regression of more than 30% of the
tumor volume. Disease control is PR plus stable disease ("SD"). SD is reduction in tumor volume of less than 30% and no more than 20% increase in tumor volume. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following is a schematic of the overall study design of our Phase&nbsp;1/1b clinical trial showing three CPI-444 single agent dose selection cohorts and one combination CPI-444 and
Tecentriq cohort followed by disease-specific expansion cohorts that will receive single agent CPI-444 or CPI-444 combined with Tecentriq. The disease cohorts include NSCLC, MEL, RCC, TNBC and one
additional cohort ("Other"), which includes bladder cancer, prostate cancer and colorectal cancer with high mutation rates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=430778,FOLIO='11',FILE='DISK104:[18ZAA1.18ZAA41901]DC41901A.;11',USER='CHE106206',CD=';1-MAR-2018;13:35' -->
<A NAME="page_dc41901_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc41901_phase_1/lb_clinical_trial_protocol"> </A>
<A NAME="toc_dc41901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Phase&nbsp;1/lb Clinical Trial Protocol    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g526457.jpg" ALT="GRAPHIC" WIDTH="655" HEIGHT="483">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CPI-444 Preliminary Clinical Trial Results  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results Presented at the American Association of Cancer Research Annual Meeting&#151;April 2017 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2017, we announced interim results from our Phase&nbsp;1/1b trial at the American Association of Cancer Research Annual Meeting. Interim safety data on 113 patients and
efficacy data for 96&nbsp;patients enrolled in the study were presented. Patients with the following histologies were enrolled: 28% triple negative breast cancer (TNBC); 25% non-small cell lung
cancer (NSCLC); 12% melanoma (MEL); 12% renal cell cancer (RCC) and 23% others. The median age of the patients was 64&nbsp;years. All patients had failed approved therapies for their disease, having
received a median of two prior treatment regimens (range: 1-5), and 56% were resistant or refractory to prior treatment with anti-PD-(L)1 antibodies. Ninety percent of patients had visceral
metastases, including 37% with liver and 9% with brain metastases. For patients with RCC and NSCLC, the median number of prior therapies was four and three, respectively. Seventy-nine percent and 75%,
of RCC and NSCLC&nbsp;patients, respectively, were resistant/refractory to prior anti-PD-(L)1 therapy. The efficacy endpoints of the study are response rate and disease control rate (defined as
complete response, partial response or stable disease). Partial response is defined as tumor regression of more than 30% of the tumor volume. Disease control is partial response plus stable disease.
Stable disease is reduction in tumor volume of less than 30% and no more than 20% increase in tumor volume. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interim
results showed that disease control (with a median follow up of 16&nbsp;weeks, range&nbsp;4-44&nbsp;weeks) was observed in 38% of those receiving CPI-444 as a single agent
(N=52) and in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=391813,FOLIO='12',FILE='DISK104:[18ZAA1.18ZAA41901]DC41901A.;11',USER='CHE106206',CD=';1-MAR-2018;13:35' -->
<A NAME="page_dc41901_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>39%
of those receiving the combination (N=44), for an overall disease control rate of 38% in 96&nbsp;evaluable patients. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
14 patients with tumor regression, three experienced a partial response (regression of more than 30% of the tumor volume) and 11 experienced minor tumor regression (change in tumor
volume of 0% to regression of less than or equal to 30% of the tumor volume). Nine of these patients were resistant or refractory to prior anti-PD-(L)1 therapy. The three patients who experienced a
partial response included one RCC patient who received single-agent CPI-444, and one NSCLC patient and one colorectal cancer patient who both received the combination therapy. The 11 patients who
experienced minor regression of their tumor included seven patients who received single-agent CPI-444 and four who received the combination therapy </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results
Presented at the American Society of Clinical Oncology Annual Meeting&#151;June 2017 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results
for NSCLC (N=45) and RCC (N=30) patients treated on the trial were presented in June 2017 at the American Society of Clinical Oncology. Of 22 evaluable RCC patients, two
experienced a partial response, one of whom received single-agent CPI-444 and had failed prior anti-PD-1 therapy. Sixteen patients had stable disease, with six having stable disease for greater than
six months. Of 34&nbsp;evaluable NSCLC patients, two experienced a partial response (one unconfirmed) and 22 patients had stable disease, with four patients having stable disease for a period
exceeding six months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results
Presented at the Society for Immunotherapy of Cancer Annual Meeting&#151;November 2017 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biomarker,
safety and efficacy data in RCC from our Phase&nbsp;1/1b clinical trial were presented in November 2017 at the Society for Immunotherapy of Cancer Annual Meeting. Of 51
patients with RCC enrolled in the study, 69% were resistant or refractory to prior anti-PD-(L)1 therapy, having failed those therapies within a median time of 1.6&nbsp;months prior to enrollment.
The RCC patients had several adverse prognostic features including visceral metastases (88%), hepatic metastases (20%), anemia (45%) and elevated serum lactate dehydrogenase (21%). Data from 14
patients receiving CPI-444 single agent therapy and 16 receiving combination therapy who were evaluable for response showed:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Four patients experienced a partial response (one confirmed and one unconfirmed with single-agent CPI-444 therapy and two confirmed partial
responses with combination therapy). Both single agent responses occurred in patients resistant or refractory to prior treatment with anti-PD-(L)1. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Disease control (stable disease and partial responses) was achieved in 29% and 69% of patients receiving single agent and combination therapy,
respectively. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Adverse events were similar to previous reports. In both the single-agent and combination arms for the entire safety data set (N=210), Grade 1
and 2 adverse events occurring in five or more percent of patients included fatigue, nausea, pruritis, pyrexia, decreased appetite, diarrhea and anemia. One patient had Grade 3 nausea, vomiting and
diarrhea in the single agent arm. Four patients had a serious Grade 3 toxicity in the combination arm, one with hepatitis, one with pneumonitis, one with hemolytic anemia, and one with hepatitis,
mucositis, pneumonitis and dermatitis. One other patient in the combination arm had both Grade 4 encephalitis and Grade&nbsp;3 thrombocytopenia. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biomarker
analysis, performed on blood and tumor tissues from the RCC and NSCLC cohorts, showed:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Tumor expression of the A2A receptor, CD73 and CD39 was increased in patients resistant to prior treatment with anti-PD-(L)1. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Patients with RCC and NSCLC had high tumor expression of the A2A receptor, CD73 and CD39 in screening, pre-treatment biopsies compared to
patients with other tumors. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=542517,FOLIO='13',FILE='DISK104:[18ZAA1.18ZAA41901]DC41901A.;11',USER='CHE106206',CD=';1-MAR-2018;13:35' -->
<A NAME="page_dc41901_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Biopsies showed that treatment with CPI-444 increased CD8 positive cell infiltration in tumors and induced expression of genes consistent with
Th1 activation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of February&nbsp;20, 2018, there were 63 patients with RCC enrolled in the trial. The disease control rate was 53% in the combination arm and 39% in the single agent arm. There are
6 partial responses (2 unconfirmed) in 57 evaluable patients. There have been 52 patients with NSCLC enrolled with two partial responses (one unconfirmed) and disease control rates are 28% and 16% for
single agent and combination, respectively. No significant change in adverse event profile has been observed. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional CPI-444 Clinical Trials  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe the preliminary data from our clinical trial indicate that CPI-444 has single agent activity in multiple tumor histologies and in
patients refractory to prior therapies with anti-PD-(L)1&nbsp;antibodies. Based on these results, we have entered into a second collaboration agreement with Genentech, pursuant to which it will
evaluate CPI-444 in combination with atezolizumab in patients with NSCLC that have previously failed a platinum containing chemotherapy regimen and an anti-PD-(L)1. This trial, now enrolling patients,
will be conducted under an umbrella protocol known as Morpheus. Up to 65 patients will be enrolled in this trial and compared to a control arm of patients receiving docetaxel, an approved treatment
for NSCLC. We are also planning to amend our ongoing Phase&nbsp;1/1b protocol to enroll up to 50 patients with RCC that have received less prior therapy by limiting enrollment to patients that have
failed only an anti-PD-(L)1 and a tyrosine kinase inhibitor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Product Candidate: A monoclonal anti-CD73 antibody for cancer  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2014, we in-licensed from Scripps a mouse anti-human CD73 antibody, CPI-006. We have genetically engineered CPI-006 to be humanized
by replacing the immunoglobulin ("Ig") heavy and light chain constant regions, and by replacing the murine variable framework regions with human heavy and light chain Ig frameworks. In addition, we
have further engineered CPI-006 to enhance binding to CD73 and to block its catalytic activity, which we expect will inhibit conversion of AMP to adenosine by tumor cells. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Role of CD73 in Cancer  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CD73 is an enzyme expressed on lymphocytes and tumor cells that regulates immune responses by producing immunosuppressive adenosine. The
catalytic production of adenosine by CD73 may play an important role in tumor immune suppression by increasing the concentration of adenosine in the tumor microenvironment. CD73 is overexpressed in
many cancers, and high levels of CD73 have been shown to be associated with poor disease prognosis. CD73 expression on tumor cells as well as on the host immune cells has been shown to promote tumor
immune suppression and metastasis in mice. Other studies in mice have shown that the targeted blockade of CD73 with antibodies can enhance the therapeutic activity of anti-PD-1 and anti-CTLA-4
checkpoint blockade. We believe CD73 and the adenosine-cancer axis may play a role in acquired resistance to anti-PD-(L)1 therapies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical Proof of Concept  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In preclinical studies using tumor cells that express the CD73 enzyme, the addition of various concentrations of CPI-006 to such cells in
culture substantially inhibited the catalytic activity of the enzyme to background levels of the assay. This was studied by measuring the conversion of AMP to adenosine. These studies demonstrated
that at concentrations of 10 &micro;g/ml, CPI-006 was capable of substantially inhibiting the production of adenosine, which indicates that CPI-006 binds to a critical site in the
CD73 enzyme necessary for its function. By blocking the cellular production of adenosine, we </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=185439,FOLIO='14',FILE='DISK104:[18ZAA1.18ZAA41901]DC41901A.;11',USER='CHE106206',CD=';1-MAR-2018;13:35' -->
<A NAME="page_dc41901_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>believe
CPI-006 could lead to enhancement of the anti-tumor immune response by lowering the amount of adenosine in the tumor environment. As compared to other reported anti-CD73 antibodies, CPI-006
has been shown in these preclinical studies to react with the active site of the CD73 enzyme and has not caused internalization of CD73. We believe this means it will act as a more potent blockade of
the enzyme. In in vitro studies with human lymphocytes, CPI-006 has been shown to restore T cell activation in the presence of AMP, indicating blockade of CD73 activity. Other preclinical studies we
conducted have shown that CPI-006 binds to a variety of different types of cancer cell lines </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2>, including those derived from human breast cancer,
lung cancer, lymphoma, leukemias and sarcomas. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-CD73 Development Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An IND for CPI-006 was filed in January 2018. Subject to FDA acceptance of our IND, we plan to conduct a multicenter Phase&nbsp;1/1b expansion
design trial that will evaluate CPI-006 as a single agent, in combination with our adenosine antagonist, CPI-444, and in combination with pembrolizumab (anti-PD-1) in three arms. In each arm, CPI-006
will be administered in increasing doses to cohorts of patients until a maximally tolerated dose is determined for each arm. This will be followed by an expansion stage that will evaluate various
tumor types, including RCC, NSCLC, and other tumors. We intend to initiate this clinical trial in the first quarter of 2018 and may enroll up to 325 patients. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Product Candidate: An antagonist of the adenosine A2B receptor  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have in-licensed several selective and potent adenosine A2B receptor antagonists from Vernalis. In addition, we are synthesizing and have
identified other A2B receptor antagonists from our internal research program. Adenosine A2B receptors have recently been found to play an important role in the immune response to tumors. Similar to
adenosine A2A receptors, adenosine binds to adenosine A2B receptors, which leads to immunosuppression. However, adenosine A2B receptor expression is found on different immune cells, and its function
in tumor induced immune suppression is not yet well understood. We intend to further develop our A2B agents to improve potency, selectivity, pharmacokinetic behavior and immune enhancing properties.
We expect to conduct studies similar to those we have conducted for CPI-444 in order to select a development candidate in 2018. Upon selection, we intend to conduct further IND-enabling studies and
potential Phase&nbsp;1 clinical trials. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ITK Inhibitor  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


ITK and Anti-tumor Immune Response  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ITK is an enzyme expressed predominantly in T-cells where it plays a key role in T-cell signaling. T-cell signaling involving ITK is required in
the development of T-cells within the thymus, where ITK regulates the production of various T-cell subsets and functions. The ITK cell signaling pathway is similar to the signaling that occurs in
B-cells, which is mediated by a homologous enzyme known as BTK, the target of ibrutinib, an approved treatment for patients with B-cell lymphomas and leukemias. We believe that inhibiting ITK in
malignant T-cells may be of therapeutic benefit in patients with T-cell leukemias and lymphomas, analogous to the effects of ibrutinib on B-cell lymphomas and leukemias. In malignant T-cells, ITK was
found to be over-expressed specifically in certain T-cell lymphomas, including peripheral T-cell lymphoma ("PTCL"), angioimmunoblastic T-cell lymphoma ("AITL") and in a
subgroup of T-lymphoblastic leukemia and lymphoma ("T-ALL"). Results presented in February 2018 with our lead compound showed that this orally administered drug demonstrated safety and
anti-tumor activity in two companion dogs with T-cell lymphomas. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
ITK genetic knockout mice, which completely lack expression of ITK, T-cells exhibit defects in T-helper cell differentiation and cytokine secretion but retain the ability to
differentiate into cytotoxic </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=62338,FOLIO='15',FILE='DISK104:[18ZAA1.18ZAA41901]DC41901A.;11',USER='CHE106206',CD=';1-MAR-2018;13:35' -->
<A NAME="page_dc41901_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>T-cells
that secrete IL-2 and IFNg, which are the cells responsible for tumor rejection. We believe that skewing T-helper cell differentiation to favor cytotoxic T-cells may be beneficial in treating
cancer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Product Candidate: An ITK kinase inhibitor  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have identified ITK as a product candidate target because it plays a key role in T-cell receptor signaling and in the differentiation of
T-cells responsible for tumor immunity. Small molecule inhibitors of ITK, such as ibrutinib, have been shown to shift the balance in signaling to enhance anti-tumor immune responses in combination
with a checkpoint inhibitor. While this observation provides important target validation, ibrutinib is primarily a BTK inhibitor and lacks the necessary potency and selectivity for ITK, which is
believed to limit the clinical use of ibrutinib as an ITK inhibitor in this setting. As a result, we believe an inhibitor specifically targeting ITK could enhance anti-tumor immune response. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have developed selective small molecule covalent inhibitors of ITK by targeting the cysteine amino acid residue at position 442 in the ITK protein. Covalent targeting of ITK is
expected to provide a selective and prolonged duration of activity without the need for high systemic exposures and thereby improve the therapeutic window. This approach was previously used by our
co-founders to generate ibrutinib. We have synthesized several covalent ITK inhibitors that are selective for ITK. It is anticipated that this selectivity will mimic the immune properties seen in ITK
knockout mice and skew the immune response toward a more favorable anti-tumor immune response. We have selected a lead development candidate under this program and are currently conducting
IND-enabling studies. Subject to the completion of such studies and the submission and acceptance by the FDA of an IND, we plan to advance the candidate into clinical trials in patients with cancers,
including patients with T-cell lymphoma and other cancers, such as solid tumors, in early 2019. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue to
rely, on third parties for the manufacture of our product candidates for clinical testing, as well as for manufacture of any products that we may commercialize. We are able to internally produce small
quantities of our product candidates required for relatively short preclinical animal studies. We believe that this allows us to accelerate the drug development process by not having to rely on third
parties for all of our research and development needs. However, we currently rely, and expect to continue to rely, on a number of contract manufacturers to produce sufficient quantities of our product
candidates for use in more lengthy preclinical development and clinical trials and in relation to any future commercialization of our product candidates. Additional contract manufacturers are used to
fill, label, package and distribute investigational drug products. This strategy allows us to maintain a more efficient infrastructure, avoid depending on our own manufacturing facility and equipment
while simultaneously enabling us to focus our expertise on developing our products. Although we believe we have multiple potential sources for the manufacturing of our product candidates, we currently
rely on single manufacturers for different components of CPI-444 and CPI-006. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The pharmaceutical and biotechnology industries are characterized by intense competition and rely heavily on the ability to move quickly, adapt
to changing medical and market needs, and to develop and maintain strong intellectual property positions. We believe that the development experience of our scientific and management team, as well as
the strength and promise of our product candidates, provide us with a competitive advantage; nevertheless, we face potential competition from myriad sources, including pharmaceutical and biotechnology
companies, academic institutions, governmental agencies and public and private research institutions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=20,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=323912,FOLIO='16',FILE='DISK104:[18ZAA1.18ZAA41901]DC41901A.;11',USER='CHE106206',CD=';1-MAR-2018;13:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de41901_1_17"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are aware of companies that have advanced adenosine A2A receptor antagonists into early- or late-stage clinical development for non-oncology indications,
primarily Parkinson's disease. These companies include Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. that has evaluated preladenant in Parkinson's disease. In addition, Kyowa Hakko Kirin Pharma,&nbsp;Inc.
has approval in Japan for an adenosine A2A receptor antagonist for use in Parkinson's disease and is currently conducting a Phase&nbsp;3 study in the United States for Parkinson's disease. Within
oncology, Merck has initiated a Phase&nbsp;1 trial with preladenant, an adenosine A2A antagonist in cancer patients with solid tumors, that will be used in combination with pembrolizumab. Novartis
has announced an exclusive licensing agreement with Palobiofarma SL and is conducting a Phase&nbsp;1 trial. AstraZeneca&nbsp;plc has licensed a preclinical A2A antagonist for use in cancer therapy
from Heptares,&nbsp;Inc. Merck KgaA has entered into a pre-clinical collaboration with Domain Therapeutics&nbsp;Inc. to develop programs targeting the adenosine pathway. In addition,
Redoxtherapies,&nbsp;Inc., which was acquired by Juno Therapeutics and Arcus Biosciences,&nbsp;Inc. are developing A2A receptor antagonists for cancer. Astra Zeneca and Bristol-Myers Squib have
initiated clinical trials with anti-CD73 antibodies in cancer patients. More generally, in the field of immuno-oncology, there are large pharmaceutical companies with approved products or products in
late-stage development that target other immune checkpoints, including PD-1, PD-L1 or CTLA-4. These companies include Bristol-Myers Squibb (nivolumab, ipilimumab), Merck (pembrolizumab), Genentech
(atezolizumab) and AstraZeneca (durvalumab, tremelimumab). Also, AstraZeneca and MedImmune&nbsp;LLC have announced the initiation of a Phase&nbsp;1 study with an anti-CD73 antibody. Bristol-Myers
Squibb also announced the development of an anti-CD73 antibody that is now in clinical trials. Arcus has a CD73 inhibitor in preclinical development. Janssen Pharmaceuticals,&nbsp;Inc. and
AbbVie&nbsp;Inc. are co-marketing Imbruvica (ibrutinib), which is a small molecule inhibitor of the kinase BTK that has also been reported to inhibit ITK. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual Property  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business,
including seeking, maintaining and defending patent rights, whether developed internally or licensed from our collaborators or other third parties. We do not yet own any issued patents relating to our
product candidates. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in jurisdictions outside of the United States
covering our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and
know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field
of immuno-oncology. We also plan to rely on data exclusivity, market exclusivity, and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and
maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets; to obtain and maintain licenses to use
intellectual property owned by third parties; to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate without infringing on the valid and
enforceable patents and other proprietary rights of third parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have in-licensed patents and patent applications directed to certain of our product candidates and related uses thereof. We also possess and in-license substantial know-how and trade
secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology. As of February&nbsp;12, 2018, our owned, co-owned, and
licensed patent portfolio consisted of ten licensed U.S. issued patents, three licensed U.S. pending patent applications, one owned U.S. pending patent application, sixteen owned or co-owned U.S.
provisional patent applications, and five owned or co-owned PCT International patent applications directed to CPI-444, CPI-006, and certain of our other proprietary technology, inventions,
improvements or other potential product candidates. In addition, our owned and licensed patent portfolio included forty-four licensed patents, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=21,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=977479,FOLIO='17',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>three
licensed patent applications, and one owned patent application pending in jurisdictions outside of the United States that are foreign counterparts to one or more of the foregoing U.S. patents
and patent applications. The patents and patent applications outside of the United States in our portfolio are held primarily in Europe, Canada, Japan, Australia and China. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the immuno-oncology product candidates and processes we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection
covering, when possible, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issued
patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents
in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20&nbsp;years from the earliest effective
filing date. In addition, in certain instances, the term of an issued United States patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively
lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the
restoration period, must not exceed 14&nbsp;years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but
typically is also 20&nbsp;years from the earliest effective filing date. The issued United States patents we license from Vernalis directed to the composition of matter of CPI-444 and its method of
use for treating disorders treatable by purine receptor blocking are expected to expire between January 2022 and July 2029, excluding any patent term extension that may be available. The pending U.S.
patent application and PCT International patent applications, if granted as patents, that we own directed to the composition of matter and methods of treatment for CPI-006 are expected to expire
between December 2036 and June 2037, excluding any patent term extension that may be available. However, the actual protection afforded by a patent varies on a product-by-product basis, from
country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a
particular country, and the validity and enforceability of the patent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in
patents in the field of immuno-oncology has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent
laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and enforce the patent rights that we license, and could
affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual
property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company-owned
intellectual property, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor
can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even the
issued patents that we license do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the
pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing
our product candidates and practicing our proprietary technology, and the issued patents that we in-license and those that may issue in the future may be challenged, invalidated, or circumvented,
which could limit our ability to stop competitors from marketing related </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=22,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=541480,FOLIO='18',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>products
or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with
protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights
granted under any issued patents that we own or exclusively in-license. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time
required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such
product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Licenses and Collaborations  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vernalis Licensing Agreement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2015, we entered into a license agreement with Vernalis, pursuant to which we were granted an exclusive, worldwide license under
certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor
antagonists, including CPI-444. The issued U.S. patents that we in-licensed from Vernalis pursuant to this agreement are directed to the composition of matter of CPI-444 and its method of use for
treating disorders treatable by purine receptor blocking. These patents are expected to expire in the United States between January 2022 and July 2029, excluding any patent term extension that may be
available. Vernalis has the first right to prosecute and maintain the licensed patent rights worldwide, subject to our right with respect to certain of the licensed patents to continue prosecution and
maintenance if Vernalis elects not to do so. We also have the right to prosecute and maintain any patent rights that we may own that cover the licensed compounds that do not fall within the licensed
patent rights. Pursuant to this agreement, we are required to use commercially reasonable efforts to conduct certain activities to obtain marketing authorizations for licensed products and to conduct
certain preclinical and clinical studies for CPI-444. We also must use commercially reasonable efforts to conduct certain preclinical and clinical studies to support the use of CPI-444 as an
immunotherapeutic agent for cancer studies, and to meet certain specified development, regulatory and commercial milestones within specified time periods. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to this agreement, we made a one-time cash payment to Vernalis in the amount of $1.0&nbsp;million upon entering into the agreement. We are also required to make cash milestone
payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon
achievement of certain sales milestones. In February 2017, we made a milestone payment of $3&nbsp;million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated
with single-agent CPI-444 in our Phase&nbsp;1/1b clinical trial. The aggregate potential milestone payments are approximately $220&nbsp;million for all indications. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing CPI-444 on a product-by-product and country-by-country
basis, subject to certain offsets and reductions. The tiered royalty rates for products containing CPI-444 range from the mid-single digits up to the low-double digits on a country-by-country net
sales basis. The royalties on other licensed products that do not include CPI-444 also increase with the amount of net sales on a product-by-product and country-by-country basis and range from the
low-single digits up to the mid-single digits on a country-by-country net sales basis. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
agreement will expire on a product-by-product and country-by-country basis upon the expiration of our payment obligations to Vernalis in respect of a particular product and country.
Both parties have the right to terminate the agreement in the event of an uncured material breach by the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=23,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=183659,FOLIO='19',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>other
party. We may also terminate the agreement at our convenience by providing 90&nbsp;days written notice, provided that we have not received notice of our own default under the agreement at the
time we exercise such termination right. Vernalis may also terminate the agreement if we challenge a licensed patent or undergo a bankruptcy event. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Scripps Licensing Agreement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2014, we entered into a license agreement with Scripps, pursuant to which we were granted a non-exclusive, world-wide license for
all fields of use under Scripps' rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives
of such hybridoma and any antibodies expressed by such hybridoma. Scripps also granted us the right to grant sublicenses in conjunction with other proprietary rights we hold, or to others
collaborating with or performing services for us. Under
this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
execution of the agreement, we made a one-time cash payment to Scripps of $10,000 and are also obligated to pay a minimum annual fee to Scripps of $25,000. The first minimum annual
fee payment is due on the first anniversary of effective date of the agreement and will be due on each subsequent anniversary of the effective date for the term of the agreement. We are also required
to make performance-based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $2.6&nbsp;million. We are also required to pay
royalties on net sales of licensed products sold by us, our affiliates and our sublicensees at a rate in the low-single digits. In addition, should we sublicense the rights licensed under the
agreement, we have agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed
time from the effective date of the agreement and the time of entry into such sublicense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
license agreement with Scripps will terminate upon expiration of our obligation to pay royalties to Scripps under the license agreement. The license agreement is terminable by the
consent of the parties, at will by us or upon providing 90&nbsp;days written notice to Scripps, or by Scripps for certain material breaches by us, or if we undergo a bankruptcy event. In addition,
Scripps may terminate our license on a product-by-product basis, or the entire agreement, if we fail to meet specified diligence obligations related to the development and commercialization of
licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports we provide to Scripps, that
we have not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Genentech Collaboration Agreements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2015, we entered into a clinical trial collaboration agreement with Genentech to evaluate the safety, tolerability and preliminary
efficacy of CPI-444 combined with Genentech's investigational cancer immunotherapy, Tecentriq, a fully humanized monoclonal antibody targeting PD-L1, in a variety of solid tumors in our
Phase&nbsp;1/1b clinical trial. Pursuant to this agreement, we will be responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of
our representatives and representatives of Genentech. Genentech will supply Tecentriq. As part of the agreement, we granted Genentech certain rights of first negotiation to participate in future
clinical trials that we may conduct evaluating the administration of CPI-444 in combination with an anti-PD-1 or anti-PD-L1 antibody. If we do not reach agreement on the terms of any such
participation by Genentech within a specified time period, we retain the right to collaborate with third parties in such activities. We also granted Genentech certain rights of first negotiation
should we decide to license development and commercialization rights to CPI-444. Should </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=24,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=46487,FOLIO='20',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>we
not reach agreement on the terms of such a license within a specified time period, we retain the right to enter into a license with another third party. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety
considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued. Further, the agreement will expire after a set period of time following the provision
by us of the final clinical study report to Genentech. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2017, we entered into a second clinical trial collaboration agreement with Genentech. Under the new agreement, CPI-444 administered in combination with Tecentriq will be evaluated
in a Phase&nbsp;1b/2 randomized, controlled clinical study as second-line therapy in patients with NSCLC who are resistant and/or refractory to prior therapy with an anti-PD-(L)1 antibody. It is
anticipated that the study will enroll up to 65 patients in the treatment arm. Genentech will be responsible for the conduct of the study and we will share the cost of the Phase&nbsp;1b/2 trial,
which began enrolling patients in the fourth quarter of 2017. We are responsible for supplying CPI-444 and retain global development and commercialization rights to CPI-444. We and Genentech each have
the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory
authority or if development of CPI-444 or Tecentriq is discontinued. Further, the agreement will expire after a set period of time following the provision by us of the final clinical study report to
Genentech. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import
of products such as those we are developing. A new drug must be approved by the FDA through the NDA process and a new biologic must be approved by the FDA through the BLA process before it may be
legally marketed in the United States. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United States Drug Development Process  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act ("FDCA"), and in the case of biologics, also under
the Public Health Service Act ("PHSA"), and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and
foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA's refusal to approve pending applications,
withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government
contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
process required by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> completion of preclinical laboratory tests, animal studies and formulation studies in accordance with GLP regulations and other applicable
regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an IND, which must become effective before human clinical trials may begin; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=25,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=600153,FOLIO='21',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice ("GCP") regulations to establish
the safety and efficacy of the proposed drug for its intended use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an NDA or BLA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance
with current Good Manufacturing Practices (cGMP) requirements to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FDA review and approval of the NDA or BLA. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity
and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND.
The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective
30&nbsp;days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed
clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. All clinical trials must be
conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. They must be conducted under protocols detailing the objectives of the trial, dosing
procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports
must be submitted to the FDA and the investigators for serious and unexpected adverse events. An institutional review board ("IRB") at each institution participating in the clinical trial must review
and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial
subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Phase&nbsp;1</B></FONT><FONT SIZE=2>:&nbsp;&nbsp;The product candidate is initially
introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening
diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. Sponsors
sometimes designate their Phase&nbsp;1 trials as Phase&nbsp;1a or Phase&nbsp;1b. Phase&nbsp;1b trials are typically aimed at confirming dosing, pharmacokinetics and safety in larger number of
patients. Some Phase&nbsp;1b studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Phase&nbsp;2</B></FONT><FONT SIZE=2>:&nbsp;&nbsp;This phase involves clinical trials
in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage
tolerance and appropriate dosage. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=26,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=173376,FOLIO='22',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Phase&nbsp;3</B></FONT><FONT SIZE=2>:&nbsp;&nbsp;Clinical trials are undertaken to
further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall
risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post-approval
trials, sometimes referred to as Phase&nbsp;4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the
treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&nbsp;4 clinical trials as a condition of approval of an NDA or BLA. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical
trial is not being conducted in accordance with the IRB's requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an
independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move
forward at designated check points based on access to certain data from the trial. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the development of a new drug or biologic, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end
of Phase&nbsp;2, and before an NDA or BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data
gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the
Phase&nbsp;2 trial to discuss Phase&nbsp;2 clinical results and present plans for the pivotal Phase&nbsp;3 clinical trial that they believe will support approval of the new drug or biologic. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the
drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. While the IND
is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to
the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to
humans exposed to the same or similar drugs, findings from animal or </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> testing suggesting a significant risk to humans, and any clinically
important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated
products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population,
phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of
their clinical trials after completion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosure
of the results of these trials can be delayed until the new product or new indication being studied has been approved. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=27,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=716660,FOLIO='23',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United States Review and Approval Process  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing
process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the
product. The submission of an NDA or BLA is subject to the payment of user fees; a waiver of such fees may be obtained under certain limited circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA reviews all NDAs and BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional
information rather than accept an NDA or BLA for filing. In this event, the NDA or BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before
the FDA accepts it for filing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA may refer the NDA or BLA to an advisory committee for review, evaluation and
recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such
recommendations. The approval process is lengthy and often difficult, and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional
clinical or other data and information. Even if such data and information are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. The FDA reviews
an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product's identity,
strength, quality and purity. The FDA reviews a BLA to determine, among other things whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packed or
held meets standards designed to assure the product's continued safety, purity and potency. Before approving an NDA or BLA, the FDA will inspect the facility or facilities where the product is
manufactured. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing
information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete
Response Letter usually describes the specific deficiencies in the NDA or BLA identified by the FDA and may require
additional clinical data, such as an additional pivotal Phase&nbsp;3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a
Complete Response Letter is issued, the sponsor must resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and
information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. If a product receives regulatory approval, the approval may be significantly limited to
specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct
Phase&nbsp;4 testing, which involves clinical trials designed to further assess a drug's safety and effectiveness after NDA or BLA approval, and may require testing and surveillance programs to
monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy
("REMS") to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if
required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for
non-compliance with regulatory requirements or if problems occur following initial marketing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=28,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=248125,FOLIO='24',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Food and Drug Administration Safety and Innovation Act ("FDASIA") made permanent the Pediatric Research Equity Act ("PREA"), which requires a sponsor to conduct pediatric clinical
trials for most drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs and supplements
thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed
indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request
a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for
approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must
send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a
disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the
cost of developing and making a drug or biologic product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be
requested before submitting an NDA or BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan
designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan
product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug or
biologic also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. However, competitors, may receive
approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has
exclusivity. Orphan exclusivity also could block the approval of one of our product candidates for seven years if a competitor obtains approval of the same drug or biologic as defined by the FDA or if
our product candidate is determined to be contained within the competitor's product for the same indication or disease. If an orphan designated product receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan exclusivity. Orphan drug status in the European Union has similar but not identical benefits in that jurisdiction. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we have not sought or obtained orphan designation for any of our product candidates, we may pursue such designation in the future if we determine that our proposed indications
meet the qualifying criteria for such designation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expedited Development and Review Programs  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain
criteria. Specifically, new drugs are eligible
for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=29,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=510863,FOLIO='25',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>demonstrate
the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is
being studied. Unique to a Fast Track product, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a
schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the sponsor pays any required
user fees upon submission of the first section of the NDA or BLA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
product submitted to the FDA for approval, including a product with a Fast Track designation, may also be eligible for other types of FDA programs intended to expedite development
and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative
therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation
of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of
the filing date as compared to ten months for review of original BLAs and new molecular entity NDAs under its standard review goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, a product may be eligible for accelerated approval. Drug and biologic products intended to treat serious or life-threatening diseases or conditions may be eligible for
accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured
earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity,
rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval
perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could
adversely impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the
development or approval process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FDASIA
established a new category of drugs and biologics referred to as "breakthrough therapies" that may be eligible to receive Breakthrough Therapy Designation. A sponsor may seek FDA
designation of a drug or biologic candidate as a "breakthrough therapy" if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track
program features, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy Designation is a distinct status from both accelerated approval and priority review, which can also
be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will expedite the development and review of such drug. All requests for
breakthrough therapy designation will be reviewed within 60&nbsp;days of receipt, and the FDA will either grant or deny the request. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-approval requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur
after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the
market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=30,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=663211,FOLIO='26',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_de41901_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>labeling
claims, are subject to further FDA review and approval. Drug and biologics manufacturers and other entities involved in the manufacture and distribution of approved drugs and biologics are
required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP
regulations and other laws and regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
drug products manufactured or distributed by us or our partners pursuant to FDA approvals will be subject to continuing regulation by the FDA, including, among other things,
record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with
certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of
information on products that are placed on the market and imposes requirements and restrictions on drug and biologics manufacturers, such as those related to direct-to-consumer advertising, the
prohibition on promoting products for uses or in patient populations that are not described in the product's approved labeling (known as "off-label use"), industry-sponsored scientific and educational
activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions
on the marketing of a product or withdrawal of the product from the market as well as possible civil or
criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or
manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical
hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated
corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Term Restoration and Marketing Exclusivity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and specifics of FDA approval of our product candidates, some of the U.S. patents that we may be granted in
the future may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration
cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the product's approval date. The patent term restoration period is generally one-half the time between the effective
date of an IND and the submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the approval of that application, less any time the applicant did not act with
due diligence. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The United States Patent and
Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for
patents that may be issued to us, depending on the expected length of clinical trials and other factors involved in the filing of the relevant marketing application. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=31,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=118721,FOLIO='27',FILE='DISK104:[18ZAA1.18ZAA41901]DE41901A.;6',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg41901_1_28"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period
of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not
previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not
approve or even accept for review an abbreviated new drug application ("ANDA") or a NDA submitted under Section&nbsp;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based
on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a
legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one
of the patents listed with the FDA by the innovator NDA holder. The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new
indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and
does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not
delay the submission or approval of a full NDA. However, an applicant submitting a
full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and
effectiveness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
exclusivity is a type of marketing exclusivity available in the United States. Pediatric exclusivity under the Best Pharmaceuticals for Children Act ("BPCA") provides for an
additional six months of marketing exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. If such written request does not include clinical trials
in neonates, the FDA is required to include its rationale for not requesting those clinical trials. The FDA may request studies on approved or unapproved indications in separate written requests. The
issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of
marketing exclusivity, except in certain circumstances. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Biosimilars and Exclusivity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an
abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, few biosimilars have been licensed under the
BPCIA, although numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be
shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate
that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the
reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference
biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=32,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=822395,FOLIO='28',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>well
as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being addressed by the FDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In
addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period
of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor's own preclinical data and
data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as
interchangeable products. At this juncture, it is unclear whether products deemed "interchangeable" by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy
law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the twelve-year reference product
exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact,
implementation and meaning of the BPCIA is subject to significant uncertainty. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation Outside of the United States  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other
things, clinical studies and any commercial sales and distribution of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
or not we obtain FDA approval for a product candidates, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of
clinical studies or marketing of the product candidates in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical study
application much like the IND prior to the commencement of human clinical studies. In the European Union, for example, a clinical trial authorization ("CTA") must be submitted to each country's
national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved in accordance with a country's requirements, clinical study
development may proceed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
requirements and process governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical studies are
conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
obtain regulatory approval of an investigational biological product under European Union regulatory systems, we must submit a marketing authorization application. The application used
to file the BLA in the United States is similar to that required in the European Union, with the exception of, among other things, country-specific document requirements. The European Union also
provides opportunities for market exclusivity. For example, in the European Union, upon receiving marketing authorization, new chemical entities generally receive eight years of data exclusivity and
an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator's data to assess a generic application.
During the additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator's data may be referenced, but no generic product can be marketed
until the expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the European Union's regulatory authorities to be a new chemical entity, and
products may not qualify for data exclusivity. Products receiving orphan designation in the European Union can receive ten years of market exclusivity, during which time no similar medicinal product
for the same indication </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=33,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=590658,FOLIO='29',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>may
be placed on the market. An orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection
certificate can be granted on the basis of pediatric studies for orphan indications. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
criteria for designating an "orphan medicinal product" in the European Union are similar in principle to those in the United States. Under Article&nbsp;3 of Regulation (EC)
141/2000, a medicinal product may be designated as orphan if (1)&nbsp;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition;
(2)&nbsp;either (a)&nbsp;such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&nbsp;the product, without the benefits derived from
orphan status, would not generate sufficient return in the European Union to justify investment; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such
condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC)
847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market
exclusivity for the approved therapeutic indication. The application for orphan drug designation must be submitted before the application for marketing authorization. The applicant will receive a fee
reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted.
Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for
example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition, marketing authorization may be granted to a similar product for the same indication at
any time if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicant consents to a second orphan medicinal product application; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicant cannot supply enough orphan medicinal product. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical studies, product
licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the
ethical principles that have their origin in the Declaration of Helsinki. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls,
seizure of products, operating restrictions and criminal prosecution. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Healthcare Laws  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to FDA restrictions on marketing of pharmaceutical and biological products, other U.S. federal and state healthcare regulatory laws
restrict business practices in the pharmaceutical industry, which include, but are not limited to, state and federal anti-kickback, false claims, data privacy and security and physician payment
transparency laws. These laws may affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements we may have with physicians, customers and third-party
payors including discount practices, customer support, education and training programs, physician consulting and other service arrangements. In addition, manufacturers can be held liable under the
False Claims Act even when they do not submit claims directly to government payors if they are deemed to "cause" the submission of false or fraudulent claims by, for example, providing </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=34,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=484228,FOLIO='30',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>inaccurate
billing or coding information to customers or promoting a product off-label. These laws are broadly written, and it is often difficult to determine precisely how these laws will be applied
to specific circumstances. Such laws include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully offering, paying,
soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the
purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual
knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The federal false claims and civil monetary penalties laws, including the False Claims Act, which prohibit any person or entity from, among
other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or knowingly making, using or causing to
be made or used a false record or statement material to a false or fraudulent claim to the federal government; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which prohibits, among other actions, knowingly and
willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a
healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Physician Payments Sunshine Act, which imposed, among other things, new annual reporting requirements for covered manufacturers for certain
payments and "transfers of value" provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act ("HITECH"), and their respective implementing
regulations, impose specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and
claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation,
administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our
operations, exclusion from participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial
results. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for
instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=35,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=950170,FOLIO='31',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>implementation
of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Coverage and Reimbursement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain
regulatory approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on
third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a
significant portion of the cost of our products. Sales of any product candidates for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of
coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities, managed care plans, private health insurers and other organizations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product typically is separate from the process for setting the price of
such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved
list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a third-party payor not to cover our product candidates could
reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor's decision to
provide coverage for a pharmaceutical or biological product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to
maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, coverage and reimbursement for new products can differ significantly from payor
to payor. One third-party payor's decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will
provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor
separately and will be a time consuming process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of pharmaceutical or biological products have been a focus in this
effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical
products, biological products, medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our product candidates to be
cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at
a profit. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare Reform  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have
attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March 2010, the Affordable Care Act was enacted, which, among other
things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid
Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals
enrolled in Medicaid managed care plans; imposed </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=36,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1031517,FOLIO='32',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>mandatory
discounts for certain Medicare Part&nbsp;D beneficiaries as a condition for manufacturers' outpatient drugs coverage under Medicare Part&nbsp;D; subjected drug manufacturers to new
annual fees based on pharmaceutical companies' share of sales to federal healthcare programs, and created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and
conduct comparative clinical effectiveness research, along with funding for such research. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that the current presidential administration and U.S. Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the
Affordable Care Act. The impact that President Trump's administration and the U.S. Congress may have, if any, is uncertain and any changes will likely take time to unfold, and could have an impact on
coverage and reimbursement for healthcare items and services covered by plans that were authorized by the Affordable Care Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower
reimbursement, and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a
similar reduction in payments from private payors. Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has
resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Additionally, individual states in the United
States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. The
implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015 led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that will
remain in effect through 2025 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, further
reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for
healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development expenses were $46.3&nbsp;million, $29.4&nbsp;million and $11.4&nbsp;million for the years ended
December&nbsp;31, 2017, 2016, and 2015, respectively. Please see "Management's Discussion and Analysis of Financial Condition and Results of Operations-Research and Development Expenses" for
additional detail regarding our research and development activities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Environment  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our third-party manufacturers are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including
U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change
frequently and have tended to become more </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=37,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=704988,FOLIO='33',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>stringent
over time. We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. We would be subject to significant penalties
for failure to comply with these laws and regulations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, we had 55 total employees, all of whom were full-time and 45 of whom were primarily engaged in research and
development activities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently lease a total of approximately 28,633 square feet of office and research and development facilities in Burlingame, California. Our
lease expires in 2021. We regularly explore alternatives which would provide us with additional space to accommodate our anticipated growth. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not currently a party to any material legal proceedings. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in Delaware on January&nbsp;27, 2014 and began operations in November 2014. Our principal executive offices are located
at 863 Mitten Road, Suite&nbsp;102, Burlingame, California&nbsp;94010, and our telephone number is (650)&nbsp;900-4520. Our website address is http://corvuspharma.com. The information on our
website is not incorporated by reference in this Annual Report on Form&nbsp;10-K or in any other filings we make with the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). We will remain an emerging growth company until the earlier of
(1)&nbsp;December&nbsp;31, 2021, (2)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (3)&nbsp;the last day of the fiscal year
in which we are deemed to be a "large accelerated filer" as defined in Rule&nbsp;12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates
exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such fiscal year, or (4)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other
significant requirements that are otherwise generally applicable to public companies. As an emerging growth company, </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may present only two years of audited consolidated financial statements, plus unaudited condensed consolidated financial statements for any
interim period, and related management's discussion and analysis of financial condition and results of operations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our
internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may provide less extensive disclosure about our executive compensation arrangements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We may not require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have chosen to opt out of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new
or revised accounting standards. Section&nbsp;107 of the JOBS Act provides that our decision to opt out of the extended transition periods for complying with new or revised accounting standards is
irrevocable. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=38,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1041439,FOLIO='34',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financial Information about Segments  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We view our operations and manage our business as one reportable segment. See Note&nbsp;2 to our audited consolidated financial statements
included in this Annual Report on Form&nbsp;10-K. Additional information required by this item is incorporated herein by reference to Part&nbsp;II, Item&nbsp;6, "Selected Financial Data." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Available Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file electronically with the SEC our annual reports on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q and current reports on
Form&nbsp;8-K pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. We make available on our website at http://corvuspharma.com, free of charge, copies of
these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The public may read or copy any materials we file with the SEC at the SEC's
Public Reference Room at 100&nbsp;F Street NE, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC
maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov.
The information on or accessible through the SEC and our website is not incorporated into, and is not considered part of, this filing. Further, our references to the URLs for these websites are
intended to be inactive textual references only.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dg41901_item_1a._risk_factors"> </A>
<A NAME="toc_dg41901_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1A.&nbsp;&nbsp;&nbsp;&nbsp;Risk Factors    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Our business involves significant risks, some of which are described below. You should consider carefully the risks and
uncertainties described below, together with all of the other information in our Annual Report on Form&nbsp;10-K, including our audited consolidated financial statements and related notes included
elsewhere in this Annual Report on Form&nbsp;10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations.". If any of the following risks are realized, our
business, financial condition, results of operations and prospects could be materially and adversely affected. Additional risks and uncertainties not presently known to us or that we currently deem
immaterial may also impair our business operations.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have a limited operating history, have incurred significant operating losses since our inception and
expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly
speculative undertaking and involves a substantial degree of risk. To date, we have focused primarily on developing our lead product candidate, CPI-444, which is currently our only product candidate
that has undergone clinical development, and researching additional product candidates. We have incurred significant operating losses since we were founded in January 2014 and have not yet generated
any revenue from sales. If our product candidates are not approved, we may never generate any revenue. We incurred a net loss of $55.7&nbsp;million, $36.4&nbsp;million and $31.3&nbsp;million for
the years ended December&nbsp;31, 2017, 2016 and 2015, respectively. We had an accumulated deficit of $123.5&nbsp;million as of December&nbsp;31, 2017. We expect to continue to incur losses for
the foreseeable future, and we anticipate these losses will increase as we continue our development of, seek regulatory approval for and begin to commercialize CPI-444, and as we develop other product
candidates. Even if we achieve profitability in the future, we may not be able to sustain it in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue
to have an adverse effect on our stockholders' equity and results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=39,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=252077,FOLIO='35',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary
capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since commencing our operations in 2014, the majority of our efforts have been focused on the research and development of CPI-444. We believe
that we will continue to expend substantial resources for the foreseeable future as we continue clinical development of, seek regulatory approval for and prepare for the commercialization of CPI-444,
as well as develop other product candidates, including our lead development candidates under our anti-CD73 program, CPI-006, and ITK program. These expenditures will include costs associated with
research and development, conducting preclinical studies and clinical trials, obtaining regulatory approvals, manufacturing and supply, sales and marketing and general operations. In addition, other
unanticipated costs may arise. Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, we may not be able to accurately estimate the actual amounts necessary
to successfully complete the development, regulatory approval process and commercialization of CPI-444 or any other product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2016, we completed our initial public offering ("IPO"), of our common stock pursuant to which we received proceeds of approximately $63.6&nbsp;million, net of underwriting
discounts and commission, and offering expenses. In April 2016, the underwriters exercised their option to purchase an additional 502,618 shares of our common stock, pursuant to which we received
additional proceeds of approximately $7.0&nbsp;million, net of underwriting discounts and commission, and offering expenses. As of December&nbsp;31, 2017, we had capital resources consisting of
cash, cash equivalents and marketable securities of $90.1&nbsp;million. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials
and remaining development program of CPI-444 through commercialization. In addition, our operating plan may change as a result of many factors, including those described below as well as others
currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity, including pursuant to the Sales Agreement we entered into with Cowen and
Company,&nbsp;LLC on September&nbsp;20, 2017 in connection with our at-the-market offering (the "Sales Agreement"), debt financings or other sources, such as strategic collaborations. Such
financing would result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business. If we raise additional capital through
strategic collaboration agreements, we may have to relinquish valuable rights to our product candidates, including possible future revenue streams. In addition, additional funding may not be available
to us on acceptable terms, or at all, and any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and
commercialize our product candidates. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market
conditions or strategic considerations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amount and timing of any expenditures needed to implement our development and commercialization programs will depend on numerous factors, including, but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the type, number, scope, progress, expansions, results of and timing of our planned clinical trials of CPI-444 and any of our planned
preclinical studies and clinical trials of other product candidates which we are pursuing or may choose to pursue in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the need for, and the progress, costs and results of, any additional clinical trials of CPI-444 or any of our other product candidates we may
initiate based on the results of our planned clinical trials or discussions with the FDA, including any additional trials the FDA or other regulatory agencies may require; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=40,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=36651,FOLIO='36',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of obtaining or maintaining manufacturing for CPI-444 and our other product candidates, including commercial manufacturing
if any product candidate is approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of establishing sales and marketing capabilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to achieve sufficient market acceptance, coverage and reimbursement from third-party payors and adequate market share for our
product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms and timing of establishing collaborations, license agreements and other partnerships; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> costs associated with any new product candidates that we may develop, in-license or acquire; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the effect of competing technological and market developments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to attract, hire and retain qualified personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to establish and maintain partnering arrangements for development; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs associated with being a public company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Several
of these factors are outside of our control and if we are unable to obtain funding on a timely basis, we will be unable to complete the clinical trials for CPI-444 and our other
product candidates, and we may be required to significantly curtail some or all of our activities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to the Discovery and Development of Our Product Candidates  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business currently depends substantially on the success of CPI-444, which will require significant
clinical testing before we can seek regulatory approval and potentially launch commercial sales, and which may not be successful in clinical trials, receive regulatory approval or be successfully
commercialized, even if approved. If we are unable to obtain regulatory approval for, or successfully commercialize, CPI-444, our business will be materially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our product candidates are in the early stage of development and will require additional preclinical studies (other than CPI-444), substantial
clinical development and testing, manufacturing bridging studies and process validation and regulatory approval prior to commercialization. To date, only CPI-444 has been the focus of advanced
development efforts. We have invested, and will continue to invest, a significant portion of our time and financial resources in the development of CPI-444. However, we need to raise sufficient funds
for, and successfully enroll and complete, our planned clinical trials of CPI-444. We cannot be certain that CPI-444 will be successful in clinical trials, and CPI-444 may not receive regulatory
approval even if it is successful in clinical trials. Even if we do receive regulatory approval necessary for the commercialization of CPI-444, we do not expect that such commercialization will occur
for at least the next several years. In particular, the future regulatory and commercial success of CPI-444 is subject to a number of risks, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not have sufficient financial and other resources to complete the necessary clinical trials for CPI-444; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not be able to demonstrate evidence of efficacy and safety for CPI-444 to the satisfaction of regulatory authorities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable foreign
regulatory bodies for marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subjects in our clinical trials, or the trials of our collaborators, may die or suffer other adverse effects for reasons that may or may not be
related to CPI-444; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we do not know the degree to which CPI-444 will be accepted as a therapy, even if approved; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=41,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=971994,FOLIO='37',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not be able to obtain, maintain or enforce our patents and other intellectual property rights. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
the large number of drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a New Drug Application ("NDA") or Biologics License
Application ("BLA") to the FDA or comparable marketing applications to foreign regulatory authorities, and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory
approval to market CPI-444, any such approval may be subject to limitations on the indicated uses for which we may market the product. Accordingly, even if we are able to obtain the requisite
financing to continue to fund our development programs, we cannot assure our stockholders that CPI-444 will be successfully developed or commercialized. If we or any of our potential future
collaborators are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize CPI-444, we may not be able to generate sufficient revenue to continue our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results
of preclinical studies and early clinical trials are not necessarily predictive of future results. Any product candidate we or any of our potential future collaborators advance into clinical trials,
including CPI-444, may not have favorable results in later clinical trials, if any, or receive regulatory approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during
the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product
candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of
companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in
earlier trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
our future trials will need to demonstrate sufficient safety and efficacy for approval by regulatory authorities in larger patient populations. Prior to licensing our lead
product candidate, CPI-444, it exhibited encouraging safety data in clinical studies performed by third parties. However, previous studies with CPI-444 had only been conducted in healthy volunteers
and patients with attention deficit and hyperactivity disorder ("ADHD"). Since the initiation of our Phase&nbsp;1/1b clinical trial in January 2016, CPI-444 been administered to cancer patients and,
while it has been well tolerated to date, there have been possibly drug-related or drug-related serious adverse events observed during the trial, and limited information is available concerning safety
and efficacy. It is possible that patients enrolled in our Phase&nbsp;1/1b clinical trial for CPI-444 could respond in unexpected ways. For instance, older patients with cancer may behave
differently and experience more toxicity with CPI-444 than the subjects in the prior clinical studies. In addition, the dosing regimen and duration of treatment in our current Phase&nbsp;1/1b
clinical trial is different from those utilized in the studies previously performed by third parties. In addition, our Phase&nbsp;1/1b clinical trial is conducted in patients with advanced cancers
who have failed other approved therapies for their disease, and as such, it may be difficult to establish safety and efficacy in this type of patient population. Furthermore, a portion of our
Phase&nbsp;1/1b clinical trial and Genentech's planned Phase&nbsp;1b/2 clinical trial under our collaboration agreement, includes the administration of CPI-444 in combination with Genentech's
cancer immunotherapy, Tecentriq, and we have recently been enrolling patients with various cancers to investigate higher doses of our drug as part of a protocol amendment, both of which could
exacerbate immune system related adverse events, cause increased toxicity or otherwise lead to unexpected adverse events. As a result, there can be no assurance that the results of historical clinical
studies of CPI-444 conducted by third parties will be indicative of the results of our Phase&nbsp;1/1b clinical trial, Genentech's planned Phase&nbsp;1b/2 clinical trial or any future clinical
trial of CPI-444. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=42,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=539648,FOLIO='38',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_dg41901_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to initiate and begin enrolling patients in our Phase&nbsp;1/1b trial evaluating CPI-006 in early 2018. No human safety data is available for CPI-006 alone or when given in
combination with other agents, however we currently expect that successive cohorts of enrolled patients will receive increasing doses of CPI-006 alone, or in combination with CPI-444 or pembrolizumab
(anti-PD-L-1). Similar to our Phase&nbsp;1/1b clinical trial of CPI-444, it is possible that patients enrolled in our Phase&nbsp;1/1b clinical trial for CPI-006 could respond in unexpected ways.
As a result, there can be no assurance that we will be able to establish the safety and efficacy of CPI-006 or that we will be able to successfully complete our planned clinical trial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the foregoing reasons, we cannot be certain that our ongoing or planned clinical trials or any other future clinical trials will be successful. Any safety concerns observed in any
one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse
effect on our business, financial condition and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any termination or suspension of, or delays in the commencement or completion of, our planned clinical trials
could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before we can initiate clinical trials in the United States for our product candidates (other than CPI-444), we must submit the results of
preclinical testing to the FDA along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an
investigational new drug ("IND") application. In addition, we may rely in part on preclinical, clinical and quality data generated by clinical research organizations ("CROs") and other third parties
for regulatory submissions for our product candidates. If these third parties do not make timely regulatory submissions for our product candidates, it will delay our plans for our clinical trials. If
those third parties do not make this data available to us, we will likely have to develop all necessary preclinical and clinical data on our own, which will lead to significant delays and increase
development costs of the product candidate. In addition, the FDA may require us to conduct additional preclinical testing for any product candidate before it allows us to initiate clinical testing
under any IND, which may lead to additional delays and increase the costs of our preclinical development. Delays in the completion of our planned clinical trials for product candidates could
significantly affect our product development costs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we initiated our Phase&nbsp;1/1b trial for CPI-444 in January 2016, we do not know whether any of our other planned trials will begin on time in the future or whether any of our
trials will be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA failing to grant permission to proceed or placing the clinical trial on hold; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subjects failing to enroll or remain in our trial at the rate we expect; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subjects choosing an alternative treatment for the indication for which we are developing CPI-444 or other product candidates, or participating
in competing clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> lack of adequate funding to continue the clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subjects experiencing severe or unexpected drug-related adverse effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a facility manufacturing CPI-444, any of our other product candidates or any of their components being ordered by the FDA or other regulatory
authorities to temporarily or permanently shut down due to violations of good manufacturing practice ("cGMP") regulations or other applicable requirements, or infections or cross-contaminations of
product candidates in the manufacturing process; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=43,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=712449,FOLIO='39',FILE='DISK104:[18ZAA1.18ZAA41901]DG41901A.;8',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di41901_1_40"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any changes to our manufacturing process that may be necessary or desired; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any failure or delay in reaching an agreement with CROs and clinical trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials
on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices ("GCP") or regulatory requirements or other third parties not performing data collection or analysis
in a timely or accurate manner; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for
violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our
marketing applications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> one or more Institutional Review Boards ("IRBs") refusing to approve, suspending or terminating the trial at an investigational site,
precluding enrollment of additional subjects, or withdrawing its approval of the trial; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patients failing to complete a trial or return for post-treatment follow-up. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety
Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the
clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in
the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions
or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with
these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our
ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product
candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. See
also the risk factor below titled "If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the
denial of regulatory approval of a product candidate. For example, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our
modified product candidates to earlier versions. Further, if one or more clinical trials are delayed, our competitors may be able to bring products to market before we do, and the commercial viability
of CPI-444 or other product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=44,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=375913,FOLIO='40',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


CPI-444 and our other product candidates are subject to extensive regulation, compliance with which is costly
and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution
of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable authorities in foreign markets. In the United States, we are not permitted to market our
product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type,
complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion
in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product
candidates, regulatory approval is never guaranteed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such authorities may disagree with the design or implementation of our or any of our potential future collaborators' clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we or any of our potential future collaborators may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities
that a product candidate is safe and effective for any indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care
is potentially different from that of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we or any of our potential future collaborators may be unable to demonstrate that a product candidate's clinical and other benefits outweigh
its safety risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant
restrictions on distribution and use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we or any of our
potential future collaborators contract for clinical and commercial supplies; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our potential future
collaborators' clinical data insufficient for approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods
and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable
foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in
obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=45,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=869227,FOLIO='41',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities
could be delayed or otherwise adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the
patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical
trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and clinicians' and patients' perceptions as to the potential
advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. We will be required
to identify and enroll a sufficient number of subjects for each of our clinical trials. Potential subjects for any planned clinical trials may not be adequately diagnosed or identified with the
diseases which we are targeting or may not meet the entry criteria for our studies. We also may encounter difficulties in identifying and enrolling subjects with a stage of disease appropriate for our
planned clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects to participate in the clinical trials required
by the FDA or other foreign regulatory agencies. In addition, the process of finding and diagnosing subjects may prove costly. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our ongoing trial of CPI-444, we have enrolled over 235 patients with many different types of cancer and disease specific cohorts for renal cell cancer and non-small cell lung cancer
are continuing to enroll. We have also been adding patients with various cancers to investigate higher doses of our drug as part of a protocol amendment. We also anticipate enrolling patients with
many different types of cancer in our Phase&nbsp;1/1b trial of CPI-006. If patients are unwilling to participate in our studies for any reason, including the existence of competitive clinical trials
for similar patient populations, the availability of approved therapies or negative perceptions of the safety or efficacy of our product candidates, the timeline for recruiting subjects, conducting
studies and obtaining regulatory approval of
our product candidates may be delayed. Our inability to enroll a sufficient number of subjects for any of our future clinical trials would result in significant delays or may require us to abandon one
or more clinical trials altogether. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe we have appropriately accounted for the above factors in our trials when determining expected clinical trial timelines, but we cannot assure our stockholders that our
assumptions are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The occurrence of serious complications or side effects in connection with use of our product candidates,
either in clinical trials or post-approval, could lead to discontinuation of our clinical development programs, refusal of regulatory authorities to approve our product candidates or, post-approval,
revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business, prospects, operating results and financial condition.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their study
doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. In clinical studies of CPI-444 performed by third parties prior to our
licensing it from Vernalis, patients exhibited mild transient hypertension as well as minor gastrointestinal disorders due to gastric irritation. However, the dosing regimen and duration of treatment
in our current Phase&nbsp;1/1b clinical trial is different from those utilized in the studies previously performed by third parties. It is possible that as we test our product candidates in larger,
longer and more extensive clinical programs with different dosing regimens and in combination with other immunotherapies, or as use of these product candidates becomes more widespread if they receive
regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials,
will be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=46,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=277995,FOLIO='42',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reported
by subjects. For example, possibly drug-related or drug-related serious adverse events have been observed during our Phase&nbsp;1/1b clinical trial in patients receiving combination therapy
with CPI-444 and Tecentriq include hemolytic anemia, encephalitis, hepatitis, pneumonitis, mucositis and dermatitis. Other toxicities observed during our Phase&nbsp;1/1b clinical trial were mild and
are commonly seen in patients with advanced cancers, such as nausea, vomiting, fatigue, rash, diarrhea, fever, abdominal pain, cough, constipation and decreased appetite. Other immune-oncology drugs
also have been found occasionally to induce immune related toxicities such as colitis, hepatitis, pneumonitis, meningitis and various endocrine diseases. Such side effects could also be exacerbated
when CPI-444 is administered in combination with Tecentriq which is provided for in a portion of our Phase&nbsp;1/1b clinical trial as well as in Genentech's planned Phase&nbsp;1b/2 clinical trial
under our collaboration agreement, or
when CPI-444 is administered in higher doses, which we have begun exploring as part of a protocol amendment. In addition, CPI-444 is known to bind to the A1 adenosine receptor. This receptor is
expressed in the heart, and although CPI-444 binds to the A1 receptor at a low affinity, it is possible that sufficient binding of the drug to the A1 receptor could occur, leading to adverse effects
on the heart such as irregular heart rate or rapid heart rate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to initiate and begin enrolling patients in our Phase&nbsp;1/1b trial evaluating CPI-006 in the first quarter of 2018. We expect that successive cohorts of enrolled patients
will receive increasing doses of CPI-006 alone, or in combination with CPI-444 or pembrolizumab (anti-PD-L-1). No human safety data is available for CPI-006 alone or when given in combination with
other agents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
times side effects are only detectable after investigational products are tested in large-scale, Phase&nbsp;3 clinical trials or, in some cases, after they are made available to
patients on a commercial scale after approval. Results of our current clinical trial and any future clinical trials we undertake could reveal a high and unacceptable severity and prevalence of these
or other side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny
approval of our product candidates for any or all targeted indications. Drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result
in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of
potentially significant negative consequences could result, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may withdraw approvals of such product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may require additional warnings on the label; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we could be sued and held liable for harm caused to patients; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results
of operations and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in our efforts to identify or discover additional product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The success of our business depends primarily upon our ability to develop and commercialize CPI-444. Although CPI-444 is currently in clinical
development, our research programs may fail to identify other potential product candidates or advance them into and through clinical development for a number of reasons. Our research methodology may
be unsuccessful in identifying other potential </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=47,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=729040,FOLIO='43',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>product
candidates or our other potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive
marketing approval. It may also take greater human and financial resources to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product
candidates through our research programs than we will possess, thereby limiting our ability to diversify and expand our product candidate portfolio. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are conducting a clinical trial for CPI-444, and may also in the future, conduct clinical trials of other
product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in foreign locations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently conducting our clinical trial for CPI-444 at 35 leading medical centers in the U.S., Australia and Canada. In the future we may
add additional clinical sites outside of the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain
conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The study population
must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the
patient population for any clinical studies conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition,
while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the studies also complied with all applicable U.S. laws
and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from our clinical trials for CPI-444 or any
other product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of CPI-444 or any other
product candidates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Reliance on Third Parties  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely, and expect to continue relying, on third parties to conduct our clinical trials. If these third
parties do not meet our deadlines or otherwise conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval
for or commercialize our product candidates when expected, or at all.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are dependent on
third parties to conduct our Phase&nbsp;1/1b clinical trial for CPI-444 and expect to continue to be dependent on third parties to conduct any future clinical studies of CPI-444, our planned
clinical trial of CPI-006 and preclinical and clinical trials for our other product candidates. The timing of the initiation and completion of these trials will therefore be controlled by such third
parties and may occur at times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, CROs and consultants to conduct our trials in
accordance with our clinical protocols and regulatory requirements. Such CROs,
investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data, and we will control only certain aspects of their
activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our
reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines
enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area ("EEA") and comparable foreign regulatory authorities for all of our product candidates in clinical
development. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=48,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1046923,FOLIO='44',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply
with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional
clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these
regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no guarantee that any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of
these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be
extended, delayed or terminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to
transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in
connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have
affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized,
which could result in the delay or rejection of any NDA or BLA we submit by the FDA. Any such delay or rejection could prevent us from commercializing CPI-444 or our other product candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties to conduct some or all aspects of our manufacturing, research and preclinical and
clinical testing, and these third parties may not perform satisfactorily.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not expect to independently conduct all aspects of our manufacturing, research and preclinical and clinical testing. We currently rely,
and expect to continue to rely, on third parties with respect to these items. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our
studies in accordance with regulatory requirements or our stated study plans and protocols, we may not be able to complete, or may be delayed in completing, the preclinical and clinical studies
required to support future IND submissions and approval of our product candidates. Furthermore, any of these third parties may terminate its engagement with us at any time. If we need to enter into
alternative arrangements, it could delay our product development activities, and we may not be able to negotiate alternative arrangements on commercially reasonable terms, or at all. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We and our contract manufacturers are subject to significant regulation with respect to manufacturing our
products and the contract manufacturers on which we rely may not continue to meet regulatory requirements.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently have nor do we plan to acquire the infrastructure or internal capability to manufacture our clinical drug supplies for use
in the conduct of our trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on several different
manufacturers who supply different parts of the CPI-444 molecule and rely on one manufacturer for CPI-006 drug substance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to
extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP requirements. These </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=49,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=928317,FOLIO='45',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>regulations
govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational
products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or
stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or BLA on a
timely basis and must adhere to the FDA's Good Laboratory Practice regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Our facilities and quality systems
and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory
approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect our manufacturing facilities or those of our
third-party contractors involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. We
do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or
audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the
relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of
a clinical study or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties, and the FDA may impose regulatory
sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, revocation of a pre-existing approval or closing one or more manufacturing
facilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if supply from an approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified
through an NDA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Changing
manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of our product
candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. We, or any manufacturing
partners, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise
during scale-up activities. If we or any manufacturing partners are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development,
testing and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which
could significantly harm our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the supply chain for the manufacturing of our product candidates is complicated and can involve several parties. If we were to experience any supply chain issues, our
product supply could be seriously disrupted. We should expect that the logistical challenges associated with our supply chain will grow more complex as additional product candidates, such as CPI-006,
commence any clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=50,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=377422,FOLIO='46',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a
competitor will discover them or that our trade secrets will be misappropriated or disclosed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We
seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with
our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to
use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other
confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation
of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor's independent discovery of our trade secrets or other unauthorized use or
disclosure would impair our competitive position and may have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade
secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future will likely expect to be granted
rights to publish data arising out of such collaboration. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our
research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third
parties, independent development or publication of information by any of our third-party collaborators. A competitor's discovery of our trade secrets would impair our competitive position and have an
adverse impact on our business. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Commercialization of Our Product Candidates  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


All of our product candidates are still in early-stage clinical or preclinical development. If we are unable
to commercialize our product candidates or if we experience significant delays in obtaining regulatory approval for, or commercializing, any or all of our product candidates, our business will be
materially and adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our product candidates are still in preclinical or early-stage clinical development. In particular, none of our product candidates, other
than CPI-444, has ever been tested in a human subject. Our ability to generate product revenue will depend heavily on our ability to successfully develop and commercialize our product candidates. We
do not expect that such commercialization of any of our product candidates will occur for at least the next several years, if ever. Our ability to commercialize our product candidates effectively will
depend on several factors, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successful completion of preclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> managing the complexity of our clinical trial designs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> receipt of marketing approvals from the FDA and similar foreign regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing commercial manufacturing capabilities by making arrangements with third-party manufacturers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successfully launching commercial sales of any approved products, whether alone or in collaboration with others; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> acceptance of any approved products by patients, the medical community and third-party payors; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=51,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=469485,FOLIO='47',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing market share while competing with other therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a continued acceptable safety profile of any approved products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintaining compliance with post-approval regulation and other requirements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product
candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we experience significant delays or an inability to commercialize our product candidates, our business, financial condition and results of operations will be materially adversely
affected. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we do not achieve our projected development goals in the time frames we announce and expect, the
commercialization of our products may be delayed and, as a result, our stock price may decline.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes
refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may
publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions, and the actual timing of these milestones can vary dramatically
compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and, as a
result, our stock price may decline. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any approved products could be subject to restrictions or withdrawal from the market, and we may be subject
to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following potential approval of any our product candidates, the FDA may impose significant restrictions on a product's indicated uses or
marketing or impose ongoing requirements for potentially costly and time consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if any, of CPI-444 or any
other product candidate, such candidate will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion,
recordkeeping and reporting of safety and other post-market information. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated
severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including
requesting recall or withdrawal of the product from the market or suspension of manufacturing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we or the manufacturing facilities for CPI-444 or any other product candidate that may receive regulatory approval, if any, fail to comply with applicable regulatory requirements, a
regulatory agency may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issue warning letters or untitled letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek an injunction or impose civil or criminal penalties or monetary fines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspend or withdraw regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspend any ongoing clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refuse to approve pending applications or supplements or applications filed by us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspend or impose restrictions on operations, including costly new manufacturing requirements; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seize or detain products, refuse to permit the import or export of product or request that we initiate a product recall. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=52,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=475626,FOLIO='48',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_di41901_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA has the authority to require a risk evaluation and mitigation strategy ("REMS") as part of an NDA or BLA or after approval, which may impose further requirements or restrictions
on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet
certain safe-use criteria and requiring treated patients to enroll in a registry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if CPI-444 or any of our other product candidates is approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing
regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the
FDA as reflected in the product's approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is
inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and
regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has
levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that
companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to
comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
the FDA's policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example,
in December 2016, the 21st&nbsp;Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and spur
innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to
maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States
or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance
of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA's ability to engage in routine regulatory and oversight activities such as implementing
statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these Executive Orders will be implemented, and the extent to which
they will impact the FDA's ability to exercise its regulatory authority. If these executive actions impose constraints on FDA's ability to engage in oversight and implementation activities in the
normal course, our business may be negatively impacted. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=53,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=760877,FOLIO='49',FILE='DISK104:[18ZAA1.18ZAA41901]DI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk41901_1_50"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we receive regulatory approval we still may not be able to successfully commercialize CPI-444 or any
other product candidate, and the revenue that we generate from sales, if any, could be limited.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if CPI-444 or any of our other product candidates receive regulatory approval, they may not gain market acceptance among physicians,
patients, healthcare payors or the medical community. The degree of market acceptance of our product candidates will depend on a number of factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> demonstration of clinical efficacy and safety compared to other more-established products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the indications for which our product candidates are approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> acceptance of a new formulation by healthcare providers and their patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain and maintain sufficient third-party coverage and reimbursement from government healthcare programs, including Medicare
and Medicaid, private health insurers and other third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prevalence and severity of any adverse effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pricing and cost-effectiveness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of market introduction of our product candidates as well as competitive drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the effectiveness of our or any of our potential future collaborators' sales and marketing strategies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unfavorable publicity relating to the product candidate. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue
from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of CPI-444 or any of our other product
candidates may require significant resources and may never be successful. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved,
could limit our ability to market those products and decrease our ability to generate revenue.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successful commercial sales of any approved products will depend on the availability of adequate coverage and reimbursement from government
health administration authorities, private health insurers and other third-party payors. Each third-party payor separately decides which products it will cover and establishes the reimbursement level,
and there is no guarantee that any of our product candidates that may be approved for marketing by regulatory authorities will receive adequate coverage or reimbursement levels. Obtaining and
maintaining coverage approval for a product candidate is time-consuming, costly and may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and
reimbursement or the level of coverage and reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or limited, we may not be able to successfully
commercialize any product candidate for which we obtain marketing approval. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of
reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices
charged for drugs and biologics. Even if we obtain coverage for a given product, the resulting </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=54,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=956393,FOLIO='50',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reimbursement
rates may be inadequate and may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty
and cost for us to obtain marketing approval for and commercialize our product candidates and affect the prices we may obtain.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and
regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and biologics and affect our ability to
profitably sell any product candidates for which we obtain marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as the Affordable
Care Act, was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both governmental and private insurers. The Affordable Care Act, among
other things, subjected biological products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate
Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program;
extended the rebate program to individuals enrolled in Medicaid managed care organizations; established annual fees and taxes on manufacturers of certain prescription drugs; created a new Medicare
Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during
their coverage gap period, as a condition for the manufacturer's outpatient drugs to be covered under Medicare Part&nbsp;D; and established a new Patient-Centered Outcomes Research Institute to
oversee, identify priorities and conduct comparative clinical effectiveness research, along with funding for such research. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments
to the Affordable Care Act in the future. The current Presidential Administration and U.S. Congress has sought and will likely continue to seek to modify, repeal, or otherwise invalidate all, or
certain provisions of, the Affordable Care Act. It is uncertain the extent to which any such changes may impact our business or financial condition. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. These new laws, among other things, included
aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that will remain in effect through 2025 unless additional Congressional action is taken and additional specific
reductions in Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers. Recently there has been heightened governmental scrutiny over the
manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government
program reimbursement methodologies. Additionally, individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control
pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that the Affordable Care Act, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other
healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=55,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=408221,FOLIO='51',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>pressure
on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private
payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if
approved. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any product candidates for which we intend to seek approval as biologic products may face competition sooner
than anticipated.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which created an
abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar
product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made
effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period of exclusivity, another company may still market a competing
version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to
demonstrate the safety, purity and potency of its product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its
ultimate impact, implementation and meaning are subject to uncertainty, and any processes adopted by the FDA to implement the BPCIA could have a material adverse effect on the future commercial
prospects for our biological products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Though
CPI-444 is a small molecule and will not be regulated as a biological product, CPI-006, which we expect to begin evaluating in a Phase&nbsp;1/1b clinical trial in the first
quarter of 2018, is a biological product. We believe that any of our future product candidates approved as a biological product under a BLA should qualify for the twelve-year period of exclusivity.
However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for
competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have
also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to
traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may fail to obtain orphan drug designations from the FDA for our product candidates, and even if we obtain
such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which
is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable
expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives
such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first
FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full
NDA or BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug
exclusivity or where the manufacturer is unable to assure sufficient product quantity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=56,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=352023,FOLIO='52',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we have not obtained nor have we sought to obtain orphan designation for any product candidate, we believe many of the potential indications of our product candidates, if approved,
could qualify for orphan drug designation. For instance, if CPI-444 or CPI-006 is approved for the treatment
of certain solid tumors with small patient populations, such as melanoma, renal or triple-negative breast cancer, it is possible that it could qualify for orphan drug designation with respect to such
indications. As a result, we may seek to obtain orphan drug designation for our product candidates for any qualifying indications they may be approved for in the future. Even if we obtain such
designations, we may not be the first to obtain marketing approval of our product candidate for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical
products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA
later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare
disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different
active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if
the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of
a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek orphan drug designation for our product candidates, we may never receive such
designations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may expend our limited resources to pursue a particular product candidate and fail to capitalize on
product candidates that may be more profitable or for which there is a greater likelihood of success.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we have limited financial and managerial resources, we focus on specific product candidates, including CPI-444. As a result, we may
forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on
viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any
commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product
candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such
product candidate. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in establishing and maintaining development or other strategic collaborations, which
could adversely affect our ability to develop and commercialize product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our Phase&nbsp;1/1b clinical trial for CPI-444, we entered into a clinical trial collaboration agreement with Genentech in
October 2015. Pursuant to the agreement, Genentech provides access to, and supplies of, its cancer immunotherapy, Tecentriq, to be used in combination with CPI-444 during the clinical trial. The
collaboration operates under a joint development committee with equal representation from both companies. In May 2017, we signed a second clinical trial collaboration agreement with Genentech. Under
the new agreement, CPI-444
administered in combination with Tecentriq will be evaluated in a Phase&nbsp;1b/2 randomized, controlled clinical study as second-line therapy in patients with non-small cell lung cancer who are
resistant and/or refractory to prior therapy with an anti-PD-(L)1 antibody. However, we and Genentech each have the right to terminate the respective collaboration agreements due to material breach by
either party, for safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued. If we fail to maintain these strategic collaborations with
Genentech (1)&nbsp;the development of CPI-444 in combination with Tecentriq may be terminated or delayed; (2)&nbsp;our cash expenditures </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=57,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=269060,FOLIO='53',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>related
to development of CPI-444 could increase significantly, and we may need to seek additional financing; (3)&nbsp;we may be required to hire additional employees or otherwise develop expertise
for which we have not budgeted; (4)&nbsp;we will bear all of the risk related to the development of CPI-444 as a combination therapy; and (5)&nbsp;we will need to seek collaborations with other
companies that have anti-PD-1 or anti-PD-L1 antibodies, which will significantly delay our development program and could have a material adverse effect on our business, financial condition and results
of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may form strategic alliances and collaborative partnerships in the future, and we may not realize the
benefits of such alliances.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to our collaboration agreements with Genentech, we may form additional strategic alliances, create joint ventures or collaborations
or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product
candidates. These relationships may result in or include non-recurring and other charges, increased near- and long-term expenditures, the issuance of securities that dilute our existing stockholders
or disruptions to our management and business. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process is time-consuming and complex.
Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure
in future clinical trials as too significant or the commercial opportunity for our product candidates as too limited. We cannot be certain that, following a strategic transaction or license, we will
achieve the revenue or specific net income that justifies such transaction. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we are successful in our efforts to establish strategic alliances or collaborative partnerships, the terms that we agree upon may not be favorable to us, and we may not be able
to maintain such strategic alliances or collaborative partnerships if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales
of an approved product candidate are unsatisfactory. In addition, any potential future strategic alliances or collaborative partnerships may be terminable by our strategic partners, and we may not be
able to adequately protect
our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if
approved, and may not conduct those activities in the same manner as we do. Any termination of strategic alliances or collaborative partnerships we enter into in the future, or any delay in entering
into collaborative partnership agreements related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach
the market, which could have a material adverse effect on our business, financial condition and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face competition from entities that have developed or may develop product candidates for cancer, including
companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our
ability to develop and successfully commercialize product candidates may be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates.
Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant
number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In
particular, there is intense and rapidly evolving competition in the immunoregulatory therapeutics field. Our competitors include larger and better funded pharmaceutical, biopharmaceutical,
biotechnological and therapeutics companies. Moreover, we also compete with universities and other research institutions that may be active in oncology research and could be in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=58,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=915056,FOLIO='54',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>direct
competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our
ability to execute our business plan. We will also face competition in establishing clinical trial sites, registering subjects for clinical trials and in identifying and in-licensing new product
candidates. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of our product candidates, if approved, will compete with a range of therapeutic treatments that are either in development or currently marketed. We are aware of companies that have
advanced adenosine A2A receptor antagonists into early- or late-stage clinical development for non-oncology indications, primarily Parkinson's disease. These companies include
Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. that has evaluated preladenant in Parkinson's disease. In addition, Kyowa Hakko Kirin Pharma,&nbsp;Inc. has approval in Japan for an adenosine A2A receptor
antagonist for use in Parkinson's disease and is currently conducting a
Phase&nbsp;3 study in the United States for Parkinson's disease. Within oncology, Merck has initiated a Phase&nbsp;1 trial with preladenant, an adenosine A2A antagonist in cancer patients with
solid tumors, that will be used in combination with pembrolizumab. Novartis has announced an exclusive licensing agreement with Palobiofarma SL and is conducting a Phase&nbsp;1 trial.
AstraZeneca&nbsp;plc has licensed a preclinical A2A antagonist for use in cancer therapy from Heptares,&nbsp;Inc. Merck KgaA has entered into a pre-clinical collaboration with Domain
Therapeutics&nbsp;Inc. to develop programs targeting the adenosine pathway. In addition, Redoxtherapies,&nbsp;Inc., which was acquired by Juno Therapeutics and Arcus Biosciences,&nbsp;Inc. are
developing A2A receptor antagonists for cancer. Astra Zeneca and Bristol-Myers Squib have initiated clinical trials with anti-CD73 antibodies in cancer patients. More generally, in the field of
immuno-oncology, there are large pharmaceutical companies with approved products or products in late-stage development that target other immune checkpoints, including PD-1, PD-L1 or CTLA-4. These
companies include Bristol-Myers Squibb (nivolumab, ipilimumab), Merck (pembrolizumab), Genentech (atezolizumab) and AstraZeneca (durvalumab, tremelimumab). Also, AstraZeneca and MedImmune&nbsp;LLC
have announced the initiation of a Phase&nbsp;1 study with an anti-CD73 antibody. Bristol-Myers Squibb also announced the development of an anti-CD73 antibody that is now in clinical trials. Arcus
has a CD73 inhibitor in preclinical development. Janssen Pharmaceuticals,&nbsp;Inc. and AbbVie&nbsp;Inc. are co-marketing Imbruvica (ibrutinib), which is a small molecule inhibitor of the kinase
BTK that has also been reported to inhibit ITK. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval
for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and
the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and
sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or
marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and
commercializing our product candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The market opportunities for our product candidates may be limited to those patients who are ineligible for
or have failed prior treatments and may be small.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cancer therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only
for third-line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first-line therapy, usually chemotherapy,
hormone therapy, surgery or a combination of these, proves unsuccessful, second-line therapy may be administered. Second-line therapies often consist of more </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=59,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=519688,FOLIO='55',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>chemotherapy,
radiation, antibody drugs, tumor targeted small molecules or a combination of these. Third-line therapies can include bone marrow transplantation, antibody and small molecule targeted
therapies, more invasive forms of surgery and new technologies. In markets with approved therapies, we expect to initially seek approval of our product candidates as a later stage therapy for patients
who have failed other approved treatments. Subsequently, for those drugs that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second-line therapy and potentially as
a first-line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for second-line or first-line therapy. In addition, we may have to conduct additional
clinical trials prior to gaining approval for second-line or first-line therapy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive later stage therapy and
who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific
literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number
of patients may turn out to be lower than expected. In addition, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our
product candidates. Even if we obtain significant market share for our product candidates, we may never achieve profitability without obtaining regulatory approval for additional indications,
including use as a first or second-line therapy. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have no sales, marketing or distribution capabilities, and we may have to invest significant resources to
develop these capabilities.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have no internal sales, marketing or distribution capabilities. If CPI-444 or any of our other product candidates ultimately receives
regulatory approval, we may not be able to effectively market and distribute the product candidate. We may have to seek collaborators or invest significant amounts of financial and management
resources to develop internal sales, distribution and marketing capabilities, some of which will be committed prior to any confirmation that CPI-444 or any of our other product candidates will be
approved, if at all. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable
financial terms or at all. Even if we determine to perform sales, marketing and distribution functions ourselves, we could face a number of additional related risks,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not be able to attract and build an effective marketing department or sales force; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by
CPI-444 or any other product candidates that we may develop, in-license or acquire; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our direct sales and marketing efforts may not be successful. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be
subject to additional regulatory burdens and other risks and uncertainties.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not
permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory
approvals for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and
efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and
ultimately commercialize our product candidates in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=60,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=659123,FOLIO='56',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>foreign
markets, we would be subject to additional risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and
the reduced protection of intellectual property rights in some foreign countries. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Governments may impose price controls, which may adversely affect our future profitability.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to seek approval to market our product candidates in both the United States and in foreign jurisdictions. In some foreign countries,
particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take
considerable time after the receipt of marketing approval for a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct clinical trials to
compare the cost-effectiveness of our product candidates to other available therapies, which is time-consuming and costly. If reimbursement of our future products is unavailable or limited in scope or
amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent U.S. tax legislation and future changes to applicable U.S. or foreign tax laws and regulations may
have a material adverse effect on our business, financial condition and results of operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to income and other taxes in the U.S. and foreign jurisdictions. Changes in laws and policy relating to taxes or trade may have
an adverse effect on our business, financial condition and results of operations. For example, the U.S. government recently enacted significant tax reform, and certain provisions of the new law may
adversely affect us. Changes include, but are not limited to, a federal corporate tax rate decrease from 34% to 21% for tax years beginning after December&nbsp;31, 2017, the transition of U.S.
international taxation from a worldwide tax system to a more generally territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. The legislation is
unclear in many respects and could be subject to potential amendments and technical corrections, and will be subject to interpretations and implementing regulations by the Treasury and Internal
Revenue Service, any of which could mitigate or increase certain adverse effects of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local
taxation. Generally, future changes in applicable U.S. or foreign tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial conditions
and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Business Operations  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our operating results may fluctuate significantly, which makes our future operating results difficult to
predict and could cause our operating results to fall below expectations or any guidance we may provide.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results.
These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and cost of, and level of investment in, research, development and commercialization activities relating to our product candidates,
which may change from time to time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our
product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with
manufacturers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=61,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=6606,FOLIO='57',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the level of demand for any approved products, which may vary significantly; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> future accounting pronouncements or changes in our accounting policies; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the
competitive landscape of our industry, including consolidation among our competitors or partners. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating
results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating
results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or
investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may
provide. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are dependent on the services of our President and Chief Executive Officer, Richard A. Miller, M.D., and
other key executives, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are dependent on the principal members of our management and scientific staff. The loss of service of any of our management could harm our
business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. If we are not able to retain our
management, particularly our President and Chief Executive Officer, Dr.&nbsp;Miller, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of
our business, we may not be able to sustain our operations or grow. Although we have executed employment agreements with each member of our current executive management team, including
Dr.&nbsp;Miller, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization
efforts. We may not be able to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical,
biotechnology and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to
attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development
objectives, our ability to raise additional capital and our ability to implement our business strategy. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we do not currently maintain "key person" life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate
compensation for the loss of the services of these individuals. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may encounter difficulties in managing our growth and expanding our operations successfully.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will need to grow our organization substantially to continue development and pursue the potential commercialization of CPI-444 and our other
product candidates. As we seek to advance CPI-444 and other product candidates, we will need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or
contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=62,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=364330,FOLIO='58',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>relationships
with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively
will depend, in part, on our ability to manage any future growth effectively. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to various federal and state healthcare laws and regulations, and our failure to comply with
these laws and regulations could harm our results of operations and financial conditions.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we do not currently have any products on the market, if we obtain FDA approval for any of our product candidates and begin
commercializing those products in the United States, our operations may be directly, or indirectly through our customers and third-party payors, subject to various U.S. federal and state healthcare
laws and regulations. These laws will affect our operations, sales and marketing practices, and our relationships with physicians and other customers and third-party payors. Such laws
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering,
receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or
recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the
federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation
of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against
individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease
or conceal an obligation to pay money to the federal government; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which imposes criminal and civil liability for executing a
scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have
actual knowledge of the statute or specific intent to violate it to have committed a violation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which also
imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is
available under Medicare, Medicaid or the Children's Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other "transfers of
value" made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers and group purchasing
organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members and payments or other "transfers of
value" to such physician owners (manufacturers are required to submit reports to the government by the 90th&nbsp;day of each calendar year); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing
arrangements and claims involving healthcare items </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=63,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=290579,FOLIO='59',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<A NAME="page_dk41901_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>or
services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry's voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and state and foreign laws governing the privacy and security of health information
in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ensuring
that our internal operations and business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our
operations are found to be in violation of such laws or any other governmental laws and regulations that may apply to us, we
may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and
Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We and our current and any future collaborators, third-party manufacturers and suppliers will or may use
biological materials and may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We and our current and any future collaborators, third-party manufacturers or suppliers will or may use biological materials and may use
hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party
manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these
materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development
efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and
our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event
of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If product liability lawsuits are brought against us, we may incur substantial liabilities and may be
required to limit commercialization of CPI-444 or our other product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face an inherent risk of product liability as a result of the clinical testing of CPI-444 and our other product candidates and will face an
even greater risk if we commercialize our product candidates. For example, we may be sued if CPI-444 or our other product candidates allegedly cause injury or are found to be otherwise unsuitable
during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers
inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product
candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result
in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> decreased demand for CPI-444 or our other product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injury to our reputation; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=64,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=932024,FOLIO='60',FILE='DISK104:[18ZAA1.18ZAA41901]DK41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:06' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm41901_1_61"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of clinical trial participants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> costs to defend the related litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a diversion of management's time and our resources; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> substantial monetary awards to trial participants or patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product recalls, withdrawals or labeling, marketing or promotional restrictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> loss of revenue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the inability to commercialize CPI-444 or our other product candidates; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a decline in our stock price. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have product liability insurance coverage in an amount and on terms and conditions that are customary for similarly situated companies and that are satisfactory to our board of
directors. Our inability to retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of
CPI-444 or our other product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not
covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a
product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by
our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We and any of our potential future collaborators will be required to report to regulatory authorities if any
of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we and any of our potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities
would require that we and any of our potential future collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events.
The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our potential future collaborators or CROs
may fail to report adverse events within the prescribed timeframe. If we or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign
regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our internal computer systems, or those of any of our potential future collaborators, CROs or other
contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other
contractors, consultants and collaborators are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such
an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade
secrets or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=65,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=567879,FOLIO='61',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>systems
could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or
inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our information technology systems could face serious disruptions that could adversely affect our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the
Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems
could cause interruptions and delays in our research and development work. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Cybersecurity breaches could expose us to liability, damage our reputation, compromise our confidential
information or otherwise adversely affect our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain sensitive company data on our computer networks, including our intellectual property and proprietary business information. We face a
number of threats to our networks from unauthorized access, security breaches and other system disruptions. Despite our security measures, our infrastructure may be vulnerable to attacks by hackers or
other disruptive problems. Any such security breach may compromise information stored on our networks, or those of our vendors, and may result in significant data losses or theft of our intellectual
property or proprietary business information. A cybersecurity breach could adversely affect our reputation and could result in other negative consequences, including disruption of our internal
operations, increased cyber security protection costs, lost revenues or litigation. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Business disruptions could seriously harm our future revenue and financial condition and increase our costs
and expenses.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons,
fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We currently rely on several
different manufacturers who supply different parts of the CPI-444 molecule, on one manufacturer for CPI-006 drug substance and other third-party manufacturers to produce our other product candidates.
Our ability to obtain clinical supplies of CPI-444, CPI-006 or our other product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or
other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in
misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct involving the improper use or misrepresentation of information obtained
in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions
and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=66,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1020427,FOLIO='62',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>a
failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If
any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the
imposition of fines and other sanctions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Intellectual Property  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our rights to develop and commercialize our product candidates are subject in part to the terms and
conditions of licenses granted to us by other companies. The patent protection, prosecution and enforcement for some of our product candidates may be dependent on third parties.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that is important or
necessary to the development of our
technology and products, including technology related to our product candidates. For example, we rely on our license agreement with Vernalis for all of our rights with respect to the intellectual
property covering CPI-444 and certain development candidates under our A2B receptor antagonist program. Further, we rely on our license agreement with The Scripps Research Institute for rights related
to our lead development candidate for our anti-CD73 program, CPI-006. These and other licenses we may enter into in the future may not provide adequate rights to use such intellectual property and
technology in all relevant fields of use or in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to develop
and commercialize our technology and products in fields of use and territories for which we are not granted rights pursuant to such licenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licenses
to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable
terms, which could have a material adverse effect on our business and financial condition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
some circumstances, we may not have the right to control the preparation, filing, prosecution and enforcement of patent applications, or to maintain the patents, covering technology
that we license from third parties. In addition, some of our agreements with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may
withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that our licensors or collaborators will prosecute, maintain, enforce and defend such intellectual
property rights in a manner consistent with the best interests of our business, including by taking reasonable measures to protect the confidentiality of know-how and trade secrets, or by paying all
applicable prosecution and maintenance fees related to intellectual property registrations for any of our product candidates. We also cannot be certain that our licensors have drafted or prosecuted
the patents and patent applications licensed to us in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue
from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize
products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our success depends on our ability to protect our intellectual property and our proprietary technologies.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product
candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by
filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. There can be no assurance that
our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=67,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=251032,FOLIO='63',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_64"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>competitors
with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be
found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary
rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the
intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we have rights to an issued composition-of-matter patent in the United States and corresponding issued patents in certain foreign territories covering CPI-444, we cannot be certain
that the claims in any of our patent applications covering composition-of-matter of our other product candidates will be considered patentable by the United States Patent and Trademark Office
("USPTO"), courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found
invalid or unenforceable if challenged. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in
protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant
jurisdiction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patent applications may not result in any patents being issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or
otherwise may not provide any competitive advantage; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing
technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both
inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign
competitors a better opportunity to create, develop and market competing product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or
in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter
into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside
scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=68,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=408462,FOLIO='64',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_65"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>parties
may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents, if issued, or the patent rights that we license from others, may be
challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable,
which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our products and product candidates. Given
the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are
commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to protect the confidentiality of our trade secrets, our business and competitive position
would be harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to
maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and
confidential information and inventions agreements with employees, consultants and advisors. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed,
and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and
outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently,
and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the
value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the
confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our commercial success depends significantly on our ability to operate without infringing the patents and
other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and
commercialization efforts.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. Other entities may
have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive
position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property
rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations, inter partes review ("IPR") proceedings and post-grant
review ("PGR") proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in
which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to
the use or manufacture of our product candidates. For example, we are aware of an issued patent in Australia that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=69,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=918495,FOLIO='65',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_66"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>may
be relevant to commercialization of CPI-444 in that country. That Australian patent is expected to expire in 2022. Our ability to commercialize CPI-444 in Australia prior to 2022 could be
adversely affected if we do not obtain a license under such patent. We are also aware of a corresponding patent application that has been issued in the United States and which is expected to expire in
2023. However, to the extent that any claims of this patent may be interpreted to cover our potential uses of CPI-444, we do not believe that such claims would be valid and enforceable if asserted. We
have filed a PGR petition challenging the patentability of certain claims of the patent and the patentee subsequently disclaimed every challenged claim. As the biotechnology industry expands and more
patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as
confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patent applications that, if issued as patents, may be infringed by
commercialization of CPI-444 or our other product candidates, and cannot be certain that we were the first to file&nbsp;a patent application related to a product candidate or technology. Moreover,
because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In
addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents,
incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming and
could:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> result in costly litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> divert the time and attention of our technical personnel and management; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cause development delays; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prevent us from commercializing CPI-444 or our other product candidates until the asserted patent expires or is held finally invalid or not
infringed in a court of law; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
no third party has asserted a claim of patent infringement against us as of the date of this report, others may hold proprietary rights that could prevent CPI-444 or our other
product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidates or processes could
subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market CPI-444 or our other
product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Defense
of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot
predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we
or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we
cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or
the failure to obtain necessary licenses, could prevent us from developing and commercializing CPI-444 or our other product candidates, which could harm our business, financial condition and operating
results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates
and technology. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=70,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=415745,FOLIO='66',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_67"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could
be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we may be
required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid,
is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product
candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or
non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a
misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and
unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability,
we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interference
proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or
patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our
business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful,
may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise
the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would
help us bring our product candidates to market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our
technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments
and if securities analysts or
investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating
losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such
litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial
resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities
analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=71,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=406888,FOLIO='67',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_68"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of our issued patents.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;16, 2011, the Leahy-Smith America Invents Act ("Leahy-Smith Act") was signed into law. The Leahy-Smith Act includes a number
of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the
Leahy-Smith Act, the United States transitioned in March 2013 to a "first to file" system in which the first inventor to file&nbsp;a patent application will be entitled to the patent. Third parties
are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, inter-partes review or
interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or
enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in obtaining or maintaining necessary rights to our product candidates through
acquisitions and in-licenses.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product
candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license or use these
proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be
unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product
candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or
acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater
clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license
or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have collaborated with U.S. academic institutions and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development
under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution's rights in technology resulting from the
collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution
may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon
development of that program and our business and financial condition could suffer. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may fail to comply with any of our obligations under existing agreements pursuant to which we license or
have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. We are
party to various agreements that we depend on for rights to use various technologies that are material to our business, including intellectual property rights covering </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=72,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=868194,FOLIO='68',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_69"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>CPI-444
and methods relating to its use and manufacture. In each of these cases, our rights to use the licensed intellectual property are subject to the continuation of and our compliance with the
terms of these agreements. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope of rights granted under the license agreement and other interpretation-related issues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the sublicensing of patent and other rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and
collaborators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope and duration of our payment obligations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our rights upon termination of such agreement; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope and duration of exclusivity obligations of each party to the agreement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements
on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future licensing agreements,
these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our
employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development
of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to,
other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed
trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, which could adversely affect our business. Even if we are successful in defending against these
claims, litigation could result in substantial costs and be a distraction to our management team. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual
property.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other
intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=73,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=442725,FOLIO='69',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>in
defending against such claims, litigation could result in substantial costs and distraction to management and other employees. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we do not obtain patent term extension for our product candidates, our business may be materially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and specifics of FDA marketing approval of CPI-444 or other product candidates, one or more of our U.S.
patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 ("Hatch-Waxman Amendments"). The Hatch-Waxman Amendments permit a
patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be granted an extension because
of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the
applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is
less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be
infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of
interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there
could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks
or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be
adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could
result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to
protect our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly,
time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either
narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our
ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts
and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might
obtain in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=74,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=309773,FOLIO='70',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<A NAME="page_dm41901_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we have issued patents directed at CPI-444 in the United States and pending patent applications directed at CPI-444 and other product
candidates in the United States and other countries, filing, prosecuting and defending patents on CPI-444 and our other product candidates in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do
not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in
all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in
jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but
enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or
sufficient to prevent them from competing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the
infringement of our patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
develop or license. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual property rights do not necessarily address all potential threats to our competitive advantage.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may be able to make adenosine antagonists that are similar to our product candidates but that are not covered by the claims of the
patents that we own or have exclusively licensed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent
application that we own or have exclusively licensed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
property rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> it is possible that our pending patent applications will not lead to issued patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our
competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
learned from such activities to develop competitive products for sale in our major commercial markets; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=75,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=955948,FOLIO='71',FILE='DISK104:[18ZAA1.18ZAA41901]DM41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:09' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do41901_1_72"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not develop additional proprietary technologies that are patentable; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the patents of others may have an adverse effect on our business. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
any of these events occur, they could significantly harm our business, results of operations and prospects. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Common Stock  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An active, liquid and orderly market for our common stock may not be maintained.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to our IPO in March 2016, there had been no public market for our common stock. Although our common stock is listed on The Nasdaq Global
Market ("Nasdaq"), an active trading market for our common stock may never be sustained on Nasdaq or any other exchange in the future. The lack of an active market may impair our stockholders' ability
to sell their shares at the time they wish to sell them or at a price that they consider reasonable. If an active market for our common stock is not maintained, it may also be difficult for our
stockholders to sell shares without depressing the market price for the shares or at all. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability
to acquire other businesses, applications or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The trading price of the shares of our common stock could be highly volatile, and investors in our common
stock could incur substantial losses.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stock price has been volatile. The stock market in general and the market for stock of pharmaceutical companies in particular have
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by those factors discussed in
this "Risk Factors" section and many others, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to enroll subjects in our planned clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> results of the clinical trials, and the results of trials of our competitors or those of other companies in our market sector; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory approval of CPI-444 and our other product candidates, or limitations to specific label indications or patient populations for its
use, or changes or delays in the regulatory review process; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory developments in the United States and foreign countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the success or failure of our efforts to acquire, license or develop additional product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> innovations or new products developed by us or our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> manufacturing, supply or distribution delays or shortages; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> achievement of expected product sales and profitability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> variations in our financial results or those of companies that are perceived to be similar to us; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=76,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=910316,FOLIO='72',FILE='DISK104:[18ZAA1.18ZAA41901]DO41901A.;9',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_do41901_1_73"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> market conditions in the pharmaceutical sector and issuance of securities analysts' reports or recommendations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> trading volume of our common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an inability to obtain additional funding; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sales of our stock by insiders and stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> general economic, industry and market conditions other events or factors, many of which are beyond our control; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additions or departures of key personnel; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> intellectual property, product liability or other litigation against us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of this volatility, investors may experience losses on their investment in our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical companies following periods of volatility in the market prices of these companies'
stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management's attention and resources, which could have a material adverse effect on our business,
financial condition and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common
stock.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid
price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair our stockholders' ability to
sell or purchase our common stock when they wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would
allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price
requirement or prevent future non-compliance with Nasdaq's listing requirements. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because a small number of our existing stockholders own a majority of our voting stock, a stockholder's
ability to influence corporate matters will be limited.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, our executive officers, directors and greater than 5% stockholders, in the aggregate, owned approximately 60% of
our outstanding common stock. As a result, such persons, acting together, have the ability to control our management and affairs and substantially all matters submitted to our stockholders for
approval, including the election and removal of directors and approval of any significant transaction. This concentration of ownership may have the effect of delaying, deferring or preventing a change
in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain
control of our business, even if such a transaction would benefit other stockholders. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders' ability
to achieve a return on their investment will depend on appreciation, if any, in the price of our common stock.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=77,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=332305,FOLIO='73',FILE='DISK104:[18ZAA1.18ZAA41901]DO41901A.;9',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_do41901_1_74"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>do
not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that
shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional funds by issuing securities may cause dilution to our existing stockholders.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. For
example, on April&nbsp;3, 2017, we filed a Registration Statement on Form&nbsp;S-3, covering the offering of up to $250&nbsp;million of shares of common stock, preferred
stock, warrants and units. On September&nbsp;20, 2017, we filed a prospectus supplement and entered into the Sales Agreement with Cowen and Company,&nbsp;LLC ("Cowen") to sell shares of our common
stock, from time to time, with aggregate gross sales proceeds of up to $125,000,000, through an at-the-market equity offering program under which Cowen will act as our sales agent. As of
December&nbsp;31, 2017, we have sold 52,569 shares of common stock for gross proceeds of approximately $894,000 pursuant to the Sales Agreement. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock by our existing stockholders in the public market
could cause our stock price to fall.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the
market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Moreover, certain holders of shares of our common stock have rights,
subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other
stockholders. We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely
sold in the public market upon issuance, subject to volume limitations applicable to affiliates. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an emerging growth company, and the reduced reporting requirements applicable to emerging growth
companies may make our common stock less attractive to investors.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company," as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to
comply with the auditor attestation requirements of Section&nbsp;404 of Sarbanes-Oxley, reduced disclosure obligations regarding executive compensation in our Annual Report on Form&nbsp;10-K and
our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments
not previously approved. We could be an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2021, (2)&nbsp;the last day of the fiscal year in which we have total annual gross
revenue of at least $1.07&nbsp;billion, (3)&nbsp;the last day of the fiscal year in which we are deemed to be a "large accelerated filer" as defined in Rule&nbsp;12b-2 under the Exchange Act,
which would occur if the market value of our common stock held by non-affiliates exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such fiscal year, or
(4)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt securities during the prior three-year period. If investors find our common stock less attractive as a
result, there may be a less active trading market for our common stock and our stock price may be more volatile. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=78,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=816416,FOLIO='74',FILE='DISK104:[18ZAA1.18ZAA41901]DO41901A.;9',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_do41901_1_75"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities or industry analysts do not publish research or reports or publish unfavorable research or
reports about our business, our stock price and trading volume could decline.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our
business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and
operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we
could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to maintain proper and effective internal control over financial reporting, our ability to produce
accurate and timely consolidated financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Section&nbsp;404 of Sarbanes-Oxley, when we lose our status as an "emerging growth company" and reach an accelerated filer
threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that
must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements
of being a reporting company under the Exchange Act, we will need to upgrade our systems including information technology; implement additional financial and management controls, reporting systems and
procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may
lose confidence in our financial reporting and the trading price of our common stock may decline. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot assure our stockholders that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to
maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude
that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our
internal control over financial reporting once that firm begin its Section&nbsp;404 reviews, investors may lose confidence in the accuracy and completeness of
our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy
any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access
to the capital markets. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may
consider favorable and may lead to entrenchment of management.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the
value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents
include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a
majority of our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=79,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=855943,FOLIO='75',FILE='DISK104:[18ZAA1.18ZAA41901]DO41901A.;9',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_do41901_1_76"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill
a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of
directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the required approval of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the shares entitled to vote to remove a director for cause, and the prohibition on
removal of directors without cause; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of
those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the required approval of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the shares entitled to vote to adopt, amend or repeal our amended and restated
bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our
stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and
proceedings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our
stockholders to force consideration of a proposal or to take action, including the removal of directors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to
be acted upon at a stockholders' meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror's own slate of directors or otherwise
attempting to obtain control of us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also subject to the anti-takeover provisions contained in Section&nbsp;203 of the Delaware General Corporation Law. Under Section&nbsp;203, a corporation may not, in general,
engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has
approved the transaction. For a description of our capital stock, see the section titled "Description of Capital Stock." </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court
of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial
forum for disputes with us or our directors, officers or employees.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of
Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant
to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the
internal affairs doctrine. This provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other
employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find this provision in our amended and restated certificate
of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=80,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=188605,FOLIO='76',FILE='DISK104:[18ZAA1.18ZAA41901]DO41901A.;9',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<A NAME="page_do41901_1_77"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>may
incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to use net operating loss carryforwards and other tax attributes may be limited.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve
profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. As of
December&nbsp;31, 2017, we had federal net operating loss ("NOL") carryforwards of approximately $42.1&nbsp;million and state NOL carryforwards of approximately $94.5&nbsp;million
available to offset future taxable income. If not utilized, the federal and state NOL carryforwards will begin to expire in various years beginning in 2034. As of December&nbsp;31, 2017, we also had
$3.0&nbsp;million of federal and $2.1&nbsp;million of state research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax
credits will begin to expire in 2035, if not utilized. The state research and development tax credits have no expiration date. Utilization of NOL carryforwards and credits may be subject to an annual
limitation due to the "ownership change" provisions under Sections&nbsp;382 and 383 of the Internal Revenue Code of 1986, as amended. An "ownership change" is generally defined as a cumulative
change in the ownership interest of significant stockholders over a three-year period in excess of 50&nbsp;percentage points. Similar provisions under state tax law may also apply. We may have
experienced an ownership change in the past, including in connection with our IPO, and we may experience an ownership change in the future as a result of subsequent shifts in our stock ownership, some
of which changes are outside our control. Such ownership changes could result in the expiration of our NOL carryforwards and other tax attributes before they can be utilized and, if we are profitable,
our future cash flows could be adversely affected due to our increased tax liability.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="do41901_item_1b._unresolved_staff_comments"> </A>
<A NAME="toc_do41901_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;1B.&nbsp;&nbsp;&nbsp;&nbsp;Unresolved Staff Comments    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="do41901_item_2._properties"> </A>
<A NAME="toc_do41901_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Properties    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently lease approximately 28,633 square feet of office and research and development facilities in Burlingame, California. Our lease
expires in 2021. We frequently explore alternatives that would provide us with additional space to accommodate our anticipated growth.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="do41901_item_3._legal_proceedings"> </A>
<A NAME="toc_do41901_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not currently a party to any material litigation or legal proceedings; however, we may from time to time be involved in various legal
proceedings incident to the ordinary course of our business.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="do41901_item_4._mine_safety_disclosures"> </A>
<A NAME="toc_do41901_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;Mine Safety Disclosures    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=81,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=851897,FOLIO='77',FILE='DISK104:[18ZAA1.18ZAA41901]DO41901A.;9',USER='JFUSS',CD=';1-MAR-2018;10:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq41901_1_78"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq41901_part_ii"> </A>
<A NAME="toc_dq41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Part&nbsp;II    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dq41901_item_5._market_for_registrant___ite04645"> </A>
<A NAME="toc_dq41901_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market Information for Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock has been listed on The Nasdaq Global Market under the symbol "CRVS" since March&nbsp;23, 2016. Prior to that there was no
public trading market for our common stock. The following table sets forth for the indicated periods the high and low sales prices per share for our common stock on the Nasdaq stock market. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Price Range </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2017</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21.37</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20.71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17.23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>2016</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter (beginning March&nbsp;23, 2016)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17.77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.04</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17.33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Holders of Record  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;1, 2018, there were approximately 27 stockholders of record of our common stock. The actual number of stockholders is greater
than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also
does not include stockholders whose shares may be held in trust by other entities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividend Policy  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently intend to retain future earnings, if any, for use in operation of our business and to fund future growth. We have never declared or
paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of
our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other
factors our board of directors may deem relevant. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Performance Graph  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following graph shows the total stockholder's return on an investment of $100 in cash at market close on March&nbsp;23, 2016 (the first
day of trading of our common stock), through December&nbsp;31, 2017 for (i)&nbsp;our common stock, (ii)&nbsp;the Nasdaq Composite Index and (iii)&nbsp;the Nasdaq Biotechnology Index. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however, no dividends have been declared on our
common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder
return. This graph and the table below it shall not be deemed "soliciting material" or be deemed "filed" for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=82,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=581159,FOLIO='78',FILE='DISK104:[18ZAA1.18ZAA41901]DQ41901A.;12',USER='JFUSS',CD=';1-MAR-2018;10:10' -->
<A NAME="page_dq41901_1_79"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>purposes
of Section&nbsp;18 of the Securities Exchange Act of 1934 as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section, and shall not be deemed to be
incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the "Securities Act"), whether made before or after the date hereof and irrespective of any general
incorporation language in any such filing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g499308.jpg" ALT="GRAPHIC" WIDTH="589" HEIGHT="291">
  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>$100 investment in<BR>
stock or index

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;23,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>September&nbsp;30,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>September&nbsp;30,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corvus (CRVS)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100.07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>115.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>145.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111.86</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72.70</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ Composite Index (IXIC)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111.39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>112.88</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>123.97</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>128.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>136.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ Biotech Index (^NBI)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>104.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>115.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>122.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>131.47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126.33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Securities Authorized for Issuance Under Equity Compensation Plans  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in PART III
Item&nbsp;12 of this Annual Report on Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of Proceeds from Registered Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of our common stock began trading on The Nasdaq Global Market on March&nbsp;23, 2016. The offer and sale of all the shares in the IPO
were registered under the Securities Act pursuant to a registration statement on Form&nbsp;S-1 (File No.&nbsp;333-208850), which was declared effective by the SEC on March&nbsp;22, 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
has been no material change in the planned use of proceeds from our IPO as described in the Prospectus filed with the SEC pursuant to Rule&nbsp;424(b) under the Securities Act on
March&nbsp;24, 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Sales of Unregistered Equity Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Issuer Purchases of Equity Securities by the Issuer and Affiliated Purchasers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=83,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=86687,FOLIO='79',FILE='DISK104:[18ZAA1.18ZAA41901]DQ41901A.;12',USER='JFUSS',CD=';1-MAR-2018;10:10' -->
<A NAME="page_dq41901_1_80"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="dq41901_item_6._selected_financial_data"> </A>
<A NAME="toc_dq41901_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;Selected Financial Data    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should read the following selected financial data together with the information under "Item&nbsp;7. Management's Discussion and Analysis
of Financial Condition and Results of Operations" and our consolidated financial statements and related notes included in Part&nbsp;II, Item&nbsp;8 of this Annual Report on Form&nbsp;10-K. The
statement of operations data for each of the years ended December&nbsp;31, 2017, 2016 and 2015 and period from January&nbsp;27, 2014 (inception) to December&nbsp;31, 2014 and the balance sheet
data as of December&nbsp;31, 2017 and 2016 are derived from our audited consolidated financial statements included elsewhere in this Annual Report on Form&nbsp;10-K. The selected balance sheet
data as of December&nbsp;31, 2015 and 2014 are derived from our consolidated audited financial statements which are not included in this Annual Report on Form&nbsp;10-K. Our historical results of
any prior periods are not necessary indicative of results to be expected in any future period. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Period from<BR>
January&nbsp;27,<BR>
2014<BR>
(inception) to<BR>
December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Consolidated Statements of Operations and<BR>
Comprehensive Loss Data:

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands, except share and per share amounts)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29,356</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,352</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,219</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,620</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,418</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>123 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,524</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,976</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>161 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(56,524</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,976</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(161</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of convertible preferred stock liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income and other expense, net.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>861</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(55,663</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(161</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(83.86</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.95</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares used to compute net loss per share, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,488,506</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,422,041</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>373,643</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>170,278 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income (loss):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized gain (loss) on marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(55,665</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,369</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(161</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Period from<BR>
January&nbsp;27,<BR>
2014<BR>
(inception) to<BR>
December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Consolidated Balance Sheet Data:

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,055</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134,896</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,386</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,517</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,265</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,089</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,593</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,855</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,775</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>140,150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,529</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,780</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,835</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>132,801</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31,101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(159</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=84,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=681509,FOLIO='80',FILE='DISK104:[18ZAA1.18ZAA41901]DQ41901A.;12',USER='JFUSS',CD=';1-MAR-2018;10:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds41901_1_81"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ds41901_item_7._management_s_discussio__ite03668"> </A>
<A NAME="toc_ds41901_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;Management's Discussion and Analysis of Financial Condition and Results of Operations    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following discussion should be read in conjunction with the consolidated financial statements and notes thereto
included elsewhere in this Annual report on Form&nbsp;10-K. This Annual Report on Form&nbsp;10-K, including the following sections, contains forward-looking statements within the meaning of the
federal securities laws. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking
statements. For a detailed discussion of these risks and uncertainties, see the "Risk Factors" section in Item&nbsp;1A of this Annual Report on Form&nbsp;10-K. We caution the reader not to place
undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form&nbsp;10-K. We undertake no obligation to update forward-looking statements,
which reflect events or circumstances occurring after the date of this Form&nbsp;10-K.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that
precisely target crucial enzymes and proteins in the immune system to treat patients with cancer. Since we began operations in November 2014, we have built a pipeline of five immuno-oncology programs,
three of which focus on the adenosine-cancer axis to modulate an immune response. Our lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an
immune checkpoint. In January 2016, we began enrolling patients in a large expansion cohort trial for CPI-444. This Phase&nbsp;1/1b clinical trial is designed to examine safety, tolerability,
biomarkers and preliminary efficacy of CPI-444 in several solid tumor types, both as a single agent and in combination with Genentech,&nbsp;Inc.'s cancer immunotherapy, Tecentriq&reg;
(atezolizumab), a fully humanized monoclonal antibody targeting PD-L1. In November 2016, we completed enrollment of 48 patients in the first step of the Phase&nbsp;1/1b clinical trial, which was
designed to determine the optimal dose of CPI-444 as both a single agent therapy and in combination with Tecentriq for use in the cohort expansion stage of the trial. The expansion cohort portion of
the trial enrolled patients with non-small cell lung cancer ("NSCLC"), renal cell cancer ("RCC"), melanoma ("MEL"), triple negative breast cancer ("TNBC") and other cancers including
colorectal cancer, prostate cancer, head and neck cancer and bladder cancer at 35 leading medical centers in the U.S., Australia and Canada. We have enrolled over 235 patients in this clinical trial
to date. In 2017, both the single agent and combination arms of the NSCLC and RCC cohorts met the protocol-defined criteria for expansion from 14 to 26 patients, and both arms of the RCC cohort
further met the protocol-defined criteria for expansion to 48 patients. In December 2017, Genentech began enrolling patients in a Phase&nbsp;1b/2 trial that is evaluating CPI-444 in combination with
Tecentriq in patients with NSCLC under an umbrella protocol known as Morpheus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
other product and development candidates in our pipeline also continue to advance. In January 2018, we filed an IND for our second program, an anti-CD73 monoclonal antibody
("CPI-006") that inhibits the production of adenosine. We plan to initiate a Phase&nbsp;1/1b clinical trial in the first quarter of 2018. In addition, in 2017, we selected a lead development
candidate for our ITK program and are currently conducting IND-enabling studies. We plan to initiate a Phase&nbsp;1 clinical trial for this candidate in early 2019. We expect to select a development
candidate for our third adenosine program, a small molecule antagonist of the A2B receptor, in 2018. In 2017, we in-licensed a monoclonal antibody to a novel target in immuno-oncology. This antibody
is now undergoing optimization and we expect to initiate IND-enabling studies in 2018. We believe the breadth and status of our pipeline demonstrates our management team's expertise in understanding
and developing immuno-oncology assets as well as in identifying product candidates that can be in-licensed and further developed internally to treat many types of cancer. We hold worldwide rights to
all of our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=85,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=209057,FOLIO='81',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_82"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, the majority of our efforts have been focused on the research, development and advancement of CPI-444, and we have not generated any revenue from product sales and, as a result,
we have incurred significant losses. We expect to continue to incur significant research and development and general and administrative expenses related to our operations. Our net loss for the years
ended December&nbsp;31, 2017 and 2016 was $55.7&nbsp;million and $36.4&nbsp;million, respectively. As of December&nbsp;31, 2017, we had an accumulated deficit of $123.5&nbsp;million. We
expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue our development of, seek regulatory approval for and begin to commercialize
CPI-444, and as we develop other product candidates, including our expected initiation of a Phase&nbsp;1/1b clinical trial of CPI-006 in the first quarter of 2018. Even if we achieve profitability
in the future, we may not be able to sustain profitability in subsequent periods. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
our inception and through December&nbsp;31, 2017, we have funded our operations primarily through the sale and issuance of stock. In November 2014, January 2015 and June 2015, we
received aggregate net proceeds of $33.3&nbsp;million from the sale of our Series&nbsp;A convertible preferred stock. In September 2015, we received net proceeds of $74.8&nbsp;million from the
sale of our Series&nbsp;B convertible preferred stock. On March&nbsp;22, 2016, our registration statement on Form&nbsp;S-1 (File No.&nbsp;333-208850) relating to our initial public offering
("IPO") of our common stock was declared effective by the SEC. Shares of our common stock began trading on the Nasdaq Global Market on March&nbsp;23, 2016. The IPO closed on March&nbsp;29, 2016,
pursuant to which we sold 4,700,000 shares of our common stock at a public offering price of $15.00 per share. In April 2016, we sold an additional 502,618 shares of our common stock to the
underwriters upon partial exercise of their over-allotment option, at the initial offering price of $15.00 per share. We received aggregate net proceeds of approximately $70.6&nbsp;million, after
underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all of our outstanding shares of convertible preferred stock were converted into
14.3&nbsp;million shares of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;20, 2017, we entered into a sales agreement (the "Sales Agreement") with Cowen and Company,&nbsp;LLC ("Cowen") to sell shares of the Company's common stock, from
time to time, with aggregate gross sales proceeds of up to $125,000,000, through an at-the-market equity offering program under which Cowen will act as our sales agent. The issuance and sale of shares
of common stock by us pursuant to the Sales Agreement are deemed an "at-the-market" offering under the Securities Act of 1933, as amended. Cowen is entitled to compensation for its services equal to
up to 3.0% of the gross proceeds of any shares of common stock sold through Cowen under the Sales Agreement. During the year ended December&nbsp;31, 2017, we received net proceeds of approximately
$0.7&nbsp;million from the sale of 52,569 shares of common stock pursuant to the Sales Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, we had capital resources consisting of cash, cash equivalents and marketable securities of approximately $90.1&nbsp;million. We do not expect our
existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and remaining development program of CPI-444 through commercialization. In addition, our
operating plan may change as a result of many factors, including those described in the section of this report entitled "Risk Factors" and others currently unknown to us, and we may need to seek
additional funds sooner than planned, through public or private equity, debt financings or other sources, such as strategic collaborations. Such financing would result in dilution to stockholders,
imposition of debt covenants and repayment obligations or other restrictions that may affect our business. If we raise additional capital through strategic collaboration agreements, we may have to
relinquish valuable rights to our product candidates, including possible future revenue streams. In addition, additional funding may not be available to us on
acceptable terms or at all and any additional fundraising efforts may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our
product candidates. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital due to favorable market conditions or strategic
considerations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=86,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=759601,FOLIO='82',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_83"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently have no manufacturing capabilities and do not intend to establish any such capabilities. We have no commercial manufacturing facilities for our product candidates. As such,
we are dependent on third parties to supply our product candidates according to our specifications, in sufficient quantities, on time, in compliance with appropriate regulatory standards and at
competitive prices. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Components of Results of Operations  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have not generated any revenues. We do not expect to receive any revenues from any product candidates that we develop unless and
until we obtain regulatory approval and commercialize our products or enter into revenue-generating collaboration agreements with third parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research and development expenses consist primarily of costs incurred to conduct research and development of our product candidates. We
record research and development expenses as incurred. Research and development expenses include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> external research and development expenses incurred under arrangements with third parties, such as contract research organizations, preclinical
testing organizations, contract manufacturing organizations, academic and non-profit institutions and consultants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative
future use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> license fees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to increase our research and development expenses substantially as we continue the development of our product candidates. Our current planned research and development activities
include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> enrollment and completion of our Phase&nbsp;1/1b clinical trial of CPI-444; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> process development and manufacturing of drug supply for CPI-444; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> process development and manufacturing of drug supply for CPI-006 and conducting a Phase&nbsp;1/1b clinical trial for CPI-006; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> process development and manufacturing of drug supply for our ITK product candidate to support IND-enabling studies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preclinical studies under our other programs in order to select development product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our product candidates that are in clinical development, we believe it is important to continue substantial investment in potential new product candidates to build the
value of our product candidate pipeline and our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties related to timing and cost to completion. The duration, costs
and timing of clinical trials and development of product candidates will depend on a variety of factors, including many of which are beyond our control. The process of conducting the necessary
clinical research to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=87,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=839244,FOLIO='83',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_84"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>obtain
regulatory approval is costly and time consuming, and the successful development of our product candidates is uncertain. The risks and uncertainties associated with our research and development
projects are discussed more fully in "Part&nbsp;1, Item&nbsp;1A&#151;Risk Factors." As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the
duration and completion costs of our research and development projects or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that
obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expenses  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses include personnel costs, expenses for outside professional services and allocated expenses. Personnel costs
consist of salaries, benefits and stock-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent
expense related to our office and research and development facility. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and potential
commercialization of one or more of our product candidates. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Results of Operations  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of the periods below as indicated (in thousands):  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change<BR>
2016 to 2017 </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change<BR>
2015 to 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29,356</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,352</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,949</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,004</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,219</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,620</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,418</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,599</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,202 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,524</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,976</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,206 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(56,524</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,976</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,206</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of convertible preferred stock liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income and other expense, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>861</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>260</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>566 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(55,663</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,040</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense for the years ended December&nbsp;31, 2017 and 2016, consisted of the following costs by program (specific
program costs consist solely of external costs): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change<BR>
2016 to 2017 </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change<BR>
2015 to 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CPI-444</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,156</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,092</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,006</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,058</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CPI-006</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,823</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>315</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,508</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ITK Inhibitor</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>539</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,116</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Programs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>581</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>591</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>181</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unallocated employee and overhead costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,769</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,137</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,225</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,632</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,912 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46,305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,356</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,352</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,004 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=88,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1040969,FOLIO='84',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_85"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2017, the increase in CPI-444 costs of $11.0&nbsp;million as compared to the year ended December&nbsp;31, 2016, primarily consisted of an
increase of $4.2&nbsp;million in clinical trial costs related to our Phase&nbsp;1/1b clinical trial, an increase of $1.6&nbsp;million in drug manufacturing costs to support our clinical trial,
an increase of $2.2&nbsp;million in contracted research costs, and a $3.0&nbsp;million license payment to Vernalis in 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2017, the increase in CPI-006 costs of $3.2&nbsp;million as compared to the year ended December&nbsp;31, 2016, primarily consisted of an
increase of $2.3&nbsp;million in drug manufacturing costs and increase of $0.8&nbsp;million in IND-enabling study costs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2017, the increase in ITK program costs of $0.1&nbsp;million as compared to the year ended December&nbsp;31, 2016, primarily consisted of
pre-clinical costs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2017, costs related to other programs of $0.6&nbsp;million were comparable to the year ended December&nbsp;31, 2016, and primarily consisted of
outside chemical synthesis and testing of research compounds. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2017, the increase in unallocated costs of $2.6&nbsp;million as compared to the year ended December&nbsp;31, 2016, primarily consisted of a
$2.1&nbsp;million increase in personnel and related costs due to an increase in headcount (including an increase in stock compensation expense of $1.0&nbsp;million). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, the increase in CPI-444 costs of $8.1&nbsp;million as compared to the year ended December&nbsp;31, 2015, primarily consisted of an
increase of $6.5&nbsp;million in clinical trial costs related to our Phase&nbsp;1/1b clinical trial that started in 2016, an increase of $1.1&nbsp;million in drug manufacturing costs to support
our clinical trial, and an increase of $1.1&nbsp;million of biology research activities which increases were partially offset by a $1.0&nbsp;million license payment to Vernalis in 2015. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, the increase in CPI-006 costs of $2.5&nbsp;million as compared to the year ended December&nbsp;31, 2015, primarily consisted of an
increase of $2.2&nbsp;million in drug manufacturing costs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, the increase in ITK costs of $1.1&nbsp;million as compared to the year ended December&nbsp;31, 2015, primarily consisted of an increase
of $0.5&nbsp;million in manufacturing costs and $0.6&nbsp;million in outside biology and pre-clinical costs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, the increase in other program costs of $0.4&nbsp;million as compared to the year ended December&nbsp;31, 2015, primarily consisted of an
increase in outside chemical synthesis and testing of research compounds. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, the increase in unallocated costs of $5.9&nbsp;million as compared to the year ended December&nbsp;31, 2015, primarily consisted of an
increase of $4.5&nbsp;million in personnel and related costs due to an increase in headcount (including an increase in stock compensation expense of $1.4&nbsp;million), an increase of
$0.9&nbsp;million in facility and related overhead costs and an increase of $0.4&nbsp;million in laboratory supplies and materials. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2017, the increase in general and administrative expenses of $2.6&nbsp;million as compared to the year
ended December&nbsp;31, 2016, primarily consisted of an increase of $1.8&nbsp;million in personnel and related costs associated with an increase in headcount (including an increase in stock
compensation expense of $1.4&nbsp;million), an increase of $0.7&nbsp;million in costs associated with being a public company and an increase of $0.1&nbsp;million in facility related expenses. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2016, the increase in general and administrative expenses of $5.2&nbsp;million as compared to the year ended December&nbsp;31, 2015, primarily
consisted of an increase of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=89,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=934506,FOLIO='85',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_86"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>$3.1&nbsp;million
in personnel and related costs associated with an increase in headcount (including an increase in stock compensation expense of $2.0&nbsp;million), an increase of
$0.9&nbsp;million in costs associated with being a public company, an increase of $0.6&nbsp;million in patent and related costs and an increase of $0.2&nbsp;million in facility related expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in Fair Value of Convertible Preferred Stock Liability  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the issuance of shares of our Series&nbsp;A convertible preferred stock in November 2014, we granted a second tranche
option to the Series&nbsp;A investors to purchase 4,460,715 shares of our Series&nbsp;A convertible preferred stock upon the achievement of certain milestones. At initial recognition, we recorded
the option as a liability on our balance sheet at its estimated fair value of $2.6&nbsp;million. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of the convertible preferred stock liability at December&nbsp;31, 2014 was $2.6&nbsp;million, resulting in no gain or loss on remeasurement for the period from
January&nbsp;27, 2014 (inception) to December&nbsp;31, 2014. In June 2015, we achieved the relevant milestones, and the investors exercised their right to purchase 4,460,715 shares of
Series&nbsp;A convertible preferred stock for net proceeds of $16.7&nbsp;million. Immediately prior to the closing of this tranche, we remeasured the convertible preferred stock liability to its
then fair value and recorded a loss from remeasurement of $17.6&nbsp;million in our statement of operations to bring the convertible preferred stock liability to its then fair value of
$20.2&nbsp;million, which was reclassified to convertible preferred stock upon the closing of the second tranche. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sources of Liquidity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, we had cash, cash equivalents and marketable securities of $90.1&nbsp;million and an accumulated deficit of
$123.5&nbsp;million, compared to cash, cash equivalents and marketable securities of $134.9&nbsp;million and an accumulated deficit of $67.9&nbsp;million as of December&nbsp;31, 2016. We have
financed our operations primarily through sales of our common stock in conjunction with the initial public offering ("IPO") and convertible preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2016, we consummated our IPO and sold 4,700,000 shares of our common stock at a price of $15.00 per share, and in April 2016, sold 502,618 shares at a price of $15.00 per share
pursuant to the partial exercise of the underwriters' option to purchase additional shares of common stock. We received net proceeds of approximately $70.6&nbsp;million, after deducting underwriting
discounts, commissions and estimated offering expenses. Immediately prior to the consummation of our IPO, all outstanding shares of the convertible preferred stock were converted into common stock on
a one-for-one basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;20, 2017, we entered into a sales agreement (the "Sales Agreement") with Cowen and Company,&nbsp;LLC ("Cowen") to sell shares of the Company's common stock, from
time to time, with aggregate gross sales proceeds of up to $125,000,000, through an at-the-market equity offering program under which Cowen will act as our sales agent. The issuance and sale of shares
of common stock by us pursuant to the Sales Agreement are deemed an "at-the-market" offering under the Securities Act of 1933, as amended. Cowen is entitled to compensation for its services equal to
up to 3.0% of the gross proceeds of any shares of common stock sold through Cowen under the Sales Agreement. During the year ended December&nbsp;31, 2017, we received net proceeds of approximately
$0.7&nbsp;million from the sale of 52,569 shares of common stock pursuant to the Sales Agreement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe our current cash, cash equivalents and marketable securities will be sufficient to fund our planned expenditures and meet our obligations through at least the next twelve
months from the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=90,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=755648,FOLIO='86',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_87"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>issuance
of these financial statements. The amounts and timing of our actual expenditures depend on numerous factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the initiation, progress, timing, costs and results of clinical trials for CPI-444; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing, progress, costs and results of preclinical and clinical development activities for our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and scope of preclinical and clinical programs we decide to pursue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs involved in prosecuting, maintaining and enforcing patent and other intellectual property rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost and timing of regulatory approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates
and satisfy our obligations as a public company; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> other factors described in the section of this report entitled "Risk Factors." </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect to increase our spending in connection with the development and commercialization of our product candidates. Until such time, if ever, as we can generate substantial revenue
from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financings. We may also enter into additional collaboration arrangements or selectively
partner for clinical development and commercialization. The sale of additional equity would result in dilution to our
stockholders. The incurrence of debt financing would result in debt service obligations and the governing documents would likely include operating and financing covenants that would restrict our
operations. In addition, sufficient additional funding may not be available on acceptable terms, or at all. If we are not able to secure adequate additional funding, we may be forced to make
reductions in spending, extend payment terms with suppliers, liquidate assets where possible and/or suspend or curtail planned programs. Any of these actions could have a material effect on our
business, financial condition and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of Statement of Cash Flows  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our cash flows for the periods indicated (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change<BR>
2016 to 2017 </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change<BR>
2015 to 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by (used in)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(27,857</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,355</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,529</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84,826</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(42,556</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(92,032</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>127,382</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,476</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71,358</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>94,948</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(69,916</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,590</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in csh and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,056</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,357 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash Flows from Operating Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash used in operating activities during the year ended December&nbsp;31, 2017 was $46.2&nbsp;million, which primarily consisted of a net
loss of $55.7&nbsp;million, adjusted by non-cash charges of $6.9&nbsp;million, primarily consisting of $6.2&nbsp;million of stock compensation expense and $0.8&nbsp;million of depreciation
expense, an increase of $3.1&nbsp;million in accounts payable and accrued and other liabilities, primarily associated with our increased research and development activities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=91,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=431589,FOLIO='87',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_88"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
used in operating activities during the year ended December&nbsp;31, 2016 was $27.9&nbsp;million, which primarily consisted of a net loss of $36.4&nbsp;million, adjusted by
non-cash charges of $5.1&nbsp;million and a net change of $3.4&nbsp;million in our net operating assets. The non-cash charges were primarily associated with stock-based compensation expense of
$3.8&nbsp;million. The change in our net operating assets and liabilities was primarily attributable to an increase in accounts payable and accrued and other liabilities of $3.4&nbsp;million,
which was primarily due to the timing of payments to vendors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
used in operating activities during the year ended December&nbsp;31, 2015 was $11.3&nbsp;million, which consisted of a net loss of $31.3&nbsp;million, adjusted by non-cash
charges of $18.2&nbsp;million and a net change of $1.8&nbsp;million in our net operating assets. The non-cash charges are primarily associated with remeasurement of our convertible preferred stock
liability to fair value of $17.6&nbsp;million. The change in our net operating assets and liabilities was primarily due to an increase of $1.3&nbsp;million of prepaid and other current assets,
including prepaid drug purchases of $0.7&nbsp;million and receivables from our landlord of $0.3&nbsp;million in connection with improvements to our facility, offset by increases in short-term
liabilities of $2.5&nbsp;million and increased long-term liabilities of $0.6&nbsp;million, primarily in connection with deferred rent. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash Flows from Investing Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by investing activities during the year ended December&nbsp;31, 2017 was $84.8&nbsp;million, which consisted of proceeds from
maturities of marketable securities of $173.4&nbsp;million, which was partially offset by purchases of marketable securities of $88.3&nbsp;million and purchases of property and equipment of
$0.3&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
used in investing activities during the year ended December&nbsp;31, 2016 was $42.6&nbsp;million, which consisted of purchases of marketable securities of $258.3&nbsp;million
and purchases of property and equipment of $2.2&nbsp;million, which were partially offset by proceeds from maturities and sales of marketable securities of $217.9&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
used in investing activities during the year ended December&nbsp;31, 2015 was $92.0&nbsp;million, which consisted of $1.7&nbsp;million of capital expenditures to purchase
property and equipment and $104.4&nbsp;million of purchases of short-term marketable securities, offset by $14.1&nbsp;million in proceeds from the maturity of marketable securities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash Flows from Financing Activities  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash provided by financing activities during the year ended December&nbsp;31, 2017 was $1.4&nbsp;million, consisting of $0.7&nbsp;million
of stock sales and $0.7&nbsp;million of proceeds from the exercise of stock options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
provided by financing activities during the year ended December&nbsp;31, 2016 was $71.4&nbsp;million, consisting of the net proceeds from our IPO. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
provided by financing activities during the year ended December&nbsp;31, 2015 was $94.9&nbsp;million, primarily consisting of net proceeds from the issuances of convertible
preferred stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-Balance Sheet Arrangements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=92,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1023634,FOLIO='88',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_89"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contractual Obligations  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We lease our facilities under a non-cancelable operating lease that expires in 2021. As of December&nbsp;31, 2017, contractual obligations
were as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payment Due by Period </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Less than<BR>
1&nbsp;year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2&nbsp;- 3&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>4&nbsp;- 5&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>More than<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Contractual obligations:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,632</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total contractual obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,632</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2015 we entered into an agreement for a line of credit of $0.1&nbsp;million for the purpose of issuing our landlord a letter of credit of $0.1&nbsp;million as a security
deposit under our facility lease. We pledged money market funds and marketable securities as collateral for the line of credit. Pursuant to our license agreements with each of Vernalis and Scripps, we
have obligations to make future milestone
and royalty payments to these parties. However, because these amounts are contingent, they have not been included on our balance sheet. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Critical Accounting Policies  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management's discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with United States generally accepted accounting principles ("U.S.&nbsp;GAAP"). The preparation of these consolidated financial statements requires our
management to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we
believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these judgments and estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies
discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management's judgments and estimates. Our
significant accounting policies are more fully described in Note&nbsp;2 of Notes to Consolidated Financial Statements in Part&nbsp;II, Item&nbsp;8 of this Annual Report on Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash, Cash Equivalents and Marketable Securities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consider all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash
equivalents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments
with remaining maturities, at the date of purchase, greater than three months, but less than one year are considered short-term. We determined the appropriate classification
of marketable securities at the time of purchase and evaluates such designation as of each balance sheet date. To date, all marketable securities have been classified as available-for-sale and are
carried at fair value with unrealized gains and losses, if any, included as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Interest and realized gains
and losses are included in interest income. Realized gains and losses are recognized based on the specific identification method. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=93,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=298706,FOLIO='89',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_90"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We record research and development expenses as incurred. We account for nonrefundable advance payments for goods and services that will be used
in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. Research and development
expenses consist of costs incurred by us for the discovery and development of our product candidates and include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> external research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract
manufacturing organizations, academic and non-profit institutions and consultants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative
future use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> license fees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Trial Accruals  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors' progress towards completion of
specific tasks, using data such as clinical site activations, patient enrollment or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are
based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. We determine accrual estimates through reports from and
discussions with applicable personnel and outside service providers as to the progress or state of completion, or the services completed. Our estimates of accrued expenses as of each balance sheet
date are based on the facts and circumstances known at the time. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain incentive plans under which incentive stock options and nonqualified stock options may be granted to employees and non-employee
service providers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
account for stock-based employee compensation arrangements in accordance with the provisions of ASC 718, "Compensation&#151;Stock Compensation." For stock options granted to
employees, we recognize compensation expense for all stock-based awards based on the grant-date estimated fair values. The value of the award is recognized as an expense ratably over the requisite
service period. The fair value of stock options is determined using the Black-Scholes option pricing model. Forfeitures are accounted for when they occur. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based
compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option
pricing model. The expense for options granted to non-employees is periodically re-measured as the underlying options vest. The awards generally vest over the time period we expect to receive service
from the non-employee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We account for income taxes under the asset and liability method. We estimate actual current tax exposure together with assessing temporary
differences resulting from differences in accounting for </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=94,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=385399,FOLIO='90',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_91"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reporting
purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and
liabilities, which are included in our balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in our statements of
operations and comprehensive loss become deductible expenses, under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of our deferred
tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
must assess the likelihood that our deferred tax assets will be recovered from future taxable income and a valuation allowance is recorded when it is more likely than not that the
deferred tax asset will not be recovered in the future. We apply judgment in the determination of the financial statement recognition and measurement of a tax position taken or expected to be taken in
a tax return. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future.
Accordingly, we recorded a full valuation allowance for all periods presented. We intend to maintain a valuation allowance until sufficient evidence exists to support its reversal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
recognize benefits of uncertain tax positions if it is more likely than not such positions will be sustained upon examination based solely on their technical merits as the largest
amount of benefit that is more likely than not to be realized upon the ultimate settlement. We recognize any material interest and penalties related to unrecognized tax benefits in income tax expense.
We are required to file income tax returns in the U.S. federal jurisdiction. We are not currently under examination by the Internal Revenue Service or other jurisdictions for any tax years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;22, 2017, the 2017 Tax Cuts and Jobs Act (the "Tax Act") was enacted into law and the new legislation contains several key tax provisions that affected us, including a
one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January&nbsp;1, 2018, among others. We are required to recognize
the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S.
deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin
No.&nbsp;118, </FONT><FONT SIZE=2><I>Income Tax Accounting Implications of the Tax Cuts and Jobs Act</I></FONT><FONT SIZE=2> (SAB&nbsp;118), which allows us to record provisional amounts during a
measurement period not to extend beyond one year of the enactment date. We consider the accounting of the transition tax and deferred tax re-measurements to be complete&#151;however, since the
Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12&nbsp;months, we are not yet able to reasonably estimate the
effect of Global Intangible Low Taxed Income ("GILTI") and have not yet made a policy decision regarding whether to record deferred taxes on GILTI. We expect to complete our analysis within the
measurement period in accordance with SAB&nbsp;118. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Accounting Pronouncements  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Note&nbsp;2 in Item&nbsp;8 "Financial Statements and Supplementary Data." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segment Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have one primary business activity and operate as one reportable segment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


JOBS Act Accounting Election  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised
accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this
exemption from new or revised accounting standards </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=95,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=288291,FOLIO='91',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<A NAME="page_ds41901_1_92"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>and,
therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We also intend to rely on other exemptions provided by
the JOBS Act, including, without limitation, providing an auditor's attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404(b) of the
Sarbanes-Oxley Act. We will remain an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2021, (2)&nbsp;the last day of the fiscal year in which we have total annual gross
revenue of at least $1.07&nbsp;billion, (3)&nbsp;the last day of the fiscal year in which we are deemed to be a "large accelerated filer" as defined in Rule&nbsp;12b-2 under the Exchange Act,
which would occur if the market value of our common stock held by non-affiliates exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such fiscal year, or
(4)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt securities during the prior three-year period.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ds41901_item_7a._quantitative_and_qual__ite02669"> </A>
<A NAME="toc_ds41901_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;7A.&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures about Market Risk    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents and marketable securities of
$90.1&nbsp;million as of December&nbsp;31, 2017, which consisted of U.S. government agency securities and corporate debt obligations. Such interest-earning instruments carry a degree of interest
rate risk; however, historical fluctuations of interest income have not been significant. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an
immediate 10% increase in interest rates would not have a material effect on the fair market value of our portfolio. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not have any foreign currency or other derivative financial instruments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=96,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=138180,FOLIO='92',FILE='DISK104:[18ZAA1.18ZAA41901]DS41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_du41901_1_93"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<A NAME="du41901_index_to_consolidated_financial_statements"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="du41901_item_8._financial_statements_and_supplementary_data"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Supplementary Data    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="du41901_corvus_pharmaceuticals,_inc._a__cor03716"> </A>
<BR></FONT><FONT SIZE=2><B>  CORVUS PHARMACEUTICALS,&nbsp;INC.    <BR>    <BR>    ANNUAL REPORT ON FORM 10-K    <BR>    <BR>    INDEX TO CONSOLIDATED FINANCIAL STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="DU41901_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#Report"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#Report"><FONT SIZE=2>94</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Financial Statements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#CBS"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Balance Sheets</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#CBS"><FONT SIZE=2>95</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#CSOP"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Operations and Comprehensive Loss</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#CSOP"><FONT SIZE=2>96</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#CSOC"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#CSOC"><FONT SIZE=2>97</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#CSOCF"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Cash Flows</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#CSOCF"><FONT SIZE=2>98</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#NCFS"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Consolidated Financial Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#NCFS"><FONT SIZE=2>99</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=97,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=307230,FOLIO='93',FILE='DISK104:[18ZAA1.18ZAA41901]DU41901A.;8',USER='CHE105948',CD='28-FEB-2018;21:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fc41901_1_94"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="Report"></A>Report of Independent Registered Public Accounting Firm  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>To
the Board of Directors and Stockholders of Corvus Pharmaceuticals,&nbsp;Inc.: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Opinion on the Financial Statements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have audited the accompanying consolidated balance sheets of Corvus Pharmaceuticals,&nbsp;Inc. and its subsidiaries as of
December&nbsp;31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders' equity (deficit), and cash
flows for each of the three years in the period ended December&nbsp;31, 2017, including the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the
consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2017 and 2016, and the results of its operations and its
cash flows for each of the three years in the period ended December&nbsp;31, 2017 in conformity with accounting principles generally accepted in the United States of America. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis for Opinion  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the
Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to
perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our
audits provide a reasonable basis for our opinion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers&nbsp;LLP </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>San
Jose, California<BR>
March&nbsp;1, 2018 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have served as the Company's auditor since 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=98,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=5957,FOLIO='94',FILE='DISK104:[18ZAA1.18ZAA41901]FC41901A.;7',USER='CHE109696',CD='28-FEB-2018;20:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fe41901_1_95"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="CBS"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED BALANCE SHEETS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (in thousands, except share and per share data)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>45,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,949</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>129,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,179</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,137 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>91,234</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>136,033</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,672</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>869</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>869 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>94,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>140,150 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities and Stockholders' Equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,454</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,900</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued and other liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,515</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,044 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,944</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>971</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,405 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,940</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,349 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies </FONT><FONT SIZE=2><I>(Note&nbsp;13)</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock: $0.0001 par value; 10,000,000 shares authorized at December&nbsp;31, 2017 and December&nbsp;31, 2016; 0 shares issued and outstanding at
December&nbsp;31, 2017 and December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock: $0.0001 par value; 290,000,000 shares authorized at December&nbsp;31, 2017 and December&nbsp;31, 2016; 21,041,250 and 20,922,428 shares
issued and outstanding at December&nbsp;31, 2017 and December&nbsp;31, 2016, respectively&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>208,408</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>200,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(123,534</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(67,871</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84,835</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>132,801 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities and stockholders' equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>94,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>140,150 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=99,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=899507,FOLIO='95',FILE='DISK104:[18ZAA1.18ZAA41901]FE41901A.;8',USER='CHE105948',CD='28-FEB-2018;20:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fg41901_1_96"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="CSOP"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (in thousands, except share and per share data)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46,305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,356</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,352</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,219</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,620</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,418 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,770 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(56,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(36,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13,770</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of convertible preferred stock liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(17,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income and other expense, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>861</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>601</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(55,663</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(36,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31,335</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share, basic and diluted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(83.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares used to compute net loss per share, basic and diluted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,488,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,422,041</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>373,643 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income (loss):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrealized gain (loss) on marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(55,665</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(36,369</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31,380</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=100,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=833227,FOLIO='96',FILE='DISK104:[18ZAA1.18ZAA41901]FG41901A.;4',USER='CHE105948',CD='28-FEB-2018;20:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fi41901_1_97"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="CSOC"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (in thousands, except share and per share data)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Convertible Preferred Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumlated<BR>
Other<BR>
Comprehensive<BR>
Income </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aditional<BR>
Paid-in<BR>
Capital </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumelated<BR>
Deficit </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Stockholders'<BR>
Equity </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance at December&nbsp;31, 2014</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,395,468</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,011</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,046,749</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(161</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(159</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series&nbsp;A convertible preferred stock, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,525,961</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,730</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Reclassification of convertible preferred stock liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series&nbsp;B convertible preferred stock, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,353,312</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>74,839</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of common stock for cash upon early exercise of stock options and lapse of restrictions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>384,866</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>428</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>428</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Unrealized loss on marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(31,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(31,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance at December&nbsp;31, 2015</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,274,741</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>125,780</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,431,615</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(31,496</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(31,101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Conversion of Series&nbsp;A and B convertible preferred stock into common stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(14,274,741</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(125,780</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,274,741</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>125,779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>125,780</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of common stock upon initial public offering, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,202,618</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>70,624</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>70,625</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Common stock issued on exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,454</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Vesting of restricted stocks issued upon early exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,828</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,828</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Unrealized gain on marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(36,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(36,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance at December&nbsp;31, 2016</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,922,428</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>200,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(67,871</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>132,801</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of common stock in conjunction with the Sales Agreement, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>52,569</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Common stock issued on exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>66,253</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>731</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>731</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Vesting of restricted stocks issued upon early exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,229</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,229</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Unrealized gain on marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(55,663</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(55,663</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance at December&nbsp;31, 2017</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>21,041,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>208,408</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(123,534</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>84,835 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0.75pt;font-size:0.75pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=101,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=246846,FOLIO='97',FILE='DISK104:[18ZAA1.18ZAA41901]FI41901A.;14',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fk41901_1_98"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="CSOCF"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CONSOLIDATED STATEMENTS OF CASH FLOWS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (in thousands)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from operating activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(55,663</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>842</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>594</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>148</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization (accretion) related to marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(195</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>648</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,229</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,828</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>428</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value of convertible preferred stock liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>290</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,265</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(869</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,554</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>518</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,240</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued and other liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,499</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,814</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,218</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other long-term liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(434</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>639 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,212</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(27,857</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from investing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(88,309</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(258,281</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(104,385</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sales of marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,199</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturities of marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>173,401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>213,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchase of property and equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(266</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,199</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,747</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84,826</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(42,556</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(92,032</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from financing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of common stock, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71,354</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of convertible preferred stock, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>95,569</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payment of offering costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(729</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from exercise of common stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>731</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>108 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71,358</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>94,948 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase in cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,056</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at beginning of the period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,517 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at end of the period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>45,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,105 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Supplemental disclosures of cash flow information</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property and equipment incurred but not paid</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>84</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred offering costs incurred but not paid</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>222</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=102,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=902807,FOLIO='98',FILE='DISK104:[18ZAA1.18ZAA41901]FK41901A.;4',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fm41901_1_99"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="NCFS"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Organization  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corvus Pharmaceuticals,&nbsp;Inc. ("Corvus" or the "Company") was incorporated in Delaware on January&nbsp;27, 2014 and commenced operations in November 2014. Corvus is a clinical
stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The Company's
operations are located in Burlingame, California. The Company has four insignificant subsidiaries. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of Presentation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United
States of America ("U.S.&nbsp;GAAP"). The Company's functional and reporting currency is the U.S. dollar. The accompanying consolidated financial statements have been prepared on a going-concern
basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. Since its inception, the Company has incurred significant losses and negative cash
flows from operations. As of December&nbsp;31, 2017, the Company had an accumulated deficit of $123.5&nbsp;million and cash, cash equivalents and marketable securities of $90.1&nbsp;million. The
Company has financed its operations primarily with the proceeds from the sale of stock. The Company will need to raise additional capital to meet its business objectives. The Company believes that its
current cash, cash equivalents and marketable securities will be sufficient to fund its planned expenditures and meet its obligations through at least the next twelve months from the issuance of these
financial statements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of Estimates  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of the Company's consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and
assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Initial Public Offering  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;22, 2016, the Company's registration statement on Form&nbsp;S-1 (File No.&nbsp;333-208850) relating to its initial public
offering ("IPO") of its common stock was declared effective by the Securities and Exchange Commission ("SEC") and the shares of its common stock began trading on the Nasdaq Global Market on
March&nbsp;23, 2016. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on March&nbsp;29, 2016, pursuant to which the Company sold 4,700,000 shares of its
common stock. On April&nbsp;26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial
offering price of $15.00 per share. The Company received aggregate net proceeds of approximately $70.6&nbsp;million, after underwriting discounts, commissions and offering expenses. Immediately
prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stocks. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=103,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=779064,FOLIO='99',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_100"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Concentrations of Credit Risk and Other Risks and Uncertainties  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Substantially all of the Company's cash and cash equivalents are deposited in accounts with two financial institutions that management believes
are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are
subject to minimal credit risk. The Company's marketable securities consist of investments in U.S. Treasury securities, U.S. government agency securities and corporate debt obligations, which can be
subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness
of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding,
possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors
developing new technological
innovations, the need to successfully commercialize and gain market acceptance of the Company's product candidates, its right to develop and commercialize its product candidates pursuant to the terms
and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be
unable to generate product revenue or achieve profitability. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segments  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment,
that of the development of and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash, Cash Equivalents and Marketable Securities  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be
cash equivalents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments
with remaining maturities, at the date of purchase, greater than three months, but less than one year are considered short-term. The Company determines the appropriate
classification of marketable securities at the time of purchase and evaluates such designation as of each balance sheet date. To date, all marketable securities have been classified as
available-for-sale and are carried at fair value with unrealized gains and losses, if any, included as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit).
Interest and realized gains and losses are included in interest income. Realized gains and losses are recognized based on the specific identification method. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=104,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=274029,FOLIO='100',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_101"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair Value Measurements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or
disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company's financial instruments, including cash equivalents,
accounts payable and accrued liabilities, approximate fair value due to their short-term maturities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deferred Offering Costs  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred offering costs consist primarily of direct incremental costs related to the Company's initial public offering of its common stock. Upon
completion of the initial public offering in March 2016, these amounts were offset against the proceeds of the offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Property and Equipment, Net  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the respective
assets: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="310pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equiipment and purchased software</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Shorter of asset's useful life or remaining term of lease</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintenance
and repairs that do not extend the life or improve the asset are expensed when incurred. When assets are retired or otherwise disposed of, the cost and accumulated
depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Impairment of Long-Lived Assets  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to
determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of
the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives.
Should impairment exist, the impairment loss to be recognized is measured by the amount by which the carrying amount of the asset exceeds the projected discounted future net cash flows arising from
the asset. All long-lived assets are maintained in the United States of America. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Consolidation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and
transactions have been eliminated in consolidation </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records research and development expenses as incurred. The Company accounts for nonrefundable advance payments for goods and
services that will be used in future research and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=105,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=346365,FOLIO='101',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_102"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>development
activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. Research and development expenses consist of costs
incurred by the Company for the discovery and development of the Company's product candidates and include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> external research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract
manufacturing organizations, academic and non-profit institutions and consultants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative
future use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> license fees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Trial Accruals  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors' progress towards completion of
specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these
activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates
through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion, or the services completed. The Company's estimates of accrued
expenses as of each balance sheet date are based on the facts and circumstances known at the time. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains incentive plans under which incentive stock options and nonqualified stock options may be granted to employees and
non-employee service providers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company accounts for stock-based employee compensation arrangements in accordance with the provisions of ASC 718, "Compensation&#151;Stock Compensation." For stock options
granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values. The value of the award is recognized as an expense ratably
over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. Forfeitures are accounted for when they occur. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based
compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option
pricing model. The expense for options granted to non-employees is periodically re-measured as the underlying options vest. The awards generally vest over the time period the Company expects to
receive service from the non-employee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=106,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1015799,FOLIO='102',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_103"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for income taxes under the asset and liability method. The Company estimates actual current tax exposure together with
assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax
purposes. These temporary differences result in deferred tax assets and liabilities, which are included in the Company's balance sheets. In general, deferred tax assets represent future tax benefits
to be received when certain expenses previously recognized in the Company's statements of operations and comprehensive loss become deductible expenses, under applicable income tax laws or when net
operating loss or credit carryforwards are utilized. Accordingly, realization of the Company's deferred tax assets is dependent on future taxable income against which these deductions, losses and
credits can be utilized. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income and a valuation allowance is recorded when it is more likely
than not that the deferred tax asset will not be recovered. The Company applies judgment in the determination of the financial statement recognition and measurement of a tax position taken or expected
to be taken in a tax return. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be
utilized in the future. Accordingly, the Company recorded a full valuation allowance for all periods presented. The Company intends to maintain a valuation allowance until sufficient evidence exists
to support its reversal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recognizes benefits of uncertain tax positions if it is more likely than not such positions will be sustained upon examination based solely on their technical merits as the
largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company recognizes any material interest and penalties related to unrecognized tax benefits in
income tax expense. The Company is required to file income tax returns in the U.S. federal jurisdiction. The Company currently is not under examination by the Internal Revenue Service or other
jurisdictions for any tax years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;22, 2017, the 2017 Tax Cuts and Jobs Act (the "Tax Act") was enacted into law and the new legislation contains several key tax provisions that affected us, including a
one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January&nbsp;1, 2018, among others. We are required to recognize
the effect of the tax law
changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax
assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No.&nbsp;118, </FONT><FONT SIZE=2><I>Income Tax Accounting Implications of the Tax Cuts and Jobs
Act</I></FONT><FONT SIZE=2> (SAB&nbsp;118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. We consider the accounting
of the transition tax and deferred tax re-measurements to be complete&#151;however, since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting
interpretation are expected over the next 12&nbsp;months, we are not yet able to reasonably estimate the effect of Global Intangible Low Taxed Income ("GILTI") and have not yet made a policy
decision regarding whether to record deferred taxes on GILTI. We expect to complete our analysis within the measurement period in accordance with SAB&nbsp;118. See Note&nbsp;12 in these notes to
the consolidated financial statements for additional information. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=107,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=847902,FOLIO='103',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_104"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comprehensive Loss  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic
events other than those with stockholders. The Company's only element of other comprehensive loss in any period presented was unrealized gains and losses on available for sale marketable securities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss per Share  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period,
without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and potentially dilutive
securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock subject to repurchase, and stock options are considered
to be potentially dilutive securities. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those
periods. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Accounting Pronouncements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&nbsp;2014-09, Revenue from
Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU
No.&nbsp;2014-09 will replace most existing revenue recognition guidance in U.S.&nbsp;GAAP when it becomes effective. The new standard is effective January&nbsp;1, 2018 for public companies.
Early application is permitted as of January&nbsp;1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. In March 2016, the FASB issued ASU
No.&nbsp;2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on
principal versus agent considerations in ASU No.&nbsp;2014-09. In April 2016, the FASB issued ASU No.&nbsp;2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance
Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No.&nbsp;2016-12, Revenue
from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to
guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of
January&nbsp;1, 2018. The Company does not believe adopting this guidance will have a material impact on its consolidated financial statements as the Company is not yet generating revenues. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, the FASB issued ASU No.&nbsp;2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard requires lessees to record right of use assets and
corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition
in the statement of income. The standard is effective for the Company beginning January&nbsp;1, 2019, with early application permitted. The new standard is required to be applied with a modified
retrospective approach to each prior </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=108,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=999829,FOLIO='104',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_105"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reporting
period presented with various optional practical expedients. The Company is currently assessing the impact of this guidance on its consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2017, the FASB issued ASU No 2017-09, Compensation&#151;Stock Compensation (Topic&nbsp;718)&#151;Scope of Modification Accounting, to clarify when to account for a
change to the terms or conditions of a share-based payment award as a modification. Under the new standard, modification is required only if the fair value, the vesting conditions, or the
classification of an award as equity or liability changes as a result of the change in terms or conditions. ASU 2017-09 will be
effective for the Company beginning January&nbsp;1, 2018 and will be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its
consolidated financial statements. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Net Loss per Share  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the calculation of net loss per share (in thousands, except share and per share data): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(55,663</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(36,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(31,335</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,958,557</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,188,980</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,269,315</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: weighted average common shares subject to repurchase</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(470,051</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(766,939</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(895,672</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding used to compute basic and diluted net loss per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,488,506</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,422,041</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>373,643 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(83.86</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferrd stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,274,741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock subject to repurchase</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>319,203</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>611,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>924,535</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,013,394</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,350,582</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>784,136 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shares of common stock equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,332,597</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,962,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,983,412 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value Measurements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that
enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value
hierarchy applies only to the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=109,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=94218,FOLIO='105',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_106"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value Measurements (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>valuation
inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation
inputs:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;2&#151;Inputs other than quoted prices included within Level&nbsp;1 that are observable for the asset or liability,
either directly or indirectly </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;3&#151;Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use
in pricing the asset or liability </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
have been no transfers of assets and liabilities between levels of hierarchy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's Level&nbsp;2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and
market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the
same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following tables present information as of December&nbsp;31, 2017 and 2016 about the Company's assets that are measured at fair value on a recurring basis and indicate the level of
the fair value hierarchy the Company utilized to determine such fair values (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value Measured Using </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Balance </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(Level&nbsp;1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(Level&nbsp;2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(Level&nbsp;3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44,555</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44,555</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44,949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44,949 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>89,504</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>89,504 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value Measured Using </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Balance </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(Level&nbsp;1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(Level&nbsp;2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(Level&nbsp;3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,999</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,999</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>129,846</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>129,846 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>132,845</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>132,845 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, marketable securities had a maximum remaining maturity of nine months. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=110,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=388091,FOLIO='106',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_107"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value Measurements (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017 and 2016, the fair value of available for sale marketable securities by type of security were as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Government agency securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,311</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,272</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate debt obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,679</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,677 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44,990</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44,949 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Treasury securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>129,885</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>129,846 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. License and Collaboration Agreements  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Scripps Licensing Agreement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2014, the Company entered into a license agreement with The Scripps Research Institute ("Scripps"), pursuant to which it was granted
a non-exclusive, world-wide license for all fields of use under Scripps' rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to
progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma. Scripps also granted the Company the right to grant sublicenses in conjunction with other
proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial
licenses with respect to such materials, other than march-in rights granted to the U.S. government. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
execution of the agreement, the Company made a one-time cash payment to Scripps of $10,000 in 2015 and is also obligated to pay a minimum annual fee to Scripps of $25,000. The
one-time cash payment was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The first minimum
annual fee payment is due on the first anniversary of effective date of the agreement and will be due on each subsequent
anniversary of the effective date for the term of the agreement. The Company is also required to make performance-based cash payments upon successful completion of clinical and sales milestones. The
aggregate potential milestone payments are $2.6&nbsp;million. The Company is also required to pay royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a
rate in the low-single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates
that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date,
no milestone payments have been made. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=111,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=985898,FOLIO='107',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_108"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. License and Collaboration Agreements (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company's license agreement
with Scripps is terminable by the consent of the parties, at will by the Company upon providing 90&nbsp;days written notice to Scripps, or by Scripps for certain material breaches, or if the Company
undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product-by-product basis, or the entire agreement, if the Company fails to meet specified diligence obligations
related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably
believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure
period. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vernalis Licensing Agreement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2015, the Company entered into a license agreement with Vernalis (R&amp;D) Limited ("Vernalis"), which was subsequently amended as of
November&nbsp;5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for
all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including CPI-444. Pursuant to this agreement, the Company made a one-time cash
payment to Vernalis in the amount of $1.0&nbsp;million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no
alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on
the indications for which such licensed products are developed and upon achievement of certain sales milestones. In February 2017, the Company made a milestone payment of $3.0&nbsp;million to
Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent CPI-444 in the Company's Phase&nbsp;1/1b clinical trial. The aggregate potential milestone
payments exceed $200&nbsp;million for all indications. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing CPI-444 on a product-by-product and
country-by-country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing CPI-444 range from the mid-single digits up to the low-double digits on a
country-by-country net sales basis. The royalties on other licensed products that do not include CPI-444 also increase with the amount of net sales on a product-by-product and country-by-country basis
and range from the low-single digits up to the mid-single digits on a country-by-country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above
when worldwide net sales reach specified levels over an agreed upon time period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company's payment obligations to Vernalis in respect of a particular product and
country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing
90&nbsp;days written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also
terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=112,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=233338,FOLIO='108',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<A NAME="page_fm41901_1_109"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. License and Collaboration Agreements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Genentech Collaboration Agreement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2015, the Company entered into a clinical trial collaboration agreement with Genentech to evaluate the safety, tolerability and
preliminary efficacy of CPI-444 combined with Genentech's investigational cancer immunotherapy, Tecentriq, a fully humanized monoclonal antibody targeting protein programmed cell death ligand
1("PD-L1"), in a variety of solid tumors in a Phase&nbsp;1/1b clinical trial. Pursuant to this agreement, the Company will be responsible for the conduct and cost of the relevant studies, under the
supervision of a joint development committee made up of representatives of the Company and representatives of Genentech. Genentech will supply Tecentriq. As part of the agreement, the Company granted
Genentech certain rights of first negotiation to participate in future clinical trials that the Company may conduct evaluating the administration of CPI-444 in combination with an anti-PD-1 or
anti-PD-L1 antibody. If the Company and Genentech do not reach agreement on the terms of any such participation by Genentech within a specified time period, the Company retains the right to
collaborate with third parties in such activities. The Company also granted Genentech certain rights of first negotiation should it decide to license development and commercialization rights to
CPI-444. Should the Company and Genentech not reach agreement on the terms of such a license within a specified time period, it retains the right to enter into a license with another third party. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to
safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued. Further, the agreement will expire after a set period of time following the
provision by the Company of the final clinical study report to Genentech. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2017, the Company signed a second clinical trial collaboration agreement with Genentech. Under the new agreement, CPI-444 administered in combination with Tecentriq will be
evaluated in a Phase&nbsp;1b/2 randomized, controlled clinical study as second-line therapy in patients with non-small cell lung cancer who are resistant and/or refractory to prior therapy with an
anti-PD-(L)1 antibody. It is anticipated that the study will enroll up to 65 patients in the treatment arm. Genentech will be responsible for the conduct of the study and the parties will share the
cost of the Phase&nbsp;1b/2 trial, which began enrolling patients in the fourth quarter of 2017. The Company is responsible for supplying CPI-444 and retains global development and commercialization
rights to CPI-444. The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to
safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=113,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=617129,FOLIO='109',FILE='DISK104:[18ZAA1.18ZAA41901]FM41901A.;11',USER='CHE109696',CD='28-FEB-2018;20:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fo41901_1_110"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Balance Sheet Components (in thousands):  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Prepaid and Other Current Assets</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest receivable</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>132</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>365</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid research and development manufacturing expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>327</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>772 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,179</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,137 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Property and Equipment, net</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,034</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,868</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment and purchased software</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,078</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,051 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,242</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,977</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(729</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,672</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,248 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Accrued and Other Liabilities</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued clinical trial related</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,870</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,617</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued manufacturing expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,056</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>955</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Personnel related</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>572</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>526</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>378</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued legal and accounting</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>224</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>255</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>383</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>313 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,515</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,044 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Other Liabilities</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>960</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,370</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares subject to vesting</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>971</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,405 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Convertible Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately prior to the consummation of the IPO on March&nbsp;29, 2016, all outstanding shares of Series&nbsp;A and B convertible preferred stock were converted into 14,274,741
shares of common stock on a one-for-one basis. As such, no convertible preferred stock shares were outstanding as of December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible Preferred Stock Liability  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;26, 2014, the Company executed the Series&nbsp;A Convertible Preferred Stock Purchase Agreement for the issuance of up to 8,921,438 shares of Series&nbsp;A
convertible preferred stock and issued 3,395,468 shares for net proceeds of $12.6&nbsp;million in connection with the first closing of the first tranche. In January 2015, in connection with the
second closing of the first tranche, the Company issued 1,065,246 shares of Series&nbsp;A convertible preferred stock for net proceeds of $4.0&nbsp;million and in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=114,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=929737,FOLIO='110',FILE='DISK104:[18ZAA1.18ZAA41901]FO41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:12' -->
<A NAME="page_fo41901_1_111"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible Preferred Stock Liability (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>June
2015, in connection with the closing of the second tranche, an additional 4,460,715 shares of Series&nbsp;A convertible preferred stock were issued for net proceeds of $16.7&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Series&nbsp;A Convertible Preferred Stock Purchase Agreement provided that, upon the earliest to occur of any of three defined triggers, each investor of the first tranche agreed
to purchase its pro-rata portion of the shares to be issued in the second tranche and the Company agreed to sell and issue said shares of Series&nbsp;A convertible preferred stock on the same terms
as the first tranche. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
convertible preferred stock liability was recorded for the Company's obligation to sell the second tranche of the Series&nbsp;A convertible preferred stock to the first tranche
stockholders at a fixed price of $3.755 per share upon the satisfaction of certain conditions. A liability was initially recorded in connection with the first tranche of the Series&nbsp;A
convertible preferred stock financing at its initial estimated fair value of $2.6&nbsp;million, with gains and losses arising from changes in fair value recognized in the statements of operations at
each period while such instrument was classified as a liability. A $17.6&nbsp;million charge was recorded for the change in estimated fair value of the Series&nbsp;A convertible preferred stock
liability for the period from January&nbsp;1, 2015 to the closing of the second tranche in June
2015. Upon the closing of the second tranche in June 2015, the liability terminated and the balance of the liability of $20.2&nbsp;million was reclassified to convertible preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
preferred stock liability related to Series&nbsp;A convertible preferred stock was valued at issuance and at December&nbsp;31, 2014 and March&nbsp;31, 2015 using a black
scholes option-pricing method based on the consideration paid for the Series&nbsp;A convertible preferred stock and the convertible preferred stock liability using an assumed term of
1.0&nbsp;years and 0.75&nbsp;years, an interest rate of 0.13% and 0.20% and a volatility of 85% and 85%, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
prior to its exercise on June&nbsp;10, 2015, the convertible preferred stock liability's fair value was estimated based on its intrinsic value, with the fair value of the
Series&nbsp;A convertible preferred stock estimated as of June&nbsp;10, 2015 and compared to the exercise price of the Series&nbsp;A convertible preferred stock liability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
estimate the fair value of the Series&nbsp;A convertible preferred stock as of June&nbsp;10, 2015, the enterprise value of the Company was estimated based on potential IPO and
sale estimates. The enterprise value was then allocated to the various classes of securities using an option pricing model that assumed a term of two years to a liquidity event, an interest rate of
0.75% and a volatility of 75% based on market conditions and expectations as of the June valuation date. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, the amended and restated certificate of incorporation authorizes the Company to issue 290&nbsp;million shares of common stock and 10&nbsp;million
shares of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
share of common stock is entitled to one vote. Common stockholders are entitled to dividends if and when declared by the board of directors. As of December&nbsp;31, 2017, no
dividends on common stock had been declared. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;20, 2017, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company,&nbsp;LLC ("Cowen") to sell shares of the Company's common
stock, from time to time, with aggregate gross sales proceeds of up to $125,000,000, through an at-the-market equity offering program under which Cowen will act as its sales agent. The issuance and
sale of shares of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=115,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=92547,FOLIO='111',FILE='DISK104:[18ZAA1.18ZAA41901]FO41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:12' -->
<A NAME="page_fo41901_1_112"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Common Stock (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>common
stock by the Company pursuant to the Sales Agreement are deemed an "at-the-market" offering under the Securities Act of 1933, as amended. Cowen is entitled to compensation for its services
equal to up to 3.0% of the gross proceeds of any shares of common stock sold through Cowen under the Sales Agreement. During the year ended December&nbsp;31, 2017, the Company received net proceeds
of approximately $0.7&nbsp;million from the sale of 52,569 shares of common stock pursuant to the Sales Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has reserved shares of common stock, for issuance as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,274,741</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares available for future option grants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,576,535</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,475,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,559,499</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,013,394</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,350,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>784,136</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unvested restricted common stock (founders and early exercise of stock options)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>319,203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>611,698</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>924,535</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares reserved for employee stock purchase plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>200,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>200,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,109,132</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,637,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,542,911 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock Option Plans  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2014, the Company adopted the 2014 Equity Incentive Plan (the "2014 Plan"), which was subsequently amended in November 2014, July 2015 and September 2015, under which it
granted incentive stock options ("ISOs") or non-qualified stock options ("NSOs"). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee
authorized by
the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over four years and have maximum exercise term of 10&nbsp;years. The 2014 Plan
provides that grants must be at an exercise price of 100% of fair market value of the Company's common stock as determined by the board of directors on the date of the grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the "2016 Plan"), became effective. Under the 2016 Plan, incentive stock options,
non-statutory stock options, stock purchase rights and other stock-based awards may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a
committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over four years and have maximum exercise term of
10&nbsp;years. The 2016 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company's common stock as determined by the board of directors on the date of the
grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and no further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective
date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of 1,136,229 shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=116,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=704646,FOLIO='112',FILE='DISK104:[18ZAA1.18ZAA41901]FO41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:12' -->
<A NAME="page_fo41901_1_113"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock Option Plans (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Activity
under the Company's stock option plans is set forth below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options Outstanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares<BR>
Available<BR>
for Grant </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at December&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,475,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,350,582</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional shares authorized</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>830,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(969,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>969,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(66,253</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options forfeited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>240,435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(240,435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.09 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at December&nbsp;31, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,576,535</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,013,394</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.78 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes information about stock options outstanding at December&nbsp;31, 2017 and 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options Outstanding<BR>
at December&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options Vested<BR>
at December&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Exercise Price

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Life (in Years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Life (in Years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$0.28&nbsp;- $4.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>535,136</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>325,397</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$6.75&nbsp;- $10.60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>701,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,688</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.87</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$11.21&nbsp;- $16.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,776,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>596,727</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.23 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,013,394</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.78</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>924,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.40 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options Outstanding<BR>
at December&nbsp;31, 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options Vested<BR>
at December&nbsp;31, 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Exercise Price

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Life (in Years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Life (in Years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>419,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159,732</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$4.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42,449</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$6.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.87</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,438</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.87</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$13.34&nbsp;-&nbsp;16.37</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,781,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>193,867</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.14 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,350,582</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>397,486</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.84</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.02 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
weighted average grant date fair value of options granted for the years ended December&nbsp;31, 2017, 2016 and 2015, was $8.93, $10.78 and $4.37, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=117,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=583075,FOLIO='113',FILE='DISK104:[18ZAA1.18ZAA41901]FO41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:12' -->
<A NAME="page_fo41901_1_114"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock Option Plans (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options
outstanding and exercisable that had vested or were expected to vest at December&nbsp;31, 2017 were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Life (years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Intrinsic Value<BR>
(in thousands) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>924,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,946</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected to vest</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,088,582</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.98</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,903</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the table above, aggregate intrinsic value represents the difference between the exercise price of the options to purchase common stock and the estimated fair value of the Company's
common stock of $10.36 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate intrinsic value of stock options exercised in the years ended December&nbsp;31, 2017, 2016 and 2015, was $332,000, $216,000 and $714,000, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
total fair value of options that vested in the year ended December&nbsp;31, 2017, 2016 and 2015, was $5.8&nbsp;million, $3.2&nbsp;million, and $0.1&nbsp;million,
respectively. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Stock-Based Compensation  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,692</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,685</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,537</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,143</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,828</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>428 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation Assumptions  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options
is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options were estimated using the following assumptions for the years ended
December&nbsp;31, 2017, 2016 and 2015: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>91.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=118,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=424915,FOLIO='114',FILE='DISK104:[18ZAA1.18ZAA41901]FO41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:12' -->
<A NAME="page_fo41901_1_115"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Stock-Based Compensation (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk-free Interest Rate:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company based the risk-free interest rate over the expected term of the options based on the constant
maturity rate of
U.S. Treasury securities with similar maturities as of the date of the grant. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Volatility:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company used an average historical stock price volatility of comparable public companies within the biotechnology and
pharmaceutical
industry using an average of historical volatilities of the Company's industry peers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected Term:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the simplified method prescribed in the ASC 718, Compensation&#151;Stock Compensation, to calculate the
expected term of options granted to employees and directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected Dividends:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company has not paid and does not anticipate paying any dividends in the near future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
December&nbsp;31, 2017, 2016 and 2015, the unrecognized compensation expense associated with respect to options granted to employees was $18.6&nbsp;million, $18.5&nbsp;million
and $4.7&nbsp;million, respectively, and is expected to be recognized on a straight-line basis over 2.85, 3.28, and 3.64&nbsp;years, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based
compensation expense related to awards to non-employees is recognized based on the then-current fair value at each measurement date over the associated service period of the
award, which is generally the vesting term, on a straight line basis. The Company used the Black-Scholes valuation model to assist it in determining the fair value of stock-based awards. Stock-based
compensation expense for non-employees was $74,000, $142,500 and $42,848 for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following assumptions were used in valuation of non-employee stock options: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.17%&nbsp;- 2.33%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.90%&nbsp;- 1.94%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.8%&nbsp;- 2.2%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80.3%&nbsp;- 83.0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92.1%&nbsp;- 92.7%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82%&nbsp;- 84.7%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.1&nbsp;-&nbsp;7.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.1&nbsp;-&nbsp;8.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.1&nbsp;-&nbsp;10.0</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Income Taxes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of loss before income tax is as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Domestic</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(28,253</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31,335</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(27,410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(55,663</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(36,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31,335</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=119,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=889621,FOLIO='115',FILE='DISK104:[18ZAA1.18ZAA41901]FO41901A.;7',USER='JFUSS',CD=';1-MAR-2018;10:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fq41901_1_116"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Income Taxes (Continued)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2017, 2016 and 2015, the Company recorded no income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of
realizing a benefit from those items. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
reconciliation of the Company's effective tax rate to the U.S. Federal statutory rate is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal tax benefit at statutory rate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State tax, net of Federal benefit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss due to change in fair value of convertible preferred stock liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign rate differential</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal rate change impact</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in valuation allowance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development tax credits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effective income tax rate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
effective tax rate is different from the federal statutory tax rate primarily due to a foreign rate differential and a valuation allowance against deferred tax assets as a result of
the Company's history of losses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
principal components of the Company's net deferred tax assets are as follows (in thousands) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net operating loss carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,438</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,339</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax credit carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,351</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,960</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>445</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalized tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>131</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>241</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>528</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accruals</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>183</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,730</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>954</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,885</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(21,885</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5,866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recorded a valuation allowance against its deferred tax assets at December&nbsp;31, 2017 and 2016 because Company management believed that it was more likely than not that
these assets would not be fully realized in the future. The valuation allowance increased by approximately $9.1&nbsp;million and $7.0&nbsp;million for the years ended December&nbsp;31, 2017 and
2016, respectively. Changes in the valuation allowance for deferred tax assets relate primarily to the increase in the Company's net operating loss carryforward. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=120,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=433693,FOLIO='116',FILE='DISK104:[18ZAA1.18ZAA41901]FQ41901A.;8',USER='CHE109858',CD='28-FEB-2018;20:50' -->
<A NAME="page_fq41901_1_117"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Income Taxes (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, the Company had federal NOL carryforwards of approximately $42.1&nbsp;million and state NOL carryforwards of approximately $94.5&nbsp;million which
are available to reduce future taxable income. The NOLs will begin to expire in 2034, if not utilized. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, the Company also had $3.0&nbsp;million of federal and $2.1&nbsp;million of state research and development tax credit carryforwards available to reduce
future income taxes. The federal research and development tax credits will begin to expire 2035, if not utilized. The state research and development tax credits have no expiration date. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilization
of NOL carryforwards and credits may be subject to an annual limitation due to the ownership change provisions provided by the Internal Revenue Code of 1986, as amended
("Code"), and similar state provisions. An annual limitation may result in the expiration of NOLs and credits before utilization. In March and April 2016, the Company issued a total of
5.2&nbsp;million shares of common stock associated with its IPO. In addition, during the third quarter of 2015, the Company issued a new series of convertible preferred stock. Such common and
preferred stock issuances may have created an ownership change under these provisions of the Code and similar state provisions. As of December&nbsp;31, 2017, NOLs and credits are not expected to
expire unused in the carryforward period as a result of these issuances of convertible preferred shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act makes broad and
complex changes to the U.S. tax code, including, but not limited to, (1)&nbsp;reducing the U.S. federal corporate tax rate from 35% to 21%; (2)&nbsp;requiring companies to pay a one-time
transition tax on certain unrepatriated earnings of foreign subsidiaries; (3)&nbsp;generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (4)&nbsp;requiring a
current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (5)&nbsp;eliminating the corporate alternative minimum tax (AMT) and changing how existing
AMT credits can be realized; (6)&nbsp;creating the base erosion anti-abuse tax
(BEAT), a new minimum tax; (7)&nbsp;creating a new limitation on deductible interest expense; and (8)&nbsp;changing rules related to uses and limitations of net operating loss carryforwards
created in tax years beginning after December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC staff issued SAB&nbsp;118, which provides guidance on accounting for the tax effects of the Tax Act. SAB&nbsp;118 provides a measurement period that should not extend beyond
one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB&nbsp;118, a company must reflect the income tax effects of those aspects of
the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company's accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a
reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should
continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
accounting for the following elements of the Tax Act is complete: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction
of US federal Corporate Tax Rate: The Tax Act reduces the corporate tax rate to 21%, effective January&nbsp;1, 2018. Accordingly, we have re-measured all deferred taxes at
21% as of December&nbsp;31, 2017. Consequently, we have recorded a decrease related to the net deferred tax asset balance of $4.9&nbsp;million, with a corresponding net adjustment to the Company's
valuation allowance. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=121,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=897482,FOLIO='117',FILE='DISK104:[18ZAA1.18ZAA41901]FQ41901A.;8',USER='CHE109858',CD='28-FEB-2018;20:50' -->
<A NAME="page_fq41901_1_118"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Income Taxes (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deemed
Repatriation Transition Tax: The Deemed Repatriation Transition Tax ("Transition Tax") is a tax on previously untaxed accumulated and current earnings and profits (E&amp;P) of certain
of our foreign subsidiaries. To determine the amount of the Transition Tax, we must determine, in addition to other factors, the amount of post-1986 E&amp;P of the relevant subsidiaries, as well as the
amount of non-U.S. income taxes paid on such earnings. the Company has a cumulative foreign E&amp;P deficit as of December&nbsp;31, 2017. As such, the Company does not have a transition tax liability in
the 2017 tax year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
accounting for the following elements of the Tax Act is incomplete: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global
Intangible Low Taxed Income ("GILTI"): The Tax Act creates a new requirement that certain income (i.e.,&nbsp;GILTI) earned by a controlled foreign corporations ("CFCs") must be
included currently in the gross income of the CFCs' U.S. shareholder. GILTI is the excess of the shareholder's "net CFC tested income" over the net deemed tangible income return, which is currently
defined as the excess of (1)&nbsp;10% of the aggregate of the U.S. shareholder's pro rata share of the qualified business asset
investment of each CFC with respect to which it is a U.S. shareholder over (2)&nbsp;the amount of certain interest expense taken into account in the determination of net CFC-tested income. Because
of the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S.&nbsp;GAAP, we are allowed to make an accounting
policy choice of either (1)&nbsp;treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the "period cost method") or
(2)&nbsp;factoring such amounts into a company's measurement of its deferred taxes (the "deferred method"). Our selection of an accounting policy with respect to the new GILTI tax rules will depend,
in part, on analyzing our global income to determine whether we expect to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Because whether
we expect to have future U.S. inclusions in taxable income related to GILTI depends on not only our current structure and estimated future results of global operations but also our intent and ability
to modify our structure and/or our business, we are not yet able to reasonably estimate the effect of this provision of the Tax Act. Therefore, we have not made any adjustments related to potential
GILTI tax in our financial statements and have not made a policy decision regarding whether to record deferred taxes on GILTI. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, the Company had unrecognized tax benefits ("UTBs") of approximately $1.2&nbsp;million. All of the deferred tax assets associated with these UTBs are
fully offset by a valuation allowance. The following table summarizes the activity related to UTBs: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrecognized tax benefits beginning of the period</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>604</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase related to the prior year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increased related to the current year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>666</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>463</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unrecognized tax benefits, end of the period</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,219</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>604</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company follows the provisions of ASC 740, Accounting for Income Taxes, and the accounting guidance related to accounting for uncertainty in income taxes. The Company determines its
uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be sustained upon examination
by the relevant income tax authorities. The Company will recognize both accrued interest and penalties </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=122,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=272094,FOLIO='118',FILE='DISK104:[18ZAA1.18ZAA41901]FQ41901A.;8',USER='CHE109858',CD='28-FEB-2018;20:50' -->
<A NAME="page_fq41901_1_119"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Income Taxes (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>related
to unrecognized benefits in income tax expense. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local
income tax authorities for all tax years in which a loss carryforward is available. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Commitments and Contingencies  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Facility Lease  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2015, the Company signed an initial operating lease, effective February&nbsp;1, 2015 for 8,138 square feet of office and laboratory
space with a one-year term. Between January 2015 and August 2016, the Company entered into a series of lease amendments to increase the amount of leased space to 28,633 square feet and extend the
expiration of the lease to February 2021. The lease agreement includes an annual rent escalation clause and a right to extend the term at the then current market rate for three years. Under the lease
and subsequent amendments, the landlord provided approximately $1.9&nbsp;million in free rent and lease incentives. The Company records rent expense on a straight-line basis over the effective term
of the lease, including any free rent periods and incentives. The lease requires the Company to pay additional amounts for operating and maintenance expenses. Rent expense related to the facilities
lease for the years ended years ended December&nbsp;31, 2017, 2016 and 2015 was approximately $734,000, $584,000 and $347,000, respectively. As of December&nbsp;31, 2017, future minimum lease
payments under the facility lease were as follows (in thousands): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payments Due by Period </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Less than<BR>
1 Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2&nbsp;-&nbsp;3&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>4&nbsp;-5&nbsp;Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>More than<BR>
5 Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Contractual obligations:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,632</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total contractual obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,632</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2015 the Company entered into an agreement for a line of credit of $0.1&nbsp;million for the purpose of issuing its landlord a letter of credit of $0.1&nbsp;million as a
security deposit under its facility lease. The Company pledged money market funds and marketable securities as collateral for the line of credit. Pursuant to the Company's license agreements with each
of Vernalis and Scripps, it has
obligations to make future milestone and royalty payments to these parties, respectively. However, because these amounts are contingent, they have not been included on the Company's balance sheet. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnifications  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements,
the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from
third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make
under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered
into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=123,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=906858,FOLIO='119',FILE='DISK104:[18ZAA1.18ZAA41901]FQ41901A.;8',USER='CHE109858',CD='28-FEB-2018;20:50' -->
<A NAME="page_fq41901_1_120"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Commitments and Contingencies (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>liabilities
that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. There have been no claims to date and the Company
has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal Proceedings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not a party to any material legal proceedings. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. Related Party Transaction  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2017, the Company purchased $461,000 of research services from a vendor during the normal course of business, where a Corvus director is also a member of the vendor's board of
directors. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


15. Quarterly Selected Financial Data (unaudited)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Quarter Ended </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>September&nbsp;30,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,189</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,944</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,174</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,217</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,929</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12,717</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14,981</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16,036</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share, basic and diluted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.79</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Quarter Ended </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>September&nbsp;30,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,476</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,825</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,426</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,086</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10,297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,347</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share, basic and diluted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.43</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5.39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="fq41901_item_9._changes_in_and_disagre__ite03576"> </A>
<A NAME="toc_fq41901_1"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fq41901_item_9a._controls_and_procedures"> </A>
<A NAME="toc_fq41901_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9A.&nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Evaluation of Disclosure Controls and Procedures.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of
achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures
are designed to provide reasonable assurance of achieving their control objectives. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of
December&nbsp;31, 2017, the end of the period covered by this Annual Report on Form&nbsp;10-K. Based upon such evaluation, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=124,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=398091,FOLIO='120',FILE='DISK104:[18ZAA1.18ZAA41901]FQ41901A.;8',USER='CHE109858',CD='28-FEB-2018;20:50' -->
<A NAME="page_fq41901_1_121"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
CORVUS PHARMACEUTICALS,&nbsp;INC. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTE TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


15. Quarterly Selected Financial Data (unaudited) (Continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>our
Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Management's Annual Report on Internal Control Over Financial Reporting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Annual Report on Form&nbsp;10-K does not include a report of management's assessment regarding internal control over financial reporting
due to a transition period established by rules of the SEC for newly public companies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Attestation Report of the Registered Public Accounting Firm  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Annual Report on Form&nbsp;10-K does not include an attestation report of our registered public accounting firm due to an exemption
established by the JOBS Act for "emerging growth companies." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Changes in Internal Control Over Financial Reporting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There were no changes in our internal control over financial reporting that occurred during the fiscal quarter ended December&nbsp;31, 2017
that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="fq41901_item_9b._other_information"> </A>
<A NAME="toc_fq41901_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;9B.&nbsp;&nbsp;&nbsp;&nbsp;Other Information    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=125,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=104017,FOLIO='121',FILE='DISK104:[18ZAA1.18ZAA41901]FQ41901A.;8',USER='CHE109858',CD='28-FEB-2018;20:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ja41901_1_122"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_part_iii"> </A>
<A NAME="toc_ja41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART III    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_item_10._directors,_executive___ite02336"> </A>
<A NAME="toc_ja41901_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;Directors, Executive Officers and Corporate Governance    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item will be set forth in the Company's proxy statement to be filed with the SEC within 120&nbsp;days after
the Company's fiscal year end and is incorporated herein by reference. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have adopted a code of business conduct and ethics that applies to all employees, including our principal executive officer, principal financial officer, principal accounting officer
or controller, or persons performing similar functions. The code of business conduct and ethics is available on our website at http://corvuspharma.com. Amendments to, and waivers from, the code of
business conduct and ethics that apply to any director, executive officer or persons performing similar functions will be disclosed at the website address provided above and, to the extent required by
applicable regulations, on a Current Report on Form&nbsp;8-K filed with the SEC.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_item_11._executive_compensation"> </A>
<A NAME="toc_ja41901_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;Executive Compensation    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item will be set forth in the Company's proxy statement to be filed with the SEC within 120&nbsp;days after
the Company's fiscal year end and is incorporated herein by reference.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_item_12._security_ownership_of__ite04004"> </A>
<A NAME="toc_ja41901_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item will be set forth in the Company's proxy statement to be filed with the SEC within 120&nbsp;days after
the Company's fiscal year end and is incorporated herein by reference.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_item_13._certain_relationships__ite03088"> </A>
<A NAME="toc_ja41901_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Certain Relationships and Related Transactions and Director Independence    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item will be set forth in the Company's proxy statement to be filed with the Securities and Exchange Commission
within 120&nbsp;days after the Company's fiscal year end and is incorporated herein by reference.  </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_item_14._principal_accountant_fees_and_services"> </A>
<A NAME="toc_ja41901_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Principal Accountant Fees and Services    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required by this Item will be set forth in the Company's proxy statement to be filed with the Securities and Exchange Commission
within 120&nbsp;days after the Company's fiscal year end and is incorporated herein by reference. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_part_iv"> </A>
<A NAME="toc_ja41901_7"> </A>
<BR></FONT><FONT SIZE=2><B>  PART IV    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_item_15._exhibits_and_financial_statement_schedules"> </A>
<A NAME="toc_ja41901_8"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Financial
Statements: </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consolidated financial statements required by Item&nbsp;15(a) are filed as part of this Annual Report on Form&nbsp;10-K under Item&nbsp;8 "Consolidated Financial Statements and
Supplementary Data."  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Financial
Statement Schedules: </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Exhibits.
</FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=126,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=654954,FOLIO='122',FILE='DISK104:[18ZAA1.18ZAA41901]JA41901A.;10',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_ja41901_1_123"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_exhibit_index"> </A>
<A NAME="toc_ja41901_9"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT INDEX    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed<BR>
Herewith </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465916108304/a16-7289_1ex3d1.htm">3.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Certificate of Incorporation.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3/29/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465916108304/a16-7289_1ex3d2.htm">3.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Bylaws.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3/29/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Reference is made to Exhibits&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465916108304/a16-7289_1ex3d1.htm">3.1</A> through <A
HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465916108304/a16-7289_1ex3d2.htm">3.2</A>.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-4_2.htm">4.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Common Stock Certificate.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916010056/a2227108zex-4_3.htm">4.3</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Investors' Rights Agreement, dated September&nbsp;16, 2015, by and among Corvus Pharmaceuticals,&nbsp;Inc. and the investors listed therein.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2/8/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_2a.htm">10.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Office Lease, dated as of January&nbsp;27, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and ARE-819/863 Mitten Road,&nbsp;LLC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_2b.htm">10.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>First Amendment to Office Lease, dated as of March&nbsp;19, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and ARE-819/863 Mitten Road,&nbsp;LLC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_2c.htm">10.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(c)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Second Amendment to Office Lease, dated as of August&nbsp;20, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and ARE-819/863 Mitten Road,&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(c)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465916137057/a16-11489_1ex10d1d.htm">10.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(d)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Third Amendment to Office Lease, dated as of June&nbsp;27, 2016, by and between Corvus Pharmaceuticals,&nbsp;Inc. and ARE-819/863 Mitten Road,&nbsp;LLC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(d)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465916154578/a16-17113_1ex10d1e.htm">10.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(e)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Fourth Amendment to Office Lease, dated as of August&nbsp;15, 2016, by and between Corvus Pharmaceuticals,&nbsp;Inc. and ARE-819/863 Mitten Road,&nbsp;LLC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11/3/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(e)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_4a.htm">10.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2014 Equity Inventive Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_4b.htm">10.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment to the 2014 Equity Incentive Plan, dated November&nbsp;26, 2014.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_4c.htm">10.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(c)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment to the 2014 Equity Incentive Plan, dated July&nbsp;24, 2015.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(c)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_4d.htm">10.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(d)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment to the 2014 Equity Incentive Plan, dated September&nbsp;14, 2015.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(d)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_4e.htm">10.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(e)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(e)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR></FONT>
</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=127,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1000800,FOLIO='123',FILE='DISK104:[18ZAA1.18ZAA41901]JA41901A.;10',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_ja41901_1_124"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed<BR>
Herewith </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_4f.htm">10.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(f)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Restricted Stock Purchase Right Grant Notice and Restricted Stock Purchase Agreement under the 2014 Equity Incentive Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(f)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465916108311/a16-7295_1ex99d2a.htm">10.3</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2016 Equity Incentive Award Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3/29/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_5b.htm">10.3</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Stock Option Grant Notice and Stock Option Agreement under the 2016 Equity Incentive Award Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_5c.htm">10.3</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(c)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Restricted Stock Award Agreement and Restricted Stock Award Grant Notice under the 2016 Equity Incentive Award Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(c)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_5d.htm">10.3</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(d)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Restricted Stock Unit Award Agreement and Restricted Stock Unit Award Grant Notice under the 2016 Equity Incentive Award Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(d)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_6.htm">10.4</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Indemnification Agreement for directors and officers.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_7.htm">10.5</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Employment Agreement, dated as of December&nbsp;22, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Richard A. Miller.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_8.htm">10.6</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Employment Agreement, dated as of December&nbsp;22, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Leiv Lea.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_9a.htm">10.7</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Offer Letter, dated as of November&nbsp;27, 2014, by and between Corvus Pharmaceuticals,&nbsp;Inc. and William&nbsp;B. Jones.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_9b.htm">10.7</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Change in Control and Severance Agreement, dated December&nbsp;23, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and William B. Jones.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_10a.htm">10.8</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Offer Letter, dated as of December&nbsp;28, 2014, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Erik J. Verner.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_10b.htm">10.8</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Change in Control and Severance Agreement, dated December&nbsp;23, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Erik J. Verner.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A HREF="a2234682zex-10_9a.htm">10.9</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Offer Letter, dated as of November&nbsp;22, 2017 by and between Corvus Pharmaceuticals,&nbsp;Inc. and Daniel Hunt.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A HREF="a2234682zex-10_9b.htm">10.9</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Change in Control and Severance Agreement dated December&nbsp;13, 2017, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Daniel Hunt.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465916108311/a16-7295_1ex99d3.htm">10.10</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Corvus Pharmaceuticals,&nbsp;Inc. 2016 Employee Stock Purchase Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3/29/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR></FONT>
</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=128,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=1037471,FOLIO='124',FILE='DISK104:[18ZAA1.18ZAA41901]JA41901A.;10',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_ja41901_1_125"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed<BR>
Herewith </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_12.htm">10.11</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>#</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Non-Employee Director Compensation Program.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916010993/a2227650zex-10_13a.htm">10.12</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>License Agreement, dated February&nbsp;25, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Vernalis (R&amp;D) Limited.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3/10/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(a)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_13b.htm">10.12</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amendment to License Agreement dated November&nbsp;5, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Vernalis (R&amp;D) Limited.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(b)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916009531/a2226867zex-10_14.htm">10.13</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>License Agreement, dated December&nbsp;20, 2014, by and between Corvus Pharmaceuticals,&nbsp;Inc. and The Scripps Research Institute</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000104746916010056/a2227108zex-10_15.htm">10.14</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Collaboration Agreement, dated October&nbsp;5, 2015, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Genentech, Inc</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2/8/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465917049313/a17-13288_1ex10d1.htm">10.15</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Phase&nbsp;1b/II Combination Study Agreement dated May&nbsp;1, 2017, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Genentech,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8/3/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> <A HREF="http://www.sec.gov/Archives/edgar/data/1626971/000110465917058101/a17-22232_3ex1d1.htm">10.16</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sales Agreement dated September&nbsp;20, 2017, by and between Corvus Pharmaceuticals,&nbsp;Inc. and Cowen and Company,&nbsp;LLC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8-K</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9/20/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A HREF="a2234682zex-21_1.htm">21.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>List of Subsidiaries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A HREF="a2234682zex-23_1.htm">23.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Independent Registered Public Accounting Firm.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A HREF="#POWER">24.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Power of Attorney (included on signature page)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A HREF="a2234682zex-31_1.htm">31.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification by Chief Executive Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A HREF="a2234682zex-31_2.htm">31.2</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification by Chief Financial Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A HREF="a2234682zex-32_1.htm">32.1</A></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 USC Section&nbsp;1350 as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.INS</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Instance Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.SCH</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Schema Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.CAL</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Calculation Linkbase Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.DEF</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Definition Linkbase Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.LAB</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Label Linkbase Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR></FONT>
</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=129,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=21662,FOLIO='125',FILE='DISK104:[18ZAA1.18ZAA41901]JA41901A.;10',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_ja41901_1_126"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Filed<BR>
Herewith </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.PRE</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Presentation Linkbase Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#134;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Confidential
treatment has been granted for a portion of this exhibit
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>#</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Indicates
management contract or compensatory plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>**</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
certification attached as Exhibit&nbsp;32.1 that accompanies this Annual Report on Form&nbsp;10-K is not deemed filed with the Securities and Exchange
Commission and is not to be incorporated by reference into any filing of Corvus Pharmaceuticals,&nbsp;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as
amended, whether made before or after the date of this Annual Report on Form&nbsp;10-K, irrespective of any general incorporation language contained in such filing.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja41901_item_16._form_10-k_summary"> </A>
<A NAME="toc_ja41901_10"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;10-K Summary    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registrants may voluntarily include a summary of information required by Form&nbsp;10-K under this Item&nbsp;16. We have elected not to
include such summary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=130,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=103121,FOLIO='126',FILE='DISK104:[18ZAA1.18ZAA41901]JA41901A.;10',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_jc41901_1_127"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="sig"></A>SIGNATURES  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> CORVUS PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Date: March&nbsp;1, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;RICHARD. A. MILLER<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Richard A. Miller, M.D.<BR></FONT> <FONT SIZE=2><I>President, Chief Executive Officer and Director<BR>
(Principal Executive Officer)</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> Date: March&nbsp;1, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;LEIV LEA<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Leiv Lea<BR></FONT> <FONT SIZE=2><I>Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)<BR> </I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=131,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=915878,FOLIO='127',FILE='DISK104:[18ZAA1.18ZAA41901]JC41901A.;7',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<A NAME="page_jc41901_1_128"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="POWER"></A>POWER OF ATTORNEY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each person whose individual signature appears below hereby authorizes and appoints Richard A. Miller, M.D. and Leiv Lea and each of them, with
full power of substitution and resubstitution, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each
person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form&nbsp;10-K and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing,
ratifying and confirming all that said attorney-in-fact and agents or his substitute or substitutes may lawfully do or cause to be done by virtue thereof. Pursuant to the requirements of the
Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="89pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;RICHARD A. MILLER, M.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Richard A. Miller, M.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director<BR>
(Principal Executive Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>March&nbsp;1, 2018</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;LEIV LEA<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Leiv Lea</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;IAN T. CLARK<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Ian T. Clark</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;TERRY GOULD<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Elisha P. (Terry) Gould III</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;STEVE E. KROGNES<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Steve E. Krognes</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;PETER MOLDT, PH.D,<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Peter Moldt, Ph.D</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;SCOTT W. MORRISON.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Scott W. Morrison</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2018</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;PETER THOMPSON, M.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Peter Thompson, M.D.</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>March&nbsp;1, 2018</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=132,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="1",CHK=205012,FOLIO='128',FILE='DISK104:[18ZAA1.18ZAA41901]JC41901A.;7',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9(A)
<SEQUENCE>2
<FILENAME>a2234682zex-10_9a.htm
<DESCRIPTION>EX-10.9(A)
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.9(a)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">November&nbsp;22, 2017</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corvus Pharmaceuticals,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">863 Mitten Road</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Suite&nbsp;102</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Burlingame, CA 94010</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.8in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re:&#160; Employment Offer Letter</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Daniel:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corvus Pharmaceuticals,&nbsp;Inc. (the &#147;<u>Company</u>&#148;), is pleased to offer you full-time employment in the exempt position of Senior Vice President and Chief Business Officer effective on or before November&nbsp;27, 2017 in which you will be responsible for such duties as are normally associated with such position or as otherwise determined by your supervisor. </font>This job offer and start date are contingent upon the successful completion of our background check process. You will receive an email from our background check vendor, TalentWise, with instructions to complete the background check process. Please respond to this request as soon as possible as the background check can take up to two weeks to process. You will initially report to Richard Miller, Chief Executive Officer, or such other individual as the Company may designate, and will work out of our offices, except for such travel as may be necessary to fulfill your responsibilities.&#160; In the course of your employment with Company, you will be subject to and required to comply with all company policies, and applicable laws and regulations.&#160; These include equal employment opportunity in hiring, assignments, training, promotions, compensation, employee benefits, employee discipline and discharge, and all other terms and conditions of employment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You will be paid a salary at the annual rate of $375,000 (subject to required tax withholding and other authorized deductions).&#160; Your salary will be payable in accordance with the Company&#146;s standard payroll policies and subject to adjustment pursuant to the Company&#146;s policies as in effect from time to time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with entering into this offer letter, following the commencement of your employment with the Company, the Company will recommend to the Board of Directors that it grant you an option to purchase 200,000 shares of the Company&#146;s common stock (the &#147;<u>Stock Option</u>&#148;) at a per-share exercise price equal to the closing trading price of a share of the Company&#146;s common stock on the date of grant, provided that you are employed by the Company on the date of grant.&#160; Subject to your continued employment with the Company through the applicable vesting date, 25% of the shares underlying the Stock Option will vest on the first anniversary of the date you commence employment with the Company and 1/48th of the total number of shares initially underlying the Stock Option will vest on each monthly</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=618858,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:06 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">anniversary thereafter.&#160; The Stock Option will otherwise be subject to the terms and conditions of the Company&#146;s 2016 Equity Incentive Plan (the &#147;<u>Plan</u>&#148;) and a stock option agreement to be entered into between you and the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You will be eligible to participate in all of the employee benefits and benefit plans that the Company generally makes available to its regular full-time employees, including group health plans, life and disability insurance and 401k Plan.&#160; In addition, during your employment, you will be eligible for other standard benefits, such as paid time off and paid holidays to the extent applicable generally to other similarly situated employees of the Company.&#160; The Company reserves the right to terminate, modify or add to its benefits and benefit plans at any time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company requires that, as a full-time employee, you devote your full business time, attention, skill, and efforts to the tasks and duties of your position as assigned by the Company.&#160; If you wish to request consent to provide services (for any or no form of compensation) to any other person or business entity while employed by the Company, please discuss that with me in advance of accepting another position.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a condition of employment, you will be required (1)&nbsp;to sign and comply with an Employee Confidentiality and Inventions Assignment Agreement, a copy of which is attached hereto as <u>Exhibit&nbsp;A</u>, which, among other things, prohibits unauthorized use or disclosure of Company proprietary information; (2)&nbsp;to sign and return a satisfactory I-9 Immigration form attached hereto as <u>Exhibit&nbsp;B</u> and </font>provide sufficient documentation establishing your employment eligibility in the United States of America (enclosed is a list of acceptable INS Form&nbsp;I-9 documentation); and (3)&nbsp;to provide satisfactory proof of your identity as required by U.S. law.&#160; By signing below, you represent that your performance of services to the Company will not violate any duty which you may have to any other person or entity (such as a present or former employer), including obligations concerning providing services (whether or not competitive) to others, confidentiality of proprietary information and assignment of inventions, ideas, patents or copyrights, and you agree that you will not do anything in the performance of services hereunder that would violate any such duty.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Notwithstanding any of the above, your employment with the Company is &#147;at will.&#148; This means that it is not for any specified period of time and can be terminated by you or by the Company at any time, with or without advance notice, and for any or no particular reason or cause.&#160; </font>It also means that your job duties, title and responsibility and reporting level, work schedule, compensation and benefits, as well as the Company&#146;s personnel policies and procedures, may be changed with prospective effect, with or without notice, at any time in the sole discretion of the Company.&#160; Without limiting this paragraph, as Senior Vice President and Chief Business Officer, you will be entitled to enter into a Change in Control Severance Agreement substantially in the form attached hereto as <u>Exhibit&nbsp;C</u> (the &#147;<u>Change in Control Agreement</u>&#148;)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you accept this offer, this letter, collectively with the Employee Confidentiality and Inventions Assignment Agreement and Change in Control Agreement, shall constitute the complete agreement between you and Company with respect to the terms and conditions of your employment. &#160;Any prior or contemporaneous representations (whether oral or written) not</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=660080,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:06 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">contained in this letter, the Employee Confidentiality and Inventions Assignment Agreement or the Change in Control Agreement or contrary to those contained in this letter, the Employee Confidentiality and Inventions Assignment Agreement or the Change in Control Agreement, that may have been made to you are expressly cancelled and superseded by this offer.&#160; This offer letter shall be interpreted and construed in accordance with California law without regard to any conflicts of laws principles.&#160; While other terms and conditions of your employment may change in the future, the at-will nature of your employment may not be changed, except in a subsequent letter or written agreement, signed by you and the Chief Executive Officer of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature Page&nbsp;Follows)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=885336,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:06 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Please sign and date this letter and the Employee Confidentiality and Invention Assignment Agreement, and return it to me by email at ** by November&nbsp;26, 2017 if you wish to accept employment at the Company under the terms described above, after which time this offer of employment will expire.&#160; If you accept our offer, we would like you to commence your employment with us on or before November&nbsp;27, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.4in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you have any questions, regarding this letter or employment with the Company, please feel free to contact me by phone at ** or by email at **.&#160; We look forward to your favorable reply and to a productive and enjoyable work relationship.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sincerely,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Corvus   Pharmaceuticals,&nbsp;Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Richard A.   Miller</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Richard A.   Miller, M.D.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and   CEO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Accepted   by:</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Daniel Hunt</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Daniel Hunt</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   November&nbsp;27, 2017</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=840418,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:06 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;A</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Proprietary Information and Invention Assignment Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=174623,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:06 2018' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;A</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Employee Confidentiality and Inventions Assignment Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Corvus Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EMPLOYEE CONFIDENTIALITY AND INVENTIONS ASSIGNMENT AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In consideration and as a condition of my employment by Corvus Pharmaceuticals,&nbsp;Inc., together with any of its successors or assigns (collectively, the &#147;<b>Company</b>&#148;), and my receipt of the compensation paid to me by the Company in the context of that employment, effective as of the date that my employment by the Company first commenced as set forth below,&nbsp;I, the undersigned, agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>NONDISCLOSURE OF CONFIDENTIAL INFORMATION</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.1</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Confidential Information</b>.&#160; During the term of my employment,&nbsp;I may receive and otherwise be exposed, directly or indirectly, to technical and non-technical confidential and proprietary information of the Company, including information relating to the Company&#146;s business, research and development activities, strategies, designs, products, services and technologies, or to the Company&#146;s suppliers, customers or business partners (collectively &#147;<b>Confidential Information</b>&#148;), whether in graphic, written, electronic or oral form.&#160; Confidential Information may be labeled or identified at the time of disclosure as confidential or proprietary, or equivalent, but Confidential Information also includes information which by its context would reasonably be deemed to be confidential and proprietary.&#160; &#147;Confidential Information&#148; may also include unpublished patent applications and other intellectual property filings, ideas,&nbsp;Inventions (as defined below), techniques, works of authorship, models, inventions, know-how, processes, algorithms, software programs, software source documents, formulae, information and trade secrets as well as financial information, bills of material, customer lists, investors, employees, business and contractual relationships, business forecasts, sales and merchandising data , and marketing plans and any derivatives, improvements and enhancements related to any of the above.&#160; Information the Company provides regarding third parties as to which Company has an obligation of confidentiality also constitutes &#147;Confidential Information.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.2</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Duties</b>.&#160; I acknowledge the confidential and secret character of the Confidential Information, and agree that the Confidential Information is the sole, exclusive and extremely valuable property of Company.&#160; Accordingly,&nbsp;I agree not to use the Confidential Information except in the performance of my authorized duties as an employee of Company, and not to disclose all or any part of the Confidential Information in any form to any third party, either during or after the term of my employment, without the prior written consent of the Company on a case-by-case basis.&#160; Upon termination of my employment,&nbsp;I agree to cease using and to return to Company all whole and partial copies and derivatives of the Confidential Information, whether in my possession or under my direct or indirect control, except for my personal copies of the following, which I am entitled to retain (i)&nbsp;my compensation records, (ii)&nbsp;materials distributed to shareholders generally, and (iii)&nbsp;this Agreement.&#160; I understand that my obligations with respect to Confidential Information shall not apply to information that (i)&nbsp;is actually in the public domain at the time of disclosure or enters the public domain following disclosure through no action of mine, (ii)&nbsp;is already in my possession without breach of any obligations of confidentiality by any party, (iii)&nbsp;is obtained by me from a third party not under confidentiality obligations and without a breach of any obligations of confidentiality by such party, or (iv)&nbsp;provided I provide the Company with notice as soon as practicable and I assist the Company to the best of my ability</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="1119-3-KO-01_PB_1_222128_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=546069,FOLIO='1',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to procure confidential treatment for such Confidential Information, is required to be disclosed pursuant to an order of any competent court or government agency or rules&nbsp;of a securities exchange.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.3</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Unauthorized Use or Disclosure</b>.&#160; I shall promptly notify my supervisor or any officer of the Company if I learn of any possible unauthorized use or disclosure of Confidential Information and shall cooperate fully with the Company to enforce its rights in such information.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PROPERTY OF THE COMPANY</b>.&#160; I acknowledge and agree that all notes, memoranda, reports, drawings, blueprints, manuals, materials, data, emails and other papers and records of every kind which shall come into my possession in the course of my employment with the Company, relating to any Inventions (as defined below) or Confidential Information, shall be the sole and exclusive property of the Company and I hereby assign any rights or interests I may obtain in any of the foregoing.&#160; I agree to surrender this property to the Company immediately upon termination of my employment with the Company, or at any time upon request by the Company.&#160; I further agree that any property situated on the Company&#146;s data systems or on the Company&#146;s premises and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice.&#160; I further agree that in the event of termination of my employment with the Company I will execute a Termination Certificate substantially in the form attached hereto as Exhibit&nbsp;A.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>INVENTIONS</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Disclosure and Assignment of Inventions.</b>&#160; For the purposes of this Agreement, an &#147;Invention&#148; shall mean any idea, invention or work of authorship, including any documentation, formula, design, device, code, method, process, discovery, concept, improvement, development, machine or contribution, in each case whether or not patentable.&#160; I agree to disclose all Inventions promptly in writing to my supervisor or, at the Company&#146;s request, to attorneys of the Company in accordance with the Company&#146;s policies and procedures, and, subject to Section&nbsp;3.2,&nbsp;I hereby assign to the Company, without requirement of further writing, without royalty or any other further consideration, my entire right, title and interest in and to all Inventions created or reduced to writing by me in the course of my employment by the Company and all intellectual property rights therein.&#160;&#160;&#160; I hereby waive, and agree to waive, any moral rights I may have in any copyrightable work I create on behalf of the Company.&#160; The Company agrees that it will use commercially reasonable measures to keep Inventions disclosed to it pursuant to this Section&nbsp;3.1 that do not constitute Inventions to be owned by the Company in confidence and shall not use any Inventions for its own advantage, unless in either case those Inventions are assigned or assignable to the Company pursuant to Section&nbsp;3.1 or otherwise.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.2</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Certain Exemptions</b>.&#160; The obligations to assign Inventions set forth in Section&nbsp;3.1 apply with respect to all Inventions (a)&nbsp;whether or not such Inventions are conceived, made, developed or worked on by me during my regular hours of employment with the Company; (b)&nbsp;whether or not the Invention was made at the suggestion of the Company; (c)&nbsp;whether or not the Invention was reduced to drawings, written description, documentation, models or other tangible form; and (d)&nbsp;whether or not the Invention is related to the general line of business engaged in by the Company, but do not apply to Inventions that (x)&nbsp;I develop entirely on my own time or after the date of this Agreement without using the Company&#146;s equipment, supplies, facilities or Confidential Information; (y)&nbsp;do not relate to the Company&#146;s business, or actual or demonstrably anticipated research or development of the Company at the time of conception or reduction to practice of the Invention; and (z)&nbsp;do not result from and are not related to any work performed by me for the Company.&#160; I hereby acknowledge and agree that the Company has notified me that the assignments provided for in Section&nbsp;3.1 do not apply to any Invention</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="1119-3-KO-01_PB_2_222330_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=690181,FOLIO='2',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">which qualifies fully for exemption from assignment under the provisions of Section&nbsp;2870 of the California Labor Code (&#147;<b>Section&nbsp;2870</b>&#148;), a copy of which is attached as Exhibit&nbsp;B.&#160; At the time of disclosure of an Invention that I believe qualifies under Section&nbsp;2870,&nbsp;I shall provide to the Company, in writing, evidence to substantiate the belief that such Invention qualifies under Section&nbsp;2870.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.3</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Records</b>.&#160; I will make and maintain adequate and current written records of all Inventions covered by Section&nbsp;3.1.&#160; These records shall be and remain the property of the Company at all times.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.4</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Patents and Other Rights</b>.&#160; I agree to assist the Company in obtaining, maintaining and enforcing patents, invention assignments and copyright assignments, and other proprietary rights in connection with any Invention covered by Section&nbsp;3.1, and will otherwise assist the Company as reasonably required by the Company to perfect in the Company the rights, title and other interests in my work product granted to the Company under this Agreement.&#160; I further agree that my obligations under this Section&nbsp;3.4 shall continue beyond the termination of my employment with the Company, but if I am requested by the Company to render such assistance after the termination of such employment,&nbsp;I shall be entitled to a fair and reasonable rate of compensation for such assistance, and to reimbursement of any expenses incurred at the request of the Company relating to such assistance.&#160; If the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified above,&nbsp;I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Section&nbsp;3.4 with the same legal force and effect as if executed by me.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.5</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Prior Contracts and Inventions; Information Belonging to Third Parties</b>.&#160; I represent and warrant that, except as set forth on Exhibit&nbsp;C hereto,&nbsp;I am not required, and I have not been required during the course of any prior work for the Company or its predecessors, to assign Inventions under any other contracts that are now or were previously in existence between me and any other person or entity.&#160; I further represent that (i)&nbsp;I am not obligated under any consulting, employment or other agreement that would affect the Company&#146;s rights or my duties under this Agreement, and I shall not enter into any such agreement or obligation during the period of my employment by the Company, (ii)&nbsp;there is no action, investigation, or proceeding pending or threatened, or any basis therefor known to me involving my prior employment or any consultancy or the use of any information or techniques alleged to be proprietary to any former employer, and (iii)&nbsp;the performance of my duties as an employee of the Company do not and will not breach, or constitute a default under any agreement to which I am bound, including any agreement limiting the use or disclosure of proprietary information acquired in confidence prior to engagement by the Company.&#160; I will not, in connection with my employment by the Company, use or disclose to the Company any confidential, trade secret or other proprietary information of any previous employer or other person which I am not lawfully entitled to use or disclose.&#160; As a matter of record,&nbsp;I attach as Exhibit&nbsp;C of this Agreement a brief description of all Inventions made or conceived by me prior to my employment with the Company (&#147;Background Technology&#148;).&#160; If full disclosure of any Background Technology would breach or constitute a default under any agreement to which I am bound, including any agreement limiting the use or disclosure of proprietary information acquired in confidence prior to engagement by the Company,&nbsp;I understand that I am to describe such Background Technology in Exhibit&nbsp;C at the most specific level possible without violating any such prior agreement.&#160; To the extent I have such right,&nbsp;I hereby grant Company a non-exclusive, royalty-free, perpetual and irrevocable, worldwide right to use and sublicense the use of Background Technology (whether or not listed on Exhibit&nbsp;C) for the purpose of developing, marketing, selling and supporting Company technology, products and services, either directly or through multiple tiers of distribution, but not for the purpose of marketing Background Technology separately from Company products or services.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="1119-3-KO-01_PB_3_222521_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=567751,FOLIO='3',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.6</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Works Made for Hire</b>.&#160; I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment with the Company and which are eligible for copyright protection are &#147;works made for hire&#148; as that term is defined in the United States Copyright Act (17 U.S.C., Section&nbsp;101).</p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>NON-COMPETITION</b>.&#160; During the term of my employment by the Company,&nbsp;I will not without the prior written approval of an executive officer of the Company, (a)&nbsp;engage in any other professional employment or consulting, or (b)&nbsp;directly or indirectly participate in or assist any business which is a current or potential supplier, customer or competitor of the Company.&#160; If I am an executive officer of the Company, any of the foregoing activities shall require the approval of the Board of Directors of the Company.&#160; Subject to continuing Board membership at Telomere Dx, Aconian Pharma and Ab Sc. LLC.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>NON-SOLICITATION</b>.&#160; During the term of my employment with the Company and for a period of one (1)&nbsp;year thereafter,&nbsp;I will not solicit or encourage, or assist others to solicit or encourage, any employees, consultants or independent contractors of the Company to terminate their employment or other engagement with the Company.&#160; During the term of my employment with the Company,&nbsp;I will not solicit the business of any customer or client of the Company on my own behalf or on behalf of any person or entity other than the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>NOTIFICATION TO OTHER PARTIES</b>.&#160; In the event of termination of my employment with the Company,&nbsp;I hereby consent to notification by the Company to my new employer or other party for whom I work about my rights and obligations under this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>EMPLOYMENT AT WILL</b>.&#160; I understand and agree that my employment with the Company is at will.&#160; Accordingly, my employment can be terminated, without cause or notice, at my option or the Company&#146;s option.&#160; The at-will nature of my employment also means that I can be transferred or demoted, and my job title, compensation, benefits and other terms and conditions of employment can be reduced, without cause.&#160; This at-will status of my employment relationship with the Company will remain in effect throughout my employment with the Company unless such status is modified by a written agreement signed by both an authorized officer of the Company and me which expressly alters such status.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>MISCELLANEOUS</b>.&#160; The parties&#146; rights and obligations under this Agreement will bind and inure to the benefit of their respective successors, heirs, executors, and administrators and permitted assigns.&#160; I will not assign this Agreement or my obligations hereunder without the prior written consent of the Company, which consent may be withheld in the Company&#146;s sole discretion, and any purported assignment without such consent shall be null and void from the beginning.&#160; I agree that the Company may freely assign or otherwise transfer this Agreement to any affiliate or successor in interest (whether by way of merger, sale, acquisition or corporate re-organization or any substantially similar process) of the Company.&#160; This Agreement, together with the Exhibits hereto, constitutes the parties&#146; final, exclusive and complete understanding and agreement with respect to the subject matter hereof, and supersedes all prior and contemporaneous understandings and agreements, whether oral or written, relating to its subject matter.&#160; Any subsequent change or changes in my duties, obligations, rights or compensation will not affect the validity or scope of this Agreement.&#160; This Agreement may not be waived, modified or amended unless mutually agreed upon in writing by both parties.&#160; If any provision of this Agreement is found by a proper authority to be unenforceable or invalid such unenforceability or invalidity shall not render this Agreement unenforceable or invalid as a whole and in such event, such provision shall be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision within the limits of applicable law or applicable court decisions and the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="1119-3-KO-01_PB_4_222822_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=944017,FOLIO='4',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">affected, impaired or invalidated.&#160; I acknowledge that the Company will suffer substantial damages not readily ascertainable or compensable in terms of money in the event of the breach of any of my obligations under this Agreement.&#160; I therefore agree that the Company shall be entitled (without limitation of any other rights or remedies otherwise available to the Company) to obtain an injunction from any court of competent jurisdiction prohibiting the continuance or recurrence of any breach of this Agreement.&#160; The rights and obligations of the parties under this Agreement shall be governed in all respects by the laws of the State of California exclusively, without regard to conflict of law provisions.&#160; I agree that upon Company&#146;s request, all disputes arising hereunder shall be adjudicated in the state and federal courts having jurisdiction over disputes arising in San Mateo County, California, and I hereby agree to consent to the personal jurisdiction of such courts.&#160; Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address as the party shall specify in writing.&#160; Such notice shall be deemed given upon personal delivery, or sent by certified or registered mail, postage prepaid, three (3)&nbsp;days after the date of mailing.&#160; This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">I ACKNOWLEDGE THAT I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL AND THAT I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION.&#160; NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT.&#160; I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY,&nbsp;IN DUPLICATE, WITH THE UNDERSTANDING THAT THE COMPANY WILL RETAIN ONE COUNTERPART&nbsp;AND THE OTHER COUNTERPART&nbsp;WILL BE RETAINED BY ME.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">SIGNATURE PAGE FOLLOWS</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="1119-3-KO-01_PB_5_222853_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=960653,FOLIO='5',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF,&nbsp;I have executed this document as of the 27th day of November, 2017.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="3" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Dan Hunt</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employee: Dan Hunt</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>
<td width="13%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.32%;">
<p style="margin:0in 0in .0001pt;text-indent:1.15in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.5%;">
<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">**</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:21.66%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="27%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.5%;">
<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">**</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="3" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date employment first commenced:&#160; November&nbsp;27, 2017</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AGREED AND ACKNOWLEDGED:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Company</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Richard Miller</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name: </font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Richard Miller</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CEO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address: </font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">863 Mitten Road,   Suite&nbsp;102</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Burlingame, CA. 94010</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE PAGE TO CORVUS PHARMACEUTICALS,&nbsp;INC. EMPLOYEE CONFIDENTIALITY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AND INVENTIONS ASSIGNMENT AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=376155,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT&nbsp;A</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Termination Certificate</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, the undersigned, hereby certify that I do not have in my possession, nor have I failed to return, any documents or materials relating to the business of Company or its affiliates (the &#147;<b>Company</b>&#148;), or copies thereof, including, without limitation, any item of Confidential Information listed in Section&nbsp;3 of the Company&#146;s Employee Confidentiality And Inventions Assignment Agreement (the &#147;<b>Agreement</b>&#148;) to which I am a party, but not including copies of my own employment records.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I further certify that I have complied with all of the terms of the Agreement signed by me, including the reporting of any Inventions (as defined in the Agreement) covered by the Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I further agree that in compliance with the Agreement,&nbsp;I will preserve as confidential any information relating to the Company or any of it business partners, clients, consultants or licensees which has been disclosed to me in confidence during the course of my employment by the Company unless authorized in writing to disclose such information (i)&nbsp;by an executive officer of the Company, in the event that I am not an executive officer of the Company, or (ii)&nbsp;by the Board of Directors of the Company, in the event that I am an executive officer of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Employee&#146;s Signature)</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Printed or Typed Name   of Employee)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=309611,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT&nbsp;B</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">California Labor Code</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">California Labor Code &#167; 2870</font></u>.&#160; Application of provision providing that employee shall assign or offer to assign rights in invention to <b>employer</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#146;s equipment, supplies, facilities, or trade secret information except for those inventions that either:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Relate at the time of conception or reduction to practice of the invention to the employer&#146;s business, or actual or demonstrably anticipated research or development of the employer; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Result from any work performed by the employee for the employer.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=213297,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT&nbsp;C</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BACKGROUND TECHNOLOGY</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(List here prior contracts to assign Inventions that are now in existence between any other person or entity and you.)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement.&#160; Continue on reverse side if necessary.)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=583614,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;B</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">INS Form&nbsp;I-9</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=619648,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;C</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Form&nbsp;of Change in Control Severance Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="2",CHK=241458,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KO-01_ZAA41903.CHC",USER="JFUSS",CD='Mar  1 23:13 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9(B)
<SEQUENCE>3
<FILENAME>a2234682zex-10_9b.htm
<DESCRIPTION>EX-10.9(B)
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.9(b)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CORVUS PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CHANGE IN CONTROL SEVERANCE AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Change in Control Severance Agreement (the &#147;<u>Agreement</u>&#148;) is made and entered into by and between Daniel Hunt (&#147;<u>Executive</u>&#148;) and Corvus Pharmaceuticals,&nbsp;Inc. (the &#147;<u>Company</u>&#148;), effective as of the latest date set forth by the signatures of the parties hereto below (the &#147;<u>Effective Date</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">R E C I T A L S</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Board of Directors of the Company (the &#147;<u>Board</u>&#148;) recognizes that the possibility of an acquisition of the Company or an involuntary termination can be a distraction to Executive and can cause Executive to consider alternative employment opportunities.&#160; The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such an event.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive&#146;s employment and to motivate Executive to maximize the value of the Company upon a Change in Control (as defined below) for the benefit of its stockholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">C.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Board believes that it is imperative to provide Executive with severance benefits upon certain terminations of Executive&#146;s service to the Company that enhance Executive&#146;s financial security and provide incentive and encouragement to Executive to remain with the Company notwithstanding the possibility of such an event.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">D.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Unless otherwise defined herein, capitalized terms used in this Agreement are defined in Section&nbsp;9 below.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The parties hereto agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Term of Agreement</u>.&#160; This Agreement shall become effective as of the Effective Date and terminate upon the date that all obligations of the parties hereto with respect to this Agreement have been satisfied.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>At-Will Employment</u>.&#160; The Company and Executive acknowledge that Executive&#146;s employment is and shall continue to be &#147;at-will,&#148; as defined under applicable law.&#160; If Executive&#146;s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Covered Termination Other Than During a Change in Control Period</u>.&#160; If Executive experiences a Covered Termination at any time other than during a Change in Control Period, and if</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=429586,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive delivers to the Company a general release of all claims against the Company and its affiliates in a form acceptable to the Company (a &#147;<u>Release of Claims</u>&#148;) that becomes effective and irrevocable within sixty (60) days, or such shorter period of time specified by the Company, following such Covered Termination, then in addition to any accrued but unpaid salary, bonus, benefits, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Severance</u>.&#160; Executive shall be entitled to receive a severance payment equal to nine (9)&nbsp;months of Executive&#146;s base salary at the rate in effect immediately prior to the Termination Date payable in a cash lump sum, less applicable withholdings, on the first payroll date following the date the Release of Claims becomes effective and irrevocable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Continued Healthcare</u>.&#160; If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<u>COBRA</u>&#148;), the Company shall directly pay, or reimburse Executive for, the premium for Executive and Executive&#146;s covered dependents through the earlier of (i)&nbsp;the nine (9)&nbsp;month anniversary of the Termination Date and (ii)&nbsp;the date Executive and Executive&#146;s covered dependents, if any, become eligible for healthcare coverage under another employer&#146;s plan(s).&#160; Notwithstanding the foregoing, (i)&nbsp;if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section&nbsp;409A of the Code under Treasury Regulation Section&nbsp;1.409A-1(a)(5), or (ii)&nbsp;the Company is otherwise unable to continue to cover Executive under its group health plans without penalty under applicable law (including without limitation, Section&nbsp;2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive&#146;s expense in accordance the provisions of COBRA.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Equity Awards</u>.&#160; Each outstanding and unvested equity award, including, without limitation, each stock option and restricted stock award, held by Executive shall automatically become vested and, if applicable, exercisable and any forfeiture restrictions or rights of repurchase thereon shall immediately lapse, in each case, with respect to that number of shares that would have vested during the nine (9)&nbsp;month period immediately following the Termination Date had Executive&#146;s employment with the Company continued during such period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Covered Termination During a Change in Control Period</u>.&#160; If Executive experiences a Covered Termination during a Change in Control Period, and if Executive executes a Release of Claims that becomes effective and irrevocable within sixty (60) days, or such shorter period of time specified by the Company, following such Covered Termination, then in addition to any accrued but unpaid salary, bonus, benefits, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Severance</u>.&#160; Executive shall be entitled to receive an amount equal to the sum of (i)&nbsp;twelve (12) months of Executive&#146;s base salary and (ii)&nbsp;one hundred percent (100%) of Executive&#146;s target annual bonus, in each case, at the rate in effect immediately prior to the Termination Date,</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="1119-3-KQ_PB_2_070626_7286"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=195973,FOLIO='2',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">payable in a cash lump sum, less applicable withholdings, on the first payroll date following the date the Release of Claims becomes effective and irrevocable.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Continued Healthcare</u>.&#160; If Executive elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive for, the premium for Executive and Executive&#146;s covered dependents through the earlier of (i)&nbsp;the twelve (12) month anniversary of the Termination Date and (ii)&nbsp;the date Executive and Executive&#146;s covered dependents, if any, become eligible for healthcare coverage under another employer&#146;s plan(s).&#160; Notwithstanding the foregoing, (i)&nbsp;if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section&nbsp;409A of the Code under Treasury Regulation Section&nbsp;1.409A-1(a)(5), or (ii)&nbsp;the Company is otherwise unable to continue to cover Executive under its group health plans without penalty under applicable law (including without limitation, Section&nbsp;2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.&#160; After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive&#146;s expense in accordance the provisions of COBRA.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Equity Awards</u>.&#160; Each outstanding and unvested equity award, including, without limitation, each stock option and restricted stock award, held by Executive shall automatically become vested and, if applicable, exercisable and any forfeiture restrictions or rights of repurchase thereon shall immediately lapse, in each case, with respect to one hundred percent (100%) of the unvested shares underlying Executive&#146;s equity awards as of the Termination Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Certain Reductions</u>.&#160; Notwithstanding anything herein to the contrary, the Company shall reduce Executive&#146;s severance benefits under this Agreement, in whole or in part, by any other severance benefits, pay in lieu of notice, or other similar benefits payable to Executive by the Company in connection with Executive&#146;s termination, including but not limited to payments or benefits pursuant to (a)&nbsp;any applicable legal requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act, or (b)&nbsp;any Company policy or practice providing for Executive to remain on the payroll without being in active service for a limited period of time after being given notice of the termination of Executive&#146;s employment.&#160; The benefits provided under this Agreement are intended to satisfy, to the greatest extent possible, any and all statutory obligations that may arise out of Executive&#146;s termination of employment.&#160; Such reductions shall be applied on a retroactive basis, with severance benefits previously paid being recharacterized as payments pursuant to the Company&#146;s statutory obligation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Deemed Resignation</u>.&#160; Upon termination of Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, and then held with the Company or any of its affiliates, and, at the Company&#146;s request, Executive shall execute such documents as are necessary or desirable to effectuate such resignations.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Other Terminations</u>.&#160; If Executive&#146;s service with the Company is terminated by the Company or by Executive for any or no reason other than as a Covered Termination, then Executive shall not be entitled to any benefits hereunder other than accrued but unpaid salary, bonus, vacation and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="1119-3-KQ_PB_3_070710_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=939233,FOLIO='3',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">expense reimbursement in accordance with applicable law and to elect any continued healthcare coverage as may be required under COBRA or similar state law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Limitation on Payments</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding anything in this Agreement to the contrary, if any payment or distribution Executive would receive pursuant to this Agreement or otherwise (&#147;<u>Payment</u>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code of 1986, as amended (the &#147;<u>Code</u>&#148;), and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<u>Excise Tax</u>&#148;), then the Company shall cause to be determined, before any amounts of the Payment are paid to Executive, which of the following alternative forms of payment would maximize Executive&#146;s after-tax proceeds: (x)&nbsp;payment in full of the entire amount of the Payment (a &#147;<u>Full Payment</u>&#148;), or (y)&nbsp;payment of only a part of the Payment so that Executive receives that largest Payment possible without being subject to the Excise Tax (a &#147;<u>Reduced Payment</u>&#148;), whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in Executive&#146;s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the Payment may be subject to the Excise Tax.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If a Reduced Payment is made pursuant to this Section&nbsp;8, (i)&nbsp;the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Executive shall have no rights to any additional payments and/or benefits constituting the Payment, and (ii)&nbsp;reduction in payments and/or benefits will occur in the following order: (1)&nbsp;reduction of cash payments; (2)&nbsp;cancellation of accelerated vesting of equity awards other than stock options; (3)&nbsp;cancellation of accelerated vesting of stock options; and (4)&nbsp;reduction of other benefits payable to Executive.&#160; In the event that acceleration of compensation from Executive&#146;s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall make all determinations required to be made under this Section&nbsp;8.&#160; If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, group or entity effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder.&#160; The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within 15 calendar days after the date on which Executive&#146;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive.&#160; If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="1119-3-KQ_PB_4_070810_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=64904,FOLIO='4',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment.&#160; Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definition of Terms</u>.&#160; The following terms referred to in this Agreement shall have the following meanings:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Cause</u>.&#160; &#147;Cause&#148; means the occurrence of any of the following events: (i)&nbsp;Executive&#146;s commission of any felony or any crime involving fraud, dishonesty, or moral turpitude under the laws of the United States or any state thereof; (ii)&nbsp;Executive&#146;s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii)&nbsp;Executive&#146;s intentional, material violation of any contract or agreement between Executive and the Company or of any statutory duty owed to the Company; (iv)&nbsp;Executive&#146;s unauthorized use or disclosure of the Company&#146;s confidential information or trade secrets; or (v)&nbsp;Executive&#146;s gross misconduct. The determination whether a termination is for &#147;Cause&#148; under the foregoing definition shall be made by the Company in its sole discretion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Change in Control</u>.&#160; &#147;Change in Control&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>A transaction or series of transactions (other than an offering of the common stock of the Company to the general public through a registration statement filed with the Securities and Exchange Commission) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d)&nbsp;and 14(d)(2)&nbsp;of the Securities Exchange Act of 1934, as amended (the &#147;<u>Exchange Act</u>&#148;)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule&nbsp;13d-3 under the Exchange Act) of securities of the Company possessing more than fifty percent (50%) of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>During any period of two (2)&nbsp;consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new director(s)&nbsp;(other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in Sections 9(b)(i)&nbsp;or 9(b)(ii)&nbsp;whose election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two (2)-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related </p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="1119-3-KQ_PB_5_070907_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=642008,FOLIO='5',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: (A)&nbsp;which results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#147;<u>Successor Entity</u>&#148;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and (B)&nbsp;after which no person or group beneficially owns voting securities representing fifty percent (50%) or more of the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this Section&nbsp;9(b)(iii)&nbsp;as beneficially owning fifty percent (50%) or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction;&#160; or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company&#146;s stockholders approve a liquidation or dissolution of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any amount which constitutes or provides for the deferral of compensation and is subject to Section&nbsp;409A of the Code, the transaction or event with respect to such amount must also constitute a &#147;change in control event,&#148; as defined in Treasury Regulation Section&nbsp;1.409A-3(i)(5)&nbsp;to the extent required by Section&nbsp;409A of the Code.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Change in Control Period</u>.&#160; &#147;Change in Control Period&#148; means the period of time commencing three (3)&nbsp;months prior to a Change in Control and ending twelve (12) months following the Change in Control.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Covered Termination</u>.&#160; &#147;Covered Termination&#148; shall mean the termination of Executive&#146;s employment by the Company other than for Cause or by Executive for Good Reason.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Good Reason</u>.&#160; &#147;Good Reason&#148; means Executive&#146;s resignation from all positions he or she then holds with the Company if (i)&nbsp;(A)&nbsp;there is a material diminution in Executive&#146;s duties and responsibilities with the Company; <i>provided</i>, <i>however</i>, that a change in title or reporting relationship will not constitute Good Reason; (B)&nbsp;there is a material reduction of Executive&#146;s base salary; <i>provided</i>, <i>however</i>, that a material reduction in Executive&#146;s base salary pursuant to a salary reduction program affecting all or substantially all of the employees of the Company and that does not adversely affect Executive to a greater extent than other similarly situated employees shall not constitute Good Reason; or (C)&nbsp;Executive is required to relocate Executive&#146;s primary work location to a facility or location that would increase Executive&#146;s one-way commute distance by more than twenty-five (25) miles from Executive&#146;s primary work location as of immediately prior to such change, (ii)&nbsp;Executive provides written notice outlining such conditions, acts or omissions to the Company within thirty (30) days immediately following such material change or reduction, (iii)&nbsp;such material change or reduction is not remedied by the Company within thirty (30) days following the</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="1119-3-KQ_PB_6_071105_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=550539,FOLIO='6',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company&#146;s receipt of such written notice and (iv)&nbsp;Executive&#146;s resignation is effective not later than thirty (30) days after the expiration of such thirty (30) day cure period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination Date</u>.&#160; &#147;Termination Date&#148; means the date Executive experiences a Covered Termination.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Company&#146;s Successors</u>.&#160; Except as set forth above, any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#146;s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.&#160; For all purposes under this Agreement, the term &#147;<u>Company</u>&#148; shall include any successor to the Company&#146;s business and/or assets which executes and delivers the assumption agreement described in this Section&nbsp;10(a)&nbsp;or which becomes bound by the terms of this Agreement by operation of law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Executive&#146;s Successors</u>.&#160; The terms of this Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or one day following mailing via Federal Express or similar overnight courier service.&#160; In the case of Executive, mailed notices shall be addressed to Executive at Executive&#146;s home address that the Company has on file for Executive.&#160; In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of the General Counsel of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Confidentiality; Non-Disparagement</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Confidentiality</u>.&#160; Executive hereby expressly confirms Executive&#146;s continuing obligations to the Company pursuant to Executive&#146;s Employee Confidentiality and Inventions Assignment Agreement with the Company (the &#147;<u>Confidential Information Agreement</u>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Non-Disparagement</u>.&#160; Executive agrees that Executive shall not disparage, criticize or defame the Company, its affiliates and their respective affiliates, directors, officers, agents, partners, stockholders or employees, either publicly or privately.&#160; The Company agrees that it shall not, and it shall instruct its officers and members of its Board to not, disparage, criticize or defame Executive, either publicly or privately.&#160; Nothing in this Section&nbsp;12(b)&nbsp;shall have application to any evidence or testimony required by any court, arbitrator or government agency.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Dispute Resolution</u>.&#160; To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, Executive and the Company agree that any and all disputes, claims,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="1119-3-KQ_PB_7_071156_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=154883,FOLIO='7',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or causes of action arising from or relating to the enforcement, breach, performance or interpretation of this Agreement, Executive&#146;s employment, or the termination of Executive&#146;s employment, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in San Mateo County, California, conducted by Judicial Arbitration and Mediation Services,&nbsp;Inc. (&#147;<u>JAMS</u>&#148;) under the applicable JAMS employment rules.&#160; <b>By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding</b>.&#160; The arbitrator shall:&#160; (i)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii)&nbsp;issue a written arbitration decision, to include the arbitrator&#146;s essential findings and conclusions and a statement of the award.&#160; The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law.&#160; The Company shall pay all JAMS&#146; arbitration fees in excess of the amount of court fees that would be required if the dispute were decided in a court of law.&#160; Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.&#160; Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over intellectual property rights by Court action instead of arbitration.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Miscellaneous Provisions</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;409A</u>.&#160; The intent of the parties is that the payments and benefits under this Agreement comply with or be exempt from Section&nbsp;409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date, and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.&#160; If the Company determines that any provision of this Agreement would cause Executive to incur any additional tax or interest under Section&nbsp;409A of the Code (with specificity as to the reason therefor), the Company and Executive shall take commercially reasonable efforts to reform such provision to try to comply with or be exempt from Section&nbsp;409A of the Code through good faith modifications to the minimum extent reasonably appropriate to conform with Section&nbsp;409A of the Code, <i>provided</i> that any such modifications shall not increase the cost or liability to the Company.&#160; To the extent that any provision hereof is modified in order to comply with or be exempt from Section&nbsp;409A of the Code, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to Executive and the Company of the applicable provision without violating the provisions of Section&nbsp;409A of the Code.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Separation from Service</u>.&#160; Notwithstanding any provision to the contrary in this Agreement, no amount deemed deferred compensation subject to Section&nbsp;409A of the Code shall be payable pursuant to Sections 3 or 4 above unless Executive&#146;s termination of employment constitutes a &#147;separation from service&#148; with the Company within the meaning of Section&nbsp;409A of the Code and the Department of Treasury regulations and other guidance promulgated thereunder (&#147;<u>Separation from Service</u>&#148;) and, except as provided under Section&nbsp;14(a)(ii)&nbsp;of this Agreement, any such amount shall not be paid, or in the case of installments, commence payment, until the sixtieth (60<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) day following Executive&#146;s Separation from Service.&#160; Any installment payments that would</p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="1119-3-KQ_PB_8_071242_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=250761,FOLIO='8',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">have been made to Executive during the sixty (60) day period immediately following Executive&#146;s Separation from Service but for the preceding sentence shall be paid to Executive on the sixtieth (60</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>) day following Executive&#146;s Separation from Service and the remaining payments shall be made as provided in this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Specified Employee</u>.&#160; Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed at the time of his or her separation from service to be a &#147;specified employee&#148; for purposes of Section&nbsp;409A(a)(2)(B)(i)&nbsp;of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i)&nbsp;of the Code, such portion of Executive&#146;s benefits shall not be provided to Executive prior to the earlier of (A)&nbsp;the expiration of the six (6)-month period measured from the date of Executive&#146;s Separation from Service or (B)&nbsp;the date of Executive&#146;s death.&#160; Upon the first business day following the expiration of the applicable Code Section&nbsp;409A(a)(2)(B)(i)&nbsp;period, all payments deferred pursuant to this Section&nbsp;14(a)(ii)&nbsp;shall be paid in a lump sum to Executive, and any remaining payments due under this Agreement shall be paid as otherwise provided herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Expense Reimbursements</u>.&#160; To the extent that any reimbursements payable pursuant to this Agreement are subject to the provisions of Section&nbsp;409A of the Code, any such reimbursements payable to Executive pursuant to this Agreement shall be paid to Executive no later than December&nbsp;31<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">st</font>&#160;of the year following the year in which the expense was incurred, the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, and Executive&#146;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Installments</u>.&#160; For purposes of Section&nbsp;409A of the Code (including, without limitation, for purposes of Treasury Regulation Section&nbsp;1.409A-2(b)(2)(iii)), Executive&#146;s right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Waiver</u>.&#160; No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).&#160; No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Whole Agreement</u>.&#160; This Agreement, the Confidential Information Agreement and any offer letter by and between the Company and Executive represent the entire understanding of the parties hereto with respect to the subject matter hereof and supersede all prior promises, arrangements and understandings regarding same, whether written or written, including, without limitation, any severance or change in control benefits in Executive&#146;s offer letter agreement and employment agreement or previously approved by the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="1119-3-KQ_PB_9_071315_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=760039,FOLIO='9',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Choice of Law</u>.&#160; The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Severability</u>.&#160; The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts</u>.&#160; This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(<i>Signature page&nbsp;follows</i>)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="1119-3-KQ_PB_10_071346_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=484624,FOLIO='10',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year set forth below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CORVUS   PHARMACEUTICALS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Leiv Lea</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CFO</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;13, 2017</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXECUTIVE</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Daniel Hunt</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Daniel Hunt</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: December&nbsp;13,   2017</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature Page&nbsp;to Change in Control Severance Agreement</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="3",CHK=322896,FOLIO='',FILE="DISK128:[18ZAA3.18ZAA41903]1119-3-KQ_ZAA41903.CHC",USER="JFUSS",CD='Feb 27 07:44 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>a2234682zex-21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZAA41901_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kg41901_exhibit_21.1"> </A>
<A NAME="toc_kg41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;21.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kg41901_list_of_subsidiaries"> </A>
<A NAME="toc_kg41901_2"> </A></FONT> <FONT SIZE=2><B>  List of Subsidiaries    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a list of subsidiaries of the Company as of December&nbsp;31, 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="134pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Subsidiary Legal Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>State or other Jurisdiction of<BR>
Incorporation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Corvus Oncology International,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Cayman Islands</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Corvus Biopharma International,&nbsp;Ltd</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Cayman Islands</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Corvus Biotech International,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Cayman Islands</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Corvus Therapeutics International,&nbsp;Ltd.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Cayman Islands</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="4",CHK=836358,FOLIO='blank',FILE='DISK104:[18ZAA1.18ZAA41901]KG41901A.;10',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZAA41901_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg41901_1">Exhibit 21.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg41901_2">List of Subsidiaries</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JFUSS,SEQ=,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a2234682zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZAA41901_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ki41901_exhibit_23.1"> </A>
<A NAME="toc_ki41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ki41901_consent_of_independent__ki402319"> </A>
<A NAME="toc_ki41901_2"> </A></FONT> <FONT SIZE=2><B>  CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hereby consent to the incorporation by reference in the Registration Statements on Form&nbsp;S-3 (No.&nbsp;333-217102) and
Form&nbsp;S-8 (No.&nbsp;333-210456 and No.&nbsp;333-216590) of Corvus Pharmaceuticals,&nbsp;Inc. of our report dated March&nbsp;1, 2018 relating to the financial statements, which appears in
this Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
PricewaterhouseCoopers&nbsp;LLP<BR>
San Jose, California<BR>
March&nbsp;1, 2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="5",CHK=362192,FOLIO='blank',FILE='DISK104:[18ZAA1.18ZAA41901]KI41901A.;5',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZAA41901_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki41901_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ki41901_2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JFUSS,SEQ=,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>a2234682zex-31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZAA41901_6">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kk41901_exhibit_31.1"> </A>
<A NAME="toc_kk41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;31.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kk41901_certifications"> </A>
<A NAME="toc_kk41901_2"> </A></FONT> <FONT SIZE=2><B>  CERTIFICATIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>I,
Richard A. Miller, certify that: </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>I
have reviewed this Annual Report on Form&nbsp;10-K of Corvus Pharmaceuticals,&nbsp;Inc. for the year ended December&nbsp;31, 2017;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter
(the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
reporting. </FONT></DD></DL>
</DD></DL>

<P style="font-family:times;"><FONT SIZE=2>Date:
March&nbsp;1 2018<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>/s/&nbsp;RICHARD A. MILLER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Richard A. Miller, M.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer<BR>
(Principal Executive Officer)</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="6",CHK=331708,FOLIO='blank',FILE='DISK104:[18ZAA1.18ZAA41901]KK41901A.;4',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZAA41901_6">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kk41901_1">Exhibit 31.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kk41901_2">CERTIFICATIONS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JFUSS,SEQ=,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="6" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>a2234682zex-31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZAA41901_7">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="km41901_exhibit_31.2"> </A>
<A NAME="toc_km41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;31.2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="km41901_certifications"> </A>
<A NAME="toc_km41901_2"> </A></FONT> <FONT SIZE=2><B>  CERTIFICATIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>I,
Leiv Lea, certify that: </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>I
have reviewed this Annual Report on Form&nbsp;10-K of Corvus Pharmaceuticals,&nbsp;Inc. for the year ended December&nbsp;31, 2017;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Evaluated
the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter
(the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial
reporting.
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
reporting. </FONT></DD></DL>
</DD></DL>

<P style="font-family:times;"><FONT SIZE=2>Date:
March&nbsp;1, 2018<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>/s/&nbsp;LEIV LEA<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Leiv Lea<BR></FONT> <FONT SIZE=2><I>Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="7",CHK=394670,FOLIO='blank',FILE='DISK104:[18ZAA1.18ZAA41901]KM41901A.;3',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZAA41901_7">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_km41901_1">Exhibit 31.2</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_km41901_2">CERTIFICATIONS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JFUSS,SEQ=,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="7" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>a2234682zex-32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZAA41901_8">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="ko41901_exhibit_32.1"> </A>
<A NAME="toc_ko41901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;32.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ko41901_section_1350_certifications"> </A>
<A NAME="toc_ko41901_2"> </A></FONT> <FONT SIZE=2><B>  SECTION&nbsp;1350 CERTIFICATIONS*    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Annual Report of Corvus Pharmaceuticals,&nbsp;Inc. (the "Company") on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017, as filed with the
Securities and Exchange Commission (the "Report"), Richard A. Miller, President and Chief Executive Officer </FONT><FONT SIZE=2><I>(Principal Executive Officer)</I></FONT><FONT SIZE=2> of the
Company, and Leiv Lea, Chief Financial Officer </FONT><FONT SIZE=2><I>(Principal Financial and Accounting Officer)</I></FONT><FONT SIZE=2> of the Company, each hereby certifies, pursuant to the
requirement set forth in Rule&nbsp;13a-14(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States
Code (18 U.S.C. &sect;&nbsp;1350), that, to the best of his knowledge: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Report, to which this Certification is attached as Exhibit&nbsp;32.1, fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Exchange Act;
and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period
covered by the Report. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Dated:
March&nbsp;1, 2018 </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>/s/&nbsp;RICHARD A. MILLER<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Richard A. Miller, M.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer<BR>
(Principal Executive Officer)</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>/s/&nbsp;LEIV LEA<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Leiv Lea<BR></FONT> <FONT SIZE=2><I>Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be
incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the
Form 10-K), irrespective of any general incorporation language contained in such filing. </FONT></DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="8",CHK=9872,FOLIO='blank',FILE='DISK104:[18ZAA1.18ZAA41901]KO41901A.;4',USER='CHE105948',CD='28-FEB-2018;20:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="18ZAA41901_8">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ko41901_1">Exhibit 32.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ko41901_2">SECTION 1350 CERTIFICATIONS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JFUSS,SEQ=,EFW="2234682",CP="CORVUS PHARMACEUTICALS, INC.",DN="8" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>crvs-20171231.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  7.3.329.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2018 1:56:44 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:crvs="http://www.corvuspharma.com/20171231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="crvs-20171231.xsd" />
  <!--Context Section-->
  <context id="As_Of_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_4_26_2016_To_4_26_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-26</startDate>
      <endDate>2016-04-26</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_3_29_2016_To_3_29_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2016-03-29</startDate>
      <endDate>2016-03-29</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_crvs_SeriesAndSeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesAndSeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_4_26_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-26</instant>
    </period>
  </context>
  <context id="As_Of_3_29_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-03-29</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvs:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvs:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvs:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvs:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-03-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-02-01</startDate>
      <endDate>2014-02-28</endDate>
    </period>
  </context>
  <context id="As_Of_8_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <instant>2015-08-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_TitleOfIndividualAxis_crvs_NonEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">crvs:NonEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_ComputerEquipmentAndSoftwareMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_ComputerEquipmentAndSoftwareMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_ComputerEquipmentAndSoftwareMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_1_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="Duration_11_26_2014_To_11_26_2014_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-11-26</startDate>
      <endDate>2014-11-26</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_CowenAndCompanyLLCMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_SalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:SalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_3_29_2016_To_3_29_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-03-29</startDate>
      <endDate>2016-03-29</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_6_1_2015_To_6_30_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_8_31_2015_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-08-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_1_31_2015_us-gaap_LeaseArrangementTypeAxis_crvs_FacilityLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">crvs:FacilityLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLaboratorySpaceInBurlingameCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="Duration_6_10_2015_To_6_10_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-10</startDate>
      <endDate>2015-06-10</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2017_To_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2017-10-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2016_To_9_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_3_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_29_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <instant>2016-03-29</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_1_31_2015_us-gaap_LeaseArrangementTypeAxis_crvs_FacilityLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">crvs:FacilityLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLaboratorySpaceInBurlingameCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_crvs_EmployeeAndNonEmployeeStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crvs:EmployeeAndNonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_crvs_EmployeeAndNonEmployeeStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crvs:EmployeeAndNonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_crvs_EmployeeAndNonEmployeeStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crvs:EmployeeAndNonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvs:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvs:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvs:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_6_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="As_Of_3_1_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <instant>2018-03-01</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvs:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_6_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-03-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_2_28_2017_us-gaap_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-02-28</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvs:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_LeaseArrangementTypeAxis_crvs_FacilityLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">crvs:FacilityLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLaboratorySpaceInBurlingameCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_11_26_2014_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-11-26</instant>
    </period>
  </context>
  <context id="Duration_9_20_2017_To_9_20_2017_us-gaap_CounterpartyNameAxis_crvs_CowenAndCompanyLLCMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_SalesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">crvs:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:SalesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-09-20</startDate>
      <endDate>2017-09-20</endDate>
    </period>
  </context>
  <context id="Duration_5_1_2017_To_5_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2017-05-01</startDate>
      <endDate>2017-05-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_8_31_2016_us-gaap_LeaseArrangementTypeAxis_crvs_FacilityLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">crvs:FacilityLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLaboratorySpaceInBurlingameCaliforniaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2016-08-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit19">
    <measure>crvs:segment</measure>
  </unit>
  <unit id="Unit18">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit17">
    <measure>crvs:subsidiary</measure>
  </unit>
  <unit id="Unit16">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="Unit15">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit14">
    <measure>crvs:Vote</measure>
  </unit>
  <unit id="Unit13">
    <measure>crvs:item</measure>
  </unit>
  <unit id="Unit12">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="Unit1">
    <measure>iso4217:USD</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <crvs:AccrualForPreclinicalAndClinicalTrialCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">1617000</crvs:AccrualForPreclinicalAndClinicalTrialCurrent>
  <crvs:AccrualForPreclinicalAndClinicalTrialCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">2870000</crvs:AccrualForPreclinicalAndClinicalTrialCurrent>
  <crvs:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">4044000</crvs:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
  <crvs:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">5515000</crvs:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
  <crvs:AccruedManufacturingExpenseCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">955000</crvs:AccruedManufacturingExpenseCurrent>
  <crvs:AccruedManufacturingExpenseCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1056000</crvs:AccruedManufacturingExpenseCurrent>
  <crvs:AmortizationAccretionRelatedToMarketableSecurities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-41000</crvs:AmortizationAccretionRelatedToMarketableSecurities>
  <crvs:AmortizationAccretionRelatedToMarketableSecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">648000</crvs:AmortizationAccretionRelatedToMarketableSecurities>
  <crvs:AmortizationAccretionRelatedToMarketableSecurities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-195000</crvs:AmortizationAccretionRelatedToMarketableSecurities>
  <crvs:AreaOfLeaseExpansion contextRef="Duration_1_1_2015_To_8_31_2016_us-gaap_LeaseArrangementTypeAxis_crvs_FacilityLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" unitRef="Unit12" decimals="INF">28633</crvs:AreaOfLeaseExpansion>
  <crvs:CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Investments with remaining maturities, at the date of purchase, greater than three months, but less than one year are considered short-term. The Company determines the appropriate classification of marketable securities at the time of purchase and evaluates such designation as of each balance sheet date. To date, all marketable securities have been classified as available-for-sale and are carried at fair value with unrealized gains and losses, if any, included as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Interest and realized gains and losses are included in interest income. Realized gains and losses are recognized based on the specific identification method.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</crvs:CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
  <crvs:ChangeInFairValueOfConvertiblePreferredStockLiability contextRef="Duration_1_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="-5">17600000</crvs:ChangeInFairValueOfConvertiblePreferredStockLiability>
  <crvs:ChangeInFairValueOfConvertiblePreferredStockLiability contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">17600000</crvs:ChangeInFairValueOfConvertiblePreferredStockLiability>
  <crvs:ClinicalTrialAccrualsPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Clinical Trial Accruals&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors' progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion, or the services completed. The Company's estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</crvs:ClinicalTrialAccrualsPolicyTextBlock>
  <crvs:CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm contextRef="Duration_5_1_2017_To_5_31_2017" unitRef="Unit13" decimals="INF">65</crvs:CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm>
  <crvs:CommonStockVotingRightsNumberOfVotesPerShare contextRef="As_Of_12_31_2017" unitRef="Unit14" decimals="INF">1</crvs:CommonStockVotingRightsNumberOfVotesPerShare>
  <crvs:CompensationOnSaleOfStockPercentage contextRef="Duration_9_20_2017_To_9_20_2017_us-gaap_CounterpartyNameAxis_crvs_CowenAndCompanyLLCMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_SalesAgreementMember" unitRef="Unit15" decimals="3">0.030</crvs:CompensationOnSaleOfStockPercentage>
  <crvs:ConcentrationRiskCreditRiskUninsuredFinancialInstitutions contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit13" decimals="INF">2</crvs:ConcentrationRiskCreditRiskUninsuredFinancialInstitutions>
  <crvs:ConvertiblePreferredStockLiabilityTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;8. Convertible Preferred Stock Liability&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On November&amp;nbsp;26, 2014, the Company executed the Series&amp;nbsp;A Convertible Preferred Stock Purchase Agreement for the issuance of up to 8,921,438 shares of Series&amp;nbsp;A convertible preferred stock and issued 3,395,468 shares for net proceeds of $12.6&amp;nbsp;million in connection with the first closing of the first tranche. In January 2015, in connection with the second closing of the first tranche, the Company issued 1,065,246 shares of Series&amp;nbsp;A convertible preferred stock for net proceeds of $4.0&amp;nbsp;million and in June 2015, in connection with the closing of the second tranche, an additional 4,460,715 shares of Series&amp;nbsp;A convertible preferred stock were issued for net proceeds of $16.7&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Series&amp;nbsp;A Convertible Preferred Stock Purchase Agreement provided that, upon the earliest to occur of any of three defined triggers, each investor of the first tranche agreed to purchase its pro-rata portion of the shares to be issued in the second tranche and the Company agreed to sell and issue said shares of Series&amp;nbsp;A convertible preferred stock on the same terms as the first tranche.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A convertible preferred stock liability was recorded for the Company's obligation to sell the second tranche of the Series&amp;nbsp;A convertible preferred stock to the first tranche stockholders at a fixed price of $3.755 per share upon the satisfaction of certain conditions. A liability was initially recorded in connection with the first tranche of the Series&amp;nbsp;A convertible preferred stock financing at its initial estimated fair value of $2.6&amp;nbsp;million, with gains and losses arising from changes in fair value recognized in the statements of operations at each period while such instrument was classified as a liability. A $17.6&amp;nbsp;million charge was recorded for the change in estimated fair value of the Series&amp;nbsp;A convertible preferred stock liability for the period from January&amp;nbsp;1, 2015 to the closing of the second tranche in June 2015. Upon the closing of the second tranche in June 2015, the liability terminated and the balance of the liability of $20.2&amp;nbsp;million was reclassified to convertible preferred stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The preferred stock liability related to Series&amp;nbsp;A convertible preferred stock was valued at issuance and at December&amp;nbsp;31, 2014 and March&amp;nbsp;31, 2015 using a black scholes option-pricing method based on the consideration paid for the Series&amp;nbsp;A convertible preferred stock and the convertible preferred stock liability using an assumed term of 1.0&amp;nbsp;years and 0.75&amp;nbsp;years, an interest rate of 0.13% and 0.20% and a volatility of 85% and 85%, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Immediately prior to its exercise on June&amp;nbsp;10, 2015, the convertible preferred stock liability's fair value was estimated based on its intrinsic value, with the fair value of the Series&amp;nbsp;A convertible preferred stock estimated as of June&amp;nbsp;10, 2015 and compared to the exercise price of the Series&amp;nbsp;A convertible preferred stock liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;To estimate the fair value of the Series&amp;nbsp;A convertible preferred stock as of June&amp;nbsp;10, 2015, the enterprise value of the Company was estimated based on potential IPO and sale estimates. The enterprise value was then allocated to the various classes of securities using an option pricing model that assumed a term of two years to a liquidity event, an interest rate of 0.75% and a volatility of 75% based on market conditions and expectations as of the June valuation date.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</crvs:ConvertiblePreferredStockLiabilityTextBlock>
  <crvs:ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche contextRef="As_Of_11_26_2014_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">3</crvs:ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche>
  <crvs:DeferredOfferingCostsIncurredButNotYetPaid contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">222000</crvs:DeferredOfferingCostsIncurredButNotYetPaid>
  <crvs:DisclosureOfShareBasedCompensationPlansTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;10. Stock Option Plans&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In February 2014, the Company adopted the 2014 Equity Incentive Plan (the "2014 Plan"), which was subsequently amended in November 2014, July 2015 and September 2015, under which it granted incentive stock options ("ISOs") or non-qualified stock options ("NSOs"). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over four years and have maximum exercise term of 10&amp;nbsp;years. The 2014 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company's common stock as determined by the board of directors on the date of the grant.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the "2016 Plan"), became effective. Under the 2016 Plan, incentive stock options, non-statutory stock options, stock purchase rights and other stock-based awards may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over four years and have maximum exercise term of 10&amp;nbsp;years. The 2016 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company's common stock as determined by the board of directors on the date of the grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and no further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of 1,136,229 shares.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Activity under the Company's stock option plans is set forth below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Shares&lt;br /&gt;Available&lt;br /&gt;for Grant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number of&lt;br /&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Balance at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,475,600
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,350,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.88
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Additional shares authorized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;830,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(969,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;969,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.80
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(66,253
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Options forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;240,435
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(240,435
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Balance at December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,576,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,013,394
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table summarizes information about stock options outstanding at December&amp;nbsp;31, 2017 and 2016:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Outstanding&lt;br /&gt;at December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Vested&lt;br /&gt;at December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Exercise Price &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (in Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (in Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$0.28&amp;nbsp;- $4.65&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;535,136
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.55
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.46
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;325,397
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$6.75&amp;nbsp;- $10.60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;701,600
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.44
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,688
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.75
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$11.21&amp;nbsp;- $16.70&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,776,658
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.57
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;596,727
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.23
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,013,394
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.69
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;924,812
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.40
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Outstanding&lt;br /&gt;at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Vested&lt;br /&gt;at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Exercise Price &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (in Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (in Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$0.28&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;419,682
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.46
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;159,732
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.44
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$4.65&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.81
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.65
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;42,449
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.81
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.65
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$6.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.75
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,438
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.75
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$13.34&amp;nbsp;-&amp;nbsp;16.37&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,781,400
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;193,867
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.14
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,350,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.88
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;397,486
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.84
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The weighted average grant date fair value of options granted for the years ended December&amp;nbsp;31, 2017, 2016 and 2015, was $8.93, $10.78 and $4.37, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Options outstanding and exercisable that had vested or were expected to vest at December&amp;nbsp;31, 2017 were as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number of&lt;br /&gt;shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Aggregate&lt;br /&gt;Intrinsic Value&lt;br /&gt;(in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;924,812
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.38
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,946
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected to vest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,088,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12.40
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.98
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,903
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In the table above, aggregate intrinsic value represents the difference between the exercise price of the options to purchase common stock and the estimated fair value of the Company's common stock of $10.36&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The aggregate intrinsic value of stock options exercised in the years ended December&amp;nbsp;31, 2017, 2016 and 2015, was $332,000, $216,000 and $714,000, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The total fair value of options that vested in the year ended December&amp;nbsp;31, 2017, 2016 and 2015, was $5.8&amp;nbsp;million, $3.2&amp;nbsp;million, and $0.1&amp;nbsp;million, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</crvs:DisclosureOfShareBasedCompensationPlansTextBlock>
  <crvs:EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="INF">-0.19</crvs:EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent>
  <crvs:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="INF">0.01</crvs:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent>
  <crvs:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="INF">0.02</crvs:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent>
  <crvs:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="INF">0.02</crvs:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent>
  <crvs:InitialPublicOfferingPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Initial Public Offering&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On March&amp;nbsp;22, 2016, the Company's registration statement on Form&amp;nbsp;S-1 (File No.&amp;nbsp;333-208850) relating to its initial public offering ("IPO") of its common stock was declared effective by the Securities and Exchange Commission ("SEC") and the shares of its common stock began trading on the Nasdaq Global Market on March&amp;nbsp;23, 2016. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on March&amp;nbsp;29, 2016, pursuant to which the Company sold 4,700,000 shares of its common stock. On April&amp;nbsp;26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial offering price of $15.00 per share. The Company received aggregate net proceeds of approximately $70.6&amp;nbsp;million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stocks.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</crvs:InitialPublicOfferingPolicyTextBlock>
  <crvs:InterestIncomeAndOtherExpenseNet contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">35000</crvs:InterestIncomeAndOtherExpenseNet>
  <crvs:InterestIncomeAndOtherExpenseNet contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">601000</crvs:InterestIncomeAndOtherExpenseNet>
  <crvs:InterestIncomeAndOtherExpenseNet contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">861000</crvs:InterestIncomeAndOtherExpenseNet>
  <crvs:LandlordProvidedFreeRentAndLeaseIncentives contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-5">1900000</crvs:LandlordProvidedFreeRentAndLeaseIncentives>
  <crvs:LeaseAgreementRightToExtendTerm contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_LeaseArrangementTypeAxis_crvs_FacilityLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember">P3Y</crvs:LeaseAgreementRightToExtendTerm>
  <crvs:LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments contextRef="As_Of_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember" unitRef="Unit1" decimals="-5">2600000</crvs:LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments>
  <crvs:LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments contextRef="As_Of_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember" unitRef="Unit1" decimals="-6">200000000</crvs:LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments>
  <crvs:LicenseAndCollaborationAgreementsMilestonePaymentsMade contextRef="As_Of_2_28_2017_us-gaap_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember" unitRef="Unit1" decimals="-5">3000000</crvs:LicenseAndCollaborationAgreementsMilestonePaymentsMade>
  <crvs:LicenseAndCollaborationAgreementsMilestonePaymentsMade contextRef="As_Of_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember" unitRef="Unit1" decimals="-3">0</crvs:LicenseAndCollaborationAgreementsMilestonePaymentsMade>
  <crvs:LicenseAndCollaborationAgreementsMinimumAnnualFee contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember" unitRef="Unit1" decimals="INF">25000</crvs:LicenseAndCollaborationAgreementsMinimumAnnualFee>
  <crvs:LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">P90D</crvs:LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination>
  <crvs:LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember">P90D</crvs:LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination>
  <crvs:LicenseAndCollaborationAgreementsUpfrontCashPaymentMade contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember" unitRef="Unit1" decimals="INF">10000</crvs:LicenseAndCollaborationAgreementsUpfrontCashPaymentMade>
  <crvs:LicenseAndCollaborationAgreementsUpfrontCashPaymentMade contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_crvs_LicenseAgreementMember" unitRef="Unit1" decimals="-5">1000000</crvs:LicenseAndCollaborationAgreementsUpfrontCashPaymentMade>
  <crvs:MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member" unitRef="Unit16" decimals="INF">1136229</crvs:MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued>
  <crvs:NumberOfInsignificantSubsidiaries contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit17" decimals="INF">4</crvs:NumberOfInsignificantSubsidiaries>
  <crvs:NumberOfSharesReservedForEmployeeStockPurchasePlan contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">200000</crvs:NumberOfSharesReservedForEmployeeStockPurchasePlan>
  <crvs:NumberOfSharesReservedForEmployeeStockPurchasePlan contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">200000</crvs:NumberOfSharesReservedForEmployeeStockPurchasePlan>
  <crvs:ObligationToIssueConvertiblePreferredStock contextRef="As_Of_11_26_2014_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="-5">2600000</crvs:ObligationToIssueConvertiblePreferredStock>
  <crvs:PrepaidResearchAndDevelopmentManufacturingExpenses contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">327000</crvs:PrepaidResearchAndDevelopmentManufacturingExpenses>
  <crvs:ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">10000</crvs:ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase>
  <crvs:ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">10000</crvs:ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase>
  <crvs:ReclassificationsOfConvertiblePreferredStockLiability contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="-3">20200000</crvs:ReclassificationsOfConvertiblePreferredStockLiability>
  <crvs:ReclassificationsOfConvertiblePreferredStockLiability contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="-5">20200000</crvs:ReclassificationsOfConvertiblePreferredStockLiability>
  <crvs:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Accrued and Other Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Accrued clinical trial related&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,870
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,617
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Accrued manufacturing expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,056
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;955
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Personnel related&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;572
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;526
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;410
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;378
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Accrued legal and accounting&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;224
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;255
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;383
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;313
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,515
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,044
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</crvs:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock>
  <crvs:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,274,741
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Shares available for future option grants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,576,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,475,600
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,559,499
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Outstanding options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,013,394
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,350,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;784,136
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Unvested restricted common stock (founders and early exercise of stock options)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;319,203
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;611,698
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;924,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Shares reserved for employee stock purchase plan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;200,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;200,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,109,132
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,637,880
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,542,911
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</crvs:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock>
  <crvs:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;5&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Computer equiipment and purchased software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;3&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Shorter of asset's useful life or remaining term of lease&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</crvs:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit18" decimals="2">10.36</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1903000</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">2088582</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2017" unitRef="Unit18" decimals="2">12.40</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2017_To_12_31_2017">P8Y11M23D</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">2946000</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">924812</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2017" unitRef="Unit18" decimals="2">10.38</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice>
  <crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2017_To_12_31_2017">P8Y7D</crvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">397486</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember" unitRef="Unit16" decimals="INF">42449</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember" unitRef="Unit16" decimals="INF">159732</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember" unitRef="Unit16" decimals="INF">193867</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember" unitRef="Unit16" decimals="INF">1438</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">924812</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember" unitRef="Unit16" decimals="INF">325397</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember" unitRef="Unit16" decimals="INF">596727</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember" unitRef="Unit16" decimals="INF">2688</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2016_To_12_31_2016">P8Y10M2D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember">P8Y9M22D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember">P8Y5M9D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember">P9Y2M5D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember">P8Y10M13D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2017_To_12_31_2017">P8Y7D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember">P7Y6M11D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember">P8Y3M11D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember">P7Y10M13D</crvs:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm>
  <crvs:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-5">4900000</crvs:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense>
  <dei:AmendmentFlag contextRef="Duration_1_1_2017_To_12_31_2017">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2017_To_12_31_2017">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2017_To_12_31_2017">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2017_To_12_31_2017">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2017_To_12_31_2017">2017-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2017_To_12_31_2017">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2017_To_12_31_2017">0001626971</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_3_1_2018" unitRef="Unit16" decimals="INF">21065834</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2017_To_12_31_2017">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2017_To_12_31_2017">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="As_Of_6_30_2017" unitRef="Unit1" decimals="-5">102800000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2017_To_12_31_2017">Corvus Pharmaceuticals, Inc.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="Duration_1_1_2017_To_12_31_2017">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2017_To_12_31_2017">No</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">1900000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">3454000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">255000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">224000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">729000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1570000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">-39000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">-41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">200709000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">208408000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">428000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">428000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">3828000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">3828000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">6229000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">6229000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">34000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">34000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">28000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">28000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">428000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit1" decimals="0">42848</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">136000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">292000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">3828000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit1" decimals="0">142500</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">2143000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">1685000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">6229000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit1" decimals="0">74000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="-3">3537000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="-3">2692000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit16" decimals="INF">15983412</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_crvs_EmployeeAndNonEmployeeStockOptionsMember" unitRef="Unit16" decimals="INF">784136</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">14274741</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit16" decimals="INF">924535</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit16" decimals="INF">2962280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_crvs_EmployeeAndNonEmployeeStockOptionsMember" unitRef="Unit16" decimals="INF">2350582</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit16" decimals="INF">611698</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit16" decimals="INF">3332597</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_crvs_EmployeeAndNonEmployeeStockOptionsMember" unitRef="Unit16" decimals="INF">3013394</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit16" decimals="INF">319203</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AreaOfRealEstateProperty contextRef="As_Of_1_31_2015_us-gaap_LeaseArrangementTypeAxis_crvs_FacilityLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" unitRef="Unit12" decimals="INF">8138</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:Assets contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">140150000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">94775000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">136033000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">91234000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">132845000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">132845000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2017_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">89504000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">89504000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">129846000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2016_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">129846000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit1" decimals="-3">129846000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">129846000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">44949000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2017_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">12677000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2017_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">44949000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2017_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit1" decimals="-3">32272000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">44949000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit1" decimals="-3">39000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2017_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="As_Of_12_31_2017_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit1" decimals="-3">39000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2016_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" unitRef="Unit1" decimals="-3">129885000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">44990000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2017_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="Unit1" decimals="-3">12679000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="As_Of_12_31_2017_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="Unit1" decimals="-3">32311000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S.&amp;nbsp;GAAP"). The Company's functional and reporting currency is the U.S. dollar. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. Since its inception, the Company has incurred significant losses and negative cash flows from operations. As of December&amp;nbsp;31, 2017, the Company had an accumulated deficit of $123.5&amp;nbsp;million and cash, cash equivalents and marketable securities of $90.1&amp;nbsp;million. The Company has financed its operations primarily with the proceeds from the sale of stock. The Company will need to raise additional capital to meet its business objectives. The Company believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its planned expenditures and meet its obligations through at least the next twelve months from the issuance of these financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;2. Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S.&amp;nbsp;GAAP"). The Company's functional and reporting currency is the U.S. dollar. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. Since its inception, the Company has incurred significant losses and negative cash flows from operations. As of December&amp;nbsp;31, 2017, the Company had an accumulated deficit of $123.5&amp;nbsp;million and cash, cash equivalents and marketable securities of $90.1&amp;nbsp;million. The Company has financed its operations primarily with the proceeds from the sale of stock. The Company will need to raise additional capital to meet its business objectives. The Company believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its planned expenditures and meet its obligations through at least the next twelve months from the issuance of these financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The preparation of the Company's consolidated financial statements in conformity with U.S.&amp;nbsp;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Initial Public Offering&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On March&amp;nbsp;22, 2016, the Company's registration statement on Form&amp;nbsp;S-1 (File No.&amp;nbsp;333-208850) relating to its initial public offering ("IPO") of its common stock was declared effective by the Securities and Exchange Commission ("SEC") and the shares of its common stock began trading on the Nasdaq Global Market on March&amp;nbsp;23, 2016. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on March&amp;nbsp;29, 2016, pursuant to which the Company sold 4,700,000 shares of its common stock. On April&amp;nbsp;26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial offering price of $15.00 per share. The Company received aggregate net proceeds of approximately $70.6&amp;nbsp;million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stocks.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Substantially all of the Company's cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company's marketable securities consist of investments in U.S. Treasury securities, U.S. government agency securities and corporate debt obligations, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company's product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Segments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Investments with remaining maturities, at the date of purchase, greater than three months, but less than one year are considered short-term. The Company determines the appropriate classification of marketable securities at the time of purchase and evaluates such designation as of each balance sheet date. To date, all marketable securities have been classified as available-for-sale and are carried at fair value with unrealized gains and losses, if any, included as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Interest and realized gains and losses are included in interest income. Realized gains and losses are recognized based on the specific identification method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company's financial instruments, including cash equivalents, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Deferred Offering Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Deferred offering costs consist primarily of direct incremental costs related to the Company's initial public offering of its common stock. Upon completion of the initial public offering in March 2016, these amounts were offset against the proceeds of the offering.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;5&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Computer equiipment and purchased software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;3&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Shorter of asset's useful life or remaining term of lease&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives. Should impairment exist, the impairment loss to be recognized is measured by the amount by which the carrying amount of the asset exceeds the projected discounted future net cash flows arising from the asset. All long-lived assets are maintained in the United States of America.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Consolidation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Research and Development Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records research and development expenses as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery and development of the Company's product candidates and include:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;external research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, academic and non-profit institutions and consultants;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;license fees; and&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Clinical Trial Accruals&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors' progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion, or the services completed. The Company's estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company maintains incentive plans under which incentive stock options and nonqualified stock options may be granted to employees and non-employee service providers.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company accounts for stock-based employee compensation arrangements in accordance with the provisions of ASC 718, "Compensation&amp;#x2014;Stock Compensation." For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values. The value of the award is recognized as an expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. Forfeitures are accounted for when they occur.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model. The expense for options granted to non-employees is periodically re-measured as the underlying options vest. The awards generally vest over the time period the Company expects to receive service from the non-employee.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company accounts for income taxes under the asset and liability method. The Company estimates actual current tax exposure together with assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and liabilities, which are included in the Company's balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company's statements of operations and comprehensive loss become deductible expenses, under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of the Company's deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income and a valuation allowance is recorded when it is more likely than not that the deferred tax asset will not be recovered. The Company applies judgment in the determination of the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be utilized in the future. Accordingly, the Company recorded a full valuation allowance for all periods presented. The Company intends to maintain a valuation allowance until sufficient evidence exists to support its reversal.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recognizes benefits of uncertain tax positions if it is more likely than not such positions will be sustained upon examination based solely on their technical merits as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company recognizes any material interest and penalties related to unrecognized tax benefits in income tax expense. The Company is required to file income tax returns in the U.S. federal jurisdiction. The Company currently is not under examination by the Internal Revenue Service or other jurisdictions for any tax years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;22, 2017, the 2017 Tax Cuts and Jobs Act (the "Tax Act") was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January&amp;nbsp;1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No.&amp;nbsp;118, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;font-size:10pt;"&gt;Income Tax Accounting Implications of the Tax Cuts and Jobs Act&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt; (SAB&amp;nbsp;118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. We consider the accounting of the transition tax and deferred tax re-measurements to be complete&amp;#x2014;however, since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12&amp;nbsp;months, we are not yet able to reasonably estimate the effect of Global Intangible Low Taxed Income ("GILTI") and have not yet made a policy decision regarding whether to record deferred taxes on GILTI. We expect to complete our analysis within the measurement period in accordance with SAB&amp;nbsp;118. See Note&amp;nbsp;12 in these notes to the consolidated financial statements for additional information.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Comprehensive Loss&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's only element of other comprehensive loss in any period presented was unrealized gains and losses on available for sale marketable securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Net Loss per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&amp;nbsp;2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No.&amp;nbsp;2014-09 will replace most existing revenue recognition guidance in U.S.&amp;nbsp;GAAP when it becomes effective. The new standard is effective January&amp;nbsp;1, 2018 for public companies. Early application is permitted as of January&amp;nbsp;1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. In March 2016, the FASB issued ASU No.&amp;nbsp;2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU No.&amp;nbsp;2014-09. In April 2016, the FASB issued ASU No.&amp;nbsp;2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No.&amp;nbsp;2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January&amp;nbsp;1, 2018. The Company does not believe adopting this guidance will have a material impact on its consolidated financial statements as the Company is not yet generating revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In February 2016, the FASB issued ASU No.&amp;nbsp;2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard requires lessees to record right of use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. The standard is effective for the Company beginning January&amp;nbsp;1, 2019, with early application permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently assessing the impact of this guidance on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2017, the FASB issued ASU No 2017-09, Compensation&amp;#x2014;Stock Compensation (Topic&amp;nbsp;718)&amp;#x2014;Scope of Modification Accounting, to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new standard, modification is required only if the fair value, the vesting conditions, or the classification of an award as equity or liability changes as a result of the change in terms or conditions. ASU 2017-09 will be effective for the Company beginning January&amp;nbsp;1, 2018 and will be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">286000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">84000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">12517000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">4105000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">5050000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">45106000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2017_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">44555000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit1" decimals="-3">44555000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-8412000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">945000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">40056000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-5">90100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;5. License and Collaboration Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Scripps Licensing Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In December 2014, the Company entered into a license agreement with The Scripps Research Institute ("Scripps"), pursuant to which it was granted a non-exclusive, world-wide license for all fields of use under Scripps' rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma. Scripps also granted the Company the right to grant sublicenses in conjunction with other proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Upon execution of the agreement, the Company made a one-time cash payment to Scripps of $10,000 in 2015 and is also obligated to pay a minimum annual fee to Scripps of $25,000. The one-time cash payment was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The first minimum annual fee payment is due on the first anniversary of effective date of the agreement and will be due on each subsequent anniversary of the effective date for the term of the agreement. The Company is also required to make performance-based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $2.6&amp;nbsp;million. The Company is also required to pay royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a rate in the low-single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date, no milestone payments have been made.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company's license agreement with Scripps is terminable by the consent of the parties, at will by the Company upon providing 90&amp;nbsp;days written notice to Scripps, or by Scripps for certain material breaches, or if the Company undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product-by-product basis, or the entire agreement, if the Company fails to meet specified diligence obligations related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Vernalis Licensing Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In February 2015, the Company entered into a license agreement with Vernalis (R&amp;amp;D) Limited ("Vernalis"), which was subsequently amended as of November&amp;nbsp;5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including CPI-444. Pursuant to this agreement, the Company made a one-time cash payment to Vernalis in the amount of $1.0&amp;nbsp;million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon achievement of certain sales milestones. In February 2017, the Company made a milestone payment of $3.0&amp;nbsp;million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent CPI-444 in the Company's Phase&amp;nbsp;1/1b clinical trial. The aggregate potential milestone payments exceed $200&amp;nbsp;million for all indications.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing CPI-444 on a product-by-product and country-by-country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing CPI-444 range from the mid-single digits up to the low-double digits on a country-by-country net sales basis. The royalties on other licensed products that do not include CPI-444 also increase with the amount of net sales on a product-by-product and country-by-country basis and range from the low-single digits up to the mid-single digits on a country-by-country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company's payment obligations to Vernalis in respect of a particular product and country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing 90&amp;nbsp;days written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Genentech Collaboration Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In October 2015, the Company entered into a clinical trial collaboration agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of CPI-444 combined with Genentech's investigational cancer immunotherapy, Tecentriq, a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1("PD-L1"), in a variety of solid tumors in a Phase&amp;nbsp;1/1b clinical trial. Pursuant to this agreement, the Company will be responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of representatives of the Company and representatives of Genentech. Genentech will supply Tecentriq. As part of the agreement, the Company granted Genentech certain rights of first negotiation to participate in future clinical trials that the Company may conduct evaluating the administration of CPI-444 in combination with an anti-PD-1 or anti-PD-L1 antibody. If the Company and Genentech do not reach agreement on the terms of any such participation by Genentech within a specified time period, the Company retains the right to collaborate with third parties in such activities. The Company also granted Genentech certain rights of first negotiation should it decide to license development and commercialization rights to CPI-444. Should the Company and Genentech not reach agreement on the terms of such a license within a specified time period, it retains the right to enter into a license with another third party.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued. Further, the agreement will expire after a set period of time following the provision by the Company of the final clinical study report to Genentech.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2017, the Company signed a second clinical trial collaboration agreement with Genentech. Under the new agreement, CPI-444 administered in combination with Tecentriq will be evaluated in a Phase&amp;nbsp;1b/2 randomized, controlled clinical study as second-line therapy in patients with non-small cell lung cancer who are resistant and/or refractory to prior therapy with an anti-PD-(L)1 antibody. It is anticipated that the study will enroll up to 65 patients in the treatment arm. Genentech will be responsible for the conduct of the study and the parties will share the cost of the Phase&amp;nbsp;1b/2 trial, which began enrolling patients in the fourth quarter of 2017. The Company is responsible for supplying CPI-444 and retains global development and commercialization rights to CPI-444. The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2016" unitRef="Unit1" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2017" unitRef="Unit1" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;13. Commitments and Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Facility Lease&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In January 2015, the Company signed an initial operating lease, effective February&amp;nbsp;1, 2015 for 8,138 square feet of office and laboratory space with a one-year term. Between January 2015 and August 2016, the Company entered into a series of lease amendments to increase the amount of leased space to 28,633 square feet and extend the expiration of the lease to February 2021. The lease agreement includes an annual rent escalation clause and a right to extend the term at the then current market rate for three years. Under the lease and subsequent amendments, the landlord provided approximately $1.9&amp;nbsp;million in free rent and lease incentives. The Company records rent expense on a straight-line basis over the effective term of the lease, including any free rent periods and incentives. The lease requires the Company to pay additional amounts for operating and maintenance expenses. Rent expense related to the facilities lease for the years ended years ended December&amp;nbsp;31, 2017, 2016 and 2015 was approximately $734,000, $584,000 and $347,000, respectively. As of December&amp;nbsp;31, 2017, future minimum lease payments under the facility lease were as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="14" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Payments Due by Period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Less than&lt;br /&gt;1 Year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2&amp;nbsp;-&amp;nbsp;3&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;4&amp;nbsp;-5&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;More than&lt;br /&gt;5 Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;Contractual obligations:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Operating lease obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,632
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,144
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,387
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total contractual obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,632
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,144
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,387
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In August 2015 the Company entered into an agreement for a line of credit of $0.1&amp;nbsp;million for the purpose of issuing its landlord a letter of credit of $0.1&amp;nbsp;million as a security deposit under its facility lease. The Company pledged money market funds and marketable securities as collateral for the line of credit. Pursuant to the Company's license agreements with each of Vernalis and Scripps, it has obligations to make future milestone and royalty payments to these parties, respectively. However, because these amounts are contingent, they have not been included on the Company's balance sheet.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Indemnifications&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. There have been no claims to date and the Company has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Legal Proceedings&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company is not a party to any material legal proceedings.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2015" unitRef="Unit16" decimals="INF">18542911</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">5637880</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">6109132</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2016" unitRef="Unit18" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2017" unitRef="Unit18" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">290000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="-6">290000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_4_30_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit16" decimals="-5">5200000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">20922428</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">21041250</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">20922428</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">21041250</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">2000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">2000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-31380000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-36369000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-55665000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Comprehensive Loss&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's only element of other comprehensive loss in any period presented was unrealized gains and losses on available for sale marketable securities.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Substantially all of the Company's cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company's marketable securities consist of investments in U.S. Treasury securities, U.S. government agency securities and corporate debt obligations, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company's product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Consolidation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ContractualObligation contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">3632000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInFourthAndFifthYear contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">101000</us-gaap:ContractualObligationDueInFourthAndFifthYear>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1144000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueInSecondAndThirdYear contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">2387000</us-gaap:ContractualObligationDueInSecondAndThirdYear>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="As_Of_3_29_2016" unitRef="Unit16" decimals="INF">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Deferred Offering Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Deferred offering costs consist primarily of direct incremental costs related to the Company's initial public offering of its common stock. Upon completion of the initial public offering in March 2016, these amounts were offset against the proceeds of the offering.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">35000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
  <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">11000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Prepaid and Other Current Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Interest receivable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;365
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Prepaid research and development manufacturing expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;327
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;720
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;772
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,179
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,137
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:DeferredRentCreditCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">378000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">410000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">1370000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">960000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">5866000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">12791000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">21885000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">4671000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">9339000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">15438000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">71000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">67000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">52000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">528000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">241000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">131000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">445000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">1960000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">4351000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">43000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">954000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1730000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">108000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">230000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">183000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">5866000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">12791000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">21885000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">148000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">594000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">842000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;11. Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,692
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,685
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;292
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,537
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,143
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;136
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,229
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,828
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;428
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Valuation Assumptions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options were estimated using the following assumptions for the years ended December&amp;nbsp;31, 2017, 2016 and 2015:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended&lt;br /&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;91.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;84.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;83.3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Risk-free Interest Rate:&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Volatility:&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company's industry peers.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Expected Term:&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company uses the simplified method prescribed in the ASC 718, Compensation&amp;#x2014;Stock Compensation, to calculate the expected term of options granted to employees and directors.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Expected Dividends:&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has not paid and does not anticipate paying any dividends in the near future.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;At December&amp;nbsp;31, 2017, 2016 and 2015, the unrecognized compensation expense associated with respect to options granted to employees was $18.6&amp;nbsp;million, $18.5&amp;nbsp;million and $4.7&amp;nbsp;million, respectively, and is expected to be recognized on a straight-line basis over 2.85, 3.28, and 3.64&amp;nbsp;years, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Stock-based compensation expense related to awards to non-employees is recognized based on the then-current fair value at each measurement date over the associated service period of the award, which is generally the vesting term, on a straight line basis. The Company used the Black-Scholes valuation model to assist it in determining the fair value of stock-based awards. Stock-based compensation expense for non-employees was $74,000, $142,500 and $42,848 for the years ended December&amp;nbsp;31, 2017, 2016 and 2015, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following assumptions were used in valuation of non-employee stock options:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2.17%&amp;nbsp;- 2.33%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.90%&amp;nbsp;- 1.94%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.8%&amp;nbsp;- 2.2%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;80.3%&amp;nbsp;- 83.0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;92.1%&amp;nbsp;- 92.7%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;82%&amp;nbsp;- 84.7%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;7.1&amp;nbsp;-&amp;nbsp;7.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;8.1&amp;nbsp;-&amp;nbsp;8.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;9.1&amp;nbsp;-&amp;nbsp;10.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DividendsCommonStock contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="0">0</us-gaap:DividendsCommonStock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit18" decimals="2">-83.86</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit18" decimals="2">-5.39</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit18" decimals="2">-2.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit18" decimals="2">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit18" decimals="2">-0.51</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit18" decimals="2">-0.55</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit18" decimals="2">-0.79</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit18" decimals="2">-2.72</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit18" decimals="2">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit18" decimals="2">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2017_To_12_31_2017" unitRef="Unit18" decimals="2">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Net Loss per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;3. Net Loss per Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table shows the calculation of net loss per share (in thousands, except share and per share data):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss&amp;#x2014;basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(55,663
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(36,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,335
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Weighted average common shares outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,958,557
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,188,980
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,269,315
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Less: weighted average common shares subject to repurchase&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(470,051
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(766,939
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(895,672
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Weighted average common shares outstanding used to compute basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,488,506
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,422,041
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;373,643
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2.72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2.36
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(83.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Convertible preferrd stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,274,741
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Common stock subject to repurchase&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;319,203
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;611,698
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;924,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Outstanding options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,013,394
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,350,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;784,136
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total shares of common stock equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,332,597
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,962,280
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,983,412
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="INF">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="INF">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="INF">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" unitRef="Unit15" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="INF">-0.18</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="INF">-0.19</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="INF">-0.16</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="INF">-0.09</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="INF">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="INF">-0.17</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="INF">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="INF">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="INF">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="INF">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="INF">0.08</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="INF">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">526000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">572000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-5">4700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-5">18500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-5">18600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2015_To_12_31_2015">P3Y7M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2016_To_12_31_2016">P3Y3M11D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2017_To_12_31_2017">P2Y10M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">P1Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">P9M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_6_10_2015_To_6_10_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit15" decimals="INF">0.85</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit15" decimals="INF">0.85</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_6_10_2015_To_6_10_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit15" decimals="INF">0.75</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit15" decimals="4">0.0013</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit15" decimals="4">0.0020</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_6_10_2015_To_6_10_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit15" decimals="4">0.0075</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;4. Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Level&amp;nbsp;1&amp;#x2014;Quoted prices in active markets for identical assets or liabilities&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Level&amp;nbsp;2&amp;#x2014;Inputs other than quoted prices included within Level&amp;nbsp;1 that are observable for the asset or liability, either directly or indirectly&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Level&amp;nbsp;3&amp;#x2014;Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;There have been no transfers of assets and liabilities between levels of hierarchy.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's Level&amp;nbsp;2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following tables present information as of December&amp;nbsp;31, 2017 and 2016 about the Company's assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td rowspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value Measured Using&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td rowspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;br /&gt;Balance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,555
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,555
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,949
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,949
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;89,504
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;89,504
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td rowspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value Measured Using&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td rowspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;br /&gt;Balance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,999
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,999
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,846
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,846
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132,845
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132,845
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2017, marketable securities had a maximum remaining maturity of nine months.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2017 and 2016, the fair value of available for sale marketable securities by type of security were as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortized&lt;br /&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;br /&gt;Unrealized&lt;br /&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;br /&gt;Unrealized&lt;br /&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Government agency securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32,311
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32,272
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Corporate debt obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,679
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,677
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,990
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,949
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortized&lt;br /&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;br /&gt;Unrealized&lt;br /&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;br /&gt;Unrealized&lt;br /&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,885
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,846
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company's financial instruments, including cash equivalents, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">2418000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">7620000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">10219000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives. Should impairment exist, the impairment loss to be recognized is measured by the amount by which the carrying amount of the asset exceeds the projected discounted future net cash flows arising from the asset. All long-lived assets are maintained in the United States of America.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-31335000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-11375000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-28253000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-31335000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-36375000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-55663000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-25000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-27410000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;12. Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The components of loss before income tax is as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,253
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,335
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(27,410
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(25,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(55,663
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(36,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,335
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;During the years ended December&amp;nbsp;31, 2017, 2016 and 2015, the Company recorded no income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of realizing a benefit from those items.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;A reconciliation of the Company's effective tax rate to the U.S. Federal statutory rate is as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Federal tax benefit at statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;State tax, net of Federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Loss due to change in fair value of convertible preferred stock liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(19
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Foreign rate differential&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(17
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(23
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Federal rate change impact&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(16
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(19
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The effective tax rate is different from the federal statutory tax rate primarily due to a foreign rate differential and a valuation allowance against deferred tax assets as a result of the Company's history of losses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The principal components of the Company's net deferred tax assets are as follows (in thousands)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,438
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,339
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,671
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,351
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,960
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;445
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Capitalized tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;131
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;241
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;528
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Accruals&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;183
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;230
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,730
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;954
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;43
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;52
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;67
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;71
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21,885
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,791
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,866
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(21,885
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(12,791
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5,866
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recorded a valuation allowance against its deferred tax assets at December&amp;nbsp;31, 2017 and 2016 because Company management believed that it was more likely than not that these assets would not be fully realized in the future. The valuation allowance increased by approximately $9.1&amp;nbsp;million and $7.0&amp;nbsp;million for the years ended December&amp;nbsp;31, 2017 and 2016, respectively. Changes in the valuation allowance for deferred tax assets relate primarily to the increase in the Company's net operating loss carryforward.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2017, the Company had federal NOL carryforwards of approximately $42.1&amp;nbsp;million and state NOL carryforwards of approximately $94.5&amp;nbsp;million which are available to reduce future taxable income. The NOLs will begin to expire in 2034, if not utilized.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2017, the Company also had $3.0&amp;nbsp;million of federal and $2.1&amp;nbsp;million of state research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire 2035, if not utilized. The state research and development tax credits have no expiration date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Utilization of NOL carryforwards and credits may be subject to an annual limitation due to the ownership change provisions provided by the Internal Revenue Code of 1986, as amended ("Code"), and similar state provisions. An annual limitation may result in the expiration of NOLs and credits before utilization. In March and April 2016, the Company issued a total of 5.2&amp;nbsp;million shares of common stock associated with its IPO. In addition, during the third quarter of 2015, the Company issued a new series of convertible preferred stock. Such common and preferred stock issuances may have created an ownership change under these provisions of the Code and similar state provisions. As of December&amp;nbsp;31, 2017, NOLs and credits are not expected to expire unused in the carryforward period as a result of these issuances of convertible preferred shares.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1)&amp;nbsp;reducing the U.S. federal corporate tax rate from 35% to 21%; (2)&amp;nbsp;requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries; (3)&amp;nbsp;generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (4)&amp;nbsp;requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (5)&amp;nbsp;eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; (6)&amp;nbsp;creating the base erosion anti-abuse tax (BEAT), a new minimum tax; (7)&amp;nbsp;creating a new limitation on deductible interest expense; and (8)&amp;nbsp;changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December&amp;nbsp;31, 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The SEC staff issued SAB&amp;nbsp;118, which provides guidance on accounting for the tax effects of the Tax Act. SAB&amp;nbsp;118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB&amp;nbsp;118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company's accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Our accounting for the following elements of the Tax Act is complete:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Reduction of US federal Corporate Tax Rate: The Tax Act reduces the corporate tax rate to 21%, effective January&amp;nbsp;1, 2018. Accordingly, we have re-measured all deferred taxes at 21% as of December&amp;nbsp;31, 2017. Consequently, we have recorded a decrease related to the net deferred tax asset balance of $4.9&amp;nbsp;million, with a corresponding net adjustment to the Company's valuation allowance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Deemed Repatriation Transition Tax: The Deemed Repatriation Transition Tax ("Transition Tax") is a tax on previously untaxed accumulated and current earnings and profits (E&amp;amp;P) of certain of our foreign subsidiaries. To determine the amount of the Transition Tax, we must determine, in addition to other factors, the amount of post-1986 E&amp;amp;P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. the Company has a cumulative foreign E&amp;amp;P deficit as of December&amp;nbsp;31, 2017. As such, the Company does not have a transition tax liability in the 2017 tax year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Our accounting for the following elements of the Tax Act is incomplete:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Global Intangible Low Taxed Income ("GILTI"): The Tax Act creates a new requirement that certain income (i.e.,&amp;nbsp;GILTI) earned by a controlled foreign corporations ("CFCs") must be included currently in the gross income of the CFCs' U.S. shareholder. GILTI is the excess of the shareholder's "net CFC tested income" over the net deemed tangible income return, which is currently defined as the excess of (1)&amp;nbsp;10% of the aggregate of the U.S. shareholder's pro rata share of the qualified business asset investment of each CFC with respect to which it is a U.S. shareholder over (2)&amp;nbsp;the amount of certain interest expense taken into account in the determination of net CFC-tested income. Because of the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S.&amp;nbsp;GAAP, we are allowed to make an accounting policy choice of either (1)&amp;nbsp;treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the "period cost method") or (2)&amp;nbsp;factoring such amounts into a company's measurement of its deferred taxes (the "deferred method"). Our selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing our global income to determine whether we expect to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Because whether we expect to have future U.S. inclusions in taxable income related to GILTI depends on not only our current structure and estimated future results of global operations but also our intent and ability to modify our structure and/or our business, we are not yet able to reasonably estimate the effect of this provision of the Tax Act. Therefore, we have not made any adjustments related to potential GILTI tax in our financial statements and have not made a policy decision regarding whether to record deferred taxes on GILTI.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2017, the Company had unrecognized tax benefits ("UTBs") of approximately $1.2&amp;nbsp;million. All of the deferred tax assets associated with these UTBs are fully offset by a valuation allowance. The following table summarizes the activity related to UTBs:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Unrecognized tax benefits beginning of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;604
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;135
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Increase related to the prior year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Increased related to the current year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;666
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;463
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;135
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Unrecognized tax benefits, end of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;604
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;135
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company follows the provisions of ASC 740, Accounting for Income Taxes, and the accounting guidance related to accounting for uncertainty in income taxes. The Company determines its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. The Company will recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company accounts for income taxes under the asset and liability method. The Company estimates actual current tax exposure together with assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and liabilities, which are included in the Company's balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company's statements of operations and comprehensive loss become deductible expenses, under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of the Company's deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income and a valuation allowance is recorded when it is more likely than not that the deferred tax asset will not be recovered. The Company applies judgment in the determination of the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be utilized in the future. Accordingly, the Company recorded a full valuation allowance for all periods presented. The Company intends to maintain a valuation allowance until sufficient evidence exists to support its reversal.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company recognizes benefits of uncertain tax positions if it is more likely than not such positions will be sustained upon examination based solely on their technical merits as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company recognizes any material interest and penalties related to unrecognized tax benefits in income tax expense. The Company is required to file income tax returns in the U.S. federal jurisdiction. The Company currently is not under examination by the Internal Revenue Service or other jurisdictions for any tax years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On December&amp;nbsp;22, 2017, the 2017 Tax Cuts and Jobs Act (the "Tax Act") was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January&amp;nbsp;1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No.&amp;nbsp;118, &lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-style:italic;font-size:10pt;"&gt;Income Tax Accounting Implications of the Tax Cuts and Jobs Act&lt;/font&gt;&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt; (SAB&amp;nbsp;118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. We consider the accounting of the transition tax and deferred tax re-measurements to be complete&amp;#x2014;however, since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12&amp;nbsp;months, we are not yet able to reasonably estimate the effect of Global Intangible Low Taxed Income ("GILTI") and have not yet made a policy decision regarding whether to record deferred taxes on GILTI. We expect to complete our analysis within the measurement period in accordance with SAB&amp;nbsp;118. See Note&amp;nbsp;12 in these notes to the consolidated financial statements for additional information.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1240000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">518000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1554000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1218000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">2814000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1499000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">869000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">639000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">695000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-434000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1265000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-290000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">44000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestReceivable contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">365000</us-gaap:InterestReceivable>
  <us-gaap:InterestReceivable contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">132000</us-gaap:InterestReceivable>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Duration_1_1_2015_To_1_31_2015_us-gaap_LeaseArrangementTypeAxis_crvs_FacilityLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember">P1Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">7349000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">9940000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">140150000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">94775000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">5944000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">8969000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="As_Of_8_31_2015_us-gaap_CreditFacilityAxis_us-gaap_SecuredDebtMember" unitRef="Unit1" decimals="-5">100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:NatureOfOperations contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;1. Organization&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Corvus Pharmaceuticals,&amp;nbsp;Inc. ("Corvus" or the "Company") was incorporated in Delaware on January&amp;nbsp;27, 2014 and commenced operations in November 2014. Corvus is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The Company's operations are located in Burlingame, California. The Company has four insignificant subsidiaries.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">94948000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">71358000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1442000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-92032000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-42556000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">84826000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-11328000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-27857000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-46212000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-31335000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-31335000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit1" decimals="-3">-6347000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-36375000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-36375000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit1" decimals="-3">-8645000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit1" decimals="-3">-10297000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-11086000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit1" decimals="-3">-16036000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-55663000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-55663000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit1" decimals="-3">-14981000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="-3">-12717000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_10_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-11929000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&amp;nbsp;2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No.&amp;nbsp;2014-09 will replace most existing revenue recognition guidance in U.S.&amp;nbsp;GAAP when it becomes effective. The new standard is effective January&amp;nbsp;1, 2018 for public companies. Early application is permitted as of January&amp;nbsp;1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. In March 2016, the FASB issued ASU No.&amp;nbsp;2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU No.&amp;nbsp;2014-09. In April 2016, the FASB issued ASU No.&amp;nbsp;2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No.&amp;nbsp;2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January&amp;nbsp;1, 2018. The Company does not believe adopting this guidance will have a material impact on its consolidated financial statements as the Company is not yet generating revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In February 2016, the FASB issued ASU No.&amp;nbsp;2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard requires lessees to record right of use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. The standard is effective for the Company beginning January&amp;nbsp;1, 2019, with early application permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently assessing the impact of this guidance on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In May 2017, the FASB issued ASU No 2017-09, Compensation&amp;#x2014;Stock Compensation (Topic&amp;nbsp;718)&amp;#x2014;Scope of Modification Accounting, to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new standard, modification is required only if the fair value, the vesting conditions, or the classification of an award as equity or liability changes as a result of the change in terms or conditions. ASU 2017-09 will be effective for the Company beginning January&amp;nbsp;1, 2018 and will be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit19" decimals="0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">13770000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit1" decimals="-3">6426000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">36976000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit1" decimals="-3">8825000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit1" decimals="-3">10476000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">11249000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit1" decimals="-3">16217000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">56524000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit1" decimals="-3">15174000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="-3">12944000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_10_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">12189000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-13770000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-36976000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-56524000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">3632000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1144000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">101000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">2387000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="0">347000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="0">584000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="0">734000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="Unit1" decimals="-5">42100000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="Unit1" decimals="-5">94500000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OptionIndexedToIssuersEquityStrikePrice1 contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_CallOptionMember_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit18" decimals="INF">3.755</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">313000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">383000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">772000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">720000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">869000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">869000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-45000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-45000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-45000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">1405000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">971000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNoncashIncomeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-40000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Other Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;960
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,370
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Shares subject to vesting&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;971
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,405
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">729000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">104385000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">258281000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">88309000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">1747000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">2199000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">266000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2016" unitRef="Unit18" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2017" unitRef="Unit18" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="-6">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;7. Convertible Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Immediately prior to the consummation of the IPO on March&amp;nbsp;29, 2016, all outstanding shares of Series&amp;nbsp;A and B convertible preferred stock were converted into 14,274,741 shares of common stock on a one-for-one basis. As such, no convertible preferred stock shares were outstanding as of December&amp;nbsp;31, 2016.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2016" unitRef="Unit1" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2017" unitRef="Unit1" />
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">1137000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1179000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Duration_3_29_2016_To_3_29_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="-5">70600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">71354000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">711000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_CowenAndCompanyLLCMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_SalesAgreementMember" unitRef="Unit1" decimals="-5">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_9_20_2017_To_9_20_2017_us-gaap_CounterpartyNameAxis_crvs_CowenAndCompanyLLCMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_SalesAgreementMember" unitRef="Unit1" decimals="0">125000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="Duration_11_26_2014_To_11_26_2014_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="-5">12600000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="Duration_1_1_2015_To_1_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="-5">4000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">95569000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="-5">16700000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">14100000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">213725000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">173401000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">4199000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">108000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">4000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">731000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProfitLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">-31335000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">-36375000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-55663000</us-gaap:ProfitLoss>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">3977000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_ComputerEquipmentAndSoftwareMember" unitRef="Unit1" decimals="-3">58000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit1" decimals="-3">1868000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit1" decimals="-3">2051000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">4242000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_ComputerEquipmentAndSoftwareMember" unitRef="Unit1" decimals="-3">130000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit1" decimals="-3">2034000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit1" decimals="-3">2078000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">3248000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">2672000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;5&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Computer equiipment and purchased software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;3&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;Shorter of asset's useful life or remaining term of lease&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;"&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Property and Equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,034
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,868
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Computer equipment and purchased software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;130
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,078
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,051
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,242
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,977
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,570
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(729
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,672
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,248
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_ComputerEquipmentAndSoftwareMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;15. Quarterly Selected Financial Data (unaudited)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Quarter Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;br /&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;September&amp;nbsp;30,&lt;br /&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;June&amp;nbsp;30,&lt;br /&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;March&amp;nbsp;31,&lt;br /&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Operating Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,189
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,944
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,174
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,217
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11,929
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(12,717
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,981
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(16,036
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.79
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Quarter Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;September&amp;nbsp;30,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;June&amp;nbsp;30,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;March&amp;nbsp;31,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Operating Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,249
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,476
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,825
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,426
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11,086
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(10,297
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,645
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(6,347
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.55
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.43
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5.39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_DirectorMember" unitRef="Unit1" decimals="-3">461000000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;14. Related Party Transaction&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;In 2017, the Company purchased $461,000 of research services from a vendor during the normal course of business, where a Corvus director is also a member of the vendor's board of directors.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">11352000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">29356000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">46305000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Research and Development Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company records research and development expenses as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery and development of the Company's product candidates and include:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;external research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, academic and non-profit institutions and consultants;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;license fees; and&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:15;"&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2022;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">-67871000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">-123534000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Convertible preferrd stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,274,741
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Common stock subject to repurchase&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;319,203
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;611,698
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;924,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Outstanding options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,013,394
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,350,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;784,136
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total shares of common stock equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,332,597
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,962,280
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,983,412
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2017 and 2016, the fair value of available for sale marketable securities by type of security were as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortized&lt;br /&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;br /&gt;Unrealized&lt;br /&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;br /&gt;Unrealized&lt;br /&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Government agency securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32,311
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;32,272
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Corporate debt obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,679
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,677
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,990
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,949
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Amortized&lt;br /&gt;Cost&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;br /&gt;Unrealized&lt;br /&gt;Gains&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Gross&lt;br /&gt;Unrealized&lt;br /&gt;Losses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,885
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,846
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The principal components of the Company's net deferred tax assets are as follows (in thousands)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,438
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,339
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,671
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Tax credit carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,351
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,960
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;445
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Capitalized tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;131
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;241
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;528
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Accruals&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;183
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;230
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;108
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,730
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;954
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;43
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;52
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;67
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;71
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21,885
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,791
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,866
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(21,885
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(12,791
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5,866
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following table shows the calculation of net loss per share (in thousands, except share and per share data):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss&amp;#x2014;basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(55,663
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(36,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,335
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Weighted average common shares outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,958,557
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,188,980
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,269,315
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Less: weighted average common shares subject to repurchase&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(470,051
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(766,939
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(895,672
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Weighted average common shares outstanding used to compute basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,488,506
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,422,041
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;373,643
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2.72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2.36
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(83.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Federal tax benefit at statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;State tax, net of Federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Loss due to change in fair value of convertible preferred stock liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(19
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Foreign rate differential&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(17
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(23
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Federal rate change impact&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(16
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(19
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company's results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,692
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,685
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;292
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,537
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,143
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;136
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,229
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,828
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;428
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The following tables present information as of December&amp;nbsp;31, 2017 and 2016 about the Company's assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td rowspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value Measured Using&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td rowspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;br /&gt;Balance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,555
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,555
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,949
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,949
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;89,504
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;89,504
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td rowspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Fair Value Measured Using&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td rowspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;br /&gt;Balance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,999
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,999
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Marketable securities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,846
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;129,846
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132,845
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132,845
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;As of December&amp;nbsp;31, 2017, future minimum lease payments under the facility lease were as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="14" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Payments Due by Period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Less than&lt;br /&gt;1 Year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2&amp;nbsp;-&amp;nbsp;3&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;4&amp;nbsp;-5&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;More than&lt;br /&gt;5 Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;Contractual obligations:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Operating lease obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,632
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,144
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,387
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total contractual obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,632
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,144
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,387
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The components of loss before income tax is as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,253
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,335
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(27,410
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(25,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(55,663
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(36,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,335
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Quarter Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;br /&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;September&amp;nbsp;30,&lt;br /&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;June&amp;nbsp;30,&lt;br /&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;March&amp;nbsp;31,&lt;br /&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Operating Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,189
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12,944
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,174
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,217
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11,929
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(12,717
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,981
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(16,036
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.79
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Quarter Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;September&amp;nbsp;30,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;June&amp;nbsp;30,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;March&amp;nbsp;31,&lt;br /&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Operating Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11,249
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,476
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8,825
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,426
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11,086
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(10,297
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,645
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(6,347
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.55
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.43
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(5.39
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Outstanding&lt;br /&gt;at December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Vested&lt;br /&gt;at December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Exercise Price &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (in Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (in Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$0.28&amp;nbsp;- $4.65&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;535,136
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.55
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.46
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;325,397
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$6.75&amp;nbsp;- $10.60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;701,600
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.44
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,688
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.75
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$11.21&amp;nbsp;- $16.70&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,776,658
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.57
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;596,727
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.23
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,013,394
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.69
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;924,812
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.40
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Outstanding&lt;br /&gt;at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Vested&lt;br /&gt;at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Exercise Price &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (in Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (in Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$0.28&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;419,682
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.46
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;159,732
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.44
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$4.65&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;144,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.81
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.65
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;42,449
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.81
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.65
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$6.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.75
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,438
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.75
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;$13.34&amp;nbsp;-&amp;nbsp;16.37&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,781,400
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;193,867
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15.14
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,350,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.88
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;397,486
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.84
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Options Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Shares&lt;br /&gt;Available&lt;br /&gt;for Grant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number of&lt;br /&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Balance at December&amp;nbsp;31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,475,600
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,350,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.88
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Additional shares authorized&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;830,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(969,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;969,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.80
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(66,253
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Options forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;240,435
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(240,435
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Balance at December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,576,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,013,394
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.78
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended&lt;br /&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;91.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;84.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;83.3
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_TitleOfIndividualAxis_crvs_NonEmployeesMember">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Year Ended December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;2.17%&amp;nbsp;- 2.33%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.90%&amp;nbsp;- 1.94%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;1.8%&amp;nbsp;- 2.2%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;80.3%&amp;nbsp;- 83.0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;92.1%&amp;nbsp;- 92.7%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;82%&amp;nbsp;- 84.7%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;7.1&amp;nbsp;-&amp;nbsp;7.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;8.1&amp;nbsp;-&amp;nbsp;8.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;9.1&amp;nbsp;-&amp;nbsp;10.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Unrecognized tax benefits beginning of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;604
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;135
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Increase related to the prior year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Increased related to the current year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;666
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;463
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;135
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Unrecognized tax benefits, end of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,219
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;604
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;135
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:SecurityDeposit contextRef="As_Of_8_31_2015" unitRef="Unit1" decimals="-5">100000</us-gaap:SecurityDeposit>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Segments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">428000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">3828000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">6229000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2015" unitRef="Unit16" decimals="INF">924535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">611698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">319203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_12_31_2015">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RangeAxis_us-gaap_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RangeAxis_us-gaap_MinimumMember">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2016_To_12_31_2016">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2017_To_12_31_2017">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="3">0.833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="3">0.846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="3">0.914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="3">0.847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="3">0.927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="3">0.830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="3">0.820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="3">0.921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="3">0.803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="3">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="3">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit15" decimals="3">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="3">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="4">0.0194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="4">0.0233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="4">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="4">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_AwardTypeAxis_crvs_NonEmployeeStockOptionsMember" unitRef="Unit15" decimals="4">0.0217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit16" decimals="INF">830000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2015" unitRef="Unit16" decimals="INF">2559499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">2475600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit16" decimals="INF">2475600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">2576535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit16" decimals="INF">2576535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="0">714000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="0">216000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="0">332000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit16" decimals="INF">240435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit16" decimals="INF">969500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit18" decimals="2">4.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit18" decimals="2">10.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit18" decimals="2">8.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2016" unitRef="Unit18" decimals="2">11.88</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember" unitRef="Unit18" decimals="2">4.65</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember" unitRef="Unit18" decimals="2">0.28</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember" unitRef="Unit18" decimals="2">15.21</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember" unitRef="Unit18" decimals="2">6.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2017" unitRef="Unit18" decimals="2">11.78</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember" unitRef="Unit18" decimals="2">1.46</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember" unitRef="Unit18" decimals="2">15.41</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember" unitRef="Unit18" decimals="2">10.44</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2015" unitRef="Unit16" decimals="INF">784136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">2350582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit16" decimals="INF">2350582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">3013394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit16" decimals="INF">3013394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit18" decimals="2">11.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit18" decimals="2">11.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Options outstanding and exercisable that had vested or were expected to vest at December&amp;nbsp;31, 2017 were as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Number of&lt;br /&gt;shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Life (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;Aggregate&lt;br /&gt;Intrinsic Value&lt;br /&gt;(in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;924,812
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.38
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.02
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,946
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Expected to vest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,088,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12.40
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.98
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,903
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-5">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-5">3200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-5">5800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit18" decimals="2">8.02</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember" unitRef="Unit18" decimals="2">4.65</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember" unitRef="Unit18" decimals="2">0.28</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember" unitRef="Unit18" decimals="2">15.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember" unitRef="Unit18" decimals="2">6.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit18" decimals="2">11.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember" unitRef="Unit18" decimals="2">1.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember" unitRef="Unit18" decimals="2">15.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember" unitRef="Unit18" decimals="2">6.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member" unitRef="Unit15" decimals="INF">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit15" decimals="INF">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit18" decimals="2">11.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit18" decimals="2">13.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit18" decimals="2">11.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company maintains incentive plans under which incentive stock options and nonqualified stock options may be granted to employees and non-employee service providers.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company accounts for stock-based employee compensation arrangements in accordance with the provisions of ASC 718, "Compensation&amp;#x2014;Stock Compensation." For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values. The value of the award is recognized as an expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. Forfeitures are accounted for when they occur.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model. The expense for options granted to non-employees is periodically re-measured as the underlying options vest. The awards generally vest over the time period the Company expects to receive service from the non-employee.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember" unitRef="Unit18" decimals="2">4.65</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember" unitRef="Unit18" decimals="2">0.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember" unitRef="Unit18" decimals="2">13.34</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember" unitRef="Unit18" decimals="2">6.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember" unitRef="Unit18" decimals="2">0.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember" unitRef="Unit18" decimals="2">11.21</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember" unitRef="Unit18" decimals="2">6.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">2350582</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember" unitRef="Unit16" decimals="INF">144500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember" unitRef="Unit16" decimals="INF">419682</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember" unitRef="Unit16" decimals="INF">1781400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember" unitRef="Unit16" decimals="INF">5000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2017" unitRef="Unit16" decimals="INF">3013394</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember" unitRef="Unit16" decimals="INF">535136</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember" unitRef="Unit16" decimals="INF">1776658</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember" unitRef="Unit16" decimals="INF">701600</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016">P9Y2M16D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFiveMember">P8Y9M22D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeFourMember">P8Y5M16D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember">P9Y5M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSixMember">P8Y10M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2017_To_12_31_2017">P8Y8M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember">P7Y6M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember">P8Y6M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember">P9Y10M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeSevenMember" unitRef="Unit18" decimals="2">16.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeOneMember" unitRef="Unit18" decimals="2">4.65</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeThreeMember" unitRef="Unit18" decimals="2">16.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_crvs_ExercisePriceRangeTwoMember" unitRef="Unit18" decimals="2">10.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharePrice contextRef="As_Of_3_29_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit18" decimals="INF">15.00</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="As_Of_4_26_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="Unit18" decimals="INF">15.00</us-gaap:SharePrice>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">1046749</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">3395468</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">1431615</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">14274741</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">20922428</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">21041250</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="-3">-159000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-161000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">-31101000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-45000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">440000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-31496000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">132801000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-39000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">200709000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-67871000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">84835000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="Unit1" decimals="-3">-41000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">208408000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-123534000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;9. Common Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As of December&amp;nbsp;31, 2017, the amended and restated certificate of incorporation authorizes the Company to issue 290&amp;nbsp;million shares of common stock and 10&amp;nbsp;million shares of preferred stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Each share of common stock is entitled to one vote. Common stockholders are entitled to dividends if and when declared by the board of directors. As of December&amp;nbsp;31, 2017, no dividends on common stock had been declared.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;On September&amp;nbsp;20, 2017, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company,&amp;nbsp;LLC ("Cowen") to sell shares of the Company's common stock, from time to time, with aggregate gross sales proceeds of up to $125,000,000, through an at-the-market equity offering program under which Cowen will act as its sales agent. The issuance and sale of shares of common stock by the Company pursuant to the Sales Agreement are deemed an "at-the-market" offering under the Securities Act of 1933, as amended. Cowen is entitled to compensation for its services equal to up to 3.0% of the gross proceeds of any shares of common stock sold through Cowen under the Sales Agreement. During the year ended December&amp;nbsp;31, 2017, the Company received net proceeds of approximately $0.7&amp;nbsp;million from the sale of 52,569 shares of common stock pursuant to the Sales Agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The Company has reserved shares of common stock, for issuance as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,274,741
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Shares available for future option grants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,576,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,475,600
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,559,499
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Outstanding options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,013,394
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,350,582
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;784,136
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Unvested restricted common stock (founders and early exercise of stock options)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;319,203
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;611,698
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;924,535
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Shares reserved for employee stock purchase plan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;200,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;200,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,109,132
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,637,880
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,542,911
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_crvs_SeriesAndSeriesBConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">-14274741</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">14274741</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_3_29_2016_To_3_29_2016" unitRef="Unit16" decimals="INF">14274741</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">384866</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_11_26_2014_To_11_26_2014_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">3395468</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2015_To_1_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">1065246</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesBConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">5353312</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">5525961</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_6_1_2015_To_6_30_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">4460715</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit16" decimals="INF">5202618</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_29_2016_To_3_29_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit16" decimals="INF">4700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_4_26_2016_To_4_26_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="Unit16" decimals="INF">502618</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">52569</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_CounterpartyNameAxis_crvs_CowenAndCompanyLLCMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_SalesAgreementMember" unitRef="Unit16" decimals="INF">52569</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member" unitRef="Unit16" decimals="INF">66253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">13454</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit16" decimals="INF">66253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">125780000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_crvs_SeriesAndSeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="-3">-125780000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">125779000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="-3">70625000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="-3">70624000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">711000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">711000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">731000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit1" decimals="-3">731000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;"&gt;6. Balance Sheet Components (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;"&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Prepaid and Other Current Assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Interest receivable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;132
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;365
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Prepaid research and development manufacturing expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;327
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;720
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;772
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,179
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,137
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Property and Equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,034
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,868
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Computer equipment and purchased software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;130
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,078
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,051
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,242
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,977
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,570
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(729
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,672
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,248
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Accrued and Other Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Accrued clinical trial related&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,870
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,617
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Accrued manufacturing expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,056
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;955
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Personnel related&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;572
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;526
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;410
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;378
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Accrued legal and accounting&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;224
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;255
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;383
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;313
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,515
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,044
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Other Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;960
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,370
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;Shares subject to vesting&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;971
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,405
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr style="CellSpacing:0;"&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B; &amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-size:1.5pt;"&gt;&amp;#x200B;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="As_Of_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit1" decimals="-5">3000000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="As_Of_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit1" decimals="-5">2100000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="As_Of_12_31_2014_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="-3">10011000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="-3">125780000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="As_Of_11_26_2014_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">8921438</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="As_Of_12_31_2015" unitRef="Unit16" decimals="INF">14274741</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit16" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="-3">74839000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_crvs_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="-3">20730000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="-3">135000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">604000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1219000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">51000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">135000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">463000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">666000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">6000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2017_To_12_31_2017">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The preparation of the Company's consolidated financial statements in conformity with U.S.&amp;nbsp;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-5">7000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-5">9100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit16" decimals="INF">373643</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit16" decimals="INF">15422041</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit16" decimals="INF">20488506</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit16" decimals="INF">895672</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
  <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit16" decimals="INF">766939</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
  <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit16" decimals="INF">470051</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit16" decimals="INF">1269315</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit16" decimals="INF">16188980</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit16" decimals="INF">20958557</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>crvs-20171231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  7.3.329.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2018 1:57:39 PM-->
<!--Modified on: 3/1/2018 1:57:39 PM-->
<xsd:schema targetNamespace="http://www.corvuspharma.com/20171231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:crvs="http://www.corvuspharma.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareNetLossPerShareDetails" id="DisclosureNetLossPerShareNetLossPerShareDetails">
        <link:definition>40301 - Disclosure - Net Loss per Share - Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" id="DisclosureFairValueMeasurementsRecurringDetails">
        <link:definition>40401 - Disclosure - Fair Value Measurements - Recurring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" id="DisclosureFairValueMeasurementsAvailableForSaleDetails">
        <link:definition>40402 - Disclosure - Fair Value Measurements - Available For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails" id="DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails">
        <link:definition>40601 - Disclosure - Balance Sheet Components - Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" id="DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails">
        <link:definition>40602 - Disclosure - Balance Sheet Components - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails" id="DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails">
        <link:definition>40603 - Disclosure - Balance Sheet Components - Accrued and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesDetails" id="DisclosureBalanceSheetComponentsOtherLiabilitiesDetails">
        <link:definition>40604 - Disclosure - Balance Sheet Components - Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>40901 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails" id="DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails">
        <link:definition>41201 - Disclosure - Income Taxes - Components of loss before income tax and Income tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails">
        <link:definition>41202 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsNetDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsNetDetails">
        <link:definition>41203 - Disclosure - Income Taxes - Deferred tax assets net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41301 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureOrganization" id="DisclosureOrganization">
        <link:definition>10101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>10301 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements" id="DisclosureLicenseAndCollaborationAgreements">
        <link:definition>10501 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>10601 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStock" id="DisclosureConvertiblePreferredStock">
        <link:definition>10701 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiability" id="DisclosureConvertiblePreferredStockLiability">
        <link:definition>10801 - Disclosure - Convertible Preferred Stock Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>10901 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlans" id="DisclosureStockOptionPlans">
        <link:definition>11001 - Disclosure - Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11101 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11301 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnaudited" id="DisclosureQuarterlySelectedFinancialDataUnaudited">
        <link:definition>11501 - Disclosure - Quarterly Selected Financial Data (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>30303 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>30603 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockTables" id="DisclosureCommonStockTables">
        <link:definition>30903 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables" id="DisclosureStockOptionPlansTables">
        <link:definition>31003 - Disclosure - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31103 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31303 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedTables" id="DisclosureQuarterlySelectedFinancialDataUnauditedTables">
        <link:definition>31503 - Disclosure - Quarterly Selected Financial Data (unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureOrganizationDetails" id="DisclosureOrganizationDetails">
        <link:definition>40101 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation, Credit Risk and Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - IPO (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails">
        <link:definition>40302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" id="DisclosureLicenseAndCollaborationAgreementsDetails">
        <link:definition>40501 - Disclosure - License and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockDetails" id="DisclosureConvertiblePreferredStockDetails">
        <link:definition>40701 - Disclosure - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiabilityDetails" id="DisclosureConvertiblePreferredStockLiabilityDetails">
        <link:definition>40801 - Disclosure - Convertible Preferred Stock Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" id="DisclosureStockOptionPlansStockOptionActivityDetails">
        <link:definition>41001 - Disclosure - Stock Option Plans - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlanExercisePriceRangeDetails" id="DisclosureStockOptionPlanExercisePriceRangeDetails">
        <link:definition>41002 - Disclosure - Stock Option Plan - Exercise Price Range (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlanVestedOrExpectedToVestDetails" id="DisclosureStockOptionPlanVestedOrExpectedToVestDetails">
        <link:definition>41003 - Disclosure - Stock Option Plan - Vested or Expected to Vest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" id="DisclosureStockBasedCompensationExpenseAllocationDetails">
        <link:definition>41101 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsEmployeesDetails" id="DisclosureStockBasedCompensationValuationAssumptionsEmployeesDetails">
        <link:definition>41102 - Disclosure - Stock Based Compensation -Valuation Assumptions Employees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails" id="DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails">
        <link:definition>41103 - Disclosure - Stock Based Compensation -Valuation Assumptions Non-Employees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesOperatingLossCarryforwardsDetails">
        <link:definition>41204 - Disclosure - Income Taxes - Operating loss carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" id="DisclosureIncomeTaxesTaxCreditCarryForwardsDetails">
        <link:definition>41205 - Disclosure - Income Taxes - Tax credit carry forwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCutsAndJobsActDetails" id="DisclosureIncomeTaxesTaxCutsAndJobsActDetails">
        <link:definition>41206 - Disclosure - Income Taxes - Tax Cuts and Jobs Act (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>41207 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesLineOfCreditDetails" id="DisclosureCommitmentsAndContingenciesLineOfCreditDetails">
        <link:definition>41302 - Disclosure - Commitments and Contingencies - Line of Credit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionDetails" id="DisclosureRelatedPartyTransactionDetails">
        <link:definition>41401 - Disclosure - Related Party Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedDetails" id="DisclosureQuarterlySelectedFinancialDataUnauditedDetails">
        <link:definition>41501 - Disclosure - Quarterly Selected Financial Data (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransaction" id="DisclosureRelatedPartyTransaction">
        <link:definition>11401 - Disclosure - Related Party Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="crvs-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="crvs-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="crvs-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="crvs-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="crvs_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="crvs_SeriesConvertiblePreferredStockMember" name="SeriesConvertiblePreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ClinicalTrialAccrualsPolicyTextBlock" name="ClinicalTrialAccrualsPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract" name="LicenseAndCollaborationAgreementsDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ScrippsResearchInstituteMember" name="ScrippsResearchInstituteMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses" name="PrepaidResearchAndDevelopmentManufacturingExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract" name="AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_AccrualForPreclinicalAndClinicalTrialCurrent" name="AccrualForPreclinicalAndClinicalTrialCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent" name="EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_NonEmployeesMember" name="NonEmployeesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_EquityIncentiveAwardPlan2014Member" name="EquityIncentiveAwardPlan2014Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_EquityIncentiveAwardPlan2016Member" name="EquityIncentiveAwardPlan2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_CommonStockVotingRightsNumberOfVotesPerShare" name="CommonStockVotingRightsNumberOfVotesPerShare" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" name="ChangeInFairValueOfConvertiblePreferredStockLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_VernalisRAndDLimitedMember" name="VernalisRAndDLimitedMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ConvertiblePreferredStockLiabilityAbstract" name="ConvertiblePreferredStockLiabilityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ConvertiblePreferredStockLiabilityTextBlock" name="ConvertiblePreferredStockLiabilityTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LeaseAgreementRightToExtendTerm" name="LeaseAgreementRightToExtendTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" name="ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ReclassificationsOfConvertiblePreferredStockLiability" name="ReclassificationsOfConvertiblePreferredStockLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_DeferredOfferingCostsIncurredButNotYetPaid" name="DeferredOfferingCostsIncurredButNotYetPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" name="CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_IncreaseDecreaseInSharesOutstandingRollForward" name="IncreaseDecreaseInSharesOutstandingRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" name="ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_DisclosureOfShareBasedCompensationPlansTextBlock" name="DisclosureOfShareBasedCompensationPlansTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" name="ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" name="ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ObligationToIssueConvertiblePreferredStock" name="ObligationToIssueConvertiblePreferredStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_NonEmployeeStockOptionsMember" name="NonEmployeeStockOptionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_EmployeeAndNonEmployeeStockOptionsMember" name="EmployeeAndNonEmployeeStockOptionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" name="LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee" name="LicenseAndCollaborationAgreementsMinimumAnnualFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" name="LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" name="LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_FacilityLeaseMember" name="FacilityLeaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" name="OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_AreaOfLeaseExpansion" name="AreaOfLeaseExpansion" nillable="true" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" name="NumberOfSharesReservedForEmployeeStockPurchasePlan" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" name="MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade" name="LicenseAndCollaborationAgreementsMilestonePaymentsMade" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_AmortizationAccretionRelatedToMarketableSecurities" name="AmortizationAccretionRelatedToMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_AccruedManufacturingExpenseCurrent" name="AccruedManufacturingExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_InterestIncomeAndOtherExpenseNet" name="InterestIncomeAndOtherExpenseNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_SeriesAndSeriesBConvertiblePreferredStockMember" name="SeriesAndSeriesBConvertiblePreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ExercisePriceRangeThreeMember" name="ExercisePriceRangeThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ExercisePriceRangeFourMember" name="ExercisePriceRangeFourMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ExercisePriceRangeFiveMember" name="ExercisePriceRangeFiveMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ExercisePriceRangeSixMember" name="ExercisePriceRangeSixMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_LandlordProvidedFreeRentAndLeaseIncentives" name="LandlordProvidedFreeRentAndLeaseIncentives" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_InitialPublicOfferingPolicyTextBlock" name="InitialPublicOfferingPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_NumberOfInsignificantSubsidiaries" name="NumberOfInsignificantSubsidiaries" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" name="CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_SalesAgreementMember" name="SalesAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_CompensationOnSaleOfStockPercentage" name="CompensationOnSaleOfStockPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" name="EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_ExercisePriceRangeSevenMember" name="ExercisePriceRangeSevenMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" name="TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>crvs-20171231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  7.3.329.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2018 1:57:39 PM-->
<!--Modified on: 3/1/2018 1:57:39 PM-->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureNetLossPerShareNetLossPerShareDetails" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareNetLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureFairValueMeasurementsRecurringDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureFairValueMeasurementsAvailableForSaleDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsOtherLiabilitiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommonStockDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsNetDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsNetDetails" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <calculationLink xlink:role="http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636555094572957867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_636555094572957867" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636555094572967868" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_636555094572967868" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636555094572967868" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636555094572967868" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636555094572967868" xlink:to="us-gaap_AvailableForSaleSecurities_636555094572967868" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636555094572967868" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636555094572967868" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_636555094572967868" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636555094572967868" xlink:to="us-gaap_PreferredStockValue_636555094572967868" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636555094572967868" xlink:to="us-gaap_CommonStockValue_636555094572967868" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_636555094572967868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636555094572967868" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_636555094572967868" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636555094572967868" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_636555094572977869" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636555094572967868" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636555094572977869" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_636555094572977869" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636555094572977869" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636555094572977869" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636555094572977869" xlink:to="us-gaap_LiabilitiesCurrent_636555094572977869" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636555094572977869" xlink:to="us-gaap_AccountsPayableCurrent_636555094572977869" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636555094572977869" xlink:to="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_636555094572977869" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_636555094572977869" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636555094572977869" xlink:to="us-gaap_OperatingIncomeLoss_636555094572977869" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636555094572977869" xlink:to="us-gaap_OperatingExpenses_636555094572977869" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636555094572977869" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636555094572977869" order="1" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636555094572977869" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636555094572977869" order="2" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_InterestIncomeAndOtherExpenseNet" xlink:label="crvs_InterestIncomeAndOtherExpenseNet_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636555094572977869" xlink:to="crvs_InterestIncomeAndOtherExpenseNet_636555094572977869" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636555094572977869" xlink:to="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094572977869" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636555094572977869" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_ProfitLoss_636555094572977869" order="1" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_DepreciationDepletionAndAmortization_636555094572977869" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AmortizationAccretionRelatedToMarketableSecurities" xlink:label="crvs_AmortizationAccretionRelatedToMarketableSecurities_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="crvs_AmortizationAccretionRelatedToMarketableSecurities_636555094572977869" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636555094572977869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_ShareBasedCompensation_636555094572977869" order="4" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094572987870" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_OtherNoncashIncomeExpense_636555094572987870" order="6" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_636555094572987870" order="7" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636555094572987870" order="8" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_636555094572987870" order="9" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636555094572987870" order="10" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094572977869" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_636555094572987870" order="11" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_636555094572987870" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_636555094572987870" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_636555094572987870" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_636555094572987870" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_636555094572987870" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_636555094572987870" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_636555094572987870" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_636555094572987870" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636555094572987870" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_636555094572987870" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636555094572987870" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636555094572987870" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636555094572987870" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636555094572987870" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636555094572987870" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_636555094572987870" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_636555094572987870" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636555094572987870" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_636555094572987870" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareNetLossPerShareDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Net Loss per Share - Net Loss per Share (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_636555094572997871" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_636555094572997871" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - Recurring (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecurities_636555094572997871" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_636555094572997871" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements - Available For Sale (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636555094572997871" order="1" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecurities_636555094572997871" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Balance Sheet Components - Prepaid and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivable_636555094572997871" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_PrepaidResearchAndDevelopmentManufacturingExpenses" xlink:label="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses_636555094572997871" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_636555094572997871" order="3" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Components - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636555094572997871" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_636555094572997871" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Components - Accrued and Other Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccrualForPreclinicalAndClinicalTrialCurrent" xlink:label="crvs_AccrualForPreclinicalAndClinicalTrialCurrent_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="crvs_AccrualForPreclinicalAndClinicalTrialCurrent_636555094572997871" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedManufacturingExpenseCurrent" xlink:label="crvs_AccruedManufacturingExpenseCurrent_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="crvs_AccruedManufacturingExpenseCurrent_636555094572997871" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_636555094572997871" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_636555094572997871" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_636555094572997871" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_636555094572997871" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_636555094572997871" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Balance Sheet Components - Other Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_636555094573007872" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_636555094573007872" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_636555094573007872" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636555094573007872" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636555094573007872" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636555094573007872" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" xlink:label="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan_636555094573007872" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Components of loss before income tax and Income tax benefits (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_636555094573007872" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_636555094573007872" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636555094573007872" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636555094573007872" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_636555094573007872" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_636555094573007872" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent_636555094573007872" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636555094573007872" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent_636555094573007872" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636555094573007872" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636555094573007872" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsNetDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Deferred tax assets net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_636555094573017873" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636555094573017873" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636555094573017873" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636555094573017873" xlink:to="us-gaap_DeferredTaxAssetsOther_636555094573017873" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636555094573017873" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_636555094573017873" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636555094573017873" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_636555094573017873" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636555094573017873" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_636555094573017873" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636555094573017873" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_636555094573017873" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636555094573017873" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_636555094573017873" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear_636555094573017873" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear_636555094573017873" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636555094573017873" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_636555094573017873" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears_636555094573017873" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears_636555094573017873" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>crvs-20171231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  7.3.329.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2018 1:57:39 PM-->
<!--Modified on: 3/1/2018 1:57:39 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.corvuspharma.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureFairValueMeasurementsRecurringDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureFairValueMeasurementsAvailableForSaleDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureLicenseAndCollaborationAgreementsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureConvertiblePreferredStockLiabilityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommonStockDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockOptionPlansStockOptionActivityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockOptionPlanExercisePriceRangeDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlanExercisePriceRangeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockBasedCompensationExpenseAllocationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesTaxCutsAndJobsActDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCutsAndJobsActDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommitmentsAndContingenciesLineOfCreditDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesLineOfCreditDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureRelatedPartyTransactionDetails" roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://www.corvuspharma.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573277899" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573277899" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636555094573287900" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_636555094573287900" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesConvertiblePreferredStockMember" xlink:label="crvs_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="crvs_SeriesConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesBConvertiblePreferredStockMember" xlink:label="crvs_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="crvs_SeriesBConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesAndSeriesBConvertiblePreferredStockMember" xlink:label="crvs_SeriesAndSeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="crvs_SeriesAndSeriesBConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636555094573287900" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_636555094573287900" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:label="crvs_IncreaseDecreaseInSharesOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="crvs_IncreaseDecreaseInSharesOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ReclassificationsOfConvertiblePreferredStockLiability" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="crvs_ReclassificationsOfConvertiblePreferredStockLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" xlink:label="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31103 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636555094573347906" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636555094573347906" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NonEmployeesMember" xlink:label="crvs_NonEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="crvs_NonEmployeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation, Credit Risk and Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636555094573347906" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636555094573347906" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RisksAndUncertaintiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" xlink:label="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - IPO (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573367908" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573367908" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ComputerEquipmentAndSoftwareMember" xlink:label="crvs_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="crvs_ComputerEquipmentAndSoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636555094573367908" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636555094573367908" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EmployeeAndNonEmployeeStockOptionsMember" xlink:label="crvs_EmployeeAndNonEmployeeStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="crvs_EmployeeAndNonEmployeeStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - Recurring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_636555094573377909" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_636555094573377909" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636555094573377909" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636555094573377909" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements - Available For Sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636555094573387910" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636555094573387910" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - License and Collaboration Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636555094573387910" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636555094573387910" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAgreementMember" xlink:label="crvs_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="crvs_LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573397911" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573397911" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScrippsResearchInstituteMember" xlink:label="crvs_ScrippsResearchInstituteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_ScrippsResearchInstituteMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_VernalisRAndDLimitedMember" xlink:label="crvs_VernalisRAndDLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_VernalisRAndDLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636555094573397911" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_636555094573397911" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636555094573577929" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_636555094573577929" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" xlink:label="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee" xlink:label="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" xlink:label="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade" xlink:label="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" xlink:label="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" xlink:label="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Components - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ComputerEquipmentAndSoftwareMember" xlink:label="crvs_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="crvs_ComputerEquipmentAndSoftwareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiabilityDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Convertible Preferred Stock Liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesConvertiblePreferredStockMember" xlink:label="crvs_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="crvs_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_636555094573597931" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_636555094573597931" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_CallOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" xlink:label="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ObligationToIssueConvertiblePreferredStock" xlink:label="crvs_ObligationToIssueConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="crvs_ObligationToIssueConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ReclassificationsOfConvertiblePreferredStockLiability" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="crvs_ReclassificationsOfConvertiblePreferredStockLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SalesAgreementMember" xlink:label="crvs_SalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvs_SalesAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CowenAndCompanyLLCMember" xlink:label="crvs_CowenAndCompanyLLCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_CowenAndCompanyLLCMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CommonStockVotingRightsNumberOfVotesPerShare" xlink:label="crvs_CommonStockVotingRightsNumberOfVotesPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="crvs_CommonStockVotingRightsNumberOfVotesPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CompensationOnSaleOfStockPercentage" xlink:label="crvs_CompensationOnSaleOfStockPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="crvs_CompensationOnSaleOfStockPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" xlink:label="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock Option Plans - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636555094573627934" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_636555094573627934" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EquityIncentiveAwardPlan2014Member" xlink:label="crvs_EquityIncentiveAwardPlan2014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvs_EquityIncentiveAwardPlan2014Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EquityIncentiveAwardPlan2016Member" xlink:label="crvs_EquityIncentiveAwardPlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvs_EquityIncentiveAwardPlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" xlink:label="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlanExercisePriceRangeDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock Option Plan - Exercise Price Range (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094573647936" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094573647936" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeOneMember" xlink:label="crvs_ExercisePriceRangeOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="crvs_ExercisePriceRangeOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeTwoMember" xlink:label="crvs_ExercisePriceRangeTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="crvs_ExercisePriceRangeTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeThreeMember" xlink:label="crvs_ExercisePriceRangeThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="crvs_ExercisePriceRangeThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeFourMember" xlink:label="crvs_ExercisePriceRangeFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="crvs_ExercisePriceRangeFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeFiveMember" xlink:label="crvs_ExercisePriceRangeFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="crvs_ExercisePriceRangeFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeSixMember" xlink:label="crvs_ExercisePriceRangeSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="crvs_ExercisePriceRangeSixMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeSevenMember" xlink:label="crvs_ExercisePriceRangeSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="crvs_ExercisePriceRangeSevenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Stock Based Compensation -Valuation Assumptions Non-Employees (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636555094573657937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636555094573657937" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NonEmployeeStockOptionsMember" xlink:label="crvs_NonEmployeeStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="crvs_NonEmployeeStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income Taxes - Operating loss carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_636555094573677939" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_636555094573677939" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Income Taxes - Tax credit carry forwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_636555094573677939" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_636555094573677939" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCutsAndJobsActDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Income Taxes - Tax Cuts and Jobs Act (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" xlink:label="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_636555094573687940" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_636555094573687940" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_FacilityLeaseMember" xlink:label="crvs_FacilityLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="crvs_FacilityLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" xlink:label="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CommitmentsAndContingenciesLineItems" xlink:label="crvs_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AreaOfLeaseExpansion" xlink:label="crvs_AreaOfLeaseExpansion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="crvs_AreaOfLeaseExpansion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LeaseAgreementRightToExtendTerm" xlink:label="crvs_LeaseAgreementRightToExtendTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="crvs_LeaseAgreementRightToExtendTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LandlordProvidedFreeRentAndLeaseIncentives" xlink:label="crvs_LandlordProvidedFreeRentAndLeaseIncentives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="crvs_LandlordProvidedFreeRentAndLeaseIncentives" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesLineOfCreditDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Commitments and Contingencies - Line of Credit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_636555094573707942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_636555094573707942" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_SecuredDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Related Party Transaction (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636555094573707942" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_636555094573707942" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>crvs-20171231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  7.3.329.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2018 1:57:39 PM-->
<!--Modified on: 3/1/2018 1:57:39 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_DocumentAndEntityInformationAbstract" xlink:label="crvs_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_DocumentAndEntityInformationAbstract" xlink:to="crvs_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total of prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of accrued liabilities and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total of accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total of other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 13)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock: $0.0001 par value; 10,000,000 shares authorized at December 31, 2017 and December 31, 2016 ; 0 shares issued and outstanding at December 31, 2017 and December 31, 2016</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2017 and December 31, 2016; 21,041,250 and 20,922,428 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xlink:to="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognized in earnings for the change in fair value of the obligation to issue convertible preferred stock at fixed terms.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Fair Value of Convertible Preferred Stock Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of convertible preferred stock liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of convertible preferred stock liability</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_InterestIncomeAndOtherExpenseNet" xlink:label="crvs_InterestIncomeAndOtherExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_InterestIncomeAndOtherExpenseNet" xlink:to="crvs_InterestIncomeAndOtherExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_InterestIncomeAndOtherExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of interest income and other expense netted together.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_InterestIncomeAndOtherExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income and other expense, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic and diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares used to compute net loss per share, basic and diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding used to compute basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:label="crvs_IncreaseDecreaseInSharesOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:to="crvs_IncreaseDecreaseInSharesOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_IncreaseDecreaseInSharesOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_IncreaseDecreaseInSharesOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Shares Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_IncreaseDecreaseInSharesOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock to founders, net of repurchase (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock sold to founders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issued with the conversion of the preferred stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock on exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ReclassificationsOfConvertiblePreferredStockLiability" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ReclassificationsOfConvertiblePreferredStockLiability" xlink:to="crvs_ReclassificationsOfConvertiblePreferredStockLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability to sell convertible preferred stock at fixed terms that was reclassified into temporary equity upon issuance of the stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications Of Convertible Preferred Stock Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of convertible preferred stock liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of liability to convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock in conjunction with the sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" xlink:label="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" xlink:to="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the liability related to shares subject to repurchase that is reclassified to equity upon the lapse of the repurchase provision.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification from Liability to Equity on Release of Shares Subject to Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for cash upon early exercise of stock options and lapse of restrictions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued on exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stocks issued upon early exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AmortizationAccretionRelatedToMarketableSecurities" xlink:label="crvs_AmortizationAccretionRelatedToMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AmortizationAccretionRelatedToMarketableSecurities" xlink:to="crvs_AmortizationAccretionRelatedToMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AmortizationAccretionRelatedToMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amortization/accretion related to marketable securities for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AmortizationAccretionRelatedToMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization Accretion Related To Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AmortizationAccretionRelatedToMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization (accretion) related to marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible preferred stock, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment incurred but not paid</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_DeferredOfferingCostsIncurredButNotYetPaid" xlink:label="crvs_DeferredOfferingCostsIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_DeferredOfferingCostsIncurredButNotYetPaid" xlink:to="crvs_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future cash outflow towards the offering costs that have been incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs Incurred But Not Yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_DeferredOfferingCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs incurred but not paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsDisclosureAbstract" xlink:label="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract" xlink:to="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConvertiblePreferredStockLiabilityAbstract" xlink:label="crvs_ConvertiblePreferredStockLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ConvertiblePreferredStockLiabilityAbstract" xlink:to="crvs_ConvertiblePreferredStockLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ConvertiblePreferredStockLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ConvertiblePreferredStockLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock Liability</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConvertiblePreferredStockLiabilityTextBlock" xlink:label="crvs_ConvertiblePreferredStockLiabilityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ConvertiblePreferredStockLiabilityTextBlock" xlink:to="crvs_ConvertiblePreferredStockLiabilityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ConvertiblePreferredStockLiabilityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for an obligation to sell convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ConvertiblePreferredStockLiabilityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock Liability [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ConvertiblePreferredStockLiabilityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plans</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_DisclosureOfShareBasedCompensationPlansTextBlock" xlink:label="crvs_DisclosureOfShareBasedCompensationPlansTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_DisclosureOfShareBasedCompensationPlansTextBlock" xlink:to="crvs_DisclosureOfShareBasedCompensationPlansTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_DisclosureOfShareBasedCompensationPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for share-based compensation plan details.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_DisclosureOfShareBasedCompensationPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Share-Based Compensation Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_DisclosureOfShareBasedCompensationPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Selected Financial Data (unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Selected Financial Data (unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_InitialPublicOfferingPolicyTextBlock" xlink:label="crvs_InitialPublicOfferingPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_InitialPublicOfferingPolicyTextBlock" xlink:to="crvs_InitialPublicOfferingPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy of Initial Public Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk and Other Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents and disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents And Marketable Securities [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ClinicalTrialAccrualsPolicyTextBlock" xlink:label="crvs_ClinicalTrialAccrualsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ClinicalTrialAccrualsPolicyTextBlock" xlink:to="crvs_ClinicalTrialAccrualsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ClinicalTrialAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for clinical trail accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ClinicalTrialAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial Accruals [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ClinicalTrialAccrualsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial Accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular Disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful lives of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of assets and liabilities recorded at fair value on a recurring basis, by level within fair value hierarchy</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of available for sale marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the (a)accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer) and (b)other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued and Other current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other liabilities</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" xlink:label="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" xlink:to="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of shares of common stock reserved for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Common Stock, Shares Reserved for Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of shares of common stock reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of information about stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of options outstanding and exercisable that had vested or were expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of expenses relating to employee and non-employee stock-based awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of share-based awards to employees was estimated using Black Scholes model</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of loss before income tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the effective tax rate to the U.S. Federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of principal components of the net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unrecognized tax benefits activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments under the facility lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Selected Financial Data (unaudited)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NumberOfInsignificantSubsidiaries" xlink:label="crvs_NumberOfInsignificantSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_NumberOfInsignificantSubsidiaries" xlink:to="crvs_NumberOfInsignificantSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_NumberOfInsignificantSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to number of insignificant subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_NumberOfInsignificantSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Insignificant Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_NumberOfInsignificantSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of insignificant subsidiaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks and Uncertainties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk and Other Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" xlink:label="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" xlink:to="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of financial institutions, wherein the company deposits the cash and cash equivalents. Such deposits could have significant balances in excess of federally insured limits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Credit Risk Uninsured Financial Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of highly credit qualified financial institutions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax benefit at statutory rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Number Of Shares Par Value And Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock reserved for issuance, on an as-converted basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from IPO</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Useful lives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share, Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Issued, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: weighted average common shares subject to repurchase</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for sale marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Fair Value to Amortized Cost Basis [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of available for sale marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" xlink:label="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" xlink:to="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of a one-time cash payment made to the counterparty upon entering into a license or collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements, Upfront Cash Payment Made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One-time cash payment</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee" xlink:label="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee" xlink:to="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum annual fee the entity is obligated to pay to the counterparty under the license or collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements, Minimum Annual Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum annual fee</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" xlink:label="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" xlink:to="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate potential amount of payments the entity may be required to make to the counterparty based on achievement of milestones under the license or collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements, Aggregate Potential Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade" xlink:label="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade" xlink:to="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payments to the entity that are required to be made to the counterparty based on achievement of milestones under the license or collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments made</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" xlink:label="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" xlink:to="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of written notice the entity is required to provide for termination of the license or collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements, Period of Written Notice for Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of written notice to terminate</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" xlink:label="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" xlink:to="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of patients in treatment arm under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Maximum Number of Patients in Treatment Arm</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest receivable</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_PrepaidResearchAndDevelopmentManufacturingExpenses" xlink:label="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses" xlink:to="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research And Development Manufacturing Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development manufacturing expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract" xlink:to="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities And Other Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and Other Liabilities</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccrualForPreclinicalAndClinicalTrialCurrent" xlink:label="crvs_AccrualForPreclinicalAndClinicalTrialCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AccrualForPreclinicalAndClinicalTrialCurrent" xlink:to="crvs_AccrualForPreclinicalAndClinicalTrialCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AccrualForPreclinicalAndClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value, as of the balance sheet date, of obligations incurred and payable related to clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AccrualForPreclinicalAndClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrual For Preclinical And Clinical Trial, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AccrualForPreclinicalAndClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical trial related</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedManufacturingExpenseCurrent" xlink:label="crvs_AccruedManufacturingExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AccruedManufacturingExpenseCurrent" xlink:to="crvs_AccruedManufacturingExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AccruedManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing expense (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AccruedManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Manufacturing Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AccruedManufacturingExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued manufacturing expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel related</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued legal and accounting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares subject to vesting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Features of Convertible Preferred Stock [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock conversion ratio</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" xlink:label="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" xlink:to="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of defined triggers, upon the earliest of which the investors of the first tranche of the convertible preferred stock agreed to purchase a pro-rata portion of shares in the second tranche and the entity agreed to sell such shares on the same terms as the first tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Number of Triggers for Issuance at Same Terms as First Tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of defined triggers for issuance of additional shares to first tranche investors on the same terms</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Strike Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed price for second tranche obligation (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ObligationToIssueConvertiblePreferredStock" xlink:label="crvs_ObligationToIssueConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ObligationToIssueConvertiblePreferredStock" xlink:to="crvs_ObligationToIssueConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ObligationToIssueConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the obligation to issue convertible preferred stock at fixed terms.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ObligationToIssueConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligation to Issue Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ObligationToIssueConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CommonStockVotingRightsNumberOfVotesPerShare" xlink:label="crvs_CommonStockVotingRightsNumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CommonStockVotingRightsNumberOfVotesPerShare" xlink:to="crvs_CommonStockVotingRightsNumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CommonStockVotingRightsNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of votes per share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CommonStockVotingRightsNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Voting Rights, Number of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CommonStockVotingRightsNumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends on common stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CompensationOnSaleOfStockPercentage" xlink:label="crvs_CompensationOnSaleOfStockPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CompensationOnSaleOfStockPercentage" xlink:to="crvs_CompensationOnSaleOfStockPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CompensationOnSaleOfStockPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of compensation entitle for sale of stock under sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CompensationOnSaleOfStockPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation on Sale of Stock, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CompensationOnSaleOfStockPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation on sale of stock, percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future option grants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted common stock (founders and early exercise of stock options)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" xlink:label="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" xlink:to="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares that are reserved for the employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Reserved for Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum exercise term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of common stock of its fair value (as a percent)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" xlink:label="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" xlink:to="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum number of options that if forfeited or lapse, may be reissued under another equity incentive award plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Number of Options Forfeited or Lapsed That May Be Reissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of options that may be re-issued under the 2016 plan</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available for Grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized for plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information about stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price, low end of range (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price, high end of range (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding, Number</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Outstanding, Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of options outstanding (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" xlink:to="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares reserved for issuance pertaining to the outstanding vested stock options as of the balance sheet date in the customized range of exercise prices.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Vested Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Vested, Number</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" xlink:to="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term of vested stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Vested Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Vested, Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of options vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value of options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding and exercisable</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">As of the balance sheet date, the number of shares into which fully vested stock options outstanding and exercisable can be converted under the option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding and Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Number of Shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">As of the balance sheet date, the weighted-average exercise price for outstanding and exercisable stock options that are fully vested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding and Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Weighted Average Exercise Price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term for fully vested options outstanding and exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding and Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested options outstanding and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding and Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">As of the balance sheet date, the number of shares into which stock options outstanding and exercisable that are expected to vest can be converted under the option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding and Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected to vest, Number of Shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">As of the balance sheet date, the weighted-average exercise price for outstanding and exercisable stock options that are expected to vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding and Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected to vest, Weighted Average Exercise Price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term for options outstanding and exercisable that are expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding and Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected to vest, Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding and exercisable that are expected to vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding and Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected to vest, Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The estimated fair value of the entity's common stock used in the valuation of options under the share-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Estimated Fair Value of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of common stock (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of stock options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of options vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions used to estimate fair value of share-based awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected period for recognizing compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of the effective tax rate to the U.S. Federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State tax, net of Federal benefit</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent" xlink:to="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Loss Due to Change in Fair Value of Convertible Preferred Stock Liability, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss due to change in fair value of convertible preferred stock liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign rate differential</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal rate change impact</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:to="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of the net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increased in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" xlink:label="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" xlink:to="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income tax expense for re-measurement of deferred tax asset from change in tax rate pursuant to Tax Cuts and Jobs Act of 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Cuts and Jobs Act of 2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease to the DTA</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits beginning of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase related to the prior year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease related to the prior year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increased related to the current year</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CommitmentsAndContingenciesLineItems" xlink:label="crvs_CommitmentsAndContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CommitmentsAndContingenciesLineItems" xlink:to="crvs_CommitmentsAndContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility Lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of leased facility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AreaOfLeaseExpansion" xlink:label="crvs_AreaOfLeaseExpansion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AreaOfLeaseExpansion" xlink:to="crvs_AreaOfLeaseExpansion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AreaOfLeaseExpansion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of real estate property added under a lease amendment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AreaOfLeaseExpansion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Lease Expansion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AreaOfLeaseExpansion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional area of lease</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LeaseAgreementRightToExtendTerm" xlink:label="crvs_LeaseAgreementRightToExtendTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LeaseAgreementRightToExtendTerm" xlink:to="crvs_LeaseAgreementRightToExtendTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LeaseAgreementRightToExtendTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of right to extend the lease as per the lease agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LeaseAgreementRightToExtendTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease agreement, Right To Extend The Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_LeaseAgreementRightToExtendTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease agreement, right to extend the term</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LandlordProvidedFreeRentAndLeaseIncentives" xlink:label="crvs_LandlordProvidedFreeRentAndLeaseIncentives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LandlordProvidedFreeRentAndLeaseIncentives" xlink:to="crvs_LandlordProvidedFreeRentAndLeaseIncentives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LandlordProvidedFreeRentAndLeaseIncentives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of lease incentives and free rent that were provided by the landlord.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LandlordProvidedFreeRentAndLeaseIncentives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Landlord Provided Free Rent And Lease Incentives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less than 1 Year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two and Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2-3 years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Four and Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">4-5 years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Due in Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less than 1 Year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Due in Second and Third Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2-3 years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Due in Fourth and Fifth Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">4-5 years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Purchases from Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of research services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesConvertiblePreferredStockMember" xlink:label="crvs_SeriesConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_SeriesConvertiblePreferredStockMember" xlink:to="crvs_SeriesConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_SeriesConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_SeriesConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_SeriesConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesBConvertiblePreferredStockMember" xlink:label="crvs_SeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_SeriesBConvertiblePreferredStockMember" xlink:to="crvs_SeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesAndSeriesBConvertiblePreferredStockMember" xlink:label="crvs_SeriesAndSeriesBConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_SeriesAndSeriesBConvertiblePreferredStockMember" xlink:to="crvs_SeriesAndSeriesBConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_SeriesAndSeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A and Series B Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_SeriesAndSeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series And Series B Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_SeriesAndSeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A and Series B convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NonEmployeesMember" xlink:label="crvs_NonEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_NonEmployeesMember" xlink:to="crvs_NonEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_NonEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Individuals who are not employees of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_NonEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_NonEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forecast</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ComputerEquipmentAndSoftwareMember" xlink:label="crvs_ComputerEquipmentAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ComputerEquipmentAndSoftwareMember" xlink:to="crvs_ComputerEquipmentAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and purchased software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment And Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and purchased software</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock subject to repurchase</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EmployeeAndNonEmployeeStockOptionsMember" xlink:label="crvs_EmployeeAndNonEmployeeStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EmployeeAndNonEmployeeStockOptionsMember" xlink:to="crvs_EmployeeAndNonEmployeeStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EmployeeAndNonEmployeeStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby the employee or non-employee holder of the instrument is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EmployeeAndNonEmployeeStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee And Non Employee Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_EmployeeAndNonEmployeeStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types of Debt and Equity Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types Of Debt And Equity Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Types of Debt and Equity Securities [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Treasury securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Government Agencies Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government agency securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAgreementMember" xlink:label="crvs_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LicenseAgreementMember" xlink:to="crvs_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement granting the entity license to certain technology and intellectual property of the counterparty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScrippsResearchInstituteMember" xlink:label="crvs_ScrippsResearchInstituteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ScrippsResearchInstituteMember" xlink:to="crvs_ScrippsResearchInstituteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ScrippsResearchInstituteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the Scripps Research Institute.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ScrippsResearchInstituteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scripps Research Institute [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ScrippsResearchInstituteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scripps Research Institute</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_VernalisRAndDLimitedMember" xlink:label="crvs_VernalisRAndDLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_VernalisRAndDLimitedMember" xlink:to="crvs_VernalisRAndDLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_VernalisRAndDLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Vernalis (R&amp;D) Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_VernalisRAndDLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vernalis R And D Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_VernalisRAndDLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vernalis (R&amp;D) Limited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed To Issuers Equity Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CallOptionMember" xlink:to="us-gaap_CallOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CallOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Call Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CallOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligation to issue second tranche</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SalesAgreementMember" xlink:label="crvs_SalesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_SalesAgreementMember" xlink:to="crvs_SalesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_SalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_SalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_SalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CowenAndCompanyLLCMember" xlink:label="crvs_CowenAndCompanyLLCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CowenAndCompanyLLCMember" xlink:to="crvs_CowenAndCompanyLLCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CowenAndCompanyLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Cowen and Company, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CowenAndCompanyLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cowen And Company L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CowenAndCompanyLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cowen</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EquityIncentiveAwardPlan2014Member" xlink:label="crvs_EquityIncentiveAwardPlan2014Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EquityIncentiveAwardPlan2014Member" xlink:to="crvs_EquityIncentiveAwardPlan2014Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EquityIncentiveAwardPlan2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entity's 2014 plan under which it may grant stock-based awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EquityIncentiveAwardPlan2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Award Plan2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_EquityIncentiveAwardPlan2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Plan</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EquityIncentiveAwardPlan2016Member" xlink:label="crvs_EquityIncentiveAwardPlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EquityIncentiveAwardPlan2016Member" xlink:to="crvs_EquityIncentiveAwardPlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EquityIncentiveAwardPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entity's 2016 Equity Incentive Award Plan under which it may grant stock-based awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EquityIncentiveAwardPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Award Plan2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_EquityIncentiveAwardPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeOneMember" xlink:label="crvs_ExercisePriceRangeOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ExercisePriceRangeOneMember" xlink:to="crvs_ExercisePriceRangeOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ExercisePriceRangeOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range one for which stock option information is provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ExercisePriceRangeOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ExercisePriceRangeOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$0.28 - $4.65</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeTwoMember" xlink:label="crvs_ExercisePriceRangeTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ExercisePriceRangeTwoMember" xlink:to="crvs_ExercisePriceRangeTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range two for which stock option information is provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$6.75 - $10.60</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeThreeMember" xlink:label="crvs_ExercisePriceRangeThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ExercisePriceRangeThreeMember" xlink:to="crvs_ExercisePriceRangeThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range three for which stock option information is provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$11.21 - $16.70</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeFourMember" xlink:label="crvs_ExercisePriceRangeFourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ExercisePriceRangeFourMember" xlink:to="crvs_ExercisePriceRangeFourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ExercisePriceRangeFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range four for which stock option information is provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ExercisePriceRangeFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ExercisePriceRangeFourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$0.28</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeFiveMember" xlink:label="crvs_ExercisePriceRangeFiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ExercisePriceRangeFiveMember" xlink:to="crvs_ExercisePriceRangeFiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range five for which stock option information is provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$4.65</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeSixMember" xlink:label="crvs_ExercisePriceRangeSixMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ExercisePriceRangeSixMember" xlink:to="crvs_ExercisePriceRangeSixMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ExercisePriceRangeSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range five for which stock option information is provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ExercisePriceRangeSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ExercisePriceRangeSixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$6.75</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeSevenMember" xlink:label="crvs_ExercisePriceRangeSevenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ExercisePriceRangeSevenMember" xlink:to="crvs_ExercisePriceRangeSevenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ExercisePriceRangeSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price range seven for which stock option information is provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ExercisePriceRangeSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ExercisePriceRangeSevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$13.34 - $16.37</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NonEmployeeStockOptionsMember" xlink:label="crvs_NonEmployeeStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_NonEmployeeStockOptionsMember" xlink:to="crvs_NonEmployeeStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_NonEmployeeStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby the non-employee holder of the instrument is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_NonEmployeeStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Employee Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_NonEmployeeStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-employee stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State And Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_FacilityLeaseMember" xlink:label="crvs_FacilityLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_FacilityLeaseMember" xlink:to="crvs_FacilityLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_FacilityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease of facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_FacilityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_FacilityLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facilities lease</label>
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" xlink:label="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" xlink:to="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space located in Burlingame, California.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office And Laboratory Space In Burlingame California [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space in Burlingame, California</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>crvs-20171231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  7.3.329.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2018 1:57:39 PM-->
<!--Modified on: 3/1/2018 1:57:39 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.corvuspharma.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureOrganization" roleURI="http://www.corvuspharma.com/role/DisclosureOrganization" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureNetLossPerShare" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureLicenseAndCollaborationAgreements" roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponents" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureConvertiblePreferredStock" roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureConvertiblePreferredStockLiability" roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommonStock" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockOptionPlans" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxes" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureRelatedPartyTransaction" roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureQuarterlySelectedFinancialDataUnaudited" roleURI="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommonStockTables" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockOptionPlansTables" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureQuarterlySelectedFinancialDataUnauditedTables" roleURI="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureOrganizationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureOrganizationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureNetLossPerShareNetLossPerShareDetails" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureFairValueMeasurementsRecurringDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureFairValueMeasurementsAvailableForSaleDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureLicenseAndCollaborationAgreementsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureBalanceSheetComponentsOtherLiabilitiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureConvertiblePreferredStockDetails" roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureConvertiblePreferredStockLiabilityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommonStockDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockOptionPlansStockOptionActivityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockOptionPlanExercisePriceRangeDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlanExercisePriceRangeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockOptionPlanVestedOrExpectedToVestDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlanVestedOrExpectedToVestDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockBasedCompensationExpenseAllocationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockBasedCompensationValuationAssumptionsEmployeesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsEmployeesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsNetDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesTaxCutsAndJobsActDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCutsAndJobsActDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureCommitmentsAndContingenciesLineOfCreditDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesLineOfCreditDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureRelatedPartyTransactionDetails" roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20171231.xsd#DisclosureQuarterlySelectedFinancialDataUnauditedDetails" roleURI="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_636555094573767948" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_636555094573767948" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers_636555094573767948" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_636555094573767948" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_636555094573767948" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_636555094573767948" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_636555094573767948" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_636555094573767948" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_636555094573767948" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_636555094573767948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_636555094573767948" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_636555094573787950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat_636555094573787950" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_636555094573787950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_636555094573787950" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_636555094573787950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_636555094573787950" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_636555094573787950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_636555094573787950" order="14" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_636555094573787950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_636555094573787950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636555094573787950" xlink:to="us-gaap_AssetsCurrentAbstract_636555094573797951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636555094573797951" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636555094573797951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636555094573797951" xlink:to="us-gaap_AvailableForSaleSecurities_636555094573797951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636555094573797951" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636555094573797951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636555094573797951" xlink:to="us-gaap_AssetsCurrent_636555094573797951" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636555094573787950" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636555094573797951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636555094573787950" xlink:to="us-gaap_OtherAssetsNoncurrent_636555094573797951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636555094573787950" xlink:to="us-gaap_Assets_636555094573797951" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636555094573797951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_LiabilitiesCurrentAbstract_636555094573797951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636555094573797951" xlink:to="us-gaap_AccountsPayableCurrent_636555094573797951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636555094573797951" xlink:to="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_636555094573797951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636555094573797951" xlink:to="us-gaap_LiabilitiesCurrent_636555094573797951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636555094573797951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_Liabilities_636555094573797951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_CommitmentsAndContingencies_636555094573797951" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_StockholdersEquityAbstract_636555094573797951" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_PreferredStockValue_636555094573797951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_CommonStockValue_636555094573797951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_636555094573797951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_636555094573797951" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636555094573797951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636555094573797951" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_StockholdersEquity_636555094573807952" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636555094573797951" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_636555094573807952" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636555094573807952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_636555094573807952" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_636555094573807952" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_636555094573807952" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636555094573807952" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_636555094573807952" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_636555094573807952" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_636555094573807952" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_636555094573807952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636555094573807952" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636555094573807952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636555094573807952" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636555094573807952" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636555094573807952" xlink:to="us-gaap_OperatingExpenses_636555094573807952" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_636555094573807952" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094573807952" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_InterestIncomeAndOtherExpenseNet" xlink:label="crvs_InterestIncomeAndOtherExpenseNet_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="crvs_InterestIncomeAndOtherExpenseNet_636555094573807952" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_636555094573807952" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636555094573807952" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636555094573807952" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_636555094573807952" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_636555094573807952" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636555094573807952" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_636555094573807952" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_636555094573807952" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_636555094573817953" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573817953" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636555094573817953" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636555094573817953" xlink:to="us-gaap_IPOMember_636555094573817953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636555094573817953" xlink:to="us-gaap_OverAllotmentOptionMember_636555094573817953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636555094573817953" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573817953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573817953" xlink:to="us-gaap_StatementClassOfStockAxis_636555094573817953" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636555094573817953" xlink:to="us-gaap_ConvertiblePreferredStockMember_636555094573817953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesConvertiblePreferredStockMember" xlink:label="crvs_SeriesConvertiblePreferredStockMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636555094573817953" xlink:to="crvs_SeriesConvertiblePreferredStockMember_636555094573817953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesBConvertiblePreferredStockMember" xlink:label="crvs_SeriesBConvertiblePreferredStockMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636555094573817953" xlink:to="crvs_SeriesBConvertiblePreferredStockMember_636555094573817953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesAndSeriesBConvertiblePreferredStockMember" xlink:label="crvs_SeriesAndSeriesBConvertiblePreferredStockMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636555094573817953" xlink:to="crvs_SeriesAndSeriesBConvertiblePreferredStockMember_636555094573817953" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636555094573817953" xlink:to="us-gaap_ClassOfStockDomain_636555094573817953" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573817953" xlink:to="us-gaap_StatementEquityComponentsAxis_636555094573817953" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636555094573817953" xlink:to="us-gaap_CommonStockMember_636555094573817953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636555094573817953" xlink:to="us-gaap_AdditionalPaidInCapitalMember_636555094573817953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636555094573817953" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_636555094573817953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636555094573817953" xlink:to="us-gaap_RetainedEarningsMember_636555094573817953" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636555094573817953" xlink:to="us-gaap_EquityComponentDomain_636555094573817953" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573817953" xlink:to="us-gaap_StatementLineItems_636555094573817953" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_IncreaseDecreaseInSharesOutstandingRollForward" xlink:label="crvs_IncreaseDecreaseInSharesOutstandingRollForward_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573817953" xlink:to="crvs_IncreaseDecreaseInSharesOutstandingRollForward_636555094573817953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward_636555094573817953" xlink:to="us-gaap_SharesIssued_636555094573817953" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward_636555094573817953" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_636555094573817953" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636555094573817953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward_636555094573817953" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636555094573817953" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward_636555094573817953" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636555094573827954" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward_636555094573817953" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636555094573827954" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_IncreaseDecreaseInSharesOutstandingRollForward_636555094573817953" xlink:to="us-gaap_SharesIssued_636555094573827954" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573817953" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636555094573827954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636555094573827954" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_636555094573827954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636555094573827954" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_636555094573827954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ReclassificationsOfConvertiblePreferredStockLiability" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636555094573827954" xlink:to="crvs_ReclassificationsOfConvertiblePreferredStockLiability_636555094573827954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6365550945738279541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636555094573827954" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6365550945738279541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573817953" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_StockholdersEquity_636555094573827954" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_636555094573827954" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_636555094573827954" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_636555094573827954" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase" xlink:label="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase_636555094573827954" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636555094573827954" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636555094573827954" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_636555094573837955" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_636555094573837955" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_636555094573837955" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_NetIncomeLoss_636555094573837955" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636555094573827954" xlink:to="us-gaap_StockholdersEquity_636555094573837955" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636555094573837955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636555094573837955" xlink:to="us-gaap_ProfitLoss_636555094573837955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636555094573837955" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636555094573837955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636555094573837955" xlink:to="us-gaap_DepreciationDepletionAndAmortization_636555094573837955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AmortizationAccretionRelatedToMarketableSecurities" xlink:label="crvs_AmortizationAccretionRelatedToMarketableSecurities_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636555094573837955" xlink:to="crvs_AmortizationAccretionRelatedToMarketableSecurities_636555094573837955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636555094573837955" xlink:to="us-gaap_ShareBasedCompensation_636555094573837955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636555094573837955" xlink:to="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094573837955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636555094573837955" xlink:to="us-gaap_OtherNoncashIncomeExpense_636555094573837955" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636555094573837955" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636555094573837955" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636555094573837955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636555094573837955" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636555094573837955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636555094573837955" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_636555094573847956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636555094573837955" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636555094573847956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636555094573837955" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_636555094573847956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636555094573837955" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_636555094573847956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636555094573837955" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_636555094573847956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636555094573847956" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636555094573847956" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_636555094573847956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636555094573847956" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_636555094573847956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636555094573847956" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_636555094573847956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636555094573847956" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636555094573847956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636555094573847956" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_636555094573847956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636555094573847956" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636555094573847956" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636555094573847956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636555094573847956" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636555094573847956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636555094573847956" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_636555094573847956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636555094573847956" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_636555094573847956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636555094573847956" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_636555094573847956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636555094573847956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636555094573847956" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636555094573847956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6365550945738479561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6365550945738479561" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_636555094573857957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636555094573857957" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_636555094573857957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_DeferredOfferingCostsIncurredButNotYetPaid" xlink:label="crvs_DeferredOfferingCostsIncurredButNotYetPaid_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636555094573857957" xlink:to="crvs_DeferredOfferingCostsIncurredButNotYetPaid_636555094573857957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureOrganization" xlink:type="extended" xlink:title="10101 - Disclosure - Organization" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_636555094573857957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_636555094573857957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="10301 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_636555094573857957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_636555094573857957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements" xlink:type="extended" xlink:title="10501 - Disclosure - License and Collaboration Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsDisclosureAbstract" xlink:label="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_636555094573857957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="10601 - Disclosure - Balance Sheet Components" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_636555094573857957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStock" xlink:type="extended" xlink:title="10701 - Disclosure - Convertible Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock_636555094573857957" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock_636555094573857957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiability" xlink:type="extended" xlink:title="10801 - Disclosure - Convertible Preferred Stock Liability" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConvertiblePreferredStockLiabilityAbstract" xlink:label="crvs_ConvertiblePreferredStockLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConvertiblePreferredStockLiabilityTextBlock" xlink:label="crvs_ConvertiblePreferredStockLiabilityTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_ConvertiblePreferredStockLiabilityAbstract" xlink:to="crvs_ConvertiblePreferredStockLiabilityTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="10901 - Disclosure - Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlans" xlink:type="extended" xlink:title="11001 - Disclosure - Stock Option Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_DisclosureOfShareBasedCompensationPlansTextBlock" xlink:label="crvs_DisclosureOfShareBasedCompensationPlansTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="crvs_DisclosureOfShareBasedCompensationPlansTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11101 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11301 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransaction" xlink:type="extended" xlink:title="11401 - Disclosure - Related Party Transaction" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnaudited" xlink:type="extended" xlink:title="11501 - Disclosure - Quarterly Selected Financial Data (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636555094573867958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_636555094573867958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_InitialPublicOfferingPolicyTextBlock" xlink:label="crvs_InitialPublicOfferingPolicyTextBlock_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="crvs_InitialPublicOfferingPolicyTextBlock_636555094573867958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_636555094573867958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_636555094573867958" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_636555094573877959" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_636555094573877959" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_636555094573877959" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_636555094573877959" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_636555094573877959" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_636555094573877959" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_636555094573877959" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_636555094573877959" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ClinicalTrialAccrualsPolicyTextBlock" xlink:label="crvs_ClinicalTrialAccrualsPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="crvs_ClinicalTrialAccrualsPolicyTextBlock_636555094573877959" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_636555094573877959" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_636555094573877959" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_636555094573877959" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_636555094573877959" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636555094573877959" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_636555094573877959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="30303 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636555094573877959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636555094573877959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_636555094573877959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_636555094573877959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_636555094573877959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Balance Sheet Components (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_636555094573887960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_636555094573887960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_636555094573887960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_636555094573887960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockTables" xlink:type="extended" xlink:title="30903 - Disclosure - Common Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" xlink:label="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_636555094573887960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stock Option Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_635938991102941940" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_635938991102941940" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636555094573887960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_635938991102941940" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_636555094573887960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_635938991102941940" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_636555094573887960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31103 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_636555094573887960" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573887960" xlink:to="us-gaap_TitleOfIndividualAxis_636555094573887960" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis_636555094573887960" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636555094573887960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NonEmployeesMember" xlink:label="crvs_NonEmployeesMember_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636555094573887960" xlink:to="crvs_NonEmployeesMember_636555094573887960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573887960" xlink:to="us-gaap_StatementLineItems_636555094573887960" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573887960" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636555094573887960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_636555094573887960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573887960" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_636555094573887960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_636555094573897961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_636555094573897961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_636555094573897961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_636555094573897961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_636555094573897961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedTables" xlink:type="extended" xlink:title="31503 - Disclosure - Quarterly Selected Financial Data (unaudited) (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_636232782167383599" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_636232782167383599" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_636555094573897961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureOrganizationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NumberOfInsignificantSubsidiaries" xlink:label="crvs_NumberOfInsignificantSubsidiaries_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="crvs_NumberOfInsignificantSubsidiaries_636555094573897961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation, Credit Risk and Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_636555094573897961" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573897961" xlink:to="us-gaap_StatementScenarioAxis_636555094573897961" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_636555094573897961" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636555094573897961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636555094573897961" xlink:to="us-gaap_ScenarioForecastMember_636555094573897961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573897961" xlink:to="us-gaap_StatementLineItems_636555094573897961" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573897961" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636555094573897961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573897961" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_636555094573897961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573897961" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_636555094573897961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions" xlink:label="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract_636555094573897961" xlink:to="crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions_636555094573897961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_636555094573897961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573897961" xlink:to="us-gaap_SegmentReportingAbstract_636555094573897961" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_636555094573897961" xlink:to="us-gaap_NumberOfOperatingSegments_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573897961" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_636555094573907962" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636555094573907962" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - IPO (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_636555094573907962" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573907962" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636555094573907962" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636555094573907962" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573907962" xlink:to="us-gaap_IPOMember_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573907962" xlink:to="us-gaap_OverAllotmentOptionMember_636555094573907962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094573907962" xlink:to="us-gaap_StatementLineItems_636555094573907962" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094573907962" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573907962" xlink:to="us-gaap_SharePrice_636555094573907962" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573907962" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636555094573907962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573907962" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_636555094573907962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636555094573907962" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636555094573907962" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094573907962" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094573907962" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573907962" xlink:to="us-gaap_EquipmentMember_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ComputerEquipmentAndSoftwareMember" xlink:label="crvs_ComputerEquipmentAndSoftwareMember_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573907962" xlink:to="crvs_ComputerEquipmentAndSoftwareMember_636555094573907962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636555094573907962" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_636555094573907962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636555094573907962" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareNetLossPerShareDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Net Loss per Share - Net Loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635941768302357381" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635941768302357381" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_636555094573907962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636555094573907962" xlink:to="us-gaap_NetIncomeLossAbstract_636555094573907962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_636555094573907962" xlink:to="us-gaap_NetIncomeLoss_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636555094573907962" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_636555094573917963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_636555094573917963" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_636555094573917963" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_636555094573917963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_636555094573917963" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636555094573917963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_636555094573917963" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636555094573917963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636555094573917963" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636555094573917963" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636555094573917963" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636555094573917963" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636555094573917963" xlink:to="us-gaap_ConvertiblePreferredStockMember_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636555094573917963" xlink:to="us-gaap_RestrictedStockMember_636555094573917963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EmployeeAndNonEmployeeStockOptionsMember" xlink:label="crvs_EmployeeAndNonEmployeeStockOptionsMember_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636555094573917963" xlink:to="crvs_EmployeeAndNonEmployeeStockOptionsMember_636555094573917963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636555094573917963" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636555094573917963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636555094573917963" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - Recurring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_635929923645574275" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_635929923645574275" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636555094573917963" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636555094573917963" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_636555094573917963" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_636555094573917963" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_636555094573917963" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636555094573917963" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_636555094573917963" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_636555094573917963" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636555094573917963" xlink:to="us-gaap_FairValueInputsLevel1Member_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636555094573917963" xlink:to="us-gaap_FairValueInputsLevel2Member_636555094573917963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636555094573917963" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636555094573917963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636555094573917963" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_636555094573917963" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_636555094573917963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_636555094573917963" xlink:to="us-gaap_AvailableForSaleSecurities_636555094573917963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_636555094573917963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_636555094573917963" xlink:to="us-gaap_AssetsFairValueDisclosure_636555094573917963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements - Available For Sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_635929924338074275" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_635929924338074275" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636555094573927964" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636555094573927964" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636555094573927964" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_636555094573927964" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636555094573927964" xlink:to="us-gaap_USTreasurySecuritiesMember_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636555094573927964" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_636555094573927964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_636555094573927964" xlink:to="us-gaap_CorporateDebtSecuritiesMember_636555094573927964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_636555094573927964" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636555094573927964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_636555094573927964" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_636555094573927964" xlink:to="us-gaap_AvailableForSaleSecuritiesAmortizedCost_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_636555094573927964" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_636555094573927964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_636555094573927964" xlink:to="us-gaap_AvailableForSaleSecurities_636555094573927964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - License and Collaboration Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsDisclosureAbstract" xlink:label="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract_635929969404914275" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_LicenseAndCollaborationAgreementsDisclosureAbstract_635929969404914275" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636555094573927964" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636555094573927964" xlink:to="us-gaap_TypeOfArrangementAxis_636555094573927964" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636555094573927964" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAgreementMember" xlink:label="crvs_LicenseAgreementMember_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636555094573927964" xlink:to="crvs_LicenseAgreementMember_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636555094573927964" xlink:to="us-gaap_CounterpartyNameAxis_636555094573927964" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636555094573927964" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ScrippsResearchInstituteMember" xlink:label="crvs_ScrippsResearchInstituteMember_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573927964" xlink:to="crvs_ScrippsResearchInstituteMember_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_VernalisRAndDLimitedMember" xlink:label="crvs_VernalisRAndDLimitedMember_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573927964" xlink:to="crvs_VernalisRAndDLimitedMember_636555094573927964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636555094573927964" xlink:to="us-gaap_IncomeStatementLocationAxis_636555094573927964" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636555094573927964" xlink:to="us-gaap_IncomeStatementLocationDomain_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636555094573927964" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_636555094573927964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636555094573927964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636555094573927964" xlink:to="us-gaap_RangeAxis_636555094573927964" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636555094573927964" xlink:to="us-gaap_RangeMember_636555094573937965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636555094573937965" xlink:to="us-gaap_MinimumMember_636555094573937965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636555094573927964" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636555094573937965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade" xlink:label="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636555094573937965" xlink:to="crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade_636555094573937965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee" xlink:label="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636555094573937965" xlink:to="crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee_636555094573937965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments" xlink:label="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636555094573937965" xlink:to="crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments_636555094573937965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade" xlink:label="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636555094573937965" xlink:to="crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade_636555094573937965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination" xlink:label="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636555094573937965" xlink:to="crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination_636555094573937965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm" xlink:label="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636555094573937965" xlink:to="crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm_636555094573937965" order="6" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Balance Sheet Components - Prepaid and Other Current Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_636555094573937965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_636555094573937965" xlink:to="us-gaap_InterestReceivable_636555094573937965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_PrepaidResearchAndDevelopmentManufacturingExpenses" xlink:label="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_636555094573937965" xlink:to="crvs_PrepaidResearchAndDevelopmentManufacturingExpenses_636555094573937965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_636555094573937965" xlink:to="us-gaap_OtherAssetsCurrent_636555094573937965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_636555094573937965" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636555094573937965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Components - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636555094573937965" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636555094573937965" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094573937965" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094573937965" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573937965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_636555094573937965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573937965" xlink:to="us-gaap_EquipmentMember_636555094573937965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ComputerEquipmentAndSoftwareMember" xlink:label="crvs_ComputerEquipmentAndSoftwareMember_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573937965" xlink:to="crvs_ComputerEquipmentAndSoftwareMember_636555094573947966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094573937965" xlink:to="us-gaap_LeaseholdImprovementsMember_636555094573947966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636555094573937965" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_636555094573947966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636555094573947966" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_636555094573947966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636555094573947966" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636555094573947966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636555094573947966" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636555094573947966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Components - Accrued and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccrualForPreclinicalAndClinicalTrialCurrent" xlink:label="crvs_AccrualForPreclinicalAndClinicalTrialCurrent_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" xlink:to="crvs_AccrualForPreclinicalAndClinicalTrialCurrent_636555094573947966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedManufacturingExpenseCurrent" xlink:label="crvs_AccruedManufacturingExpenseCurrent_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" xlink:to="crvs_AccruedManufacturingExpenseCurrent_636555094573947966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_636555094573947966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" xlink:to="us-gaap_DeferredRentCreditCurrent_636555094573947966" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_636555094573947966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_636555094573947966" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_636555094573967968" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract_636555094573947966" xlink:to="crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent_636555094573967968" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Balance Sheet Components - Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesNoncurrentAbstract_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrentAbstract_636555094573967968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract_636555094573967968" xlink:to="us-gaap_DeferredRentCreditNoncurrent_636555094573967968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract_636555094573967968" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_636555094573967968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrentAbstract_636555094573967968" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636555094573967968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573967968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573967968" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_636555094573967968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_636555094573967968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_636555094573967968" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636555094573967968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_636555094573967968" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_636555094573967968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiabilityDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Convertible Preferred Stock Liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConvertiblePreferredStockLiabilityAbstract" xlink:label="crvs_ConvertiblePreferredStockLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_ConvertiblePreferredStockLiabilityAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_636555094573967968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636555094573967968" xlink:to="us-gaap_StatementClassOfStockAxis_636555094573967968" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636555094573967968" xlink:to="us-gaap_ClassOfStockDomain_636555094573967968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SeriesConvertiblePreferredStockMember" xlink:label="crvs_SeriesConvertiblePreferredStockMember_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636555094573967968" xlink:to="crvs_SeriesConvertiblePreferredStockMember_636555094573967968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_636555094573967968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636555094573967968" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_636555094573967968" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_636555094573967968" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_636555094573977969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_636555094573977969" xlink:to="us-gaap_CallOptionMember_636555094573977969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636555094573967968" xlink:to="us-gaap_TemporaryEquityLineItems_636555094573977969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_636555094573977969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636555094573977969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636555094573977969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche" xlink:label="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche_636555094573977969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_636555094573977969" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ObligationToIssueConvertiblePreferredStock" xlink:label="crvs_ObligationToIssueConvertiblePreferredStock_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="crvs_ObligationToIssueConvertiblePreferredStock_636555094573977969" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ChangeInFairValueOfConvertiblePreferredStockLiability" xlink:label="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="crvs_ChangeInFairValueOfConvertiblePreferredStockLiability_636555094573977969" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ReclassificationsOfConvertiblePreferredStockLiability" xlink:label="crvs_ReclassificationsOfConvertiblePreferredStockLiability_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="crvs_ReclassificationsOfConvertiblePreferredStockLiability_636555094573977969" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_636555094573977969" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_636555094573977969" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636555094573977969" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_636555094573977969" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_636555094573977969" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636555094573977969" xlink:to="us-gaap_StatementEquityComponentsAxis_636555094573977969" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636555094573977969" xlink:to="us-gaap_EquityComponentDomain_636555094573977969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636555094573977969" xlink:to="us-gaap_CommonStockMember_636555094573977969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636555094573977969" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636555094573977969" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636555094573977969" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573977969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_SalesAgreementMember" xlink:label="crvs_SalesAgreementMember_636555094573977969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636555094573977969" xlink:to="crvs_SalesAgreementMember_636555094573977969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636555094573977969" xlink:to="us-gaap_CounterpartyNameAxis_636555094573987970" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636555094573987970" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573987970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CowenAndCompanyLLCMember" xlink:label="crvs_CowenAndCompanyLLCMember_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636555094573987970" xlink:to="crvs_CowenAndCompanyLLCMember_636555094573987970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636555094573977969" xlink:to="us-gaap_ClassOfStockLineItems_636555094573987970" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="us-gaap_CommonStockSharesAuthorized_636555094573987970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="us-gaap_PreferredStockSharesAuthorized_636555094573987970" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CommonStockVotingRightsNumberOfVotesPerShare" xlink:label="crvs_CommonStockVotingRightsNumberOfVotesPerShare_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="crvs_CommonStockVotingRightsNumberOfVotesPerShare_636555094573987970" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="us-gaap_DividendsCommonStock_636555094573987970" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636555094573987970" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636555094573987970" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CompensationOnSaleOfStockPercentage" xlink:label="crvs_CompensationOnSaleOfStockPercentage_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="crvs_CompensationOnSaleOfStockPercentage_636555094573987970" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_636555094573987970" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636555094573987970" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573987970" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573987970" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_636555094573987970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573987970" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636555094573987970" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573987970" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636555094573987970" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573987970" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636555094573987970" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan" xlink:label="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573987970" xlink:to="crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan_636555094573987970" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_636555094573987970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636555094573987970" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_636555094573987970" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock Option Plans - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_635939049595832050" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_635939049595832050" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094573997971" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094573997971" xlink:to="us-gaap_PlanNameAxis_636555094573997971" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636555094573997971" xlink:to="us-gaap_PlanNameDomain_636555094573997971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EquityIncentiveAwardPlan2014Member" xlink:label="crvs_EquityIncentiveAwardPlan2014Member_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636555094573997971" xlink:to="crvs_EquityIncentiveAwardPlan2014Member_636555094573997971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EquityIncentiveAwardPlan2016Member" xlink:label="crvs_EquityIncentiveAwardPlan2016Member_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636555094573997971" xlink:to="crvs_EquityIncentiveAwardPlan2016Member_636555094573997971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636555094573997971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636555094573997971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_636555094573997971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued" xlink:label="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" xlink:to="crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued_636555094573997971" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_636555094573997971" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636555094573997971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_636555094573997971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636555094573997971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_636555094573997971" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636555094573997971" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636555094573997971" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6365550945739979711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6365550945739979711" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636555094573997971" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636555094573997971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6365550945739979711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6365550945739979711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636555094573997971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636555094573997971" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636555094573997971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636555094574007972" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636555094574007972" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094573997971" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636555094574007972" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636555094574007972" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636555094574007972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636555094574007972" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636555094574007972" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636555094574007972" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636555094574007972" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636555094574007972" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636555094574007972" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6365550945740079721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636555094574007972" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6365550945740079721" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlanExercisePriceRangeDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock Option Plan - Exercise Price Range (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_636555094574007972" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_636555094574007972" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_636555094574007972" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_636555094574007972" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeOneMember" xlink:label="crvs_ExercisePriceRangeOneMember_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" xlink:to="crvs_ExercisePriceRangeOneMember_636555094574007972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeTwoMember" xlink:label="crvs_ExercisePriceRangeTwoMember_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" xlink:to="crvs_ExercisePriceRangeTwoMember_636555094574007972" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeThreeMember" xlink:label="crvs_ExercisePriceRangeThreeMember_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" xlink:to="crvs_ExercisePriceRangeThreeMember_636555094574007972" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeFourMember" xlink:label="crvs_ExercisePriceRangeFourMember_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" xlink:to="crvs_ExercisePriceRangeFourMember_636555094574007972" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeFiveMember" xlink:label="crvs_ExercisePriceRangeFiveMember_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" xlink:to="crvs_ExercisePriceRangeFiveMember_636555094574007972" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeSixMember" xlink:label="crvs_ExercisePriceRangeSixMember_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" xlink:to="crvs_ExercisePriceRangeSixMember_636555094574007972" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ExercisePriceRangeSevenMember" xlink:label="crvs_ExercisePriceRangeSevenMember_636555094574007972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636555094574007972" xlink:to="crvs_ExercisePriceRangeSevenMember_636555094574007972" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_636555094574007972" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_636555094574017973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_636555094574017973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_636555094574017973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_636555094574017973" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_636555094574017973" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions_636555094574017973" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm" xlink:label="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm_636555094574017973" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_636555094574017973" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_636555094574017973" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636555094574017973" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlanVestedOrExpectedToVestDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stock Option Plan - Vested or Expected to Vest (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber_636555094574017973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice_636555094574017973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm_636555094574017973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue_636555094574017973" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber_636555094574017973" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_636555094574017973" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm_636555094574017973" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636555094574017973" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue_636555094574017973" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock" xlink:label="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock_636555094574017973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock_636555094574017973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_636555094574027974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_636555094574027974" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636555094574027974" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636555094574027974" xlink:to="us-gaap_IncomeStatementLocationAxis_636555094574027974" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636555094574027974" xlink:to="us-gaap_IncomeStatementLocationDomain_636555094574027974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636555094574027974" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_636555094574027974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636555094574027974" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_636555094574027974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636555094574027974" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636555094574027974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636555094574027974" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636555094574027974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsEmployeesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stock Based Compensation -Valuation Assumptions Employees (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574027974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574027974" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_636555094574027974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574027974" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636555094574027974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574027974" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636555094574027974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574027974" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_636555094574027974" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574027974" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_636555094574027974" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574027974" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636555094574027974" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Stock Based Compensation -Valuation Assumptions Non-Employees (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094574027974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094574027974" xlink:to="us-gaap_AwardTypeAxis_636555094574027974" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636555094574027974" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636555094574027974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_NonEmployeeStockOptionsMember" xlink:label="crvs_NonEmployeeStockOptionsMember_636555094574027974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636555094574027974" xlink:to="crvs_NonEmployeeStockOptionsMember_636555094574027974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094574027974" xlink:to="us-gaap_RangeAxis_636555094574037975" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636555094574037975" xlink:to="us-gaap_RangeMember_636555094574037975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636555094574037975" xlink:to="us-gaap_MinimumMember_636555094574037975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636555094574037975" xlink:to="us-gaap_MaximumMember_636555094574037975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636555094574027974" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094574037975" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094574037975" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636555094574037975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636555094574037975" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574037975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574037975" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_636555094574037975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574037975" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_636555094574037975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574037975" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_636555094574037975" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574037975" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_636555094574037975" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574037975" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636555094574037975" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636555094574037975" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_636555094574037975" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes - Components of loss before income tax and Income tax benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_636555094574037975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_636555094574037975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636555094574037975" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636555094574037975" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_635933104230954422" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_635933104230954422" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636555094574037975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636555094574037975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent_636555094574037975" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_636555094574037975" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_636555094574037975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_636555094574037975" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636555094574047976" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent" xlink:label="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent_636555094574047976" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636555094574047976" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636555094574037975" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_636555094574047976" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsNetDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes - Deferred tax assets net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636555094574047976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636555094574047976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_636555094574047976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_636555094574047976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_636555094574047976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_636555094574047976" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsOther_636555094574047976" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsGross_636555094574047976" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636555094574047976" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_636555094574047976" xlink:to="us-gaap_DeferredTaxAssetsNet_636555094574047976" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636555094574047976" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_636555094574047976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income Taxes - Operating loss carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_636555094574047976" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_636555094574047976" xlink:to="us-gaap_IncomeTaxAuthorityAxis_636555094574047976" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_636555094574047976" xlink:to="us-gaap_IncomeTaxAuthorityDomain_636555094574047976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_636555094574047976" xlink:to="us-gaap_DomesticCountryMember_636555094574047976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_636555094574047976" xlink:to="us-gaap_StateAndLocalJurisdictionMember_636555094574047976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_636555094574047976" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_636555094574047976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_636555094574047976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_636555094574047976" xlink:to="us-gaap_OperatingLossCarryforwards_636555094574047976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Income Taxes - Tax credit carry forwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable_636555094574057977" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_636555094574057977" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636555094574057977" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636555094574057977" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636555094574057977" xlink:to="us-gaap_IPOMember_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_636555094574057977" xlink:to="us-gaap_TaxCreditCarryforwardAxis_636555094574057977" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_636555094574057977" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_636555094574057977" xlink:to="us-gaap_ResearchMember_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_636555094574057977" xlink:to="us-gaap_IncomeTaxAuthorityAxis_636555094574057977" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_636555094574057977" xlink:to="us-gaap_IncomeTaxAuthorityDomain_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_636555094574057977" xlink:to="us-gaap_DomesticCountryMember_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_636555094574057977" xlink:to="us-gaap_StateAndLocalJurisdictionMember_636555094574057977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_636555094574057977" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_636555094574057977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_636555094574057977" xlink:to="us-gaap_TaxCreditCarryforwardAmount_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_636555094574057977" xlink:to="us-gaap_CommonStockSharesIssued_636555094574057977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCutsAndJobsActDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Income Taxes - Tax Cuts and Jobs Act (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_636555094574057977" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094574057977" xlink:to="us-gaap_StatementScenarioAxis_636555094574057977" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_636555094574057977" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636555094574057977" xlink:to="us-gaap_ScenarioForecastMember_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094574057977" xlink:to="us-gaap_StatementLineItems_636555094574057977" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094574057977" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636555094574057977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense" xlink:label="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense_636555094574057977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636555094574057977" xlink:to="crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense_636555094574057977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_636555094574067978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_636555094574067978" xlink:to="us-gaap_UnrecognizedTaxBenefits_636555094574067978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_636555094574067978" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_636555094574067978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_636555094574067978" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_636555094574067978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_636555094574067978" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_636555094574067978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6365550945740679781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_636555094574067978" xlink:to="us-gaap_UnrecognizedTaxBenefits_6365550945740679781" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable_636555094574067978" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094574067978" xlink:to="us-gaap_LeaseArrangementTypeAxis_636555094574067978" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis_636555094574067978" xlink:to="us-gaap_LeaseArrangementTypeDomain_636555094574067978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_FacilityLeaseMember" xlink:label="crvs_FacilityLeaseMember_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_636555094574067978" xlink:to="crvs_FacilityLeaseMember_636555094574067978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094574067978" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094574067978" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636555094574067978" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094574067978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember" xlink:label="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636555094574067978" xlink:to="crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember_636555094574067978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_CommitmentsAndContingenciesLineItems" xlink:label="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636555094574067978" xlink:to="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" xlink:to="us-gaap_AreaOfRealEstateProperty_636555094574067978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_636555094574067978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_AreaOfLeaseExpansion" xlink:label="crvs_AreaOfLeaseExpansion_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" xlink:to="crvs_AreaOfLeaseExpansion_636555094574067978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LeaseAgreementRightToExtendTerm" xlink:label="crvs_LeaseAgreementRightToExtendTerm_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" xlink:to="crvs_LeaseAgreementRightToExtendTerm_636555094574067978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="crvs-20171231.xsd#crvs_LandlordProvidedFreeRentAndLeaseIncentives" xlink:label="crvs_LandlordProvidedFreeRentAndLeaseIncentives_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" xlink:to="crvs_LandlordProvidedFreeRentAndLeaseIncentives_636555094574067978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_636555094574067978" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_CommitmentsAndContingenciesLineItems_636555094574067978" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636555094574067978" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636555094574067978" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_636555094574067978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636555094574067978" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636555094574067978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears_636555094574067978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636555094574067978" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears_636555094574067978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636555094574067978" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_636555094574077979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityAbstract_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636555094574067978" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityAbstract_636555094574077979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract_636555094574077979" xlink:to="us-gaap_ContractualObligation_636555094574077979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract_636555094574077979" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_636555094574077979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract_636555094574077979" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear_636555094574077979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityAbstract_636555094574077979" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear_636555094574077979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesLineOfCreditDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Commitments and Contingencies - Line of Credit (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable_636555094574077979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_636555094574077979" xlink:to="us-gaap_CreditFacilityAxis_636555094574077979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_636555094574077979" xlink:to="us-gaap_CreditFacilityDomain_636555094574077979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_636555094574077979" xlink:to="us-gaap_SecuredDebtMember_636555094574077979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_636555094574077979" xlink:to="us-gaap_LineOfCreditFacilityLineItems_636555094574077979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_636555094574077979" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_636555094574077979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_636555094574077979" xlink:to="us-gaap_SecurityDeposit_636555094574077979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Related Party Transaction (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636555094574077979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636555094574077979" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636555094574077979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636555094574077979" xlink:to="us-gaap_RelatedPartyDomain_636555094574077979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636555094574077979" xlink:to="us-gaap_DirectorMember_636555094574077979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636555094574077979" xlink:to="us-gaap_RelatedPartyTransactionLineItems_636555094574077979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_636555094574077979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636555094574077979" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_636555094574077979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Quarterly Selected Financial Data (unaudited) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_636232785054493599" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636555094574087980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_636232785054493599" xlink:to="us-gaap_OperatingExpenses_636555094574087980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636555094574087980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_636232785054493599" xlink:to="us-gaap_NetIncomeLoss_636555094574087980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636555094574087980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_636232785054493599" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636555094574087980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g863102.jpg
<DESCRIPTION>G863102.JPG
<TEXT>
begin 644 g863102.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$P-#I;,3A:04$Q+C$X6D%!
M-#$Y,#$N3U544%5473$Q,3E?,5]025!%3$E.15\T0U]/4D<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M3.]4*UK&BXY$<P5/ BD3)0<8J;+'0LR9@H:+BY@&"IH SB$,6-%QPQ #!8?
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MOE>^ZUK6]N][VM3VK7]J]K7M?VKVOXKVOXKVO[5[<5_:K*XI:*]S5P>:+O\
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M],9R<D#0=*L#0.^W:SI&44)LR5'#/DB/(Z1P#KE:XH:))!>,TGV$%'^TE88
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MF.56AE"JJ)&LS4YCRMB\:2MK 6ZFXE[2"*TW [C#JF-@H$/M),BU5O,YM$?
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MZ[PY</!]_MMP>XQI[VOHN3WSH^7#]9WP]-N'NE=PG@GT <K^:N8D:?)3P3Z
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M4@H:6X5F,'BE/%.0E[)2!15@PEY"_P!S505),$U,(F;"&$"%%3S1<V%;*P@
MV F-KUC5FBVCZT=4U#HQHY)6K33-21S71=XBDJA$QITE(A0ZMI<@?JTZDGJU
MQS#)H]*;]:KIEK-([\2D:>):EXKRJ]8D!=1*R8N_5*F)'4/M'WK=8[AC6JK;
M>IZ"9>"KK76T9@AIK-54Z25C4OIL38U<Y5_BO\LU@V6_#*QBVG@H'3T62&FG
M4AOJ!Y60E1I*J<O$4TWB7",>U&U.;=M:LJF M5$I)J4BMMHO%1<CBF2$6TU
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MKO<A5V2)*TK-LP6;DIK,H*#!2D!_. ^30XP>&3D<++=+&)]6E'&@JY%P.QU
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M .A)"'%X_P"X:O\ :W\7]VN/^3?Q\7CI;8P;+:__ ,$D(?RH:M;Q\?MK5O\
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M<B2#_P R*WINMGU*BXTZ3=T5^^=J_P"L;OV]DVNXN:/]HKG\V46[]3N%M8/
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MT'^7[OV]DVWP<)!M!^1F6Z/YEMXO^MU[1MHSM#2XF00^B\($7&V-\@Q8]F;
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M)#E14IQMU83E] 7DLBMH2ZBJ("HC+2,J%@SJ8KI"F3%&***8HE!@C1(Z5%$
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MK;JKTZT6R:SW/+DU>;)K.&7ODSX!BF;A67-AB<N..&!PPQM;TGTPS9/=,O\
MSY<^3@-S9LF(&?+P7'+C@,V&&.S':;:O^$>V@O(R+='TR\7M\7]M\7'Q\7M\
M?CIPC^T&Y&9?H^F;[>_?^Z_'OX]_CW\>^MJ?6A^IZKK1GJ;Y];MEUL?J;B]5
M?#K5K]3NN+U=KX=;M?J^KM?#J>JM>U?*8, E#Y5*-CXE%0\5.G228;%[&43A
M)-S(AJ)PH1'R#-&2B>(J)@9XR"%F"3$4D_ SF%D=*V%H+\T4.SW/KC)PQP%;
M>W6&!)_&NL!B=VS'EM7I+ID.OT2](!UAMH+FZY( 'XIRG ;R=]M6W"/[0;D9
ME^C^9K>WO^_/'>_COX[TX1[:"\C(MT?3+Q<>_B_MOBX^/B]OC\=;,'@Z4!@-
ME0>3T5<&VUDL,L(>7%$%0N3#[.422.1# P)E39L^:/JZDG)1 DFE3AX^I'R9
M$F6'-&00L\?R-J A&(%=,0)2E9EQ\L+"=VY3R+K6,TK,5'[:XH7;@P8S S(I
MB19:RLE9*BN:3T_ ];(#,SC<,2^$L5ZZ-SE1#T.+HF+%U415-\R%FC"-(%"5
M))**X9P,2H9"V 88QR79I9""9>BA?<04(6,E)<B90Y*H6S4PP#LK*A.QRK 8
MD-:"%MH_M!K>+1F7Z/IE^/\ =?C^&G"0;0?D9E^CZ9?I=;/4=637#@HB()\)
M9P2' KM-4S3!,SF!!T(!GL-;;QG,&V6."NE&[7+GB-KY"@#6OA>U[VONJ^1<
MSC87+(N;QQ+[NR,L@3&-B_5?M>R+WQM8#JM]NIZ[?#JM]MV_?49OO153@W0]
MN,$=<&MO8$=;'8:K'E/HM(+ETQ(!'1+T@(/6(H+F(/6ZQX)@>3V)MJLMM(-H
M/>]K=YF7X[V_Y/IE^EUN#TUR"_)5A"/Y DYHXL-].5,.FW$TL"*NF8HIHNMJ
MA  O8BNYB*Q>PQ$H4-]2=SR$R[(ZO"_6LP[6LS/ 4.]K"8#A7RMU6-A,10[Y
M8VONZK&V=L;Y6M>V[?;?;?;=OWVK/[-O>[92;WO>][@";[WX[W_MD;VZYC2F
M\;EK**".[=&+NN.9:I7>IHZBNFDEC$,JF!EJ9Y4"%V63%5#@QJ,<"PMV&AEW
MW_27C4R7KI;>E_P-1.D=)74U!#'%*9Z=A4*U+!%(7"*\85F*%96.&8 VN:E*
M5PMO2;*4I2RV*I,\:)^-0_J*5BRLIR9XT3\:A_44K%E=)=_XI#_K/\5[<3>_
M^D:C_4_X$5E*4K,MK;*4I2RRE*4LLI2E++*4I2RRE*4LL]O'_&Q_UK5<3R_?
M$L?Q@7Z&7JW?;Q_QL?\ 6M5Q/+]\2Q_&!?H9>HF_#P_V51_OTMIU_%IO[>G_
M ,.JM_,5VG7^^):VO_N8E;_Q$/41H^8CHE%^,J-&0FW67G(;M;C'::38< K9
M2<CK6":$B$LS9G,,L4",*)XO@.<,B!ER@%Q#(^>(06=[2YVG7^^):VO_ +F)
M6_\ $0]1#83Y=,8OEF22QE85 >L?.MO/9HK@ )8P*CN9K*Q1<0E+ L<!,$S-
MR:D1+#Y%3A<P4,X89%S0 P H@>7WQ<NOXM75P;5BIZ247!]=FU.OX#'JM;DZ
MO5ZS+GR]5EQR[<+?&-Z:GI_7\)$AI^FL^O$6&M,/"FUHCS=3K,F;)FV9L,=E
MI=GMG[-#@<95NZ=5Z-]8V=TQ?.K1[3*X%5RV9YYMNK%F'$)X(K];T=.A"4EU
M?$ +QL(,AB)\Q%AKFHK-NWL50!)V7WB&L;*/+2N'ISDL6/LF@H/W%RA)R;F7
MNTDQM"/(VKY$+*W;H+#%J%SSA!(C)@:H:1TI=4"A <LWE\1,RZD[2.2F^L#&
MF] >CU ; YYO.C.-TF!;E6+>4FA(1J46A,PH?LSS=QN1FF\3IP=M7.O RQT9
M!-&F:19 +2-&4<6SAMH'/IPT(H*6+"4U4R"@8GU<ZU!<E%2-M_3G*VF !4.B
MEUDL%DI'XZF5Z'U(8N"7!&=XR<L%"Q).)"(AK21RZ?+F44]R/&BJT4E6\C54
MV)Q:*<T<L%-'+@V!DAAU*:I<JS&9C!OGCT#.1N$7P'=I%ECIH@M/#E"ZN6'A
M.MJ)(W(/V.236=6Q9D$:B6Y7KLS-5L?/UX,%SLOL0VA-5?=#-7BQ=;46S,7:
M-WQFQPT",U-/23(@KB65Z7&-@EISS+,_J""VFJJH*G)BLBFU+&BKH)UE(AEZ
M$U33C)I,U'C)!D5X YIR7EFCLP?!U"8K5L@U?,-3ZS@Q7OD>2D;-174JS-==
MU9+(V;BS<EFU0VIFHDTX@7*EM"!FF<%6S[O<)9IQLHI1)ZR"J.F#G,HR*\,1
MGB>-J3P.A:=XP;8XY$XE(N3>3E:V*'@O+I]>O0X[VED^1JS%-B(S:A]01E1D
MO2/QC*LSE_%;#;;_ %G4 MN<G@KH3V0AS 1TWJ3D7,(@J8*2(4- -1:"2+N-
MNAK)J*&;HB)3!Y:71^:I @5HB\R*QQPFE5TG"IU*8ZLF3,\V=&B6'@\ETT>@
M#5!2&HOJ.GPD839%9@2@,<3(T;,^#L<)%$?4Q96#&;61T]R;-+5H@*+5;)-B
M%'D_':HK@))C,1:).8\GH*#&402H:>2TZP,@(Y2VUDAS<QTKKIMY!*19R&<D
MPVG! J+;.KN$GEI#U.1Y'"C+C[@V1&A&Z.MF&XL.MPHV"831ULF\ER/#I!7(
MF#6*VF9DGXVUIG'1SR4 3)N4E9',F0CAQ.".9VOM'IB-D"#?7XWT^.YDYLL9
MBO6/75'"TJ,R4T@9BZ>V%8X_B ;Y**0BX7*:7H;<))5:"NT!"3K;II2+!!D5
M8XE98^ES7'.<XD9 *2**SE,>36,''KL5"+7Q25$PWPM1ZYJB#LG]AJ.)!,-!
M2,OF2 /8Q"Q$%FE$U"#(8FBEU@;*HI-.@](E;!<;1F6 UTJ:\2:EJAA4BF5*
MC(KK3X-&)%<(5CQ>I:>1*+'JTT)*5+4DU\B3).*2)EC*AQ!$8#.[IBRF?6*^
M3(6!8Y(5B1JBZ6AH*>ZV $??4P0-!2+FBP2,,X)H<[O;B(0>NI-O++XB",5,
MX@L5T9I3J5HX2+24ZEI3 )Q_'+*4TU1>[P2#0@Y(#(R)LM9M<;-8#M1)%A=1
M,/8BPE90;A94D,0TS$23R,KFF(LJ;LPCK*,7<17AX==1''",'V]SY'LE"5CQ
M(!OJ JL4H!C:#.(DKX*Z?%<3OXFYV?IQ.2*QYZ89&2F#E/FF=@YQ.R9J8B03
M5V\:2SIIA$T\-6;J^95&NLG%EU(KF;3C;F:0"7QN%KTU)8KL,*P[RN=1X&;
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MA8&\"!,ZH%KS>&TEU'OU66UMT6CQ14G \,7JHF/8D<POFK Z@X[U*% L,<G
M)?(F4?L7-)/#[*R-*)EK@'R:DI'UU0'<=L]+6U$L-I[3VJBQB2[XM84;$I E
M5716J7;IUC%2&IQ'3FHEAH0Q5W+I),1=4#M(-4LY3!05F73BI@VLOX3(G9,P
MYJGHA04\4:T-T5$\]3J-;&S.::)TF<U$KF:FA,<3&-%(IBP$.#0SM4YJ?+BI
M] II9G:LO2"*"G>41R($%0ZR4R)%%@)I=8ZZ\LF?:7#"2-(6+:^G_IFU!Q6)
M&X$C0W(+.-2ZDIRS&Y-90!\#CL*JHJ2 3+IY4KF:' 6;CKZ"$9;BG@0<1"ZZ
MB9GTDJ$L)@AK*V6SVULXK;S;M]-4FW6(];J*['B6#)(HH**W'"3="@CJN2D$
MMYI*D <(LAZ&[@HI]3.%"[0= I\L5P0%7(ID&1]I]JYDU38RFKO4@BW:::DI
MKE26L"XDIJS.&FCLH<U:;&6:=2FT'HG.+N?-@)SM4@B-QDK 98WUQLABGS M
MY0Q]M>3A]7>SKU#P^@OI=!:2.2B%)8R82(H#9>*"U)_9R6Z5):D9P/5[(2R6
M1-0CL2O9(W%98SS;P>"/=JXJ@2,Z4.6LK]/Z>B@FBN:Y*BJU<G"88*F>7[,:
MR%*=84EEI0$X*93(6G?;A,6AR&F>*DHM!9ZR:*6]+V@I2\9IY9H(H\(EI)7F
MUK*DV+FI$:H @(&,:+-F$H@HFZ =:*LM-=O$=-DH9K+S8H,EMLB92TY.S4&,
M*KM=!R7QAU-5)%$@,HK/=FDU-,7#"6NHUW6W!UA*(%5E/'']&>B#4*1?.GJ/
MG UDYLN+4H26U1BEEE>3NNH:.TGBZV8^%*1$].S/K#'P8IMD.E5=9)53NV2<
MBHQT7$H,IE3J44R9*.TNU+3$D I+ZRCX_81@-YB+9LJVELN(Y!$%]0G(0CR4
M4XR[CZ"G.Y<6]/\ '19<$:R.W6X;22BH7!;94\I64BWPIFO5Z+$\0Q,DFLEE
MK>$:*TWDW$49Z8=;2V](^U)OJ5GG+35-GU!;64T$T3$G&4 8Y40T\J*W[K)(
M-;'<&) ,Q:=9].C 9)Z2Y$E$-?C!2F:1M='1534!CEGJE1EFK>"QNK1*5C1V
M8J)CP>$PZ$Z_5155[-&9:,+/4!(UU3U=,M7G2*G9D,5(*EPV+!F=0N)B!D_;
M+V?CU? $0$$^<=.*3(4UF8=4&?#KF>[G0I0O'L]/@!DQ?)8J0;9':%52US Z
MG/@\QFFY7'+:#&JF3>RNPBR98YB3MZ=M"TEP4Q>Z:=>+ ?;#.Y1/FVUQF@20
MFG7.3ET><B",=)M21X^8;Q1PT-9T]R D+X#F0$8P)GVB56]@NH2M93+U1L:_
MI49)")RR"QX.571!YF)4Q@S.ZHG(GYO-1[ CT >D1QZXW:77\$X-"0#:>DIZ
M@>;"0A/95;:<59A]]'FN6P)"8Y3M:FI]++NH<O-$BYO)VO9@/PW*QM]/8]+J
M8J1LU).9+;34&1#CD'7TMO8MF7'BE'4C 8; 4H8*%RPQ,L"9 .U@334SM+)-
M=^H29,*>0QJ)XFJ4UH62*F,D"+ &U,DFMF1"R2PS3.LE.JFT,6,10)7M(T;#
MA"*Y:!UIV$9=)*@1SR-.1K5C5('(5XYH8T9)[P8&@>>9&#TU"(XD?)EM4C@=
MJ(R,7(\K(^3/(M#!CF#+LEFUTHS9A-9<3Y&9RFTS(UU-7<A%PH A!%N,YFN7
M6_#1T%3F\FLR70FCL0"\DOV5HS8#:-N8>[N=#NBIANE^YEBJ(42378";(95E
M.AOQ:KJILD5=CE212^6*:D#E5H?)+2VLFNIFI<5I*;,?9A>)7;=THPRRTFBI
MGG$6P!C@N4:#W.BHV!AQM)/!BULX$0;YDG$%GV68$<PQH%$'1+@96U3U%=M6
M;>9UO&5VO&TH.&>V0@"(;60S9672L9O1E1<5.+::F$#&,8LI?=@3E,MH((TJ
M&BR;VE+*-B0P()7%GDZ(B"=T@N!D45#QI#43R3-A)>1@C19:6"-F,;W8A,DT
M8.HE9F5JAA3Y<$?0^<Q(\]]*["%7>6)(H58Q4"RN[QR3N%$J5\@"1G9-&@V1
M*[XJ@/0-)>H>%#DV-)\Q\B)G;J6T%";;F3);NHKRA"T:H$K/+LIW-:+W1%D?
MDQ6LXB6" H2L_6*06E@,TFEC6.0.0UJR7V=LB&U!H-@*:M-84C*@+<4Y*BU2
MD9<17Y ;6<,3JTX#O24D]7990@I-AFQ@BG5^3#<3*,F'(Y/C)39=! HX5E-(
M&,1Q-K&F^%X]1(J92X5 8"6<G,TK-<SFX,$1]A:A8F1(:?J9(:.EN),27<D%
MFF@$C;3(*1'*S=<.9A7P%.=<Q*AY3!VB\VEU%FN0%C:>K/YOX(!)[R:8AE)4
M7].Z WHM5X4 :<W+"FJ'"CA:ZS%J\J--Y);13&)D^<1BR\[#*LYTM)6B4]4F
MG JJPTDMWM2OPEJ%7,(:)]9,M*E26@+-3<'6-Y-67J!6O"=8:7A$28U,VA)I
MJ85*5RU*<'6K8"8B5,(C4M3Y)<HFUK.$,BQQ<'21=7KC#(\7ICBTK$KH3D-,
ME"*YB0UUJH+Q;[[B!Q**ZVE!(< 1C($DII[A0VN\V4[$L<H9)N!D/MK-QU(H
MN)<P:3,DY13#QS$]KWM>U[7O:]K[[7MQ7M>WBO:_M7M65)@E8U,#J)N,5BQA
M&B<D-E!:#>8\0,[!ELI 0&\"/@3!+DQU%<7EE5-F#9Q06G.[G&Y'2MGC60BD
MM#@ $BY3%=K7O?=:V^]^*UK>.]_M5UE#PH4E/PTXU6J778F,MG[\PJD)DPPU
MAA58C)F,0$>46Y6NX+PNHX%^*ZPZG9( 4V;5$K/*$)Q*"5FD"9=82^-M^NQ\
MVP:QHZ6$O3YJ"5%)>TK+RGE@CK&6)E368 6%0S<0RMHA8.PQQ1C11-BYFG>S
MRF(@Z*.(8=;4 N;NL(ZWWE&%]#=22SW*V5E*<3=7V2VU="7T)0*JJ*M)*@3N
M9(*J0J$A!B:BFGBP@9@F=*BB & ,\! \KVO7 ?LB-D.XM;KB)37-9)7:^DYK
MJ^88@H68Z4N3FN)1BV)QFLPYC; P19Y$QA<J^GV4O:Y>]AFPUQA'"(?/M[OG
M#:C98K?9#-9C?1VHTFNQ6RA-ILMY/+I2$@(B:3R+)R0CII7' N13B)?#  J6
M"QMB&'C;??+.^6>7RAT8ET:726'I/_I4BH-^+3A>!"<K'JR<,,*\]5PM8P4Q
MRF4BIUP/TGT+FO\ ;1V?IJ/N>#3]*&FS<+:#%PPP/\D&S@[/U9VA,8<AMZ:4
MI7E%O0[*4I2RRE*4LLI2E++*4I2RRK@7/W$U_P#(./Z8/5OU<"Y^XFO_ )!Q
M_3!ZBD_"0_UV_P )[3Q_@*K^I#_Q$5K?J'TBL*;TN3Y=<\6,F)) 1YZB2/X[
M5QY2=II#3V"KQ]:04D"SH: 31<F4N16NI4ACKRFQTU00%,5PIBNECYW3W==;
M1I@TK-IJEJ9G94CE61 DD<H<HRK+'.F.K>-P4FABD&5P"4RN'C9T;!G@6=5!
M>2-D<NCQE0ZDH\3??HZ$/%)(AQ0D!LRE7"LNIU6T;3HM*LFE38[9!Q=@$CI;
MKD8C,DB%%&?&T])IB]XL)O+$<@ !)L,)\,1HUW,ST8HW5Q0")A"$FZR3H2"Y
M7(;#LR2M%[AC@\VUJ/(^3W&FNF?>T[P99&49'3 7M&I_5XVY#A=HNE7MFN]H
MF4PX:(N=K&>O%,FXT 5@5HGP3K67%4;'<K7FU[VW[KWMOM?&^Z][;\;^/&^[
MQXW]NU^*_MVK<)I)>*-'M0QHQ=X5:>-)24"]7DF4@(0&A5"JTQ5%I5ABA@CB
MU;W#0L&V/K&"JLI6!WC"N&Z@/"5)8#+,75C4!I&J3-)+*[Z:U/15J8'8Y8C<
MTS5< VO,0ZM1:=D NNHIB.T)RZO%A#ALZOO]H+" \&_#I*;(E*MT=T(N2:X1
M&(8,I *2;;S8%'MA=T#ZAP6P?;R39NN=05EAH+$A+J]):*()+J\7TBM"'"+O
M7C+E9"J7'<,12DW5Y91EU29B.X#95T$)#8]BKR0^P@MW51^U&OZ2HW:+3<<<
MIS).!#RW#C7?)EX&UNQI-8[ZE9DL5:'9R0D)HY5;=@X#F$+D,5U80$A'QOFM
M9BJYDH C&<JETCO6:HCBB2A#SR90)(V2-F<QA0Y$HS!3&-7FS/F*E<TB0&/&
MJ+ANV*!Y9&K<D,8)*2!W"H&Q*+JC@6SMGP 7+F&"QO,)(IZL=+NH*7&E!+;9
MKS+N$PQXO<K+>*JX7>E("E:4E%!CQ-:\_$5!883C+F7>UCS;=ATBXD)O)#\0
M3SD$5VL $*HJR=:EN+1,^SGL\44I3+YN:4S^H O)KA$D]]IA]ZM][ZD(;?\
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MF.07&:U!BX:M8VF-D.)PL@Z0*)L7J4.PZVWDPD)-3CQ^PAUQ8-IKF"30OB<
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M1:Q@'U*[+:B*F.@W(1]9:*;BK]KC*XRD!O/$5"6"#/<2^I)PA<7>M<EZJ7'
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M%M*O?1!W00V_2E/"(MI5[Z(.Z"&WZ4IP3HU=L]&^3\A=WQ?X_3UOR7">A/\
M!+[YG^L^/V.R0_@QNK/E$Z:?YF7?46G@QNK/E$Z:?YF7?46H\>$1;2KWT0=T
M$-OTI3PB+:5>^B#N@AM^E*<$Z-7;/1OD_(7=\7^/T];\EPGH3_!+[YG^L^/V
M.R0]_P!C&ZLK6O>^HK33NM:]_P"\2Y?Q?_X-7VGOV+_JX3Q0P1M16F>^0I4L
M;QZD&7+VZT:#ZZ'OW,:^[*V/%E;VK\5]U^*HUW_9$.TJO:]O91!W'Q?X"&WZ
M4KZ#7[(LVF!L3 09U0=ED& "7QO>"F]EN" PL&'COS5L[VMCC;=;&U[88VXL
M,<;<56FDZ-F9<+ST;RX'-U";2<F7WOQV=7C_ /C#9(M3T),CYJ.^\^*9"!)@
M!U6?'[9 _HX8X]8]:V?_  8W5GRB=-/\S+OJ+3P8W5GRB=-/\S+OJ+4>/"(M
MI5[Z(.Z"&WZ4IX1%M*O?1!W00V_2E7<$Z-7;/1OD_(7=\7^/T];\F/A/0G^"
M7WS/]9\?L=DA_!C=6?*)TT_S,N^HM/!C=6?*)TT_S,N^HM1X\(BVE7OH@[H(
M;?I2GA$6TJ]]$'=!#;]*4X)T:NV>C?)^0N[XO\?IZWY+A/0G^"7WS/\ 6?'[
M'9(?P8W5GRB=-/\ ,R[ZBT\&-U9\HG33_,R[ZBU'CPB+:5>^B#N@AM^E*>$1
M;2KWT0=T$-OTI3@G1J[9Z-\GY"[OB_Q^GK?DN$]"?X)??,_UGQ^QV2'\&-U9
M\HG33_,R[ZBT\&-U9\HG33_,R[ZBU'CPB+:5>^B#N@AM^E*>$1;2KWT0=T$-
MOTI3@G1J[9Z-\GY"[OB_Q^GK?DN$]"?X)??,_P!9\?L=DA_!C=6?*)TT_P S
M+OJ+6;].W[&=>2/+366=3TW1HZX;1S&2FYF;$^#])NQYYE+AB$6MFMN)OHA9
MO-]5&WX.)93QQUX-,#&)(H)4Z>P5DV!/A$6TJ]]$'=!#;]*5?\6?LCK7,@2$
MTU:6B$22/&I17 N]68WXV2&(X%I %MD">#;[M(GC B,NE0Q.S4D<R6-)8YXN
M"45BXB>8,9!XU70]&IZ6H3IE<9S02#"D,<=4<4ZU/(U#&L<YVB)S)'D<ALZ$
M9DR*6KZ$Z5,#\#O3%9HR.%)(],"&7 SJ)V+1 [7&5L5!!4@D6[B6TV6XRFVA
M-!GH20UFHUD<@WVTVF^0+I2$WT)*+XE4Q'1TTIA@7(IQ$OAB$7+@XVMC:V6>
M>0@P@HN>0G/_ 'U%_P VD;_L1*C;IYU#Q)JGB-JS;"3K+NUA.TKGD6-8X6*J
MR*K%<0[+#4=:1<00PWW:WS N)1:135[Y@YY G"8QU*.IZ@;DDY_[ZB_YM(W_
M &(E?+]7%405FIJHY8JJ.6H2HCG5EF292HD657P<2!\P<-U0;'';C;Z$I9(9
M:)I*=XW@=*=H7B*F)HCB4,97J2A7#+EV8886MJE*5;:VRE*4LLI2E++*4I2R
MRE*4LLJX%S]Q-?\ R#C^F#U;]7 N?N)K_P"0<?TP>HI/PD/]=O\ ">T\?X"J
M_J0_\1%:WZ4KQOMOW;[;^+BWVW\=]UN+X;\5OMWJ6T%O-*4I995*64)%<9+%
M-7THBLI^"BBJ^!)1+X&2V*JW%I/<;?4<0L_L;&T9?24Q93AOVQ913RAG#[,'
M&JK2J@E2&4E64@JP)!!!Q!!&T$':"-H-J$ @@@$$$$$8@@[""#L((V$'KVMG
MV&-+M<BI'L;1>U;<<))VH"?V #V(CNE-6#;A(.)/!W=2762B\?/+()^V\?%2
M.&3=\LAAL\KVDQH/AV,EE9<,>1FS66NN'MI995F\D8DCI[!<<)IW+877,A!;
M$P%MUG33F6BR;@2+*[@'R6%,(VH8AF,,ITJ03SA7032A)3C(@D<+(<2V+J&P
M<YB3U0.TD]<VL,,)9',41:/\&QC0M'L ZAB,4V #J2-@ ZVRT<US2%I<<KN-
M/U<@*,%%Z'E%P*YUS"-ZP"L:4W<EFD-XG1129DL!8=ZHIXZCO;,,N'=YI9PV
M0=%U8L9&#SN9%T[06WF,[XR1HJ:!./'^GXI+U9>150/-USI6"=BCX)BL05%(
M]85/P2L,$[$D"( 6Q)X!@V"MCAAU.9J5,U?7,JHU;5LB9,B-43%4U39X\JER
M%U;]6F &1NJ7 [;1+1T:LSK24RLV?,RP1!FU@RR9B$!.L78Y)ZL;&Q!M@<72
M]IU,MXBU#L+L%2;B:YC3S((ZPEF5PH5=!]-"1E!9"R6CZ@:Z\II (24K$\S.
M:4L)P>))53SI>UP[W\ZXPCA]%'.1>C%:SJ)/5LIK,=Q5=1RJ@ XVFC*BBMH[
M>5<!<=PZ6D+2LI*Z4#AUK--5#HZ@2% -];%#OKX?:^W[7%QWMO\ %OM:]KWM
M[5KVW^.U>.JQOXKVOXO;M[>_=\>Z^[[>Z]6-5U;,K-4U#,C%D9II"RL65RRD
ML2K%T1R1@2R*Q.*@BY:6F4,JT\"JRA658HP&4*R!6 4 J$=T .("LRX8,0;4
M9+$9<;-PFT(_:R(SFNGC'C)-#0">),B$;5#HRBIG1+7R$,'%!2/F!SJBHGC!
MI0/&1<AC9H;/=>UV4I4+N\C,\C,[N2SN[%G9B<2S,Q+,Q.TDDDG:3:555%5$
M5410%554*JJ!@%55 "J!L    V 64IOM;QW\?%;X;_:IOMNW[[;OM^U5MKK*
MD"S/WL)'\0)^DC5'VU[7\5[7_%>U_P"JI!,S]["1_$"?I(U:R]/P$?\ :C_<
M>V\N#\;E_P#3M_B16N>E*5HK=992E*66Q5)GC1/QJ']12H>S^W8776.F'=0"
ML@)49,Q^L9^'_9BMIZ.Q5%Q-U7O@RDY[@JV&:4X4'-U**8=+-A2M<FK.4BWL
MQ S(A,(J-,*3/&B?C4/ZBE0PU(L1W2-'J&VV.H**,O@S- 3GLOI&#<&5&RCL
MR8F>Z7$YD\J[2BBW3YQ 0TH\I@)RFFJ@1_,O8J&FGAQ R^?77%AC0!IFIU,X
M5YU?5M$C3L&D$@5BA0$MF"L5PQ"L0 >!TBQU]X98A.PA4K"RYQ*RTT96,IF7
M,&8 %<RYL<,PQQ$>V[I7TC3.7?[L@Y]+)))? LGM%ZFM-<I(Z*W@R$HL]AMV
M5&"62FVC*J4ST]QE6,S'BHIB612%M.=^!AZHJBF".-4NH9("T1PH *]Q0KR*
M$@OY%?* JM<)Z" ,\CG)*402WNIH94LB@* *ZM%B-S862LN+B:@**FLJ;91D
M4PJCYU"B4-/6JQ,=$KXHEG]*S9>$X$WRX720S8Z(^Y81;:66>RF!9716+-&E
ME))I\,R2W5AM)F:8Y&F:*8FFD^5YN2)DFBJY'[ (=UF%4:30S1::UK44,S'L
MG,?41A.;,18T,LT>"VPBL>/ST;E7L,EF9'+R,$XQ#BH39C6P(R3?NPVF$5$.
M8E#?;-'*R1F+2:(1R11E(Y*I3)$K"+ 2R2O3DB)BX?[$M4L93+2M))/#3\2K
MQ!G$NC[ETE?&1*9PDKJ7!,4:1SA3(H3)C(:9W#YJD)'#+-/%_:38S?SI<CO/
MG91:KJ=@JV&[%1@R"M,HZN-ISL=C,)U,=5Q(E1;793D;D<L\50( AEE<DL)7
MLA;J^A*1HP.)9V6BV"U=YGWB.<>BP93<S".@H-G@G#H<:E E!B+9MH-@4BA8
M.XBW$\5DM?%+8CL=KB;;*2!\R#206V5,IF9+7$H1[J83G.38&3<U)GR#JB;5
M:X(SBMJRTG14J1ZZ@"6G5KQ?)"OU6K"1C-FFCR8IN59S3%R8GT<;1YP*SA)L
M8-!7+I)?)1S3]J,11Y)(W:.H1P&'4ZYF<RPL1'J%SC$HX)Y?T00:5BR=$Y45
MI+;MQXV:;T0I=(K[?+DRI1HKQ]#4E6(GPCED,-(+230I$HTDC56IV$&66%0L
M"2F/)]DK$,1^Q% I*@L^KB>6-Y' U4,SR,UP.66=#*&BF9C.\22YB$I&$@^R
M!B<&;!-9(D;I&IGPZ-(<..U!;J&HEG<4": "]@U55*=&1980#SAF!#G0TM$C
M1Q,42!A6)R WR!I.R54Q230T$0^W#R6H)BB9QS\(D-0(_P"+0H7).#*4F+&4
MMDC#R3#3W3WL8/2?'KR*R*>94MY%"XI!1Q(.PVCJCGC0XFI"4 7+(*-FB)J$
M5+)=Z-%31F>,VW/[^=5G1*LR'EA:462@&GX..TW6$U(L9 ;526&W5A9)LF.D
M-ZRF0=QXU<1,;I^W;HR:7\BZ<&G$2L((GT<ZFX8*J$=&%TJXVQ-!/3 ]Y??D
M+K"[#ZRG2RQ)M2!M1:FMJ1F1#KK4ER:8K=:X:7G<R<T0!8(QUVELE):BH)&!
MO"A1I8YDDOX1M3U--/1@R@++42L)*VHC+2#(U,LK2QN[1-42EA&-:6"Y<K"-
MH7CN5GX13SPU6$9S1P1KDHX) $)=:AHEC=52401Y6?&/!FF@IZ*81%D+-WM%
M7?\ $SJ!<:C(Y)"B-U-AGH3?=3@938BE8?+;8)ME+R*V%E;;;)2$8TY$1)(&
M1%+!:%)G0#JXNX'+E4]'$&K>#K-+S=4UQZNR2&3+"K*ZN;3S$R$'S'0C#NS#
M[?D;%!!6VN01,(X;I0NWT; FB"DQG 2&(9@N%2Q$@NY=/<]M)5?"BT61-3P7
MC\<.R,66X0IV>!LXEQJFZXG ^DA"4%LW-K/7E=:M +B3%%GI!UWMAQ.Y+2EI
MD'I29:YD,:-1G?*AJ B] +L62UK4 C2630THOIY04;4@F-E13PW#K#<A=4/N
M5@DIX=;BF;%TQ Y68PV@E%7#/SB9P+76VLI$VZ($F/=>V,%!4U1AX-I"KNDL
M5+&#)$*@PJR2+(H6L,AI(9Q&[AV"KA))&LLB)')@S5M/3"37W$R(T<E0YR2F
M$2E0IC.:F"+4RPLZH47%B5C9DC9G3HDRO?/+(3J;6Z[F)G:P>%\0]]\[WRQ"
MQMOM;#"^74XX8WO8/&V./M52>W:-9P>Q2ZJG^RCM+[)/8YV6%V\]CUU/M+9<
M[5]5V9VINK_W+L?ZUV-=0_M2PG7OL*U8KL)ZK5UR.@H"9GANFS[R>Y&6W=AJ
M+"LS93:JYJICEPQN?@)"17H,?BD)@P"FO%+5Q4EOQ0HI:&9/L7(N_EQ7*K '
ME_PMJ702BRVVAG.JE'I-WR.GH :!)1Q]N;V!*>HM-=K((K)=>FR,Y(>;5]@>
M9]//D4J961(:*UQ BQ5V!DD8ZVU;3+<](3&K7M28R$@X/$5C50N,A99GSYRV
M:",!7EC*ES!-F@7:O>E2 [+=E45101BLN9V;$Y IA7*% RRR$E8Y 0@FB*SM
MM:#-%AAC1<$R7%,$LP SI<(P"*8)9F@+&BN!P //(8IF:*Y8FBV!G +(P6RQ
M, V$!RL)?WU O1K&<DL9S2NXI89+V;;TD%F:<SRFLK4D+4EMQ54&?&HC)7D<
M%95GHXQ+/)&44<N;<%AD_(R&15B)4-YO,$$=4,3TK5UM/'2U+013K4(B0G7)
MD*,[PQR2*ICDE1ECD9HPP<YLF)"DE1L:2=ZB!9I(6@=GE&J;/F54E>-"PDCB
M8,Z*LA4H,,V +#!B]O'_ !L?]:U7$\OWQ+'\8%^AEZMWV\?\;'_6M5Q/+]\2
MQ_&!?H9>M>WX>'^RJ/\ ?I;;!?Q:;^WI_P##JK?S%=IU_OB6MK_[F)6_\1#U
M&J#8L49RFJ(862%0FAJDNR<PXR3EI0 '-$D@X^G0EMH!4-%"M\31P%/S4NR\
MB1:^)D[<&Q0#+ 4;#/&2NTZ_WQ+6U_\ <Q*W_B(>H/DSAM/-E3Y T9(GR)DN
M=(GB1@8H=)'2@V!DH<)FRV81@J;*F @C!8R7%#'+CAAC B8"X89V^^+E69]&
M;J2GE$,[W)1+#,R"18I6H8Q'(T9(#A'(8H2 P&!Z]OC&]&B32"N>HC,T"7K.
MTT2L4:6):IC)&'&U"Z J&&U2<1MMLNST-Q?+)VRWIXEQY,.,4 V<:C_>NM".
MUB-DI&?9B8D>%&"E-M=AY"D\H[<9'=B\1+GTPBCX#PJ<+GDZ4UP##--4#WU&
MME--1!!''59<T\HC^+$ ;&(C5'+(UWN5="LTYN=K191@\FQ>H,+-<>!73O+!
M5*.%GH*W"([>*BN%<1BRZCBFHX":\-:HK]+2D)JMG[.1B;3-,0H\\I.<UUXN
MSCRN$X3S=#-=F]19..N, !RF\;@W',N<N6<PP^:^6 4@\9EM1$\$^P;EI@D4
M'),P;@9#.SI4LA"N+017TW&OUL407,6^:"@R?(J0F"YYYBER+W<X/5Y=MS66
M>GCN_35$9!?5 JJJF$2Q"KES9F+13SF@I=8BJQ&N6%))0(%"0M#/)6[N:\-#
M9)!(+GK,6=A*L<IIH<N1,)(85JIM6Q921"961,926D$L2TVQQV[*^Z*K289;
M$PM]^-!N-I&3&^*B#FB+L:<S.I/TRK#58DSI"ZTDM/*):B@:B0'(,K1>>>A<
M%,0Q4[-6 <A8XD"VD2V24WK2P[DQKS#IV=))K,I\.@!S([AE&S;<:W'#WER/
M7G'Z.>4XE31P72BN2$GV'V6LE$IL+!$NF*#<7%HL?SR*P\7]8FJQU%T FY=1
M4Q+Q1JH8;:;915?2T=*H: $ILY8!2$TN,/D"7)@*4>,,T!CCA<0#V&MDN")@
M31B)8+\MG6#JG9H)TLU=04KH)51R61#Q5/=QX,L:&<2^[G2OF!2PG70.R5IP
M/]]*:H:Q#Q,G17FZ@1Q<R:^IE3,*7=I['3!5ORZ7J@47&:F9XFC5$4NS+21G
M6LR%^HB1<LSHV=T2<R27AH/+/B;FO&.G^^PAG".&8NSH :AL8P&54S2.P,88
M%59HS-AX;,=(16POKR+J-8V;=9"DC+$AS$]49Z-2*&5':WI_TTRP4/*C?2&8
M\)9-N<5Y:F6:RB@2$V5A),)8P"VI60A2ZZ D88EC9T2]"\>2&]GN_P"&0E^,
M,'HI.>*DIRNE4D&[2C_4&3TT.1\I0@;)"8QYLX20K(-TNPCS*.!9;RR&K$T'
MJTQ8*$L*(>LG5>V5EMN%NZBI@0UMH)H2,VE-*>JH1-(Z0"S$&.PTLOD!GA@,
MGXL1K-AH]AGL#9?) ;J$0$#SP22%R^/5B<9D<)%635^47XN$5](7D!>+++F4
MU3%;1G5) ,PN9-5Q#XY@=1*N"52X$BK.)P8;-1>(6"Z9S$.6ZN^10W?II#)3
M"KON[ZB!)H'JFX,IGJ(E)U\29:2&.)I ,<Z *P=(XHJ4T[RUN-65VB$L<YIK
MHKH)FAE2G J"(H92JZJ5LT\CR*IQ 1\S*4=Y9:G7(M//=L:'X5;;21WC.L@S
MB$2.EM(;04TB!XW;<AN1*EC64QGE,S* P2EE23;JC59,0(S7S4$1+%-OB2I,
M<1MFLK%- 3+'1<TLG9A0JY8ZT[+2U-KY:CSFI>CXH"75[0\1*N8H[IJEZ*W
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M_P!U..U[>W7G)]ON_'F]7KOONMOR=KEX]WBMONJ<>ZWB^U5/<[TXSJWNF7H
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MO:]K7M>U[7MOM>W':]K^*]K^W:]*\HMZ/92E*664I2EEE*4I995P+G[B:_\
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MVK7' QO;4S*UKVR&"QO:_LB&XKVOG:]KV]NU[;[7XK\=07Z\!_#EK_C'!O\
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M"Q\N(A&V\92KV5 %T%4L5R2!$V_9_9_8^!2V8^>&&5')@BJ!LJ03\,CY\\9
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M#23F^*(T;T.1VU(R:AA:-MYG)PJ:EF'"HAJBN( .HGE02Q@R7*)Q$$ ,TH&
M4Y+2$Q*0D)+#)(: DI:*G$2!?75@NDTT3T1J5JBZB2*5A(@CU9+DOJ8AG$N
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M>F-+@"6IR ?N?CM"GE_);9:9=,+A%/(ATKT;S--3L%Z5U>8JD<P9A]U>LI8
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MEP,S U\;X  Y#8YCBWQ!"MF+GAAE:U[:5HI=[RT^1%&9V:LO-550 69F,@
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M,4$\)A5_92EJ48ZF(_TXJ64](Y)EG,&. OFWS=QIGL4S<0Z"HI@+'6@3:PK
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M<6(ALB:'23+J;N6"RUSIHL5&L@.4C>]T!RXHRN;Q$3B9P/+6A*&F'6*[D)1
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M#7'XZ8F<<8HJ$B+T;(#4;6DUIR<@SZC-E.R0GD;27/+QH92+/ P[4UHO=H/
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MN\"WGT]C;-#*06!?'*UG\Q-]\;_^^K5^U?\ YWJX''(T>#'2F04@,//'%&2
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ML"2]0V4LR8Q!A-"#+%A*HA4(5V%;UN2]@TC<7JS!DP"<$0@G-,V!)3&,$21
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MLV5)8CG"N1I0)V=+.N![,B)U!T"L%28\@M1IMUS*C84RK,D!+=P#QT^.::$
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MSC_O;AS6C/WEVCWDJZ=>AMA^A*=Y=H]Y*NG7H;8?H2I,4IP^N^&57E$N[O\
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M^^VE73KOMQV_VFV'Z$K9Y [/:;"B1E-%C-E 9K41$\V71FTUT@BA(*27&55
MV* FI*:"7)$@1#1@P9S#+@AX9#CC"WM?,3*]XMU,:,_WBM[_ .E'_335:N]J
MFHF@C6:>:51*"%DE=P"$8 @,Q&(!(QZ^!/9-N<TDED>D@#R.X%2" SLPQ$4@
M!P).T#9XK7U2E*T%N,LI2E++1^G3QMC\:O\ U)]1C<+90G63(D'"F@JA--<+
M9=9$N.(8#P+N)G+I%RME5PR+# 9W'2%U-(J)<///,L(,7PP- &"^68.>!]K5
MJ-UB0#E _>H:7%+4E[*;R1[.NU['DUXV9]D;%F>QRXW<[%#[7=O;J2S;#MOO
M[*[59=@[NL&JTW<(SMAOP7;BZ$=3'TJNYN6X*ZLNZGJX9[OC20RE!->5)3S+
MDF>,EHI)5D3JD)7$#%<&&PC'T>X*-Y;JI9!/2(&,V"RU<$<@RSR+U2.X9<<,
M1B!B""-A%M]9^,6&J8NC$^VR9G%Z.IGO=TVS'4,;++J8&+2Q9RT8ZV<PN$90
M<6*TK%0BMRY0:R(7[-+&NO'.R?>4CMEIZA(JH1;Y,H=EH<N;D?,N*="!=IXN
MUPF5BI*)+$U8B$JF&F7)H"@JIQ8BHJI!.2\50T<&2T\8OH-X1G;#?@NW%T(Z
MF/I5.$9VPWX+MQ=".ICZ56VXLWIAAPNZ\, ,.G-#A@,F /V?K#(FSO%PZRVW
M/ )?A5#Y?3;OUFX<P[%MXXT!P\81!VV,Q$L1#-'6ZHF$ZYI9L$*>:48APRW#
M&6>*G8>V:5& (;/ QQ&Q#$3\+&3. ZK>ZA>EO333!4BIBJC/:-T9PI:X@I38
M5B1PZO@A'D%#8CAC)*3!<B"P3&P!)L-UN)M!B "@FLB:J.8$,9J(98Z!I,X1
MG;#?@NW%T(ZF/I5.$9VPWX+MQ=".ICZ55PT<O=2"*V[ 1A@1?5%B,,O6/".3
M*O6_HCL"S@$HZU50^7TV[]9N',+;G#.D^ CB&LH)EC&!PG 9<!Y86S#UD$X]
M#RFY4YGI"BKBOX^ZS;TR6"R9'S'(("GDNYFFL5:B*"VLTH,MGB+]N6EV Q%5
MXK0\<)YI1?P;@#= AU;=ITH:$>"DE+3V/)2.:<(J&U%9^+2&DK+]6&>F-]4>
MJJ2P/.4VIC#&LA]*W",[8;\%VXNA'4Q]*IPC.V&_!=N+H1U,?2JKQ=OCX==W
MGNCY2"?Y1V0"=ZX\@M7@,WPNB[/X_3]?L_A+=%(F>8H@@HF5\A!1,Q1,K[K7
MS$$SOF)E>UK6M:^6>5\KVM:UK7OQ6M;BK\5SL\(SMAOP7;BZ$=3'TJG",[8;
M\%VXNA'4Q]*J+BK>/PBZ/.]!Z_VP.[&WI?)\)H/+J;UENB:E<[/",[8;\%VX
MNA'4Q]*IPC.V&_!=N+H1U,?2J<5;Q^$71YWH/7^V!W8NE\GPF@\NIO66Z)J5
MSL\(SMAOP7;BZ$=3'TJG",[8;\%VXNA'4Q]*IQ5O'X1='G>@]?[8'=BZ7R?"
M:#RZF]9;HGQ_;8?X^'^O:KSDG]^CB_CB_P#W<4KFEX1G;#<7_P#"[<7%>U_\
M".ICVK[_ +ZJJ+6TNVQJXJG%8ULN%[ P=SP$%P"A'4UUNV6 (8%NHMD:O?=U
M(6-[VO[>_=Q5&=%+R,J-PBZ,HCD4GIO=_79HB!AK\>LK8\FS>,86NR8U,4@J
M*#(L%0C'A]+L:22F91AK,3B(WV]88;>N+<L^TO,E<-H;K9QS-%<,K:F)2M?'
M,R!CEC>RW??;+'(2U[7MXKVO:U[7XKU;,#Z^-4&F9EJ<>PK,9=J-$^XS3U()
M:@U8R>PC*?IU%NW3<AQ<J/QK.97BF0C"+8)/&>L=GVXOYA%20USG9A(J9!Z0
M%O4-KZ<RPIN%R;#J+G"X%LZ.I+*ZNZ,926%I74C6?5FE%55E)$,J"B?,Y_9F
M#ATP.9'S^R%%SOQU2^[5K@_ 10S_ $()&]7:[E5D>FAIJBFNF=(XX4*R7S=;
MHS1(JALCLPQV$CKX8@8]>VT:!)(UCE-WRH @*R5U&ZDJ  <K,0>L2,1V-]N5
MY^S"\I0+QF7?SK*N;*(&1>.H^.J :-DKHS1S>[MD<5/-+6 .*LOFS+U?3L7C
MBTX#BFM'3*R.$;/C%PP @\L(NM/4&W]0[NU4I<I$\)O?ZB]E!].,\WF&M-YX
MXR00%2WZD.:.%Q"4HX66R[$X7(HM-@ZUA40P%8/+ F$,""*'TD]VK7!^ BAG
M^A!(WJ[3NU:X/P$4,_T()&]7:O.9ER-1W0R9)(RAOBZBN29E>9,I.&25ES2+
MA@[!2P)&-A@C9<K=+BN5T*FMHRN20JTBX$X99&&9UZS$*6!(MS[WVDNK_+*6
M!A)N3A3LSCW'=RJ-'\-B+:+OCVT1]CQ0N9,>ZM!I#"*<<(T 3(<.,A.*L</!
M *%0"]LLLK"F/6QJ*G^.V5%4MRV&ZV.PC"0>24S!!8+=/K2NW6J78K:<,AN)
MK-]$<<J.AL,HJ&TVTYI'57.NH3?S-)Z>?!P/'LS'2+W:M<'X"*&?Z$$C>KM.
M[5K@_ 10S_0@D;U=J-(8XW61+ON1'0J4=+VNA70JJH,C# K@@RK@1@H &RUB
MTE.K*ZQW6KKAE9:NA#+@H496!!&"@J,#L4 =:W(WV83^_"?G9?\ 64[,)_?A
M/SLO^LKKD[M6N#\!%#/]""1O5VG=JUP?@(H9_H02-ZNUE<(J?S5W>?;MW=_X
M_1OM/E/YRB\X4N[O_'Z-]N1OLPG]^$_.R_ZRG9A/[\)^=E_UE=<G=JUP?@(H
M9_H02-ZNT[M6N#\!%#/]""1O5VG"*G\U=WGV[=W?^/T;[,I_.47G"EW=_P"/
MT;[<C?9A/[\)^=E_UE.S"?WZ3\[+_K*ZY.[5K@W;N BAG^@_(N_X_8[7WJ<\
M:X%(Z*<X!B$"?7<0,>QR>AR1@R^'60 P.JPQNW=]LA.M]<$O?]L)EE?VZIPB
MJS :F[L""2W3Z[=A!7 89MN(+''K#  ]>U,'S 9Z(J58ENF5)L(*8+AFQ.8%
MSCUAE /WUN0SLPG]^$_.R_ZRG9A/[\)^=E_UE=<G=JUP?@(H9_H02-ZNT[M6
MN#\!%#/]""1O5VJ\(J?S5W>?;MW=_P"/T;[5RG\Y1><*7=W_ (_1OMR-]F$_
MOPGYV7_64[,)_?A/SLO^LKKD[M6N#\!%#/\ 0@D;U=IW:M<'X"*&?Z$$C>KM
M.$5/YJ[O/MV[N_\ 'Z-]F4_G*+SA2[N_\?HWVY&^S"?WX3\[+_K*=F$_OPGY
MV7_65UR=VK7!^ BAG^A!(WJ[3NU:X/P$4,_T()&]7:<(J?S5W>?;MW=_X_1O
MLRG\Y1><*7=W_C]&^W(WV83^_"?G9?\ 64[+)_?A/SLO^LKKD[M6N#\!%#/]
M""1O5VEYIUOWM?&^PAAB]LK7QRM?0_(M[98WMNOC>UV[NOC>U]U[7XKVXKVO
M3A%3^:N[S[=N[O\ Q^C?9E/YRB\X4N[O_'Z-]HG['?8[F-1AAO:I-4C=,%-/
M1,P$J1K&BH$,4.3P<*#7N NKH-^M&2D-$S(5[6QM<(S)9D+,B1S":(9\^J]I
MQ<N7)ERQ,H7+E"9,L7)DR90 $H3)DR@.!8H3)E"V 18H3*%@@BQ0H6""+%2P
M01<N$&"'AACSLEMHAM?218L2)[+);*$R98N3)E"D%:DRQ0H3* !EB90H6 '#
M *E"A8((L5*@!A@%BX08  880>&&/NX1G;#?@NW%T(ZF/I5<E>=T7S>=09IJ
MFZ%1<5AA%\4!2)"1L'V89G;87<@%B.L%"*,*6DFF;,U30 #[U>'TV"C9CA]D
MZYPQ)Y?%@+=$F?[3+_%R_JO5[OK_ '43/\UFS_W;C7-)?:,;86]KVOLNG%NO
M:]K_ .TCJ8]O_K5516VEVV-6# !@QLN%[#,NGD4["P4(:F;8W!( 6 !ROO-?
MM\L+6OG?Q7OXOMWU1T4O(R(W"+HP59 3TWH-A;)A_'[CS>+'$>[)C/#(*B@R
MI',K'A]+UW,679K,3CD;Q8;Q;H2I7.SPC.V&_!=N+H1U,?2J<(SMAOP7;BZ$
M=3'TJI.*MX_"+H\[T'K_ &P.[&;I?)\)H/+J;UENB:E<[/",[8;\%VXNA'4Q
M]*IPC.V&_!=N+H1U,?2J<5;Q^$71YWH/7^V!W8NE\GPF@\NIO66Z)J5SL\(S
MMAOP7;BZ$=3'TJG",[8;\%VXNA'4Q]*IQ5O'X1='G>@]?[8'=BZ7R?":#RZF
M]9;HFI7.SPC.V&_!=N+H1U,?2J<(SMAOP7;BZ$=3'TJG%6\?A%T>=Z#U_M@=
MV+I?)\)H/+J;UENB:E<[/",[8;\%VXNA'4Q]*IPC.V&_!=N+H1U,?2J<5;Q^
M$71YWH/7^V!W8NE\GPF@\NIO66Z)<O%?\5_ZJOE]?NAL?YDMO]'&KFAOM&-L
M->V[@NW%QVO;_ CJ8^E555;:7[8U7S(9F-EPOX73THBD@];A'4UNR+D,,L L
M\^J-?WW*V5[YWM]C>_B^"-M%+R,D;"HNC!0^/W7N_9F"X?Q_CZW8\6,#W7,T
M\$@J*#+&)@QX?2[,ZJ%V:S$[0>M;H1I7.SPC.V&_!=N+H1U,?2J<(SMAOP7;
MBZ$=3'TJI.*MX_"+H\[T'K_; [L9^E\GPF@\NIO66Z)J5SL\(SMAOP7;BZ$=
M3'TJG",[8;\%VXNA'4Q]*IQ5O'X1='G>@]?[8'=BZ7R?":#RZF]9;HFI7.SP
MC.V&_!=N+H1U,?2J<(SMAOP7;BZ$=3'TJG%6\?A%T>=Z#U_M@=V+I?)\)H/+
MJ;UENB:E<[/",[8;\%VXNA'4Q]*IPC.V&_!=N+H1U,?2J<5;Q^$71YWH/7^V
M!W8NE\GPF@\NIO66Z)J5SL\(SMAOP7;BZ$=3'TJG",[8;\%VXNA'4Q]*IQ5O
M'X1='G>@]?[8'=BZ7R?":#RZF]9;HGQ\=OQV_KJ\77_N:Q?\T\/^\SM<U'",
M[8;\%TXNA'4Q]*_\_;M534-I;MC5$!)+C;+A?QP1TZR:7OA"&IFV68-AQ1[9
M"[S6Z^?5BY<=N+J;6MQ>U8VBEY%HR*BZ,%+$_=>@V8H0/X_LG#9^RT,EV3-)
M PJ* A'<L>'TNP&)U'\9B>J8#9X^M;H2I7.SPC.V&_!=N+H1U,?2J<(SMAOP
M7;BZ$=3'TJK^*MX_"+H\[T'K_; [L9NE\GPF@\NIO66Z)J5SL\(SMAOP7;BZ
M$=3'TJG",[8;\%VXNA'4Q]*IQ5O'X1='G>@]?[8'=BZ7R?":#RZF]9;H>-E2
MQ\H;('0 C1(^4-$#I4?"P@!LD>+BE#A0P'?B$+FBHPI<<._$($)GA?BRO5I*
ML;1^NH2.V%IEMM5;K>2CB&A(9Y+ '3$A&4&@H1\?2T\IE;K98B<8JLJ- P!A
M]B(WU XG7_L0V5:#N$9VPWX+MQ=".ICZ53A&=L-^"[<70CJ8^E54:+WF.M57
M4-N.R^* 8'##'9/U\"1XL1V,:\ E^$T'E]-ZRV]ULPY%#+=C@?;2CMHMMYNJ
MQVSB<R0D!%595LI'"JBJ6&'MED&6Q5U$@145K%.!)8K:D2***Q8\>+ F,/K%
MBJ,AP'04'8#1,%'NAN=LO(H90R9DJZFZ]EI9<CP0E\L/@( J)+H<#C7UE<(F
M@Q %%26E(R/CEF:SK0OPC.V&_!=N+H1U,?2J<(SMAOP7;BZ$=3'TJJ\6;U)Q
M-9=>/4[3?-#CU.&7;K_R>3L8;.3%P"7X30^7TW(,!_&<@V>*V\ AIU@=+>)"
M04Z(F(4>R5FC#);D"1[Y'DTRW6X09[?.D@13 J:64T-JI2:WDA7"(8JR:E$"
MA8H=!L!AE:HKD&P^Y7X1E%>CELJ<C)N#;#)/48$\ OA!LXV=/M,(4R2/E03H
M3;.J2B910CY<V$0%4#UP<+8FS&(FB[A&=L-^"[<70CJ8^E4X1G;#?@NW%T(Z
MF/I55XMWMB#PV[,0N0'IU18A-G48\(QR][UMG6ZV+@$OPJAZV'X_3=;L?A.M
M;>B@07"[50'DU6S%;$06U(=S7LZ0DIODRB6ZPSN)O P56BN%KX&$Z^"@?P 2
M0^LI)'$^>Q3B)2QTUU[Z;PQ$EY*SF2\;,V\KB X YR%=% ]E&=@TG) #'S/;
M^MYJ(2#EDAA+&1>ZR$BWND!J&*=?L:M$O",[8;\%VXNA'4Q]*IPC.V&_!=N+
MH1U,?2J<6KU))X9=F+ ACTZHL6#!00WV?:"%4$'$$*!MP%G )?A5#Y?3>LW#
MFMT34KG9X1G;#?@NW%T(ZF/I5.$9VPWX+MQ=".ICZ55G%6\?A%T>=Z#U_M@=
MV-.E\GPF@\NIO66Z)J5SL\(SMAOP7;BZ$=3'TJG",[8;\%VXNA'4Q]*IQ5O'
MX1='G>@]?[8'=BZ7R?":#RZF]9;HFJ8T9_O%;W_TH_Z::KD4QVC&V%O>UK[+
MMQVMOM:]^XCJ8\6_Q_NKVK5TWZ$W_+$I:388?LY1L8B"5G(@*IMY1P:1G&WS
M#6/@.I?(%20B.[<LW$1N82RA!1L&IY7&SQ.XC![BX@-JT&D%S55VTD,T\M#(
MKU B I:ZFJG#&*1\62"1V5<%(S$ 9L!CB1;FM**5H**!VEII :I5PAJ(9F&,
M4IQ*QNQ"[,,2,,2!CB1:6U*4KD;<+92E*667MO\ M_'>W]51NU62\[8.AU4?
MK&0D=RN<NOM)%349>$4<$X[=P.$DDCAY9)@X!NQGL<P)V%U&?4=E]9L+@('?
M+"^0Y&FB)XBND6D^0VBP[K_9W:7V4K1-'[:=K>Q;G^P>RQ,.R.P['2ES'6]_
M6K& >JW=7C6 GKJ5T5R"FIR0Z)YB@^02W*V':5 #D @3M99:"V3<"(*+D5-A
MY#EP5,@7$,$A;Y%3H..98T&( )GA?F=(+VH4H;SNZ'2&ZKHOAZ2:*GDJ;PHH
M)Z.IFAQ@G:*=V92@=)DSPL&4JV1E(QU];4PB&HITKJ:EJC$RQM)/$CQ2.@*.
M5<D@C,K#%"""#@0;6,TM<!59DM_D5-N!YQ&D*4%H30>2#80R>R.RXI9-@XNN
MX0^IE$TFT45Y];;^:DE@#&"PM[9FBXUKB9%[FOKWA;!88:.,G/8N(_L$PZ3,
MC)J/@$CH+B?BM'S1<*H4R<.*L<376J(YE43PVTG.!036T*57W&11B0W58QP<
MY?0,##SYBZ+)ZAIE#/1BDHZS5EI]F74636^$]UQZBGBY$1QD!Q'&04W4OJ""
ML9';"$U/M-<W@=34@%/RR?D\MGKVW82Z7G)@IJK'C9:C.2S*#,9]M!++:8YG
M \U4=WI[>6DU.=J>CJ.(A\J36RIH#$<T=#SPS*&S!?/@::_M)(U6%]+]"C(5
M2KGJ)KRHIX==67K5S34%(4>GF-/=M E/!&T\$;S0S]3,LZ9X]+'67@,$-YW3
MFP65Y'GBDCSS5,CO!$5:-S'3PB-%+(I=' #B09A>2%K91"32159[LMVG53%+
M<CK?QR/D2RJV8W8J9*SMC1)=;F,*RZ54LRAT9K'S0Y-OEW"K8 )BTIV3 DPI
MAEE3'?K1,-!A/8V"T%1ZR"A :C5,B5:3=-Y-5";L)O)49I)S/?,\Y@U4% .*
MX280.FT',\IGLKJ2H21$Y-*B=C6(HGMFRJ@()4Y,4>W*H9503!2A::5<@4<J
M"I/-0D(=LO8H0<!4L]&R&\%0\M%$%Q!'TXH,:,%P <29@<N+^W:I[.%Z$Q22
MS-3%!P,FI.&/#(<W+#;-*A*7UW-SOQ"5C*"OIXJJV59P9!JH3<4+F$=.,EP>
MP2@(5A Q+GOG2'@TL::9Z%ZY;OIJ>GE-\TH<UA%*M742'@[H.HCE:-VBG)G>
M9D6"*6*.F&JK]6RK>UTEQ!&D;FKC!,IU8ED8ZL@=2&*DHY+LQ41JZK'GS4%.
ML@1DU8W6VLW$SL-WV-"NI[K38D5[-1A8%VZ K)X:NWHQ(J3NR+N)0&S3"JY;
M'%'1,2PIA5%%S%*@#?IHZM&HK,\JN+2=<PJ%F] ZJN",54).QI"')Z?"A'C?
M";+A,#(QA5))3A2S0J[F?2TLZG$?[!<H95BYH@%8;]F;0S(A%K%5G4*R$L\R
M1!<VFXV?,R@R78@V,IV"2H $7.UEM+6,22HFAAE54@*9$)J. 0 AH 08N ('
MCH0]LV;G&R:*S''Z8$UB++($TY*FQ;3TA2QCYW&'RTCKF2BSCP).M627.>5%
M4-7<02BHCF%=3$,F!1#@@EMA57W7QWI55-!I=HE)=\M,D<-+67Y2!HYQ0I$)
M5$<+HJQUP>J=3FDFC9XWJ&22"&[\B2KG6IDD@O.[&@:,*D<M9&"KZE$# *A
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M\IA_?WCGM)K=;X?CO\M-UOA^._RU&7OS]*'*&B3GJC_KZ=^?I0Y0T2<]4?\
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M0!L\+5T<T%;#"Z-'P<%;!J>D5L&BCF4Y6 88Q2Q2=;8CH>L1:@NS1XX 45V
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M%VL-K.3+?3S>HB"VRAY' LSY#+M00XKAK2RG*")'82<(?%.J+;LM/NQ@C@.
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M>#)IB42+)R>4#R6U,7+ L2)A E@,,A1!!,L0@\,;B9YYWM?++*]U*]HZ!O\
C\SWG_P#L,W_'W9;L="O](5/_ *)O\6FMG*E*5]26]+M__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g843870.jpg
<DESCRIPTION>G843870.JPG
<TEXT>
begin 644 g843870.jpg
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M@1<C<9&A"C*QP='P&"0E0C,T0U*2X29B\?_$ !T! 0 " P$! 0$
M   $!0(#!@<!" G_Q  ^$0 " 00" 0,# P,"! 0$!P ! @, !!$2!2$3!B(Q
M%$%1!S)A%2-"<8$D4I'P%A<S0V)RL<$()32"DJ'Q_]H # ,!  (1 Q$ /P#]
M_'''"KZ^_P#[_P#?^.*4XY1OLSS,AI;^WRO5.*AWQ]#934]MH;_12Y'%MLPI
M%AM*^E/!HM/=Z,BJ*;)7V!8-+#1064)=<RYG-",'@]C-^8E5*"QFWZT["HKE
M!'SN3'49W9N=-G8C$_"UEOGA![:$B5RN6$?29O/R/9Z5CY/ZO5K_ $7D_$DW
MTI*OC6,20F<@@,";82&X4$'.6C&!V<#NJH<WQ1F>W^LC\D9(?(D$89>F7S%!
M"64]%1(2#UC.15QB21PQYRRYX1A1H92""")&0P000L=+----*YD<4,4;722R
MR.;''&USWN:UJJE6@O,?ILVQ#C677!YRPLH:P/=6&1LPL=(I1# @;.8^=6V5
M?G3C7LA&TUG3A4'T'Q6D]C!2SCV4L2]D[S6=XA29J2@+Q75AL8<EO37$HK]M
MNF->L\E'HA:PDZMRF0=(P=UE4#VMEH=.Q)*FX7.5/X^NN<2*Q@Y,)$1 L4\1
M,4L!,4T3)8IX"(W0D0SQO:L<D,\+WPS0O:L4D3WQ.8L;E:LZUXJV2,_7%VF<
MC$<$J 0(?N[ZR*\S'O0$I$%UD+2.RP5M]S4_D0<<D;Q)W)++&Y$IR/;& R%4
M ^7()8G*@(H:39=)+'%')++(R..)KGRR/<C&1L8U7/?(]RHUC&M17.>]4:UJ
M*Y51/OS%:+?X74'$5F:V>4T-D)&Z4NOH]'36YPL3'MB?(2)7'$D01LD<V-SY
M(VL:]S6.<CG(G-8%_@I#:"+*V5SK[G(B##B"8V]V.IM\E "$UK0Z]<Z=:S5I
MM>%'%'$&!:PV(HT,<<,,,<,44;,.PV*?'W;TC#054(UO#V."? =7BC R5%#2
M4]S:ZV9Y [('P5I^=%+S9@K%= 9)?AB2PO;(U\6R/@;9HIV:^?>.*:53X%2,
M+%&T@+EIF8A@I#:@>, LIEZ4ZF]23&YMX8^.8I++#"Y:;W@RR*F458BI"[9&
M6&^,>SYK<]QSA/LB(O[(G^?V_OSGG,5UE....*4XXYB5AO\ #55N[/V>RRE=
M?M_#)^1G:*G$N54QJ.#1*L@V,U5+1445/H(I"*BP_-%15R56<D(K,0,D*"Q
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MOI?[+Z1?7^O*JZONW2:N_L,ATJRG=7T-B14;/MJ^$(N,M668S21S\QU[4 F
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M<E<V3+R]WS/,3Q<FMJ]S;VMK>7<UEQR696TM[6-)WO/,TD)KO3?HZXXF\O\
ME^1Y"4W?(<G]<MO975W:V/CBLK3CK59K3S"*XN);>SCGO))8R9KEY%5-%1CG
M8F9R8L1%]=5U1'&.Z"Q.L#!F+%]8)(T&.,C5KH"S!/IP-#*)@(-ADC&8)(R2
M.!K/K%V6$1]9BX6\.HIF2PD&$/K5>2+*UT4R24Y"21S0D1/<V08@K_?0R.C(
M:U7OB7%>QK#Z$>+JWO5E;971DIJM=_NYY*X:*42&1R>V/8DA#R8V_P!2/="U
MZ(OTT5+"4@F97-HKD@^HD">D](JJBM_7W\4^_P"_M?O_ ,OO^4K)I)[B:TM+
MB&T^B@1Y6FCC<RLT:3K&-R56+1P&P/(69R& '?=%E506#,6SC!/M ('^QR#C
M[#('Q76S5+CWU45GD*^I$K+"2*65:NM&KEFE$_W*06$,,,,OXH%BO'_"F(KP
MV.=#"D<<B*_U<9W#8];8&HPU9U5HIM)40&QGW5E:9BMPME<DEDGV6E_-P+>T
MT98][9F$6B"PY1UTCIY(+* &5BSK'/5]I''K=KG@VM6K_+PKSXL^[![%#%KE
M1JM],8A0[D5[6M]N41KE5?@O,H*&9J-W7X/^8@,9 54_S%9Z.Q_ H3/516JU
M\E+CX+1?RTW33.8Z4THZ(X3-UTP5A+4VL]@'!#VWIOE>33PS^GS;V_*<AY^*
M)\5NT?FCN0LK0/=;1QH9;;S*SEET&) [*"-;JI_>"5PKC.<X^V0"">B01C)/
MVJ&>Q>X.[+,*=EIV;8YT:?XOECPP-7C 1Y&?%SHP[@N&XTS84<GQ^4NA265B
M*LC8_DK&X!XZ]I=[V7<F:I\9N]QVA2S:*H!W];HKTS;YNER,Y*_GML=='?7C
MS%K7UR$&TOX:X#(M+. :K2MM(2)1V['\[U%X]Y94^59D+VXED6:6[VUJ!L=!
M.0Y45TD9^E*L) XU5/\ =!540%<,B_3$#'C],Y/H(X HT,%= *,&UB?AX0HH
M816L5/:+#&.UL*-]*GWC3UZ_?G:<9^FOJRXYFQYKE_U#Y/>SN8;F:PX^[O;A
M9!$XD-JTT]S% D$O<<J#CI(FC9T"X8$8-<Q+&R) IV! 9E4?;]V "21U_D#T
M#\UW$_1/?'''/=J@TXXXXI3CCCBE....*5^;/^*WVUI.P_) +H=;%T77/4N4
MQ>HFS1$D455==H;%E]=0:BY21R0GR9#*@4P>,&+C=#57=[>6XZ/N'51%=4+$
MYT>914_WTDZP1RS?6="]_P")61/J2)[:LOX-8E<R-'>R?Q/I'O6-'(EPOXI'
M7]?G/-3#ZQ+JG@KNX>CW3W5?&^6PT-+H^F=')2@W1E-!].5<_LJCL.GSP=BC
MV_A+C)%-D^O!(]H\)X*-RC0L]$2LC^H6P!DWN%3)(88)9(HW.; TJ>(>$9Q"
MHWY1QQ-<Y(V^^>6<\)6YR[$S; "/P_#:Q"*)E4+DE<,SMD8+,QZZ)K]"^DYK
M6+T?QPM5"-(LYN\*RF2Y%U,DCNVH63VQQ*N2P1%7L=5(=-FG(E<))%-**OXI
ML22DI^&$>1].6=D(\S_@C[&2.-96C1M<1)$UTB2*W^F0(LFZOA+6"HH#6&U1
M-9\+D"4E:YI$GR0^J^C+$V$Z-?:>W(B2.8.K9H?I2-GR;,5,MA!(D0]6KSZ\
MJG5MG73&I!',0B1V5;'.T(F$B3UZ8PJ =97(.LCH_P .SZM<[OR"+O=39OZ-
MPH&[I*][JY_8VNTLE3C= > ,^F/CPPU!1W.IT5&%,$\:>]++S^6M+MA5IG8K
MX=J6LFA(U"ESJ " 6(48#8  )[.0,ZC)QD_"G$=[B>6;PQ LZJ2416_P*^]V
MR%126P79@N=1VS@'U+O"L))" 8X8=QEA$'"18/A'%'(M)!1G$GFM@69@J.'A
M<JS.EB'<Z1@<,3C)$E];QM[XC\(N[^Q+VZS1.\Q6\J,GB>P%Q)0MA?4<V!N=
M/89G5Y44QX0>B$'BW.G"U.8_&5]]/%""71?CK6GGH;B)0N^K"RV=;A>U<6/U
M[:Z;W7XZWK-!_,>$U^@00\E^1'(L*JCN\_K"PQ"+2KK[VMG"OA@B:^BOC;)L
ME6OSW%(ZJ;56]QG2R<_:?B)@63RS4X=V+&ST^,2Q'1TP\3%GB)27Z<:NA1)&
M(X65\O"7$O'3QWMN$#H20Y&T;QL-&5PGNT.=3V"A '3 "I;6D7,6LO%<EY#%
M/JIB0^.=9T*2Q21,Y""0:Y *O$PRSG7)&]KMSN#KCO;HK$;;KC8 Z[J;3=F4
ME'KK.O0F$-@XCK>!V:V-;9C!GTOQV0]#4:#/:(( QADX59: ?ACGLD\C;!92
MH&PUAAG)!M1])FXLVZN3Z1[K,BU$@_+1U@2.60,\5Q 5N#\D#)IWFQ'1.#9*
MK*5?P4:?.;KJSR,[$&VF7W&"[&[%JL:SK^(R"Y92&=7U5GF=%>ZW/$SRQT=E
MO2#!H:^NLZD0RVQF0RF@?*:#:5J";B\AU-U9B[B>QRF4I:RZ1KW?B&+,6=70
MDM5DD5<T\HN2D#G8YS'"UK 196.5BQ*URM7VWC[Z>VM((^1LKRPO8@99K"6,
MPG>=$)BO(I])(LC7(:)G:(HC!2,G\U<WQ5LW+W?],Y&TY'CQ+]/;\@A67*6T
MS8ELY8BT3LQV!9'T\B>1&9<"I03[I_JO_+VOK_ISGCCE94VG'''%*<<<<4J#
M/(OM@GISJRZU-/7PW6O/*J\I@Z.=\;![3::DV.IHT/60D3W2U+Y9])I/I$1D
MMS5'</#24ML$,FM3#Y+\M'D:39'W]M8G%76DU%R^.:\U>CLI&26^DNB&11)+
M864C(V,B;'&/5U8U90UT0]14 "P6/\V?Q5AO^@*E3S&559!VOM":N.96 FW
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M[I++)+#,IPQ2:)V8'8'4R "0#W*X;#59A;:X)CD@C4=':)$1D&1CQL%&IQ@
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MABG,%L0R*ZQ':6/&0V"PKRF1E!&PMD2(L,J-A I#)()F-EB<U.]\4]>OO_\
MR=[_ .?OW_UYD;RQ *-Q$.P<[-]3=*PP"I4!7"@ X/N5NP?R:Q%K>;;KR<NA
M0!4-O PR3G8EE+'()& 5^W?54)9Y<]H6!5B)3>.^DDL:T, DBIN"-+7"0MLL
MOGM?&PS5BX>RK6W0->9=U1V8K0;6P!OQZVMOR,^26D+NCMO*GO*7J[5:WKCH
M*T9JZ?MW.X"FS&CB-O+8^@.M3!+J[N,]4E9XK/F@ ALL6M*N):C\NLZX\2PM
MGO:!/L$])_G_ )K_ .O'K_C^OO\ 5?\ U_3_ !^G,5O+)3&1Q<)*/&QWN+E@
MX4J71EW"Z2%2/@LJ,PV9L,,FM;ME=?ZC*NZNH9((%*[9T=3J2'0'L@ZLP!U4
M94T B\S-TZHL[;_8%>21 3:]E?$MGH1K'3IDL]#;0UU31+A"[NKTNO6:.ZR=
M+J Z4<W&M,L9+5M[7%T"=>N\RNQ+FX;3 ]&QLGJS<(W4*+J[O1/K*_4)BRYR
M8G4F$?5>[JNVP:X%)KI9[(VMLX=:!D!X)"8=@_Q3_/\ _)W_ *\_AL4;'2/8
MQK72N:^5S4].D>UC(VOD5/2O>D<<<:.>KG?38QGOX-:U'U=AV?Z7'G[?\7<X
M!V7&1M@C0,",#+D,,!2A?37O7_YB^,]@VT'8P>L_(.VI!R?:"N,ML*=8+R![
MJ[*'?-F>C* 6$.LKCB[/5=@ZS.U-A/:66@$C$S,LO3Y)UI^414:0:"8\&HD"
MN2)0!AC H!K4]RY")Z_O_JJK_P"*KQS2US;%B4X^!5STK2W3D#KY;S+D_/PH
M'8P,#O:MO. -[R5F^[".!0?CX7QMCH?DGH$DX[J7LNWNSKCL.\Q/5M;G ZK&
M315^BT.C .NBK:_(K +1:^@K@[2H'!KZ6 \>&RM+"<R<^RDE" !$@ E/*_.M
M_%E\5>@\]XB=K>3>5Z[P?B[Y8>-.KRF@K^PNAHBNK*[MD+N7=OSMF"6+0%C6
MS-%8LL;Z1[YSR+>KL0#EK=#)G- =7,_1KK>NNQ\ON[[:=;B5FC V14!MM1FV
MD5(?2VL-5" 08"4<T@*RKK- 1I9!7O +KC)298G'"SMA%[>9Z J]1G-R%WMG
MLCN1^SA:(/28.TKA]+D1Z>A+DMJZI.CM!D#ORV7,RVI![JT4>(L<!@,2_@6F
MD=OZ1]5?^#^5XKF;2:1;>UNN,GOK.QNF@N>4MXKB+^I\?>QL7BF@NK1[ZW*W
M43V^LW]M0"N>0]0<#-ZEM.1XRZB4R30\A%:W%U;H]M8/)"_]/O;.50LZ7$-R
MEK,S02+*&C??I1FC,N(Q6 _A[^*1/673])TK@G5/4O9FQQF3I"1JW"S:'J>R
MMK"PT<K8R;2=\&KM:X72:[2D%6LLKXS]-9JJE%1Q%E=W!=6(U#CWNWNE,&4J
MJS.(G#T5Y91-^+62LB#+<'7!.D?''+=WIM50 I(V6PM1845_-U/9.L_V?=<[
MO<1US+3^2L7J=5'5.(4*.P7-4%A<MKW$QC%N%87^!059V"$K V7ZC1YO@D3]
M=G6_\13&V=P$!8=.F9&"SH>GEMWTA@Q=D)V=L[[49GMC%?E4U%GY;X;IF_I0
M:\RZK)3+#6O-L9J>BBCJV_C(MKRM[?Q<A=#C9;UGO;BY>1^0W?>\G\H2=IU>
MZNW!D >82B69%V<HP>2E_P +91W5A')R2VGCLH+<0QV016CM4*EXC$5M[9"
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M<V]RGA<JQ?VEDE#1G&<?W%!"DBLCY6RRC)."VX"@)(3L,Y! 7[$:M^&PA]Q
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M^T1?[I[Y 6*Z0EI=&'JMGKIMQ:TJN?FH%IH:.II2I@I 2;1 T/MB3[9\!!<
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MIT@TLHWX^0I@\T\3&3RS'Z3_ -_O_P ?[_Z\<L+F_-S&R>%(VE=99W5F/D=
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MZVN5!C<V1E:,0Z*""OK?K-:3*%7C"P%%M846T@B.*2.3N..?999)G,DKM(Y
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M31PDR,;%(1'5 0 M(DC8YS(WSI!]5\;'*QCGJUJJU$7E :/S0V70UK6]?_Q
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M.^[E;&QK5<OW<J>U^Z\F<@MNHB\2VZR;2["VD\B&(:>)G(>15<DR# <MJ 7
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M=B1Y#N1TJ$-&XU(P18/G"I[14_3W^Z?JG]E3_*+]T7]EYSSA51/[_P"B*O\
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M^ZU&PGKGKK!]1X;*=9=89#.X'K[#45=F<=C,E4!T.;S6?J(&BUU12U%?# &
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MI&Q*Q(Y)E^?S;'=VD=G=BSNS.['LLS$EF)^Y)))_FI"JJ*J(H5$4*J@8"JH
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MO[IA,&HU=129^>[L0J_(U&=N[+/AU -2$7$")9K'5M)OK)B2GGW$Q,CRHQX
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M5EY@@D0%EY3:&2H*EG"/-1((;BH.HQ911B2! ; (VRA()B)C D98U5])[_\
M?^G^?[<_ Y_VCW_M"VVZ[[[SG@_X>6VCS59TAVEB=GY*]I@):9T_>Z+KO4T^
MJ@Z6P-K'8U\A?7X1M:HG:-HHR0[*[$;C:\B7* 7[]1*CO+A)HYFD:9HU9 )F
M>13&ZLCQG+9",K,"%92,Y4A@"(LEE;20R0>)8TE97;Q*L;>1&5TD&%QNKHK
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MWC9W$^G@[HZ6R52!$?1M/ASG;73M/-#DL'W/BH;*4HT4 L8:NR?8.6.L#[G
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M<R%VSL*"[FSNXU9]Q-0=0=8V< :SF :'7B@V1>RV%9+*)"?UQUR#>7]7-/\
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M>UV$J.KZW$Y:MZYS]'4YF@PU=15P&4H<]0BP!45+240@\-=45E&(**/3!UT
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M9 U]:RBM4%NP[K^,O?EAW!5:?+;FI SG<G5Y=76=BT])%:KDK82_&*.Q_8>
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M,T:"*![+KN;K !:><J;\TV?6>#K66&B7P^ZO$O(1UP.BJX$QNXS[Q[/(=C9
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MGB9(D7P?&Y49(C_C\58YCD1S7(OV^+FH[W]O7O[<I92PE=^>8'4H^9F23/\
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M3UKJZV"P;, ?84=UX[LN):D^!@EI7PNK"I% M24;1"X_LG;)4-$Q'1/MDC)
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MKR]_&@2)(KEH$10JJ!;XA.JC"@%D9CC&22Q[[J<(K%OP3^KU_=?U_P _^?\
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M4V7MO/QUT1EIJ9NIXK6BZC\EL=7P$:2DS=)U7Y'4E789S1]F,KI?U,9N(Y&
M7VO$7Q\;E"I8_905*YS@;9/1)'.Q\==OQ=Y90O)(WEM[V.WR3N($G2X6%!D-
M*1,DI11LZP' +*JUL?H 6JC?;47[??[(OOU[]K]T_=47[_IZ1$YCW=7=N0Z!
MR]5;7=7<Z[5ZJPFH^O.M,HZL_F_=70HS3K*.N?<& 5%-09NM>ESLME>F#466
MJ%BD(>9;6-'27&8YD@<D48D6<<H4L<<L4H6>$H0L,J)A0I8A8[Y1BQ#!9(B@
MRAI91BQIX2!Y98)62.H;VY+->^:.BAT(,3!,=TYU%3X<B98Y5DH=E:[W3[(P
M-'(KQ4L=?2!U5FC%13%QE.LZO:&*D>R*'ZR\2%W*HQ=F*XV*1H9"JYR-F"ZJ
M2&UR&(;&M0IKL<7Q,MY'%'),AMXHDDR(_-=7$%LC2X97,4;S"21$96=5**Z$
MAU]4KR4\N3#([FKZF\=0,TC%<_)6NG[=M-%.Q?FYJ/["KJ2KIQ"$16->H_65
M@(KFOD8KV*UG)JZ-\E,SWJ5J,;8Y>WZO[?PPHMIK>KM&>!<D?RS9'3U=+V#B
MM34Q15.VZ[O[00VL$N(!ZK045N-)1;7*Y>WF!%/ENLH\NN9^2H/]1!T]-^+?
MU^/]_7O[_;_KZ_3FMK>S1YCS'\-;3,GR W%UW9KNN+,8/W_]?Z]V/2?9MUN*
M8]K?M)5A$X7*;16R(Z,:VR-06Q630M<LN6TM3#,\$;PR6Z[Y,DC+(JE=@=V;
M5L'*E-06P""#UJ,O)V5QQT?(7=MR$'*'QCQP002VTC1N\;(8$4/'LNDBS*[J
MA\BR*4*O>3L_KW']@YXW([S-UNJRY[D<33V<#9&PD,=\AK6G+1J&4&CK2&L,
MHM-2S WU#91#6=2>*:-#*VQ?@UV7H-CU1>=?[S7&;GLSQ]WEUTOM]9;H/'?:
MR&IKZC4]=;6^B'1C'W>TZFU>&O[XZ**(:PT9-X5!'"CW011;?N1S57]_:*J?
MV57?^7_ESCPZ%&KO(_RF@%8Z/\^Z_P#&+8V"(KUCFN?H]TX&0MR*Y6-FDS^#
MS0;O@U/E'71.>KG)[2KOD#VJ2D89&4 __"PQC^06P1^/M\FNC])7,D',7-D&
M8V]Q \FF?:LT11E<#['QF1&Q^[V[9U7&R3CCCE-7IE....*4XXXXI3CCCBE.
M...*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXX
MI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3G\O]^D]?_OC_ .7S;[_Z<_KA
M4145%3VB_947]%3^R\4K1IXSPR!]0@518TP5Q1]@]]4>E"*A>.6+JJOR%[6@
MTK"AY&LEBEFME(.:LC&+,,8,2UOTIXG.GYDCXU]L<K?^"_9?^*?HO)C[5\-+
M*\WVG[0Z4[>L^H=%MWP'[7'7.1JNR>G-5IA@AJ[^>",2389?1YG;6597U=7H
M+S#[O.BZ46KKB]%36UP(VRDKPSQF_B#O+:+)V)X4#5_U48Z\AZN\ABK+Z'M$
M6=F<F[C'KT(^/M4A?H'P(Y$]O5JJB7L/(6XB17V5D14(U+ Z@+D%<]'&>P/O
MG\GRWDO2'+/?7,UL()H9[B69&\RQLBRR-(%=9-3E-M3H7!QD'\9,1;-#&)*,
M+"!##&)--//(@! KP0X7D&6%@<5+"(!7 #1REGG%RPB!BQ3$E3101/D;0GQ4
M+N]9O23XJ^2'!UM1Y(]KY2SE:C7V-9YF>7>B[2Z_(;&O^]&9HNHNJ<QV2 '.
MUA$>;[$R]C/'&RZ&^5X.Q?$')X?![GN7S [@VGD%@^M<??ZVTZ,HL]G.J>C=
M4S/B+;C WO7%0=97_:%K9%",I:C,=F=G:;#69=D,+8Y,N98B(\4Z+RFCH\Z7
M>;Y7+VAV1H#NRNSV*2A@]/KM(."R/!TTS41D>2ZFS%=G.I\6'%[@%S.)KEB<
M]Y$TTOU9UNIE:-"([<,Y<@ EV4HH"C/0!9N^R5'0^^NYXV7@>.FCNYT>\Y8Q
MVR01%G2*WBECGGD9V"EV+)%$ JZKN2&?)UL!4UB*UOMOI$3]?2_9/[)]_NJI
MZ]^OO]_MS.A*E%9_W4:UK5557TB(C4]JJO<J,8U&HJN<YR-:U/D]6M153J5$
M#52-OV7W[5?T]>T_;[?V7[_O[5/2_9.5Q_B Z>WQ?B+V//2&I5RZV\ZCZHM[
M=%DCDJLEW+W%@^K=L;!/$^-PI+\CK+JN%+1[4$)L8IT^2QL18TLC/(J@]O($
M&>A[F502?G&3G_3_ $K[:6L<<)=A[8XR[:C8E44.<#K)P"0/R,9%1'K?,FPO
MSYP/&SJD7N&M!M3:LGLC9[EW6G6%M^6D2AG%]?&5.4WVL[#JF&Q/&#U(6>HL
M;<MCG*SFBO@61%R^?G_+8ZN+ J_(GJN'IR.VN1Z>OW^8VR=C=3"D6$T8E5_.
M=]9YG!:GKF XY[ 6WV@RI6*$+(!AM==6*9&Y)(Z R.4BIP08 *ZOKPAA@0 !
M8!AA*VO"'@$"KQ!(8V0B!5PD, 0@L#&1"BCQ#0LCCBC:GW\@</C+&CL*BPKJ
MZUJ;@4FIM*HJ" H*VK;.*0*QK3198Y(B1#PIY@BAI6/BFAE?&]JHY4Y>BPME
MD^E3S>90!YV;5#)TH/C\>/&6'[=MPN"';!+<PU]R<G%?U\KQYX\ZR-QW?U"V
MS . +CR__JA&02S1B RX_M!.A*%J$L$CG?%S5:OI_P!E:Y%1RHBK^BM>UR>E
M]+[:Y/?M%]+S(/#^P(R';G<G53+ A^3U=31=]Y"A<@\8N9T&DO[_ "O;P50D
M,<<\=3HM55T'8A(LCY88=9MM;..V <Z.!M3/#'6W>[\3^I;S2'OMK( ;=X=E
MU*Y[YKJEZN[0W76.8MRIY'2/*--R^-IGG&N>KCSFE'+_ %$*JRQU1W#B>M>Q
M.Z^W]C!?S 9L3$^-_6]'GJB2_P!;VIV2-%?]L]A9OK?-@N<=H#*=FCR=!=&/
M?7TM!89/8&::RIZ/-65P+57A#V>" 7$B*@'9+Y&0OQDZ[8P#_IUUT_IE)+;G
MCHVEN+:Y>Z9B%00*@(9SG50)C"<D]9/>,UM,(Q..+/2U*RF;(LT>DB6,]#43
M'I(B_)'H9(&XE'HOW1R2HY%^Z+[Y WEKU'H>U>IHVX*OJ++LWK;8Y'MKK&NO
M;%:>HMM=A+%279D^X:(<M(+M<P9I,.^[_"$14;=&EK,*2,'*-+!9'?WE'LKJ
M.7-9CIWJ#'.#D:D6WGT?</9<I,DKE'E*J,3=83K>C^F.K$G&$W^X2,AK_@7/
M"Y%3OLF\CK14<3Y&1U[W/>][,[T5A0H6L<OML4?\Q:373)]-/:(^265RI_4[
MVOOE2()HRK:Z,"&7)7((*D$K\C'1P1]OCJNZEYKB9TD@,_U$<B/%((XY71D=
M2CJ'"A2K D91B,=YP,U7/']F9/8EE40LYV<V]3),+H>K=P*F6[4RQ@TT@\XM
M[B+&5EL\?ZD3GUVEI8K;':8!PUYE=#=49P5A/U>VNY>K>B,N3L>X-[F^O* =
M/C!+I+%@EG<F/14%I\OG(_JZ38:*RE1HE/F\K47%]<'20A5M>23*R-9#[9\3
MIO(-*EO=/=G8&R@HG2R4C8.N/&"EL:%2?IH7_+VJ*Z$T>VS3S&PQ-+ESFGJ9
MYFQL225R-:UO1ZO\ O$_IC7A=E8SIC-&=KUHZ# ]O;F2Q[&[3 9]-8Y%IMGM
M"K@_,.F:KDE;D(L[!_4YD<$<;OII:+R+8 >--_NP<Z_;L+J?YZW_  ,UP<WI
MVR$I>"\NGMS[A$ULBR@=>PSF;7XS_<%NW\Q_>J887!]N^6&M?VUW#E]+T]XY
M#TEI2=0]%:6-U-VIV;F];6R Z??=Z4S6-L^K0=W1DIF?]D'Y@NO?@'&4&SGS
MHNQV^>O;R-#C B@"@@@%%#''##%%@B%$%"$A8.&(&*.R(<0,0:.(80,>*(<0
M>*(<>*.&.-C9RL@/?R^2*JK\E1R_=SE^ZJKG+[57>_NKO?\ 4JJY57VO(VM@
M'?/XQL<^1SD;%&Q%5[I'.^*1L:B?=9'*B,:B?U.5/7I5YOMI06;/;.068XV)
MQT/_ )5'07X7[9))-7RD3ZQ*HU@MU*0PJ?9&&(+L 3[GD;+2RMEW8=D*J*M5
MNWNR\C@NQO'U^V)-#R>5V&V\BMT>$.I+Z[#^.?7UM90I]%)8?Q%EI.UM]U-D
M<K5(_P#$Z'47(%+6LGL"(1I;9^/.7V%-UQ3S=D UU9V1K;C9=E]BT]20\RJH
MMSVGM+_L/19NN)DCBD*%RQ.C;EF%NCC_ !;J5Y3(VMF:G-9G3]H[RA\M^PMI
M77(UUT5TX3D\<$QE4\FDUMYUSHK7058===S*ZOM C^\!3.SM#"*V=B ='^/Y
M,GTX-(CY=RE%+]22&)JHLDTL<<:O<OITDSTC:KU^ZHBR/3Y.^ZHGM5^_ZP[D
MEY9)?D?^E&?R$_<<8[RX8 Y(QV,@]=#9:6UA9<<V!)L;Z[!_QFN54PQG/[6C
MM3%Y%/P[D=,IK,!P$5K6M;[547XM1%555/U1$^ZK_P"7I>13VKU1DNS:8.IT
MXQ\)5#=":C)Z6@LR,_ML'L*V H:LV.&U 2+89K3 #&G!--@282PJ3[.AOJ^Y
MSMI:5!M"8=;VUY7:V]N:WL;;8'I\&[OZ+KS$]<:2TQ,NEH:BVFJH=YV+HZ"4
M/4W5YHYP#3ZC.5]_78V@RYE1!-4VNCDL;=OU&U':WC#O<LS1]AZO?]+Z[4YS
M&:^D[-TEAK;/KA^HLH\YG]S@M7<MGTD (VIMJ0/:Y/2WEQ1$9H@FYSC:&[I5
MAN\EXJ\$7G9HB3&)FMRS&<0E0^[#0QC*,'T+A]2/;M@5K_K=EY52&.]2-;GZ
M-.2$02S^M201"".?RB4MYL0JZP^,RC4.5]U1DZ\[:\%KJ.+6T8NZ\9S[(81^
MDPM35YX7%6=LMJ=9:./#LG$J.JC])I"8OYAPT%XWH337ATMST\=TEIK>+I'4
MS7W#@A?(JEQ_>_CQJ\X?V)DJRSS0$%U8VM+D]]EB366MOU;OO5:1?]?;+-7W
M_P!:S%G<9I^@P.C(N:+6YF3/:B\@%MQJX1C@["MLA!C SA#:VSKCQH# C0CH
M9 K"ML02HYA#@C!I9A#P2XIA#!I)128)H)9(W5&\;?'$&Y["\@<+B=3;]4:'
MJ^SZFU/6V^R+X;4JTZXW^2OX .GNZLQHG'TG;V4Z[O\ &WE1UU8:9(>Q<7U9
M-C,=C^P,Z#GAI9L5:6U$5RCL!&X"X[:,D=?NSNA]RLC?8ZG96P,_!:\])<<=
M-'%]3/ [R*0RVUZBLF^XC :WNE)619X< NOD CG42M$G\W>2]<,ZCF\:^\9;
M1J.B;'6"];6U%,YJMC62':C=EQ9)PBJY',+,LZ_W$UTL@T'Q=&W.>@N@M[6=
M@$=_]_.H0]V'1W>7ZMZRH+(;4U75%#HYX/YHU5SLHA X-)VMO*L&LH+EM&/)
MD<+F 2<UEK;23:+2Z$^Q6A,\A.J80H>V>FK3:!R&1@2]D>-H%MV)G?C+(5^'
MM;_JH][>X,8*HL#);*&B'[= K")$C31$PR,<V/QO(CIV_N5S(7:V#'U/MC79
M&^TU;D=K&]ZN:UDF'V,M!L(I'.:]B)+2-<KF2,;[<QZ-LOKI;Y/&7MT1BOD6
M%?&TA&#A]F+8! .H"J?G4X&.;EX(\'-YI+;D998D=+>:[E:YAMU=0CBVDC41
M M&2A=S)+H63=0\@:4[4I)Y51%]HBJYR_LB_?TGK_"+[7_*_XY[OA!%:WG;O
MEUN)!5ASH.GZBZ3H"W+Z2U*ZNP!>PV),"?)?J05FR[DM\U).B(W\PH3Q51)!
M)$2OW87:E1B@P@::(;=]F:I\E;U=U-GS@;/8=E:E_P!.,.MJJ04M;!<W73D0
M6F^UKHXZ'#XP>XT][8""@L2?9+XQ]-%="])XKKBWT"Z_6@CV=]V#M'#Q#/V?
M96RN;#7=A:E(8AQEA$N-==6T]2)*QTE?2-K*U7N0-J\@\E(J1) I&6.S ?95
M^,C.068Y&?G!_C/2^BK&66\N.3D0B)(F@B9@0'FD92Q0GY$<:E6(^#*H!^14
M]\<<<I:]*IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4
MIQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G''
M'%*<<<<4IQQQQ2J=^?,?KQ3[,LY@YC:G+F]<;C5Q0H]?IX3 ]KX7:[\N=&?=
M0@,507UA8-5KV/KQ"F/8YCG(L%594,Q#IX2("X"'M*@,'F9.,:.3ZF@,&(B<
M^(D4R"6,L4B)[X2!YHIX7R1R,<[9F2,.8/.*5#$0,3%) 0//&R:&>"9CHY89
MH96OCEBEC<Z.6*1CHY&.<Q[7,<J+K$V_B9V/T2\B\\71H][U:.C7KXNZ"Y"I
MK/+-)LR2[)?'_LS0EL!H:N&(I$I^E^Q"4Z[KHQ_RS$:[K*L4>M;865RD(>*3
MI9""''>I'6& [U(^XR0?M@DCD?5'"7/)&VN[,AYK165K=FU,L;,&S$20@D4@
MY5L;J1A@RA7F2HG:B1N14^R+[_;U\O?Z_I^J^O?^J_V3GV[*Z]RO<_6.ZZHV
MT)$V6["R]IEKAP,D4-H#%8P>A+JD)FBFC"T&>LX@=#GK!8G_ ("]JZXYK54?
MTL&]7=NY'L."W;0%V MSEK"2FVF+U-/99+L#"7$<LD'Y7M\/?0"7^<(G?$]]
M4:2+)1:8+Z=OD[J_I9QK*:=1+9$1%1Z+^G[^E_?[?Y^_K]?O]OWYG-$2<@Y'
M3*RG;(Z(P1UWT?\ 3XKG;2Y,!TE5HY$(5XY%*LK# *LK+T?L01WD_GK40+:^
M2_C*81C>X^LNQ]V)4-@@J_(+I[K_ $78'779@:(K6Z&US77XFCV746O)9&A.
MJQ.FS[\[7VDI<V0U^AH)!'#_ "M+?R2\E28\;U9UYV/UI27(TL=WY!]NX2YP
MN3P +Y&1DG9#&;J&@W':F_8-)++E:*MSH.)&M&C6>NV@=6)-6V6X>2Y<G];'
MK&]$5$>URM<GOW^CF_U)^R_]Y$_S^_,7LK5'?-ZO^<CD]/D<Y7.=^OI/DO\
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M*H;>.6LT!.(R%--#F*"RBEJ[?=:+)PW$4]-%9#3QYHY))5CC7:21@J '[L0
M,G &21V>AG.1\UOL)H8;<S2N$B@B::9SDA(XHS)*YQDD*BL2!EL#H$X%7RN=
M?B,>X2/9;/&Y"0Y&N!BUNLSF6E-:Y/Z'AQ7]G72%L?[3X/'9*QRK_2Y>9 K@
MS!!S@2!C@3(OKA'A$0& F0>_7U@C19)13(45?BLH\LL:.]HKO:>N:<>J/#+
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M]VC>9EQROKL*C#%=)=-=;6!5MUUU+UG@;0T=PAMEBL%E,J>8*Y[97#%&T50
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M#<G57Y)<]H]AZ W==G7-3^)C-DJ2=19,ABJ*.8R 8LC-Y&LS&9)+$#,)IIS
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#2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g526457.jpg
<DESCRIPTION>G526457.JPG
<TEXT>
begin 644 g526457.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@ ^1$E32S$P-#I;,3A:04$Q+C$X6D%!
M-#$Y,#$N3U544%5473$Q,3E?,5]$3U-%7U-%3$5?2U]/4D<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@!X0*/ 0$1 /_$ !X  0 " @(# 0
M           ("08' @4!! H#_\0 <Q    4$ 0$ !@X/$ T)" ,! P0%!@<
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ME5-3ARMMJ"YEV!8RWK=-SDB+5!S:_MK8_8AK*T2&6A&'?%H;86VDX!F IO\
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ME%UY#5D4=4;:R?;KA3@55/,$!3Z"X$H4!40UDG@8R,I:PFC@GTP\&7/$Q0S
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MJJJG2B:F)I0R?4%$^9!)D2!$F#F8-G3ILQF&7*E"A<(0P:,CB!@%P Q!AA,
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MW3U15<,!4[8"+38&38R> AH%U$<B91#P'52X@BB<O>Q9+40A$%?[>@J0I5P
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M3:OTI2E*4I2E*4I2E*K1_3?/W.'^M55EO6W_ .[7M_IKS2]^GAKQ:]K^*_\
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M5RBFQQ)PK9?#?7<6M8GBM72-\P=RN:,SR^)%CAN3NP&T]8^=LCH03=?#V9"
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MW'O*>KH;4*(L'J4^\ET#8L9O"#)">EQ6H;D;+1]DU444N)<RF%";3,9):<*
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MJO(LFW5%%&9SL'+(L@9(8%C13R*Y#[#-N5);2OD+D&A+R@G+8I8X$GYDS%<
M7%4JMM\AY(+]C*1(=(OYYN9F1IL%$XK^!B<M*+KA"1I"6X_#:KA8C;)O6[XB
M]XYM Z50$(DWTF2,"X@APNW%=*?6K(5XT$,L5:<193C%@SPA-Z1&E["Q_'K?
M/YDUK7$>'(.(90LM)N:PE&VR-,;SU<BJ7C+A'3NT!IAB1VJ223P;G'<5NC)<
M6<F,N3(+;*<91U]H+DA1D?V*E5KHJ*V\'G!<9ZV0RUI.B*4T]6<0;E6#$U;
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M$Z1. YES9(X3,8"%S1,V7$$ -%1PA #  F8(P>8>>6-ZJ3^O<Y\?YTX\]&T
M]+^J_DP95>_'J96R2>K1X5-"YCK3CT)>#I/%45DBXBB"JAC4Q^+25"2\+VT&
M('1!:GF.DNR=>NVRT.;3Q_C(T,.S!PI!5846JZ$5135-L/J.GTAY8!N2.92C
M]QE$QXQK(S8'$P!<+'>:,CN%,N( 8$)9D#9(X9WQ2E*57MN9\T3Q;>W??/\
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M('07>R7FBD7"V'&D&;XYB$%='4@1R9P"PH81@&X@5Q2IL$ X4$ -EP!PZSK
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MJD$<<$YILM&L7:L?MEIM%/3$$G)>E+VM>U[7MUM?P7M?Q7MZEZ@3L5I5F\I
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MQ.DR.\5^2I/DE[NR0",.:[QJX' _I;D1>R.N(XFMMKII@WF DIQI<S26"R"
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M#1TV!4 P7779OQ;XS]. (#>>NT40)#D&L)_*<3*;K)QG%+(1@7"8AQW-MTM
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MOB%M'L!K[&J'ID=F(=.@8_%B,><+Y-ST"QL#[@49$BF3!1RI%NA9%21).Q3
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M;9(\GIAQ?-(K97%)1 1BBBK)9 RIB%\28!Q2(EA1L1C8& DFZ@7RF^AI[_\
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M-:"G$OS+(3S7]B=L9!1@$63-F9(()I=U'D(,WW3PC>+6LFV$;D%P6DJF7DI
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MH7<:9)]4YU-:FVZXG8CRA?9ED/"09Z?.M;V2G2V(L()4%2Y'TB,..5MLR6_
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MS9L#MI6*M4X+9\FE&OGF:&%LG.*;MGDUUFI0' )B %Q%ENPC"9,4T#D."AV
MO; 3W>]+W3]E.GOW-6CW_ .G>E[I^RG3W[FK1[_@'6@=FN*B6=QX@78%V3Y"
MIGE"*'(JM5;5VJJZXZ6$L!E5E.9+=S=.%U%,@LHI$A"JRD%<37D0T%BI)(ZF
MAG[#I2J?*C[Y U#W,*@ EBO*1.Q8L7"# +EB^LVC@0!< +#$,$  +" [8!
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MM%KVE=G'%!\-^7'2W3R4KEUAL#(4#W:^,N'U)YI61QHH&+&R>3>Q6@5Y;33
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M@+#;15%^084(KB^O.0WB,]V">+1PYD=G2X=1'XU%PHP!DI0%-%9'0?R5Z6;
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M6_AP# QMGV7]U\_Q</X55/[KY_BX?PJJ?W7S_%P_A54_NOG^+A_"JI_=?/\
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M7EF:)-@5^@C/F-&HHPZU&NW6@9),U,<83D;2 ]2<<Y)X,-PGTB/$VN;/@/\
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MDP&*Y'2 D(Z"N9")F"LM#IH!!/53">M72AQ,38*(J#8!E<J_C6X>Y&7+3IC
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M636K%$I;R-5\/1/D1)TWV5BZ?IL)20G#%&@FPN^Y\>T**[+B87%R+379*9*
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M1U,VM1Q)"PM.)]L1NCJSS/YQPT72X'"L+ZPWHSNSTLRN'.['D;%1+E3 &8[
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H*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g499308.jpg
<DESCRIPTION>G499308.JPG
<TEXT>
begin 644 g499308.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@!!1$E32S$P-#I;,3A:04$Q+C$X6D%!
M-#$Y,#$N3U544%5473$Q,3E?,5]35$]#2U]015)&7S1#7TQ)3D4N15!3_]L
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MB6!L\]4W866GVFI*.I"NO.TGK^%3LT3%J6"M.E?^)"6Z$*^K%A:_^-@Y60:
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MEH!D26&:)94(<Y/?GX<'-P, JH R3L0G=G?*1I054V5=Q[>N(B&\_=8 "(B
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MDRV3TE+&JQFK$QBD9&LUD+)M#TX!PX< X?)\6J@[,[L[<%G9F8@!068DGA5
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MV365#O+\<ER6Z9[NZNP3!Y8H(C&$T[ZJH8U$"L&>LTQ+,'F=!&B7OKK^D/\
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MJ;<=P6/;[LKIF)GEUH#',%D8U2KSF)]RT1/Y&EJC<C8^7:1S^,M>+Y><GZI
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M./1V%J@%V^Z3Q^+?;/:2G@=TIXR#H90NC9%)NWVUY<0;HD*DB@C*X/2123(
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MUQ-^2!7J[4.4 E$P&Z-24VZ#<%DD12P+M8MA8Y<.+2\9PD&^.X $Q P Z3@
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MJE U2-C+2#>&CFS55PRR/DN#3D7Q4RC(RZL7"7%A%-7<L][,_=D9M$$NSKF
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M,.!(Z#R7E.'8%#ZF<==FS?\ U%,1UD48Q2@8QC 4"@)C"(@ %* "(F,/>*4
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M0*0O H 'R  !\7#AK7E@8.83=?F?;TOP9TO+":F?<0HB/86C=X]4[3R'6X]
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MG1\!Y@M!DELO5S,66%.7RW$3);@Z55ZBH(CQ,FG7JU&-A*CRN\';Q>(  "4
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MSN.;_P#$237,(;56K1JR03:LVZ#5LB0$TF[9%-!NF0.@")H(E(D0H!T !2
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ML^1;F*5=5HE*/6JCA)$QBD542*<A#F*4Q@,/#79%%+.XCACDFD;GMCB1I'/
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MY@5?U9KI-^QKM'QA7W-HO>-,+5N%; (=LOZ-5P4=+ '**TCV:44H\DGJ@?\
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ML='*0I\F[>:;674@T*5/LJOPDQO*1;:;B)-%(>R/F!V\4+40X=A.!BF'5O\
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MA\M>EL$_@7GN)Y\\^YYE3\7_ (FIRL/66ZH C@IK)DU*@'N]DUL515\.P!4
M@'@<<+Q@SGCW.S%[[&JT?@:OQ<?D;W^B'#><M^0;4Y1)# X4&;;"=\\F&?9%
MVPD(CQBS+<2\"N4ORA'&/$?N>F?*5E7&EQFG^,AAZI?:E9)4&-S=N'HQT+-L
MY!X#1 ]>;D6<]KH*=@2,NB513DE%4@#R@W!]S?M]ZD<4>8%7]6:=S?M]ZD<4
M>8%7]6:JFU^ WPXVF[I;U=5)J;-#Y,P5=&U;5Z\R4;!L0S25*]4)),SD+-*6
M[Y8TC1C]Q2+WH_Z3_P 7=)TWL>F&WJ;RGM/M%;-SJ5;>\VHBV55*<\$.PN76
MEBKI$C-7@4>G#+++(J\R-S8"NV@B!2N6PF,;@ %62$3&,/0 !RNDPB(  =\1
MZ-:Y(Y9#==NW<3SA9%S@W:9(JQD#RE$CQEUSD[(7WQDB&,8$GK*E(I%30,0Z
MQ$WK5DY1,*,JL77DWAU?#>+,=Q]9QW@_%+O,N89E+'.*XY"@5@SM*8F (VD;
M*4@10B5O5V+D'@N1$"-I!>-5.8J93F+[]AB39WM=Q74JSE2'Q7*3D-"MTI&7
MLM9A+%<[?-J@9>3D&S \:\L,@FZD%%B1Z?8#(LF -&HK$20Y6OHBD1I]3/MG
M(2[LQ/K=3R>&AK%?3VNQ4^ZGTW^S:S^S//>="LE0'/E:\#N-O!J5'?1UC5]E
MMN/*S6@PEU6N;_FX=/M.RGNJ04D<&.V><^.W&?TMM^O2_CUZ6P6^JU2)<SME
ML<)!0[,O+<R<K)LV+)$. \ ,NX63()S" @1,HF44-^2F0QA -:X J:^9![#@
MW:#B/'53<@)$\HYHQS6FKA=NH'$'E>HB$6NZ=&X$/VLX?=NLCB8@K$;"(B%;
MQGL(Q!4G8SUX1)DNRK."O5@D(J/K].;.R\.!H^DP9$(L$DP#D)IR2D@D0H!V
M)!#B8HUCO+#]&O/^IN57Z>1R.6\<GP.#Q[Y9^T#\1 _4/)__ $/WGD?EGLI'
M=I)7IX\@=M>-YG*KYL<6[FZS)AJ&,XE40 P*.9>5%H^DNQ@!^+1LFP57X%%H
MLN!B@/XT]N5VRFJ20W+9C=62/.<BP8NQR[4J6/&X%-RRMY%=(Z4S82EX\D5'
M/:JH& >#E0H@(7HVW+;^<1$^$\4F$3&./&@U<?RSCQ.;A[V<.4<>DQN^8>D1
M'7\]S?M]ZD<4>8%7]6:=G=Y=BW^GV0?]/U_ZBV.[C\([?U^[?QX''[@#^O.X
MTRF8^QW$IP5'@JW5HI,"@+2&;LV15C$ 0*J[53_X[Y?@80%P]5<+FXCQ4'7;
M^W&?TIM^O2_CU'^YOV^]2.*/,"K^K-.YOV^]2.*/,"K^K-=@ '@#@?D,QRP=
MNL_I;;]>E_'IVZS^EMOUZ7\>H_W-^WWJ1Q1Y@5?U9IW-^WWJ1Q1Y@5?U9IC+
M!VZS^EMOUZ7\>G;K/Z6V_7I?QZC_ '-^WWJ1Q1Y@5?U9IW-^WWJ1Q1Y@5?U9
MIC.<^8T@\WX?OV+Y!VT(-L@'3.,=&71XQ\\W$CZO213?EF*+&:;,7!A3 #F2
M*JF40 XZF6S#+KG*&!JTI:5R-[[0G#W&.0F;E0J;E"UTDY8I==<JJ@J&4E(]
M-A*'5X<@Z[EP4HCV,W"F=S?M]ZD<4>8%7]6:P4<X@Q1B'>VWK%CQE0I#%FY>
MH"O3&<I48-U$5/*5(2XRL/"I/&2K:+;V.).#TS)@1 CF1>M"E3 $.&K%K?[P
MU.SU)\S5@V\UP^I>K&$VE=/_ %M</G&]R3JXT'E\KFS_ +OV^LVX\06BNCV1
M]@$M2]^JL/\ ^AL&--?H!M)&/X1FTOMUG]+;?KTOX].W6?TMM^O2_CU'^YPV
M^#_[D<4>8%7]5Z=S?M]ZD<4>8%7]6:KN6/+!VZS^EMOUZ7\>G;K/Z6V_7I?Q
MZC_<W[?>I'%'F!5_5FG<W[?>I'%'F!5_5FF,L';K/Z6V_7I?QZ=NL_I;;]>E
M_'J/]S?M]ZD<4>8%7]6:=S?M]ZD<4>8%7]6:8RP=NL_I;;]>E_'IVZS^EMOU
MZ7\>H_W-^WWJ1Q1Y@5?U9IW-^WWJ1Q1Y@5?U9IC+!VZS^EMOUZ7\>G;K/Z6V
M_7I?QZC_ '-^WWJ1Q1Y@5?U9IW-^WWJ0Q1Y@5?U7IC+ +QH/0#IMQ'H#@NF(
M\1Z    W$1$>\ =(CWM?+/OPEEK'NKR[)EG6]IC&,U#5^,DX]4SR+C$H^MQ9
M1JZ+HO+:(O(B0]\TWS%!7C[XB_7$@K'<<G9MG*N8URQD%WM8VR8IQ7'7!$"F
MS+E]G0*V>+Q!7.S%2>Q48\;Q@&<7V0'BS009N6[B-4%5HBY0?DD7<%FC0=GV
MW6ATZ!J"6**-92PC1-)6=M]4KU@L,R^ QE7$M,R3^.54=/G*ZBJG .2W:(G*
MQ9)(,D4D2^B=,;4=".-S;KBUL-E4]&KJC(*\L.OFDAG^T;,YBF:OZYAC6E7$
M1DL0L]ES% :S6/.^I]4>NU^QZ=DU-?K+AFM;81FQ'+L(HY8?L^K )H5L?+B9
MVN6#*(Z\RI6C$LPL"O$?<S2S+':C5_A!*MG#1U9[DYJK<9-!T:+K0RW8$8XZ
M153^]XIRR$PZ)&' AV:+M(ID4>6"9<_^W6?TMM^O2_CUJ7>XBQ1MAW/)0UUQ
MO1IO;[N/?II4V5LE7@I1IBK+"?*Y=53?2#%<T75[.1431C7EH,VRBK4B?!"&
M>K#L(#;AM\'_ -R&*/,"K^K-5_JH&?;3[>/M:EO7EVE*1$[%[+$C&:LZ@L%L
MTK'J5;*]QYDC]9>8IHV:?Z480ZF#42=R7=$D6KNQ2-W-WUXE$-F,D*6JW8/3
MLU3P.V-_1;B6&15L';K/Z6V_7I?QZ=NL_I;;]>E_'J/]S?M]ZD<4>8%7]6:=
MS?M]ZD<4>8%7]6:K>67+!VZS^EMOUZ7\>G;K/Z6V_7I?QZC_ '-^WWJ1Q1Y@
M5?U9IW-^WWJ1Q1Y@5?U9IC+!VZS^EMOUZ7\>G;K/Z6V_7I?QZC_<W[?>I'%'
MF!5_5FG<W[?>I'%'F!5_5FF,L:;A!41*DNBH8 XB5-0AQ .]Q$"F$>'$0#CW
MNG7FU/:GB7%M#D5I>DXZI%1E7#,\>XDJW5X:%?+L%%D7"C-5U',VZZC4Z[9N
ML= QQ2,J@DH)1,F00H6F,::::8QK6CO"_.G#_P" 8G]Y;AK9=K6CO"_.G#_X
M!B?WEN&F,R3V8?V4=OG^5%/_ -K2UDWK&39A_91V^?Y44_\ VM+62";]DLZ<
ML4G3=5ZR3;K.VB:R:CEJD[[-VHHX;D,*R";KM=?M8ZI"%<=@6[")^Q*<EC/U
MZ:_.J\:HH@X6<()(&432!914A$Q455*@DF!S& O9%%SD13)QY9UCE2*45#%*
M/(N6X+D:BLD#E1(ZZ;<5"@L=%(Z::BI$A$#F23452(HH!1(0ZB9#F*90@&8S
MSZ:\!W+=-9%NHND1PX!0R")E"%56*B!3+&23$P'4!$IR&5$A3 D4Y#*"4#%$
M>4G+=<RY$5DE3ME>P."IJ$.9!8$R*BBL4HB*2H)*I*"FH!3]C434Y/(4(8S&
M>;375'][I,6\7CY*WU>/?M3 1RR?6&&:.VYQ3*J!5VSAZDNB84CD4 JB91%,
MY3@'), C[:(G86P-CO(*7C)EHFL9NHYBI!G)-TW!"$4,@==DLND18I%4SF2,
M<%"D4(82@4Y1'72U5DD,,=F!Y5+!HDEC:0%. X**Q8%">&!'W3X/&;,E*Y%$
ML\M2S' P0K,\$JQ,)!RA$C*$(<>4(/#?3G/:Z::XXA\H?;K8S6SG37 " ]X0
M'^X0'_MIQ#Z_L'\-,9SIK@! >]Q_U*8/^X!KUSJ8BF)0.]DX]F0R@I%,Z>M6
MY3*@ B*9166( G  $1('Y0  B(= ZQ9T0<NZJ/S9@![\<^2/')'G,E1W/"*S
MG\E4L?X '/9::Z(]RCC6- PR.0:/'@1;M<POK;7FH%7#E<4#=FDB<E8 (H/8
MQX'#D'XE#DFX:;1]T\SNLO+ QQMBU9!C)+LV@G-;P.]1(]603634&;(D8 ;$
M2<&4*/8C@<13$"\.-4WO6NET%C7U+ V%ZULXME-4K:;7V=O.T>JKI:N%XJ22
MO&5A<>BC 269 8*ZR3%8VN_37P\ZAZHJ;2_4;5:VCIYM/7O7.H=M1T-9)M]:
M>EK5CFV4L"2B2=#Z\B$Q4X3\S;>&L'E7>;KI=XR)2,;0RD_>K-$UF*)R@(XD
MW14E':A0 W:\>T("CV3=F 0$C2/;NG)N/$J0ATZU$73W2'*LE7J=5J;0&T;D
MRUQB!5CP[%U:7TA++*G2,G0ZORWJYF7**4K63GC2!W!BN%$8H4$>SZ[7B?8Y
ME?,,LVR1NTMT^W(Y BZ% ;SRLA;';8PBH1I:+0DJHWK;$X"7LE<J/(6(F<4E
M)*+6(HVU8I7V9UM78U-/<9+U>.Q3.Q U,3I*BLI=K@6Q(L;,([(H5;\U:3E9
M81P>*M7AU7VI;UM_>T(3K[,U:XVM)W<W=!(R.*\= M6#2A&DIOLKNLJ7(QS#
M;)(!]AE;W1>;L4JI1=N%+EYN>=F,V;2KB#<SUB<&-^25:&I<>5R#,@B F2?6
M54P%(/*7A" 41";4?:/N^S)8DKSERSQ]$.Y*0S:3O!6^0[Y%MU#F5,,)5S++
M5>O.!X\$2/%&?O<(%%"+15#E:V_4/&./<7Q187'M.KU0C>! 40@HQLQ.Z,0.
M!5G[I,G;DBX$.D[E^X<KG'B8ZAC"(Z[V  '0 < ^0-5";IK>[N0OU%U):JTF
M''V#TL\FHK]IXY2YOO\ W_;<#E3-KI]!%(I*O3()[KS!U?TST[$(^E>D*-[8
MKP?ZS=;Q0[VT) /$NOZ7//2U",G[XK[>MU5/"X#Q;$$*%PWH.QO"-5E$;3<F
M<UF>]E*D96W9;DU+8N19, '_ ,GP;D K\<W(8 %L@1@N9J4B9$EOR>.LP6[9
MNT01;-D$6[=NF1%N@@DFBB@DF4")IHHIE(FDF0H 4A$R%*4H    !KSZ:L.F
MZ>T?3T#U])JJ6MCE;OG-6!$FLR?6:W8(-BY.WN\]J669SR7=B2<JW4'574G5
M5B.UU%N]CMY8$]*LMVS))7I0#CBM0J<BK0JIP!'5I0P5XP L<2J  TTTU,Y7
M\::::8QIIIIC/Y,0IRF*<H&*8!*8I@ 0,4P<#%$!Z! P= @/0(= ]&L&LC;+
MV+:R.\I[9K<ZV^Y:5,+AZ,"D*F-[HH4PJBRN=)(4\:=%RJ!>R/(]IR4SF.Z5
MBWKKD*DSGTUOT-G=UDC24YS&)%[)X65):UF+GDPVJLJO7LQ$^?3FC=0>& #
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M&^"\]KPKN%FJ'F5-Q 2M=;N$@2L+^/,=J"5B;H0QI \>\8$(JB(I2#]DR;$
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MZ6_L+HU$FGZ0U%;51VB==53HO7UM9JI_E)8Y(I)#62[)* L7=<V$U@L0JQ'
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MTYIL7=7%"\S:UZKUVN G8BT0D18X"0;RL'.QK*7B))H83MG\;(MTW3)V@80
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M*' 1Z!^OAQ^0>G3&01/=+MX6(15',-$624+RDU49M)9)0H]XR:J93)J%'@/
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M;9ZV:31'34P$*RD&[Y-(_)7;(I. *L&S7B'RA]H:_,X:,G8HF=-FKDS=3LJ
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MA$&Y';E)N@X<E22*X71:F7.V267 H*JI-S.G)D$U#F(B9PN*92BLH)F,_0
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=O#D UFO?* AG!U#% W)+R@*( /)+Q[P<&FF,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753439936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 01, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Corvus Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001626971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,065,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753834720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 45,106<span></span>
</td>
<td class="nump">$ 5,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">44,949<span></span>
</td>
<td class="nump">129,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">91,234<span></span>
</td>
<td class="nump">136,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">3,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">869<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">94,775<span></span>
</td>
<td class="nump">140,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,454<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">5,515<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,969<span></span>
</td>
<td class="nump">5,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">971<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,940<span></span>
</td>
<td class="nump">7,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.0001 par value; 10,000,000 shares authorized at December 31, 2017 and December 31, 2016 ; 0 shares issued and outstanding at December 31, 2017 and December 31, 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2017 and December 31, 2016; 21,041,250 and 20,922,428 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">208,408<span></span>
</td>
<td class="nump">200,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(123,534)<span></span>
</td>
<td class="num">(67,871)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">84,835<span></span>
</td>
<td class="nump">132,801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 94,775<span></span>
</td>
<td class="nump">$ 140,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of accrued liabilities and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753508928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">21,041,250<span></span>
</td>
<td class="nump">20,922,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">21,041,250<span></span>
</td>
<td class="nump">20,922,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753373008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 46,305<span></span>
</td>
<td class="nump">$ 29,356<span></span>
</td>
<td class="nump">$ 11,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,219<span></span>
</td>
<td class="nump">7,620<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">56,524<span></span>
</td>
<td class="nump">36,976<span></span>
</td>
<td class="nump">13,770<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(56,524)<span></span>
</td>
<td class="num">(36,976)<span></span>
</td>
<td class="num">(13,770)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ChangeInFairValueOfConvertiblePreferredStockLiability', window );">Change in fair value of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_InterestIncomeAndOtherExpenseNet', window );">Interest income and other expense, net</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,663)<span></span>
</td>
<td class="num">$ (36,375)<span></span>
</td>
<td class="num">$ (31,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (83.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">20,488,506<span></span>
</td>
<td class="nump">15,422,041<span></span>
</td>
<td class="nump">373,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (55,665)<span></span>
</td>
<td class="num">$ (36,369)<span></span>
</td>
<td class="num">$ (31,380)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ChangeInFairValueOfConvertiblePreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognized in earnings for the change in fair value of the obligation to issue convertible preferred stock at fixed terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ChangeInFairValueOfConvertiblePreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_InterestIncomeAndOtherExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income and other expense netted together.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_InterestIncomeAndOtherExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762255504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>IPO </div>
<div>Common Stock.</div>
</th>
<th class="th">
<div>IPO </div>
<div>Additional Paid-In Capital</div>
</th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Series A convertible preferred stock</div></th>
<th class="th"><div>Series B convertible preferred stock</div></th>
<th class="th"><div>Series A and Series B convertible preferred stock</div></th>
<th class="th"><div>Common Stock.</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,395,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,046,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_IncreaseDecreaseInSharesOutstandingRollForward', window );"><strong>Increase (Decrease) in Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock to founders, net of repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,525,961<span></span>
</td>
<td class="nump">5,353,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,274,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,730<span></span>
</td>
<td class="nump">$ 74,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ReclassificationsOfConvertiblePreferredStockLiability', window );">Reclassification of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (161)<span></span>
</td>
<td class="num">$ (159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase', window );">Issuance of common stock for cash upon early exercise of stock options and lapse of restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,335)<span></span>
</td>
<td class="num">(31,335)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(31,496)<span></span>
</td>
<td class="num">(31,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_IncreaseDecreaseInSharesOutstandingRollForward', window );"><strong>Increase (Decrease) in Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of common stock issued with the conversion of the preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,274,741)<span></span>
</td>
<td class="nump">14,274,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">5,202,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock on exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,922,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (125,780)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">125,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,624<span></span>
</td>
<td class="nump">$ 70,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued on exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Vesting of restricted stocks issued upon early exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,375)<span></span>
</td>
<td class="num">(36,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">200,709<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(67,871)<span></span>
</td>
<td class="nump">132,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_IncreaseDecreaseInSharesOutstandingRollForward', window );"><strong>Increase (Decrease) in Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock on exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,041,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in conjunction with the sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued on exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Vesting of restricted stocks issued upon early exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,663)<span></span>
</td>
<td class="num">(55,663)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 208,408<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (123,534)<span></span>
</td>
<td class="nump">$ 84,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_IncreaseDecreaseInSharesOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_IncreaseDecreaseInSharesOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the liability related to shares subject to repurchase that is reclassified to equity upon the lapse of the repurchase provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ReclassificationFromLiabilityToEquityOnReleaseOfSharesSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ReclassificationsOfConvertiblePreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability to sell convertible preferred stock at fixed terms that was reclassified into temporary equity upon issuance of the stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ReclassificationsOfConvertiblePreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities and unrealized holding gain (loss) related to transfers of securities into the available-for-sale classification and out of the held-to-maturity classification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crvs_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crvs_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crvs_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crvs_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crvs_SeriesAndSeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crvs_SeriesAndSeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6745600496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (55,663)<span></span>
</td>
<td class="num">$ (36,375)<span></span>
</td>
<td class="num">$ (31,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_AmortizationAccretionRelatedToMarketableSecurities', window );">Amortization (accretion) related to marketable securities</a></td>
<td class="num">(195)<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,229<span></span>
</td>
<td class="nump">3,828<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ChangeInFairValueOfConvertiblePreferredStockLiability', window );">Change in fair value of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="num">(1,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">2,814<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(434)<span></span>
</td>
<td class="nump">695<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46,212)<span></span>
</td>
<td class="num">(27,857)<span></span>
</td>
<td class="num">(11,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(88,309)<span></span>
</td>
<td class="num">(258,281)<span></span>
</td>
<td class="num">(104,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Sales of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">173,401<span></span>
</td>
<td class="nump">213,725<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(266)<span></span>
</td>
<td class="num">(2,199)<span></span>
</td>
<td class="num">(1,747)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">84,826<span></span>
</td>
<td class="num">(42,556)<span></span>
</td>
<td class="num">(92,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">711<span></span>
</td>
<td class="nump">71,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">71,358<span></span>
</td>
<td class="nump">94,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">40,056<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="num">(8,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">5,050<span></span>
</td>
<td class="nump">4,105<span></span>
</td>
<td class="nump">12,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">$ 45,106<span></span>
</td>
<td class="nump">5,050<span></span>
</td>
<td class="nump">4,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment incurred but not paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_DeferredOfferingCostsIncurredButNotYetPaid', window );">Deferred offering costs incurred but not paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AmortizationAccretionRelatedToMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amortization/accretion related to marketable securities for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AmortizationAccretionRelatedToMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ChangeInFairValueOfConvertiblePreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognized in earnings for the change in fair value of the obligation to issue convertible preferred stock at fixed terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ChangeInFairValueOfConvertiblePreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_DeferredOfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow towards the offering costs that have been incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_DeferredOfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749869472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">1. Organization</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corvus Pharmaceuticals,&nbsp;Inc. ("Corvus" or the "Company") was incorporated in Delaware on January&nbsp;27, 2014 and commenced operations in November 2014. Corvus is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The Company's operations are located in Burlingame, California. The Company has four insignificant subsidiaries.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904213456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">2. Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Basis of Presentation</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S.&nbsp;GAAP"). The Company's functional and reporting currency is the U.S. dollar. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. Since its inception, the Company has incurred significant losses and negative cash flows from operations. As of December&nbsp;31, 2017, the Company had an accumulated deficit of $123.5&nbsp;million and cash, cash equivalents and marketable securities of $90.1&nbsp;million. The Company has financed its operations primarily with the proceeds from the sale of stock. The Company will need to raise additional capital to meet its business objectives. The Company believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its planned expenditures and meet its obligations through at least the next twelve months from the issuance of these financial statements.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Use of Estimates</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of the Company's consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Initial Public Offering</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;22, 2016, the Company's registration statement on Form&nbsp;S-1 (File No.&nbsp;333-208850) relating to its initial public offering ("IPO") of its common stock was declared effective by the Securities and Exchange Commission ("SEC") and the shares of its common stock began trading on the Nasdaq Global Market on March&nbsp;23, 2016. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on March&nbsp;29, 2016, pursuant to which the Company sold 4,700,000 shares of its common stock. On April&nbsp;26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial offering price of $15.00 per share. The Company received aggregate net proceeds of approximately $70.6&nbsp;million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stocks.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Concentrations of Credit Risk and Other Risks and Uncertainties</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Substantially all of the Company's cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company's marketable securities consist of investments in U.S. Treasury securities, U.S. government agency securities and corporate debt obligations, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company's product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Segments</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Cash, Cash Equivalents and Marketable Securities</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments with remaining maturities, at the date of purchase, greater than three months, but less than one year are considered short-term. The Company determines the appropriate classification of marketable securities at the time of purchase and evaluates such designation as of each balance sheet date. To date, all marketable securities have been classified as available-for-sale and are carried at fair value with unrealized gains and losses, if any, included as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Interest and realized gains and losses are included in interest income. Realized gains and losses are recognized based on the specific identification method.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Fair Value Measurements</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company's financial instruments, including cash equivalents, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Deferred Offering Costs</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred offering costs consist primarily of direct incremental costs related to the Company's initial public offering of its common stock. Upon completion of the initial public offering in March 2016, these amounts were offset against the proceeds of the offering.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Property and Equipment, Net</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Laboratory equipment</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">5&nbsp;years</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Computer equiipment and purchased software</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">3&nbsp;years</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Shorter of asset's useful life or remaining term of lease</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Impairment of Long-Lived Assets</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives. Should impairment exist, the impairment loss to be recognized is measured by the amount by which the carrying amount of the asset exceeds the projected discounted future net cash flows arising from the asset. All long-lived assets are maintained in the United States of America.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Consolidation</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Research and Development Expenses</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records research and development expenses as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery and development of the Company's product candidates and include:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense;&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, academic and non-profit institutions and consultants;&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use;&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">license fees; and&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Clinical Trial Accruals</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors' progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion, or the services completed. The Company's estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Stock-Based Compensation</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains incentive plans under which incentive stock options and nonqualified stock options may be granted to employees and non-employee service providers.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for stock-based employee compensation arrangements in accordance with the provisions of ASC 718, "Compensation&#x2014;Stock Compensation." For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values. The value of the award is recognized as an expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. Forfeitures are accounted for when they occur.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model. The expense for options granted to non-employees is periodically re-measured as the underlying options vest. The awards generally vest over the time period the Company expects to receive service from the non-employee.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Income Taxes</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for income taxes under the asset and liability method. The Company estimates actual current tax exposure together with assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and liabilities, which are included in the Company's balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company's statements of operations and comprehensive loss become deductible expenses, under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of the Company's deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income and a valuation allowance is recorded when it is more likely than not that the deferred tax asset will not be recovered. The Company applies judgment in the determination of the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be utilized in the future. Accordingly, the Company recorded a full valuation allowance for all periods presented. The Company intends to maintain a valuation allowance until sufficient evidence exists to support its reversal.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes benefits of uncertain tax positions if it is more likely than not such positions will be sustained upon examination based solely on their technical merits as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company recognizes any material interest and penalties related to unrecognized tax benefits in income tax expense. The Company is required to file income tax returns in the U.S. federal jurisdiction. The Company currently is not under examination by the Internal Revenue Service or other jurisdictions for any tax years.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;22, 2017, the 2017 Tax Cuts and Jobs Act (the "Tax Act") was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January&nbsp;1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No.&nbsp;118, </font><font style="display:inline;font-family:Times;font-style:italic;font-size:10pt;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</font><font style="display:inline;font-family:Times;font-size:10pt;"> (SAB&nbsp;118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. We consider the accounting of the transition tax and deferred tax re-measurements to be complete&#x2014;however, since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12&nbsp;months, we are not yet able to reasonably estimate the effect of Global Intangible Low Taxed Income ("GILTI") and have not yet made a policy decision regarding whether to record deferred taxes on GILTI. We expect to complete our analysis within the measurement period in accordance with SAB&nbsp;118. See Note&nbsp;12 in these notes to the consolidated financial statements for additional information.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Comprehensive Loss</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's only element of other comprehensive loss in any period presented was unrealized gains and losses on available for sale marketable securities.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Net Loss per Share</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&nbsp;2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No.&nbsp;2014-09 will replace most existing revenue recognition guidance in U.S.&nbsp;GAAP when it becomes effective. The new standard is effective January&nbsp;1, 2018 for public companies. Early application is permitted as of January&nbsp;1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. In March 2016, the FASB issued ASU No.&nbsp;2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU No.&nbsp;2014-09. In April 2016, the FASB issued ASU No.&nbsp;2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No.&nbsp;2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January&nbsp;1, 2018. The Company does not believe adopting this guidance will have a material impact on its consolidated financial statements as the Company is not yet generating revenues.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2016, the FASB issued ASU No.&nbsp;2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard requires lessees to record right of use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. The standard is effective for the Company beginning January&nbsp;1, 2019, with early application permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently assessing the impact of this guidance on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2017, the FASB issued ASU No 2017-09, Compensation&#x2014;Stock Compensation (Topic&nbsp;718)&#x2014;Scope of Modification Accounting, to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new standard, modification is required only if the fair value, the vesting conditions, or the classification of an award as equity or liability changes as a result of the change in terms or conditions. ASU 2017-09 will be effective for the Company beginning January&nbsp;1, 2018 and will be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749867120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">3. Net Loss per Share</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the calculation of net loss per share (in thousands, except share and per share data):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss&#x2014;basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55,663
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,375
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,335
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Weighted average common shares outstanding</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,958,557
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,188,980
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,269,315
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Less: weighted average common shares subject to repurchase</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(470,051
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(766,939
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(895,672
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Weighted average common shares outstanding used to compute basic and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,488,506
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,422,041
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373,643
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.72
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.36
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(83.86
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Convertible preferrd stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,274,741
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Common stock subject to repurchase</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>319,203
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>611,698
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>924,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Outstanding options</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,013,394
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,350,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>784,136
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total shares of common stock equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,332,597
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,962,280
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,983,412
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6902521968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">4. Fair Value Measurements</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Level&nbsp;1&#x2014;Quoted prices in active markets for identical assets or liabilities&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Level&nbsp;2&#x2014;Inputs other than quoted prices included within Level&nbsp;1 that are observable for the asset or liability, either directly or indirectly&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Level&nbsp;3&#x2014;Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have been no transfers of assets and liabilities between levels of hierarchy.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's Level&nbsp;2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables present information as of December&nbsp;31, 2017 and 2016 about the Company's assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td rowspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value Measured Using</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td rowspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total<br />Balance</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,555
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,555
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,949
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,949
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,504
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,504
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td rowspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value Measured Using</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td rowspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total<br />Balance</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,999
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,999
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,846
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,846
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,845
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,845
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, marketable securities had a maximum remaining maturity of nine months.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017 and 2016, the fair value of available for sale marketable securities by type of security were as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortized<br />Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross<br />Unrealized<br />Gains</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross<br />Unrealized<br />Losses</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Government agency securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,311
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,272
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Corporate debt obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,679
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,677
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,990
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(41
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,949
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortized<br />Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross<br />Unrealized<br />Gains</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross<br />Unrealized<br />Losses</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">U.S. Treasury securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,885
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,846
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749872800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsDisclosureAbstract', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">5. License and Collaboration Agreements</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Scripps Licensing Agreement</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2014, the Company entered into a license agreement with The Scripps Research Institute ("Scripps"), pursuant to which it was granted a non-exclusive, world-wide license for all fields of use under Scripps' rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma. Scripps also granted the Company the right to grant sublicenses in conjunction with other proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon execution of the agreement, the Company made a one-time cash payment to Scripps of $10,000 in 2015 and is also obligated to pay a minimum annual fee to Scripps of $25,000. The one-time cash payment was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The first minimum annual fee payment is due on the first anniversary of effective date of the agreement and will be due on each subsequent anniversary of the effective date for the term of the agreement. The Company is also required to make performance-based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $2.6&nbsp;million. The Company is also required to pay royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a rate in the low-single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date, no milestone payments have been made.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company's license agreement with Scripps is terminable by the consent of the parties, at will by the Company upon providing 90&nbsp;days written notice to Scripps, or by Scripps for certain material breaches, or if the Company undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product-by-product basis, or the entire agreement, if the Company fails to meet specified diligence obligations related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Vernalis Licensing Agreement</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2015, the Company entered into a license agreement with Vernalis (R&amp;D) Limited ("Vernalis"), which was subsequently amended as of November&nbsp;5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including CPI-444. Pursuant to this agreement, the Company made a one-time cash payment to Vernalis in the amount of $1.0&nbsp;million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon achievement of certain sales milestones. In February 2017, the Company made a milestone payment of $3.0&nbsp;million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent CPI-444 in the Company's Phase&nbsp;1/1b clinical trial. The aggregate potential milestone payments exceed $200&nbsp;million for all indications.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing CPI-444 on a product-by-product and country-by-country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing CPI-444 range from the mid-single digits up to the low-double digits on a country-by-country net sales basis. The royalties on other licensed products that do not include CPI-444 also increase with the amount of net sales on a product-by-product and country-by-country basis and range from the low-single digits up to the mid-single digits on a country-by-country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company's payment obligations to Vernalis in respect of a particular product and country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing 90&nbsp;days written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Genentech Collaboration Agreement</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2015, the Company entered into a clinical trial collaboration agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of CPI-444 combined with Genentech's investigational cancer immunotherapy, Tecentriq, a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1("PD-L1"), in a variety of solid tumors in a Phase&nbsp;1/1b clinical trial. Pursuant to this agreement, the Company will be responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of representatives of the Company and representatives of Genentech. Genentech will supply Tecentriq. As part of the agreement, the Company granted Genentech certain rights of first negotiation to participate in future clinical trials that the Company may conduct evaluating the administration of CPI-444 in combination with an anti-PD-1 or anti-PD-L1 antibody. If the Company and Genentech do not reach agreement on the terms of any such participation by Genentech within a specified time period, the Company retains the right to collaborate with third parties in such activities. The Company also granted Genentech certain rights of first negotiation should it decide to license development and commercialization rights to CPI-444. Should the Company and Genentech not reach agreement on the terms of such a license within a specified time period, it retains the right to enter into a license with another third party.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued. Further, the agreement will expire after a set period of time following the provision by the Company of the final clinical study report to Genentech.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2017, the Company signed a second clinical trial collaboration agreement with Genentech. Under the new agreement, CPI-444 administered in combination with Tecentriq will be evaluated in a Phase&nbsp;1b/2 randomized, controlled clinical study as second-line therapy in patients with non-small cell lung cancer who are resistant and/or refractory to prior therapy with an anti-PD-(L)1 antibody. It is anticipated that the study will enroll up to 65 patients in the treatment arm. Genentech will be responsible for the conduct of the study and the parties will share the cost of the Phase&nbsp;1b/2 trial, which began enrolling patients in the fourth quarter of 2017. The Company is responsible for supplying CPI-444 and retains global development and commercialization rights to CPI-444. The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory authority or if development of CPI-444 or Tecentriq is discontinued.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LicenseAndCollaborationAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LicenseAndCollaborationAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6897337408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">6. Balance Sheet Components (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Prepaid and Other Current Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Interest receivable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>365
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Prepaid research and development manufacturing expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>327
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>720
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>772
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,179
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,137
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Property and Equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,034
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,868
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Computer equipment and purchased software</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,078
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,051
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,242
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,977
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Less: accumulated depreciation and amortization</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,570
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(729
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,672
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,248
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Accrued and Other Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Accrued clinical trial related</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,870
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,617
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Accrued manufacturing expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,056
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>955
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Personnel related</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>572
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>526
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Deferred rent</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>410
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>378
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Accrued legal and accounting</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>224
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>255
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Other accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>383
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>313
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,515
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,044
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Other Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Deferred rent</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>960
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,370
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Shares subject to vesting</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>971
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,405
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749867120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">7. Convertible Preferred Stock</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately prior to the consummation of the IPO on March&nbsp;29, 2016, all outstanding shares of Series&nbsp;A and B convertible preferred stock were converted into 14,274,741 shares of common stock on a one-for-one basis. As such, no convertible preferred stock shares were outstanding as of December&nbsp;31, 2016.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905209184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ConvertiblePreferredStockLiabilityAbstract', window );"><strong>Convertible Preferred Stock Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ConvertiblePreferredStockLiabilityTextBlock', window );">Convertible Preferred Stock Liability</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">8. Convertible Preferred Stock Liability</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;26, 2014, the Company executed the Series&nbsp;A Convertible Preferred Stock Purchase Agreement for the issuance of up to 8,921,438 shares of Series&nbsp;A convertible preferred stock and issued 3,395,468 shares for net proceeds of $12.6&nbsp;million in connection with the first closing of the first tranche. In January 2015, in connection with the second closing of the first tranche, the Company issued 1,065,246 shares of Series&nbsp;A convertible preferred stock for net proceeds of $4.0&nbsp;million and in June 2015, in connection with the closing of the second tranche, an additional 4,460,715 shares of Series&nbsp;A convertible preferred stock were issued for net proceeds of $16.7&nbsp;million.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Series&nbsp;A Convertible Preferred Stock Purchase Agreement provided that, upon the earliest to occur of any of three defined triggers, each investor of the first tranche agreed to purchase its pro-rata portion of the shares to be issued in the second tranche and the Company agreed to sell and issue said shares of Series&nbsp;A convertible preferred stock on the same terms as the first tranche.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A convertible preferred stock liability was recorded for the Company's obligation to sell the second tranche of the Series&nbsp;A convertible preferred stock to the first tranche stockholders at a fixed price of $3.755 per share upon the satisfaction of certain conditions. A liability was initially recorded in connection with the first tranche of the Series&nbsp;A convertible preferred stock financing at its initial estimated fair value of $2.6&nbsp;million, with gains and losses arising from changes in fair value recognized in the statements of operations at each period while such instrument was classified as a liability. A $17.6&nbsp;million charge was recorded for the change in estimated fair value of the Series&nbsp;A convertible preferred stock liability for the period from January&nbsp;1, 2015 to the closing of the second tranche in June 2015. Upon the closing of the second tranche in June 2015, the liability terminated and the balance of the liability of $20.2&nbsp;million was reclassified to convertible preferred stock.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preferred stock liability related to Series&nbsp;A convertible preferred stock was valued at issuance and at December&nbsp;31, 2014 and March&nbsp;31, 2015 using a black scholes option-pricing method based on the consideration paid for the Series&nbsp;A convertible preferred stock and the convertible preferred stock liability using an assumed term of 1.0&nbsp;years and 0.75&nbsp;years, an interest rate of 0.13% and 0.20% and a volatility of 85% and 85%, respectively.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately prior to its exercise on June&nbsp;10, 2015, the convertible preferred stock liability's fair value was estimated based on its intrinsic value, with the fair value of the Series&nbsp;A convertible preferred stock estimated as of June&nbsp;10, 2015 and compared to the exercise price of the Series&nbsp;A convertible preferred stock liability.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To estimate the fair value of the Series&nbsp;A convertible preferred stock as of June&nbsp;10, 2015, the enterprise value of the Company was estimated based on potential IPO and sale estimates. The enterprise value was then allocated to the various classes of securities using an option pricing model that assumed a term of two years to a liquidity event, an interest rate of 0.75% and a volatility of 75% based on market conditions and expectations as of the June valuation date.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ConvertiblePreferredStockLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ConvertiblePreferredStockLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ConvertiblePreferredStockLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an obligation to sell convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ConvertiblePreferredStockLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6906719200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">9. Common Stock</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, the amended and restated certificate of incorporation authorizes the Company to issue 290&nbsp;million shares of common stock and 10&nbsp;million shares of preferred stock.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of common stock is entitled to one vote. Common stockholders are entitled to dividends if and when declared by the board of directors. As of December&nbsp;31, 2017, no dividends on common stock had been declared.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;20, 2017, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company,&nbsp;LLC ("Cowen") to sell shares of the Company's common stock, from time to time, with aggregate gross sales proceeds of up to $125,000,000, through an at-the-market equity offering program under which Cowen will act as its sales agent. The issuance and sale of shares of common stock by the Company pursuant to the Sales Agreement are deemed an "at-the-market" offering under the Securities Act of 1933, as amended. Cowen is entitled to compensation for its services equal to up to 3.0% of the gross proceeds of any shares of common stock sold through Cowen under the Sales Agreement. During the year ended December&nbsp;31, 2017, the Company received net proceeds of approximately $0.7&nbsp;million from the sale of 52,569 shares of common stock pursuant to the Sales Agreement.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has reserved shares of common stock, for issuance as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,274,741
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Shares available for future option grants</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,576,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,475,600
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,559,499
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Outstanding options</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,013,394
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,350,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>784,136
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Unvested restricted common stock (founders and early exercise of stock options)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>319,203
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>611,698
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>924,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Shares reserved for employee stock purchase plan</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>200,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>200,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,109,132
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,637,880
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,542,911
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749867408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_DisclosureOfShareBasedCompensationPlansTextBlock', window );">Stock Option Plans</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">10. Stock Option Plans</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2014, the Company adopted the 2014 Equity Incentive Plan (the "2014 Plan"), which was subsequently amended in November 2014, July 2015 and September 2015, under which it granted incentive stock options ("ISOs") or non-qualified stock options ("NSOs"). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over four years and have maximum exercise term of 10&nbsp;years. The 2014 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company's common stock as determined by the board of directors on the date of the grant.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the "2016 Plan"), became effective. Under the 2016 Plan, incentive stock options, non-statutory stock options, stock purchase rights and other stock-based awards may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over four years and have maximum exercise term of 10&nbsp;years. The 2016 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company's common stock as determined by the board of directors on the date of the grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and no further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of 1,136,229 shares.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Activity under the Company's stock option plans is set forth below:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Shares<br />Available<br />for Grant</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number of<br />Options</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted-<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Balance at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,475,600
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,350,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.88
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Additional shares authorized</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>830,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Options granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(969,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>969,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.80
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(66,253
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Options forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>240,435
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(240,435
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.09
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Balance at December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,576,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,013,394
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.78
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes information about stock options outstanding at December&nbsp;31, 2017 and 2016:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Outstanding<br />at December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Vested<br />at December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Exercise Price </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (in Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (in Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$0.28&nbsp;- $4.65</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>535,136
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.55
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.46
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>325,397
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.53
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$6.75&nbsp;- $10.60</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>701,600
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.86
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.44
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,688
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.87
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.75
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$11.21&nbsp;- $16.70</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,776,658
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.57
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.41
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>596,727
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.23
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,013,394
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.69
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.78
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>924,812
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.40
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Outstanding<br />at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Vested<br />at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Exercise Price </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (in Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (in Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$0.28</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>419,682
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.46
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>159,732
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.44
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$4.65</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.81
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.65
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,449
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.81
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.65
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$6.75</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.87
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.75
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,438
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.87
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.75
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$13.34&nbsp;-&nbsp;16.37</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,781,400
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.42
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.21
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>193,867
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.18
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.14
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,350,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.21
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.88
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>397,486
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.84
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The weighted average grant date fair value of options granted for the years ended December&nbsp;31, 2017, 2016 and 2015, was $8.93, $10.78 and $4.37, respectively.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options outstanding and exercisable that had vested or were expected to vest at December&nbsp;31, 2017 were as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number of<br />shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Aggregate<br />Intrinsic Value<br />(in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>924,812
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.38
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,946
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected to vest</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,088,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.40
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.98
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,903
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the table above, aggregate intrinsic value represents the difference between the exercise price of the options to purchase common stock and the estimated fair value of the Company's common stock of $10.36</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate intrinsic value of stock options exercised in the years ended December&nbsp;31, 2017, 2016 and 2015, was $332,000, $216,000 and $714,000, respectively.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The total fair value of options that vested in the year ended December&nbsp;31, 2017, 2016 and 2015, was $5.8&nbsp;million, $3.2&nbsp;million, and $0.1&nbsp;million, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_DisclosureOfShareBasedCompensationPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based compensation plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_DisclosureOfShareBasedCompensationPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6902521968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">11. Stock-Based Compensation</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,692
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,685
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>292
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,537
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,143
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,229
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,828
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>428
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Valuation Assumptions</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company estimated the fair value of employee stock options using the Black-Scholes valuation model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options were estimated using the following assumptions for the years ended December&nbsp;31, 2017, 2016 and 2015:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended<br />December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.6
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91.4
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>84.6
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83.3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk-free Interest Rate:</font><font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Volatility:</font><font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;The Company used an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company's industry peers.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected Term:</font><font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the simplified method prescribed in the ASC 718, Compensation&#x2014;Stock Compensation, to calculate the expected term of options granted to employees and directors.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expected Dividends:</font><font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;The Company has not paid and does not anticipate paying any dividends in the near future.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2017, 2016 and 2015, the unrecognized compensation expense associated with respect to options granted to employees was $18.6&nbsp;million, $18.5&nbsp;million and $4.7&nbsp;million, respectively, and is expected to be recognized on a straight-line basis over 2.85, 3.28, and 3.64&nbsp;years, respectively.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense related to awards to non-employees is recognized based on the then-current fair value at each measurement date over the associated service period of the award, which is generally the vesting term, on a straight line basis. The Company used the Black-Scholes valuation model to assist it in determining the fair value of stock-based awards. Stock-based compensation expense for non-employees was $74,000, $142,500 and $42,848 for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following assumptions were used in valuation of non-employee stock options:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2.17%&nbsp;- 2.33%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.90%&nbsp;- 1.94%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.8%&nbsp;- 2.2%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">80.3%&nbsp;- 83.0%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">92.1%&nbsp;- 92.7%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">82%&nbsp;- 84.7%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">7.1&nbsp;-&nbsp;7.6</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">8.1&nbsp;-&nbsp;8.6</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">9.1&nbsp;-&nbsp;10.0</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">0%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">0%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">0%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6645766336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">12. Income Taxes</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of loss before income tax is as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Domestic</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,253
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,375
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,335
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Foreign</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,410
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(25,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55,663
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,375
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,335
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2017, 2016 and 2015, the Company recorded no income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of realizing a benefit from those items.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A reconciliation of the Company's effective tax rate to the U.S. Federal statutory rate is as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Federal tax benefit at statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">State tax, net of Federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Loss due to change in fair value of convertible preferred stock liability</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Foreign rate differential</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Federal rate change impact</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Research and development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The effective tax rate is different from the federal statutory tax rate primarily due to a foreign rate differential and a valuation allowance against deferred tax assets as a result of the Company's history of losses.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The principal components of the Company's net deferred tax assets are as follows (in thousands)</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,438
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,339
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,671
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Tax credit carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,351
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,960
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>445
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Capitalized tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>528
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Accruals</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>183
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Stock compensation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,730
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>954
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,885
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,791
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,866
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(21,885
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,791
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,866
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recorded a valuation allowance against its deferred tax assets at December&nbsp;31, 2017 and 2016 because Company management believed that it was more likely than not that these assets would not be fully realized in the future. The valuation allowance increased by approximately $9.1&nbsp;million and $7.0&nbsp;million for the years ended December&nbsp;31, 2017 and 2016, respectively. Changes in the valuation allowance for deferred tax assets relate primarily to the increase in the Company's net operating loss carryforward.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, the Company had federal NOL carryforwards of approximately $42.1&nbsp;million and state NOL carryforwards of approximately $94.5&nbsp;million which are available to reduce future taxable income. The NOLs will begin to expire in 2034, if not utilized.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, the Company also had $3.0&nbsp;million of federal and $2.1&nbsp;million of state research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire 2035, if not utilized. The state research and development tax credits have no expiration date.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilization of NOL carryforwards and credits may be subject to an annual limitation due to the ownership change provisions provided by the Internal Revenue Code of 1986, as amended ("Code"), and similar state provisions. An annual limitation may result in the expiration of NOLs and credits before utilization. In March and April 2016, the Company issued a total of 5.2&nbsp;million shares of common stock associated with its IPO. In addition, during the third quarter of 2015, the Company issued a new series of convertible preferred stock. Such common and preferred stock issuances may have created an ownership change under these provisions of the Code and similar state provisions. As of December&nbsp;31, 2017, NOLs and credits are not expected to expire unused in the carryforward period as a result of these issuances of convertible preferred shares.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1)&nbsp;reducing the U.S. federal corporate tax rate from 35% to 21%; (2)&nbsp;requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries; (3)&nbsp;generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (4)&nbsp;requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (5)&nbsp;eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; (6)&nbsp;creating the base erosion anti-abuse tax (BEAT), a new minimum tax; (7)&nbsp;creating a new limitation on deductible interest expense; and (8)&nbsp;changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December&nbsp;31, 2017.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC staff issued SAB&nbsp;118, which provides guidance on accounting for the tax effects of the Tax Act. SAB&nbsp;118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB&nbsp;118, a company must reflect the income tax effects of those aspects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company's accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our accounting for the following elements of the Tax Act is complete:</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reduction of US federal Corporate Tax Rate: The Tax Act reduces the corporate tax rate to 21%, effective January&nbsp;1, 2018. Accordingly, we have re-measured all deferred taxes at 21% as of December&nbsp;31, 2017. Consequently, we have recorded a decrease related to the net deferred tax asset balance of $4.9&nbsp;million, with a corresponding net adjustment to the Company's valuation allowance.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deemed Repatriation Transition Tax: The Deemed Repatriation Transition Tax ("Transition Tax") is a tax on previously untaxed accumulated and current earnings and profits (E&amp;P) of certain of our foreign subsidiaries. To determine the amount of the Transition Tax, we must determine, in addition to other factors, the amount of post-1986 E&amp;P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. the Company has a cumulative foreign E&amp;P deficit as of December&nbsp;31, 2017. As such, the Company does not have a transition tax liability in the 2017 tax year.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our accounting for the following elements of the Tax Act is incomplete:</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global Intangible Low Taxed Income ("GILTI"): The Tax Act creates a new requirement that certain income (i.e.,&nbsp;GILTI) earned by a controlled foreign corporations ("CFCs") must be included currently in the gross income of the CFCs' U.S. shareholder. GILTI is the excess of the shareholder's "net CFC tested income" over the net deemed tangible income return, which is currently defined as the excess of (1)&nbsp;10% of the aggregate of the U.S. shareholder's pro rata share of the qualified business asset investment of each CFC with respect to which it is a U.S. shareholder over (2)&nbsp;the amount of certain interest expense taken into account in the determination of net CFC-tested income. Because of the complexity of the new GILTI tax rules, we are continuing to evaluate this provision of the Tax Act and the application of ASC 740. Under U.S.&nbsp;GAAP, we are allowed to make an accounting policy choice of either (1)&nbsp;treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred (the "period cost method") or (2)&nbsp;factoring such amounts into a company's measurement of its deferred taxes (the "deferred method"). Our selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing our global income to determine whether we expect to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Because whether we expect to have future U.S. inclusions in taxable income related to GILTI depends on not only our current structure and estimated future results of global operations but also our intent and ability to modify our structure and/or our business, we are not yet able to reasonably estimate the effect of this provision of the Tax Act. Therefore, we have not made any adjustments related to potential GILTI tax in our financial statements and have not made a policy decision regarding whether to record deferred taxes on GILTI.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017, the Company had unrecognized tax benefits ("UTBs") of approximately $1.2&nbsp;million. All of the deferred tax assets associated with these UTBs are fully offset by a valuation allowance. The following table summarizes the activity related to UTBs:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Unrecognized tax benefits beginning of the period</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>604
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Increase related to the prior year</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(51
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Increased related to the current year</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>666
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>463
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Unrecognized tax benefits, end of the period</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,219
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>604
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company follows the provisions of ASC 740, Accounting for Income Taxes, and the accounting guidance related to accounting for uncertainty in income taxes. The Company determines its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be sustained upon examination by the relevant income tax authorities. The Company will recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6897337408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">13. Commitments and Contingencies</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Facility Lease</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2015, the Company signed an initial operating lease, effective February&nbsp;1, 2015 for 8,138 square feet of office and laboratory space with a one-year term. Between January 2015 and August 2016, the Company entered into a series of lease amendments to increase the amount of leased space to 28,633 square feet and extend the expiration of the lease to February 2021. The lease agreement includes an annual rent escalation clause and a right to extend the term at the then current market rate for three years. Under the lease and subsequent amendments, the landlord provided approximately $1.9&nbsp;million in free rent and lease incentives. The Company records rent expense on a straight-line basis over the effective term of the lease, including any free rent periods and incentives. The lease requires the Company to pay additional amounts for operating and maintenance expenses. Rent expense related to the facilities lease for the years ended years ended December&nbsp;31, 2017, 2016 and 2015 was approximately $734,000, $584,000 and $347,000, respectively. As of December&nbsp;31, 2017, future minimum lease payments under the facility lease were as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Payments Due by Period</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Less than<br />1 Year</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2&nbsp;-&nbsp;3&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">4&nbsp;-5&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">More than<br />5 Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">Contractual obligations:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Operating lease obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,632
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,144
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,387
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total contractual obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,632
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,144
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,387
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2015 the Company entered into an agreement for a line of credit of $0.1&nbsp;million for the purpose of issuing its landlord a letter of credit of $0.1&nbsp;million as a security deposit under its facility lease. The Company pledged money market funds and marketable securities as collateral for the line of credit. Pursuant to the Company's license agreements with each of Vernalis and Scripps, it has obligations to make future milestone and royalty payments to these parties, respectively. However, because these amounts are contingent, they have not been included on the Company's balance sheet.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Indemnifications</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. There have been no claims to date and the Company has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims.</font>
		</p>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Legal Proceedings</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not a party to any material legal proceedings.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749867120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transaction</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">14. Related Party Transaction</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2017, the Company purchased $461,000 of research services from a vendor during the normal course of business, where a Corvus director is also a member of the vendor's board of directors.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905209184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Selected Financial Data (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Selected Financial Data (unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Selected Financial Data (unaudited)</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">15. Quarterly Selected Financial Data (unaudited)</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,<br />2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">September&nbsp;30,<br />2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">June&nbsp;30,<br />2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">March&nbsp;31,<br />2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Operating Expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,189
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,944
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,174
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,217
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,929
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,717
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,981
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,036
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.58
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.62
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.73
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.79
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">September&nbsp;30,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">June&nbsp;30,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">March&nbsp;31,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Operating Expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,249
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,476
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,825
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,426
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,086
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,297
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,645
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,347
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.55
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.51
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.43
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5.39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747393776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Basis of Presentation</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S.&nbsp;GAAP"). The Company's functional and reporting currency is the U.S. dollar. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business. Since its inception, the Company has incurred significant losses and negative cash flows from operations. As of December&nbsp;31, 2017, the Company had an accumulated deficit of $123.5&nbsp;million and cash, cash equivalents and marketable securities of $90.1&nbsp;million. The Company has financed its operations primarily with the proceeds from the sale of stock. The Company will need to raise additional capital to meet its business objectives. The Company believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its planned expenditures and meet its obligations through at least the next twelve months from the issuance of these financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Use of Estimates</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of the Company's consolidated financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_InitialPublicOfferingPolicyTextBlock', window );">Initial Public Offering</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Initial Public Offering</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;22, 2016, the Company's registration statement on Form&nbsp;S-1 (File No.&nbsp;333-208850) relating to its initial public offering ("IPO") of its common stock was declared effective by the Securities and Exchange Commission ("SEC") and the shares of its common stock began trading on the Nasdaq Global Market on March&nbsp;23, 2016. The public offering price of the shares sold in the IPO was $15.00 per share. The IPO closed on March&nbsp;29, 2016, pursuant to which the Company sold 4,700,000 shares of its common stock. On April&nbsp;26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial offering price of $15.00 per share. The Company received aggregate net proceeds of approximately $70.6&nbsp;million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stocks.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Concentrations of Credit Risk and Other Risks and Uncertainties</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Substantially all of the Company's cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company's marketable securities consist of investments in U.S. Treasury securities, U.S. government agency securities and corporate debt obligations, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company's product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Segments</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash and Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Cash, Cash Equivalents and Marketable Securities</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments with remaining maturities, at the date of purchase, greater than three months, but less than one year are considered short-term. The Company determines the appropriate classification of marketable securities at the time of purchase and evaluates such designation as of each balance sheet date. To date, all marketable securities have been classified as available-for-sale and are carried at fair value with unrealized gains and losses, if any, included as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Interest and realized gains and losses are included in interest income. Realized gains and losses are recognized based on the specific identification method.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Fair Value Measurements</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company's financial instruments, including cash equivalents, accounts payable and accrued liabilities, approximate fair value due to their short-term maturities.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Deferred Offering Costs</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred offering costs consist primarily of direct incremental costs related to the Company's initial public offering of its common stock. Upon completion of the initial public offering in March 2016, these amounts were offset against the proceeds of the offering.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Property and Equipment, Net</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Laboratory equipment</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">5&nbsp;years</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Computer equiipment and purchased software</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">3&nbsp;years</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Shorter of asset's useful life or remaining term of lease</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Impairment of Long-Lived Assets</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives. Should impairment exist, the impairment loss to be recognized is measured by the amount by which the carrying amount of the asset exceeds the projected discounted future net cash flows arising from the asset. All long-lived assets are maintained in the United States of America.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Consolidation</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Research and Development Expenses</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company records research and development expenses as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery and development of the Company's product candidates and include:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:15;margin-left:0pt;">
			<tr style="CellSpacing:15;">
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.00%;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense;&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, academic and non-profit institutions and consultants;&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use;&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 12pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">license fees; and&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:15;">
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2022;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0.8pt 0.8pt 0.8pt 0.8pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ClinicalTrialAccrualsPolicyTextBlock', window );">Clinical Trial Accruals</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Clinical Trial Accruals</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Costs for preclinical studies and clinical trial activities are recognized based on an evaluation of the vendors' progress towards completion of specific tasks, using data such as clinical site activations, patient enrollment or information provided to the Company by its vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services are performed. The Company determines accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion, or the services completed. The Company's estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Stock-Based Compensation</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains incentive plans under which incentive stock options and nonqualified stock options may be granted to employees and non-employee service providers.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for stock-based employee compensation arrangements in accordance with the provisions of ASC 718, "Compensation&#x2014;Stock Compensation." For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values. The value of the award is recognized as an expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. Forfeitures are accounted for when they occur.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense related to stock options granted to non-employees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model. The expense for options granted to non-employees is periodically re-measured as the underlying options vest. The awards generally vest over the time period the Company expects to receive service from the non-employee.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Income Taxes</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for income taxes under the asset and liability method. The Company estimates actual current tax exposure together with assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and liabilities, which are included in the Company's balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in the Company's statements of operations and comprehensive loss become deductible expenses, under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of the Company's deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income and a valuation allowance is recorded when it is more likely than not that the deferred tax asset will not be recovered. The Company applies judgment in the determination of the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Based on the available evidence, the Company is unable, at this time, to support the determination that it is more likely than not that its deferred tax assets will be utilized in the future. Accordingly, the Company recorded a full valuation allowance for all periods presented. The Company intends to maintain a valuation allowance until sufficient evidence exists to support its reversal.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recognizes benefits of uncertain tax positions if it is more likely than not such positions will be sustained upon examination based solely on their technical merits as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company recognizes any material interest and penalties related to unrecognized tax benefits in income tax expense. The Company is required to file income tax returns in the U.S. federal jurisdiction. The Company currently is not under examination by the Internal Revenue Service or other jurisdictions for any tax years.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;22, 2017, the 2017 Tax Cuts and Jobs Act (the "Tax Act") was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January&nbsp;1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No.&nbsp;118, </font><font style="display:inline;font-family:Times;font-style:italic;font-size:10pt;">Income Tax Accounting Implications of the Tax Cuts and Jobs Act</font><font style="display:inline;font-family:Times;font-size:10pt;"> (SAB&nbsp;118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. We consider the accounting of the transition tax and deferred tax re-measurements to be complete&#x2014;however, since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12&nbsp;months, we are not yet able to reasonably estimate the effect of Global Intangible Low Taxed Income ("GILTI") and have not yet made a policy decision regarding whether to record deferred taxes on GILTI. We expect to complete our analysis within the measurement period in accordance with SAB&nbsp;118. See Note&nbsp;12 in these notes to the consolidated financial statements for additional information.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Comprehensive Loss</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss includes net loss as well as other changes in stockholders' equity (deficit) that result from transactions and economic events other than those with stockholders. The Company's only element of other comprehensive loss in any period presented was unrealized gains and losses on available for sale marketable securities.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Net Loss per Share</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt 5pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&nbsp;2014-09, Revenue from Contracts with Customers, which required an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No.&nbsp;2014-09 will replace most existing revenue recognition guidance in U.S.&nbsp;GAAP when it becomes effective. The new standard is effective January&nbsp;1, 2018 for public companies. Early application is permitted as of January&nbsp;1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. In March 2016, the FASB issued ASU No.&nbsp;2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which clarifies the implementation guidance on principal versus agent considerations in ASU No.&nbsp;2014-09. In April 2016, the FASB issued ASU No.&nbsp;2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU No.&nbsp;2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which relates to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January&nbsp;1, 2018. The Company does not believe adopting this guidance will have a material impact on its consolidated financial statements as the Company is not yet generating revenues.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2016, the FASB issued ASU No.&nbsp;2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard requires lessees to record right of use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. The standard is effective for the Company beginning January&nbsp;1, 2019, with early application permitted. The new standard is required to be applied with a modified retrospective approach to each prior reporting period presented with various optional practical expedients. The Company is currently assessing the impact of this guidance on its consolidated financial statements.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2017, the FASB issued ASU No 2017-09, Compensation&#x2014;Stock Compensation (Topic&nbsp;718)&#x2014;Scope of Modification Accounting, to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new standard, modification is required only if the fair value, the vesting conditions, or the classification of an award as equity or liability changes as a result of the change in terms or conditions. ASU 2017-09 will be effective for the Company beginning January&nbsp;1, 2018 and will be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents and disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ClinicalTrialAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for clinical trail accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ClinicalTrialAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_InitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy of Initial Public Offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_InitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749922752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of estimated useful lives of property and equipment, net</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Laboratory equipment</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">5&nbsp;years</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Computer equiipment and purchased software</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">3&nbsp;years</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="top" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">Shorter of asset's useful life or remaining term of lease</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular Disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749928880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share, basic and diluted</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the calculation of net loss per share (in thousands, except share and per share data):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 30pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss&#x2014;basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55,663
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,375
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,335
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Weighted average common shares outstanding</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,958,557
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,188,980
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,269,315
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Less: weighted average common shares subject to repurchase</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(470,051
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(766,939
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(895,672
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Weighted average common shares outstanding used to compute basic and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,488,506
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,422,041
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373,643
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.72
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.36
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(83.86
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Convertible preferrd stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,274,741
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Common stock subject to repurchase</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>319,203
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>611,698
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>924,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Outstanding options</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,013,394
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,350,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>784,136
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total shares of common stock equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,332,597
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,962,280
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,983,412
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762275200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value of assets and liabilities recorded at fair value on a recurring basis, by level within fair value hierarchy</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables present information as of December&nbsp;31, 2017 and 2016 about the Company's assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td rowspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value Measured Using</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td rowspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total<br />Balance</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,555
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,555
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,949
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,949
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,504
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89,504
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td rowspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value Measured Using</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td rowspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" rowspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total<br />Balance</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,999
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,999
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Marketable securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,846
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,846
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,845
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132,845
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of fair value of available for sale marketable securities</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017 and 2016, the fair value of available for sale marketable securities by type of security were as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortized<br />Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross<br />Unrealized<br />Gains</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross<br />Unrealized<br />Losses</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Government agency securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,311
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,272
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Corporate debt obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,679
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,677
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,990
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(41
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,949
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Amortized<br />Cost</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross<br />Unrealized<br />Gains</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Gross<br />Unrealized<br />Losses</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Fair Value</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">U.S. Treasury securities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,885
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>129,846
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6750082464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid and other current assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Prepaid and Other Current Assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Interest receivable</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>365
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Prepaid research and development manufacturing expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>327
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>720
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>772
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,179
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,137
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Property and Equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,034
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,868
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Computer equipment and purchased software</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>130
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,078
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,051
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,242
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,977
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Less: accumulated depreciation and amortization</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,570
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(729
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,672
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,248
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued and other liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Accrued and Other Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Accrued clinical trial related</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,870
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,617
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Accrued manufacturing expense</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,056
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>955
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Personnel related</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>572
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>526
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Deferred rent</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>410
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>378
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Accrued legal and accounting</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>224
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>255
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Other accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>383
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>313
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,515
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,044
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of other liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-style:italic;font-size:10pt;">Other Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Deferred rent</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>960
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,370
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Shares subject to vesting</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>971
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,405
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a)accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer) and (b)other liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6900087056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock', window );">Schedule of shares of common stock reserved for issuance</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,274,741
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Shares available for future option grants</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,576,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,475,600
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,559,499
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Outstanding options</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,013,394
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,350,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>784,136
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Unvested restricted common stock (founders and early exercise of stock options)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>319,203
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>611,698
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>924,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Shares reserved for employee stock purchase plan</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>200,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>200,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,109,132
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,637,880
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,542,911
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of shares of common stock reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6640596400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Shares<br />Available<br />for Grant</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number of<br />Options</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted-<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Balance at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,475,600
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,350,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.88
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Additional shares authorized</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>830,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Options granted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(969,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>969,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.80
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(66,253
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Options forfeited</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>240,435
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(240,435
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.09
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Balance at December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,576,535
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,013,394
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.78
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of information about stock options outstanding</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Outstanding<br />at December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Vested<br />at December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Exercise Price </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (in Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (in Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$0.28&nbsp;- $4.65</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>535,136
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.55
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.46
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>325,397
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.53
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$6.75&nbsp;- $10.60</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>701,600
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.86
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.44
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,688
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.87
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.75
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$11.21&nbsp;- $16.70</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,776,658
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.57
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.41
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>596,727
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.23
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,013,394
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.69
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.78
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>924,812
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.40
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Outstanding<br />at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Options Vested<br />at December&nbsp;31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Exercise Price </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (in Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (in Years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise<br />Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$0.28</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>419,682
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.46
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>159,732
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.44
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.28
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$4.65</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144,500
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.81
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.65
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,449
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.81
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.65
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$6.75</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.87
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.75
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,438
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.87
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.75
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">$13.34&nbsp;-&nbsp;16.37</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,781,400
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.42
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.21
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>193,867
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.18
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15.14
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,350,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.21
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.88
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>397,486
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.84
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of options outstanding and exercisable that had vested or were expected to vest</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options outstanding and exercisable that had vested or were expected to vest at December&nbsp;31, 2017 were as follows:</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Number of<br />shares</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Exercise Price</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Weighted<br />Average<br />Remaining<br />Contractual<br />Life (years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Aggregate<br />Intrinsic Value<br />(in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>924,812
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.38
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.02
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,946
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected to vest</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,088,582
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.40
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.98
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,903
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number of fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term for both options (or share units) currently outstanding and options (or share units) exercisable (or convertible).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6659700912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of expenses relating to employee and non-employee stock-based awards</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,692
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,685
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>292
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,537
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,143
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,229
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,828
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>428
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of share-based awards to employees was estimated using Black Scholes model</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended<br />December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.6
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.7
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>91.4
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>84.6
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83.3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=crvs_NonEmployeesMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of share-based awards to employees was estimated using Black Scholes model</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Year Ended December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">2.17%&nbsp;- 2.33%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.90%&nbsp;- 1.94%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">1.8%&nbsp;- 2.2%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">80.3%&nbsp;- 83.0%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">92.1%&nbsp;- 92.7%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">82%&nbsp;- 84.7%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">7.1&nbsp;-&nbsp;7.6</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">8.1&nbsp;-&nbsp;8.6</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">9.1&nbsp;-&nbsp;10.0</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">0%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">0%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">0%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=crvs_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=crvs_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749843264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of loss before income tax</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The components of loss before income tax is as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Domestic</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,253
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,375
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,335
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Foreign</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,410
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(25,000
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55,663
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,375
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,335
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the effective tax rate to the U.S. Federal statutory rate</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Federal tax benefit at statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">State tax, net of Federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Loss due to change in fair value of convertible preferred stock liability</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Foreign rate differential</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Federal rate change impact</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(18
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Research and development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">%</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of principal components of the net deferred tax assets</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The principal components of the Company's net deferred tax assets are as follows (in thousands)</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,438
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,339
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,671
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Tax credit carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,351
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,960
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>445
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Capitalized tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>241
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>528
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Accruals</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>183
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Stock compensation</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,730
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>954
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,885
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,791
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,866
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(21,885
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,791
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,866
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits activity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Unrecognized tax benefits beginning of the period</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>604
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Increase related to the prior year</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(51
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Increased related to the current year</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>666
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>463
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Unrecognized tax benefits, end of the period</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,219
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>604
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=75116239&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6639590400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments under the facility lease</a></td>
<td class="text"><div> <div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">As of December&nbsp;31, 2017, future minimum lease payments under the facility lease were as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Payments Due by Period</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Less than<br />1 Year</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">2&nbsp;-&nbsp;3&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">4&nbsp;-5&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">More than<br />5 Years</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:10pt;">Contractual obligations:</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Operating lease obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,632
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,144
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,387
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Total contractual obligations</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,632
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,144
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,387
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:right;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B; &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-family:Times;font-size:1.5pt;">&#x200B;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916462384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Selected Financial Data (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Selected Financial Data (unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Selected Financial Data (unaudited)</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,<br />2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">September&nbsp;30,<br />2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">June&nbsp;30,<br />2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">March&nbsp;31,<br />2017</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Operating Expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,189
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,944
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,174
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,217
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,929
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,717
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,981
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,036
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.58
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.62
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.73
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.79
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;CellSpacing:0;margin-left:0pt;">
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">December&nbsp;31,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">September&nbsp;30,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">June&nbsp;30,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:auto;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">March&nbsp;31,<br />2016</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;text-align:center;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:7.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Operating Expenses</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,249
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,476
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,825
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,426
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,086
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,297
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,645
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,347
				</td>
				<td valign="bottom" style="width:auto;background-color: #FFFFFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
			<tr style="CellSpacing:0;">
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;font-size:10pt;">Net loss per share, basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.55
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.51
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.43
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">$</font></p>
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;;font-family:Times;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5.39
				</td>
				<td valign="bottom" style="width:auto;background-color: #CCEEFF;">
					<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:115%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753338144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>subsidiary</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_NumberOfInsignificantSubsidiaries', window );">Number of insignificant subsidiaries</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_NumberOfInsignificantSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the information pertaining to number of insignificant subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_NumberOfInsignificantSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760293872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Basis of Presentation, Credit Risk and Income Taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>segment </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (123,534)<span></span>
</td>
<td class="num">$ (67,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentrations of Credit Risk and Other Risks and Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions', window );">Number of highly credit qualified financial institutions | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of financial institutions, wherein the company deposits the cash and cash equivalents. Such deposits could have significant balances in excess of federally insured limits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ConcentrationRiskCreditRiskUninsuredFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753538640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - IPO (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Apr. 26, 2016</div></th>
<th class="th"><div>Mar. 29, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">502,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757818176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753801632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss - basic and diluted</a></td>
<td class="num">$ (11,929)<span></span>
</td>
<td class="num">$ (12,717)<span></span>
</td>
<td class="num">$ (14,981)<span></span>
</td>
<td class="num">$ (16,036)<span></span>
</td>
<td class="num">$ (11,086)<span></span>
</td>
<td class="num">$ (10,297)<span></span>
</td>
<td class="num">$ (8,645)<span></span>
</td>
<td class="num">$ (6,347)<span></span>
</td>
<td class="num">$ (55,663)<span></span>
</td>
<td class="num">$ (36,375)<span></span>
</td>
<td class="num">$ (31,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,958,557<span></span>
</td>
<td class="nump">16,188,980<span></span>
</td>
<td class="nump">1,269,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Less: weighted average common shares subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(470,051)<span></span>
</td>
<td class="num">(766,939)<span></span>
</td>
<td class="num">(895,672)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding used to compute basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,488,506<span></span>
</td>
<td class="nump">15,422,041<span></span>
</td>
<td class="nump">373,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (5.39)<span></span>
</td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (83.86)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762323248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock equivalents</a></td>
<td class="nump">3,332,597<span></span>
</td>
<td class="nump">2,962,280<span></span>
</td>
<td class="nump">15,983,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,274,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Common stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock equivalents</a></td>
<td class="nump">319,203<span></span>
</td>
<td class="nump">611,698<span></span>
</td>
<td class="nump">924,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crvs_EmployeeAndNonEmployeeStockOptionsMember', window );">Outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares of common stock equivalents</a></td>
<td class="nump">3,013,394<span></span>
</td>
<td class="nump">2,350,582<span></span>
</td>
<td class="nump">784,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crvs_EmployeeAndNonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crvs_EmployeeAndNonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760939120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Recurring (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 44,949<span></span>
</td>
<td class="nump">$ 129,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">44,555<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">44,949<span></span>
</td>
<td class="nump">129,846<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">89,504<span></span>
</td>
<td class="nump">132,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,846<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">44,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">44,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">$ 89,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760136656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Available For Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Fair value of available for sale marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 44,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">44,949<span></span>
</td>
<td class="nump">$ 129,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Fair value of available for sale marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Fair value of available for sale marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">32,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">32,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Fair value of available for sale marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">12,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 12,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761884240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2017 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm', window );">Collaboration Agreement, Maximum Number of Patients in Treatment Arm | item</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=crvs_LicenseAgreementMember', window );">Licensing Agreement | Scripps Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee', window );">Minimum annual fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade', window );">Milestone payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination', window );">Period of written notice to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=crvs_LicenseAgreementMember', window );">Licensing Agreement | Scripps Research Institute | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade', window );">One-time cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=crvs_LicenseAgreementMember', window );">Licensing Agreement | Vernalis (R&amp;D) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade', window );">Milestone payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination', window );">Period of written notice to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=crvs_LicenseAgreementMember', window );">Licensing Agreement | Vernalis (R&amp;D) Limited | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=crvs_LicenseAgreementMember', window );">Licensing Agreement | Vernalis (R&amp;D) Limited | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade', window );">One-time cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of patients in treatment arm under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CollaborationAgreementMaximumNumberOfPatientsInTreatmentArm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate potential amount of payments the entity may be required to make to the counterparty based on achievement of milestones under the license or collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LicenseAndCollaborationAgreementsAggregatePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payments to the entity that are required to be made to the counterparty based on achievement of milestones under the license or collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LicenseAndCollaborationAgreementsMilestonePaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum annual fee the entity is obligated to pay to the counterparty under the license or collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LicenseAndCollaborationAgreementsMinimumAnnualFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of written notice the entity is required to provide for termination of the license or collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LicenseAndCollaborationAgreementsPeriodOfWrittenNoticeForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a one-time cash payment made to the counterparty upon entering into a license or collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LicenseAndCollaborationAgreementsUpfrontCashPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=crvs_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=crvs_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=crvs_ScrippsResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=crvs_ScrippsResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=crvs_VernalisRAndDLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=crvs_VernalisRAndDLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6660088128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_PrepaidResearchAndDevelopmentManufacturingExpenses', window );">Prepaid research and development manufacturing expenses</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">720<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total of prepaid and other current assets</a></td>
<td class="nump">$ 1,179<span></span>
</td>
<td class="nump">$ 1,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_PrepaidResearchAndDevelopmentManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_PrepaidResearchAndDevelopmentManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753799344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,242<span></span>
</td>
<td class="nump">$ 3,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(1,570)<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">3,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,078<span></span>
</td>
<td class="nump">$ 2,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753821568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract', window );"><strong>Accrued and Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_AccrualForPreclinicalAndClinicalTrialCurrent', window );">Accrued clinical trial related</a></td>
<td class="nump">$ 2,870<span></span>
</td>
<td class="nump">$ 1,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_AccruedManufacturingExpenseCurrent', window );">Accrued manufacturing expense</a></td>
<td class="nump">1,056<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Personnel related</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total of accrued and other liabilities</a></td>
<td class="nump">$ 5,515<span></span>
</td>
<td class="nump">$ 4,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AccrualForPreclinicalAndClinicalTrialCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value, as of the balance sheet date, of obligations incurred and payable related to clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AccrualForPreclinicalAndClinicalTrialCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of accrued liabilities and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AccruedLiabilitiesAndOtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AccruedManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing expense (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AccruedManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749867408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">$ 960<span></span>
</td>
<td class="nump">$ 1,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Shares subject to vesting</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total of other liabilities</a></td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753301088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 29, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Conversion</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of common stock issued with the conversion of the preferred stock (in shares)</a></td>
<td class="nump">14,274,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Preferred stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760684480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock Liability (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 10, 2015</div></th>
<th class="th">
<div>Nov. 26, 2014 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,274,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ChangeInFairValueOfConvertiblePreferredStockLiability', window );">Change in fair value of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crvs_SeriesConvertiblePreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,921,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,395,468<span></span>
</td>
<td class="nump">4,460,715<span></span>
</td>
<td class="nump">1,065,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,525,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche', window );">Number of defined triggers for issuance of additional shares to first tranche investors on the same terms | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ObligationToIssueConvertiblePreferredStock', window );">Convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ChangeInFairValueOfConvertiblePreferredStockLiability', window );">Change in fair value of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ReclassificationsOfConvertiblePreferredStockLiability', window );">Reclassification of liability to convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crvs_SeriesConvertiblePreferredStockMember', window );">Series A convertible preferred stock | Obligation to issue second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Fixed price for second tranche obligation (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Assumed term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Interest rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ChangeInFairValueOfConvertiblePreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognized in earnings for the change in fair value of the obligation to issue convertible preferred stock at fixed terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ChangeInFairValueOfConvertiblePreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of defined triggers, upon the earliest of which the investors of the first tranche of the convertible preferred stock agreed to purchase a pro-rata portion of shares in the second tranche and the entity agreed to sell such shares on the same terms as the first tranche.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ConvertiblePreferredStockNumberOfTriggersForIssuanceAtSameTermsAsFirstTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ObligationToIssueConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the obligation to issue convertible preferred stock at fixed terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ObligationToIssueConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ReclassificationsOfConvertiblePreferredStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability to sell convertible preferred stock at fixed terms that was reclassified into temporary equity upon issuance of the stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ReclassificationsOfConvertiblePreferredStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6940734&amp;loc=d3e22047-110879<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crvs_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crvs_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760656896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_CommonStockVotingRightsNumberOfVotesPerShare', window );">Number of votes per share of common stock | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends on common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711,000<span></span>
</td>
<td class="nump">$ 71,354,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Shares of common stock reserved for issuance, on an as-converted basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,274,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,576,535<span></span>
</td>
<td class="nump">2,475,600<span></span>
</td>
<td class="nump">2,559,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,013,394<span></span>
</td>
<td class="nump">2,350,582<span></span>
</td>
<td class="nump">784,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock (founders and early exercise of stock options)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,203<span></span>
</td>
<td class="nump">611,698<span></span>
</td>
<td class="nump">924,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan', window );">Shares reserved for employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,109,132<span></span>
</td>
<td class="nump">5,637,880<span></span>
</td>
<td class="nump">18,542,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_SalesAgreementMember', window );">Sales Agreement | Cowen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_CompensationOnSaleOfStockPercentage', window );">Compensation on sale of stock, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock sold to founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CommonStockVotingRightsNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CommonStockVotingRightsNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CompensationOnSaleOfStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of compensation entitle for sale of stock under sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CompensationOnSaleOfStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares that are reserved for the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_NumberOfSharesReservedForEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=crvs_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=crvs_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=crvs_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760802736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,475,600<span></span>
</td>
<td class="nump">2,559,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 731<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,576,535<span></span>
</td>
<td class="nump">2,475,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350,582<span></span>
</td>
<td class="nump">784,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,013,394<span></span>
</td>
<td class="nump">2,350,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum exercise term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price of common stock of its fair value (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued', window );">Maximum number of options that may be re-issued under the 2016 plan</a></td>
<td class="nump">1,136,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum exercise term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price of common stock of its fair value (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,475,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares authorized for plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(969,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,576,535<span></span>
</td>
<td class="nump">2,475,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">969,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(240,435)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,013,394<span></span>
</td>
<td class="nump">2,350,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.78<span></span>
</td>
<td class="nump">$ 11.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of options that if forfeited or lapse, may be reissued under another equity incentive award plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_MaximumNumberOfOptionsForfeitedOrLapsedThatMayBeReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753711792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Exercise Price Range (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Information about stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number</a></td>
<td class="nump">3,013,394<span></span>
</td>
<td class="nump">2,350,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 8 months 9 days<span></span>
</td>
<td class="text">9 years 2 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options outstanding (in dollars per share)</a></td>
<td class="nump">$ 11.78<span></span>
</td>
<td class="nump">$ 11.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions', window );">Options Vested, Number</a></td>
<td class="nump">924,812<span></span>
</td>
<td class="nump">397,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm', window );">Options Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 7 days<span></span>
</td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options vested (in dollars per share)</a></td>
<td class="nump">$ 11.40<span></span>
</td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in dollars per share)</a></td>
<td class="nump">8.93<span></span>
</td>
<td class="nump">10.78<span></span>
</td>
<td class="nump">$ 4.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeOneMember', window );">$0.28 - $4.65</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Information about stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price, low end of range (in dollars per share)</a></td>
<td class="nump">0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price, high end of range (in dollars per share)</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number</a></td>
<td class="nump">535,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options outstanding (in dollars per share)</a></td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions', window );">Options Vested, Number</a></td>
<td class="nump">325,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm', window );">Options Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 6 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options vested (in dollars per share)</a></td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeTwoMember', window );">$6.75 - $10.60</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Information about stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price, low end of range (in dollars per share)</a></td>
<td class="nump">6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price, high end of range (in dollars per share)</a></td>
<td class="nump">$ 10.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number</a></td>
<td class="nump">701,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">9 years 10 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options outstanding (in dollars per share)</a></td>
<td class="nump">$ 10.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions', window );">Options Vested, Number</a></td>
<td class="nump">2,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm', window );">Options Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">7 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options vested (in dollars per share)</a></td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeThreeMember', window );">$11.21 - $16.70</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Information about stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price, low end of range (in dollars per share)</a></td>
<td class="nump">11.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price, high end of range (in dollars per share)</a></td>
<td class="nump">$ 16.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number</a></td>
<td class="nump">1,776,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 6 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options outstanding (in dollars per share)</a></td>
<td class="nump">$ 15.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions', window );">Options Vested, Number</a></td>
<td class="nump">596,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm', window );">Options Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 3 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options vested (in dollars per share)</a></td>
<td class="nump">$ 15.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeFourMember', window );">$0.28</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Information about stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price, low end of range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 5 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions', window );">Options Vested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm', window );">Options Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 5 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeFiveMember', window );">$4.65</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Information about stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price, low end of range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 9 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions', window );">Options Vested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm', window );">Options Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 9 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeSixMember', window );">$6.75</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Information about stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price, low end of range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions', window );">Options Vested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm', window );">Options Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeSevenMember', window );">$13.34 - $16.37</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Information about stock options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price, low end of range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price, high end of range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions', window );">Options Vested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm', window );">Options Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of options vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding vested stock options as of the balance sheet date in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfVestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of vested stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeVestedOptionsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=crvs_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760783424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Vested or Expected to Vest (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber', window );">Vested, Number of Shares (in shares)</a></td>
<td class="nump">924,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice', window );">Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm', window );">Vested, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue', window );">Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber', window );">Expected to vest, Number of Shares (in shares)</a></td>
<td class="nump">2,088,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice', window );">Expected to vest, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm', window );">Expected to vest, Weighted Average Remaining Contractual Life</a></td>
<td class="text">8 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue', window );">Expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,903,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock', window );">Fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 10.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="nump">$ 332,000<span></span>
</td>
<td class="nump">$ 216,000<span></span>
</td>
<td class="nump">$ 714,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated fair value of the entity's common stock used in the valuation of options under the share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding and exercisable that are expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which stock options outstanding and exercisable that are expected to vest can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding and exercisable stock options that are expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for options outstanding and exercisable that are expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested options outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested stock options outstanding and exercisable can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding and exercisable stock options that are fully vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested options outstanding and exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAndExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904765552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,229<span></span>
</td>
<td class="nump">$ 3,828<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,692<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,537<span></span>
</td>
<td class="nump">$ 2,143<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747872768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation -Valuation Assumptions Employees (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.40%<span></span>
</td>
<td class="nump">84.60%<span></span>
</td>
<td class="nump">83.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 18.6<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected period for recognizing compensation expense</a></td>
<td class="text">2 years 10 months 6 days<span></span>
</td>
<td class="text">3 years 3 months 11 days<span></span>
</td>
<td class="text">3 years 7 months 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760539632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation -Valuation Assumptions Non-Employees (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,229,000<span></span>
</td>
<td class="nump">$ 3,828,000<span></span>
</td>
<td class="nump">$ 428,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected Volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected Volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crvs_NonEmployeeStockOptionsMember', window );">Non-employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="nump">$ 142,500<span></span>
</td>
<td class="nump">$ 42,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.17%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">2.33%<span></span>
</td>
<td class="nump">1.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected Volatility, minimum</a></td>
<td class="nump">80.30%<span></span>
</td>
<td class="nump">92.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected Volatility, maximum</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">92.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crvs_NonEmployeeStockOptionsMember', window );">Non-employee stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crvs_NonEmployeeStockOptionsMember', window );">Non-employee stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions used to estimate fair value of share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=crvs_NonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=crvs_NonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762697040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of loss before income tax and Income tax benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (28,253)<span></span>
</td>
<td class="num">$ (11,375)<span></span>
</td>
<td class="num">$ (31,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(27,410)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">(55,663)<span></span>
</td>
<td class="num">(36,375)<span></span>
</td>
<td class="num">(31,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917983408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of effective tax rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the effective tax rate to the U.S. Federal statutory rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of Federal benefit</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent', window );">Loss due to change in fair value of convertible preferred stock liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(17.00%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Federal rate change impact</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(19.00%)<span></span>
</td>
<td class="num">(18.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent', window );">Research and development tax credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_EffectiveIncomeTaxRateReconciliationLossDueToChangeInFairValueOfConvertiblePreferredStockLiabilityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAndDevelopmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6748973568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 15,438<span></span>
</td>
<td class="nump">$ 9,339<span></span>
</td>
<td class="nump">$ 4,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">4,351<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Capitalized tax assets</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">21,885<span></span>
</td>
<td class="nump">12,791<span></span>
</td>
<td class="nump">5,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21,885)<span></span>
</td>
<td class="num">(12,791)<span></span>
</td>
<td class="num">(5,866)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increased in valuation allowance</a></td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749946672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Operating loss carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 42.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 94.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6918039168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Tax credit carry forwards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">21,041,250<span></span>
</td>
<td class="nump">20,922,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and development credits | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and development credits | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753445504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax Cuts and Jobs Act (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense', window );">Net decrease to the DTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense for re-measurement of deferred tax asset from change in tax rate pursuant to Tax Cuts and Jobs Act of 2017.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6753805488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized tax benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Summary of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits beginning of the period</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to the prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease related to the prior year</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increased related to the current year</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, end of the period</a></td>
<td class="nump">$ 1,219<span></span>
</td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761579776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">20 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_CommitmentsAndContingenciesLineItems', window );"><strong>Facility Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LandlordProvidedFreeRentAndLeaseIncentives', window );">Landlord Provided Free Rent And Lease Incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734,000<span></span>
</td>
<td class="nump">$ 584,000<span></span>
</td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating lease obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Less than 1 Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears', window );">2-3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears', window );">4-5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract', window );"><strong>Contractual obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Less than 1 Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondAndThirdYear', window );">2-3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthAndFifthYear', window );">4-5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=crvs_FacilityLeaseMember', window );">Facilities lease | Office and laboratory space in Burlingame, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_CommitmentsAndContingenciesLineItems', window );"><strong>Facility Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased facility | ft&#178;</a></td>
<td class="nump">8,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_AreaOfLeaseExpansion', window );">Additional area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_crvs_LeaseAgreementRightToExtendTerm', window );">Lease agreement, right to extend the term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AreaOfLeaseExpansion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of real estate property added under a lease amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AreaOfLeaseExpansion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LandlordProvidedFreeRentAndLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of lease incentives and free rent that were provided by the landlord.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LandlordProvidedFreeRentAndLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LeaseAgreementRightToExtendTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of right to extend the lease as per the lease agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LeaseAgreementRightToExtendTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthAndFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth and fifth fiscal years following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthAndFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondAndThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second and third fiscal years following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondAndThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth and fifth fiscal years following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second and third fiscal years following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=crvs_FacilityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=crvs_FacilityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLaboratorySpaceInBurlingameCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747808768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Line of Credit (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of credit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of credit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6747249936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchase of research services</a></td>
<td class="nump">$ 461,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904331120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Selected Financial Data (unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Selected Financial Data (unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">$ 12,189<span></span>
</td>
<td class="nump">$ 12,944<span></span>
</td>
<td class="nump">$ 15,174<span></span>
</td>
<td class="nump">$ 16,217<span></span>
</td>
<td class="nump">$ 11,249<span></span>
</td>
<td class="nump">$ 10,476<span></span>
</td>
<td class="nump">$ 8,825<span></span>
</td>
<td class="nump">$ 6,426<span></span>
</td>
<td class="nump">$ 56,524<span></span>
</td>
<td class="nump">$ 36,976<span></span>
</td>
<td class="nump">$ 13,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,929)<span></span>
</td>
<td class="num">$ (12,717)<span></span>
</td>
<td class="num">$ (14,981)<span></span>
</td>
<td class="num">$ (16,036)<span></span>
</td>
<td class="num">$ (11,086)<span></span>
</td>
<td class="num">$ (10,297)<span></span>
</td>
<td class="num">$ (8,645)<span></span>
</td>
<td class="num">$ (6,347)<span></span>
</td>
<td class="num">$ (55,663)<span></span>
</td>
<td class="num">$ (36,375)<span></span>
</td>
<td class="num">$ (31,335)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (5.39)<span></span>
</td>
<td class="num">$ (2.72)<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (83.86)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MP^\J[(-U>_>/C2^"JH-?=Z&^ %!+ P04    "  GA&%,F5R<(Q &  "<)P
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MLH=^>#7^O;W<KRZ%WIVFNV-TO<!N_@=02P,$%     @ )X1A3+I(Z70_ @
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M)EO26'^L;;:H%^7N@_*,<L:4.YGR)5-H,>7+3 &, A3;2 XAS!&*4.8F4MW
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M!8X-&;X!PS=@Z(C0.I@8.J+$)'',]Q/Q_42T'[28;B/23Q3I*(U1%N\8'40
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M_,O&_E>(#KR4S94?H<9_L-E04+EP_.3/9ARST7#833^(S=\X_P-02P,$%
M  @ )X1A3)!#1_&R 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q]4V&/U" 0_2N$'W!TNWMZ;MHFMV>,)IILSJB?V7;:D@.F MV>_UZ@7*U:
M_0+,,._-FV$H)C1/M@=PY%E);4O:.S<<&;-U#XK;&QQ ^YL6C>+.FZ9C=C#
MFPA2DN59]HHI+C2MBN@[FZK T4FAX6R('97BYL<))$XEW=$7QZ/H>A<<K"H&
MWL%G<%^&L_$66U@:H4!;@9H8:$MZOSN>#B$^!GP5,-G5F81*+HA/P?C0E#0+
M@D!"[0(#]]L5'D#*0.1E?$^<=$D9@.OS"_N[6+NOY<(M/*#\)AK7E_2.D@9:
M/DKWB--[2/7<4I**_PA7D#X\*/$Y:I0VKJ0>K4.56+P4Q9_G7>BX3^GF38)M
M _($R!? 7<S#YD11^5ON>%48G(B9>S_P\,2[8^Y[4P=G;$6\\^*M]UZKW6U6
ML&L@2C&G.29?QRP1S+,O*?*M%*?\+WB^#=]O*MQ'^/X?"G\C.&P2'"+!X;\E
M;L7\621;]52!Z>(T65+CJ.,DK[S+P-[G\4U^A<_3_HF;3FA++NC\R\;^MX@.
MO)3LQH]0[S_88DAH73B^]F<SC]EL.!S2#V++-ZY^ E!+ P04    "  GA&%,
M#%+;L[,!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q]4]MN
MU# 0_17+'U#O>E.H5DFD;A$"":15$?39FTP2J[X$V]F4OV?LI"% X,7VC.><
M.3,>YZ-US[X#".1%*^,+VH70'QGS50=:^!O;@\&;QCHM IJN9;YW(.H$THKQ
MW>X-TT(:6N;)=W9E;H>@I(&S(W[06K@?)U!V+.B>OCH>9=N%Z&!EWHL6OD#X
MVI\=6FQAJ:4&XZ4UQ$%3T/O]\93%^!3P3<+H5V<2*[E8^QR-CW5!=U$0**A"
M9!"X7>$!E(I$*./[S$F7E!&X/K^ROT^U8RT7X>'!JB=9AZZ@=Y34T(A!A4<[
M?H"YGEM*YN(_P144AD<EF*.RRJ>55(,/5L\L*$6+EVF7)NWC=,.S&;8-X#.
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M_:\1/00IFYLP0FWX8+.AH/;Q>!?.=ARST?#833^(S=^X^ 502P,$%     @
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M[A&'!YCJ^4#)5/Q7.(/TX4&)SU&BM'$E96\=JHG%2U'\;=R%COLPWFPOL'5
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MW\-<SQM*YN(_PA44AD<EF*.RRJ>55(,/5L\L*$6+EVF7)NWC=,-O9]@V@,\
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M*:!( 0@R1P1AYEBDA"(E(' O'F$"%T]2G$&I3S%W#PR!BL K)H%,)8"B='4
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M:&5E=#(W+GAM;'53VV[<(!#]%<0'!)O=7+2R+6431:W42JM4;9]9>WQ1N+B
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MV^PEHU&4D(L3FC#'$4,7F.V,(%9]MJ ABR/]CT[#]"A88>3IT=(]CL("NZ#
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MXZO5CFDA&YHET7<V68*=4[*!LR&VTUJ8/R=0V*=T3=\=C[*J77"P+&E%!;_
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MHQX?8*IGC]%4_ ^X@/#A08G/46EAXXJJP3HM)Q8O1;*WM',5]S'=[/<3;!U
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MG7_9V/]6:P=>R.[&:^C]!UL, :T+QSM_-FG,DN'T,/\@LGSCZB]02P,$%
M  @ )X1A3)M!F[1] @  9 @  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&ULE5;;CILP%/P5Q'L7;*Z)"%)N52NUTFJKML\.<0):@ZGMA.W?US:$Y>*D
M[4NP#S-SQL?F.$E#V2O/,1;66TDJOK)S(>JEX_ LQR7B3[3&E7QSHJQ$0D[9
MV>$UP^BH225QH.N&3HF*RDX3'7MF:4(O@A05?F86OY0E8K\WF-!F90/[%G@I
MSKE0 2=-:G3&W[#X7C\S.7-ZE6-1XHH7M+(8/JWL-5CN@:<(&O&CP T?C"VU
ME .EKVKR^;BR7>4($YP))8'DXXJWF!"E)'W\ZD3M/J<B#L<W]8]Z\7(Q!\3Q
MEI*?Q5'D*SNVK2,^H0L1+[3YA+L%!;;5K?X+OF(BX<J)S)%1PO6OE5VXH&6G
M(JV4Z*U]%I5^-IW^C68FP(X >P(('Q*\CN#U! \^)/@=P>\)$#PD!!TA>+?D
MZ_*V:]?%W"&!TH31QF+M>:B1.G9@&<CMRE10[XY^)^O)9?2:PM!/G*L2ZC";
M%@,'&- C'*G>IX"F%!LXH\,P&*?8FC#A&+,S8:(Q9C_'#&1&7CUC.3S-]P?\
M $ZLMI!(0RH-^0"@%WB3JNT,N#"*HSNE\XUV_)D=&,83/_XLS\(%KFM.$QC3
M!%K"&VYP#,T"H5$@-/A<3'RVF&#@\TZ*R)@B,GCTS0*Q42">>XS<B<=XYO'.
M=BV,*19SCX,3.A( KOES= TNP<2E$30YIKM_ >W_ AH[OM- @$'"NR-A;!!K
M /^C;N;O%LP_W%G=-D;0] PY@\Y98G;6UQBW,GJIA.HL@VA_5:YU;Y_$-^H*
MU1WY7::]?[\B=BXJ;AVHD'U==]\3I0)+C^Z3/'RYO/+["<$GH8:1'+/VWFLG
M@M;=G>[T?RS2/U!+ P04    "  GA&%,;-SVJ@X"   :!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S-2YX;6R-5>F.FS 0?A7D!UASA"L"I$U652NU4K15
MV]].,@EH#::V$[9O7Q\$L<3M+C]BC_F.&0]VBH'Q%U$#2.^UI9TH42UEO\98
M'&IHB7A@/73JS8GQED@5\C,6/0=R-*26XM#W$]R2ID-58=9VO"K81=*F@QWW
MQ*5M"?^S <J&$@7HMO#<G&NI%W!5].0,WT'^Z'=<17A2.38M=*)AG<?A5*+'
M8+T-?$TPB)\-#&(V]W0I>\9>=/#E6")?9P04#E)+$#5<80N4:B65Q^]1%$V>
MFCB?W]0_F>)5,7LB8,OHK^8HZQ)ER#O"B5RH?&;#9Q@+BI$W5O\5KD 57&>B
M/ Z,"O/K'2Y"LG944:FTY-6.36?&8=2_T=R$<"2$$R%8_9<0C81H0< V,U/J
M$Y&D*C@;/&Z[U1/]403K2&WF02^:O3/O5+5"K5ZK,(T+?-5"(V9C,>$;3/(6
MLW5AT@F#50Y3(J$SD= (K&8"6>3F1TY^9/C1C!]DOEM@Y118W240IMFB2HM)
M#::S)K';(W9ZQ'<>^7(C+22>6:Q27S]NG\3IDSAJR1=&%I/,C%+_(<[GC]LR
M=5JF]Y;_VO_,*9!]O(&Y4R!_OX&;_,,-5'>3\[SX[[9P,V+F/8S], FRA1.>
M'5)]:WXC_-QTPMLSJ<Z[.94GQB0H3=49Y-7JHIX""B>IIZF:<WM;V4"R?KR)
M\?1W4/T%4$L#!!0    ( ">$84QC'"_-W $  /H$   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,V+GAM;(U4;6_;(!#^*X@?4&*2.%YD6VHZ39NT25&G;9^)
M?7Y1P7B X^[?#[#C>AV5^L5PQW///7?F2$>IGG0#8-"SX)W.<&-,?R1$%PT(
MIN]D#YT]J:02S%A3U43W"ECI@P0G=+.)B6!MA_/4^\XJ3^5@>-O!62$]",'4
MGQ-P.68XPC?'8ULWQCE(GO:LAN]@?O1G92VRL)2M@$ZWLD,*J@S?1\=3XO >
M\+.%4:_VR%5RD?+)&5_*#&^<(.!0&,? ['*%!^#<$5D9OV=.O*1T@>O]C?V3
MK]W6<F$:'B3_U9:FR7""40D5&[AYE.-GF.O98S07_Q6NP"W<*;$Y"LFU_Z)B
MT$:*F<5*$>QY6MO.K^/,?PL+!] Y@"X!4>QKF1)YY1^987FJY(C4U/N>N5\<
M':GM3>&<OA7^S(K7UGO-:1*EY.J(9LQIPM 5Y@5!+/N2@H92G.A_X30<O@TJ
MW/KPW3\*WR#8!0EVGF"[EO_AC0+V08)]0,'V58]"F%TX21Q,$@<(]F&"0Y#@
M\/XRDR!!\HXR0YCX51*RNGL"5.VG3J-"#IV?^)5W&>Q[ZN_N"WQZ%;XQ5;>=
M1A=I[ 3X>UI):<!*V=S9EC?V(5H,#I5QVX/=JVD<)\/(?GYIR/+<Y7\!4$L#
M!!0    ( ">$84RW[S"_5@,  %D-   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;(V7;9.;+!2&_XKC]T8!0=Q),M-DW_+RS.STF;:?W80D3E52)9OV
MWQ=?XL;CZ39?HI#K/MS  6%\UL6/\J"4<7YE:5Y.W(,QQSO/*S<'E<7E2!]5
M;O_9Z2*+C2T6>Z\\%BK>UJ(L]:CO"R^+D]R=CNNZEV(ZUB>3)KEZ*9SRE&5Q
M\7NF4GV>N,2]5'Q)]@=357C3\3'>J_^5^7I\*6S)ZZ)LDTSE9:)SIU"[B?N9
MW*VCBJ^!;XDZEU?O3M635ZU_5(7%=N+ZE2&5JHVI(L3V\:;F*DVK0-;&SS:F
MVS59":_?+]$?Z[[;OKS&I9KK]'NR-8>)*UUGJW;Q*35?]/E9M?WAKM-V?JW>
M5&KQRHEM8Z/3LOYU-J?2Z*R-8JUD\:_FF>3U\]S&O\AP 6T%M!/8MC\2L%;
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M;8>I&<ONRM%-M&C[ZU0PW.E6_P!02P,$%     @ )X1A3+F&AU_0 @  7 L
M !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULE5;M;MHP%'V5* _0^",?
M@ "IA4Z;M$G5IFV_73 0-8DSVT#W]K,=-PW)#:-_B.V<>\Z]MD^X\[.0+^K
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M^G>WER9"$\NIX="J1K2!A',9?HDWN\SB'>"U@5[-]H%U<A#BS0;?3V4864'
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M"AA5$% %\?'T1D4,$U"0@'J"^(8@F:318S*/:3TF)O$TDSF(+K(,EA*#4F)
M2CJ1TF.2JU4^X"2+)EH 5$86L)8$U)+,M4RE)+-%2)I-79F#*(ES6$D**DEG
M2DA.8((,),@>WR(Y2) _L$7RN1D1C2=FS$$X3^^8L0"E+  S$I@ 1W#91H_;
M@>]4/G[ D %TDRR=[E, E-SQ \/UCPF@Y4[58?@$P/0_'($K%T.E.W,DGIT0
M),KRJ240*L$3.>CJE';7YG>F#G6K@XTT]L#WQ_)>2L,M8_1D[:WL33T.!-\;
MU\UL7_7753\PLANN8C3^#Y3_ %!+ P04    "  GA&%,P\ODD#8"   +!P
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MN&!$Z5 <L1P$D-J2&,6A[Z>8D:Y'96YS>U'F_*1HU\->>/+$&!%_MD#Y6*
M71)OW;%5)H'+?"!'^ GJU[ 7.L*+2MTQZ&7'>T] 4Z#'8+-+#=X"?G<PRJNY
M9SHY</YA@M>Z0+XQ!!0J912('LZP TJ-D+;Q.6NBI:0A7L\OZL^V=]W+@4C8
M<?K>U:HMT#?DU="0$U5O?'R!N9\$>7/SW^$,5,.-$UVCXE3:KU>=I.)L5M%6
M&/F:QJZWXSCK7VAN0C@3PH40Q/\E1#,A6A'PY,RV^D04*7/!1T],/VL@YDP$
MFTAO9F62=N_LFNY6ZNRYC-(@QV<C-&.V$R:\PH19=HO9W6,B?X%@;6'Q$3I]
MA)8?W?@(W0*14R"R O&-0+0R.6$2B^DMYA\>8V>)V.$Q=@LD3H'DSF/@KS9R
MF]QY#.(PB[,X<%=*G952QVXDJTKI?:55"7QUBLRM_D'$L>NE=^!*'TA[;!K.
M%6@U_T$+M?HA60(*C3+33,_%=)VF0/%A?BGP\ER5?P%02P,$%     @ )X1A
M3-=7VS4Y P  JPT  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULC9?M
M;ILP%(9O!7$!!1L;FRJ)M*1-&VF3JD[;?M/$25 !9^ TW=W/@$N#?4CSIWSD
M><\'/GX+DY.L7NN]$,I[+_*RGOI[I0ZW05"O]Z)(ZQMY$*7^92NK(E7ZLMH%
M]:$2Z:85%7F PS .BC0K_=FDO?=4S2;RJ/*L%$^55Q^+(JW^S44N3U,?^1\W
MGK/=7C4W@MGDD.[$3Z%^'9XJ?17T4399(<HZDZ57B>W4_X9N5SAL!"WQ.Q.G
M^NS<:UIYD?*UN5AMIG[85"1RL59-B%0?WL1"Y'D32=?QUP3U^YR-\/S\(_JR
M;5XW\Y+68B'S/]E&[:<^][V-V*;'7#W+TZ,P#5'?,]U_%V\BUWA3B<ZQEGG=
M_O76QUK)PD31I13I>W?,RO9X,O$_9+  &P'N!8A<%$1&$/6""%T4$",@GP)V
M44"-@/8"?%D0&T%\;0_,"-AGALL]<"/@UY:4&$%BE11TZ]<.Q%VJTMFDDB>O
MZF;ZD#9;!]TF>N36S<UVPMK?]$S4^N[;+(KC2?#6!#+,O&/P@&%#9@$Q?,C<
M04PR9.X!AH5#9@DQ:,@\0 P>,H\0$PV9%<20G@GTL^T?, 8?,&X#1(.F,1P@
M @-$;0 RJ(!:G70,;9FR91#!C#""X$P$S$2 3-8L/'8,.\N44'JVBH,T%$Q#
MG33.RE G"V)Q&,)98C!+[&3A%-8S4,^N7S<.!N!?K]N".^O&$XQ(Q.%$"9@H
M 1+9VS-Q$D510HFS15V.D#ADR"K\WN50&%-,['%Q.4HQ3>*1N40A;%+AUY.Y
M,-!@:/#YT!@3 K"8V=@]@)%P; +1B+<BH&QNEXW<I1G) AL,PD"6Q,Z"G7;P
MZ(9"L!$AUXGLC?M@F"MW+H)]" %&Q)UU=)T(AW@T$VQ%R/6BB(_-)NPS*+[>
M*!!L-8@!56"[WPYJYO)S4&X8'3$U!)L2 ER)6__SYB!$AM 2A"R;6(%0/%(Q
M[&X(L#?.[(HAB-L50U!B5PQ R<A08=BM,.!6B?5^,@<A:\V7(&2_H7P!=14'
M9^^#S6?,C[3:967MO4BE7RW;%\"ME$KH@.&-WA1[_>747^1BJYI3IL^K[O.A
MNU#R8#Z-@O[[;/8?4$L#!!0    ( ">$84PY1A"W2@,  .P-   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;(U7;6_:,!#^*U%^0)/S2YQ4@+0"TR9M
M4M5IV^<4#$1-8I:8TOW[.2^EB7UA\('$YKF[Y^[L!WMV5M5+?9!2>V]%7M9S
M_Z#U\3X(ZLU!%FE]IXZR-+_L5%6DV@RK?5 ?*YEN6Z,B#T@81D&19J6_F+5S
MC]5BIDXZSTKY6'GUJ2C2ZN^#S-5Y[H/_/O&4[0^ZF0@6LV.ZES^D_GE\K,PH
MN'C99H4LZTR57B5W<_\3W*\);0Q:Q*],GNO!N]>D\JS42S/XNIW[8<-(YG*C
M&Q>I>;S*I<SSQI/A\:=WZE]B-H;#]W?OG]OD33+/:2V7*O^=;?5A[L>^MY6[
M])3K)W7^(ON$N._UV7^3KS(W\(:)B;%1>=U^>YM3K571>S%4BO2M>V9E^SSW
M_M_-< /2&Y"+ 8&K!K0WH!<#>MV ]0;L(X*X:L![ _YAT.80=+FWQ5RE.EW,
M*G7VJFX]'--FV<$]-^W:-)-M=]K?3#UK,_NZH F;!:^-HQ[ST&'(",/'F"6&
MB<:8%8818\P:P\073&!RN21$T(1(ZX .'$ $N .*.J"M S9BD%C9=AC>8LH6
M0Y*P^U@YWX(<D6(H*>:08G:H)7-" <[I!N"($D<I<8026)2X&PD/$:$A(B0$
ML4)T&#$(,9&%0$,() 2U0@@GA !PRXK!*&>398U10K&S?EG(< <)ZB!!,K)V
MZSIQ^\*(8()-M ="7#Q")%9D*T/H;@$N(DZY+0\(D D>V85>HQYYP@;;=,Q^
M0OK W>DAL]F#$XN&0!V17"% 0GG(8V*S=X$B9D"C"?*XS %!2B]L\L0E#PFQ
M%_@*P44 T4!X>^HN+B%LV,DQ=5Q@P558%L8V=40X,2W[/VY,"9=7</4UL84&
M7-F,($R $IN2"^01%7'LK&-$B&/.2 )3VQ!78L"D>&HOX$H+T>U_FX K*=P@
MI0_@BB00COU++1&HN-997$XA=COK*%3L-HSP:*J"N.P"HKL0VNECH(DR$UQS
MB:NY\=0!"=<] K?WFDP<LESU<:I*7+&X4E6":P5!M )L126N!M"8Q9&MJ,'@
M4-S<@[ZGU3XK:^]9:7.^;D_!.Z6T-#[#.^/M8*Y>ET$N=[IY%>:]ZNX?W4"K
M8W^W"BX7O,4_4$L#!!0    ( ">$84RVW(/S P0  #P3   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;)5878_J-A#]*U'>NXD]<3X0("TL52NUTNI>
MM7W.@H'H)C$W"<OMOV^^EB7V,>6^D,2<F3ECSQPGGE]4]:T^2MDX/XJ\K!?N
ML6E.,\^KMT=9I/63.LFR_6>OJB)MVL?JX-6G2J:[WJC(/>[[H5>D6>DNY_W8
M:[6<JW.39Z5\K9SZ7!1I]>]*YNJR<)G[,? E.QR;;L!;SD_I07Z5S5^GUZI]
M\JY>=EDARSI3I5/)_<)]9K,-Q9U!C_@[DY?ZYM[I4GE3ZEOW\/MNX?H=(YG+
M;=.Y2-O+NUS+/.\\M3R^CT[=:\S.\/;^P_NO??)M,F]I+=<J_R?;-<>%&[O.
M3N[3<]Y\49??Y)B0<)TQ^S_DN\Q;>,>DC;%5>=W_.MMSW:AB]-)2*=(?PS4K
M^^ME]/]AA@WX:,"O!FWL>P8T&M"G07#7(!@-@D^#\*Z!& V$%L$;<N\G\R5M
MTN6\4A>G&NKAE'9EQV:B7:YM-]BO3O]?.Y]U._J^#!C-O??.T8A9#1A^@R'.
MII@7$_.)\%H&5QH<T5AQPYPG&HVUB0E8H-$ ?J:(C8D@'S,E.&'4V].$A< .
M N@@Z!T$$P>AEL: $3VF'-(((A'ZOI8,P F1!$F""0E(2 !"D49HP$0W@2+2
M2F!C8@),(X0T0D CUFB$(-\H%"0T*@"GS=^$4 0)16"E+1,;0P?Q RL=FTQ)
M^"+6R];$17';J2'FDT ^R0,SG!AQR&=$B=9H&Q.G\YX08CY6']^DQ"V+Q"P"
MQHQE8B%97$#Q>68<L-"J>PU!MFRQ=# "+G25@R!+(S&L, Q(#!=Z' 2RE!/#
MPL& <O!(WSR$42FLK5O.+:W$L#HP( \\MKC _<S,AK97"NYH!EI:KY05!-DJ
M!7<J ZVJ5\H*@BR5PG'_<=1_6J6L(,A2*1PW*3>;U+IK<MRD'/2?H:8CZ&'A
MY[A1.>K!1(]%1JR8?-\:"O<J!VU(OA[*W.=_2<)$6&/A?N6@7_5=_(6;_<H#
M/R#;:N%VY8_LYOS1[1P![RXK%@#^$SLZQP+ ']G3^?]OZM-86 0XZ&^S-,R-
M^%YE$-8! BVNOP-N1M"D"L.0"XN$$I8"8@\4X0B:A+I7A80U@Y!FZ%5(IF;@
M5QX O+NL9/F  %\09'.!18.0:)">UP!*)AOO4VS9,PE+!B')T#^Z1A!C6BA+
M)*P8!!3#$((1I.7DVV8/RP!%()+>PR-HFA,]^1:Y("P7!.2"]&^K$:0E%<5Z
M[A!FK*=W\^5?R.K0'\/4SE:=RZ:KNIO1ZU'/,^].#K3Q%9NM&1A_8;/-<)#S
MZ7XX5_HSK0Y963MOJFE4T9\J[)5J9,O>?VIKY"C3W?4AE_NFNXW:^VHXSQD>
M&G4:SZJ\ZX'9\C]02P,$%     @ )X1A3+17F^>;!0  KR$  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3 N>&ULE9KM;JM&$(9OQ?(% /L-D6,I)JI:J96B
M4_7T-[$WL77 N$#BT[LO8.*:W7>BS9_8D'=G9X=YQOO!ZEPW/]J]M=WB9U4>
MV_OEONM.=W'<;O>V*MJH/MEC_Y^7NJF*KK]L7N/VU-AB-S:JRI@GB8ZKXG!<
MKE?CO:=FO:K?NO)PM$_-HGVKJJ+Y=V/+^GR_9,N/&]\.K_MNN!&O5Z?BU?YI
MN[].3TU_%5^M[ Z5/;:'^KAH[,O]\H'=/1HS-!@5WP_VW-Y\7PQ#>:[K'\/%
M;[O[93)X9$N[[0831?_Q;G-;EH.EWH]_)J/+:Y]#P]OO']9_&0??#^:Y:&U>
MEW\?=MW^?IDN%SO[4KR5W;?Z_*N=!J26BVGTO]MW6_;RP9.^CVU=MN/?Q?:M
M[>IJLM*[4A4_+Y^'X_AYGNQ_-,,-^-2 7QMP_6D#,340H0WDU$!>&S Y1NLR
ME#$VCT57K%=-?5XTE\=[*H8L8G>RC_YVN#D&>_Q?'YZVO_N^EB)=Q>^#H4FS
MN6CXC89=%7%O_=H%1UULN-><SSO(?85(YI)'7Z(U=D+ <8JQO9B-,\,&)#0@
M1P/RUH!TG-Q<-&K4'*=Q,"$RZ8S7UW&A$I5R[)""#BG@$',<0AHW^$@CL",:
M.J*! 6?$FXLFNQDQ8Y%Q$BV'JC3%SACHC '.*,<9XX4_XS)E;F!\F<B,3(FT
M2Z$[*7!'.^X@C7%\01HB+AET) ,&,L>1#(7?S5U?E$8)D;@LP34G\9U1+DN3
MB+%93YEPW$$REGBI]3CI;OV6D3"$WT2M9,!OHA0R6 L?& ^O0PQ7,B: %]R-
MGO##DD2<2!F&2QX#-4\)MR<) JL5T1$N90S5("\AE,>C$HH)@D>&BQ5#U<HM
MFTBD)-$/KD,,%2*W*DZB&7&1I :$*PQ#I<&M>)-H5LNXZLL9T16N(0P5$;>:
M(9$BTH'C^L!!??"*%?>!9I$@'A+'0',$-!%^CH'F7P":8Z!Y"- < *TC0P46
M \U#@.8^T'U!I:*"@>8A0',?:),PG21$5QAH'@(T$BDB^3D&FH< S0'0222I
MK,1$\Q"BN4\TU]14B6.>>0C/2*2(?@3F683P+'R>Z?P6F&>!>"9@%)AG\06>
M!;'4".%9 )[[V18GIA," RU"@!8 Z#ZT1$<8:!$"M/"!9L9H3:8+)EJ$$(U$
MFJ@< A,M0H@6@&@52>HQ8:)%"-'")UIEVG#J06&F10C32*2)(4G,M QA6H+?
M:!5Q8G4I,=22>4;HF:S$5,LO4"TQU3* ZGP2!?I*;#0$[#3DTM]"D"S3U Z"
MQ%3+@#V$'(DTU0\F6@9L$>327_U_$CN,M Q8_N?27]@SE1E!C0DS+0.6]CD2
M:2K],= R8.6>2W]53L=.8:(56B%3"SF%654LG#.%454\@+-)%.@K!EH!H#W.
M)M$L5_J,HN:H"B.M$-(N9TBDB9FC(K8$$<\N9Y,H,'88:(6 =CF;1+,:Q6]S
M=]X3)EHAHEW,D(@,'<99(9Q=S"918.@PS\I'E9[G:HRJ3L(QTYA4C:;*+F;:
M_^G]Q%?,LP8\>YA-HMG<)Z$@TYAGC7AV(4,BZ@%J#+-&,+N0:7_._4GD,,T:
MT>Q"IL&<^_8$9]X1L8&/:'890R(R<IAEC5AV&=/^A/N3R&&8-?K9)78P-,94
M9^&(&4RI0=O<WB$#VK\6Y$:6P30;1+.[56Y\FOMU(+4';C#.)@1GX^/,3,HD
M1;3!1)L0HI%(4V/"1)L0H@U812MRO6XPTB8$:0.0SD1*#@I#;4*@1B)-G;<1
M!VXA4!NXBF9NDL<WI]:5;5['-P+:Q;9^.W;#X>_-W>M;!P]\./5V[F_8W>/E
MW8'_S5Q>9?BC:%X/QW;Q7'==78TGWR]UW=G>RR3J0[ZWQ>YZ4=J7;O@Z/)'F
M\@K!Y:*K3]/K$?'U'8WU?U!+ P04    "  GA&%,SM7E9+ "  !0"0  &0
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MFIYK32<A-#=NHH6IWHNYWO23BI^T'69F+'V/]Q,MVN[^$O67J/5?4$L#!!0
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M4XON+M&&\+,I4,(IV:65^BZZ&YUJX(NO+V%K/%>U<2AE_V2&POH-\W/="N?
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MA(XQ_*3+:J='_O-#(3:JO4WT?=W/O?V#DOMAI@_.?RS,_@%02P,$%     @
M)X1A3%<4-M9! @  S@8  !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&UL
MA55=CYLP$/PKB/>> ?-QC0C2D:AJI5:*KFK[[)!-0&<PM9UP_?>U#2$$W/0E
MMI>9V=DEK-..\3=1 DCGO::-6+NEE.T*(5&44!/QQ%IHU),CXS61ZLA/2+0<
MR,&0:HH"SXM13:K&S5(3V_$L96=)JP9VW!'GNB;\3PZ4=6O7=Z^!U^I42AU
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MF,EP9$R",N@]J3Z6ZG(9#Q2.4F\3M>?]B.T/DK7#[8'&*RS["U!+ P04
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MHU##6(Y9WS'T$T';H1MRQI8L_0=02P,$%     @ )X1A3!UY9#3= @  ZPH
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MYG*Z&%.@Q3#?>;P\/.4+4$L#!!0    ( ">$84S4I5 X+0(  .L&   9
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;(U5VX[:,!3\E2@?L(Z=&Z 0J0NJ
M6JF5T%9MGPT<2+1.G-J&;/^^MN.-TF!:>""^S,PY<WPK>BY>906@@K>&M7(=
M5DIU*X3DH8*&RB?>0:MG3EPT5.FN."/9":!'2VH8(E&4H8;6;5@6=FPGRH)?
M%*M;V(E 7IJ&BM_/P'B_#G'X/O!2GRME!E!9=/0,WT!][W9"]]"H<JP;:&7-
MVT# :1U^P*LM)H9@$3]JZ.6D'1@K>\Y?3>?S<1U&)B-@<%!&@NK/%3; F%'2
M>?QRHN$8TQ"G[7?UC]:\-K.G$C:<_:R/JEJ'BS XPHE>F'KA_2=PAM(P<.Z_
MP!68AIM,=(P#9]+^!X>+5+QQ*CJ5AKX-W[JUWWZ8R5-'\Q.((Y"1@)-_$F)'
MB!\E)(Z0S AHL&)KLZ6*EH7@?2"&Y>VHV45XE>CJ'\R@+;:=T^61>O1:ICDI
MT-4(.<SS@"$3S RQN47$T=^0[2TDS>,1@W228Z;$FRFQ O%4((O\ K%7(+8"
MR40@BV=.!TAJ(>W@%$<))NG,S<8#C):$)&3ASRCQ9I3<9)3FB5\@]0JDC]<D
M\PIDG@S265$&3#[Q>F?=<F^(W!,B\PLLO *+QTTNO0++!TP.F&RZH$_8'P1'
M_I,4W819W"D4OG,6\>-.L?^08/+?3;YUF.GF3?5#H7^S4&ARB9AGX"L5Y[J5
MP9XK?1_96^/$N0(M&CUIN4J_/&.'P4F9IKXH S%<OT-'\<X]+6A\W\H_4$L#
M!!0    ( ">$84P5'2S*$0(  /D%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8P+GAM;(U4[8[;(!!\%<L/$.+O:^18NN12M5(K15>U_4WL36P=&!=(?'W[
M N9\CH/2^V-@F9F=!;-YS_B+J &D]TI)*]9^+66W0DB4-5 L%JR#5NT<&:=8
MJB4_(=%QP)4A48+"Y3)%%#>M7^0FMN=%SLZ2-"WLN2?.E&+^=P.$]6L_\-\"
MS\VIECJ BKS#)_@!\F>WYVJ%1I6JH="*AK4>A^/:?PQ6NU3C#>!7 [V8S#U=
MR8&Q%[WX6JW]I38$!$JI%; :+K %0K20LO'':OIC2DV<SM_4/YO:52T'+&#+
MR.^FDO7:?_"]"H[X3.0SZ[^ K2?Q/5O\-[@ 47#M1.4H&1'FZY5G(1FU*LH*
MQ:_#V+1F[(>=++ T-R&TA' D!.E=0F0)T3LAODN(+2'^*"&QA&1&0$/MYC"?
ML,1%SEGO\>%WZ+#^ZX)5HJZKU$%S.V9/G:=0T4N19%F.+EK(8C8#)IQ@@A&!
ME/J8(G2EV(0W]#!-KE-L'9AKQ-,M(EI>0W:WD#1U&XV<9Q$9?CPUD04SHR[,
MW.H',+O[F"NSL=-L?".09 \SLP,F-9C68.+%)W>2Q)DD<;B,W *I4R#]_Y%N
M7)AXE@1-_F<*_&2:B_!*=FZEOO))=.Q?CZ%^#[/X1O6UH0V]RPQ-\3OFIZ85
MWH%)]=K,FS@R)D%97"[40=2J#X\+ D>IIYF:\Z$;#0O).MMHT=CMBW]02P,$
M%     @ )X1A3'PXQ4X^ @  V08  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C$N>&ULC57;CILP$/T5Q'O7W*$1(&T25:W42M%6;9\=,@EH#::V$[9_7U]8
MEH"[Z@O8PSEGS@QXR ?*GGD-()R7EG2\<&LA^@U"O*JAQ?R!]M#))V?*6BSD
MEET0[QG@DR:U! 6>EZ 6-YU;YCIV8&5.KX(T'1R8PZ]MB]F?+1 Z%*[OO@:>
MFDLM5 "5>8\O\!W$C_[ Y Y-*J>FA8XWM',8G OWT=_L,X77@)\-#'RV=E0E
M1TJ?U>;+J7 ]90@(5$(I8'F[P0X(44+2QN]1TYU2*N)\_:K^2=<N:SEB#CM*
M?C4G41=NYCHG..,K$4]T^ QC/;'KC,5_A1L0"5=.9(Z*$JZO3G7E@K:CBK32
MXA=S;SI]'\R3-!EI=D(P$H*)X+]/"$="^$:(WB5$(R%:$) I1?=FCP4N<T8'
MAYFWVV/U$?F;2':_4D'=;/U,MH?+Z*V,TX\YNBFA$;,UF&"&\2<$DNI3BL"6
M8ANLZ,%]@MT:$7KWD/T:DB1V$Z&USE#SPWF=F6<7B*P"D1:([@3\1:,,)M68
MSICTHD6M:XP?QG8CL=5(;#&R;*C!Q',C]A2)-45B21$N:DU6*3[$__@L4FN2
MU))DT:QMNJYC]MI-K6M,E"S,[M/_;WIF-9M9S,8+L]DZ2> OSM)N#5I](GN+
MT,HMFAWP%MA%#T_N5/3:"75.9M%I/C\&:D LXELYM\V8?9,Q0_\;9I>FX\Z1
M"CE^]) X4RI 6O0>9+]K^9^9-@3.0BU3N69FVIJ-H/WX(T'3WZS\"U!+ P04
M    "  GA&%,2RZ]N0@#  !##   &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6R-5V%OFS 0_2N('U"P#0:B)%*3MMJD3:HV;?M,$R=!!<S 2;I_/]NX
MC-A'1S\4;-Z]=^?CCLORRMO7[L28\-ZJLNY6_DF(9A$$W>[$JKR[XPVKY9,#
M;ZM<R&5[#+JF9?E>&U5E@,.0!E5>U/YZJ?>>V_62GT59U.RY];IS5>7MGPTK
M^77E(_]]XUMQ/ FU$:R737YDWYGXT3RW<A4,+/NB8G57\-IKV6'EWZ/%$]8&
M&O&S8-=N=.^I4%XX?U6+S_N5'RJ/6,EV0E'D\G)A6U:6BDGZ\=N0^H.F,AS?
MO[,_Z>!E,"]YQ[:\_%7LQ6GEI[ZW9X?\7(IO_/J)F8!BWS/1?V$75DJX\D1J
M['C9Z?_>[MP)7AD6Z4J5O_77HM;7:_\D(<8,-L#&  \&*/G0@!@#,ACTISEI
M$!F#:*Y!; SBN0;4&% KAJ _+'WZ#[G(U\N67[VV?X&:7+VG:$%E?G=J4Z=3
M/Y,)Z.3N91VG=!E<%)'!;'H,'F$(1K>8K8NQ$$\N(DZ3 1-(+P=7,>3J!@,$
MJ>6&BR&8W&(>7 RFR2WF$>*)K( @?S(X( *>/=$$9$R0A3!!!!)$FB"Z(; 3
MTV,2C:G[Q&2A^H.%8E H!H2P)=1CXI%00J*Q3G_ZL>-/G+JP1Q=&HF32:PIZ
M38'S)3!! A(D3MA.U(D3-:$$3SJ:@CHI<+S6V[9-'2&$HFA2* .%,D HMH0R
M1PB3=/KH40CWE1"0HG;3"-V@0C0M-='"$)#GB<Z"P-9RC_#_,VTPLU.-X*)'
M9$:R#6AVMA'<'Q#4(.Q\&]#\A,,M D$]PDFX6]8?)ARN:T0!J72" JYLE,SO
MO0@N6@15;78;\ :Y99LB,N4K7+3(K5IJ]\L- "*C#_GMYQ4N6>R6+ WMKSAV
M2Q:GE$RT50Q7+$: DEUO  @[$06C.:=B[5%/J9VWX^=:J&_S:'>8A.^QFI.L
M_2U://;S[#^:?KS^FK?'HNZ\%R[D%*9GI0/G@DD?PSMY#B<YT0^+DAV$NDWD
M?=N/M?U"\,:,[,'PNV']%U!+ P04    "  GA&%,\2IMC;H!  !!!   &0
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MWD>XQ58I"TY-<N/D]&Y,%X-#:_UV[_8Z/M9H6#7.<TB6GT'U!U!+ P04
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M8&MZFR4W>;GTUDHT')8$8NN$[C_,C4MUK$%V:K@!*%(:X7P!\Q9)/I^O%N4
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MHKD*(,T0&TMN,92=-^:LCZ\7S-%D$V5C:!B#6T!AY@940) OO9V!*IWQK=D
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MP!3@)5T]-0%N]S:3D558O+K'=W% ,;HT=YEEOSXO9_,3<A(@BLC^[G$U7F
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M0AOV.&[^&7U]X=!BC\D[GE!R)".5P+"@6HBMN?/R+,PE HI('EJRFOF/$4.
MO#F.!F4VUBJC?PD/PW>1>:*$RV;, !Z_\9B$>*:K*8'7#?3Z* 9UE/:N+Y+3
MT5F?8V9U(*2%H_&/G!CJ/A@^PE"9UH9C._4=I(8FU5'^:*Q:[@Y3ID4>'M!,
M \(1J]I8@XUH-B:#F:10'(:51D,7T?QH)P=B#;=E;4T&%"A%E,R<#EUI'MU/
MDO8AD=?V%KLFBF=%"ONZGH#$BQ=B*70OIQCU>3G-BB'"=99I-%IEQ&?1RU3>
M@F6":ETIGG?+'*[IJ/.X7%2L6T!J74!WTZQ_.6/V/W_;"%(7#799)1\',AS2
MW@=&_Q+=D"YQ0=J6#H<.! EW9;RR\;?XR!X^&>*%A+LHC&N<F.2BC*B"8(>A
M_.Y"T6M!"N_[]%-+Q? NM:C%#;XEU,>QT#BVVK4:CSVFX03N"3^4J$D8T TG
MN&4; W,(XR7#J%P05BIE:1E156MXH9VYCVRT"STF*Y4&&B]7%5J#1$^#Z<T?
M*%53PBG@6LT=:54X76TDJGNF["CQR58*9(THU.?J370')W#4V<:MX+*G:H_%
MC^.F<)7UVCZ!E@G!Y5>DJRHN]:.35-F2P\Q5#L5GJD]8<P)K8G3-%52&6R[1
M0E6NZF+M&1[:*ZN]M/^6C24L\ (3$^HYP+52KR@=5I:P> H2[GUM=$;*O3;N
M44Z!K31HAHP><&)\Y1"NH#B0.V5(D?DFFJ@5$.[O*P95HK08ORL!G!:V[FK5
M0&T$L=ILEZB6$_C-*ZXU$,BLTY<;5G4CUT=LJ[]F17Y7$JT0,63SNE6GQW/\
M2+Y%3NN*+Q_O1&(%=W,_E%174V.Y90V\K&11:U;3\1J9E87KD4#NLO&6U+)F
MD.>I3GY936\E,TA&$_NA>V@1HY"BK''2SZW#BV1#OLYD D1ND_Z:D;&7"2YS
M@)M,_H[TA]ZO,@#88I@\<[F4C3G(4)@"0/EB2%Y+4(7XBC$C(L<L%HIR62(A
MBVQ- M(WPY<#H[K/6_%)H<<'WKH%;9&)CC=-,*(DB@4J-JF)5 A-^P3)73"M
M.=B;!=\.M$*Z7KAQ\PI'MHC6+J XL E3N]-B&)C01-HS= X.>J4AF-Z!U^@=
MW@!=8A3V91O;7XL=DQ.Q/Z7FO&[$#U/@.(P9(+R0V8!T5+1O-K7*"@4FF^"M
M-F996;.<:]>A"]T6YS M@D2/0DSC</H-)^D%8;P*'-9$ -78J^GXJX&PI04I
MK(X4ARYV0_P])D)^:T.>A8BW<*#6^'\::Y;[))VOD\FRH:A*"2J%BU_E]93+
M)?B#6@:=,\=FKN$=!EOTR*"+=J]W$KET+;*3^I.\65ABP!EP;>1&&V)TO\FX
MD0!_R;BA>FD@9B47*V'J?R]O:LPK2/;P^2-\!K]).B# =F("BX&7F8!ZC(DK
M,$6@X+6C'8"4Q!K1'!;_:\8K<E0H)SV"1%_7?)AB/,F !,HYS,$^13)@*ZG[
M1,89QU<&^\[R6RHL@)X_$8O@>(1G*9VU :WN(>+OL*?QZ#LGP4 S'*5D;!\Q
M'05CA#J(+__(Q&IDD<.@&3M0.?=#)A;^GTQLAKEC\T"='J'+7BZ5\92<JEK@
M@P"9/[,$DM=7E62H;9?77)<0Q@8;J?:./24B5(CTC"(1#+[#N"3365PS>';]
MX@+9VFRF-2"NZ1<GQ? 94&J,S:0$DA$"VRH![GN7<Y*KO C%#@2^/G^&(^T;
MX;0@U\_*E#FHIA8?T1HH?OHIPS/UV*T<DQ P<1+?9.L2S4,:^R3K,0<I(47_
ML!%1KGO'R75NH3:;<QUH6TW-^"QO,F-!$IO#G098UY3.IY!!6.#E7>*182F7
MQH2B8)HI:#6_ 9:+0YV/C&Q>$B%]N\JGQF'N1M9PG&/66.^TD3N,2DC97J.Q
MB1F[YRN#4%RCDB91FA45,R93@G&0^A=(4F^ &,+E(8'[57E/"N)4$67OT4^7
MK]Y?2IJ/,7[C/.A>@?-<8AKKVH1%.G91=21;Q'#!SP'<-#H=)N]32Z'A"=#]
M2 &)UABJ@ZJB0#B"0A'CDF#J$&@[9E!AA=*QG%&=<;*7FS&RV9%(#,"&8COV
MXF'/KVB%)>Y:?^(X =;@:EL!Q"$78HFW1&QS.!F3>5$F6=UW_9#DW8<]E>@O
M00;7Z P2<0B**L/(G29(N%X@YA1&,.XJS$FP!]XH)V&$/KH?&^+PB-=X4;D4
MW-<1J(_U$5YI73PJSD5YTY-(P3SD_B!8382'W: *#G*C2XI9WV19X#[#:!V4
M;)&KWF9.W+^&+05E'Y6<65[3)X!B:+)2):.(+ '5-+>'"OBQL<;L+7DN5?TZ
MML(Q/E]P(QSCL'%1WF;5[ZEF1S2Y&F.*QAQW[T'/PB1 ;ZS=X66[.?D8MII:
MWQ9GM39P/T"62?E6P#_+)NFJSCQ%YRYUDDE3NY].Y:8?W[L+<LUUKU/4HFLI
MZ-C].@,<;ZG,-NR]R]#X[]4/J."&HQ+# 5R7&"6WIE(0#.67AHXY'UWCF9+U
MXUF)ANB]1R_/KY\!>1<1(OKJAR69N/<>G5]_@%=1F,!I!@=/^D: )BIT83Q5
M1%TN0"D")E(92Y:1ZCBD7V)S?/G.*CZ:56#R,//&-7O>9#Q&84*%A.7/&.=!
M"IGGR)PYS@#IBPEG ":C:P.=]_J#NR?6Z0 %BG2"@=FUQ-]PH#\OR;4A&%ZN
MB6&4W:Q6$#9JU58 9C*+LGTM $;LZ)2/V?/*$9$FHVB8O*!(,;&':8[#$L7:
MIF'#,T# '^J49S:S\MMBH>8H^"P7+D$!=E5I@A'1A,9* ?XF$H0C7ZDI^#((
MU4P0OPQV64B?# [.=L2>9.]]N83MGQR<[#\%M*>:%8#6J.NOL&087HP+E^K"
M)[:;@,[Q4X5W33X"=F)$6,R!1L>9YC1H,1O_=-E5X$^=TM03?VI @Q9&$5PD
M%7@[7$8'GP672X[L)B_#E<TV2=XZQ0.0;KZB2 /*(VMO7^TA:<V7#-W0SJA.
M#HM7DH#5%1FU"WZ"&^N=(##^+ B\2:NJO!]<3\IEABJ-"6ZE%5[A &1PP3BK
M:<XQV4J7I!9(V:Y?9(->.W;?#\6X5+MIT( N DW* @-%107LVX@=7V90 \#2
MJ0=#SCTJ(F8C-TQ"(DG3,KB:<!T"QQZ)VM!S$N,-/[*DAYW=&M7&-UNS5UID
MJ14JH#EGDD$,HC(R9I)3@"X9$!!EI=E3Q]($8TP:S>;<H6Y#W3:BJD8B09X.
MH:9DG>1E=E-Q5:4=J!+@'H5(&^0Z.QH;@9MX0FWY 45 .S@>D'93Y *3>K+,
MU9(YT1 -D77F:O[P$,/ 2Y:]> ;7RB"6/<_O8V?V8<U]&IB'2EK-FH?DF#RF
M]U*6A8Q?ZCIA>;:=-L26)2/YI@V:T8AS&"^O98RBK3F%+68FC<7C1![_4U9N
M"[%H"3,?!9_("K. $QHV&&>UKFGI)C.9+.R*1#<P!U'X#) R,C \!.T4^"]7
M''"\C8'V@^-]!-):KM37C+D-A@IEA@H%EE%KQ_2-2'I39JUKM>O5&3I"XFG7
M/:"')-KM%(&AM^1T=+:O+Q$!AE6^)EC*J5C)LB_86"$R<B!!J480%K-%$_83
M:5$&\?)H4Y:6)>A XZ(XP((RNN;._,/D@W%FNQC1]][R\(,4X'S6"CCH2[ :
M$P"[(A.+%&;:84$#796H\F7E.-)5[Z=%BU:OAE53##\"!!9=Y;R,*^+A5^F,
MZ(Y^KQ=B:=&_6!N)<RIA$ZZXN0&!-<POCL'F6NZ,P;&RB;Y9H/W&X3")V XH
M<J9$VR4MC<T-=Z7)NC :*^7)ACKM'A$W*1C+=2^6C3QCCXF^B8&)^T][VB K
M\]NH]/#T\/].\/^.>V]6\XRB-9_VM-F W*J@"4#O<6_?_ ]?.CC\\4_S[_,,
MK5,+WND_VH:+3KM+[Q60PZ>AI</_(&HU "#M?T5 [;Z'H.5#V-XA1+@__, >
M^N].K3+^U"C\WA@KC-N)Z0@(P>4])R8"7>"P'1.3U2(MW2?>]],]L3K0P!BQ
MF,;O3%4N0H.;&-!Z0EW,OQ=;S6\]I^&=VM^^'I"YA9-3J,E9GI-=^X=CPP/_
M#7KZQ1.PVZ\=#9/.5.VM&=A59C/#.%%30SK<C.J-?GK-PO8"YCEDHVM::TOU
M\K9)H<HH^H6B7UG2=9-H\L5RI:F %##G>VW-N$&\K3/+70[$&-!6*H3!BC#0
MP4TGI#F\V-+R!NV$=),7:2/E==@:RZ]OF$6#DTAT%.DUF.T!.[*PL!4GN%P2
M*;W&FQJ^%]3MPC7;A:(GB<M$8/6) K-<Z'ZU%VLSE%[A.\E(Z,1_K<J&9,3<
MA&$286+OC822DNUH8C&R])H0MD8>R\B7#"3'7_5;:RXAJ>(0E'4EIFZ <WXJ
M '-PF2MS]U7WY02:8LU9(/I;:VV'LK8/"V=P.4VQ#% &<"O@CI(!G-J57+I&
M%F3^*K6**'$*K8N44$49H"LN!:X1RO&=(!^J,B>-;E$:,WC=JF;KWLN;K+G'
MU^W9&^SPPJ=@'W) /A96$MAN ZSS:CK 7:S-BKDJCEP8\T>UPDL,&H)]53?5
MVJH#%@LI*MN+8KD!S' #$AE\&J0O:CJ&C'*8NL0H>/5UY>1\9-F"$:2T&C]Z
MBUP:TF#RLLQ=QJ*7DG2"L0U5^6M6_3#-4NQ82XAM##IDC"NM5<^!=E_JH^FE
MEK[0E <XN4,(^&]3V592AV&J68KZI*3Q$L89<@<Z&)9OPRM*^5/6M!C@^3"F
M,ADOF,</TG@Y8AJ=^FO:>V!Q3#.D]19;3N6QC6@5#\ZHI&QUMFL23IL8T!BA
M=M5B$POII<%S04'+6WR5#S2Z8(.1*BK3Y ->#A9C>GM"J_;UI['YZ7"_)S4!
M+EIU0T V5MGLL?=SM)=N(,_]J^6;KM5^(W+75_LWZ(WZU;"A#=5O&QOBJ_VC
M3^MK_]M9D;VK]M64/"*?\OEJ'E83HV#!!563H9"O8=?XAL3VVY0/^<^.L384
M3K)F"Z[\=<W:+/50X'B_[<10.@^!DD^.5_E_>REZ/VVHDMI"'#007'363#4O
M_NMM".$R_VC,^]?3N:T'W54M]_\]Z 7M<"7K'Z_M!;; H%1]\I9H'[3 !' \
M3';YK'<]J?+ELK;^?ONPUXHG/O)3/:C8I@:DIUJJ%"ZI?,ZN+10'=0Y38^-2
MJC%@L) \?+0?*ZF><_BL9E6FG*N(UC*,*^R# E05T\$]YH>;T@BFU%Q6<%TO
MU(\XQ%_F^IZ=JMQX0((9,"=[<%=*6+VIF^IF,J"G",>Z6]]4^;2<8_L<##_.
M/J%X2[!#"P5:X.Y6<_CQXOGI(?U^4TZE5BL,@\GJ&=85G*^H_ 0*\ZN%<2C"
M.JD,@=1L(OG2SJA5IF34G+S,-#U'_OFO#PWHTZ(N;7*J<XID4=!:MO0"FO-,
MW=E8&SX6_=TZLP).+SZN+*;B[)(ZR!QZ($B(<;\T5J41$Y[.UW))6:\<B/$!
MHO7-+C$HC_YL@L5Y1P0QI].'J7)J"^Q*@<Y:HXL)D!I\@!NQAH8YXC"VJ9=M
MMVKSMFI[#WL?.-4'")J;"^$LWX6;A$N;% SN$J;%'$JS52J\S\T%8"5HOE6+
M#QVU\#U>%7R.R(L%SE=S*6&()43:XXV/<3Q6P^,+N$^=#+YT>[DABL+HK'SB
M%9-"X89C0[ P4HWB1E[?B0VR(>/%/17Z[BB2(N:VO*J;V%:=@C_35682Q.EU
M>"VGC#!NQ-2*=&F?E^<%E;'(UX_%H$ &YU>\$6T\O1G5A")*D3QOBL"X2F?J
M6EBI_8D3:Z0I]<YA2<,'6]^Y52#%5#^A,%F*&9KG\/\-'+W88FS/!A,C:]^Q
M\Z B_GALNS9L7SYB9%6N)5NLY'S<6IL?RJ6<:EDD:=I!E56X^G8ZFP$*V3I)
M3>U0+2Y/FR:5DVT!TN@ *72!(<BWN61 *TWHHU,736GN3;0#6B)9V[4Y2>_V
M)N>-2X/,U8.#PK#<E/M#.0,[@:+2):/1PC495:[2HEIP'ZHFH4J)JQO=A#.N
MM*&2/L5$P)S=>B]Z5NR,N@M/N7Z \3[M<@,(>:7\+_RM6K,@0'33[M"IZ;LH
M8[AC#9)4AZME4NP0*I1HT2W4I-=,<RJ7N0VJ]_LBA:CG4$![H,&L[9R'+<O"
M,&Y>%/GYUB9YQ'%;F )8IF):R]JT-#6&D#,^.0 HKF''%8924#(GYB':Y1.K
MA3%T#6[Q A-#=\/5J/CEW*]O1]N_Q0B]%%!D\6NU6C:3->>%M"Z+SH$E8RST
M7<B1_4UN[^!F/=#Z9M)?36@?4I3*OS_^FK!Q06T:<MF+,87+?YNU TQ;56=W
MZE$8D)JAMSLB7/X6G5LP:[3Z!M4TVT[T@XO$2<1."I;V5NG;:ZJUDUS 2-V=
MVD. =BZ_:8RQDFHKLGVJQR STA)I^-1QX45IF]?TPIZ%8")!V!:^'/9^ILS9
MO%.S<*,MCS]'LS 3[+W[CW2^_/'Y/DS%W3+V'NG#1R9\&X4'RZ$Q1@GC;TT0
MO&F2>=R7%<&.MG5Y\G231=)63#R]A&&J5W*9-E1D@)D* D\5$#\55_M_=(OH
M_0Z-Q[:FZ#LE\[+@*F26RTKF, 6L:8SW-%N46'R46-2RH01GX"/E A/KW;5>
M7%T.CHZ.ALF5U]\BKS]7TC7G*RS<9GP\'@T/;(<H>[S?M&2Z59JC_4<XI L*
MD["_FU3'Q8(I@=N*=ESN+Q"QN"Z)TWA-7"4FL5UZ:2!_#[_F]@\$90$,+57:
M?*B_7K$JE#9;!.$TBBH!< @9#BTR>+!RG%!WI*1CL+I$6@+0L) UY?]PI3^C
M 9*"B('ZTIVBH2X,$J@K0A4G= C&AQ5MKJ@5PNB'T4VKZ.&#I&IIDO5X?&#W
MIU?=.1N_B 5)GXA>O@AJ@ )[9<IJ2[9;8<B3#$5WVB*8.R1#P='%^YGPK%!4
MQ#_+CRH21%I8<;GV6C!9R]\P#&4?O/:U2,I<?;)[951ESDJY\WSJZP2 LRH\
MH+[@BMK2&""R?@L@V@DOS]-MV'00PLZM?*X.85TJG:%I]&VJX%D:Z)S+9\";
M8>J#(U"1''"$H'H0.-JT+[!.N/>VBTAPY6)VWT[1.?PQX[!PRVOMY!5KY$9*
MT?"%C]3+2&\'DU-;.HWODBMG% 4K%-TB[48P&WKM:R4^N3#$S.W?ZO,_-4P1
M[>(0$*P"GT06,4R>8>B#MNHR23Q&@N@29[EX"=:[(1]D2VE0_42,?QB_T6[3
MMTU<;C1X&U0*:M.&8VY3<?I.H=4N^=9HSR*+JMYW3_73**XA(M%Z/6P\\5-:
M8TK_&K>H$@%Q:(]FZZ9;"LWD#JAWQE'\#D5@8;"L-BMAO9\R[#L#0DN7.1_E
MZK>3IA2#_6:QNE6/=^(-V9*U[<P8WB+]?20<998U%/929%7JE#1>5E+='#M2
M8&6F=$)RE5(X$%MNJ!*2/P$U":&T";X*J6'$W("JH;93,.%[RG2N\M_Z4FL*
M\ &M[A2B,2\7)1KG20YB^WO28,DDZ6<.?)<BIDH0I[$_*'/\*7!Z%&YN<?VC
MO4=7SP>O1JA!2.4I-'?3'BC[(&E6<ZSP2P\WL/Q=Y6%;8PVSNNK<C4S3;GM\
MSVMC10 8PVF@0L"%EOL.HM>K)9K3K<SS2YEC611'%D8] "];QA(6T'O*9;0)
MA4[/$;<.?N05<X!#!UEH2UAY"P['G!<U(D<"LL42KHJ5'4XY@VA-\#G;;Q?9
M+5Q\Q\(C(7)L_A-!O-6D,*0F>)<5SJU\E'2*%F73@]G!8O*/("*GUC^B3B!
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MAHI4:?2(#\F65W$^ND:4(./+,RKZLO?HY?GU,VKC0A),]-4/2S*X[STZO_X
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MKI?C63]=;T>Q*4(%_7R@D!$YJ2Q=4\6RA>)9,NWDH4[D?E#2U(:#^Q*'M?6
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M97OZWO&6ZQR\%Z<.^MH3L[SX30AO3"<X)!O],:6C=\'?+A]'V4JSCJ-SQ=C
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MS_!/:R9PE^']G&^?<9WZZ?Z)TL.X)8?KZ\TO\>O4/Q%A6E&>?P-02P,$%
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M     %]R96QS+RYR96QS4$L! A0#%     @ )X1A3&;S"V""    L0   !
M             ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  G
MA&%,S74P^.X    K @  $0              @ &9 0  9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  GA&%,F5R<(Q &  "<)P  $P
M@ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ">$84Q210LG
MF@(  )T)   8              "  ?<(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  GA&%,R;)CT64#  #,#@  &
M@ ''"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ )X1A
M3+I(Z70_ @  N <  !@              ( !8@\  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( ">$84S?+IU!&0,  .$+   8
M      "  =<1  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  GA&%,OHQW)W$%  "W'   &               @ $F%0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ )X1A3..'-R"E!   )Q8  !@
M             ( !S1H  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( ">$84S?O*B(LP$  -(#   8              "  :@?  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  GA&%,V!'39[0!  #2
M P  &               @ &1(0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ )X1A3)!#1_&R 0  T@,  !@              ( !>R,
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ">$84P,4MNS
MLP$  -(#   9              "  6,E  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ )X1A3!BE&4NT 0  T@,  !D
M ( !32<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  G
MA&%,!/0P![0!  #2 P  &0              @ $X*0  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ">$84S9_PM'M $  ,\#   9
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M970Q-RYX;6Q02P$"% ,4    "  GA&%,/<%R8+,!  #2 P  &0
M    @ &W-   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M ">$84S)T*7(M $  -(#   9              "  :$V  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ )X1A3'@$IY.S 0  T@,  !D
M             ( !C#@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  GA&%,V+;#(+,!  #2 P  &0              @ %V.@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ">$84Q;6Y/OI0(
M *P*   9              "  6 \  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ )X1A3!,$Z:"X 0  T@,  !D              ( !
M/#\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  GA&%,
M$4(OB\ !   W!   &0              @ $K00  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( ">$84RF%QHBP@$  #<$   9
M      "  2)#  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ )X1A3/=\!%[? 0   04  !D              ( !&T4  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  GA&%,\[^^-[<!  #2 P
M&0              @ $Q1P  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( ">$84RSMI=[S@$  )P$   9              "  1])  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ )X1A3*.7^:3+
M 0  G 0  !D              ( !)$L  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  GA&%,/Q"&3=X!   !!0  &0
M@ $F30  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ">$
M84P:N&A\N $  -(#   9              "  3M/  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ )X1A3#VM4YJY 0  T@,  !D
M         ( !*E$  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    "  GA&%,:G_E&;P!  #2 P  &0              @ $:4P  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ">$84R;09NT?0(  &0(
M   9              "  0U5  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ )X1A3&S<]JH. @  &@8  !D              ( !P5<
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  GA&%,8QPO
MS=P!  #Z!   &0              @ $&6@  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( ">$84RW[S"_5@,  %D-   9
M  "  1E<  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M)X1A3+HR.*-_ @  4P@  !D              ( !IE\  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    "  GA&%,Z8%J@7L"  "#"0  &0
M            @ %<8@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( ">$84SB>*N6A0(  -\)   9              "  0YE  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ )X1A3+F&AU_0 @
M7 L  !D              ( !RF<  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    "  GA&%,)QXL#/ !  !)!0  &0              @ '1
M:@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ">$84P=
M!N8+5@(  !L(   9              "  ?AL  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ )X1A3,/+Y) V @  "P<  !D
M     ( !A6\  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
M"  GA&%,TQ\H;]P!  #B!   &0              @ 'R<0  >&PO=V]R:W-H
M965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ">$84P6^<]JUP$  +H$   9
M              "  05T  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L!
M A0#%     @ )X1A3-=7VS4Y P  JPT  !D              ( !$W8  'AL
M+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  GA&%,.480MTH#
M  #L#0  &0              @ &#>0  >&PO=V]R:W-H965T<R]S:&5E=#0X
M+GAM;%!+ 0(4 Q0    ( ">$84RVW(/S P0  #P3   9              "
M 01]  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ )X1A
M3+17F^>;!0  KR$  !D              ( !/H$  'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    "  GA&%,SM7E9+ "  !0"0  &0
M        @ $0AP  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( ">$84Q^+KDA3P(  $('   9              "  ?>)  !X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ )X1A3#9XRJE> @  /0@
M !D              ( !?8P  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    "  GA&%,5L#F&G0#  !D$   &0              @ $2CP
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ">$84Q7%#;6
M00(  ,X&   9              "  ;V2  !X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ )X1A3%562O2( @  G@D  !D
M ( !-94  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  G
MA&%,'7ED--T"  #K"@  &0              @ 'TEP  >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( ">$84RA+J&%R0$  (0$   9
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M970V,BYX;6Q02P$"% ,4    "  GA&%,\2IMC;H!  !!!   &0
M    @ %HIP  >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M ">$84P3 UUORP$  !@$   9              "  5FI  !X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ )X1A3$V&;-$U P  QPP  !D
M             ( !6ZL  'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    "  GA&%,ZLS)UBQT  "8Z0$ %               @ ''K@  >&PO
M<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  GA&%,,:ZBC%H"  ""#
M#0              @ $E(P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ">$
M84P0:E^-!04  )(J   /              "  :HE 0!X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    "  GA&%,VKGW5R\"   X)P  &@              @ '<
M*@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  GA&%,
M,&^I3/4!  "/)@  $P              @ %#+0$ 6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     2@!* #@4  !I+P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Convertible Preferred Stock Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiability</Role>
      <ShortName>Convertible Preferred Stock Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlans</Role>
      <ShortName>Stock Option Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Related Party Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureRelatedPartyTransaction</Role>
      <ShortName>Related Party Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Quarterly Selected Financial Data (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnaudited</Role>
      <ShortName>Quarterly Selected Financial Data (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureCommonStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Stock Option Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables</Role>
      <ShortName>Stock Option Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureStockOptionPlans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Quarterly Selected Financial Data (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Selected Financial Data (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnaudited</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureOrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureOrganization</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation, Credit Risk and Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationCreditRiskAndIncomeTaxesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Basis of Presentation, Credit Risk and Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - IPO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIpoDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - IPO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Net Loss per Share - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureNetLossPerShareNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Share - Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements - Recurring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails</Role>
      <ShortName>Fair Value Measurements - Recurring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Fair Value Measurements - Available For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails</Role>
      <ShortName>Fair Value Measurements - Available For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40501 - Disclosure - License and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails</Role>
      <ShortName>License and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Balance Sheet Components - Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Balance Sheet Components - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Components - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Balance Sheet Components - Accrued and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccruedAndOtherLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Balance Sheet Components - Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsOtherLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Convertible Preferred Stock Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiabilityDetails</Role>
      <ShortName>Convertible Preferred Stock Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureConvertiblePreferredStockLiability</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureCommonStockTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Stock Option Plans - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plans - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Stock Option Plan - Exercise Price Range (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlanExercisePriceRangeDetails</Role>
      <ShortName>Stock Option Plan - Exercise Price Range (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Stock Option Plan - Vested or Expected to Vest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlanVestedOrExpectedToVestDetails</Role>
      <ShortName>Stock Option Plan - Vested or Expected to Vest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails</Role>
      <ShortName>Stock-Based Compensation - Expense Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Stock Based Compensation -Valuation Assumptions Employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsEmployeesDetails</Role>
      <ShortName>Stock Based Compensation -Valuation Assumptions Employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Stock Based Compensation -Valuation Assumptions Non-Employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockBasedCompensationValuationAssumptionsNonEmployeesDetails</Role>
      <ShortName>Stock Based Compensation -Valuation Assumptions Non-Employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income Taxes - Components of loss before income tax and Income tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxAndIncomeTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Components of loss before income tax and Income tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of effective tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Income Taxes - Deferred tax assets net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesDeferredTaxAssetsNetDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Income Taxes - Operating loss carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Operating loss carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Income Taxes - Tax credit carry forwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCreditCarryForwardsDetails</Role>
      <ShortName>Income Taxes - Tax credit carry forwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41206 - Disclosure - Income Taxes - Tax Cuts and Jobs Act (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesTaxCutsAndJobsActDetails</Role>
      <ShortName>Income Taxes - Tax Cuts and Jobs Act (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41207 - Disclosure - Income Taxes - Unrecognized tax benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized tax benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Commitments and Contingencies - Line of Credit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingenciesLineOfCreditDetails</Role>
      <ShortName>Commitments and Contingencies - Line of Credit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Related Party Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionDetails</Role>
      <ShortName>Related Party Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureRelatedPartyTransaction</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="crvs-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Quarterly Selected Financial Data (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Selected Financial Data (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureQuarterlySelectedFinancialDataUnauditedTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvs-20171231.xml</File>
    <File>crvs-20171231.xsd</File>
    <File>crvs-20171231_cal.xml</File>
    <File>crvs-20171231_def.xml</File>
    <File>crvs-20171231_lab.xml</File>
    <File>crvs-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2016-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001047469-18-001209-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001047469-18-001209-xbrl.zip
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M?VX\B?3R)FG9WBLM22\?+&5)+^]<+V^6XBW2RWO4RZV]TI+T<EDH2YEE.YJ
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M>^2"PSL(-=P( _7(@M>6TU%_ [0;!)X7/,KS%U!GEC+S6OZ/2(;N8*IOF1^
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MZKT3R^$VE.[)7TX:)^_JM6JS$P.QW69O$J#O$XYG1-\%OW,97D>A#,'< ^%
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MY>G2#?DM%P_@HFK[^ANW@Z&O2IG/L9\=B]NYL;B]JKNMQFQ?M]OVXB*51CG
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M""@5#@K#;$>'"*MX39Q*D?FDHI\,DYEK4*PJSB/SH[0=S^X#D/TPZ\ FX1D
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MN997G!6V\+_:D$:LMQ,J-)6UG2@EX*L8? 6F-M86>$(< 5]=X8,V0QP!W[[
M!VV&. *^?8$/V@QQ!'S[ A^T&>*X^_CO>_._O8[_SH5[/Y5W<Q=#OMN3]6?
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M.WF"ZMJG.I@9HW1RF6JOD\%?RC%1Y;$7L"N3-20B*9VGT>53T409VM.&5[V
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M V@1M.AY6M3%NAS$E??7OP6B"*(<5F<BB((@"B@1E A*!"6"$D&)!Q-71C]
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MZ+9\F='CQ@#IZJ9\/=.*15L]NVAK$\EDG[:>[=;681#Z[GS:,5/T25,P6L+
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MQF%U)B8U,*D!2@0E@A)!B:!$4"(H$90(2@0E@A)!B151G6IV)B@1E A*Q&K
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MR\CGJQM/W6IK63)+D)I!XFRE8\/-S-HWA 1ASS:0_O&(W7WN!M]T@S5Q1:M
MO#Y143RUY9!UF'#O-9C67<5D3E"(VY&B-T?TF.LY,@XC\PIOUMEC.17J.^DB
MW>HY(W%+=93TO73YC")K[ZC$<M4UF]%9U1.MAHEO6V!M7E8!R8\G.K7N\8CL
MI.(2C&:F;5%4AT!>&Z- UC K-K.3IN'TO;5I4Z[,M2$2NH58P6,&X9+",1FX
M*!P+1L64;QV"_!YC18=^>,N&?IB0G:,"2-!"EV[4XE;Y[$B8=QIF4M>>(S0-
M\+PA01<XY1KIU'P6[/@@T02Y)G &?RDGMFA\&86)[Q81-V@WS+.%;\DA,44.
M2MX*X36V)M,5@ZE]N_4BZ)/ML/AN%\-4E-[G*.7:AI',<-6H-':"^%[N&HM%
M0/?F&!$DD:>Y2(-I7EI37!!,"W)IO*RQ](*8_G"]K2O%AH$^?6'7R0C>Q9@
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M''B^%T\1U:D).0*^7<*W8'$JAR?OY6Z?U ?1R@%8+X$$?-#G2B%:.0#K)9"
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M'^"KYZQ4![)0D7WT>X0:- BR  V"!CU0@]J0A5IGHCB\>9=/\4A%",O4A-@
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MMD.(V#N6 QZ5FU>^>7=QQ:;2D'ZA,E3@V;("[8T%B\F]PX)I&<YC,ZVT9=-
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M^VH"N-#F9>6XF1M27=C;,&P@YX?-OB<'GN_%T\R[,-. V3@%BKE9\SUS2V'
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M12R#]\.!;PTMZHD)G11=J=L:M*%1++B@_OA:3&4,V?!\]CNO@Z_.E]CYRSM
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MHXUUN[D50@'L#EQ4>K8,D?E<<?9<9XHZ>7UP'2"7SG:$U*P9-?)JG\P3'0%
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M:%U=YP0F5 !?X?#E[QIKU?66#GN0U!X GV)T,NK];A?V4 Y/<Q6G^WW_](5
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MO0QCNY?!#D CT&@WC?JM%NP - *-CJ%1NZYU02/0"#0ZBD:=NJYE<7)BB>Q
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MI#G+K/B>CNB3U:.)\]GY@Q.>7P'KXD!T3<.)Z!)6[_,C-K"H>!9EO=RHR(9
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M72!U[+4YK(N A3T$+)2P=I\\N@#\*9X_&PZ@4C4!DD,/BT8(V^JV",)G";J
M+J#+OG3!*4^@"^BR-UW:H$OQ=,EZ>('0Z/QAO[& N%,FIH>=>V*[OD],ZGFS
MD>L]4F^($.F("8L@E^L*G$Z0RW:]9?1@!Z 1:'0$C?IU(\O@RF4P [ (+-K!
MHE:]T]5@!I6/MZSH&.:6_B2FQX964-38)<7UX8H:.N K'+XBV@VCG46[ 7L
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M-A> K8HDTN%Q!XE*12(X(F1!5#H L7-)SC%4LM O&D/-Y] F'-<<U_R5R$T
MGYNJ\!70_X/+39KN7XE@4U""T/V#00*^\L '/L,@91C.56]*[&*Q"E(L@(QB
MY1-JV^XC=<P< U# >0'X"H>OB&FQ#JQ!EB%=B6"K&(FR\(N4R!I (I!H-XFP
M'U+Q]7S5FXOZP7Q&/7-,J#,D0_; ;'<ZX5F/PNJ9'AM:@8\1NR+2!_C4G)72
M80N2[*,O$6I@$&P!# *#]F20!EM0.A)%]>9=KH(Q\^"64438 )^J7BT8 SS#
MX-!QNXY@#. 0."1K.Z2J ;PM\:!D$VO']2;4?A7::8X^-LZ&$FL:F^=J=J,K
MB6AQ1])5N#))]BU5R>MUJS6M;$57ET6@3HDJ$Y((280D0A(AB9!$2"(DL1A)
M+, E5+TEMI]'(V8&UH/8(FBZD^C0-QQ.K9+3&_"IN::I"5O JD P" P"@V1"
M#0R"+51A76UYQXU %,[):E4FG)-P3D(2(8F01$@B)!&2"$F$)$(2(8F0Q((E
M$2XA.>H!B**QKU9EHK%'8P])A"1"$B&)D$1((B01D@A)A"1"$N5R"<67=&"S
MQ<W)VJSYMSDOEMH!STMKY!;EF<[+(E:AO=LL&%F]^/ N]$_N*9V>WIAC-@QM
M=C5:[$GX&FU)N*4_?]" _6"FZYB6;46'&-T*R&XY^<YMU_S[TZ^_$/+AB2=-
MIK8[8^R&>0^6R6[&U&/GU&?#"W<R98X?/>K,YH^(4E<C\9)[A^,RO.8XN?QW
M?N O7D-X#@3A?[#1Q]IEZ$4WW6G\3V]JW;M;]T[3[XSXJO8I 6!1Y!WUVH[K
M-8O-(L>8?'/-XN-*3R5U.V9$5 -U9O_RB<?\T Y\XHZ(.V4QLK[8DV*'0T;8
M3U%;3/S,YE\Y]R1P"4LJ-XH.SZ7_9/&!'_#*.AF(BB;TD7I#GU"?C%QQ[I5/
MWE@."<9NZ//[_+>G+YCP"Q3<T1;\%?J!-9K%'R47'.Z -U?6D+GW'IV.<ZK8
MC*L1*:200@HII)1*[6[V5_90Q .=J#NVV$01]=J)R6P[&>%\K#5KT;4?3^I&
MU\G R62B\5\,G)*A*Q\IV73JL]-YXGW\(M)K-L2[UF>(X]Y'/%S>[@>D.:^L
M^.:-Z)/'.!L#UQ[FM+,GA=.18S-)!<=N^C NG][=& F_'E9N^9PN'-=>36YW
M4C5K]T]&/?+9&?*1U"4SV63 O&6%&UH=5"J>2EFO,BJR-9 <>EAT/HV#CL9!
MPMH5?D[0!70!7?:E2P=T 5U EWWIT@9=BJ=+UL,+Q.&[?_ZHZ_Q6:Y0H;DOF
M@[ERP_?/W%';39+4S^2M=_HXEQ<L HN..I>WWNFU809@$5AT3%N$EB@3#A4P
M<#EBR;.B Y=_,X=YU([&+70XL1S+#\3RS8<<(XBGN-!<45,'?(7#EW^[8=3;
M1A?V(*D] #[%Z*37M98!>Y#4'@"?8G32C ZLH?*CFO)NY 2BB!90K<I$M !$
M"X D0A(AB9!$2"(D$9((280D0A(AB05+8@$NH>JMT+UU VKG9^A8O@'XJK,$
MJE/7]3[, "P"BXY:$-+3>S #L @L.H)%+7 ($]<E'BT"4;@DJU69<$G")0E)
MA"1"$B&)D$1((B01D@A)A"1"$@N61+B$Y*@'((K&OEJ5B<8>C3TD$9((280D
M0A(AB9!$2"(D$9((293+)11?XGSL#$^U?N[P["_4\OZ@=LC.?)\%_IDS_&;1
M@65;@<7\[XSZH<>&5PY_>.AYW(!Y%BQ__5QN')B=XHF5XL#L^ SKZ !L ;1/
MIA[S&<^HY8R$! A\Q5G7[NCIX]J(0#J*U2@.(R%TX(8!"=9.XJ91;?,/:4"X
M89%)4M.$7X^X20BM"QD1[R'>O.[)0%1^]&#+&5K<\%CT6%M$LA>Y$1<K=X\M
MYHEP][/5EY,PX-;%K52<[CUD ?,F'&WBA^9XY5X<X%WXT:E((8444D@A55QJ
M=[./ [P5W682?8(#O%.'<?GT#$[1TS0<HR=A]3X_#@2+BF=1UBN@<';W3HOV
MW,<#C@&%=1_31O1J!\*-YB+GFA9>7Q*Y?<G<QTM^]SD.:"TDY%.FDE4A0&&G
MZ-64 WKT:@I18?1JI*[I1?"^@1=/N)]3FSIF5F?451-D-!:J00^+EJB;CD8A
MY]I]\TVL3EG6L?86Y %Y0)Y7D4<'>4 >D.=UY#% '@G(D_5 I)IA])^NK>73
MX]7E&=D_ K$"OC+!M[6="GC"' &?HO"!S3!'P%<6^,!FF"/@*PM\8#/,L7C_
MT!$A(L0_70'_T(8[Z(+Z8\+^&UH<+Y[C'!U#*8;C4-3  5]\=XZG7!V)FORM
ME(@!H[5@AZ!Q!6B\NXU+_;"Z5KW=;L,.0*,2T0BMH2R(2@<@:*P.C=$:RF@'
MZC@_CEP<HZ#SXSOU_F9Q6!I?A-:+0BW"Q:=(8P'XX+"7JO,'@P1\A<-72"^P
MW^K#("0U","']A'M(PP2\*%]+)M!%. EP2DB:9LQ$#T.T9(?:21G9>*HJF/K
M%4=501)!G1)5)B01D@A)A"1"$B&)D$1((B01D@A)A"1"$@N61+6\Y.)?IH&V
M='7GL+ N%O!AEXCR"R%*9(>@L6(TSG_]0Z]?;S=;L /0J$0T0FLH"Z+2 0@:
MJT-CM(8RV@%6 RKM;P*BF-2H5F5B4@.3&I!$2"(D$9((280D0A(AB9!$2"(D
M$9(H"77DK$Q((B01DHC5@!6L!R"*QKY:E8G&'HT])!&2"$F$)$(2(8F01$@B
M)!&2"$F$)$I"'3DK$Y((280D%NDECR_%23&+FY/U_/-O-R%JQQ!EL65]!S0O
M+:%?E&7Z4MXW\[U-HK]"/[!&L_BCY(*_/^ \MX;,O??H=/RJDC8/*>E*E3?7
M:CPN.%)((8444DA5+[6[V5_9L!CW$*/^R6+'8GPPGLEL.^D:?JPU:]&U'R\0
MB*Z3'J?)1.._Z'$F?7[>Q;3IU&>G\\3[^$6DUVR(=ZVO-HA['_$X8[L?D.8:
M!<4W24:?/,;9&+CV,*?-QRGL>8_-)!4<N^G#N'QZ=V,(\7I8N>5SNG!<-:TF
M]T"\FM5[R4PV&3!O6<V&5B=Z4^N 1<6S*.O%:D4V!))#/P?1<Q]C =/WT2]8
M]S%M1*]V(-QH+G*NZ2_4\L@?U X9^<ZH'WIL2'[W.0YH+23D4Z:252% 8:?H
MU90#>O1J"E%A]&JDKNE;-Z"V>/; (^_$!^?4IH[)T%@43R<T%H4K&2Q:@FXZ
M&H6<:_?--_; [&4=:V]!'I 'Y'D5>720!^0!>5Y''@/DD8 \60]$GEB:?''Q
M^;.LQTAEL(QC^?CET\]\GP5^1O:?+N02K9#)9]0'^"2#3_[3-=3"$_ !/K"Y
M+'@"/L '-I<%3\ '^,#FLN!9 O@*\ \=L75=_-,5\ ]MN(,NJ#\F[+^AQ?'B
M.<[1,83SY0!??'<5CFG4Z_U^'V8 %I6(1>7MZ^',8M 8- :-*VR'H+%B-$:?
M5D(S4,?U<>32& 5=']^I]S>+@]+XS P]*[ 8%L:HTE8 OC3@R[_1T/1^O=?J
MP"(DM0C A_DO.093,$C IRQ\X#,,$O#)!Q\ZO&6RB +\)#C=(&TS!J+'(5KR
MHU;DK$P<H7-LO>(('4@BJ%.BRH0D0A(AB9!$2"(D$9((280D0A(AB9!$2&+!
MDJB6EUS\RS30EGYT]6"!-.##^O+L9TX-O=YKM6$(X%&)>(051;(@*AV H#%H
M7+P5@L:@<65HC%ZME(: ]8!*>YR **8UJE69F-; M 8D$9((280D0A(AB9!$
M2"(D$9((280D2D(=.2L3D@A)A"1B/6 %ZP&(HK&O5F6BL4=C#TF$)$(2(8F0
M1$@B)!&2"$F$)$(2(8F24$?.RH0D0A(AB45ZR>-+<5K,XN9D0?_\VYS7UN^
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MB9!$2"(D$9((280D0A(AB9!$2*(DU)&S,B&)D$1(8I&GZ>4Q<7AD!!A=O1T
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M$9O"%!W^_\8"8KM^CH/^%#?>*6K8@*]P^/)O*-YH6KVO9S'\3XJDJA6\!7?
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M7OWXFS5BY(WED#\9]?RL)OFK65T@8YEK=T\RSKN'JY]%/450#50#U=!1!&%
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MJE696)%6D8EGK$A34!*!J(J(*J((*D,,1(&H[(A"!F"TZ$BK7ID8(%5$!S%
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M\<0CPGO>-IWZ['2>>!^_B/2:#?&N]5FVN/<1>V&V^P%ISLTIOOH[^N0QSL;
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M;!IMBW;CT1,?/'G1UNC\3!YKSP%?X?#EWPU\T\[B@/6D.*I:P%OP!KS9X8*
M+4AJ"X"OZ-UC&$7!(#$ME?LH:K@YC#)#S^-%R'D@!=\!X"L<O@(ZA)TLNH2P
M!L!7.'SYDZG5,6 -DEH#X%.,3)CI+<W@)L4191($XS6PISF*V5CY*,;HS7,U
MQ^B51+2X!=<5KDR2??M5\GK=:F,K6]'591&H4Z+*A"1"$B&)D$1((B01D@A)
M+$82U7()*3K?_>PVS#H1,?P+VH&)Q1Z +_>=+X4M?]3JNM:'&8!%8)%T^YA+
M9 3@$#A4R.QVB8P L]M*#RF!*/R6U:I,^"WAMX0D0A(AB9!$2"(D$9((280D
M0A(AB05+(EQ"<M0#$$5C7ZW*1&./QAZ2"$F$)$(2(8F01$@B)!&2"$F$),KE
M$HHOQ4'KBYN395KS;W->-;4#GI<62"W*,YV712Q(>[=9,+)Z\>%=Z)_<4SH]
MO3'';!C:[&JTNEWAEOX\3S8K_'!M^XOK/5*/?\H!N^74.[==\^]/O_Y"R(?%
M<Y@9>E8PNV13U[<"8O+<\5_^8*./M3/_[FITU[LSM#MQ#EN-A(X5?_,[3V@U
M,F2FQ0W-_U@[:=<^:9'0K&1Q_=&;[[V?,(<_;>IZ ;?W:RY6YBS^[R*K:[FY
M##T:6*YSI]U%^>G>W;IWFI[DKEO[E$"X &V'9;03RVCGNTOE=83:/M=-W'UJ
M!5QIS,TED-'+$H#]%VQN!S+RE'ZC:"N$2B5U-67"M)Q[XB>@$>HQ8@E+L$86
M&Q+J<U.<3'F#*;YT1X0Z)#K[;^I9/B-TX(8!>1Q;YI@_8DKYTQCA13,]QA,C
MRZ&.:5&;6,Y(*+.P8F+QESQ0RQ;<)/QCPGBK$<;?#69Q?,VQQ4;$7>1.T,WG
MWY],Z-_,XT\C/+'ZA4\\=L\)+S[SF.^&GLDS9W,JQ<^ECBB*SWQ?_((_-\J.
M8[(&N>7ON^!%I,Z,/%CLT2?BW+GDW>+)XE[^6WK/XJ\&(7\(?Y+(ANA(N)L@
MUGD9:##?+C5D#\QVI^*+&#]Q].9DPCP!C/5_<?[X%X[+?T>LR21TW!/7$8WC
M?82&1Z<6?W7T3%$[0^;S-C8.1CJF7I05\:+H5D;\F1^PB?B2!@$54B+*Z1&3
MV;;?2%.(]Q&R#>WC^67G(J*J0)PY?ESZE\2NO29V+TNQ4?O4TGOK4OSD&X_.
M56<M5YU=N3)Z^61KLV78D:V.KO=3RM:9YU'GG@F#.)\M?W)-9^*C,]$81__Y
M@_F1K41["+6G"Z/'A6F)PNAW>B^^2-Y_=VU3YS<Z86<_+?_.]![\N\__#7EC
M^]41AY):#RQZC_B5N.T[FPR85_MTW?IS5S%?5X2\P3%6#-"8V]_KP.FH LZ\
M#'[@A5$K=25D\79,G:MII-&_N<X#?S$;_A:*$CW1EWM>03JKK/CZVY?:I[[>
M:AOM%! Y--\2PK4E;=MP=32MT^\!KB<E=QLN0^OK34,.N :[7SO8>NW/J15K
M44SR'#5<:V[J5!H%R!673.0[-UQ>8Z9?J.7]P3OX[,SWPTELF?Q5S.2&>6D]
MB+'&\(<8-AS1"VROLHQW;)J-/;HU*>9=)JAV=$T!U;-0+6@8O>%V-EWA(=?2
MSY.I[<X8NPGXN":1V(2"+V'<2C"N*L@[QB2PQV>A*K4]OJ:%>NEUM\R;/#-D
M>J8-^73=^5/[WKE,H>G<F3$9 5B8UP_QVLBTYI]\IS^M23A)N8-1.I0L9PVE
M?K7,:;.C(?A4U<*_6JH/(&'OSVZ%S2L3A#<(W*L6@;?F$:M$X+3Z6@<0N%LM
M N>!\ :!NT42..T.]!^NS1]C6\$L??=(STC# [E_[N6"ZV 72:_5J3!<!X_@
M^UJKW' ERIXR)UO=7%%+"B$E>+EXYF);U8%ZKOZGI/W)VOTD">IQ!R5EH=!S
M!B\NA)3@Y2D4&E#/7RA2F2J7"?4?EO_W%X^QKV(5)?.##.8^M:R:M*?R+A-4
MA\]]:EEU[&6'ZO!IN<ST3P*H,NG0-W4]1\2R[^*\%K@<I]FU?E8C3[4@SW$F
M6<_,E201Y"EWXQ-C[675CW^A#!(BEZL^ /*\]2'7WFBZD,<+9Z]&9\.A)6ZA
M=O0[_RP,QJX7'9/T&I1?M<QSY\+BGI'2JI[=I4X9WN3Q\TUA7USOW_S>I[9D
M'K*,7V^W^ZU^/T5 GLEG\6CLL4I?;W7;G53-0UXT,B9:A:#<8S^#WNYVTMDN
M(S\:61N68E!>S3UI8C.KS_ROR<Z!6S>@-F^5/<OQ+3-JMM/:X]FL?>IJK73:
MN0.R+QE@!VP_Y8#I6J?J@!VP,98#9ABZXH!QHH^8%83>\IT2]53U5K.5BLP]
M7]ITX8Q$<_'L?WNN[TL$9[_3;Z=IKD^4-DLX_Q/%V6##LP?FT7L6?7G)AW*+
M(=\Q;4=O%2V]]JG5,-(8CKZN(/*BN*-!V411:S:Z:>SX+1N,.YJ931A[C7X:
MOM/44!SL?OG@F9<O]AH?!N"N<>R6X6F-WJ;AY9)K*=%:M"M/F\ZFU^9W9\B\
M%1^>:&?\\]F\=W+M629;KK&-FZ>M[[[P5NKIAFE;:CN;;3RJ*M>J<D-OOZIJ
M-G2PJLBJNF$/S-FOKK1V8VLF'I65:V59/_>KJDZC"P7<MS/$F_:M/F5UT2K"
MKJ^</5MVK;&U'P(UE6=-W8X]MF]=M1LM-!>%5M:CNV=5-1NMS>5+1575$>/0
MJS#P ^J(6)RIA&/K]EJ:D<8RS>?R5V#Q]YFX-=K-=B^-E80REC]K3W.9P=LG
MV%Q3,XQ4UD3*6/Z,C4=A\#8D?ZU1RH^/^WCOLB^O=""G:[?[C*-4 _F/J-]R
MY@P7>^Y=\=%*7J+OHO='(?[7XOSG$3R_0B'BHQHA[A+[*(8Y6Z(?AR8?TR&)
M^YO$]<@C\QC_35Q[(ABY^(KPGUTR,S+CY1L,K4Y$5<3W4)^,7-MV'_W35P3P
MWZR9[=-7_@K]P!K-XH^2"XYPP+P3:\C<>X].QSG59<8UAQ122"&%%%)*I78W
M^^*8DK6CQ:(>6&U^<$ET3E9TX$ERIIA8U1<?@!(?HQY=)T>5B9ZVZ%4GSTL.
MBS-Y'X1.?78Z3[R/7T1Z(GCJ_[Q?/Y,][GW$!]1M]P/2/,D]C4/24CH!+)4C
MG5XZ)RR]0^=>B]I*OS$VDU1P[*8/X_+IW8VSYUX/*[=\3A='#"KE/L"QFK6;
M^,?<D7C^P(N/;?*C"0RP""P"B_:JW;E/:Y5$B7]K]:.YKXM$SB[P"_P"O]+D
MUP\VH9;#X5G]\((_T*-F$%)[]>-OUHB1-S-&/?\MF @F@HE[U>[9_;TX(S58
MX]UB#QJ)%H*L?O7&<D@P=D.?.D,030:B;1P)GKIOX8FCV2\N/G]^Y='LS7Q/
METYK_BR>>LS(W--%6"*_3CYN',"7$7R[N;$BN%&S^K[&&]5'CTX_UN+_7SA?
M5WRS(]NEP:EHQ1??SH^1[NNM>D_381&26D09X/MG!7BD-1M&#V8 %I41OOSI
MU&LTT2;):@YE@*\*;9)>[[<Z,(,,6%2 !^!+]+\J>0 ^;ZQ:S8^Q1V!=$@,'
M?(7#5T1[T>SUZNU>%CTOV 3@R[WG51B3-+W1:L(,P*(RPE>$-Z"?A6\-Y@#X
M*M0FU?M- V:0O3<@OA1;'S:K8/YMSGCL ..EHB_*,UTUMG>;!2.K%^GM>3YN
M^W&Z@6_BO,RC>BY"MKQ\]/H! =5/VB+PS!,GAV209PF0.2!RND F"@1>$6@.
MB)$NH&GW%(8FUVC)8E(I;9AR#K^5 6I5"EZ+.E,OBBWJ+*]PMEJ*0>]0:\K%
MM56VR@Z,]J]IC5;JW27U89,\TJT!<9*BR@X+>:MOGJN!6I,[]JW*3<IUZ)EC
MFA3[:L3OGG X!7)\*"NV)SU=2WI<2RU12_J=WHLO7A4:L+7':;Q12,LT(D'O
M+&ZQL!HK_2DCD["6\L#ZDH_3/_10NKW#6>[;=<THNN66,R4W%%*N@2>.K7MU
M'61YXMQ6'1B-YB''*J>,0\JU\.*Q69)6@-;H'7+>7WH0[(-]_- S9[@H8M1U
MN'9MRYSE$9N5M/-=>/JZ5:?;NX3%W:=60#E.3RY,C1J#DPAOL@KX"S-G.Y"2
M!XV,8Z'>CED$&75F1$2:"/@_GUAS R538:&<=;S+2Q['ECE>^<X7L!,WB8,K
M8M\ZKO/?D%?3R.(UL?[UA,[(@)%[P:AX"3&;3&UWQMCBUI/Y)X1#^2!T9>JY
M#Q9_M=] 51Y4E=0TW9!+%QFY7EP1)U&_:@$ZEYLE3PA=D41>P='MWI#RFB:/
MUO]O[UI[&\>1[?<%]C_H>O9B9P G8[WMS'0 M]-]D8ON23#IWHOY%# 2'6M&
MEKRDE.[LK[\DY;>3^"E+LLXTIENV]6"=JCID%:EB,M"2P5@7/"MYW->Z=SW-
MU=M-K;'@<+(Q/WR7 ^_,*1?<\;RA?9PT9VH7+QE$4SUP(@NC7OP8">SX8J-E
M$>6(4R4B"<,%,8DD<:YE'^)(W4\]Z<P7<8XFHB#1:<C']D7((Y=9I)2?:Q)!
M=2PEE)>HVV@!G[7!EW68R>SA@J?)0_BLQ:)/4)<P*GHQ'B1S1JPZC^SNL\?)
M1RPB(1[CTX2RH3 A7TNY+"@M[_@^)$*N.V\0AP*"[&RAC4"^SJ -8Y^&Y]K<
M2$$HDT[T+P64-:<'5$$@FNEY*8,SK3^ZFS.F%ZV.T9",[?95@Y[G-+YD1@NF
MN6@6\IN%>S9W-PQI=/..LDDK,X,-/.%4TOO.AI1P85G*].5S56\0/LNG3&XG
M7P?)'C;VO$<:B4&2O(&J;SYU#^%W$X]8</*L(CJ7[1$@4=6]C/VGS^*A.G>^
MH6_9\&%6Q;PY6MMDN+=1WF@U,_0I_D99=A0,@U=B^?+,C>PU<YP39M#.0>:(
MH9T2S0:;JQ,NT$^)YWU/6SDEF$'9>*JR=LQ6 N5L,RFIKV[;#/V4>/JQ>LK)
M*H+?].?6J4]V;SK*%I0';W;YL"I7Z+&J*=VR[)4UV5!4T5'(JJ(LO>/ H\H7
MD+S@4FY;M^!398M-5A5EK[Z-4D,M'6Y3X!I@5:J [@6+-NT-=CZ'GHX=V[W4
M2;B.8^<5?T-5.X9YJXIR13]6CFYB98W@C@]=?=C2 I[IWAIS^VE\H6QH;/6.
MX^5MYP_CL^Y<K5OJ>'0Q*H]MP4'EY6W[C\YGPX!F3T.SLRA4:M:&SYZ*9N?#
M5DG'0K70[&EH=AKE2I?56Y]U$YK=7[,KZXD%N.W/'4![<&B+#:0O;]T_G,]Z
M&XH]"<7.1][299W/!H8P)Z+:::0N!S"RHVM50K.'RA!\'8TJM3)HBY5;SKGI
MYI1764*M)/HI@3MMO#@HQT6I4,X!%@<YYVY>24GH9]_%07KKW"E..ZNOGF8I
M=_/>Z"QU#.D##_R L.<[$M*;OGJZ0F!RQO7MS08B9S,:]OE*GORU5T!?:Z)U
M;SC;-O%&=,[=,(P3^996!ET>3>;7G*?JI9=7IS)FM1CN$I*HM\:R5W>EVN-(
MOD2VT/*Y-_8WGC9J68YK+;]+/6[;P5K="PGG+V$M!CX"[21X" 5.M$\9H_Y6
M[3?-CFTYR]->>[7?/@+JEJD[^G)_>.A6YX>Z;AFNY5K+JTGW$L#)'W:CU3$,
M:V61\E[-=H_0;.&DNF$O$\O+S98W'L2A?)<W:\>;KOIFB56S<7FFVYW%12TK
M]]_K^5N"U_7]0/(Q"6])X%]'/3*2;ZN_#.2R+$:)!/F=RO>_J?^!,!G_\<TD
M.!.DD:,0;U=IEL\W=;V5:PNVM0?/2X>I>C_T)AE0)D]C="!&1,$3O8Z\>/C*
M\'=%,LLNDUC[F+EEM4HDRHZ&;NI6Q\E1C+?+;IOR-3"CG:NI;]O='<[4S3P9
M?6NQ]F1TMU4F:=9V[L?LD[9M_(ZNZKAM-T]'>;L,O&A!VVJ;>;+WMB.\ W9*
MN>)Z7$]M6ZUVB:0IE:=NV_A=1X^&:9O6GG+\%B?T*N!>&,M2%=,M1XY15:L\
M-5%6*V<M%DGIG&N9@6D*0)2!67O45<6.KJBG3'GVO:DW-6DS6:4B(ES#E_51
M(E\3 7"B"L-X,I71#SQ9;TC<(Q ,RT8Q&Q=<FJ1#^4(5E"36 AD]:T:G-7N8
MD#F4%W$57LN;>9D6N=2B>JK^YNFC238ENP+U?]8??2#>($-P!>^ :[(>3!)F
MY7,$$6I/@GVFOL7GR$D58YH_6U!*X MKX5K05YI3M9D$(X9$ZN?A6=G#0RSK
M3HD'^P&C7A(S?JZM-\5H_O:B(0NM'A!Q=SKW+%C!^J,;P91TE"PA;K3FG7]:
MP4AT-%*%02343#1.9%$F\LBHZCBU'^6YC3OU;7?R;>.GK+Y:+_XF-"/-87RW
MYNQIGS[UM!\;Z@QQNBPW166QLZESS[7AGWQ!Y\UQZ219<DE<)_]M9L\CCZ(%
MCY*9'EG,^;BQ(Q9[E/KJKNE(7O(/W;";HF=6_XLGL3A]',CR9R0Y$\\]$V;Q
M%TTTF@TEXKY@&5D52MSHD9'A0MG 3,1O@ILTXB6RE%20\"E* HNL?)2D/U5W
M3H(A?U5UTEXFOK&S3!0P2IF\-E&RBN^7L%:NZ,MC2=1:8T&$QJSQ6:/5#:B7
M,C&XE'<131:/USNFV505X#+&/Q^+M40)"P7#9-4M)6I6SHI+M$@H3\LP-L];
M_SW18Z:->3U(P5X1GPN*F>HD:\=<VQ>%/]?$X&=2-^R9$J9E/=:ZGFV"[;@F
MEZ]%0MT+[1N)3]]5,;WP6?M'Z]Q=[8BF!;PF^K2-INUT7I-KC1[!6]N5@AP0
M67=.6I_L_U^$O)D9Z=3U9-G(,(R_\8L=L%[&.8J9&.S/[Y[Y9\K%R.@Y^VK\
M0> EZ/-,=%Z2.D:#(VDF9SW@"$<XPA&.<%2IH_7=_MP>U]EVU&H\-=WD6FVW
MK'DB5!GO0_VNT6JHSWQ$O,GG\?;6GHJ=IMM;/\1,#&/E?M8A&7%Z,3GX)7N0
MUFZ=RV?UQ,WNLIM=M'[)1A]G<J?MB]5Q0,(F-U^\:FZ/ZHVWW*[XQMHKF<+C
M[%>_*VISX\;,3 Z"HWMX&&=W=\_M%P:4N\ J+%^XB\"UW=AD+_C,;Y)X=*$+
M]"*9F?KAJB/_:),?E7^\^FMV;_6[B"X#7_M!;67<FI[ ,M17KJ^G=E^,GN$_
MQ?M/]IF=9!=0<NAAT<?I$0ST""74KLR<PEW@+G"73=W%@;O 7> NF[J+#7<I
MWEWR#B\>B/?7(XO3R)=)L)A=:#_T>A\^?/RXDYI:Q]WT<6=M+<W%S;T-MKR
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M\)7$GQAO4<*\@<H ^O2)AO%(OC&CB2:E?>(EZKT;C7X?T8A3Y .KTI< OD/
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MB+QRG?4 1-'9UTN9Z.S1V8,208F@1% B*!&46)OXIP8O=FZ_"RAV_JSJ4@+
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M'/%I=U1-<)V=B9]^_?G[ PLO_Q]02P,$%     @ )X1A3%A*:[\C$P  D>
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MI*&$N!:R>AO/8ZSC48]$46A9V5WH7::B+>FWY;>DT0\[HMN.:$=U9W_Q$<-
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M^U@E-9E?UXU)V,GKN,2?B6#8HW*B_?\A7>D=[=W.8Z5H:J<QEIU*S>X+H8U
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M2T>3UJ!83G")0'"Z^<__!5!+ P04    "  GA&%,J@@U'<00   Y\P  %0
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M<D$+VRH->?SF\-4$Q>4HTC:]_50D*2[D-,I)SO77(]97=@?:]_\'4$L#!!0
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MSMF;[E""G7W 72D  !KP[?X!\QTV1[$T:";K ,&_,5;I/)PRYD" ]5OXC'#
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M>2+3=@C4[5T\1/TU0!#[.+X6C?)@*>?9RQT[(N"YM%=VA*YM+WE"P.B#Z(:
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M>@K1"KN=/_-7L@:G<];H<L$N9MP$*2%7:(XP-839X1PA*,JHK*XUT^K($/P
M.>*MLCNLG\#<%R_BQ9,H)^PY/H^23Q76M!KV:?G!I-S8W#4HC/[F'[1,Z"VB
M$LI=L%*4H!8W'Y.7(.8"@/E319S44Y!U .(JJ+1,!0X@=Z%%>(IGK9_.SM\?
MP3E4;@>R2A:[,%"N;8=?M.>DB*LA5S:#X+RIU2HS(2IY@!;=O<,A7;BC-:O*
M'%$;X?._8F^5W.!5;#%:/>%D.JEW&RV&($.F7.*T>@+9B@P44PO$UK8GP<(V
MG<\]A^<PVH\A9MW6]RO;H;["18QI]R=[B2YMWYN'./!L\<I7;QP(2Z.!7F9K
M9#UN.W>C)7Z3*-AET*__V)<Q4_L8"IM@9+,WL6S_,V$L;?15L%B*FP\9M&J$
MI)@E:&;)+2($(68Y4<[R-:"W-\^85458U9OIG$E 4N^V[F!#AJH:X5R7X<[7
MU40!^>2?7U=V:KB5U]'J=D.6/:N%AX27SD6=."I/&''D9^R5]X?P,X_O,=BK
MI*[L,F3-KOH *-GJ'@L[<'W*%EUO68DCEU4.G2%N)''B;@*'_LM[1I5&A4GO
M(6M2-4#(@$-H.]7.DLK(3H/_7Y%H0U+TZ17$LQ;W'05?P*&[CJ,8;RJ<ID7+
MR%6,%-7TC4?I%=Y/W<&KYG2D@#<#&H8S7E.W:\ ]6I@O8XR1,.W8=! (F0S]
M@9ZQ/5+L;X*'EY N?@]T;O1_R,;J B[&XT'(=.A/(ZHD,%KEN YC3'FYIB9G
M*\I1'@]"">\^E:,L 6C*L0F#Q+8_??2])Y[1=>T1Q_89Q5]LRAJK^2&W!HU'
M@5 'NP5%,.9[%/";@ S#[JNIQ4HH1P(87VN^HM?HX07YS^@+;;,0K=XF T"P
M[KJ"5L#R>/"^9TFX+K<]/.PR61@C7C4$!/NM4\RKF!X/ZLRBB!;<IIA'BUJH
M5PT!P3#K%/4JIL%F*;-XU'2>7-HTS5@^,<M8/K#89%8XMY+IQI+"G!?1)N5,
MELTL:3_(!UX@1))O5M403C*S$H7"QUG!"H2UMD"6-).LNBF0U#&Q2HE! )2Y
MW!"&0BKOV='9^?L3.-G*]:&I9 L 6M2(HKN+>X4>%3=2R^U ^(L292LD@97)
M!R#\JE6W=(2EL?_=0KB8JL5,(<U'O.>,-4>OBJ7T/;Z+$./PA=IKE_:*_D68
MMV<V! 3'OA7@Q2Q"<^GX4L(6&[0*B2=\I'ZW%01WW!BI$A?#>EHSY-L1>Y$-
MTY4B5Q',R+-Z7[X+FHYK\8&MW,AC<:+NG05R8U8S32 B<K$N_$5V7;3>6,-4
MZ]0A4.*4F0P QUEKA':Q J@^^P!6WCQ14K^BJB$0Y\Y<946  7+Y&@ #VMUK
M&RRH3N"5AY%#QY8_IK#3"(+[)U:\POL).Y0#D+A LU3.G[K;</Z?+DO%\E"U
M=K*QNH<")N]B["QXY@(5:+Z-F19(AH'@)M;1#W-.:SDHOQPF8DXM^#__/U!+
M P04    "  GA&%,M>=O]OYZ   W( @ %0   &-R=G,M,C Q-S$R,S%?;&%B
M+GAM;.R]>W/D-I8G^O^-N-\!MW=B;4>DRBZ[VS/VS.Q&EA[=NJLJ:265>SL<
M-R:H)%+)-I/,)IFJRO[T%P< 23"3#Q $B4.58W?:*@DX+^+\<  <'/S'__R\
M#<D+3=(@CO[S#V_??/<'0J-5[ ?1\W_^89^>>>DJ"/[P/__'__U__<?_<W9&
MSA/J9=0G3P?RGB9)$(;D/$YV<>)EC  Y.Y,-_\^[^QOBQZO]ED896<E>GX)L
M4_1[EP3^,R7D7]_\\.:'[W]Z\UW9^YV7LM:,'B?S_9NWQ5]R_G'T,_GAV[??
M?O_=VW\C;W_^T[_^_,-/Y.Y]T>X]TV ==#4,@^BWG^%_GAA#\CD-?DY7&[KU
M;N(5U^<__[#)LMW/WW[[Z=.G-Y^?DO!-G#PS4M_]\&W1J[$%_.LL;W8&OSI[
M^_W9#V_??$[]/Q!F]BCEO#68Y,V9A)76GW[(V[[]]O^\OWG@PI\%49IYT:KL
MQ6@&+5Q.VI]()?F\_>FGG[[E?_T#LQXA_Y'$(;VG:\)_]W-VV-'__$,:;'<A
MT.*_VR1T7<\Z3))OH?^W$7V&3PH6^@DL]/9'L-!_D[^^\9YH^ <"+3_>7S=J
M\5.%ENS$U=$R[[="'S$>H/,-^ZFB%OV<T<BG?JX8L&LAS:4I+06TXU6%8 AC
M+$ZJAEHE+RDSQ-M_??N]&"C_#7[S7Q?2D9:1?QEE07:XCM9QLN5C=/F49HFW
MRG)"7'Q!2;=?3S.!,L!DF50U\I)5+@3[L<- LL6WJYB-O%UV%LI/QKNODWC;
M3P4A1MRCTW^%3P9#)->]HGA"TWB?K&BOL:'JV_>;%;*SGH#3-#K[^-!#F?^1
M,R%>Y!/!ABA\_D.(UVOH2JZ<X]I+GSA;-H$\>]X.T/?';VF8I?EO8)#_>/;=
M6XF'_TW^^K\>,N:_(-FC]U2BB+1/8R.D [A=*1BM]2T0#LT.04W'84&._,H)
M_G\(1AZ#?GK-?DR[3* VG,L(/%&N=A06K>8P$D^%M3 :@2CA5$^&I!7-,A9Q
MTQM'Z@UULI2NWCS'+]_Z- #_^B/\ &[U1\6MV*_^2TPL]_0Y@&DKRCYXVV-(
M;VF&U*6Z% .':FJ#T)TZ134=;3*J**D2(#OMT/LK#</_%<6?H@?JI7%$_>LT
MW=.DT03-[=$/Q@Y5JZ.RH3'JX=DE\\!Q"N3/?@/Z)&= !(=IA^PO<;B/,B\Y
M7 4AFR,:S7':#OT0;5"M.C2/&J$>DDVR#AR*!5DBZ$X[ ,]9@)!XX77DT\__
MBQX:E3]MAWX -JA6'8!'C5 /P"99!PY 299PNH01GFH$YML2CXQLC=)'?T8\
MWNH4R8>9^C>DHZM6Q,%[34!MZI%T1Y,@]B\C_X*M?5HT/6XW@[%5J]KQ(*LT
M0C[:ZF4=/.P$6<+H$B \U0A<,N8^"' 5>L\U6A__'?&(JU4E'VF5/R(=8?4R
MFHZL@AH!<E.-I_-]DH &0;KRPK]1+VD&M9:FB$=9EX+Y@&MJAW3L=8IK.@PE
M82(H$R ].<C),%1(<D]W<9(%T3-L-.Z;EZZ-S1$/3AU%C]81M6V1#E(MD8>N
M*N1X+<@307_:L<J7U.?,19[CI'EQ>]P*_<BL5:LZ("M-4(_#>DD'#C].E.14
MIQUT=_NG,%A=A;%WG*;1U ;]@*M1J3K<E :H!UN=G .'FB!).,V)9^)XNXVC
MARQ>_?:P\9BQ;O<9)'=!.E\S[+=W0C\4=90^FIM;>J >K%J"#YVG.0_"F2R(
M8$,4/E-OX921\Q7[35U8V=P2\=CM4.]X(^>H&=)1VB7MX,T<=;'#2;L9C6)/
M26\\5MO.9D36J%@_)I6&LQB5=?+:&I=RK]'*R+20RG:[O@HB+UH%3.LX#5K2
MA7MV13J*30Q0FP#7T@_A&#<2WWC;Z?;#P^W-]<7R\?*"O%O>+#^<7Y*'OUQ>
M/CZX&_'+-*59VC&V3QHA'\7U2JGCM=H"\<AL$-1X!YZ3([_F!!WE:(ZBE6LG
MDMMT6KYTVG86+M6@XJEG'35$[V!-\@X;D8MBZQ:'P]G6,M?.X]1_=N> YUZZ
M648^_.?R'_O@Q0N96.DR._>2Y,!6WK]XX;[I3HQN7^0.VLL$JL-J=43LP/WD
M-Q[JC#R_\\5_4!@MB)>1G!?AS$9Q\5V>X]'FYA/;8@4_T)(1F(*RW\=KDFTH
M$2*/: T6MB<9<GL\T><@BF!LC&^5SFG L3T<1F@O7A#"/;FK.'E@PCS0U3YA
MRSO:=%>MM0/RJ:!;V4K UM@:,>AK"&T<NN6DS]9Q<I8RXJ2D[BAZ&T_;]U[R
M&\V -DG'U?*%)D^Q,SVOO""IGYVG Z&[A.Z\P+_\O*-12AD.W[+Y(*F$Y@V&
MT>N)')9ZJ*_BDT8WQ$#51WK3L2UY$,F$3[V<#3E:AKI!KRE- *K'7/5596TZ
MCN9QYH6N-7\$(2"VW/4T@:/M,9T-"OQ8UHE:<\$GNX-Q$KSI\KHQ_ N+*]TE
M,5L_9H<[I@TO=,,65SLXN/I FV.'UB[('4U'X6JTT-P>L1MJB6T^.0KB"\+)
MB])%.8,%82Q<!083*,VUI:6VT5C:=@<#.+2=#JR4:.<#\_36^;^I+7)X:E51
MQ:7:AH@!J5U>TV%:7964A-W@SY@ZN@X4A%JM$1)^[ZHJ<1I>(_:?(P'M9C9,
M&4=;"J!=^\--X#T%(=]+9',O3]'>Q*'/( +FX>S0D;71HSMRG^IK"-7K=/LB
M]LO>*I@.>X51$7"S^,QU(H@S_5567TEKH( #O;2MU@[S<7F-!*[FUO-P:]M)
M3@II//E<(^J;JQB6+!QF=BU7JW@?9>F==X"#P8Y-Y*;&R!VT7<E*W%O;$K%C
M=@AL'!=+LD32=7S$-;:6.T'7Q T;"N,STLF>^M5P@"]=3Z'E2&F3_D@=T-@4
M1<'\/IT=NVG^J @O5#_TFUI($I,IDR^0E,'6AWE^W),7PIL:)-U0FA'?RRC\
MQ1.RJ;,2#RO5?Z]"MLH4CY< .1#\#?D(#Z)D,6'.$-)5QEGDISF\G$8<Y9Q5
M6E_[3"AX=25@?XXH.<"]R3C)?P7-(RCZ'Q+8>/5X58[58152$JQ)&$?/-/GF
MS2A@5(>VTW\^R8P<A_EB]ZLN9IH6F=U9I#Q_5\;3M#LXTRM?9"%X?:S@<KVG
M'5CCG;VZE6M?UR$.&T<8HM-A4M?&ZFC^MSI=NCD^_5-4U3L";.J W 6[E3TY
M#*QMC=@E-80>=F16<5 49X-C:NLL.)A PR(:P!D!=,,R?L"I4:=ALD<,*752
M6IC>G<_JEAP(A=] 4:L@V_)[8I%_'D>PU*71JMF/VGL@]RL-=2N79YN;(_8[
M':F-]W5*VN*^K$I]G!V1[FN/$^J[4JF3KS_$&25O?_C&94VCGKD.<\YNZ)?/
M,,L,AA'/[.O.Z,DRRY+@:2_N"&8QN?-0G(!.9@;*B3L\ KUCM"@+S$6V1ELI
MB_J6R%VV1;VC:X#'S1 [:9NT ^ZX"9IYA5%.=B$>6W-44&!</5,@^C/YE^_>
M?/?==V_)SDO$:=&_D[??+=BOX/](*NJL>OML$R?!/V'O.2,7=$6W3VSM^</;
M!8'33SXW'__V1_+OI" 0<#.*C>NR9FL/8FYC=%G<MK72S6DSY-C0I-AQ"*ZV
M08P*C:(."3[+BL/CXX'&'?ZQ=&S&@N]_L@,&C-+;Q7=_?+OX_D_?\1;??[?X
MZ?OO%W_\_M^L8<2",#([NLJ"%QHZS']<^CXO;NF%=U[@7T?GWB[(O%#Y> V?
M5ZLC<E315[Z2>M79"S'R]!#>^/R[8$& !PDB(KDL*I71'65H36H N(A_Q@RP
M$ER<ID_NM_O0RZ@X^F?Z[A*ZH5'* .@Z6L5;>A.GZ0>:W:X?O<]-QNM-!3L"
MF)GE*!.S#PG,V&"HR8!$F9R?3!>J<"2")?D:F'[#KR?#41+C["RWTYEY9!V/
MBGE"QLP=H-S3S LBZE]Z"12U2Q5I+^@Z6 5-NXI:'9'#AK[R*E)T]T(,#CV$
M-QWP.0N2\R!?JSX@V9SLH$_C_1/HKRKK"YJ83@NT]U_Q^V^S<NVG HC]LT78
M"4X!W%6Z'4'O=R+QW&6]VIEIU9D3,8(^(C4BK3FB09%;5'NIML$Z&MV0 ZJN
MXGTND2,&6VW1[5X:=Y[/-(ZR)TE.7&5<GET]WV*3WFW"WPKR^=[V'4WX*W]:
MAV,MG9%[>3\C-!_:-O5$[/$]%;!VM'LG;IL)7N)@!YY($X]*8CCJG< 4J3!%
M<=)#O@XBXL=AZ"4I5-$7AS(.,ZNJ%A'O?2Z+DR<M,]9TFA48-"G=# +'/6;C
M_(V"6W-Z^6)LR0*#HX^HMG3PDS-;5T?7SA4G:X;Y<,9<MV)SBVLBJ:"'X8H.
M,\2SJK)=6"9:SPS'CH2VC6%X<M)&4K?JPD&MNFX]MOD!>_U>,_3=AB?L-;O,
MS(MM/F+?Y,HM#]B[\^=Q%*\Z==RLN)/4SIZ[#WH]D7MX#_4;<D)GN.G01WH;
M697]U]C3.#Y^.SC! <V-AO8>\_%[G2V&EN;S\'/KB\UJ9CB2G84)%,:VI^!0
M922["2<6:-U*:&X]-\1JWD1H:#HGI+*TGJY#*;<7VD;6%->VP8FRW7L&'5WF
MYJ0=NP5M[>?DKC:7R_4^ZWR78 J=$>X/B 1TOC+:=E>Q;VZ-W'$[U%1]MJ$I
M8G?MDMAXU-Y^>+B]N;Y8/EY>D(=']I_WEQ\>'\CM%;F]N[Q?/EZS!F3YX8*<
MW[Z_N[_\R^6'A^M?+LG-[<.#P[J!>3U=^6QJVC&FV]HC']6=JE:*!C8U1CRR
MNV4V+J)75%W.23NO2#*%LE22=EB.Y)ZFE(WQS3+R+^@+#6/^U*#4N<$T77V0
M^ZF6RM4K/RT=$/NKGMSF%WT$=7DUOJ"?N["K&SZ3Z>R7]-WY[Y]IQ- D9.HN
M_6T0!8!14(Z@W8.[>R'W84VU52_NZ(+8CW4E-QW5DCX?U%4.;GUY2KV]"@=$
M\;)N>(+?9QM5:XV+$?MELZSVXF!'U:2M:R:+2)^$O@@\K;SUWV6-2LNY>-NI
M>K7^5C:;@\?52#O<YRJE*AP[GD4%@0B!P9&[7QP9N5W#VV/G&R86O8ZNO"#A
MV1RWZ_,X>J%)%CR%M)KNE=]".[Y#.8@04D<<;ISB63(C*MC?)QNFE/$\M*'$
MV\([?"2AJ_@YXF?K041H7JX"SMGYLV)</OC3FDDH$XGDVV+Q4Q@\<\W@]CP_
M^(-2T;GP9%=-0H22<NO@,SQ=1I/M2'6SZW#3H:'/"_,!7WGIC9E/84V.DE2+
M-T,LWY']21@HHL^0<58'ORCL5!UF;<,I',=.6J^PO0(K#9CLKB-F'9IF8GK.
MGV"34?('6ONXID8?S%.8KLK%;-75 ?O$I"V_<8D@,?^PX1M(5NP''GJ6[^S)
M]1&):);Q)R^?*7\!<]JI8W137'<98 $6<+=(9#IV+@^/VR!UYE:5U"5AI0'B
MQ6"]G*8C$0H35A: 4Q9)ZMP*M:]K7>'!:=:X,])%(R5X'&W(&6&_"%;BH"D(
M]YG+S,*\7%Y^3^,=B 8G;$*P!LMT]T*.E)IJJ]C9T04QFNI*;CJRBW*01>&3
M!7E7#/&+^B$^#;B.K7KAU,75H\6I=Z.[H_17&CQOF&!+!H+>,_VPA]+WMVMN
M(24;4P\+C(DAAXAA1E*1PXP28D 9J)"IL^5LB>1+!&-8;9U>@48#08Z,)2VR
M3_D2DY>F9G1AR:4)6")YVM%AB>L1YLD1MI+YY">)Y">&/37BJ:D=O_'=41#]
MCI<^9;]/*#/&!17_[4KJM4$8^4Q@SW@G;XL/HHIXAK"HG/'A;Y\7"\;.2=98
M;:(Q6?45 [E[]S4@V3<.LYG;S+-\\8(0]G*NXN3!"^D#7>T341#5__L^Y8^^
M=KR<8I'\C-',Q)"ZF-:']DR1S4C%$?&MD.=L'2=G*9.(E"*14B;W;[>@L>K'
MB$%JR#,'GCT6!0O<(RP&W'K);U3L&*>%!$ZO!!\;JP/BVGL@1RT-=8_N S<U
M1XPM.E(/N!FK$P@M)CT;Z5H&3F<0MX\U%5=*V1*W_ROP>GV1.W@O$U1?@='H
MB-CI^\EOO!V4<TEYIA;/N4GYTX\M25NPFU'[R,S736\]#<J_J:YJKJ.3\@#W
M<1BR(."3EQQO1IM10.H2 \RA9.KTZ8X_;\=(&^,L'L+$"B%=%,B1("4>3RF-
M5D$8B-Q0YD0>D=]09&!#\N@3?0XB.' 2?Q>/"<$D"G^DD !3_GKR?)])39BS
M Z@0/WT#:'.Z3T]^!;9$\IWX1C@ZRS@,0;I+?LVKSE=7<:^95/2R6MQJ@L)=
M>H_"V51*/IPV^J&5[M-P$^LV\9.30K&+?<)@46Q'JPK#%@U-7H)5X^W6WD2P
MPXR144Z>L=2F@!FJS!0Q7]+ &D70)8(A$1R/*Q3RBS\Y7S<;G!/;YEI6$Q47
M*<J::!"+KN-]!*LYGG\-#1*Z8_IN>$PR,H9JG(--/8KDT?Z1G5*VXE6-A11U
MQ>H]92N2REV=<HO<Q,@Z1.>,RMI&TT;I3HIS16U]Q<9$\5**XVN&#XTG,0A@
M?7SCE0EP%? 2Y6K)IR#;B/NN%?O!;XXOU.&/+S_03_Q/1HBF=IXS<IT801NA
MBIYS1:)3!<9$',9-M,"(*_9,H8:)<P$"_L?;':]U<?F9)JL@;=ZQ,B$T9X!H
M-8XV6-12F2MPM"LS:-EP!C_[/ >'1JDX&%@F"9RM\7*)3P>BMKOS#OS72]A'
M7A ITX+D4O'S."'ZU%42'%JRH(1RP3F.SHW+<_8#E5Q*3(X%>QS8?'I:\DBW
MNSCQDH,X'&X^I#4D@1R/30QR5 9=NS]B##92P_(96L$QSU-P>;:(R3 M21[N
MD.3(#.=>DAP8^HH2&FH6VF,L<M :#&Q"!SFF&)M&!9;>1!"CB[DNQM7$CK!D
M07*F1'"=-%-2ZU1U>B/)XTF7QZUHE'8&G WQ*Z_@U;5K9DAJ7O#9RT M"*I%
M9SX@VD\=>SC:MO_&F;O??G-BJ>JBL+'XG<64VWNZ"KTT#=;!2M2.-:WO:DH(
M*8X,-TZ1AVM$!7LZ[C"EAM?6*\H_0M254K;$TZ_02K(-^\4G+X6,7JD%+Q,+
M6;H%5E&Q?MSOXJAXF34_.^-4)\[>=6/Q$Z[DUDF55ZTT7APF<EO?M66W$YF-
M*BYL>;8;:Z/S]'J.R5YG%Q6D<^) L[3O>+:20!Q1FVIB^^Y W1TMG'N?".PC
M[ZZA.][FRPG+"7W:-)&CCA63:9Q_ZQ%$C$AV]!HCM48N[6>7RS>1Z:IV:0LA
M^5)%/37&B60#+X0TTI@Q4@VY#E)/8*9(-.UE$(D\V.^"C&29IEP3G*AAF.8[
MMQ,*XR.)N9]!3+.5/H,C!A=G"NH5@0ABC+_OHQ7?D2FN"D"1L)0LGQ-*164P
MPS<Z-$\<KIA7%!M-C[%8$=Y&]S2$Q9LL^)H^[)_^3E?98WQ?W%33V=T:0API
M?HQCQ,;3"F/*<SO!&*[H\%,-<+]R6S2AH2>>!\JK#Z>"._Q&N;')CS."H],,
MUD0]P>"4O5U:'&$H_7=)_!+ LL/QB8:[+W"R/<W+N=RH&]1R2XW]3<JCU!Q_
M*#]+*12"\P]W!FV<="#T7GGI1HQ*ZB7AH27=&:I/%:,67I)*@I7Q"Z?C1ZX6
M[J6TTD$Z(PTVC6YT^THNI6CH,F+4*YI(SF3<JQ>#0N OZZ[)B"J?UUP,;KME
MX@Y<RVJ^Z6.\]/T Y/'".R_PKZ-S;Q=D7I@_XD-]]=*5:KE["'S2(*-R T48
M^%X\"%P3#D[/'3F03_P95/B?B#7B26-J"QBO6DHY(? M)24@*K]R(H1=D*:;
MDD>3T8(44N?;LW+R(HK@KG![+M_E%Q8FR_*3><2<GQNE.?KK!-\SF 6>CBW=
M:5T^RP[]P.9L7PON#S2\$> ;\GP-2#]4=:<0[PS3.Q<?Z.W/)PYIU)5:84 ^
MGSW?IWC>T76<T./]*N6#C/Q63Q_^R$%[\D]A\[4?;>:(87QZ&Z!X+^B)BTU.
MMLX5P>?_J-!TWT9Y=8B_&(GON2'EE8IS+]U<A?&G5/]ADKHNR)%51^&&9TA.
MVB/&+RVQC?<>;S\\W-Y<7RP?+R_(PR/[S_O+#X\/Y/:*G"\?_D*N;F[_^N!N
M3#/W!9WOX 34I_Z[PT<6:UU'MSN:>+"*7JZRX(7[W7D<L5_LV>_D']D2N6/T
M6R..W$_L&E'U*#N4$?N>906-BXBR:1KD(+D@4+?L:Y"%+?*^(84XI)2'IW%+
MB4@ITMBOJ';.^$@LRJVY!B@5N01Q84*O$, =[#'KK(,,@J &*U8:((>?4V54
M""G_BA@&:H0<XLI',3W[9[CG#^W<Q8F(T8_*UGQ@5F;>P.0,H=EUQ-R,IN/4
ML='8:K=L#K</^U5VF>[E$U+PAF&Y$GF,-2&K(^ 8B15R_Q_3P(T[U9;X(,:D
M4=6UM"-=B$5.8 _^W#.D<1Z[S,'D26'R2$(K_!9^%FE]PL"U\8[#I^,OZ(X)
M+A[N8S^'E&_C1/YR"S/B/^N2A'MV10Z2?0R@@IY./\0@UDM\4P]1F2Q(P89G
MKZJ,W(#*Y";@>GLM>@^X/*(*O5RM$BI.XWB>_&/\OM@P;;PL;TX%J8,/-$MQ
M[Z,_">P7/ 9H9%SI;D,K(_];+^>K7N:HW=?GF?'\71873\,ZL)7*DA0\B61*
M'F-2LG56& "%<;XN1M$WG</(\>NQ)[EO36<.38V1HJR>DB=ORYZT1!PJ=0AL
M^Y4,1_<-1E*R(5''<8(.;.NQ19E8/5Z*G*&V@_*&]LA]LE/5DX25NL:(/;-;
MYF$)(9)TL7\BJ5M^_E/_!9J1]<543[#8N)'IAAT;O+T(('?;_L9H+R#8U!NQ
M8QLH8;DL7KD-*ADZWP.=T";G&WBF*SW:KDQ3FLF;Q_+JM-NMRU.#W"5TYP7^
MA:P))L%Q&?D<WI9< 6WK:A*;'9CT,5([L.A0FA7(]%+(,N!(WD0RY7XFHA#!
MUU7,X<A*N3G ##$W UO(PQ,E$H<PP4X1E@D)>^),4^_9 4NK&3I"E+JNLX*.
M=@UL!R?%ZD3Z!#:(&,<:0FU\_K]<K:!.47KG'6#34=M*I_UFY_,-JK=[^U&G
M6?EYD^R6/3QG0R0?+$L.V^H7>N[J]73LULF>(5^YV,ECG&+AI?RMCPG[D9TC
M*!@8KA,S>M"<&Z28J&8?<4 *HK!2UB#E=HCR=T2@-*4!<TN52Y.PV2:(UB4F
M8-5*8G; U&V07LN4N0*.AAIC+U@0HLB(5A'JAW'T? ;OK.' "_W[0 TF[$4
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M7CIYP<V2,UO#DUDO\&06)YGNV8<Y(E((XD]=?,ZE'P!7LH1,1?A!X<]_64I
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M)0%U/J0K],FO.0='JYYQM3Z'\15EB2>O)ZW)>4+96H8 6Z7688-U+*YW*I(
M.R$(_/211:C\?11EN9=F0;;G0M>%3T.((75W.T8JUDW&E+"OIX8K-GB=E8KC
MY"+ 7A?[!8'";T$^,<^BLA@K'$=[T8'X=!>G@23!9UQPNN.I]PU;GZPV9>-5
MO ]]LO'@K30EEG_R0JC-!!5GX>$TFG(/7XM<G/! I#E(&&P9E8G7=NX^5(6S
M0#H5]0KNE?VPDK^#Y: [6Y7+Q$WPO&%C9B4L]8^]%[)A!E7 :D>WPPUX^@P
MP;P1JB-'SQW17TMSI#.!KJ*5G?*&MHC#O4Z1C4^7!&&'0S3?W2E.T7*1&DS1
MUA[Y(.U451VEC8T1#]-NF8=#;WE<W#1VIUF+3*%K68X^=>ZG.IG6RTSF-C_D
MJ<V5Q@V6M$,9N>];-)^*$A;((L83F]J9>J/NY8@%/ R:I_87LAQW6D % @A?
MW8 6!H/F-E+R]L!T[;<AK)CGA29/,7X#G<<)"_/XK1%Y?<3AV5-9=3F?\$2A
MNSM//N$KG],H'V/KVF(>2!(YSMLP6.7$:@ ]Q,AN12US!RN+H)/RT%M6JV02
MB->VR;+8\E6D<+X)[M1T#SW*H"_XX]CL_Z=GS'$8^$*^T!,\D.T*W9V:[CH*
M,M@9NML_A<&*#;@U3=R7W^1U2)MV'=0&R''W5)F3$I'\KX@QL4;(06XJRN@Z
M?:5T1:F?7K$/E;_0()U ^$#N @WVZ-,?^>CL;8JCITOU.B,>V_UU&/"0*>=$
MX N4KYEHHN\T4_ATUOA ,WC%5+7(W2V&"P'-+[E"_DP30NIW1PX(?0U1G^G?
MWA<Q'/1680 :=#YK?!+'(WC(^R:(Z'5&MTVG(%H=D?N OO):#WD7O1"/^Q["
MCS3B@1'AG+ ]X6W?!%7=:Y_MGFKEZ5#K#V:/E8\,<!]3NMZ'-\&Z::[7ZSE7
MB#M57POCRFYS!+D:Z4=!N041G BP0H9R%FUP650!E>J&P8O+?/-++X'K4^D=
M3?(:J[Q^X$40[N'M@?9C ?W>R'V^IQDJI[EZ71'[?E\-C,>^Y /'J6+C?D$X
M+XX$DIOSK?JIK &K_!NHFMEF#8<I7C03)Z0@8P<,-+5%[O2M*E;2NNH:(G;H
M=GF'#%B9&?$U$/Z&++,L"9[VXO94%L,I'%^O./;@D=3?;R&Q*TY^=N>4?Z7!
M\P9 B*U>O&=:/0]3G@62Z%&>B/'52H<76R..W.WM&E'%"3N4$0.+905-73$7
M@T@Y2)E]*<^ZU=?!CNOA.D8G)#:\H%&\#2+,@ :G+-3G,9&)+:O=YPQ*-8;0
MAAVE[UR!I4Z%\:!#<).Q.$*(&,4:GK1&GB D,X8P/#C;:@PE.>AA__1WNLH>
MXWNZ8U]DPQ2\3<[AE#8,ZRY;CD%_SB!C8DIM%.I#?*XP9:3C:#BV()6,22D1
MK-)*F>"%3E4JNVCWD[!G1)]AO],8[R8UZPU-TY_)IW983$M;)H4@&/(SEE$6
M^! V!B_TH2AF<OEY%>Y]ZD/B"CQ)N,_D.X3'.UUZ61R6F""'RG&,6I\18H,#
M8M <25$;M5E5@4@I$<E%$ME7BE#\Y963;6SW.2D#+7O3D;EBD3QRO[=M2-7C
M;=%&[.O6533U<FN>?>,Z]P:-2:NF$^5=PM4^+,SGRQ,\>(>$OP>W8V9,Q<F6
MO^<G!!Y3YJSX+N+-I=FBYG(;[Z.FW71;M%\W7E9-:!$L!>'7BY1'^CF&R041
M\KC*U,-AS(9[=DK9*W=0=^4%\K9<S7M5[ZG'*S#=1O=@/+C$P!I\B.'%%O%/
MV&Y,V]:'-NDCASSKIE1ASQIQQ-!G7T?CL@;PBK>X-RSY;D6MW((W3\91N;M?
MZ]DP7]>"SS:/+\"E6Y=^5AF\<M>VMV(IW7O1]+9D+A-<>V]Q>B[8^(M!C5#G
M55O8X5*0"U\8M\RZZ$B:TNF''/RT5:\LS[HZ(08I?=F-EU6<PX(H\47)Q7D&
MTE3ZNWU]@P'?T>L"-1HW6*A/?^3>W=L4QT]O:'5&[.W]=1CRR@2?V$[?WJ@%
M G?/;DQH#Q2['XV(UQ<A\?M[IZI:LSAB?^Z6>919>QQGC3,O-)JJ!RO["*R)
MZXE:R0UX\8(0=E:NXN2!X46YC:N9EM+9'[GC]C9%0S))>V?$CMU?!RLI(#FO
MLW6<G*6,FWH.XGRS3\<H79MY?6F\ D=IW8SK16#F#F-OJZ>'TXR]3=;CI=TI
M+%/PX)4TN360O2K7;(4BM'B,EUMXI^*?U#^/TXQOQW7M?0VFBAQI+)FM$G$/
M(XD8C6QI-M@+ZS"I$M1G,2GD("!(OKWO>E_.L06YB5ZXB1C&>S-&M8J1>EO[
MN/=L4:K6#'IH5.DZ2]2IUV D=*G#$T<[!E,9I*(Q2A!8K?9;2$^E_I^3.$T_
M1@GU0A 9ZD*\H^Q#PO,/_>VH37>^P-'/=)J0HD=TGF#34[>Q8*@4@W Y2"D(
M+S:T($]<%GC;QM5M/_=6K#6-RTBF7*^>QR$3 EZ2"5[H,DF8@B(G3>1QK!K^
M_,A^2ED,""]7ZNV76F2$'.;&,V[]II(M+HB!<$1E;6Q/580BJE1YWM'9JJD)
M445SO_]KP;Y=V\.662!'@S$,6GW[R1Y]Q @PBIKF;T-9\W?G6]>H#'L3K&B4
M4I'44G*.([)\3B@U?MT4W@0'Q/O7M]]+O..OA$MVD)VB,BMY?=PQ9XXR2"RY
M\P[PJ_>>?QSK#"2%%+]L& AP:@@=QWCDQVQYP$2IJ^9C1:T!>R%[AB2P:4KB
MB)YEP18NQZ8;LA-<R):Q@7UG?FL6&M-DYT'=]_V..1.%?T,2=!#!'5D22K>+
M$[*J>)V7:_)F%'"J WRGAM7!GP61S$7:G61/@/^T".[44K=UPVY*:'X?1,%V
MOUU&T=X+KZ@9*-<0F34<-QE%'XB/*<P>@AL5,DYD8Y"Z%4093@!5LJ:4(RWC
M%S",#5(2/X4!WY@"$&;>48_%D4\3_NOY ;!UL^I!KV1+!%_"&&/$7.O&>7\R
MWJ:$VN4S^Q%&\UV<P1#WPO=!2-.,A1YR2CE>ZMND.VM [F$Z?8S6(#I[V.ZC
MXQ D]W(^9)<S(EX17LNX)E71?<O0_(F2!"X:) +@M]YO]=$V\.$7$;W5)J O
M8@. T=WFNJ2SG@2F^$AZ\T(A"2E$(84L>8P^T@GYL+EB"ALN:P9Y,02+03YM
M]'ZDH_&^2A.E64\;K>;I$\S7D)G]U-"NU:#)H ;X8Q7[LXV7$2C3IJ+_$VW>
M;GGE$\ XG^+]"31Q V-$;Z<&&!.@[V@2Q/[M^J])D+$IXT.<L1Y7<?)($_Z*
M@ZGSZM&=-7CW,)T^E&L0G3VP]]'1^$U(S@,@^)/@0B+.YFC_1L7W71*_!+Y(
M2\Y*48#&/%%["COKA>WEUY"R$"$,M[4B#D;H=SM:XV(HVIP6ZE5][WV&W:>\
M3/X=^RL8X#IZ3*B708MELJVSX3!RF"<!"X8JL'\ +>R0;T.U0?OT@A.)BL<J
M=I(9"2*2Y>Q82+^5<3@."'=IMP:T7A#)7GGYXTXQ9B$#84*X?$N<[KS O_R\
MD^A]R^;H1)0=.-\G\%YDQRW#?A20@M0 <U3?&-?NCCAWS$0+XQE;\"*2&8]_
M.#N25_N0')W?_G-AE=(:N15<%P2YAKT:MMB^IRL:O+1DLM<V1.[]S<JI3G[:
M"K$OMPAK.CASDJ2DZ<8CQ]0M:=1MP')!NO4]32D;E5#EZX*^T##>B6@EVJ\9
M>.PATTRB3.TYL1$5I)XWT"S%FJ _">Q+@0$:64B3A%F&^4"8I^2P3Y@&/I5!
M+I^;6 SK^2_PN!O??4BDH'S.\DM1"94S.S\+D'M#*8$W?^-ML")/-*+K@,7$
MGX)L S3)>I]!%<Y=L9:'C=T#(PY;1K"#%,7)U@M)O./R1,]D=5B%=$&"-0GC
MZ)DF$Z\^''RJ/$#(>1+&E"A<285M'EVY.-!U:)S&(;FM&(<V&&>ZH.HTDFR8
M\6H;(H7V;N74H.JT%>*@JD58X_S@NC6/F[!J+.U<;G+ 7)$=[ICX&4,@J*O*
MD8!?-&Y<[W5T0NYW>DI7=R_:>B#V1TW!S><307Y!. ,^G10L%N(BOZL]B4D4
MYQK34N/G.HTG+"E2EB&XH#NV4@MX6,I^#BG? (Y\6?V$_[[12 U&M4@>.438
M-F2ESH@EVHAAQ[J*Q@LWI:R(*LF"%+)P%U:E86!6A;5%%=><51_!8E3QU+BG
MF-97Y.'&\A1!+&X3,1,D>ZJ^&Y/O-BN_:C^<&4('*6@--DVQ661"!/MVT2"=
M3%WD0\Q\8AU$@?"(O&[0Q-LO3E273"LO*2V+TQKUMZ[/K]S;R*NSBVV\],*K
M.+EC^,S:!RLOA$0D^>-C$GAA_<:*27_T^-C3%%5<U.P\"SSLJXOI0+^'P" M
M+CZMO"0YP,[BBWAXS4OSW,<G+^0;YNF&THSX+*I8\ UN<?N55S@)(GAQ37K-
MSCOP:J[J3KQ4@&2@0?J&?$S%'YB'A'25"0DDYNP@/E%3+TM8^AI>_)9[[NH&
MN_R5UC[[-RZ0?JJ/*ID1QHTH[#C*YPP)Y^AHO\Z12=AHJX[!?'3:CX#KC@>Z
M<+RK%WKTUE+[.)9MZ3(+I-;3P/RA*Q606_&X$8ZS31+OGS?B&).W5 $:3D!K
M3Y7,<=8QS([[17(DJ3VF=(ZGT^A>.U[<[:I>;G=A?*#T7J#YZ;J@8<-&IQ]2
MT.VMNKK!V=D)\<ZEONRF@SSG<):'K@H/Q^>;XRM_QT2(HX@."HWL>/4%75.8
MO^Z97N?LOT'6[LUM[9%[<:>JJO<V-D;LM=TRFP[8G#(!TD30=NRE$RA;I]RD
MIY@0!MPE\9JF*0LV>>FCCLFVLQ-R']53^N@<L:4'8F_5%'QH%*G2A_I>KF?7
MB=0.Z3-4'H)#N!6O(,%B:-<)?"=[[#K)?"V=D/NRGM*G27Y-/1#[LJ;@ Y/_
M3H^44&0"CJRV)]5&DH:KZ GEO+6N0&IUG(,W:RE_XM&MO;![M9[PPX9XQ:-+
M+LZO-+HP *:E<*FO]B*DT@6Y2^LHW+XF+MLC=F,ML>VNC$L&6!;'8ZCL=GV<
MBW$>;R$PX.<Q#QLOH;Q&G/KR1HXNA_/08TN.=4!];<\>3GTF(&#)C'5X,9#T
M#*#%EH:#75(5A'!)SD3)1%6613'?'M@"HI '#VRY-B?GF9)T__1WGC$3DQ>:
MNMU!>*3;79QXR0$2F+/#.Z'X[?HABU>_M;T8J-41.4;I*Z_"3W<OQ,C20WCC
M@DXY"R)X+,C30< !)#EP1DWOYTT#![AMX,SW;SK> VQI/B\_/U&TQ;MO9O#F
M7J?(MD8Q@F?P1M/U/(Y>:)(%D%5UE^1Q#_?4431ES)YB!+KN"EW3.ETGK0@G
M!.$VSXOGB9#ISDM^@12Z_/+ 19"NPCC=LS]U5XD;2!4YMEDRVU$UN2$D$2.E
M+<T&5 A1@66AU&@40BP($X/\(M)%B^LKBBC.]VY=FQ E=ATAM;#&[3Y+,_81
MV?I.#^#KNB%''UW%6R*LDSZ(\4-;='OK!KEGH#!!$H[85[Y;U>D\^HIZ4 TL
MA9?L"\"I8E]'Y-&/ G(_-S"'ZO(]NB/V?A,M3'TAYP6A0<O2Q'DX,*5-!(?4
ML.B!'5QHU%* UW6:[JG_<1='I; -EC.CA!PG!IA'Q0L#,HAQ8X@V(VQG%#&%
M8"R>&F_VK6EPQ(6-[JK+!R@V*DD37G 4V7IBN<\V<1+\D_I] K1*+^3HH:EV
MYV*B[((8%70EM[Z4*'F@V,*UKGC+#L&"I,(&WK@V,%U-6;1"Y\<>]/Q0 UCG
MVT&/2?#\S,;!59P <L-=YV7VX&TI/+J4+M.K($FSQX3]?E/[FJAM!DAQ;SQC
M*H\66:2._4K_.,H: S!<L2_V=WG!*KC/+T58B+B+/V?G)6$ Q?_A_;!-L-KP
MWP81)(?$25$T8 W"L?Y<NOR7JV:P$Z\BB:?QF*DW'CQS I70SUATXZDU6B0H
MRK( *=1(]PM&L VM/+I7$DUI&))TS\25_:4Z*;,G?_4LA8H')Y)/_D03IC'1
M&I:7AP&Y3+R^0RX5\3("<O$'][AMN6A$RN:@: $NVWYH]#5NQB W([PSX/N\
M=IP7YF.7C>>J?RGN=SRL'=X4V8'4UY%//U/_,>:KHB25$033]C?V'8(5?=L0
M<_3HCG3&-#5$Y>Z(9E_$:X?>*AA?H^",B.0$7B)X?966JPK.CW"&CJZ33&6-
MJP",L$ORET^/9LJR?@_YFLVE/CS0Q_!CQT")H\PW%D/PVX*75+@1B^N NU=O
MI%!@:(8B,M;OBCWL-=#$V .\()'5K&0 J@QZA@XPR78$I1F;:#F6P%0Z<3 X
MH:5N*W;AS-H.<AQ$;Q,:HV5+IB@.>7!XV,M&M4A<86;8\MDDA>);JXS-)_3D
MS>0>W9!B9U_%*V>Y'7T0ATW:H@^"1Y&]I;!8D)P)7[HY.J@=6W=.5^(Z+E>^
M#]+?KA)*BW<;O:SI5DN/[C-T[39#=+EX7=^9N7JK"K9='I@1X$;*=TL9/SS.
M/XHURG=,H5+IUUX*.XZ4J1-E1JN?\>?W7^*0Q4 0?_2$A48",P2&=F/HSO[5
MWC,#APXE1HL(2G[(\&$D@RCZ8H&'A]6&^ON0RAN \CY@V^77]A[( 4!#7=7C
M6YHC=G$=J8V/UB7M\BIG<;G3^9U.]2KK3<>%SJ:VR,=OJXJ5+,*ZAHC';+N\
MQGLO1[>.;UQ?X1Q)S7B[A=H4IA>!&E-=@"RG^DL,I1KN@^=-EN8'G.QW-+VC
M"<^VJ3\B[=4?J>L9FT+)0]'OC'V_W4@7TW%]],9/F5#R FS*PR7XU4KX -]7
MG3S-8D*;J+Z^(((?$0S5+ K.E#"N(O/128+$A%;YH#LT'-;6"EX"GT9^JABF
M899H:(H4('44K)2PJFF'.#)I%=>XN%1.=$':)N]I@I)Q-80<HJ$>V!R@%#6M
M;J,'KUCRW(EUM??<%)=H=$/J;7T55Z.0KCXS"#ZT51B2N;HKR,GIHZS_QC-!
MY>-3J2?6P>(L=Q_Y5/PN%8FBH,KTD<CH!JJ4PP/@\I3=@ 4I.;F).2;7OS(*
M%LK8<;BI!Y'/.ZCOIPJKU/I[=RB;W'D'^-7RDY?XU9(6R_QQX:LX^3/KVW3;
M>T1V2$%X*D-7]B)'XH4X]!I=Y4$7C&05T H>*++!QJC:3LI'N("GU6]((26?
M6[B<HR H Z@@]B\CORTD1&OY2UX;(W]$<D0#/61>DLW21._H<Q!%8UNI<U6!
MUC[2W[R*OZWW4,J!Q"+G^QD8.;SK8&P[D0ZN5J81UK3]C5KXO-8IN\NT5N;J
M)B:O<9+NU-7A['R;YRHHTN5S]@QGY=%,_0JFX]%L,\T\K''='I]I%(IRRIWC
M9"MN65U':9;P?:N4%WY\W'B1--R'F%^DI/XXD[ !_]<Z.9M^"BN3=E_FKW$R
M-[:!PTE>%O96A)8U9S,F=AD"%)*/&@",MYZ:_--\E.0(9$,G 4_U5$^ R-?K
MF.^6I[S  I2 .!#ZF2:K(%4VU.7$8//F:'5I>4]3FKQ0GZTL\_?)Q6:QK!AQ
MQ_2OVV4VHH(4>0>:I3A=ZD\"^V'3 (VLY[ODA1HV7D8@J2&1TO"M"UZ@1,HD
M7:>H>;)CDDQ\!N7 ;B=[J?>J?7*^,@DPYTR M8,S*@?VD5:IC)JV$>.RQ&B1
M@7#N[8+,"T_,=,5WZO*2*@V3I0D=I @]V#35XJ(]B2".5<UUL9-[)YG68HY@
M7)0O&@=F8L:]-=EX<@,]@D@H+K-T!<MI4[2L>?5E,'WD:&/=E W7:H811XQ.
M]G6T<F5'8]6<MBZ;W3Y?]Z59=0:[H#<=-ZVL$,:.EM:,9V5#\F8&%[XL*N=L
M"Q'!A3(,9N0+2%DM#]:K<SS+X?_SBWB1^(Z?.#85DK3,XK4B6XM!K6!<#?W7
MB'9M:CH\.A'P)^4B0K"9 > 8ELT-LJLUR,0P^-1ME*>3LZ+/NX"__Q$)D[09
MW1+].0"@35.>H)\-XMBASZJ.+H^,"YG<@QX*F[[W/@?;_;8\OG5; L_8,,5Y
M"Q0XA@?=BJU3>77(]I?08?A:H5';V%:PLI/;:P1/?:4=HFEY%,O+BO/G'M43
M%BGJS#!V?--?YF"[R^U62:]A_PZRE*S+>M7#JXTU)-1(^,_/M&5"T56<K&F0
M4?\VN?%VS#R/&R][[QW>T7O*JV0?QY5#:2$%2BLF*E)L3 EA3[09K)>E=)NM
M#&7*M!N9@2;R;H(UG.P*F4B<D!"D6K!>!_($&3F!?%&27P/WHIAG$E*18AA$
MX'C!"R4>7S@[2,MQ9N4\0BR3="1O<J6:4[ GP)\P <@[2G(1'"3I.+=6PR L
M1MM99;C!\(6(V#A[IP'>C3=7&N[NW<=AR'Z&%G56'Y<=YDEB D,7\\B(O+!/
M-5.H;IS$&(NWN_CC7.7MU(FG"<P6LK#BD+E:-7?MR:\@*I&R3GR:-P_3:]4H
MF,%97SZK+XN7\*0%NQZ9'I<CTOEI0G-;+7?2S [[?L_(6J,H>E+*B>5I;O2F
M5U_NYOCK-E7?V%YR,<5GC_1:'D3\.8E3ZQEDK9Q>*]QVF]=FI8H:-J\17C6T
MQ5"M0L@'CUD+">$W3$:[@/J3L'-$G[V,CEJO8@QS<YJSFV.F-\A\)A*Y*[=G
M7^Q:(VW%.J=7/I&TF-?F1%+#YA5/)&W:8IA(%/G*V62NT\@8QBZ. N8YD4QJ
MDOE,)4I=HN:CBM&9O?()I=W((Y71PW-(,>:TTJ$PAIE%+?WE<LL=N<E/3LM?
M!:C^E<(;,-1?OM#$>Z9Y'A//E +KK:<"7'U!OAPP[OEQ1@)J32F^#!#O:PQD
M +\@N0)$:D"*U$61\OGK\BG-$F^5S1_]I_I6.9^S>I.^^GG"[9?\?48X^@P.
MIH'?L7^V@/\J:F>/^F6J%;7)UT%$?#9[>(GRJ.%)!K]%,TY9:'M40YZ4W]:T
M):()L[&$3>UQT!B3IE4)YCYQVO\<O29/>^SG/(&.8(4Q)]'VLD^M1_<NIM+A
M"R9$WT>>;+\^W,_-Y!3Z^PKQVM'?Z*-8G0!Z2?":YP S0Z"8!@K17_],,.U7
MRJF]PNF@YC#?Q8307XS7/B48?ABKDT)/&5[SM&!J"A030VU&UFN=&J;^4N5-
M='230T?!X^.K)A_A/C@O-B),R>MQOCM43Z/@,PRI<SZ8*7;@G\3H?2JB#^.(
M&=2G47S,*M^+TQMLLBS#:67<!<#]T1DX%Q=K 7 M^Y]:_\:H*+@%9MB1950C
M=P>.0SEA1I)Q%;8=!/9#C7K(N,%9?=RYS:^C=9QL1:SM/<7[K/JB((G+(\C7
M@K?Q)YI(*VZ#UF*5X['\HK"WWN#C(7"5WQ>#PPUJXT/C!>&R2FCFTKX&3+9L
M_ZKE%B2,/Q$:^1!>\\T!?.MOF];\N-M-C=*G++\DE&XP^&@H?<3O2T'I)K4Q
MHC27]96AM&W['Z/T)GC>?$$P753]+)<)<E]ZBH_9ROU+ N_NSS :CC>S_E(@
M7<,"&-%=N3:IW#-MN$(Y0Z0?\;/D59DKZ?R"'[;W/ R-=VJTHT/%>[KU D@9
M/X\C?BMM[X6/--E^W_9I44@WAWD!A:'JYPWWHF&?5Q!9"..\4S/;U.1F%+H1
M13GR6/-BTH13TROXLK53EZ;U;X*UZSNS)U] XY$9J?*'.'JA*=/RR-8\]?W"
MR^B5%R2_P!LPO8; 2 +,<I8:\V-8>=^J-_?9S36C&@'#%=I"[!K8$M7I078"
MPA,N/:;Y N77*<SH23,6#Q06;V;5G 9;W-?J]:+*P-7@+]RH]7M4TW%%BNX3
MF[WCF16;+.?YVLHH%C"%B<<-59Y:2L4Z !X%2UYDD75X9XG?'F=PD,GX,8OY
MBTLJ< A<.\HS\5*@"DWS*^CIAM*,^ #F#&G@+ZL]Z[/EBPZQM<YZ5+$J1?$$
M#*K/-LT6HI#9S>[A7+Y$OO3Z188OYAN&4TR8%=TUEZ>C?QA#H;Z8Z7;(1QMG
M-C:1Z(N:K <9R%K(GQ0;/BMEPP<>* =TKYNQ%S K?W47_2UZ'UT\1G]A_WGX
MBHADT@4/!^AG;[L+V33QU=W;O_WI_=L?+KYB?"KOB+)_Q@F07C..?*$147*@
M7L(HP!.@6R;,AK%BD0-K'["FE"TZO,.LYWDG7WS,,* Z^2/>S'TEW_(XD/@B
MMF]_<;IWJ\\=::SAZ#/8W+759/V*MVS[6@##?FTC2+VBS=JIODN/G5H9LLTC
M^=#T5:=!L\&D4LQA5IC^LXSWNM[L9PD'EL P6VB4]L,V;\SH2YW,'\_<EGR/
M?0VV? $VZC3"&[S">43,V,O(O_R\HROVXV,,O\I+[(_TO;NYOO)Y0M/L-N>%
M#I:O>![0U1P#[LLM)-CGRZ6%HT/X]>P?OAC[.^3;0>H9*QA2+@Z@5LKHATQ]
MK:&D'W+#%)**0S']?3O[C)%"\/3&[S@0LLQUGH<^8QG!% N6+6D4"_[[DQ2.
M(&) ^VD3K#9DO0_#0WU^1@NXD)47D2<*)T<LK,R* P2>]R&.#W9,%A1'-MB^
MUQ@[;;='GTJ1NBGIP-FQ"[;O4<W-*$J9I7P!)!QF_!1':T;I4=H6@3A?\,2K
M6^K6M2Q?^"0]:F'5[JG[4_Z<7</V/R1=M,W3U1D]VW@98;:HS/JO:Y)V7K+8
MZM2-JG[Q[#]?X[GD48Z+HVL.8QEQ>.JF \E^CPPL)7%.+=;O\0*Z=$X($BKK
M?(T5_N^YGO,;$^[#DQED?<[NJTZ4\NDF5%D^/R?TF2UWKID&090&J[HD'K>2
M?,&A2,?GF2KT:!#C"P\UNJQBO"NQC?=BHA!'!.(>9I+ -%%-&8&_\(W_\  P
M)#8;Z.<5I;X( $Z3%?O&(:\K$ACKDTT^\Q>*D$(3%UE9<_YFN9VU3>EP%J^F
M,3@XR>\KP&N>LXT^AK6INA?WUSY#FQG#S4F__N%^<4Q E;PLF+)?Y['_M!_1
MYE1]G#?W6A,!IOU"ET>C?C:I 9IFFCI%P(Y8O\_HTZ8,6)#I]]G_%:<0',<&
MKW/2GTTZ0<]0X/4E%F#XH*>1P^Q3#<S,.F7*@74)?X\TG*4@V!7O]_@#=4K"
MH*V(W_,3YCM0,,4]KRIC =EWU@B'9I'#H&G6"7,9!DOT>XPS66[#,'%^CV'F
MF^LP*,!YG2'&'!(@>H84KRD5PO%7/ T89I$<D68!6W50OZC:<[MFE-CB@1<3
M'>4[=;)\U1.\GL'MS>#M_%[]%*VI_I!7)FC.HV;69>($V>&KE*PX4SGU[@'"
MY2L1T%S O3+KEJD)J0+Z*W5RF&.RPL@?P^I$6GS4LFH;?"$AKZ@V/<=)<N1/
M<%7Q@,J@?VTUV?+3D*(@WF.<>6'K^GEBUDCG41<?P&:)-AV^K[A.6R_U44!Y
M+K!:I]/I>F=6GZ)<Q@2%S0J$KR98Y-L(_MSK]N?V+&;)MVU?<!QV<T#O$0UM
MOQ3_*2_L*#VFRAB069;15& 918EDC&:_JJUW+.ZB.43;U8;Z^Y M(BZWNS ^
M4/I DY=@11MFMI#+PGZZ7=_35?P<P=LUPE;G<9JEC[!#U_1I1N*%'6?'-'$%
M9,=@A!EA1]77&%ZE5.#EN5Q$"D::L'=!2NF@8RF?!%;")22_<AE/ZA)/AQ=V
M+'T31/0ZH]OC!Y''XX(<(T8RJXH.EED@QH6Q-'48<%6Z@7CD5Y"/< $=E2E'
M9V98R=9LM+L#2ZD\]>MM P>.4=H4+6EW1@YM_8R@(I9>3\1 U%,!X_V=G$UC
M>$$D*S= ,9$9FOR?)[?4*#^#@XIB^;E,T_U6+!F7D?^>9IO8C\/X^3#6 S*]
M."-'H G-;^640I\M8NR;4GN'@9ERMJS(R_.T%(GG^Z3,A%_CK\=713W%H#SA
M(HN+5(VC3 TUR<(#N=-7@O;W0?K;54(AUXVRD9'=,]VG^,8-?+\DI&\S_6@X
M7\?T2T'Y5MW18?R"@+P$!":YQ 1$?@4(/\J7 *)G:S!7D)LKJ3'73($ZSQ[^
M)0X9F3#(#E-!=2/G+PFLV\T_&ES7L_U2 +M#>X207>3XER*_%LP>Z6,4%GLI
MZ,XP-ZC-8'#;U'IVD [#.>#SJ,:VDB'4R0T[&H^K-&80GOZB^PP,7UY#@U(5
MD',/-2',2OTACI,O@I? IY$_=91\Q'<.&#R%Z4>/D%6FV!%Y$MTQ W,N\&N+
MC:U^B,):?FZM0T!#A[F<6@D9'Z!Z,G\?GF^3\_L&ZM\A*>-#G/V-9F6ZQI $
M$$-^R'%Y=%/WSMPR8888A\?7V=CM]7,Z"_D$\*9U>5Q,/A;@94K&)^)L+B<&
M_Q@E938LKL2.T8PF;Q_$B?P5M&O:HYA<B"\5FUL_RB2 72O!EXCB[89 "^V+
M/)L?2D0JHK\RR!_IZ^3Q]JZT83XSB#*?F*:&T<]CWP=1L-T?%S5VP![Y=##U
MAY@T-43R1CP%3&X"A/LJ#8DB"R)E?P4[+&-^F8;$D079UIOO-8&\]]DIR!?L
MOWB0KWZ(:4%>\/ZB0?[(!+,">2'[:P5Y2U^F&>3KS3=3D*_/TIDPEN\2X$L"
M>JV/,7'NX!<6T>L9 2'<-V42OJ:@?MR/4V/!UQ;2-QAPNJ"^2X#?T7ZJP+Z5
M^Q>.]OB#^Q:T?S71_;@?IQ[M7<?VU]$JWM*;.$VO&/# *T!!M ^BY]L=3;@M
MTW=T'2=4M'OT/M/T@OV09L&JX9,,HX@<CRV82P78 >00(Z8-K4R]3- D7P/W
M;PA\/%(*0$H)R!,7@<CV7(@%R<5P V8N[=:D.6HDNF+_#)Z/7UVP0O#UX="1
ML0;"D*3VNE#H6"DW("2EF T&V;):@]ZH$>CR<Y9X<>('D9<<>!6W#\QYX2W%
M.&3R/><;Q?:LW8/CZ\.PON8>"'*Z[%X7"O;6V@U,5H4JSIS&@4U(^K(,FY.9
MF6>LN495IK(L<_>.1G0=M"-B7>M9H%FCFJ=(=-(4/8HT2SP0 1CAO$ C^5K2
M/KGN.67\,YJF&=/T29!T6*#K<KVFJRQX*>$(-KKJ4$O^"=)8HU40!F)[K;WD
MHCWJR%W>LADK"?1V2".&%-L:&F_+YG(HX07?V295ACQS?04[Y:Y+&6*Q7)5L
M\5QD84_ .LA@@:J%\)>/;Q[>D"OJ,^E"DF9>MF?P=G!< JO>F%75'IBL=!GY
M-TR,4(G@>GT?;9*S!+U^!NM&.CUZLX.WGFJ-CVE<!%ZLE0MQM,22B(<)YB:R
MH+ +0[ %B6@&V)8#EXS>+#Z K:,HK"PO]O0Q/M_ R>9U5'G\-'JA218\A?2.
M\:%)0GU>"OPF\)[X.:/\CD>&GIPY4F1S\Q&*Y[$GXXS]H>SI#6&*#I(.E&B6
M48\?,.$3RL88 XCL$Z412>@N3L3;<,72C^:+7(DBWW#HI7EF0&M+N-VWAU9/
M!^+M=N$!=KTX[S$/+>OFN)E]+?W9$.0E3&"(6(7(\+#?\>O9A=RD$%P\IDT*
MT1U-G3/[,-S<OC#WJC!WM:[Y2C'WKC"W>+,US 7"O7R0YUJ5%A<2+[+ &Q+_
M:)!&.NF.8<"^RXHNNC-?7FBK-SZP2E%.VJGBS&"Y,;I%<SOQ;1-?H8P;X?)9
MY#+R>!E(T6: H1L)O@(T:S=67PRKIS9SY.I0:GR\*H,_*4+1= 8H-9+U\@T0
MCDUYN+;=,1[S *<+&3RR1LLTI5D*\:[8$0_#^),7K6P@EAZ75P1C/<QJBFT:
M+%X)X/71=$H4S.7B;85DI!"-%++-"!RGL'1IOY?"5EY.?>(-9/;+<Z9ND-W3
ME#(HV"PC_X*^T##>P:;<P!UB;>I(@6\D,_;:X]4C_1HV<7MJ^KIV:<GZY 1<
M(0C!50K[8;N$PK_EG[X.RQ3)59DB&9<IDEZ6)<'3/O-@HXSU3Z1I.=45M_8;
M?!O$$XT$_2D/_B D6I!<)O[U%:FP;^Y.9-2*>?R2OC+BT*6X50UUR_PR6?I_
MWZ<9"#XDGZ.&%-*ISH:!^@;RQW1F'JTWJC,^/G'61.$]@Y#;NKDX06S04I=_
M-SB!;ZXPTF8,LS37V4%&JQ*3):NZN0WCQ")'4;0[?#AG2X X J2[79]L,W3D
MSNOV18X*O4R@ H)61\18T$]^XXVE@@NL;.LVYUSGJ+NP ZRR(5G3S^T!4.!Q
MCN[ X$3Y#S2[79]N-G;@@@$9Y!!A:A@5+?K20 P<QJH8%_PX18T%^2!RG6NV
M]ITCBCL#E3#R,R(<D3%4] Q9=.=>DAS6<<)?J- U8"N%N:%'MSE:@:.Y^YPP
M0T,+JW!1\!.9LQ6.2%!B1)-PL"PL #OT9-5F 8=@46P)&P%%8^^Y@42[&5H!
MHK[KG,"A0P.KP% >HZ $A9%,\5@<?* %@KL$$"L[W#$5LV7D7_YC'_!3&UW3
MM1&8&QQT&J,5$1I[SPD4NI6PB@LY._83,.1'AP5+). PGDG.O5V0>2%_QA/E
MW@3[(?^=+'\"A[S)"TV9'9:K5;+WPCY1@Q:QN:%&+R-UQ13=E.:$)OT4LAYQ
M%'^0S$4*![#G0),+@ 1GIC%6D]*H4.9<K=T=^;+F4EI?W!O>VS2WL0FK^2.4
ML8%[XE=O/O-&-W-U)\ ^E3?'OUR\1>.KOOS57K3P.+VUQ:WNE4(6$8SR+!CM
M;3#9>&Y05E&R?0<76LX)3JH"V]V7K4N0<K4!:T5-QRE?)UK].8E3[950WGAN
MSE=1LM7Y>,LY.5]58*O.QTF[R;L:24U>0!AY6H7V9<Y7<4'3\-+EO"]23G%E
MK]:C:](A[/KW3T+YB#Y[&?5[>?@(-OC%SF7%\?*G>F2(S-"5%06[<IWFY*RJ
MN!/E+"&9A&UH_@%;7N,I[ASKG=^T7F[C?>/YH@$9Y/YL:AC5U_O20(P#QJH,
MG[V4L@2GP+& &Q0)]>#R[@45/WVS($((-TOGR4V56\"W6*+ #KHT9VT]P@7G
M!@-V]T*.'9IJJU#1T04Q,NA*;KQEU)*<2'[E/$Y2F3&,\)L@HOPYH-YV4WO.
M=J2?J*\WVHMNLQSQI]*/,^J!#^&,'&7Q3V$"O'FYO7/VYYRBWR\C?Y8)^",F
ME^-+K1\SD_[V!HN+UJ8&MP6=K1V0NVBWLJJ+-K=&[*(:0@])]ZY)<G<?6];J
MW!56=G::XUAN#2;;>\QM3-N+GQK'M?/H<0+%<=W?J%6X=4.UO<<<?;AYF[2E
M^=R\U]*.7H/KNMW7'%-AC2)TPWVYH>PJZ+7/(%O[_XV?TN4JNUU#HWR3]E&^
M#W"TAWO\P.R1T>Q21NKO(YBO*+5JARSV,JN6M32^7<"]&(Y?:XJB,I<C"3W;
M4B_=)Y1[)6MX>HHIRYH6Q9*S_-W0W3Y)]W!-+(O%C5*F,7=TT)DPI8$>J#UQ
M95,DQF\U25Z\^SI27ELY.053RXA)L1P4-45B3W'&+@\%Y9NU%X]+=]'?41G%
M]<<H8;]YCN "(=,[3X"__+P*]WX0/0MO3.]HDGE!Q'[Q&%]^]K8L/N:/0-!L
MGT3I?1R&5V(R;)BO)V"+=%Z:VO!J,#LV3\01\62JFT>9QR]=JR)R]"POUQ1B
MRJ [):6@ "NYJ *7A;#D5Q"72'D=K:[1?X:'_7;K)0>P_UZU/P0,L@"[P[5Z
M@[D:C-W<&CDV=JBI0EI#4\1(U"6QZ<AMA(M1/'U'DR#V+Z/63.))5%4]<T$H
MBU-EG48AXHC:/V1>DJ'2G_WP'$1\%F@U@G/$RM/"TGN:[D,X\;MB"'#'9$WN
MN,2L[5V<!FTEKBV1GB<6&AE0 SA[T9T?RIJI9QV2E<S00A"Q1<%%(4(6WJ60
MQDW AL*.A;$2&L+ME7SEO./&.E#/X;7-!@/E^;XC %Q?TO,$.",#:@!<+[KS
M S@S]48 N%P05P"G?]\-A24+<\T'XNKG@/-]DH@7H$:(XMJ(SQ/F#(UH',DU
M4IX?U)DJ.&$T)X69:SPWGBW+:T%'>+>2%C-%O(9S]/-XNPW$TU#+R!>OQ#S3
M:!70QKL0??HAQ9[>JA<GW#J=L)]?]]+!^$ OAM/F( K$M;87+P@A,W/BT^))
M5%68\./@"AN'F7O36>#*@Z.+[$!N +O<!61+AIVWZWOJA9?PPBO-R\DV8'Y+
M<Z3 I:NH&@8UM44<V'2*;)PSPPC##C"0)H)V41?93=PQNJJA""?6TD7=.><-
M35-* 2'@_#))(,&$XU)YN85'6H\TV=ZN :E:WF0R)H;<L8<9275[,TJ(06&@
M0J9^)-@2R9>HC"N/L'#>"P+<P>UR_FY0Q9FM>/H6(VIQB2(0DI.^_+SSHK0A
MK&UHA]3A.U4KEAQUC; O,5IE'CJC)3!Y4S%Y[^1T23S?9[/</O)I0CPQZ1&/
MR>B#G!.O.D;57OA80=?!DF(<]7R?+Q79I_74R,4BD'")E\\)Y5!X'SQO,LB:
MRM@@ 1RL4[6["V9XT52X0)J.]MA!1U=\TR$J-RL!@8 V[,Q13IUOT$G(22&S
M1/U%+L\"TNN_NHO^%KV/+AZCO[#_/'P%>?I;C_T-\O7I9V^["^F"M7K[MS^]
M?_O#Q5<,ZW;,5GQK 6BR?\9))L)YGFX>1Y1O"3(*\ [SELWD&Q:%>%RH@#6E
M$?&]0SHQ H[]*6Z.;<M9D$?(\.1?Y)$9Z[$F#ID 'B?7O6XT6H[!;MB "N/$
M9ZO3EX!-M%>,^3WE3_1P<:XC>/"<C<#:S>)>O5$#:F\SE-BJW14]S/;7Q#SW
MNX)^7G'C26!K4'#B@+=F@A!^2))MO(Q\H@F/#[F0Y.D@0%D*/S4>3F>SG!7)
M>1%@1H ;8>QD_%@RQ%"11YZP19F\3M1<9[:K#U+TZ*5R?6F>F@Z(-VOTY+90
MH$=NN_#A73R_PGBXKM,SAMI<25I_5="9VU[MLWU"WP=1L-UO[[P#WV:ZV)^\
M'=]N*0TJ\W)M7;.T.'L7B?FXO[8F]@!!L"22)\F9$L:5_3%(5UY(_L863N2]
MQQK"V>6ON33.R_--;3,13<5/8?#LU:;@H .7829\-6 R $3F#Q[3@H:;>O93
MF8*_,H/>ZV7:W3!;E41>!P8<&<4 "B2%^2/"L2(311,?Z.>,/'ZBX0MKP3=@
M40<0MJP$9\RPTQ*1MSR20@\?U]'CIW@9^8^,-P6)NRO_]J?W.D"EV50&^')*
M;/Y0TZ+3Z*BS -B!TR0F M_XY$)P'\2-/",8[?NS'_CY%_XERW5TQ0S/M+\*
M7NR@3PV]UX(^3:8R0I]C8J\!?1IUF@Y]0 0./R#$+-#'NM'^>/8GU^B3Y^[M
MO?"VV, 1^UN@8[Z[U;$;VY\*<J0Q-(N*+SU)($854TW,+\04_$C)$.FVJTOC
MH-ARK35 'V/-% VT?7YNGCV2_[K9 1U'0\?[G;5*\1 %]I+$5I+82>ICE28"
M<W3.5F-T>FQM[[FY<;L2MN=F&=3SO4QEGD8T)X]C#SR[F,U*/T!Q4)]OG 2)
M#U+VMELMB=D"0[-!]*#AM/\LP:%%C9'@07"4FXZ,)TJ,&,$L"+89F_6%;8UL
MPS<VUMG&"!YJ2<P6'IH-H@</I_UG"0\M:HP$#X*CW!1D/%'"PPAF0; />!-$
M]'8MWOK)RW&T/9W8UAZYXW>J6KD&W]08L4MWRVP<[4(M&KB=+EYG*NJV.'\V
ML4[EFXY7$[OZS' 8GZC<-91OD!2=ZCN<3^6V/J1O7+^8.(W>XJ$U7)[[WOL,
MAV_OXB2)/P71\[FW8W]IK,/4D\0,_;K+(%UNWM1_9E[?J89E$%@0R9$4+$G.
M$P\FC&X5UQ#!%N3\#.V"[J!09H-I3ELA=_0&M51?/FJ"V%V;)#4=>SD](@FZ
M<;?1M/+KM9K0IU8;ZN]#"K7C>*'8.R]AJX3$BU*VZH43Y7>'RE]:UH*FM+#[
MYQ 35;S8A!!F7Q^DC['O2*ZB_J(H;LS)$Y7S F[J5__L?'':8*6N]:E&-^0>
MI*MX]2W%]CZ(_4);=/,+W W#'L%JU9WRZ!S[CAEWPU-)F3>H;?J9KHW,/!V_
MTS :0-!(8W[ T*V*=5]9D(*I>$FATA(5<HQGG9RR* :94C:P-R2ER4NP<EG/
MYF'_E 9^X"6'!P^"JX<L7OVV_!PTQ0=M[9'C0Z>JE?"YJ3%BC^^6V3@,]D0(
MS"F27X&FP]!6T>Z#MV4_*@Y\$6^]H"D36*LC]E&LK7QE.'?VPCRN]84?-,!O
M\P$.7.!?E6!7<'(4Z$YE@M+'&]2=SLNO[V[?T^T3;4H,4O^.W&=/5%%=L_@C
M8@\\E=%TE%V3.W)+?A74'#F316WN;AW>X7VAR3(,8_Y0SNT.H*#58=K:(W>@
M3E4K=VR;&B-VL&Z9C>_(,LJD($T$;<<..*ZV9\?:.HQ4H=X_2'(>>FFJL;IJ
M:8_<13M5K82C38T1NVBWS,8)JD 0S_)*U:]U.57;$/DP;5:NDF9]T@KQP&P1
M=MB(O.U:#$R4%3V6?H@6.^=QQ&:N+'@*Z1TC2Y.$^ERVUHBNNQ=V;]13^^@&
M1%L7S'ZJ*?F >PXY?5(PR$>XTWC/H>86WY-XH$E TWZ>VJLC4F?MKWSQ@(16
M+^QO1_13PCQ+"[B0I3* 4^ZZ_%V(K7<@3Y30SZL-/(OGDR#*8K**MUNVF$LW
M'E.<Q F)LPT\Y,-LP6>W5&1^ 5TOXT])Q)\BFGS%_L@71A,_*#&I(?&AH8O!
MM%*LL*L.+.O(^,X8&C5ZXL=&7?6/P+&KVSS045N+@2/ZW:N'Q^DLB1HAIS/#
ME!"YC/RA6-F'!'[0[&V0(_34[C\/&.VOSN ( >Z]?S'@.KU]5>NB!ES70\\R
M#%L^O[G\QS[(#N?Q=A='4)I5YPRGH0]24.ZE<NU93ET'Q-MQ>G*;#G)!E)14
MG1_K'*G9>K+3U!;YV&U541VSM0T1C]5V>6V-4<?G/(Z5G/*P!T(GG>.=TW;(
M/;!1M>H1SE$CQ)[7+*OY804/G'&<RXRIW$F$/YV'+7T_@$6&%]YY@7\=G7N[
M(//"5F_KZH/<\[145KVPM0-BC]23VW0 E]0)D"?7$9$,'/OJI&J?E6H[=.+5
M:K_=\RM8M["W %-X0C<T2H,7>'P\WM)VA^[1'[MS]S5%Q=%U.V-V^MXZ&'M"
MR8EP5J3"BPAFKL$ F3E<WH;.6#!/_4LOB8+H.6U%A,;&R-V_7<GJ_>6ZEH@=
MNT-@\[O(@BS)Z3IVV)'45+WS@JZ#E<OJ/H]!!I?4KB,_> G\O1>V;)(VM47N
MB*TJJGY8VQ"Q&[;+:SH\.54X#"KI.M\&/='TKT&VX3?]H9+/)M@]QI=1!N6W
MVC9(^U.9V\C6,TOKF&\G,2=OT-1DF)_<5OP$6!*5)WF,B>#J>)]V:NM4C)!U
M&F% DL:'.+K<[L+X0&E](-G<"JE[=ZA59%.<-L&>,-$BL?%MWF)$I^33)B9>
M0DD49X3F?& J@TP&RD?@Q!D,(RC,2)*"ILL4A'%T.RL^'((,@H<5C;PDB'4R
M!X[:(L46+15K,P74AHC#@'9YS4M*"F+.(^%<D(]1NJ.K8!U0O[UZ3DM[[$.T
M2]5JY=2&QIB':J?,@X>K0MIU,9S1E5UH:3N]JU[%"5UY:=:ZR]G8>"9.6J]D
MG8=66\[ /1L$'NR;.5W'NYPCJ9F3<^=_=TF\HTEVN&,:9,O(AZ2B'40&[PZ/
MC'=+3*?7$[EG]E!?=5.-;HA]MH_TQD5!)8\%X5QX1G3!9T& C_,PL=$.(%UK
MP*C7<ZYC_U1]K;%?=IOCV*^1?NC8ET-_J0Y].?*=1IE3VJ#5_YU'GX5$K6'G
M:2ODGMV@UG&>N-($L<<V23HD;5JXHMN0TK9>C%><@*,<",U)6SQ!@.28/5.J
M$!NN5<7K[).7U">KZ?="ZDT]U2Y.'+J[8#^!Z*'!@'1JSJ(<JWR*V,E:\CY)
M);^)SR*F5+U$(GZ94G)Q>5J!Z<,[3,^-LL /PGT6O-"'XK+OY>=5N/>I#^\G
M""6X_]RN\\RG.YH\P)WA=X=Z BUKZ7$Y(L77"<U=21H>CQWB*&H*K8US_132
MI*3M?'^@7F6H4M^Z.:#1;98>>:IXMUN5?6;G&S6BVQ[@_#4&MWL!KG1?M"L_
M99I]FB7!*M.I2MK4%KD[MZI8S;&O:8C8<=OE-<_*RZFBN,HZCI+R.JLHAI/N
MG_Y.5QFD("8TC\0M[AWD&5!L-:'D0W%U1!W[EIS$'GV1NJ&1"8K=!-V.V/<4
M>NMA/N$0+TF@GA-?7'[:T(0^'41VH^0*19TB)8N.;.+09TM2F0091,SCN#8D
M2$5*9,C @'O'BL(\%D2\X7J?[1.Z4/WGA7DKO&L/:UI1-RJ1_BN>T_5(M <U
M>2$I46%*$A.IEU!2RB-EAL:.=64<O)3X=,WO_<CFWG-"N883;Y!,]AUSTGQS
M1,WGE*@LN;G<+IG,%K?[+,W8D(*1)8J,.4S\O/*"Y!<OW+-%X7OJI<P#8!A>
M)?0?>QJM#BW;''H]D<*X@?IJ;*71#7&DU4=ZTT&N$"8%9>>; (7F=7JW[@/H
M]9S+:.]6OW:T-W>;PVC7D-XX]8OQ()P):1CX3O<%IC7!HJ<-W+I_>@_;& F;
MC%MW"S2[SA  F@S0A0#'_68& 8WBV\6 E!1\'&\]3&*$@AX")W]W*'[\2T 3
MYB:;PPU]H6T7_K4[S\71M8S0$-JV])R#L^LI8&.^*\BC#'#34S/T#G7;:,S%
M%?J8I'/R:R(P!\?HI8?MZ5#YO>(VZ,+C20S3;0 'R'$=[?99RH'RK5Y(7-MC
M+JC0K&XM!IPVGX/'MTAM81@+ZD20QQ+ECJ R)T;>XO+1[WO[Z/=S]M'O^_GH
M][/TT6.I+?OH]PA]U);*PD>_=^>C[[V_QPG<B$EOUQ?T*;^2DQVT<D?U>R/W
MW9YF4/U8LRMBG^ZK@?$A"_#AUZ]XS1]@5=S-R@Z8LB\U+-*Z)NW3?_Z>T;P6
MU>X\;^^PM-12_>-6^L>RWC^<+D#=6*0#,9RO2#\^/"9\0:Z8H378;>V '!6Z
ME55AH+DU8K_7$-IT6'\D#R0G7AG$3N/<,15^\_"FU+A\Q-"EM_XY?J%)Q"^:
M/=-H!:#%X$7;=[6[H_?D?H:H^K5>7]1>WE.%(3Y?LB(Y+S&G(<* B<RAF,)[
MYOD6&%#A/$YV<)&=]H""KC[(_5]+Y>H[8RT=$'NZGMSF=QHD=60./976/F@=
M/X7!L^<X11A6"[?K99F&W_9@0D-;Y#[;JF*E>'Q=0\0^VBZO<2%X*/C#EH\*
M7;Z*A&+&ZG6-1_9CZJUD:K_K"\"E8*G(\5=$525M?ZVK-Q7D0]_0+)7;POU(
M('874TV,KS<I_/*K,<T.Y/8M+Y>FZ087^Z\LW 0K&J5TF5_-:K[5V-@2J>MK
MJ%?<6*QOAOU^8H?4QF,RIT>>V>#C5P.5RWZA8 H7!U<T@8>T2$97FR@.X^<#
M'\)!E-$PI*L,7D[9Y84%Y47%5;QG?TYV7C+YFPTCF4N2):79'%[O&U5'& D%
M99>K[7((046&ED"]H2E2Q-)1L+JD/FV'..QH%==\*5D2E?4Y'$?@]T4Y@L)7
MCC5O/03NTQ_Y0.YMBFIE#\W.B(=\?QW,KZ3DG)2)J,8YG)X 3V<.?<T'Q,X/
MJR38[=)[FE+(;[Z.4A8A[;.6VJ*=/9 Z= ]UBYBZO3GVV%I3^@'NRL3FJSY1
MOF,=)ULN#-F)J)J'W3'_JY2%Y,*00IJ)(^B1C=*LI\N0VIG2%I'J%YI$7ABD
M]\O(O[@)MD%&_6:4:FV-&:&ZU2S0J;DI=F32D'QT5,IE(%_?_W=ON_OWBV^(
ME&1B1!K1&(6.]WS/\B+7T"463:'NR2=UMY2ZCE;QEA8O_]T )S886Q;\[3V0
M8E</==4%4DMSQ$LB':E-Q["@30KB)*?N?%.@0>O6C8"N/O,<S<T+_M8.\QO1
MEE:R+6/:Z5H>F]:3EM_ED3K,P7 /*^9/ EQ^WL'.>U<Q7HV>R/VZA_I'A7J[
MNB'V\3[2#RCB*U: /-PLN1#)QGU1W^E, .>(?LG%H;/#27Q+P*G^';OC'JM2
M<<_\CYB=\$1&XW$&E)P'A5R*]@FCTF(.XZME BC_C'V,V4(S,<K<HK9]?9P'
M8.^#*-CNMZV><]P&N>_4JE2Y$JLV0.P_]7(:7^04U!S[T"@ZN7.?&\KD@/+Q
MU]M=$K^(Y,-69VKO@=RU--15':VE.6*WTY':O-B(I$U4XHY]<AJ% X6X.X<5
MA?FO(Y]^IOYC?)VF>V8><9D=+BFT+$\TNR)WX3X&4'U9IQ]BI^XEOO$[#9P)
MD5S@<$_P^2J5Y1+REZ\=+Y:ZC-&ZE:[=>>:.T+RYKM=SQLY@:>/YR!T><W?(
MO:']&?AIYCXWIFA&!N<+PG,O#(6T[5>N3YLA]_<FQ2I9X$=M$/MPHZC&:9Z,
MH'Q5R?6%:=NJW1:7HL'S O \J'401\P3$R]:;6SFASUX(4TU[H UM$/J19VJ
ME;FJ-8VPYX&URFPA ZPY^RL%SLY><QM%;TX4QQ6N*?2S"!WG\2<:+2,?WN+V
MHL/-S7DS?+2TQ0PA72H6,-+4$#N4=,H]*IQP[OS$5_)?$";!Q*@RF@F$=LM2
M.W+#_M^Y2X095U=WRX [)G;'A="C)DA1ITTA-?17_XXX[*\5TW2, 3$<%SUS
MM5IWGDX:S63(->\D55O,8-A9V@Y1!I[3W9_)U1KRBCK?)[IFHR[*@A>Z_.0E
M/C!D+?_8'"9J]4+J1SW5+M],[^R"/8CLH8%Q1:ZB#,E7*0&Z9 >C=Q_!2^B?
M-L%J0X*,;+V#J%Q"4GC6^@SZ^L0#>=*I7QX?WR9R6[K@03@3DG-Q^M;X^-IS
M%8'F-*#UHQ%H_3AWT/JQ/VC].'O0.M; %FC]2%I<=IY89LM4[5CV(U(LLZ4]
M5]$4R^PL:1XV7D+?P1B#O0$:I=QQ^&_3Y3[;Q$GP3^I_A#'Z .-1G'B S.F[
MP^5GFJR"E-XEP8IVY<V/PPDIODY@7G6%-@(;Q,N\,;4U!C))EG"Z!,=U@P&&
M.C53ZZ;'.)Q>KW-WF=>2<S>Q>9W.W:FM\5D:<"=<**)*1818I)2+<,$(ERQ/
M4^"RD7J <+JOA-;4,NA5I5K4V'K?8.M%/V,/63B>F.$V:BD&UMX<*=KI*EJN
M$9O;HE\<:H@^.$+8\3')"SZ3.*)D'>?+/[[B([$8RNKQ:9!"6=V7P)^\W,XD
M%E&]E)%WNNH;4=]_^>[-]_]&SLB__/'-CW\:%84>/\5]4$AM/B\4.E&T!86*
MMO-#H5/1K:)0]BF>&PJ-8!$5A1AY7"AD3]]_^?'-O_X)4.CM=V]^_&Y<&&+M
M>X5#U0XS@Z)39=O J&P]0SBJ$=XN( &#V4'2&%:I@!*W"BY8LJCSO[Q]^^;[
MMQR9&$2-BTQ7S#)]@*G2?EZX=*IJ"RR5C>>'2C6R6P6E-:,_-TP:PR8J) %]
M7(CT_Y=W;;M1PT#T5_S 8P&A(O&"D-IR$8B;@!]P$P>,0E(YV=+\/;:3W3@;
M7[+>.!Z+MVI[/)[CG9GU9>Q9D;%<KX4-0_3^I/G1!)]8&)I1M86A SC!,#37
M?=TP)([)4PM# <9D$H;$F, *0^LQ#K]=])T^G!*%5'A:06A&U!*##MCT0M!<
M]?\^ @48$C4 <?&PXL]Z?.5^4=CP0^Z)_A[_H@:)A: Y65L0&M$)AB&-\JL&
MHD9TD%PD"C$JDU@D1P56-%J1\Z-GET\NGP_;1)<OXF57O2,58;B\JO*K_ ^M
M:-,R+#)%E[P+OK0MT-CF-01J3M.BAH"SE$[3W]?4AU[D7>)I/T!>"-]V&,2%
M<3SI)Y[SRW1PQU-\QQC@SJREI#KM! #8.?5Z^EI??R,!Q(MX^H0]M:+\=3=B
MON).?";U'X>DRA?=8@[4%7 7"#G [I3>\_H![)!!Z:Z>U*OJA:X[I ('W89K
M2DIH$#_14.Z+@QSNX:97/V0!4G$_U]6;/W=EW1&B)"OK7[E>U !HJ%I.]K"M
M8$5#WU98IKSWCWN%\.@7Z.\OPLAM)VMA5G7UF P](_$V-&&H+H8RF7P"*M46
M.PORJF?9OY?)2$;$])Q6$ECLVATC%ZC9W?XF62L0]Z1IQ3-(8C);<PSC;;@T
MFDE:%PBC:B>HB;Z:/N5]$-9?*46XY9CFCF2TH+Q3N1_"FS4H)P6M^"<#/-9K
M;6&_,"X=[<5/4O]C/4^^#>?1$M4]KH@OE'_"#^Z*'$<8H!'52FE2D4,% )YN
MZ?7TM;Y!6NR*'"$XQ:X.^@,_#->9VLY9XE8#!NY0=I+S0J#'2, NYE#8URZ'
M(IA<+CH(CK[K,.>ZH(BM%IZ<O;I*U\ZQ2=GLNJ5;CZP60*W:V%RW\U&N@%A7
M9#?UKFI99YV6F;# O=-*475-+1"P7]KU]374O50TB(T\?PM#\BW)Q<E0Q!UY
M4:[ZJLI%L>KRPX[1)N]7\E8/=+<"[HL+:4^VO.U- /OG4LV]-Z*%?+F!+'M
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MF"  >YA!4>_[#H.XV/<<PK!2R;Q\.G;\D?_%/]Q_-+1[]0]02P,$%     @
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MSN=NM!Q/G^$L0 L.ST53C^>%*9I[@MDCPMV#0$AOXFUK$?P!)-C./(+H&0D
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M *WHXQ).UV */4A;VS97M(]$+66V<75;Q9)[#[2!T=<#A-'1P'G!*2,U4\*
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MM+W+TZJA/;.DHV=6:);$PZ8'I L$?*:(FP\\]FB'I=3R>[ZU!:EKD-5%1JL
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M\J^JWC=<-*@M:QPE)-A];CF5QL'INKR\WM9RWBI@U#".'?RZ96[XN>14?)5
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M$-!OHV!R#=Z!'RZP_/D*IC91IT#-H1"%H>8J5=K*;0EA?@$!B%P?23^:S&$
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M/W_)M)?/L__Q_P%02P$"% ,4    "  GA&%,1% "H<U2 0!*+R( $0
M        @ $     8W)V<RTR,#$W,3(S,2YX;6Q02P$"% ,4    "  GA&%,
M6$IKOR,3  "1X   $0              @ '\4@$ 8W)V<RTR,#$W,3(S,2YX
M<V102P$"% ,4    "  GA&%,J@@U'<00   Y\P  %0              @ %.
M9@$ 8W)V<RTR,#$W,3(S,5]C86PN>&UL4$L! A0#%     @ )X1A3+X<3R,2
M*   :Z8" !4              ( !17<! &-R=G,M,C Q-S$R,S%?9&5F+GAM
M;%!+ 0(4 Q0    ( ">$84RUYV_V_GH  #<@"  5              "  8J?
M 0!C<G9S+3(P,3<Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  GA&%,%1:RHK-,
M  !4Q04 %0              @ &[&@( 8W)V<RTR,#$W,3(S,5]P<F4N>&UL
64$L%!@     &  8 B@$  *%G @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
